Id,Name,Type
1,ADRA2A,Gene
2,(R)-(-)-apomorphine,Chemical Compound
3,ADRA2B,Gene
4,ADRA2C,Gene
5,CALY,Gene
6,DRD1,Gene
7,DRD2,Gene
8,DRD3,Gene
9,DRD4,Gene
10,DRD5,Gene
11,HTR1A,Gene
12,HTR1B,Gene
13,HTR1D,Gene
14,HTR2A,Gene
15,HTR2B,Gene
16,HTR2C,Gene
17,HTR5A,Gene
18,PDE4A,Gene
19,(R)-(-)-rolipram,Chemical Compound
20,PDE4B,Gene
21,PDE4C,Gene
22,PDE4D,Gene
23,PDE5A,Gene
24,GABBR1,Gene
25,(R)-baclofen,Chemical Compound
26,GABBR2,Gene
27,(S)-(+)-rolipram,Chemical Compound
28,TACR1,Gene
29,"[sar9,met(o2)11]-substance-p",Chemical Compound
30,GSK3A,Gene
31,A-1070722,Chemical Compound
32,GSK3B,Gene
33,RBP4,Gene
34,A-1120,Chemical Compound
35,P2RX3,Gene
36,A-317491,Chemical Compound
37,EHMT1,Gene
38,A-366,Chemical Compound
39,EHMT2,Gene
40,A-412997,Chemical Compound
41,P2RX7,Gene
42,A-438079,Chemical Compound
43,CHRNA7,Gene
44,A-582941,Chemical Compound
45,ADRA1A,Gene
46,A-61603,Chemical Compound
47,ADRA1B,Gene
48,ADRA1D,Gene
49,AKT1,Gene
50,A-674563,Chemical Compound
51,PKIA,Gene
52,PRKACA,Gene
53,TRPV1,Gene
54,A-784168,Chemical Compound
55,SCN10A,Gene
56,A-803467,Chemical Compound
57,A-804598,Chemical Compound
58,A-839977,Chemical Compound
59,CHRNA3,Gene
60,A-867744,Chemical Compound
61,CHRNA4,Gene
62,A-887826,Chemical Compound
63,DGAT1,Gene
64,A-922500,Chemical Compound
65,SCD,Gene
66,A-939572,Chemical Compound
67,TRPA1,Gene
68,A-967079,Chemical Compound
69,ADORA1,Gene
70,A-987306,Chemical Compound
71,AVPR1A,Gene
72,CCR1,Gene
73,CHRM1,Gene
74,CHRM2,Gene
75,CHRM3,Gene
76,CHRM4,Gene
77,HTR3A,Gene
78,TACR2,Gene
79,GABRA1,Gene
80,AA-29504,Chemical Compound
81,GABRA4,Gene
82,GABRB3,Gene
83,abamectin,Chemical Compound
84,MMP9,Gene
85,abametapir,Chemical Compound
86,GNRHR,Gene
87,abarelix,Chemical Compound
88,SPHK2,Gene
89,ABC-294640,Chemical Compound
90,CDK4,Gene
91,abemaciclib,Chemical Compound
92,CDK6,Gene
93,CYP11B1,Gene
94,abiraterone,Chemical Compound
95,CYP17A1,Gene
96,abiraterone-acetate,Chemical Compound
97,HRH1,Gene
98,ABT-239,Chemical Compound
99,HRH2,Gene
100,HRH3,Gene
101,PTAFR,Gene
102,ABT-491,Chemical Compound
103,CACNA1G,Gene
104,ABT-639,Chemical Compound
105,CACNA1H,Gene
106,CACNA1I,Gene
107,ADK,Gene
108,ABT-702,Chemical Compound
109,ABT-724,Chemical Compound
110,BCL2,Gene
111,ABT-737,Chemical Compound
112,BCL2L1,Gene
113,BCL2L2,Gene
114,TUBB,Gene
115,ABT-751,Chemical Compound
116,ESR2,Gene
117,AC-186,Chemical Compound
118,RARB,Gene
119,AC-261066,Chemical Compound
120,F2RL1,Gene
121,AC-264613,Chemical Compound
122,PARP2,Gene
123,AC-55541,Chemical Compound
124,RARA,Gene
125,AC-55649,Chemical Compound
126,CSF1R,Gene
127,AC-710,Chemical Compound
128,FLT3,Gene
129,KIT,Gene
130,PDGFRA,Gene
131,PDGFRB,Gene
132,UTS2R,Gene
133,AC-7954-(+/-),Chemical Compound
134,BTK,Gene
135,acalabrutinib,Chemical Compound
136,PIK3CB,Gene
137,acalisib,Chemical Compound
138,PIK3CD,Gene
139,acamprosate,Chemical Compound
140,GABRA2,Gene
141,GABRA3,Gene
142,GABRA5,Gene
143,GABRA6,Gene
144,GABRB1,Gene
145,GABRB2,Gene
146,GABRD,Gene
147,GABRE,Gene
148,GABRG1,Gene
149,GABRG2,Gene
150,GABRG3,Gene
151,GABRP,Gene
152,GABRQ,Gene
153,GRIN1,Gene
154,GRIN2A,Gene
155,GRIN2B,Gene
156,GRIN2C,Gene
157,GRIN2D,Gene
158,GRIN3A,Gene
159,GRIN3B,Gene
160,GRM5,Gene
161,AMY2A,Gene
162,acarbose,Chemical Compound
163,MGAM,Gene
164,ACDPP,Chemical Compound
165,ADRB1,Gene
166,acebutolol,Chemical Compound
167,SCN5A,Gene
168,acecainide,Chemical Compound
169,aceclidine,Chemical Compound
170,CHRM5,Gene
171,PTGS2,Gene
172,aceclofenac,Chemical Compound
173,acefylline,Chemical Compound
174,PTGS1,Gene
175,acemetacin,Chemical Compound
176,CES1,Gene
177,aceneuramic-acid,Chemical Compound
178,SELE,Gene
179,SELP,Gene
180,VKORC1,Gene
181,acenocoumarol,Chemical Compound
182,acepromazine,Chemical Compound
183,AQP1,Gene
184,acetazolamide,Chemical Compound
185,CA1,Gene
186,CA12,Gene
187,CA14,Gene
188,CA2,Gene
189,CA3,Gene
190,CA4,Gene
191,CA7,Gene
192,ABCC8,Gene
193,acetohexamide,Chemical Compound
194,KCNJ1,Gene
195,KCNJ10,Gene
196,KCNJ11,Gene
197,MMP12,Gene
198,acetohydroxamic-acid,Chemical Compound
199,acetophenazine,Chemical Compound
200,PPARG,Gene
201,acetyl-farnesyl-cysteine,Chemical Compound
202,HSD11B1,Gene
203,acetyl-11-keto-beta-boswellic-acid,Chemical Compound
204,HSD11B2,Gene
205,ACHE,Gene
206,acetylcholine,Chemical Compound
207,CHRNA2,Gene
208,ACY1,Gene
209,acetylcysteine,Chemical Compound
210,CHUK,Gene
211,GSS,Gene
212,IKBKB,Gene
213,RELA,Gene
214,SLC7A11,Gene
215,GAST,Gene
216,acexamic-acid,Chemical Compound
217,HCAR2,Gene
218,acifran,Chemical Compound
219,HCAR3,Gene
220,acipimox,Chemical Compound
221,acitretin,Chemical Compound
222,RARG,Gene
223,RBP1,Gene
224,RXRA,Gene
225,RXRB,Gene
226,RXRG,Gene
227,STAT3,Gene
228,CTPS1,Gene
229,acivicin,Chemical Compound
230,TOP1,Gene
231,aclarubicin,Chemical Compound
232,TOP2A,Gene
233,aclidinium,Chemical Compound
234,HIF1A,Gene
235,acriflavine,Chemical Compound
236,acriflavinium,Chemical Compound
237,acrivastine,Chemical Compound
238,EDNRA,Gene
239,ACT-132577,Chemical Compound
240,EDNRB,Gene
241,HCRTR1,Gene
242,ACT-462206,Chemical Compound
243,HCRTR2,Gene
244,KDR,Gene
245,ACTB-1003,Chemical Compound
246,TEK,Gene
247,HDAC1,Gene
248,ACY-1215,Chemical Compound
249,HDAC2,Gene
250,HDAC3,Gene
251,HDAC6,Gene
252,HDAC8,Gene
253,PNP,Gene
254,acyclovir,Chemical Compound
255,AKR1B1,Gene
256,AD-5467,Chemical Compound
257,adapalene,Chemical Compound
258,adaprev,Chemical Compound
259,GPI,Gene
260,HK1,Gene
261,M6PR,Gene
262,PYGM,Gene
263,CCR5,Gene
264,adaptavir,Chemical Compound
265,adarotene,Chemical Compound
266,adatanserin,Chemical Compound
267,ACACB,Gene
268,adenine,Chemical Compound
269,ACP1,Gene
270,APRT,Gene
271,MTAP,Gene
272,PECR,Gene
273,SRPK2,Gene
274,adenosine,Chemical Compound
275,ADORA2A,Gene
276,ADORA2B,Gene
277,ADORA3,Gene
278,PI4K2A,Gene
279,PI4K2B,Gene
280,TRPM4,Gene
281,ACSL1,Gene
282,adenosine-phosphate,Chemical Compound
283,ACSS1,Gene
284,ACSS2,Gene
285,ADCY1,Gene
286,CREB1,Gene
287,FBP1,Gene
288,HINT1,Gene
289,PIM1,Gene
290,PRKAA1,Gene
291,PRKAB1,Gene
292,PRKAB2,Gene
293,PYGL,Gene
294,ABCA1,Gene
295,adenosine-triphosphate,Chemical Compound
296,ABCB1,Gene
297,ABCB11,Gene
298,ABCC2,Gene
299,ABCC9,Gene
300,ABCG1,Gene
301,ABL1,Gene
302,ABL2,Gene
303,ACVR1,Gene
304,ACVR1B,Gene
305,ACVRL1,Gene
306,ADRBK1,Gene
307,ADRBK2,Gene
308,AFG3L2,Gene
309,ALK,Gene
310,AMHR2,Gene
311,APAF1,Gene
312,ARAF,Gene
313,ASNA1,Gene
314,ASNS,Gene
315,ASS1,Gene
316,CDK15,Gene
317,GPR17,Gene
318,ITPR1,Gene
319,NAE1,Gene
320,NT5C2,Gene
321,P2RY1,Gene
322,P2RY11,Gene
323,P2RY13,Gene
324,P2RY2,Gene
325,P2RY4,Gene
326,RYR1,Gene
327,RYR2,Gene
328,RYR3,Gene
329,SLC25A4,Gene
330,TNK2,Gene
331,TRPM7,Gene
332,CHRNA1,Gene
333,adiphenine,Chemical Compound
334,SLC22A6,Gene
335,adipic-acid,Chemical Compound
336,ADIPOR1,Gene
337,adiporon,Chemical Compound
338,ADIPOR2,Gene
339,OPRD1,Gene
340,ADL5859,Chemical Compound
341,adoprazine,Chemical Compound
342,adrenalone,Chemical Compound
343,adrenosterone,Chemical Compound
344,ADX-10059,Chemical Compound
345,ADX-47273,Chemical Compound
346,EGFR,Gene
347,AEE788,Chemical Compound
348,ERBB2,Gene
349,ERBB4,Gene
350,FGFR2,Gene
351,FGFR3,Gene
352,afalanine,Chemical Compound
353,afatinib,Chemical Compound
354,ESR1,Gene
355,afimoxifene,Chemical Compound
356,ESRRG,Gene
357,PLD1,Gene
358,PRKCD,Gene
359,PRKCE,Gene
360,PRKCQ,Gene
361,PRKCZ,Gene
362,SORT1,Gene
363,AF38469,Chemical Compound
364,IGF1R,Gene
365,AG-1024,Chemical Compound
366,PARP1,Gene
367,AG-14361,Chemical Compound
368,AG-490,Chemical Compound
369,JAK2,Gene
370,JAK3,Gene
371,CDK2,Gene
372,AG-555,Chemical Compound
373,IDH1,Gene
374,AGI-5198,Chemical Compound
375,IDH2,Gene
376,AGI-6780,Chemical Compound
377,METAP2,Gene
378,AGM-1470,Chemical Compound
379,agmatine,Chemical Compound
380,ASIC3,Gene
381,CACNA1B,Gene
382,NISCH,Gene
383,AGN-192403,Chemical Compound
384,AGN-194310,Chemical Compound
385,AGN-195183,Chemical Compound
386,agomelatine,Chemical Compound
387,MTNR1A,Gene
388,MTNR1B,Gene
389,FFAR4,Gene
390,AH-7614,Chemical Compound
391,AH11110,Chemical Compound
392,PTGDR,Gene
393,AH6809,Chemical Compound
394,PTGER1,Gene
395,PTGER2,Gene
396,PTGER3,Gene
397,CBFB,Gene
398,AI-10-49,Chemical Compound
399,AIM-100,Chemical Compound
400,AJ76-(+),Chemical Compound
401,SIRT2,Gene
402,AK-7,Chemical Compound
403,ALOX5,Gene
404,AKBA,Chemical Compound
405,MAPK14,Gene
406,AL-8697,Chemical Compound
407,ACE,Gene
408,alacepril,Chemical Compound
409,alantolactone,Chemical Compound
410,SLC6A4,Gene
411,alaproclate,Chemical Compound
412,GNRH1,Gene
413,alarelin,Chemical Compound
414,TUBA1A,Gene
415,albendazole,Chemical Compound
416,TUBB4B,Gene
417,ADRB2,Gene
418,albuterol,Chemical Compound
419,alcaftadine,Chemical Compound
420,alclofenac,Chemical Compound
421,CYP3A4,Gene
422,alclometasone-dipropionate,Chemical Compound
423,NR3C1,Gene
424,SERPINA6,Gene
425,alcuronium,Chemical Compound
426,ALDH2,Gene
427,alda-1,Chemical Compound
428,aldoxorubicin,Chemical Compound
429,alectinib,Chemical Compound
430,MET,Gene
431,ATP6V1A,Gene
432,alendronate,Chemical Compound
433,FDPS,Gene
434,PTPN4,Gene
435,PTPRE,Gene
436,PTPRS,Gene
437,PTPMT1,Gene
438,alexidine,Chemical Compound
439,CYP27B1,Gene
440,alfacalcidol,Chemical Compound
441,VDR,Gene
442,alfuzosin,Chemical Compound
443,SCN11A,Gene
444,SCN1A,Gene
445,SCN2A,Gene
446,SCN3A,Gene
447,SCN4A,Gene
448,SCN7A,Gene
449,SCN8A,Gene
450,SCN9A,Gene
451,alimemazine,Chemical Compound
452,AURKA,Gene
453,alisertib,Chemical Compound
454,REN,Gene
455,aliskiren-hemifumarate,Chemical Compound
456,allicin,Chemical Compound
457,XDH,Gene
458,allopurinol,Chemical Compound
459,allylestrenol,Chemical Compound
460,PGR,Gene
461,SLC6A9,Gene
462,allylisothiocyanate,Chemical Compound
463,ATP1A1,Gene
464,almitrine,Chemical Compound
465,almorexant,Chemical Compound
466,almotriptan,Chemical Compound
467,CASP8,Gene
468,aloe-emodin,Chemical Compound
469,DPP4,Gene
470,alogliptin,Chemical Compound
471,alosetron,Chemical Compound
472,CTSG,Gene
473,aloxistatin,Chemical Compound
474,PIK3CA,Gene
475,alpelisib,Chemical Compound
476,PIK3CG,Gene
477,HMGCR,Gene
478,alpha-asarone,Chemical Compound
479,ELOVL4,Gene
480,alpha-linolenic-acid,Chemical Compound
481,FADS1,Gene
482,FADS2,Gene
483,FFAR1,Gene
484,SLC8A1,Gene
485,alpha-methylhistamine-dihydrobromide-(R)-(-),Chemical Compound
486,alpha-methylhistamine-dihydrobromide-(S)-(+),Chemical Compound
487,alpha-methylserotonin,Chemical Compound
488,HTR1E,Gene
489,HTR1F,Gene
490,HTR4,Gene
491,alpidem,Chemical Compound
492,alprenolol,Chemical Compound
493,CATSPER1,Gene
494,alprostadil,Chemical Compound
495,CATSPER2,Gene
496,CATSPER3,Gene
497,CATSPER4,Gene
498,PTGER4,Gene
499,PTGIR,Gene
500,alrestatin,Chemical Compound
501,altanserin,Chemical Compound
502,altinicline,Chemical Compound
503,CHRNB2,Gene
504,altiratinib,Chemical Compound
505,altrenogest,Chemical Compound
506,alverine,Chemical Compound
507,HSP90AA1,Gene
508,alvespimycin,Chemical Compound
509,alvimopan,Chemical Compound
510,OPRK1,Gene
511,OPRM1,Gene
512,CDK1,Gene
513,alvocidib,Chemical Compound
514,CDK5,Gene
515,CDK7,Gene
516,CDK8,Gene
517,CDK9,Gene
518,ALX-5407,Chemical Compound
519,CNR1,Gene
520,AM-1241,Chemical Compound
521,CNR2,Gene
522,AM-24,Chemical Compound
523,AM-251,Chemical Compound
524,GPR18,Gene
525,GPR55,Gene
526,AM-281,Chemical Compound
527,AM-404,Chemical Compound
528,FAAH,Gene
529,AM-580,Chemical Compound
530,AM-630,Chemical Compound
531,AM-92016,Chemical Compound
532,amantadine,Chemical Compound
533,ambenonium,Chemical Compound
534,ambrisentan,Chemical Compound
535,ambroxol,Chemical Compound
536,amcinonide,Chemical Compound
537,CXCR4,Gene
538,AMD-3465,Chemical Compound
539,AMD11070,Chemical Compound
540,amezinium,Chemical Compound
541,amfenac,Chemical Compound
542,amflutizole,Chemical Compound
543,EIF2AK4,Gene
544,AMG-PERK-44,Chemical Compound
545,AMG-208,Chemical Compound
546,MDM2,Gene
547,AMG-232,Chemical Compound
548,AMG-319,Chemical Compound
549,AMG-337,Chemical Compound
550,CXCR3,Gene
551,AMG-487-(+/-),Chemical Compound
552,AMG-517,Chemical Compound
553,MAPK11,Gene
554,AMG-548,Chemical Compound
555,MAPK12,Gene
556,MAPK13,Gene
557,AMG-837,Chemical Compound
558,AMG-925,Chemical Compound
559,AMG-9810,Chemical Compound
560,AMG319,Chemical Compound
561,AMG458,Chemical Compound
562,AMG900,Chemical Compound
563,AURKB,Gene
564,AURKC,Gene
565,PRMT1,Gene
566,AMI-1,Chemical Compound
567,ADRB3,Gene
568,amibegron,Chemical Compound
569,MAOA,Gene
570,amiflamine,Chemical Compound
571,SLC6A2,Gene
572,ALPPL2,Gene
573,amifostine,Chemical Compound
574,ENPP1,Gene
575,AOC1,Gene
576,amiloride,Chemical Compound
577,ASIC1,Gene
578,ASIC2,Gene
579,PKD2,Gene
580,PKD2L1,Gene
581,PLAU,Gene
582,SCNN1A,Gene
583,SCNN1B,Gene
584,SCNN1D,Gene
585,SCNN1G,Gene
586,SLC9A1,Gene
587,TRPC7,Gene
588,TRPV2,Gene
589,amineptine,Chemical Compound
590,LPA,Gene
591,aminocaproic-acid,Chemical Compound
592,PLAT,Gene
593,PLG,Gene
594,CYP11A1,Gene
595,aminoglutethimide,Chemical Compound
596,CYP19A1,Gene
597,aminoguanidine,Chemical Compound
598,NOS2,Gene
599,TIMP3,Gene
600,aminomethyltransferase,Chemical Compound
601,aminopentamide,Chemical Compound
602,aminophylline,Chemical Compound
603,PDE3A,Gene
604,PDE3B,Gene
605,DHFR,Gene
606,aminopterin,Chemical Compound
607,SLC46A1,Gene
608,aminopurvalanol-a,Chemical Compound
609,aminosalicylate,Chemical Compound
610,PLA2G2E,Gene
611,aminothiadiazole,Chemical Compound
612,IMPDH1,Gene
613,aminothiazole,Chemical Compound
614,amiodarone,Chemical Compound
615,CACNA2D2,Gene
616,KCNA7,Gene
617,KCNH2,Gene
618,amisulpride,Chemical Compound
619,amitifadine,Chemical Compound
620,SLC6A3,Gene
621,amitraz,Chemical Compound
622,amitriptyline,Chemical Compound
623,HRH4,Gene
624,HTR6,Gene
625,HTR7,Gene
626,KCNA1,Gene
627,KCND2,Gene
628,KCND3,Gene
629,KCNQ2,Gene
630,KCNQ3,Gene
631,NTRK1,Gene
632,NTRK2,Gene
633,SIGMAR1,Gene
634,FGF1,Gene
635,amlexanox,Chemical Compound
636,IL3,Gene
637,S100A12,Gene
638,S100A13,Gene
639,CACNA1C,Gene
640,amlodipine,Chemical Compound
641,CACNA1D,Gene
642,CACNA1F,Gene
643,CACNA1S,Gene
644,CACNA2D1,Gene
645,ammonium-glycyrrhizinate,Chemical Compound
646,SLCO1B1,Gene
647,SLCO1B3,Gene
648,HCAR1,Gene
649,ammonium-lactate,Chemical Compound
650,ammonium-perfluorocaprylate,Chemical Compound
651,GRM7,Gene
652,AMN-082,Chemical Compound
653,HNMT,Gene
654,amodiaquine,Chemical Compound
655,amonafide,Chemical Compound
656,TOP2B,Gene
657,amoxapine,Chemical Compound
658,CYP2C19,Gene
659,amoxicillin,Chemical Compound
660,SLC15A1,Gene
661,SLC15A2,Gene
662,AMPA-(RS),Chemical Compound
663,GRIA2,Gene
664,AMPA-(S),Chemical Compound
665,GRIA1,Gene
666,ampalex,Chemical Compound
667,GRIA3,Gene
668,GRIA4,Gene
669,amperozide,Chemical Compound
670,ampiroxicam,Chemical Compound
671,amrinone,Chemical Compound
672,TNF,Gene
673,amrubicin,Chemical Compound
674,amsacrine,Chemical Compound
675,amthamine,Chemical Compound
676,amtolmetin-guacil,Chemical Compound
677,amuvatinib,Chemical Compound
678,CASP3,Gene
679,amygdalin,Chemical Compound
680,ALOX5AP,Gene
681,AM679,Chemical Compound
682,ANA-12,Chemical Compound
683,CETP,Gene
684,anacetrapib,Chemical Compound
685,anagliptin,Chemical Compound
686,anagrelide,Chemical Compound
687,GHSR,Gene
688,anamorelin,Chemical Compound
689,anandamide,Chemical Compound
690,GLRA1,Gene
691,KCNA2,Gene
692,KCNK3,Gene
693,KCNK9,Gene
694,TRPM8,Gene
695,anastrozole,Chemical Compound
696,AR,Gene
697,andarine,Chemical Compound
698,IL1B,Gene
699,andrographolide,Chemical Compound
700,IL6,Gene
701,NFKB1,Gene
702,NFKB2,Gene
703,SLC5A1,Gene
704,anguidine,Chemical Compound
705,aniracetam,Chemical Compound
706,GGCX,Gene
707,anisindione,Chemical Compound
708,anisodamine,Chemical Compound
709,NHP2L1,Gene
710,anisomycin,Chemical Compound
711,RPL10L,Gene
712,RPL11,Gene
713,RPL13A,Gene
714,RPL15,Gene
715,RPL19,Gene
716,RPL23,Gene
717,RPL23A,Gene
718,RPL26L1,Gene
719,RPL3,Gene
720,RPL37,Gene
721,RPL8,Gene
722,RSL24D1,Gene
723,anlotinib,Chemical Compound
724,anpirtoline,Chemical Compound
725,ANR-94,Chemical Compound
726,MAPK8,Gene
727,antagonist-g,Chemical Compound
728,CRHR1,Gene
729,antalarmin,Chemical Compound
730,antazoline,Chemical Compound
731,CDC25B,Gene
732,anthraquinone,Chemical Compound
733,CYCS,Gene
734,antimycin-A,Chemical Compound
735,AP-18,Chemical Compound
736,BRD3,Gene
737,apabetalone,Chemical Compound
738,apafant,Chemical Compound
739,CSK,Gene
740,apatinib,Chemical Compound
741,RET,Gene
742,APC-100,Chemical Compound
743,APcK-110,Chemical Compound
744,GPR119,Gene
745,APD597,Chemical Compound
746,APD668,Chemical Compound
747,API-001,Chemical Compound
748,API-1,Chemical Compound
749,AKT2,Gene
750,AKT3,Gene
751,apigenin,Chemical Compound
752,CFTR,Gene
753,CYP1B1,Gene
754,HSD17B1,Gene
755,F10,Gene
756,apixaban,Chemical Compound
757,NOX4,Gene
758,apocynin,Chemical Compound
759,BCHE,Gene
760,apoptosis-activator-II,Chemical Compound
761,TP53,Gene
762,APR-246,Chemical Compound
763,apraclonidine,Chemical Compound
764,ADAM17,Gene
765,apratastat,Chemical Compound
766,MMP1,Gene
767,MMP13,Gene
768,apremilast,Chemical Compound
769,aprepitant,Chemical Compound
770,CALM1,Gene
771,aprindine,Chemical Compound
772,aptiganel,Chemical Compound
773,KLF4,Gene
774,APTO-253,Chemical Compound
775,ERN1,Gene
776,APY-29,Chemical Compound
777,IL12A,Gene
778,APY0201,Chemical Compound
779,IL12B,Gene
780,PIKFYVE,Gene
781,MTOR,Gene
782,AP1903,Chemical Compound
783,AP26113,Chemical Compound
784,AQ-RA741,Chemical Compound
785,AR-A014418,Chemical Compound
786,SLC16A1,Gene
787,AR-C155858,Chemical Compound
788,SLC16A7,Gene
789,PDPK1,Gene
790,AR-12,Chemical Compound
791,AR-42,Chemical Compound
792,CLCN2,Gene
793,arachidonic-acid,Chemical Compound
794,KCNJ4,Gene
795,KCNK10,Gene
796,KCNK18,Gene
797,KCNK2,Gene
798,TRPC6,Gene
799,TRPM2,Gene
800,arbidol,Chemical Compound
801,TYR,Gene
802,arbutin,Chemical Compound
803,ARC-239,Chemical Compound
804,arctigenin,Chemical Compound
805,MAP2K1,Gene
806,CCND1,Gene
807,arcyriaflavin-a,Chemical Compound
808,SERPIND1,Gene
809,ardeparin,Chemical Compound
810,arecaidine-but-2-ynyl-ester,Chemical Compound
811,arecaidine-propargyl-ester,Chemical Compound
812,arecoline,Chemical Compound
813,F2,Gene
814,argatroban,Chemical Compound
815,FNTA,Gene
816,arglabin,Chemical Compound
817,aripiprazole,Chemical Compound
818,arofylline,Chemical Compound
819,arotinolol,Chemical Compound
820,ARQ-092,Chemical Compound
821,KIF11,Gene
822,ARQ-621,Chemical Compound
823,ARRY-334543,Chemical Compound
824,LYZ,Gene
825,arsanilic-acid,Chemical Compound
826,arsenic-trioxide,Chemical Compound
827,JUN,Gene
828,MAPK1,Gene
829,MAPK3,Gene
830,TXNRD1,Gene
831,artemether,Chemical Compound
832,CYP2B6,Gene
833,artemisinin,Chemical Compound
834,arundic-acid,Chemical Compound
835,S100B,Gene
836,BRD4,Gene
837,ARV-825,Chemical Compound
838,AS-1269574,Chemical Compound
839,ROCK1,Gene
840,AS-1892802,Chemical Compound
841,INPP5D,Gene
842,AS-1949490,Chemical Compound
843,AS-2034178,Chemical Compound
844,IRAK4,Gene
845,AS-2444697,Chemical Compound
846,AS-252424,Chemical Compound
847,AS-604850,Chemical Compound
848,AS-703026,Chemical Compound
849,MAP2K2,Gene
850,KCNA3,Gene
851,AS-77,Chemical Compound
852,KCNA5,Gene
853,KCNN4,Gene
854,asaraldehyde,Chemical Compound
855,ASC-J9,Chemical Compound
856,FKBP1A,Gene
857,ascomycin,Chemical Compound
858,SLC23A1,Gene
859,ascorbic-acid,Chemical Compound
860,SLC23A2,Gene
861,asenapine,Chemical Compound
862,asiatic-acid,Chemical Compound
863,asimadoline,Chemical Compound
864,ASP-2535,Chemical Compound
865,TAS1R2,Gene
866,aspartame,Chemical Compound
867,AKR1C1,Gene
868,aspirin,Chemical Compound
869,HSPA5,Gene
870,NFKBIA,Gene
871,PRKAA2,Gene
872,PRKAG1,Gene
873,PRKAG2,Gene
874,PRKAG3,Gene
875,RPS6KA3,Gene
876,ASP3026,Chemical Compound
877,AST-1306,Chemical Compound
878,astemizole,Chemical Compound
879,KCNH1,Gene
880,asymmetrical-dimethylarginine,Chemical Compound
881,NOS3,Gene
882,AT-1015,Chemical Compound
883,AT-7519,Chemical Compound
884,AT-9283,Chemical Compound
885,RPS6KA6,Gene
886,STK17A,Gene
887,DMD,Gene
888,ataluren,Chemical Compound
889,ATB-346,Chemical Compound
890,atenolol-(+/-),Chemical Compound
891,LTF,Gene
892,atiprimod,Chemical Compound
893,atizoram,Chemical Compound
894,ITGA5,Gene
895,ATN-161,Chemical Compound
896,ITGAV,Gene
897,ITGB1,Gene
898,ITGB3,Gene
899,atomoxetine,Chemical Compound
900,AHR,Gene
901,atorvastatin,Chemical Compound
902,atosiban,Chemical Compound
903,AVPR1B,Gene
904,AVPR2,Gene
905,OXTR,Gene
906,GRIK1,Gene
907,ATPA,Chemical Compound
908,atrasentan,Chemical Compound
909,atropine,Chemical Compound
910,atropine-oxide,Chemical Compound
911,AT13148,Chemical Compound
912,ROCK2,Gene
913,SGK3,Gene
914,AT13387,Chemical Compound
915,AT7867,Chemical Compound
916,auranofin,Chemical Compound
917,PRDX5,Gene
918,aurora-a-inhibitor-i,Chemical Compound
919,PRKCI,Gene
920,aurothioglucose,Chemical Compound
921,ENPP2,Gene
922,autotaxin-modulator-1,Chemical Compound
923,AV-412,Chemical Compound
924,AV-608,Chemical Compound
925,PSEN1,Gene
926,avagacestat,Chemical Compound
927,avanafil,Chemical Compound
928,avasimibe,Chemical Compound
929,MPL,Gene
930,avatrombopag,Chemical Compound
931,MRGPRX1,Gene
932,AVE-0991,Chemical Compound
933,AVL-292,Chemical Compound
934,YES1,Gene
935,AVN-944,Chemical Compound
936,IMPDH2,Gene
937,CSF1,Gene
938,axitinib,Chemical Compound
939,FLT1,Gene
940,FLT4,Gene
941,PLK4,Gene
942,AZ-10417808,Chemical Compound
943,AZ-10606120,Chemical Compound
944,DHH,Gene
945,AZ-12080282,Chemical Compound
946,BRAF,Gene
947,AZ-628,Chemical Compound
948,RAF1,Gene
949,DNMT1,Gene
950,azacitidine,Chemical Compound
951,DNMT3A,Gene
952,azacyclonol,Chemical Compound
953,azaguanine-8,Chemical Compound
954,azaperone,Chemical Compound
955,azapropazone,Chemical Compound
956,azasetron,Chemical Compound
957,HTR3B,Gene
958,azatadine,Chemical Compound
959,HPRT1,Gene
960,azathioprine,Chemical Compound
961,PPAT,Gene
962,AZD1080,Chemical Compound
963,AZD1208,Chemical Compound
964,PIM2,Gene
965,PIM3,Gene
966,P2RY12,Gene
967,AZD1283,Chemical Compound
968,AZD1446,Chemical Compound
969,JAK1,Gene
970,AZD1480,Chemical Compound
971,PTGDR2,Gene
972,AZD1981,Chemical Compound
973,AZD2014,Chemical Compound
974,AZD2858,Chemical Compound
975,AZD3264,Chemical Compound
976,AZD3463,Chemical Compound
977,AZD3514,Chemical Compound
978,AZD3759,Chemical Compound
979,BACE1,Gene
980,AZD3839,Chemical Compound
981,AZD3965,Chemical Compound
982,AZD3988,Chemical Compound
983,AGXT,Gene
984,AZD4282,Chemical Compound
985,AGXT2,Gene
986,ALAS1,Gene
987,ALAS2,Gene
988,BAAT,Gene
989,GARS,Gene
990,GATM,Gene
991,GCAT,Gene
992,GCSH,Gene
993,GLDC,Gene
994,GLRA2,Gene
995,GLRA3,Gene
996,GLRB,Gene
997,GLYAT,Gene
998,GLYATL1,Gene
999,GLYATL2,Gene
1000,GNMT,Gene
1001,GPRC6A,Gene
1002,PIPOX,Gene
1003,SHMT1,Gene
1004,SHMT2,Gene
1005,SLC32A1,Gene
1006,SLC36A1,Gene
1007,SLC6A5,Gene
1008,FGFR1,Gene
1009,AZD4547,Chemical Compound
1010,FGFR4,Gene
1011,CXCR2,Gene
1012,AZD5069,Chemical Compound
1013,AZD5363,Chemical Compound
1014,AZD5438,Chemical Compound
1015,BIRC2,Gene
1016,AZD5582,Chemical Compound
1017,BIRC3,Gene
1018,XIAP,Gene
1019,AZD6482,Chemical Compound
1020,ATR,Gene
1021,AZD6738,Chemical Compound
1022,AZD6765,Chemical Compound
1023,PDK1,Gene
1024,AZD7545,Chemical Compound
1025,AZD7687,Chemical Compound
1026,CHEK1,Gene
1027,AZD7762,Chemical Compound
1028,CHEK2,Gene
1029,AZD8055,Chemical Compound
1030,AZD8186,Chemical Compound
1031,MAP3K1,Gene
1032,AZD8330,Chemical Compound
1033,AZD8835,Chemical Compound
1034,AZD8931,Chemical Compound
1035,ERBB3,Gene
1036,AZD9272,Chemical Compound
1037,AZD9496,Chemical Compound
1038,ELANE,Gene
1039,AZD9668,Chemical Compound
1040,AKR1D1,Gene
1041,azelaic-acid,Chemical Compound
1042,SRD5A2,Gene
1043,azelastine,Chemical Compound
1044,AGER,Gene
1045,azeliragon,Chemical Compound
1046,azelnidipine,Chemical Compound
1047,AGTR1,Gene
1048,azilsartan,Chemical Compound
1049,AGTR2,Gene
1050,azilsartan-medoxomil,Chemical Compound
1051,azimilide,Chemical Compound
1052,MLNR,Gene
1053,azithromycin,Chemical Compound
1054,SRC,Gene
1055,AZM-475271,Chemical Compound
1056,SLC12A1,Gene
1057,azosemide,Chemical Compound
1058,SLC12A2,Gene
1059,DYRK1B,Gene
1060,AZ191,Chemical Compound
1061,AZ20,Chemical Compound
1062,SMYD2,Gene
1063,AZ505,Chemical Compound
1064,AZ5104,Chemical Compound
1065,AZ960,Chemical Compound
1066,PNKP,Gene
1067,A12B4C3,Chemical Compound
1068,ICAM1,Gene
1069,A205804,Chemical Compound
1070,A61603,Chemical Compound
1071,A66,Chemical Compound
1072,A740003,Chemical Compound
1073,A77636,Chemical Compound
1074,A922500,Chemical Compound
1075,IDE,Gene
1076,bacitracin,Chemical Compound
1077,baclofen,Chemical Compound
1078,KCTD12,Gene
1079,KCTD16,Gene
1080,KCTD8,Gene
1081,BADGE,Chemical Compound
1082,bafetinib,Chemical Compound
1083,BCR,Gene
1084,LYN,Gene
1085,BAG-956,Chemical Compound
1086,baicalein,Chemical Compound
1087,GLO1,Gene
1088,PREP,Gene
1089,SELL,Gene
1090,baicalin,Chemical Compound
1091,bakuchiol,Chemical Compound
1092,balaglitazone,Chemical Compound
1093,CTSK,Gene
1094,balicatib,Chemical Compound
1095,balsalazide,Chemical Compound
1096,bambuterol,Chemical Compound
1097,BAX,Gene
1098,BAM7,Chemical Compound
1099,OPRL1,Gene
1100,BAN-ORL-24,Chemical Compound
1101,banoxantrone,Chemical Compound
1102,barasertib,Chemical Compound
1103,barasertib-HQPA,Chemical Compound
1104,bardoxolone,Chemical Compound
1105,bardoxolone-methyl,Chemical Compound
1106,baricitinib,Chemical Compound
1107,basimglurant,Chemical Compound
1108,ADAM28,Gene
1109,batimastat,Chemical Compound
1110,ADAMTS5,Gene
1111,MMP16,Gene
1112,MMP2,Gene
1113,MMP8,Gene
1114,bavisant,Chemical Compound
1115,BAX-channel-blocker,Chemical Compound
1116,BAY-K-8644-(s)-(-),Chemical Compound
1117,BAY-11-7082,Chemical Compound
1118,BAY-11-7085,Chemical Compound
1119,GUCY1A3,Gene
1120,BAY-41-2272,Chemical Compound
1121,GUCY1B3,Gene
1122,BAY-60-6583,Chemical Compound
1123,PDE2A,Gene
1124,BAY-60-7550,Chemical Compound
1125,SYK,Gene
1126,BAY-61-3606,Chemical Compound
1127,BAY-87-2243,Chemical Compound
1128,bazedoxifene,Chemical Compound
1129,ZNF215,Gene
1130,BAZ2-ICR,Chemical Compound
1131,BC-11,Chemical Compound
1132,BCTC,Chemical Compound
1133,CFD,Gene
1134,BCX-1470,Chemical Compound
1135,BD-1047,Chemical Compound
1136,BD-1063,Chemical Compound
1137,BE-2254,Chemical Compound
1138,beclomethasone,Chemical Compound
1139,GPR97,Gene
1140,beclomethasone-dipropionate,Chemical Compound
1141,begacestat,Chemical Compound
1142,belinostat,Chemical Compound
1143,HDAC10,Gene
1144,HDAC11,Gene
1145,HDAC4,Gene
1146,HDAC5,Gene
1147,HDAC7,Gene
1148,HDAC9,Gene
1149,bemegride,Chemical Compound
1150,bemesetron,Chemical Compound
1151,ACLY,Gene
1152,bempedoic-acid,Chemical Compound
1153,benazepril,Chemical Compound
1154,bendazac,Chemical Compound
1155,bendroflumethiazide,Chemical Compound
1156,SLC12A3,Gene
1157,benfluorex,Chemical Compound
1158,CYP1A1,Gene
1159,benfluralin,Chemical Compound
1160,CYP1A2,Gene
1161,SULT2A1,Gene
1162,UGT1A1,Gene
1163,benfotiamine,Chemical Compound
1164,benidipine,Chemical Compound
1165,benperidol,Chemical Compound
1166,benproperine,Chemical Compound
1167,DDC,Gene
1168,benserazide,Chemical Compound
1169,HPN,Gene
1170,bentiromide,Chemical Compound
1171,benzamil,Chemical Compound
1172,ABCC1,Gene
1173,benzbromarone,Chemical Compound
1174,benzethonium,Chemical Compound
1175,benzocaine,Chemical Compound
1176,DAO,Gene
1177,benzoic-acid,Chemical Compound
1178,HRSP12,Gene
1179,RAB9A,Gene
1180,benzoin,Chemical Compound
1181,benzonatate,Chemical Compound
1182,benzoquinonium-dibromide,Chemical Compound
1183,CCKAR,Gene
1184,benzotript,Chemical Compound
1185,CCKBR,Gene
1186,benzthiazide,Chemical Compound
1187,benztropine-mesylate,Chemical Compound
1188,LIPE,Gene
1189,benzyl-benzoate,Chemical Compound
1190,bepotastine,Chemical Compound
1191,KCNQ4,Gene
1192,bepridil,Chemical Compound
1193,LDLR,Gene
1194,berberine,Chemical Compound
1195,bergenin,Chemical Compound
1196,APP,Gene
1197,beta-amyloid-synthesis-inhibitor,Chemical Compound
1198,beta-CCB,Chemical Compound
1199,beta-elemene,Chemical Compound
1200,beta-funaltrexamine,Chemical Compound
1201,beta-hydroxy-beta-methylbutyrate,Chemical Compound
1202,beta-hydroxybutyrate,Chemical Compound
1203,beta-lapachone,Chemical Compound
1204,betahistine,Chemical Compound
1205,betamethasone,Chemical Compound
1206,betamethasone-acetate,Chemical Compound
1207,betamethasone-dipropionate,Chemical Compound
1208,betamethasone-valerate,Chemical Compound
1209,betaxolol,Chemical Compound
1210,betazole,Chemical Compound
1211,bethanechol,Chemical Compound
1212,GLP1R,Gene
1213,BETP,Chemical Compound
1214,betrixaban,Chemical Compound
1215,GPBAR1,Gene
1216,betulinic-acid,Chemical Compound
1217,bexarotene,Chemical Compound
1218,PPARA,Gene
1219,bezafibrate,Chemical Compound
1220,PPARD,Gene
1221,BGT226,Chemical Compound
1222,ATP2A1,Gene
1223,BHQ,Chemical Compound
1224,RPS6KA1,Gene
1225,BI-D1870,Chemical Compound
1226,RPS6KA2,Gene
1227,BI-2536,Chemical Compound
1228,PLK1,Gene
1229,PLK2,Gene
1230,PLK3,Gene
1231,BI-78D3,Chemical Compound
1232,BI-847325,Chemical Compound
1233,CALCA,Gene
1234,BIBN4096,Chemical Compound
1235,CALCRL,Gene
1236,RAMP1,Gene
1237,TERT,Gene
1238,BIBR-1532,Chemical Compound
1239,BIBU-1361,Chemical Compound
1240,BIBX-1382,Chemical Compound
1241,bicalutamide,Chemical Compound
1242,bicuculline-(+),Chemical Compound
1243,KCNN1,Gene
1244,HSPA1A,Gene
1245,bicyclol,Chemical Compound
1246,HSPB1,Gene
1247,bifemelane,Chemical Compound
1248,MAOB,Gene
1249,BIIB021,Chemical Compound
1250,bilastine,Chemical Compound
1251,bilobalide,Chemical Compound
1252,AKR1C3,Gene
1253,bimatoprost,Chemical Compound
1254,PTGFR,Gene
1255,BIMU-8,Chemical Compound
1256,GRM2,Gene
1257,BINA,Chemical Compound
1258,CCL2,Gene
1259,bindarit,Chemical Compound
1260,CCL7,Gene
1261,CCL8,Gene
1262,binimetinib,Chemical Compound
1263,ITGA4,Gene
1264,BIO-1211,Chemical Compound
1265,BIO-5192,Chemical Compound
1266,ACACA,Gene
1267,biotin,Chemical Compound
1268,HLCS,Gene
1269,MCCC1,Gene
1270,MCCC2,Gene
1271,PC,Gene
1272,PCCA,Gene
1273,PCCB,Gene
1274,SLC5A6,Gene
1275,CTSC,Gene
1276,bipenamol,Chemical Compound
1277,biperiden,Chemical Compound
1278,birinapant,Chemical Compound
1279,BIRT-377,Chemical Compound
1280,PTPN1,Gene
1281,bis(maltolato)oxovanadium(IV),Chemical Compound
1282,bisindolylmaleimide-IX,Chemical Compound
1283,LCK,Gene
1284,PRKCA,Gene
1285,RPS6KB1,Gene
1286,SIRT1,Gene
1287,NOS1,Gene
1288,bismuth-subgallate,Chemical Compound
1289,bisoprolol,Chemical Compound
1290,bisphenol-A,Chemical Compound
1291,bithionol,Chemical Compound
1292,MCL1,Gene
1293,bitopertin,Chemical Compound
1294,bivalirudin,Chemical Compound
1295,BIX-01294,Chemical Compound
1296,MAP2K5,Gene
1297,BIX-02188,Chemical Compound
1298,BIX-02189,Chemical Compound
1299,MAPK7,Gene
1300,MYH14,Gene
1301,blebbistatin-(+/-),Chemical Compound
1302,MYH2,Gene
1303,blonanserin,Chemical Compound
1304,BLU9931,Chemical Compound
1305,BML-190,Chemical Compound
1306,CCR2,Gene
1307,BMS-CCR2-22,Chemical Compound
1308,BMS-182874,Chemical Compound
1309,KCNMA1,Gene
1310,BMS-191011,Chemical Compound
1311,BMS-265246,Chemical Compound
1312,FABP4,Gene
1313,BMS-309403,Chemical Compound
1314,BMS-345541,Chemical Compound
1315,BMS-387032,Chemical Compound
1316,MC1R,Gene
1317,BMS-470539,Chemical Compound
1318,BMS-536924,Chemical Compound
1319,CCNE1,Gene
1320,BMS-566419,Chemical Compound
1321,ITGAL,Gene
1322,BMS-587101,Chemical Compound
1323,ITGB2,Gene
1324,BMS-599626,Chemical Compound
1325,BMS-649,Chemical Compound
1326,BMS-688521,Chemical Compound
1327,BMS-690514,Chemical Compound
1328,BMS-754807,Chemical Compound
1329,AXL,Gene
1330,BMS-777607,Chemical Compound
1331,MERTK,Gene
1332,MST1R,Gene
1333,TYRO3,Gene
1334,BMS-817378,Chemical Compound
1335,SMO,Gene
1336,BMS-833923,Chemical Compound
1337,CDC7,Gene
1338,BMS-863233,Chemical Compound
1339,LPAR1,Gene
1340,BMS-986020,Chemical Compound
1341,BMY-14802,Chemical Compound
1342,BMY-45778,Chemical Compound
1343,BMY-7378,Chemical Compound
1344,BNTX,Chemical Compound
1345,CMA1,Gene
1346,boceprevir,Chemical Compound
1347,CTSA,Gene
1348,CTSF,Gene
1349,CTSL,Gene
1350,CTSS,Gene
1351,PSMA1,Gene
1352,bortezomib,Chemical Compound
1353,PSMA2,Gene
1354,PSMA3,Gene
1355,PSMA4,Gene
1356,PSMA5,Gene
1357,PSMA6,Gene
1358,PSMA7,Gene
1359,PSMA8,Gene
1360,PSMB1,Gene
1361,PSMB10,Gene
1362,PSMB11,Gene
1363,PSMB2,Gene
1364,PSMB3,Gene
1365,PSMB4,Gene
1366,PSMB5,Gene
1367,PSMB6,Gene
1368,PSMB7,Gene
1369,PSMB8,Gene
1370,PSMB9,Gene
1371,PSMD1,Gene
1372,PSMD2,Gene
1373,bosentan,Chemical Compound
1374,bosutinib,Chemical Compound
1375,CAMK1D,Gene
1376,CAMK2G,Gene
1377,FRK,Gene
1378,FYN,Gene
1379,HCK,Gene
1380,MAP3K2,Gene
1381,MAP4K5,Gene
1382,STK10,Gene
1383,STK24,Gene
1384,STK4,Gene
1385,TXK,Gene
1386,BP-554,Chemical Compound
1387,BP-897,Chemical Compound
1388,BQ-123,Chemical Compound
1389,BQ-788,Chemical Compound
1390,RALA,Gene
1391,BQU57,Chemical Compound
1392,RALB,Gene
1393,BRD4770,Chemical Compound
1394,BRD7389,Chemical Compound
1395,BRD9876,Chemical Compound
1396,ARF1,Gene
1397,brefeldin-A,Chemical Compound
1398,CYTH2,Gene
1399,bremelanotide,Chemical Compound
1400,MC2R,Gene
1401,MC3R,Gene
1402,MC4R,Gene
1403,MC5R,Gene
1404,DHODH,Gene
1405,brequinar,Chemical Compound
1406,bretazenil,Chemical Compound
1407,bretylium,Chemical Compound
1408,brexpiprazole,Chemical Compound
1409,briciclib,Chemical Compound
1410,brigatinib,Chemical Compound
1411,brimonidine,Chemical Compound
1412,brinzolamide,Chemical Compound
1413,CA5A,Gene
1414,brivanib,Chemical Compound
1415,brivanib-alaninate,Chemical Compound
1416,BRL-15572,Chemical Compound
1417,LPL,Gene
1418,BRL-26314,Chemical Compound
1419,BRL-37344,Chemical Compound
1420,BRL-44408,Chemical Compound
1421,PDE7A,Gene
1422,BRL-50481,Chemical Compound
1423,PDE7B,Gene
1424,BRL-52537,Chemical Compound
1425,BRL-54443,Chemical Compound
1426,brolitene,Chemical Compound
1427,bromfenac,Chemical Compound
1428,bromocriptine,Chemical Compound
1429,bromopride,Chemical Compound
1430,bromperidol,Chemical Compound
1431,brompheniramine,Chemical Compound
1432,broxaterol,Chemical Compound
1433,brucine,Chemical Compound
1434,BS-181,Chemical Compound
1435,ATP5F1,Gene
1436,BTB06584,Chemical Compound
1437,KIF18A,Gene
1438,BTB1,Chemical Compound
1439,BTS-54505,Chemical Compound
1440,BTS-72664,Chemical Compound
1441,ITGA2,Gene
1442,BTT-3033,Chemical Compound
1443,BU-224,Chemical Compound
1444,bucladesine,Chemical Compound
1445,buclizine,Chemical Compound
1446,budesonide,Chemical Compound
1447,budipine,Chemical Compound
1448,bufexamac,Chemical Compound
1449,buflomedil,Chemical Compound
1450,bumetanide,Chemical Compound
1451,GPR35,Gene
1452,SLC12A4,Gene
1453,SLC12A5,Gene
1454,bunazosin,Chemical Compound
1455,buparlisib,Chemical Compound
1456,buphenine,Chemical Compound
1457,bupicomide,Chemical Compound
1458,bupivacaine,Chemical Compound
1459,bupranolol,Chemical Compound
1460,bupropion,Chemical Compound
1461,buspirone,Chemical Compound
1462,TPP2,Gene
1463,butabindide,Chemical Compound
1464,butaclamol,Chemical Compound
1465,butalbital,Chemical Compound
1466,GRIK2,Gene
1467,butein,Chemical Compound
1468,SQLE,Gene
1469,butenafine,Chemical Compound
1470,GCLM,Gene
1471,buthionine-sulfoximine,Chemical Compound
1472,butylated-hydroxytoluene,Chemical Compound
1473,butylphthalide,Chemical Compound
1474,BVT-2733,Chemical Compound
1475,BVT-948,Chemical Compound
1476,PTPN11,Gene
1477,PTPN2,Gene
1478,BW-A4C,Chemical Compound
1479,BW-B70C,Chemical Compound
1480,BW-180C,Chemical Compound
1481,BW-373U86,Chemical Compound
1482,BW-616U,Chemical Compound
1483,BW-723C86,Chemical Compound
1484,BX-795,Chemical Compound
1485,BX-912,Chemical Compound
1486,BYK-204165,Chemical Compound
1487,CCR4,Gene
1488,C-021,Chemical Compound
1489,C-1,Chemical Compound
1490,cabazitaxel,Chemical Compound
1491,TUBA1B,Gene
1492,TUBA1C,Gene
1493,TUBA3C,Gene
1494,TUBA3D,Gene
1495,TUBA3E,Gene
1496,TUBA4A,Gene
1497,TUBB1,Gene
1498,TUBB2A,Gene
1499,TUBB2B,Gene
1500,TUBB3,Gene
1501,TUBB4A,Gene
1502,TUBB6,Gene
1503,TUBB8,Gene
1504,cabergoline,Chemical Compound
1505,cabozantinib,Chemical Compound
1506,CLCA1,Gene
1507,CaCCinh-A01,Chemical Compound
1508,caffeic-acid,Chemical Compound
1509,MIF,Gene
1510,caffeic-acid-phenethyl-ester,Chemical Compound
1511,caffeine,Chemical Compound
1512,ATM,Gene
1513,ITPR2,Gene
1514,ITPR3,Gene
1515,PDE10A,Gene
1516,PDE11A,Gene
1517,PDE1A,Gene
1518,PDE1B,Gene
1519,PDE1C,Gene
1520,PDE6A,Gene
1521,PDE6B,Gene
1522,PDE6C,Gene
1523,PDE8A,Gene
1524,PDE8B,Gene
1525,PDE9A,Gene
1526,PRKDC,Gene
1527,calcifediol,Chemical Compound
1528,calcipotriol,Chemical Compound
1529,calcitriol,Chemical Compound
1530,CASR,Gene
1531,Calhex-231,Chemical Compound
1532,camicinal,Chemical Compound
1533,CaMKII-IN-1,Chemical Compound
1534,CAMK2A,Gene
1535,CAMK4,Gene
1536,MYLK,Gene
1537,PRSS1,Gene
1538,camostat-mesilate,Chemical Compound
1539,camphor-(1R),Chemical Compound
1540,camptothecin,Chemical Compound
1541,canagliflozin,Chemical Compound
1542,SLC5A2,Gene
1543,candesartan,Chemical Compound
1544,canertinib,Chemical Compound
1545,NR3C2,Gene
1546,canrenone,Chemical Compound
1547,capadenoson,Chemical Compound
1548,TYMS,Gene
1549,capecitabine,Chemical Compound
1550,capsaicin,Chemical Compound
1551,capsazepine,Chemical Compound
1552,TRPV4,Gene
1553,captopril,Chemical Compound
1554,LTA4H,Gene
1555,RRM1,Gene
1556,caracemide,Chemical Compound
1557,caramiphen,Chemical Compound
1558,carazolol,Chemical Compound
1559,carbachol,Chemical Compound
1560,carbamazepine,Chemical Compound
1561,carbendazim,Chemical Compound
1562,GJA1,Gene
1563,carbenoxolone,Chemical Compound
1564,GJA10,Gene
1565,GJA3,Gene
1566,GJA4,Gene
1567,GJA5,Gene
1568,GJA8,Gene
1569,GJA9,Gene
1570,GJB1,Gene
1571,GJB2,Gene
1572,GJB3,Gene
1573,GJB4,Gene
1574,GJB5,Gene
1575,GJB6,Gene
1576,GJB7,Gene
1577,GJC1,Gene
1578,GJC2,Gene
1579,GJC3,Gene
1580,GJD2,Gene
1581,GJD3,Gene
1582,GJD4,Gene
1583,GJE1,Gene
1584,PANX1,Gene
1585,PANX2,Gene
1586,PANX3,Gene
1587,carbetapentane,Chemical Compound
1588,carbetocin,Chemical Compound
1589,carbidopa,Chemical Compound
1590,TPO,Gene
1591,carbimazole,Chemical Compound
1592,carbinoxamine,Chemical Compound
1593,CXCL8,Gene
1594,carboxyamidotriazole,Chemical Compound
1595,carboxylosartan,Chemical Compound
1596,CTNNB1,Gene
1597,cardionogen-1,Chemical Compound
1598,carebastine,Chemical Compound
1599,carfilzomib,Chemical Compound
1600,CPS1,Gene
1601,carglumic-acid,Chemical Compound
1602,NQO2,Gene
1603,caricotamide,Chemical Compound
1604,cariporide,Chemical Compound
1605,cariprazine,Chemical Compound
1606,carmofur,Chemical Compound
1607,carmoterol,Chemical Compound
1608,carmoxirole,Chemical Compound
1609,GSR,Gene
1610,carmustine,Chemical Compound
1611,caroxazone,Chemical Compound
1612,carprofen,Chemical Compound
1613,carteolol,Chemical Compound
1614,carvedilol,Chemical Compound
1615,carzenide,Chemical Compound
1616,CA6,Gene
1617,CA9,Gene
1618,CDC42,Gene
1619,casin,Chemical Compound
1620,GAA,Gene
1621,castanospermine,Chemical Compound
1622,GBA,Gene
1623,CTSB,Gene
1624,cathepsin-inhibitor-1,Chemical Compound
1625,CTSV,Gene
1626,CAY10505,Chemical Compound
1627,CB-03-01,Chemical Compound
1628,VCP,Gene
1629,CB-5083,Chemical Compound
1630,GLS,Gene
1631,CB-839,Chemical Compound
1632,CBiPES,Chemical Compound
1633,CBS-1114,Chemical Compound
1634,CC-115,Chemical Compound
1635,CC-223,Chemical Compound
1636,CC-401,Chemical Compound
1637,RHOC,Gene
1638,CCG-1423,Chemical Compound
1639,SRF,Gene
1640,RGS4,Gene
1641,CCG-50014,Chemical Compound
1642,RGS8,Gene
1643,CCG-63802,Chemical Compound
1644,CCG-63808,Chemical Compound
1645,CCMI,Chemical Compound
1646,CCT-031374,Chemical Compound
1647,CCT018159,Chemical Compound
1648,HSP90AB1,Gene
1649,CCT129202,Chemical Compound
1650,CCT137690,Chemical Compound
1651,CC4,Chemical Compound
1652,CD-1530,Chemical Compound
1653,CD-437,Chemical Compound
1654,CDK1-5-inhibitor,Chemical Compound
1655,CDK9-IN-6,Chemical Compound
1656,CDPPB,Chemical Compound
1657,cebranopadol,Chemical Compound
1658,cediranib,Chemical Compound
1659,cefadroxil,Chemical Compound
1660,SLC22A8,Gene
1661,PON1,Gene
1662,cefazolin,Chemical Compound
1663,MPO,Gene
1664,cefdinir,Chemical Compound
1665,cefradine,Chemical Compound
1666,celecoxib,Chemical Compound
1667,celiprolol,Chemical Compound
1668,CEP-32496,Chemical Compound
1669,CEP-33779,Chemical Compound
1670,CEP-37440,Chemical Compound
1671,ceritinib,Chemical Compound
1672,INSR,Gene
1673,TSSK1B,Gene
1674,FASN,Gene
1675,cerulenin,Chemical Compound
1676,ceruletide,Chemical Compound
1677,cetaben,Chemical Compound
1678,PNLIP,Gene
1679,cetilistat,Chemical Compound
1680,cetirizine,Chemical Compound
1681,cetrorelix,Chemical Compound
1682,LHCGR,Gene
1683,cevimeline,Chemical Compound
1684,cevipabulin,Chemical Compound
1685,RAPGEF3,Gene
1686,CE3F4,Chemical Compound
1687,CFTRinh-172,Chemical Compound
1688,CF102,Chemical Compound
1689,CGH2466,Chemical Compound
1690,CGK-733,Chemical Compound
1691,CGM097,Chemical Compound
1692,CGP-12177,Chemical Compound
1693,CGP-13501,Chemical Compound
1694,CGP-20712A,Chemical Compound
1695,CGP-37157,Chemical Compound
1696,CGP-37849,Chemical Compound
1697,CGP-52411,Chemical Compound
1698,CGP-53353,Chemical Compound
1699,PRKCB,Gene
1700,CGP-54626,Chemical Compound
1701,CGP-55845,Chemical Compound
1702,CGP-57380,Chemical Compound
1703,MKNK1,Gene
1704,MKNK2,Gene
1705,SGK1,Gene
1706,CGP-60474,Chemical Compound
1707,NPY5R,Gene
1708,CGP-71683,Chemical Compound
1709,CGP-74514,Chemical Compound
1710,CGP-7930,Chemical Compound
1711,CGS-15943,Chemical Compound
1712,CGS-20625,Chemical Compound
1713,CGS-21680,Chemical Compound
1714,CGS-9896,Chemical Compound
1715,CH-5183284,Chemical Compound
1716,CHC,Chemical Compound
1717,chenodeoxycholic-acid,Chemical Compound
1718,NR1H4,Gene
1719,CHF5074,Chemical Compound
1720,chicago-sky-blue-6b,Chemical Compound
1721,chidamide,Chemical Compound
1722,CHIR-124,Chemical Compound
1723,CHIR-98014,Chemical Compound
1724,CHIR-99021,Chemical Compound
1725,CD55,Gene
1726,chloramphenicol,Chemical Compound
1727,chlorisondamine-diiodide,Chemical Compound
1728,chlormadinone-acetate,Chemical Compound
1729,chlormezanone,Chemical Compound
1730,SLC37A4,Gene
1731,chlorogenic-acid,Chemical Compound
1732,chloroprocaine,Chemical Compound
1733,CHRNA10,Gene
1734,chloropyramine,Chemical Compound
1735,chloroquine,Chemical Compound
1736,chlorothiazide,Chemical Compound
1737,chlorotrianisene,Chemical Compound
1738,chloroxine,Chemical Compound
1739,chlorproguanil,Chemical Compound
1740,chlorpromazine,Chemical Compound
1741,ORM1,Gene
1742,ORM2,Gene
1743,SMPD1,Gene
1744,TRPC5,Gene
1745,chlorpropamide,Chemical Compound
1746,chlorprothixene,Chemical Compound
1747,chlorpyrifos,Chemical Compound
1748,chlorthalidone,Chemical Compound
1749,chlorzoxazone,Chemical Compound
1750,cholecalciferol,Chemical Compound
1751,RORA,Gene
1752,cholesterol,Chemical Compound
1753,ADH1C,Gene
1754,cholic-acid,Chemical Compound
1755,COX4I1,Gene
1756,COX5A,Gene
1757,COX5B,Gene
1758,COX6A2,Gene
1759,COX6B1,Gene
1760,COX6C,Gene
1761,COX7A1,Gene
1762,COX7B,Gene
1763,COX7C,Gene
1764,COX8A,Gene
1765,FABP6,Gene
1766,FECH,Gene
1767,MT-CO1,Gene
1768,MT-CO2,Gene
1769,MT-CO3,Gene
1770,PLA2G1B,Gene
1771,choline,Chemical Compound
1772,PCYT1A,Gene
1773,PCYT1B,Gene
1774,PHOSPHO1,Gene
1775,PLD2,Gene
1776,CHPG,Chemical Compound
1777,GSG2,Gene
1778,CHR-6494,Chemical Compound
1779,chrysin,Chemical Compound
1780,chrysophanic-acid,Chemical Compound
1781,CH223191,Chemical Compound
1782,CH5132799,Chemical Compound
1783,CH55,Chemical Compound
1784,SLC6A1,Gene
1785,CI-966,Chemical Compound
1786,ACAT1,Gene
1787,CI-976,Chemical Compound
1788,cianidanol,Chemical Compound
1789,ciclesonide,Chemical Compound
1790,ciclopirox,Chemical Compound
1791,cicloprofen,Chemical Compound
1792,CID-16020046,Chemical Compound
1793,PKD1,Gene
1794,CID-2011756,Chemical Compound
1795,CID-2745687,Chemical Compound
1796,CID-5458317,Chemical Compound
1797,ciglitazone,Chemical Compound
1798,DPEP1,Gene
1799,cilastatin,Chemical Compound
1800,cilazapril,Chemical Compound
1801,cilengitide,Chemical Compound
1802,cilnidipine,Chemical Compound
1803,cilomilast,Chemical Compound
1804,cilostamide,Chemical Compound
1805,cilostazol,Chemical Compound
1806,TRPM3,Gene
1807,CIM-0216,Chemical Compound
1808,cimaterol,Chemical Compound
1809,cimetidine,Chemical Compound
1810,SLC29A4,Gene
1811,SLC47A1,Gene
1812,SLC47A2,Gene
1813,cimetropium,Chemical Compound
1814,cinacalcet,Chemical Compound
1815,cinaciguat,Chemical Compound
1816,CYSLTR1,Gene
1817,cinalukast,Chemical Compound
1818,cinanserin,Chemical Compound
1819,cinchocaine,Chemical Compound
1820,CYP2D6,Gene
1821,cinchonine,Chemical Compound
1822,cinnamaldehyde,Chemical Compound
1823,CINPA-1,Chemical Compound
1824,NR1I3,Gene
1825,cipemastat,Chemical Compound
1826,MMP3,Gene
1827,ciprofibrate,Chemical Compound
1828,ciprofloxacin,Chemical Compound
1829,ciproxifan,Chemical Compound
1830,CIQ,Chemical Compound
1831,cirazoline,Chemical Compound
1832,ACO2,Gene
1833,cis-aconitic-acid,Chemical Compound
1834,cis-ACPD,Chemical Compound
1835,GRM3,Gene
1836,GRM6,Gene
1837,GRM8,Gene
1838,"cis-exo-camphanediol-2,3",Chemical Compound
1839,cis-urocanic-acid,Chemical Compound
1840,cisapride,Chemical Compound
1841,cisatracurium,Chemical Compound
1842,cisplatin,Chemical Compound
1843,citalopram,Chemical Compound
1844,CITCO,Chemical Compound
1845,citicoline,Chemical Compound
1846,SLC1A2,Gene
1847,citric-acid,Chemical Compound
1848,ANG,Gene
1849,BHMT,Gene
1850,C8G,Gene
1851,CPB1,Gene
1852,CS,Gene
1853,CTDSP1,Gene
1854,HGS,Gene
1855,HS3ST3A1,Gene
1856,IL4I1,Gene
1857,ITPA,Gene
1858,LSM6,Gene
1859,MDH2,Gene
1860,PLEKHA1,Gene
1861,RNASE1,Gene
1862,RNASE3,Gene
1863,TNFSF13B,Gene
1864,UCK2,Gene
1865,CJ-033466,Chemical Compound
1866,ACTR2,Gene
1867,CK-636,Chemical Compound
1868,ACTR3,Gene
1869,ARPC1B,Gene
1870,ARPC2,Gene
1871,ARPC3,Gene
1872,ARPC4,Gene
1873,ARPC5,Gene
1874,CKD-712,Chemical Compound
1875,STAT1,Gene
1876,CSNK1G2,Gene
1877,CKI-7,Chemical Compound
1878,CL-218872,Chemical Compound
1879,ADA,Gene
1880,cladribine,Chemical Compound
1881,POLA1,Gene
1882,POLE,Gene
1883,POLE2,Gene
1884,POLE3,Gene
1885,POLE4,Gene
1886,RRM2,Gene
1887,RRM2B,Gene
1888,clarithromycin,Chemical Compound
1889,clebopride,Chemical Compound
1890,clemastine,Chemical Compound
1891,clenbuterol,Chemical Compound
1892,cleviprex,Chemical Compound
1893,clidinium,Chemical Compound
1894,clinofibrate,Chemical Compound
1895,clioquinol,Chemical Compound
1896,clobenpropit,Chemical Compound
1897,clobetasol-propionate,Chemical Compound
1898,clobetasone-butyrate,Chemical Compound
1899,clocortolone-pivalate,Chemical Compound
1900,clodronic-acid,Chemical Compound
1901,SLC25A5,Gene
1902,SLC25A6,Gene
1903,clofarabine,Chemical Compound
1904,POLD1,Gene
1905,clofedanol,Chemical Compound
1906,clofibrate,Chemical Compound
1907,clofibric-acid,Chemical Compound
1908,clofilium,Chemical Compound
1909,clomethiazole,Chemical Compound
1910,clomifene,Chemical Compound
1911,GSTP1,Gene
1912,clomipramine,Chemical Compound
1913,clonidine,Chemical Compound
1914,clonixin,Chemical Compound
1915,clopidogrel,Chemical Compound
1916,cloprostenol-(+/-),Chemical Compound
1917,TBXA2R,Gene
1918,cloranolol,Chemical Compound
1919,clorgiline,Chemical Compound
1920,clorotepine,Chemical Compound
1921,clorprenaline,Chemical Compound
1922,clotrimazole,Chemical Compound
1923,NR1I2,Gene
1924,cloxyquin,Chemical Compound
1925,clozapine,Chemical Compound
1926,CL316243,Chemical Compound
1927,UCP1,Gene
1928,UCP2,Gene
1929,UCP3,Gene
1930,CMPD-1,Chemical Compound
1931,CNQX,Chemical Compound
1932,CNX-2006,Chemical Compound
1933,CNX-774,Chemical Compound
1934,CO-101244,Chemical Compound
1935,CO-102862,Chemical Compound
1936,cobicistat,Chemical Compound
1937,CYP3A43,Gene
1938,CYP3A5,Gene
1939,CYP3A7,Gene
1940,cobimetinib,Chemical Compound
1941,ACAT2,Gene
1942,coenzyme-A,Chemical Compound
1943,CRAT,Gene
1944,DBI,Gene
1945,KAT2A,Gene
1946,KAT2B,Gene
1947,KAT5,Gene
1948,AASS,Gene
1949,coenzyme-I,Chemical Compound
1950,ACADS,Gene
1951,ADH1A,Gene
1952,ADH1B,Gene
1953,ADH4,Gene
1954,ADH5,Gene
1955,ADH7,Gene
1956,AKR1C2,Gene
1957,AKR1C4,Gene
1958,ALDH1A1,Gene
1959,ALDH1A2,Gene
1960,ALDH1A3,Gene
1961,ALDH1B1,Gene
1962,ALDH3A1,Gene
1963,ALDH3A2,Gene
1964,ALDH3B1,Gene
1965,ALDH3B2,Gene
1966,ALDH4A1,Gene
1967,ALDH5A1,Gene
1968,ALDH6A1,Gene
1969,ALDH7A1,Gene
1970,ALDH9A1,Gene
1971,AMT,Gene
1972,BDH1,Gene
1973,BLVRA,Gene
1974,BLVRB,Gene
1975,CDO1,Gene
1976,CYB5R3,Gene
1977,CYP4A11,Gene
1978,DHCR7,Gene
1979,DLAT,Gene
1980,DLD,Gene
1981,EHHADH,Gene
1982,GAPDH,Gene
1983,GAPDHS,Gene
1984,GLUD1,Gene
1985,GLUD2,Gene
1986,GPD1,Gene
1987,H6PD,Gene
1988,HADH,Gene
1989,HADHA,Gene
1990,HIBADH,Gene
1991,HMOX1,Gene
1992,HMOX2,Gene
1993,HPGD,Gene
1994,HSD17B10,Gene
1995,HSD17B2,Gene
1996,HSD17B3,Gene
1997,HSD17B4,Gene
1998,HSD17B7,Gene
1999,HSD17B8,Gene
2000,HSD3B1,Gene
2001,HSD3B2,Gene
2002,IDH3A,Gene
2003,IDH3B,Gene
2004,IDH3G,Gene
2005,LDHA,Gene
2006,LDHAL6A,Gene
2007,LDHAL6B,Gene
2008,LDHB,Gene
2009,LDHC,Gene
2010,MDH1,Gene
2011,ME1,Gene
2012,ME2,Gene
2013,ME3,Gene
2014,MSMO1,Gene
2015,MT-ND1,Gene
2016,MT-ND2,Gene
2017,MT-ND3,Gene
2018,MT-ND4,Gene
2019,MT-ND4L,Gene
2020,MT-ND5,Gene
2021,MT-ND6,Gene
2022,MTHFD1,Gene
2023,MTHFD2,Gene
2024,NDUFA1,Gene
2025,NDUFA10,Gene
2026,NDUFA11,Gene
2027,NDUFA12,Gene
2028,NDUFA13,Gene
2029,NDUFA2,Gene
2030,NDUFA3,Gene
2031,NDUFA4,Gene
2032,NDUFA4L2,Gene
2033,NDUFA5,Gene
2034,NDUFA6,Gene
2035,NDUFA7,Gene
2036,NDUFA8,Gene
2037,NDUFA9,Gene
2038,NDUFAB1,Gene
2039,NDUFB1,Gene
2040,NDUFB10,Gene
2041,NDUFB2,Gene
2042,NDUFB3,Gene
2043,NDUFB4,Gene
2044,NDUFB5,Gene
2045,NDUFB6,Gene
2046,NDUFB7,Gene
2047,NDUFB8,Gene
2048,NDUFB9,Gene
2049,NDUFC1,Gene
2050,NDUFC2,Gene
2051,NDUFS1,Gene
2052,NDUFS2,Gene
2053,NDUFS3,Gene
2054,NDUFS4,Gene
2055,NDUFS5,Gene
2056,NDUFS6,Gene
2057,NDUFS7,Gene
2058,NDUFS8,Gene
2059,NDUFV1,Gene
2060,NDUFV2,Gene
2061,NDUFV3,Gene
2062,NNT,Gene
2063,NSDHL,Gene
2064,OGDH,Gene
2065,PDHA1,Gene
2066,PDHA2,Gene
2067,PDHB,Gene
2068,PHGDH,Gene
2069,PYCR1,Gene
2070,PYCR2,Gene
2071,QDPR,Gene
2072,RDH5,Gene
2073,SORD,Gene
2074,TSTA3,Gene
2075,UGDH,Gene
2076,colchicine,Chemical Compound
2077,ADCY2,Gene
2078,colforsin,Chemical Compound
2079,ADCY5,Gene
2080,compound-w,Chemical Compound
2081,compound-401,Chemical Compound
2082,conivaptan,Chemical Compound
2083,copanlisib,Chemical Compound
2084,SLC15A3,Gene
2085,copper-histidine,Chemical Compound
2086,SLC15A4,Gene
2087,SLC38A5,Gene
2088,COR-170,Chemical Compound
2089,corosolic-acid,Chemical Compound
2090,corticosterone,Chemical Compound
2091,NCOA1,Gene
2092,cortisone,Chemical Compound
2093,cortisone-acetate,Chemical Compound
2094,cortodoxone,Chemical Compound
2095,MAP3K8,Gene
2096,cot-inhibitor-1,Chemical Compound
2097,cot-inhibitor-2,Chemical Compound
2098,coumarin,Chemical Compound
2099,CYP2A6,Gene
2100,CP-316819,Chemical Compound
2101,CP-339818,Chemical Compound
2102,CP-376395,Chemical Compound
2103,CP-471474,Chemical Compound
2104,CP-532623,Chemical Compound
2105,CP-640186,Chemical Compound
2106,CP-673451,Chemical Compound
2107,CP-724714,Chemical Compound
2108,CP-775146,Chemical Compound
2109,CP-91149,Chemical Compound
2110,CP-93129,Chemical Compound
2111,CP-94253,Chemical Compound
2112,"CP-945,598",Chemical Compound
2113,CP-99994,Chemical Compound
2114,CPA1,Gene
2115,CPA-inhibitor,Chemical Compound
2116,CPA2,Gene
2117,GRM1,Gene
2118,CPCCOEt,Chemical Compound
2119,CPI-0610,Chemical Compound
2120,CPI-1189,Chemical Compound
2121,EZH2,Gene
2122,CPI-169,Chemical Compound
2123,CPI-203,Chemical Compound
2124,CPI-360,Chemical Compound
2125,CPI-613,Chemical Compound
2126,CPP,Chemical Compound
2127,CPSI-1306-(+/-),Chemical Compound
2128,CKB,Gene
2129,creatine,Chemical Compound
2130,CKM,Gene
2131,CKMT1A,Gene
2132,CKMT2,Gene
2133,GAMT,Gene
2134,SLC6A8,Gene
2135,crenolanib,Chemical Compound
2136,cridanimod,Chemical Compound
2137,crisaborole,Chemical Compound
2138,crizotinib,Chemical Compound
2139,NUDT1,Gene
2140,crizotinib-(S),Chemical Compound
2141,KCNJ8,Gene
2142,cromakalim,Chemical Compound
2143,cromoglicic-acid,Chemical Compound
2144,S100P,Gene
2145,cryptotanshinone,Chemical Compound
2146,CCNA2,Gene
2147,CR8-(R),Chemical Compound
2148,CS-110266,Chemical Compound
2149,CS-917,Chemical Compound
2150,CT-7758,Chemical Compound
2151,CTEP,Chemical Compound
2152,CTS-1027,Chemical Compound
2153,CTS21166,Chemical Compound
2154,TLR3,Gene
2155,CU-CPT-4a,Chemical Compound
2156,TLR1,Gene
2157,CU-T12-9,Chemical Compound
2158,TLR2,Gene
2159,CUDC-101,Chemical Compound
2160,CUDC-427,Chemical Compound
2161,CUDC-907,Chemical Compound
2162,PIK3R1,Gene
2163,CUR-61414,Chemical Compound
2164,IHH,Gene
2165,curcumin,Chemical Compound
2166,DNMT3B,Gene
2167,EP300,Gene
2168,curcumol,Chemical Compound
2169,cutamesine,Chemical Compound
2170,CV-1808,Chemical Compound
2171,CVT-10216,Chemical Compound
2172,CW-008,Chemical Compound
2173,CSNK2A1,Gene
2174,CX-4945,Chemical Compound
2175,CSNK2A2,Gene
2176,DAPK3,Gene
2177,HIPK3,Gene
2178,cyamemazine,Chemical Compound
2179,MUT,Gene
2180,cyanocobalamin,Chemical Compound
2181,cyanopindolol,Chemical Compound
2182,CNGA3,Gene
2183,cyclic-AMP,Chemical Compound
2184,cyclizine,Chemical Compound
2185,SULT1E1,Gene
2186,cyclobenzaprine,Chemical Compound
2187,cycloheximide,Chemical Compound
2188,cyclophosphamide,Chemical Compound
2189,CYP2C18,Gene
2190,CYP2C8,Gene
2191,CYP2C9,Gene
2192,cyclopiazonic-acid,Chemical Compound
2193,cycloserine-(D),Chemical Compound
2194,cyclosporin-A,Chemical Compound
2195,CAMLG,Gene
2196,FPR1,Gene
2197,PPIA,Gene
2198,PPIF,Gene
2199,PPP3CA,Gene
2200,PPP3R2,Gene
2201,SLC10A1,Gene
2202,cyclothiazide,Chemical Compound
2203,ABCG2,Gene
2204,cyclovalone,Chemical Compound
2205,CYC116,Chemical Compound
2206,S1PR4,Gene
2207,CYM-50260,Chemical Compound
2208,CYM-50358,Chemical Compound
2209,NPBWR1,Gene
2210,CYM-50769,Chemical Compound
2211,S1PR1,Gene
2212,CYM-5442,Chemical Compound
2213,S1PR2,Gene
2214,CYM-5520,Chemical Compound
2215,S1PR3,Gene
2216,CYM-5541,Chemical Compound
2217,cyproheptadine,Chemical Compound
2218,cyproterone-acetate,Chemical Compound
2219,NPY2R,Gene
2220,cysteamine,Chemical Compound
2221,SST,Gene
2222,CYT-997,Chemical Compound
2223,cytarabine,Chemical Compound
2224,POLB,Gene
2225,cytisine,Chemical Compound
2226,CHRNA6,Gene
2227,CHRNB4,Gene
2228,ACTB,Gene
2229,cytochalasin-B,Chemical Compound
2230,cyt387,Chemical Compound
2231,CY208-243,Chemical Compound
2232,LRRK2,Gene
2233,CZC-54252,Chemical Compound
2234,CZC24832,Chemical Compound
2235,ABAT,Gene
2236,C11-Acetate,Chemical Compound
2237,CELA1,Gene
2238,FFAR2,Gene
2239,FFAR3,Gene
2240,SOD1,Gene
2241,TXN,Gene
2242,TLR4,Gene
2243,C34,Chemical Compound
2244,C646,Chemical Compound
2245,D-(+)-maltose,Chemical Compound
2246,CCBL1,Gene
2247,D-phenylalanine,Chemical Compound
2248,CRH,Gene
2249,D-serine,Chemical Compound
2250,SERPINB3,Gene
2251,CSNK1A1,Gene
2252,D-4476,Chemical Compound
2253,CSNK1D,Gene
2254,TGFB1,Gene
2255,D-64131,Chemical Compound
2256,TSPO,Gene
2257,DAA-1106,Chemical Compound
2258,dabigatran,Chemical Compound
2259,dabigatran-etexilate,Chemical Compound
2260,dabrafenib,Chemical Compound
2261,LIMK1,Gene
2262,NEK11,Gene
2263,SIK1,Gene
2264,PGD,Gene
2265,dacarbazine,Chemical Compound
2266,POLA2,Gene
2267,dacinostat,Chemical Compound
2268,dacomitinib,Chemical Compound
2269,POLR2A,Gene
2270,dactinomycin,Chemical Compound
2271,ESRRA,Gene
2272,daidzein,Chemical Compound
2273,ESRRB,Gene
2274,daidzin,Chemical Compound
2275,dalargin,Chemical Compound
2276,dalbavancin,Chemical Compound
2277,dalcetrapib,Chemical Compound
2278,dalfampridine,Chemical Compound
2279,KCNA10,Gene
2280,KCNA4,Gene
2281,KCNA6,Gene
2282,KCNB1,Gene
2283,KCNB2,Gene
2284,KCNC1,Gene
2285,KCNC2,Gene
2286,KCNC3,Gene
2287,KCNC4,Gene
2288,KCND1,Gene
2289,KCNF1,Gene
2290,KCNG1,Gene
2291,KCNG2,Gene
2292,KCNG3,Gene
2293,KCNG4,Gene
2294,KCNH3,Gene
2295,KCNH4,Gene
2296,KCNH5,Gene
2297,KCNH6,Gene
2298,KCNH7,Gene
2299,KCNH8,Gene
2300,KCNJ13,Gene
2301,KCNJ5,Gene
2302,KCNQ1,Gene
2303,KCNQ5,Gene
2304,KCNS1,Gene
2305,KCNS2,Gene
2306,KCNS3,Gene
2307,KCNV1,Gene
2308,KCNV2,Gene
2309,daltroban,Chemical Compound
2310,KDM2A,Gene
2311,daminozide,Chemical Compound
2312,KDM7A,Gene
2313,PHF8,Gene
2314,danazol,Chemical Compound
2315,GNRHR2,Gene
2316,danirixin,Chemical Compound
2317,dantrolene,Chemical Compound
2318,danusertib,Chemical Compound
2319,SLK,Gene
2320,dapagliflozin,Chemical Compound
2321,dapiprazole,Chemical Compound
2322,dapivirine,Chemical Compound
2323,dapoxetine,Chemical Compound
2324,EGLN1,Gene
2325,daprodustat,Chemical Compound
2326,dapsone,Chemical Compound
2327,PLA2G7,Gene
2328,darapladib,Chemical Compound
2329,darglitazone,Chemical Compound
2330,darifenacin,Chemical Compound
2331,darolutamide,Chemical Compound
2332,darunavir,Chemical Compound
2333,darusentan,Chemical Compound
2334,dasatinib,Chemical Compound
2335,BLK,Gene
2336,EPHA2,Gene
2337,FGR,Gene
2338,SRMS,Gene
2339,STAT5B,Gene
2340,DAU-5884,Chemical Compound
2341,daunorubicin,Chemical Compound
2342,TBXAS1,Gene
2343,dazmegrel,Chemical Compound
2344,dazoxiben,Chemical Compound
2345,DBeQ,Chemical Compound
2346,DBPR108,Chemical Compound
2347,DC-260126,Chemical Compound
2348,DCC-2618,Chemical Compound
2349,KCNN2,Gene
2350,DCEBIO,Chemical Compound
2351,KCNN3,Gene
2352,DCPIB,Chemical Compound
2353,DDR1,Gene
2354,DDR1-IN-1,Chemical Compound
2355,DDR2,Gene
2356,debrisoquin,Chemical Compound
2357,decamethonium,Chemical Compound
2358,decernotinib,Chemical Compound
2359,decitabine,Chemical Compound
2360,PTK2,Gene
2361,defactinib,Chemical Compound
2362,deferasirox,Chemical Compound
2363,UGT1A6,Gene
2364,deferiprone,Chemical Compound
2365,deflazacort,Chemical Compound
2366,deforolimus,Chemical Compound
2367,degarelix,Chemical Compound
2368,dehydrocorydaline,Chemical Compound
2369,dehydroepiandrosterone,Chemical Compound
2370,G6PD,Gene
2371,SULT2B1,Gene
2372,dehydroepiandrosterone-sulfate,Chemical Compound
2373,delanzomib,Chemical Compound
2374,delapril,Chemical Compound
2375,delavirdine,Chemical Compound
2376,delivert,Chemical Compound
2377,delphinidin,Chemical Compound
2378,delta-tocotrienol,Chemical Compound
2379,KRAS,Gene
2380,deltarasin,Chemical Compound
2381,demecarium,Chemical Compound
2382,deoxycholic-acid,Chemical Compound
2383,deoxycorticosterone-acetate,Chemical Compound
2384,deoxyepinephrine,Chemical Compound
2385,deptropine,Chemical Compound
2386,dequalinium,Chemical Compound
2387,deracoxib,Chemical Compound
2388,deserpidine,Chemical Compound
2389,SLC18A2,Gene
2390,desipramine,Chemical Compound
2391,deslanoside,Chemical Compound
2392,ATP1A2,Gene
2393,ATP1A3,Gene
2394,ATP1A4,Gene
2395,ATP1B1,Gene
2396,ATP1B2,Gene
2397,ATP1B3,Gene
2398,FXYD2,Gene
2399,desloratadine,Chemical Compound
2400,desmethylclozapine,Chemical Compound
2401,desmopressin-acetate,Chemical Compound
2402,desogestrel,Chemical Compound
2403,desonide,Chemical Compound
2404,desoximetasone,Chemical Compound
2405,desoxycorticosterone-pivalate,Chemical Compound
2406,desoxycortone,Chemical Compound
2407,desoxypeganine,Chemical Compound
2408,desvenlafaxine,Chemical Compound
2409,detomidine,Chemical Compound
2410,ANXA1,Gene
2411,dexamethasone,Chemical Compound
2412,NR0B1,Gene
2413,dexfosfoserine,Chemical Compound
2414,GRM4,Gene
2415,REG1A,Gene
2416,RHO,Gene
2417,SMAD2,Gene
2418,TAOK2,Gene
2419,ATP4A,Gene
2420,dexlansoprazole,Chemical Compound
2421,dexloxiglumide,Chemical Compound
2422,dexmedetomidine,Chemical Compound
2423,dexniguldipine,Chemical Compound
2424,dexrazoxane,Chemical Compound
2425,dextromethorphan,Chemical Compound
2426,CYBA,Gene
2427,CYBB,Gene
2428,NCF1,Gene
2429,NCF2,Gene
2430,NCF4,Gene
2431,PGRMC1,Gene
2432,RAC1,Gene
2433,RAC2,Gene
2434,DFB,Chemical Compound
2435,DG-172,Chemical Compound
2436,DH-97,Chemical Compound
2437,diacerein,Chemical Compound
2438,diadenosine-tetraphosphate,Chemical Compound
2439,diarylpropionitrile,Chemical Compound
2440,diazoxide,Chemical Compound
2441,dibutyl-phthalate,Chemical Compound
2442,diclofenac,Chemical Compound
2443,PLA2G2A,Gene
2444,diclofenamide,Chemical Compound
2445,diclofensine,Chemical Compound
2446,CRYZ,Gene
2447,dicoumarol,Chemical Compound
2448,NQO1,Gene
2449,dicycloverine,Chemical Compound
2450,didanosine,Chemical Compound
2451,didox,Chemical Compound
2452,dienestrol,Chemical Compound
2453,dienogest,Chemical Compound
2454,diethylcarbamazine,Chemical Compound
2455,diethylstilbestrol,Chemical Compound
2456,diflorasone-diacetate,Chemical Compound
2457,diflunisal,Chemical Compound
2458,difluprednate,Chemical Compound
2459,digitoxigenin,Chemical Compound
2460,digitoxin,Chemical Compound
2461,digoxin,Chemical Compound
2462,dihomo-gamma-linolenic-acid,Chemical Compound
2463,dihydrexidine,Chemical Compound
2464,dihydroergocristine,Chemical Compound
2465,dihydroergotamine,Chemical Compound
2466,dihydrotachysterol,Chemical Compound
2467,dihydroxyphenylglycine,Chemical Compound
2468,SLC29A1,Gene
2469,dilazep,Chemical Compound
2470,diltiazem,Chemical Compound
2471,CACNG1,Gene
2472,dimaprit,Chemical Compound
2473,dimemorfan,Chemical Compound
2474,dimenhydrinate,Chemical Compound
2475,dimercaptosuccinic-acid,Chemical Compound
2476,dimethindene-(S)-(+),Chemical Compound
2477,KEAP1,Gene
2478,dimethyl-fumarate,Chemical Compound
2479,dimetindene,Chemical Compound
2480,diminazene-aceturate,Chemical Compound
2481,dimpylate,Chemical Compound
2482,dinaciclib,Chemical Compound
2483,dinoprost,Chemical Compound
2484,dinoprostone,Chemical Compound
2485,dioscin,Chemical Compound
2486,diosmetin,Chemical Compound
2487,diosmin,Chemical Compound
2488,diphemanil,Chemical Compound
2489,diphenhydramine,Chemical Compound
2490,diphenidol,Chemical Compound
2491,diphenyleneiodonium,Chemical Compound
2492,diphenylpyraline,Chemical Compound
2493,dipraglurant,Chemical Compound
2494,DIPT,Chemical Compound
2495,dipyridamole,Chemical Compound
2496,PDE6D,Gene
2497,PDE6G,Gene
2498,PDE6H,Gene
2499,HBB,Gene
2500,disodium-sebacate,Chemical Compound
2501,disopyramide,Chemical Compound
2502,disulfiram,Chemical Compound
2503,DBH,Gene
2504,ditiocarb-sodium-trihydrate,Chemical Compound
2505,ditolylguanidine,Chemical Compound
2506,dizocilpine-(+),Chemical Compound
2507,DMAB-anabaseine,Chemical Compound
2508,DMeOB,Chemical Compound
2509,DMH1,Chemical Compound
2510,DMH4,Chemical Compound
2511,DMP-777,Chemical Compound
2512,DNQX,Chemical Compound
2513,dobutamine,Chemical Compound
2514,docebenone,Chemical Compound
2515,docetaxel,Chemical Compound
2516,MAP2,Gene
2517,MAP4,Gene
2518,MAPT,Gene
2519,doconexent,Chemical Compound
2520,TLR7,Gene
2521,docosanol,Chemical Compound
2522,dodecyl-sulfate,Chemical Compound
2523,dofequidar,Chemical Compound
2524,dofetilide,Chemical Compound
2525,KCNJ12,Gene
2526,dolasetron,Chemical Compound
2527,dolastatin-10,Chemical Compound
2528,dolutegravir,Chemical Compound
2529,POU2F2,Gene
2530,domperidone,Chemical Compound
2531,donepezil,Chemical Compound
2532,donitriptan,Chemical Compound
2533,dopamine,Chemical Compound
2534,doramapimod,Chemical Compound
2535,doripenem,Chemical Compound
2536,dorsomorphin,Chemical Compound
2537,BMPR1A,Gene
2538,BMPR1B,Gene
2539,dorzolamide,Chemical Compound
2540,dosulepin,Chemical Compound
2541,dovitinib,Chemical Compound
2542,doxazosin,Chemical Compound
2543,doxepin,Chemical Compound
2544,doxercalciferol,Chemical Compound
2545,doxifluridine,Chemical Compound
2546,doxofylline,Chemical Compound
2547,doxorubicin,Chemical Compound
2548,doxycycline,Chemical Compound
2549,doxylamine,Chemical Compound
2550,DPCPX,Chemical Compound
2551,DPI-201106,Chemical Compound
2552,DPO-1,Chemical Compound
2553,DPPE,Chemical Compound
2554,DQP-1105,Chemical Compound
2555,DR-2313,Chemical Compound
2556,PARP3,Gene
2557,DR-4485,Chemical Compound
2558,DRF053-(R),Chemical Compound
2559,droloxifene,Chemical Compound
2560,dromostanolone-propionate,Chemical Compound
2561,dronedarone,Chemical Compound
2562,CACNB1,Gene
2563,CACNB2,Gene
2564,CACNB3,Gene
2565,CACNB4,Gene
2566,droperidol,Chemical Compound
2567,drospirenone,Chemical Compound
2568,droxicam,Chemical Compound
2569,droxidopa,Chemical Compound
2570,PAH,Gene
2571,droxinostat,Chemical Compound
2572,DSR-6434,Chemical Compound
2573,ITGA2B,Gene
2574,DU-728,Chemical Compound
2575,duloxetine,Chemical Compound
2576,DUP-697,Chemical Compound
2577,SRD5A1,Gene
2578,dutasteride,Chemical Compound
2579,SRD5A3,Gene
2580,duvelisib,Chemical Compound
2581,dyclonine,Chemical Compound
2582,dydrogesterone,Chemical Compound
2583,DNM1,Gene
2584,dynasore,Chemical Compound
2585,DNM1L,Gene
2586,DNM2,Gene
2587,dynole-34-2,Chemical Compound
2588,dyphylline,Chemical Compound
2589,DY131,Chemical Compound
2590,APH1A,Gene
2591,E-2012,Chemical Compound
2592,APH1B,Gene
2593,PSENEN,Gene
2594,E-4031,Chemical Compound
2595,E-64,Chemical Compound
2596,ANO1,Gene
2597,eact,Chemical Compound
2598,EB-47,Chemical Compound
2599,ebastine,Chemical Compound
2600,EBPC,Chemical Compound
2601,ebrotidine,Chemical Compound
2602,ALB,Gene
2603,ebselen,Chemical Compound
2604,EC-144,Chemical Compound
2605,EC-23,Chemical Compound
2606,NOXO1,Gene
2607,ecabet,Chemical Compound
2608,NPY1R,Gene
2609,econazole,Chemical Compound
2610,TRPV5,Gene
2611,edaglitazone,Chemical Compound
2612,edaravone,Chemical Compound
2613,edoxaban,Chemical Compound
2614,edrophonium,Chemical Compound
2615,EED,Gene
2616,EED226,Chemical Compound
2617,HBA1,Gene
2618,efaproxiral,Chemical Compound
2619,efaroxan,Chemical Compound
2620,efatutazone,Chemical Compound
2621,efavirenz,Chemical Compound
2622,CYP51A1,Gene
2623,efinaconazole,Chemical Compound
2624,ARG2,Gene
2625,eflornithine,Chemical Compound
2626,ODC1,Gene
2627,EGF816,Chemical Compound
2628,eglumetad,Chemical Compound
2629,NRP1,Gene
2630,EG00229,Chemical Compound
2631,EHop-016,Chemical Compound
2632,RAC3,Gene
2633,EIPA,Chemical Compound
2634,EIT-hydrobromide,Chemical Compound
2635,EI1,Chemical Compound
2636,elacridar,Chemical Compound
2637,XPO1,Gene
2638,elactocin,Chemical Compound
2639,DCK,Gene
2640,elacytarabine,Chemical Compound
2641,elafibranor,Chemical Compound
2642,elagolix,Chemical Compound
2643,eldecalcitol,Chemical Compound
2644,elesclomol,Chemical Compound
2645,eletriptan,Chemical Compound
2646,UGCG,Gene
2647,eliglustat,Chemical Compound
2648,elinogrel,Chemical Compound
2649,eliprodil,Chemical Compound
2650,ellagic-acid,Chemical Compound
2651,CA5B,Gene
2652,BDKRB1,Gene
2653,ELN-441958,Chemical Compound
2654,eltanolone,Chemical Compound
2655,eltoprazine,Chemical Compound
2656,eltrombopag,Chemical Compound
2657,eluxadoline,Chemical Compound
2658,embelin,Chemical Compound
2659,EMD-1214063,Chemical Compound
2660,EMD-386088,Chemical Compound
2661,TNNC1,Gene
2662,EMD-53998,Chemical Compound
2663,EMD-66684,Chemical Compound
2664,emedastine,Chemical Compound
2665,RPS2,Gene
2666,emetine,Chemical Compound
2667,emodin,Chemical Compound
2668,empagliflozin,Chemical Compound
2669,CASP1,Gene
2670,emricasan,Chemical Compound
2671,CASP7,Gene
2672,enalapril,Chemical Compound
2673,enalaprilat,Chemical Compound
2674,enasidenib,Chemical Compound
2675,enciprazine,Chemical Compound
2676,encorafenib,Chemical Compound
2677,TNKS,Gene
2678,endo-IWR-1,Chemical Compound
2679,TNKS2,Gene
2680,endoxifen,Chemical Compound
2681,enflurane,Chemical Compound
2682,enilconazole,Chemical Compound
2683,CYP2J2,Gene
2684,AOX1,Gene
2685,eniluracil,Chemical Compound
2686,DPYD,Gene
2687,ENMD-2076,Chemical Compound
2688,CMPK1,Gene
2689,enocitabine,Chemical Compound
2690,enoxacin,Chemical Compound
2691,enoximone,Chemical Compound
2692,enoxolone,Chemical Compound
2693,enprofylline,Chemical Compound
2694,COMT,Gene
2695,entacapone,Chemical Compound
2696,entinostat,Chemical Compound
2697,entrectinib,Chemical Compound
2698,NTRK3,Gene
2699,ROS1,Gene
2700,enzalutamide,Chemical Compound
2701,enzastaurin,Chemical Compound
2702,PRKCG,Gene
2703,ERO1A,Gene
2704,EN460,Chemical Compound
2705,EO-1428,Chemical Compound
2706,IDO1,Gene
2707,epacadostat,Chemical Compound
2708,epalrestat,Chemical Compound
2709,eperisone,Chemical Compound
2710,ephedrine,Chemical Compound
2711,ephedrine-(racemic),Chemical Compound
2712,ATF1,Gene
2713,ATF2,Gene
2714,ATF3,Gene
2715,ATF4,Gene
2716,ATF5,Gene
2717,ATF6,Gene
2718,ATF7,Gene
2719,FOS,Gene
2720,IL2,Gene
2721,JDP2,Gene
2722,NFATC1,Gene
2723,epiandrosterone,Chemical Compound
2724,epicatechin-gallate-(-),Chemical Compound
2725,epigallocatechin-gallate-(-),Chemical Compound
2726,MMP14,Gene
2727,epinastine,Chemical Compound
2728,epinephrine,Chemical Compound
2729,epirizole,Chemical Compound
2730,CHD1,Gene
2731,epirubicin,Chemical Compound
2732,epitiostanol,Chemical Compound
2733,eplerenone,Chemical Compound
2734,CYP7A1,Gene
2735,epomediol,Chemical Compound
2736,epoprostenol,Chemical Compound
2737,PTGIS,Gene
2738,epothilone-B,Chemical Compound
2739,epothilone-D,Chemical Compound
2740,TAAR1,Gene
2741,EPPTB,Chemical Compound
2742,eprobemide,Chemical Compound
2743,SAA1,Gene
2744,eprodisate,Chemical Compound
2745,eprosartan,Chemical Compound
2746,eptifibatide,Chemical Compound
2747,DOT1L,Gene
2748,EPZ-5676,Chemical Compound
2749,EPZ004777,Chemical Compound
2750,EPZ005687,Chemical Compound
2751,EPZ011989,Chemical Compound
2752,PRMT5,Gene
2753,EPZ015666,Chemical Compound
2754,PRMT6,Gene
2755,EPZ020411,Chemical Compound
2756,equilin,Chemical Compound
2757,equol,Chemical Compound
2758,ER-27319,Chemical Compound
2759,ER-50891,Chemical Compound
2760,VDAC2,Gene
2761,erastin,Chemical Compound
2762,erbstatin-analog,Chemical Compound
2763,ercalcitriol,Chemical Compound
2764,erdafitinib,Chemical Compound
2765,ergocalciferol,Chemical Compound
2766,ergonovine,Chemical Compound
2767,ergotamine,Chemical Compound
2768,ERK5-IN-1,Chemical Compound
2769,erlotinib,Chemical Compound
2770,erteberel,Chemical Compound
2771,ertugliflozin,Chemical Compound
2772,erythromycin,Chemical Compound
2773,erythromycin-estolate,Chemical Compound
2774,erythromycin-ethylsuccinate,Chemical Compound
2775,escitalopram,Chemical Compound
2776,eseroline-(-),Chemical Compound
2777,ESI-09,Chemical Compound
2778,RAPGEF4,Gene
2779,eslicarbazepine-acetate,Chemical Compound
2780,esmolol,Chemical Compound
2781,esomeprazole,Chemical Compound
2782,estetrol,Chemical Compound
2783,estradiol,Chemical Compound
2784,GPER1,Gene
2785,estradiol-acetate,Chemical Compound
2786,estradiol-benzoate,Chemical Compound
2787,estradiol-cypionate,Chemical Compound
2788,estradiol-valerate,Chemical Compound
2789,estramustine,Chemical Compound
2790,MAP1A,Gene
2791,estramustine-phosphate,Chemical Compound
2792,estriol,Chemical Compound
2793,estrone,Chemical Compound
2794,estropipate,Chemical Compound
2795,etacrynic-acid,Chemical Compound
2796,etazolate,Chemical Compound
2797,PORCN,Gene
2798,ETC-159,Chemical Compound
2799,F12,Gene
2800,ethanolamine-oleate,Chemical Compound
2801,ethinyl-estradiol,Chemical Compound
2802,ethisterone,Chemical Compound
2803,ethosuximide,Chemical Compound
2804,ethotoin,Chemical Compound
2805,ethoxzolamide,Chemical Compound
2806,CA13,Gene
2807,ethynodiol-diacetate,Chemical Compound
2808,eticlopride,Chemical Compound
2809,etidronic-acid,Chemical Compound
2810,etifoxine,Chemical Compound
2811,etilefrine,Chemical Compound
2812,etilevodopa,Chemical Compound
2813,etizolam,Chemical Compound
2814,etodolac,Chemical Compound
2815,etofenamate,Chemical Compound
2816,etofibrate,Chemical Compound
2817,etofylline,Chemical Compound
2818,etofylline-clofibrate,Chemical Compound
2819,etomidate,Chemical Compound
2820,CPT1A,Gene
2821,etomoxir,Chemical Compound
2822,etonogestrel,Chemical Compound
2823,etoposide,Chemical Compound
2824,etoposide-phosphate,Chemical Compound
2825,etoricoxib,Chemical Compound
2826,ETP-45658,Chemical Compound
2827,etravirine,Chemical Compound
2828,etretinate,Chemical Compound
2829,eucalyptol,Chemical Compound
2830,eugenol,Chemical Compound
2831,EUK-134,Chemical Compound
2832,SOD2,Gene
2833,evacetrapib,Chemical Compound
2834,evans-blue,Chemical Compound
2835,evatanepag,Chemical Compound
2836,everolimus,Chemical Compound
2837,evodiamine,Chemical Compound
2838,EVP-6124,Chemical Compound
2839,EW-7197,Chemical Compound
2840,TGFBR1,Gene
2841,EX-527,Chemical Compound
2842,GHRHR,Gene
2843,examorelin,Chemical Compound
2844,exatecan-mesylate,Chemical Compound
2845,exemestane,Chemical Compound
2846,exenatide,Chemical Compound
2847,CDH2,Gene
2848,exherin,Chemical Compound
2849,exifone,Chemical Compound
2850,exisulind,Chemical Compound
2851,exo-IWR-1,Chemical Compound
2852,ezatiostat,Chemical Compound
2853,ANPEP,Gene
2854,ezetimibe,Chemical Compound
2855,NPC1L1,Gene
2856,SOAT1,Gene
2857,UTRN,Gene
2858,ezutromid,Chemical Compound
2859,E7449,Chemical Compound
2860,F-11440,Chemical Compound
2861,fadrozole,Chemical Compound
2862,GLB1,Gene
2863,fagomine,Chemical Compound
2864,falecalcitriol,Chemical Compound
2865,famotidine,Chemical Compound
2866,fananserin,Chemical Compound
2867,HRAS,Gene
2868,farnesyl-thiosalicylic-acid-amide,Chemical Compound
2869,fasudil,Chemical Compound
2870,febuxostat,Chemical Compound
2871,fedratinib,Chemical Compound
2872,TYK2,Gene
2873,felbamate,Chemical Compound
2874,felbinac,Chemical Compound
2875,felbinac-ethyl,Chemical Compound
2876,felodipine,Chemical Compound
2877,fenbendazole,Chemical Compound
2878,fenbufen,Chemical Compound
2879,fenclonine-(+/-),Chemical Compound
2880,TPH1,Gene
2881,TPH2,Gene
2882,fendiline,Chemical Compound
2883,fenigam,Chemical Compound
2884,fenobam,Chemical Compound
2885,MMP25,Gene
2886,fenofibrate,Chemical Compound
2887,CLCN1,Gene
2888,fenofibric-acid,Chemical Compound
2889,fenoldopam,Chemical Compound
2890,fenoprofen,Chemical Compound
2891,SLC5A8,Gene
2892,fenoterol,Chemical Compound
2893,fenoxaprop-p-ethyl,Chemical Compound
2894,fenretinide,Chemical Compound
2895,fentiazac,Chemical Compound
2896,FERb-033,Chemical Compound
2897,ferulic-acid,Chemical Compound
2898,fesoterodine,Chemical Compound
2899,fexaramine,Chemical Compound
2900,fexofenadine,Chemical Compound
2901,FG-2216,Chemical Compound
2902,EGLN2,Gene
2903,FG-4592,Chemical Compound
2904,EGLN3,Gene
2905,FGIN-1-27,Chemical Compound
2906,FGIN-1-43,Chemical Compound
2907,FH-535,Chemical Compound
2908,fidarestat,Chemical Compound
2909,filanesib,Chemical Compound
2910,filgotinib,Chemical Compound
2911,fimasartan,Chemical Compound
2912,finasteride,Chemical Compound
2913,fingolimod,Chemical Compound
2914,S1PR5,Gene
2915,FIPI,Chemical Compound
2916,firategrast,Chemical Compound
2917,firocoxib,Chemical Compound
2918,fisetin,Chemical Compound
2919,FIT,Chemical Compound
2920,FK-33-824,Chemical Compound
2921,FK-3311,Chemical Compound
2922,NAMPT,Gene
2923,FK-866,Chemical Compound
2924,FK-888,Chemical Compound
2925,ACAD8,Gene
2926,flavin-adenine-dinucleotide,Chemical Compound
2927,ACADM,Gene
2928,ACOX1,Gene
2929,AIFM1,Gene
2930,CYB5R1,Gene
2931,ERO1LB,Gene
2932,FDXR,Gene
2933,GCDH,Gene
2934,GFER,Gene
2935,IVD,Gene
2936,POR,Gene
2937,flavoxate,Chemical Compound
2938,flecainide,Chemical Compound
2939,fleroxacin,Chemical Compound
2940,flibanserin,Chemical Compound
2941,flindokalner,Chemical Compound
2942,floctafenine,Chemical Compound
2943,flopropione,Chemical Compound
2944,floxuridine,Chemical Compound
2945,flubendazole,Chemical Compound
2946,fluconazole,Chemical Compound
2947,flucytosine,Chemical Compound
2948,fludarabine,Chemical Compound
2949,fludarabine-phosphate,Chemical Compound
2950,fludrocortisone-acetate,Chemical Compound
2951,fludroxycortide,Chemical Compound
2952,flufenamic-acid,Chemical Compound
2953,TRPM5,Gene
2954,flumatinib,Chemical Compound
2955,flumazenil,Chemical Compound
2956,flumethasone,Chemical Compound
2957,flumethasone-pivalate,Chemical Compound
2958,flunarizine,Chemical Compound
2959,flunisolide,Chemical Compound
2960,fluocinolone-acetonide,Chemical Compound
2961,fluocinonide,Chemical Compound
2962,fluorescein,Chemical Compound
2963,fluorometholone,Chemical Compound
2964,fluorometholone-acetate,Chemical Compound
2965,fluoxetine,Chemical Compound
2966,flupentixol,Chemical Compound
2967,fluphenazine,Chemical Compound
2968,fluphenazine-decanoate,Chemical Compound
2969,flupirtine,Chemical Compound
2970,fluprazine,Chemical Compound
2971,flurbiprofen-(S)-(+),Chemical Compound
2972,flurizan,Chemical Compound
2973,IKBKG,Gene
2974,PSEN2,Gene
2975,fluspirilene,Chemical Compound
2976,flutamide,Chemical Compound
2977,fluticasone-propionate,Chemical Compound
2978,PLA2G4A,Gene
2979,fluvastatin,Chemical Compound
2980,fluvoxamine,Chemical Compound
2981,FOLR2,Gene
2982,folic-acid,Chemical Compound
2983,FOLR3,Gene
2984,SLC19A1,Gene
2985,fomepizole,Chemical Compound
2986,AKR1A1,Gene
2987,CAT,Gene
2988,fondaparinux,Chemical Compound
2989,SERPINC1,Gene
2990,foretinib,Chemical Compound
2991,formestane,Chemical Compound
2992,formononetin,Chemical Compound
2993,formoterol,Chemical Compound
2994,forodesine,Chemical Compound
2995,foropafant,Chemical Compound
2996,forskolin,Chemical Compound
2997,GNAS,Gene
2998,fosaprepitant-dimeglumine,Chemical Compound
2999,CDH5,Gene
3000,fosbretabulin,Chemical Compound
3001,fosfestrol,Chemical Compound
3002,fosfosal,Chemical Compound
3003,fosinopril,Chemical Compound
3004,fosinoprilat,Chemical Compound
3005,fosphenytoin,Chemical Compound
3006,fostamatinib,Chemical Compound
3007,WNT5A,Gene
3008,foxy-5,Chemical Compound
3009,FPL-64176,Chemical Compound
3010,FPS-ZM1,Chemical Compound
3011,FR-139317,Chemical Compound
3012,FR-180204,Chemical Compound
3013,PAK1,Gene
3014,FRAX486,Chemical Compound
3015,PAK2,Gene
3016,PAK3,Gene
3017,PAK4,Gene
3018,freselestat,Chemical Compound
3019,frovatriptan,Chemical Compound
3020,fruquintinib,Chemical Compound
3021,ftorafur,Chemical Compound
3022,fulvestrant,Chemical Compound
3023,fumagillin,Chemical Compound
3024,CERS1,Gene
3025,fumonisin-B1,Chemical Compound
3026,furamidine,Chemical Compound
3027,furegrelate,Chemical Compound
3028,furosemide,Chemical Compound
3029,F351,Chemical Compound
3030,g-caryophyllene,Chemical Compound
3031,G-1,Chemical Compound
3032,G-15,Chemical Compound
3033,gabapentin,Chemical Compound
3034,CACNA1A,Gene
3035,CACNA1E,Gene
3036,CACNA2D3,Gene
3037,CACNA2D4,Gene
3038,CACNG2,Gene
3039,CACNG3,Gene
3040,CACNG4,Gene
3041,CACNG5,Gene
3042,CACNG6,Gene
3043,CACNG7,Gene
3044,CACNG8,Gene
3045,gabapentin-enacarbil,Chemical Compound
3046,gabazine,Chemical Compound
3047,gabexate,Chemical Compound
3048,TPSAB1,Gene
3049,gaboxadol,Chemical Compound
3050,GABRR1,Gene
3051,GABRR2,Gene
3052,GABRR3,Gene
3053,gadopentetic-acid,Chemical Compound
3054,galantamine,Chemical Compound
3055,CHRNA5,Gene
3056,CHRNA9,Gene
3057,CHRNB1,Gene
3058,CHRNB3,Gene
3059,CHRND,Gene
3060,CHRNE,Gene
3061,CHRNG,Gene
3062,galeterone,Chemical Compound
3063,gallamine-triethiodide,Chemical Compound
3064,gallic-acid,Chemical Compound
3065,ATP2A2,Gene
3066,gallopamil,Chemical Compound
3067,gambogic-acid,Chemical Compound
3068,gamma-aminobutyric-acid,Chemical Compound
3069,gamma-linolenic-acid,Chemical Compound
3070,ganaxolone,Chemical Compound
3071,ganetespib,Chemical Compound
3072,GLI1,Gene
3073,GANT-58,Chemical Compound
3074,GANT-61,Chemical Compound
3075,GLI2,Gene
3076,garenoxacin,Chemical Compound
3077,gavestinel,Chemical Compound
3078,GBR-12935,Chemical Compound
3079,GBR-13069,Chemical Compound
3080,GDC-0068,Chemical Compound
3081,PRKG1,Gene
3082,GDC-0152,Chemical Compound
3083,BIRC7,Gene
3084,GDC-0349,Chemical Compound
3085,GDC-0810,Chemical Compound
3086,GDC-0834,Chemical Compound
3087,GDC-0879,Chemical Compound
3088,GDC-0941,Chemical Compound
3089,GDC-0980,Chemical Compound
3090,MAP3K9,Gene
3091,GDC-0994,Chemical Compound
3092,gedunin,Chemical Compound
3093,gefitinib,Chemical Compound
3094,geldanamycin,Chemical Compound
3095,gemcitabine,Chemical Compound
3096,gemcitabine-elaidate,Chemical Compound
3097,gemfibrozil,Chemical Compound
3098,SLCO2B1,Gene
3099,geniposide,Chemical Compound
3100,genistein,Chemical Compound
3101,NCOA2,Gene
3102,PTK2B,Gene
3103,HSPA8,Gene
3104,gentamycin,Chemical Compound
3105,gentiopicrin,Chemical Compound
3106,genz-123346,Chemical Compound
3107,genz-644282,Chemical Compound
3108,gestrinone,Chemical Compound
3109,GF109203X,Chemical Compound
3110,GGT1,Gene
3111,GGsTop,Chemical Compound
3112,CDKN1A,Gene
3113,GGTI-298,Chemical Compound
3114,gilteritinib,Chemical Compound
3115,gimeracil,Chemical Compound
3116,ginkgolide-A,Chemical Compound
3117,ginkgolide-B,Chemical Compound
3118,ginsenoside-C-K,Chemical Compound
3119,ginsenoside-RE3,Chemical Compound
3120,givinostat,Chemical Compound
3121,GCK,Gene
3122,GKA-50,Chemical Compound
3123,NOX1,Gene
3124,GKT137831,Chemical Compound
3125,TGM2,Gene
3126,GK921,Chemical Compound
3127,glafenine,Chemical Compound
3128,glasdegib,Chemical Compound
3129,glimepiride,Chemical Compound
3130,glipizide,Chemical Compound
3131,gliquidone,Chemical Compound
3132,GLPG0492,Chemical Compound
3133,GLPG0492-R-enantiomer,Chemical Compound
3134,LCT,Gene
3135,gluconolactone,Chemical Compound
3136,glucosamine,Chemical Compound
3137,ESD,Gene
3138,glutathione,Chemical Compound
3139,GLRX,Gene
3140,GLRX2,Gene
3141,GPX1,Gene
3142,GPX2,Gene
3143,GPX3,Gene
3144,GPX4,Gene
3145,GPX5,Gene
3146,GPX6,Gene
3147,GPX7,Gene
3148,GPX8,Gene
3149,GSTA1,Gene
3150,GSTA2,Gene
3151,GSTA3,Gene
3152,GSTA4,Gene
3153,GSTA5,Gene
3154,GSTK1,Gene
3155,GSTM1,Gene
3156,GSTM2,Gene
3157,GSTM3,Gene
3158,GSTM4,Gene
3159,GSTM5,Gene
3160,GSTO1,Gene
3161,GSTO2,Gene
3162,GSTT1,Gene
3163,GSTZ1,Gene
3164,HAGH,Gene
3165,HPGDS,Gene
3166,LTC4S,Gene
3167,MGST1,Gene
3168,MGST2,Gene
3169,MGST3,Gene
3170,TXNDC12,Gene
3171,glyburide,Chemical Compound
3172,glycitein,Chemical Compound
3173,glycopyrrolate,Chemical Compound
3174,GM-1485,Chemical Compound
3175,GMX1778,Chemical Compound
3176,GNF-2,Chemical Compound
3177,GNF-5,Chemical Compound
3178,GNF-5837,Chemical Compound
3179,GNF-7,Chemical Compound
3180,GNTI,Chemical Compound
3181,go-6983,Chemical Compound
3182,GBF1,Gene
3183,golgicide-A,Chemical Compound
3184,golvatinib,Chemical Compound
3185,gonadorelin,Chemical Compound
3186,goserelin-acetate,Chemical Compound
3187,gossypol,Chemical Compound
3188,GPBAR-A,Chemical Compound
3189,GPI-1046,Chemical Compound
3190,GPP-78,Chemical Compound
3191,GPR120-modulator-1,Chemical Compound
3192,GP1a,Chemical Compound
3193,GP2a,Chemical Compound
3194,GR-103691,Chemical Compound
3195,GR-113808,Chemical Compound
3196,GR-127935,Chemical Compound
3197,GR-144053,Chemical Compound
3198,TAC1,Gene
3199,GR-159897,Chemical Compound
3200,GR-235,Chemical Compound
3201,GR-79236,Chemical Compound
3202,granisetron,Chemical Compound
3203,grapiprant,Chemical Compound
3204,KRT12,Gene
3205,griseofulvin,Chemical Compound
3206,GR125487,Chemical Compound
3207,GR46611,Chemical Compound
3208,BTRC,Gene
3209,GS-143,Chemical Compound
3210,GS-39783,Chemical Compound
3211,GS-6201,Chemical Compound
3212,GS-9620,Chemical Compound
3213,GS-9973,Chemical Compound
3214,KDM6B,Gene
3215,GSK-J1,Chemical Compound
3216,KDM6A,Gene
3217,GSK-J4,Chemical Compound
3218,KDM1A,Gene
3219,GSK-LSD-1,Chemical Compound
3220,GSK-3-inhibitor-IX,Chemical Compound
3221,GSK0660,Chemical Compound
3222,GSK1059615,Chemical Compound
3223,GSK1070916,Chemical Compound
3224,GRPR,Gene
3225,GSK1292263,Chemical Compound
3226,GSK1562590,Chemical Compound
3227,GSK163090,Chemical Compound
3228,GSK1838705A,Chemical Compound
3229,GSK1904529A,Chemical Compound
3230,GSK2110183,Chemical Compound
3231,GSK2126458,Chemical Compound
3232,GSK2190915,Chemical Compound
3233,GSK2193874,Chemical Compound
3234,GSK2194069,Chemical Compound
3235,EPHX2,Gene
3236,GSK2256294A,Chemical Compound
3237,SLC10A2,Gene
3238,GSK2330672,Chemical Compound
3239,GSK2334470,Chemical Compound
3240,GSK256066,Chemical Compound
3241,GSK2578215A,Chemical Compound
3242,EIF2AK3,Gene
3243,GSK2606414,Chemical Compound
3244,MYLK2,Gene
3245,GSK2636771,Chemical Compound
3246,GSK269962,Chemical Compound
3247,BAZ2A,Gene
3248,GSK2801,Chemical Compound
3249,BAZ2B,Gene
3250,GSK2816126,Chemical Compound
3251,PPM1D,Gene
3252,GSK2830371,Chemical Compound
3253,GSK2837808A,Chemical Compound
3254,GSK2879552,Chemical Compound
3255,GSK37647,Chemical Compound
3256,GSK3787,Chemical Compound
3257,GSK429286A,Chemical Compound
3258,GSK461364,Chemical Compound
3259,GSK503,Chemical Compound
3260,GSK650394,Chemical Compound
3261,SGK2,Gene
3262,GSK690693,Chemical Compound
3263,PAK6,Gene
3264,PAK7,Gene
3265,PRKX,Gene
3266,GSK9027,Chemical Compound
3267,CENPE,Gene
3268,GSK923295,Chemical Compound
3269,GTP-14564,Chemical Compound
3270,GTS21,Chemical Compound
3271,guaiacol,Chemical Compound
3272,guanaben-acetate,Chemical Compound
3273,guanethidine,Chemical Compound
3274,guanfacine,Chemical Compound
3275,guanidine,Chemical Compound
3276,DLG4,Gene
3277,guanidinoethyldisulfide-bicarbonate,Chemical Compound
3278,guanidinopropionic-acid,Chemical Compound
3279,guanosine,Chemical Compound
3280,OXER1,Gene
3281,Gue-1654,Chemical Compound
3282,guvacine,Chemical Compound
3283,SLC6A11,Gene
3284,SLC6A12,Gene
3285,SLC6A13,Gene
3286,GW-0742,Chemical Compound
3287,GW-1100,Chemical Compound
3288,GW-1929,Chemical Compound
3289,GW-2580,Chemical Compound
3290,GW-311616,Chemical Compound
3291,NR1H2,Gene
3292,GW-3965,Chemical Compound
3293,NR1H3,Gene
3294,GW-405833,Chemical Compound
3295,GW-4064,Chemical Compound
3296,GW-438014A,Chemical Compound
3297,GW-441756,Chemical Compound
3298,GW-501516,Chemical Compound
3299,GW-5074,Chemical Compound
3300,GW-542573X,Chemical Compound
3301,GW-583340,Chemical Compound
3302,GW-627368,Chemical Compound
3303,GW-6471,Chemical Compound
3304,GW-7647,Chemical Compound
3305,GW-788388,Chemical Compound
3306,GW-803430,Chemical Compound
3307,MCHR1,Gene
3308,GW-842166,Chemical Compound
3309,GW-843682X,Chemical Compound
3310,GW-9508,Chemical Compound
3311,GW-9662,Chemical Compound
3312,GYKI-52466,Chemical Compound
3313,GZD824,Chemical Compound
3314,G007-LK,Chemical Compound
3315,H-89,Chemical Compound
3316,HA-130,Chemical Compound
3317,HA-966-(R)-(+),Chemical Compound
3318,HA-966-(S)-(-),Chemical Compound
3319,halcinonide,Chemical Compound
3320,halobetasol-propionate,Chemical Compound
3321,halofantrine,Chemical Compound
3322,COL1A1,Gene
3323,halofuginone,Chemical Compound
3324,halopemide,Chemical Compound
3325,haloperidol,Chemical Compound
3326,haloperidol-decanoate,Chemical Compound
3327,halothane,Chemical Compound
3328,KCNK12,Gene
3329,KCNK13,Gene
3330,KCNK15,Gene
3331,harmane,Chemical Compound
3332,HA14-1,Chemical Compound
3333,HC-030031,Chemical Compound
3334,HC-067047,Chemical Compound
3335,NEDD4,Gene
3336,heclin,Chemical Compound
3337,SMURF2,Gene
3338,WWP1,Gene
3339,HEMADO,Chemical Compound
3340,hemomex-s,Chemical Compound
3341,hesperadin,Chemical Compound
3342,hesperetin,Chemical Compound
3343,MTTP,Gene
3344,SOAT2,Gene
3345,hesperidin,Chemical Compound
3346,hexachlorophene,Chemical Compound
3347,SDHD,Gene
3348,hexamethonium,Chemical Compound
3349,hexamethylenebisacetamide,Chemical Compound
3350,hexestrol,Chemical Compound
3351,hexoprenaline,Chemical Compound
3352,hexylcaine,Chemical Compound
3353,hexylene-glycol,Chemical Compound
3354,PGF,Gene
3355,hexylresorcinol,Chemical Compound
3356,higenamine,Chemical Compound
3357,histamine,Chemical Compound
3358,HJC-0350,Chemical Compound
3359,HKI-357,Chemical Compound
3360,HLCL-61,Chemical Compound
3361,HMN-214,Chemical Compound
3362,homatropine,Chemical Compound
3363,homatropine-methylbromide,Chemical Compound
3364,homochlorcyclizine,Chemical Compound
3365,homoharringtonine,Chemical Compound
3366,homoquinolinic-acid,Chemical Compound
3367,honokiol,Chemical Compound
3368,NUAK1,Gene
3369,HTH-01-015,Chemical Compound
3370,HTMT,Chemical Compound
3371,huperzine-A,Chemical Compound
3372,C1QBP,Gene
3373,hyaluronic-acid,Chemical Compound
3374,CD44,Gene
3375,HABP2,Gene
3376,HAPLN1,Gene
3377,HAPLN3,Gene
3378,HAPLN4,Gene
3379,HMMR,Gene
3380,NCAN,Gene
3381,VCAN,Gene
3382,hydrochlorothiazide,Chemical Compound
3383,hydrocortisone,Chemical Compound
3384,hydrocortisone-acetate,Chemical Compound
3385,hydrocortisone-butyrate,Chemical Compound
3386,hydrocortisone-valerate,Chemical Compound
3387,hydroflumethiazide,Chemical Compound
3388,hydroquinone,Chemical Compound
3389,hydroxyamphetamine,Chemical Compound
3390,hydroxychloroquine,Chemical Compound
3391,TLR9,Gene
3392,hydroxyfasudil,Chemical Compound
3393,hydroxyprogesterone,Chemical Compound
3394,hydroxyprogesterone-acetate,Chemical Compound
3395,"hydroxytacrine-maleate-(R,S)",Chemical Compound
3396,hydroxyurea,Chemical Compound
3397,hydroxyzine,Chemical Compound
3398,hymecromone,Chemical Compound
3399,hyoscyamine,Chemical Compound
3400,hyperin,Chemical Compound
3401,hypoestoxide,Chemical Compound
3402,hypoxanthine,Chemical Compound
3403,H2L-5765834,Chemical Compound
3404,LPAR3,Gene
3405,BRD2,Gene
3406,I-BET-762,Chemical Compound
3407,I-BET151,Chemical Compound
3408,BRD9,Gene
3409,I-BRD9,Chemical Compound
3410,CREBBP,Gene
3411,I-CBP-112,Chemical Compound
3412,IB-MECA,Chemical Compound
3413,ibandronate,Chemical Compound
3414,IBC-293,Chemical Compound
3415,IBMX,Chemical Compound
3416,ibotenic-acid,Chemical Compound
3417,ibrolipim,Chemical Compound
3418,ibrutinib,Chemical Compound
3419,BMX,Gene
3420,ibudilast,Chemical Compound
3421,ibuprofen-(S),Chemical Compound
3422,ibuprofen-piconol,Chemical Compound
3423,ibuproxam,Chemical Compound
3424,GHR,Gene
3425,ibutamoren,Chemical Compound
3426,ibutilide,Chemical Compound
3427,ICA-069673,Chemical Compound
3428,ICA-110381,Chemical Compound
3429,ICA-121431,Chemical Compound
3430,icariin,Chemical Compound
3431,icaritin,Chemical Compound
3432,BDKRB2,Gene
3433,icatibant-acetate,Chemical Compound
3434,ICG-001,Chemical Compound
3435,"ICI-118,551",Chemical Compound
3436,ICI-162846,Chemical Compound
3437,ICI-192605,Chemical Compound
3438,ICI-199441,Chemical Compound
3439,"ICI-215,001",Chemical Compound
3440,ICI-89406,Chemical Compound
3441,icilin,Chemical Compound
3442,LTB4R2,Gene
3443,icomucret,Chemical Compound
3444,ACSL3,Gene
3445,icosapent,Chemical Compound
3446,ACSL4,Gene
3447,icotinib,Chemical Compound
3448,iCRT-14,Chemical Compound
3449,TCF4,Gene
3450,IC261,Chemical Compound
3451,CSNK1E,Gene
3452,INS,Gene
3453,ID-1101,Chemical Compound
3454,idalopirdine,Chemical Compound
3455,idarubicin,Chemical Compound
3456,idasanutlin,Chemical Compound
3457,idazoxan,Chemical Compound
3458,idelalisib,Chemical Compound
3459,IDO5L,Chemical Compound
3460,IDRA-21,Chemical Compound
3461,ENOX2,Gene
3462,idronoxil,Chemical Compound
3463,SPHK1,Gene
3464,IEM1460,Chemical Compound
3465,IEM1754,Chemical Compound
3466,ifenprodil,Chemical Compound
3467,ifosfamide,Chemical Compound
3468,igmesine,Chemical Compound
3469,iguratimod,Chemical Compound
3470,IKK-16,Chemical Compound
3471,IKK-2-inhibitor,Chemical Compound
3472,IKK-2-inhibitor-V,Chemical Compound
3473,ACAN,Gene
3474,ilomastat,Chemical Compound
3475,iloperidone,Chemical Compound
3476,iloprost,Chemical Compound
3477,imatinib,Chemical Compound
3478,imetit,Chemical Compound
3479,imidafenacin,Chemical Compound
3480,imidapril,Chemical Compound
3481,imiloxan,Chemical Compound
3482,imipramine,Chemical Compound
3483,imiquimod,Chemical Compound
3484,TLR8,Gene
3485,immepip,Chemical Compound
3486,immethridine,Chemical Compound
3487,impentamine,Chemical Compound
3488,INC-280,Chemical Compound
3489,INCA-6,Chemical Compound
3490,INCB-3284,Chemical Compound
3491,indacaterol,Chemical Compound
3492,indalpine,Chemical Compound
3493,indapamide,Chemical Compound
3494,indatraline,Chemical Compound
3495,indeglitazar,Chemical Compound
3496,indinavir,Chemical Compound
3497,indiplon,Chemical Compound
3498,indirubin,Chemical Compound
3499,indirubin-3-monoxime,Chemical Compound
3500,CDK5R1,Gene
3501,indisulam,Chemical Compound
3502,indobufen,Chemical Compound
3503,indocyanine-green,Chemical Compound
3504,indole-3-carbinol,Chemical Compound
3505,indomethacin,Chemical Compound
3506,PTGR2,Gene
3507,CXCR1,Gene
3508,indoprofen,Chemical Compound
3509,indoramin,Chemical Compound
3510,indoximod,Chemical Compound
3511,ingenol,Chemical Compound
3512,ingenol-mebutate,Chemical Compound
3513,NDC80,Gene
3514,INH1,Chemical Compound
3515,iniparib,Chemical Compound
3516,inosine,Chemical Compound
3517,CDIPT,Gene
3518,inositol,Chemical Compound
3519,INT-767,Chemical Compound
3520,integrin-antagonist-1,Chemical Compound
3521,ITGB6,Gene
3522,iodipamide,Chemical Compound
3523,iodophenpropit,Chemical Compound
3524,IOWH032,Chemical Compound
3525,IOX1,Chemical Compound
3526,KDM3A,Gene
3527,KDM4C,Gene
3528,IOX2,Chemical Compound
3529,KDM5C,Gene
3530,IPA-3,Chemical Compound
3531,ipidacrine,Chemical Compound
3532,ipragliflozin-L-proline,Chemical Compound
3533,ipratropium,Chemical Compound
3534,iproniazid,Chemical Compound
3535,ipsapirone,Chemical Compound
3536,irbesartan,Chemical Compound
3537,irinotecan,Chemical Compound
3538,TOP1MT,Gene
3539,IRL-2500,Chemical Compound
3540,irosustat,Chemical Compound
3541,STS,Gene
3542,irsogladine,Chemical Compound
3543,isamoltane,Chemical Compound
3544,isavuconazole,Chemical Compound
3545,ISO-1,Chemical Compound
3546,HBE1,Gene
3547,isobutyramide,Chemical Compound
3548,HBG1,Gene
3549,isocarboxazid,Chemical Compound
3550,isoconazole,Chemical Compound
3551,isoflupredone-acetate,Chemical Compound
3552,isoflurane,Chemical Compound
3553,isoflurophate,Chemical Compound
3554,isoguvacine,Chemical Compound
3555,isoliquiritigenin,Chemical Compound
3556,isoniazid,Chemical Compound
3557,CYP2E1,Gene
3558,isoprenaline,Chemical Compound
3559,isopropamide-iodide,Chemical Compound
3560,GUCY1A2,Gene
3561,isosorbide-dinitrate,Chemical Compound
3562,GUCY1B2,Gene
3563,NPR1,Gene
3564,isosorbide-mononitrate,Chemical Compound
3565,isotretinoin,Chemical Compound
3566,isoxicam,Chemical Compound
3567,isoxsuprine,Chemical Compound
3568,ispinesib,Chemical Compound
3569,isradipine,Chemical Compound
3570,EIF2A,Gene
3571,ISRIB,Chemical Compound
3572,istaroxime,Chemical Compound
3573,istradefylline,Chemical Compound
3574,NEUROD1,Gene
3575,ISX-9,Chemical Compound
3576,itacitinib,Chemical Compound
3577,TGFBR2,Gene
3578,ITD-1,Chemical Compound
3579,ITE,Chemical Compound
3580,ITI214,Chemical Compound
3581,itopride,Chemical Compound
3582,TRIO,Gene
3583,ITX3,Chemical Compound
3584,IT1t,Chemical Compound
3585,USP14,Gene
3586,IU1,Chemical Compound
3587,HCN1,Gene
3588,ivabradine,Chemical Compound
3589,HCN3,Gene
3590,HCN4,Gene
3591,ivacaftor,Chemical Compound
3592,ivermectin,Chemical Compound
3593,ivosidenib,Chemical Compound
3594,IWP-L6,Chemical Compound
3595,ixabepilone,Chemical Compound
3596,JAK3-inhibitor-V,Chemical Compound
3597,JDTic,Chemical Compound
3598,JHW-007,Chemical Compound
3599,KDM4E,Gene
3600,JIB04,Chemical Compound
3601,JLK-6,Chemical Compound
3602,JNJ-10191584,Chemical Compound
3603,JNJ-10397049,Chemical Compound
3604,JNJ-16259685,Chemical Compound
3605,JNJ-1661010,Chemical Compound
3606,JNJ-17203212,Chemical Compound
3607,JNJ-26481585,Chemical Compound
3608,JNJ-27141491,Chemical Compound
3609,JNJ-37822681,Chemical Compound
3610,JNJ-38877605,Chemical Compound
3611,JNJ-40411813,Chemical Compound
3612,PDK2,Gene
3613,JNJ-42041935,Chemical Compound
3614,JNJ-42165279,Chemical Compound
3615,JNJ-47965567,Chemical Compound
3616,GPR139,Gene
3617,JNJ-63533054,Chemical Compound
3618,JNJ-7706621,Chemical Compound
3619,JNJ-7777120,Chemical Compound
3620,JQ1-(+),Chemical Compound
3621,BRDT,Gene
3622,JTC-801,Chemical Compound
3623,P2RY10,Gene
3624,JTE-013,Chemical Compound
3625,IL10,Gene
3626,JTE-607,Chemical Compound
3627,JTE-907,Chemical Compound
3628,JW-55,Chemical Compound
3629,MGLL,Gene
3630,JW-642,Chemical Compound
3631,APC,Gene
3632,JW-67,Chemical Compound
3633,AXIN1,Gene
3634,JW-74,Chemical Compound
3635,JX-401,Chemical Compound
3636,JZL-184,Chemical Compound
3637,JZL-195,Chemical Compound
3638,K-Ras(G12C)-inhibitor-12,Chemical Compound
3639,K-strophanthidin,Chemical Compound
3640,K-858,Chemical Compound
3641,kaempferol,Chemical Compound
3642,ALOX15B,Gene
3643,UGT3A1,Gene
3644,kainic-acid,Chemical Compound
3645,GRIK3,Gene
3646,GRIK4,Gene
3647,GRIK5,Gene
3648,karenitecin,Chemical Compound
3649,FLNA,Gene
3650,kartogenin,Chemical Compound
3651,KB-R7943,Chemical Compound
3652,TRPC3,Gene
3653,KB-SRC-4,Chemical Compound
3654,MME,Gene
3655,KBG,Chemical Compound
3656,KD-023,Chemical Compound
3657,KD025,Chemical Compound
3658,CCNB1,Gene
3659,kenpaullone,Chemical Compound
3660,ketanserin,Chemical Compound
3661,SLC18A1,Gene
3662,ketoconazole,Chemical Compound
3663,ketoprofen,Chemical Compound
3664,ketorolac,Chemical Compound
3665,ketotifen,Chemical Compound
3666,KF-38789,Chemical Compound
3667,KG-5,Chemical Compound
3668,CLK1,Gene
3669,KH-CB19,Chemical Compound
3670,CLK3,Gene
3671,DYRK1A,Gene
3672,KHK,Gene
3673,KHK-IN-1,Chemical Compound
3674,TACC3,Gene
3675,KHS-101,Chemical Compound
3676,KI-16425,Chemical Compound
3677,KI-20227,Chemical Compound
3678,KI-8751,Chemical Compound
3679,MAN1B1,Gene
3680,kifunensine,Chemical Compound
3681,MAN2A1,Gene
3682,ki16198,Chemical Compound
3683,CRY1,Gene
3684,KL-001,Chemical Compound
3685,CRY2,Gene
3686,KML29,Chemical Compound
3687,KN-62,Chemical Compound
3688,KN-93,Chemical Compound
3689,Ko143,Chemical Compound
3690,KPT-185,Chemical Compound
3691,KPT-276,Chemical Compound
3692,KRCA-0008,Chemical Compound
3693,KRN-633,Chemical Compound
3694,KS-176,Chemical Compound
3695,KU-0063794,Chemical Compound
3696,KU-55933,Chemical Compound
3697,KU-60019,Chemical Compound
3698,CD38,Gene
3699,kuromanin,Chemical Compound
3700,KW-2449,Chemical Compound
3701,KW-3902,Chemical Compound
3702,KX2-391,Chemical Compound
3703,kynurenic-acid,Chemical Compound
3704,DKK1,Gene
3705,KY02111,Chemical Compound
3706,BMP1,Gene
3707,K02288,Chemical Compound
3708,K145,Chemical Compound
3709,AARS,Gene
3710,L-alanine,Chemical Compound
3711,AARS2,Gene
3712,GPT,Gene
3713,GPT2,Gene
3714,KYNU,Gene
3715,NFS1,Gene
3716,PHYKPL,Gene
3717,SLC1A4,Gene
3718,SLC7A8,Gene
3719,L-arginine,Chemical Compound
3720,ASL,Gene
3721,AZIN2,Gene
3722,SLC7A1,Gene
3723,SLC7A3,Gene
3724,SLC7A4,Gene
3725,L-asparagine,Chemical Compound
3726,ASRGL1,Gene
3727,NARS,Gene
3728,NARS2,Gene
3729,SLC1A5,Gene
3730,SLC38A3,Gene
3731,L-aspartic-acid,Chemical Compound
3732,ACY3,Gene
3733,ADSS,Gene
3734,ADSSL1,Gene
3735,ASPA,Gene
3736,ASPH,Gene
3737,CAD,Gene
3738,DARS,Gene
3739,DARS2,Gene
3740,GOT1,Gene
3741,GOT2,Gene
3742,PAICS,Gene
3743,SLC1A1,Gene
3744,SLC25A12,Gene
3745,SLC25A13,Gene
3746,L-citrulline,Chemical Compound
3747,DDAH1,Gene
3748,DDAH2,Gene
3749,OTC,Gene
3750,PADI1,Gene
3751,PADI2,Gene
3752,PADI3,Gene
3753,PADI4,Gene
3754,PADI6,Gene
3755,CARS,Gene
3756,L-cysteine,Chemical Compound
3757,CARS2,Gene
3758,CBS,Gene
3759,CDO-1,Gene
3760,CSAD,Gene
3761,CTH,Gene
3762,GCLC,Gene
3763,MGMT,Gene
3764,SLC19A3,Gene
3765,L-cysteinesulfinic-acid,Chemical Compound
3766,HMGCS2,Gene
3767,PAPOLA,Gene
3768,PRDX2,Gene
3769,CTNS,Gene
3770,L-cystine,Chemical Compound
3771,SLC3A1,Gene
3772,SLC7A9,Gene
3773,AADAT,Gene
3774,L-glutamic-acid,Chemical Compound
3775,ALDH18A1,Gene
3776,BCAT1,Gene
3777,BCAT2,Gene
3778,CCBL2,Gene
3779,DNPEP,Gene
3780,EARS2,Gene
3781,ENPEP,Gene
3782,EPRS,Gene
3783,FOLH1,Gene
3784,FPGS,Gene
3785,FTCD,Gene
3786,GAD1,Gene
3787,GAD2,Gene
3788,GATB,Gene
3789,GLS2,Gene
3790,GLUL,Gene
3791,GMPS,Gene
3792,GRID1,Gene
3793,GRID2,Gene
3794,LGSN,Gene
3795,NADSYN1,Gene
3796,NAGS,Gene
3797,OPLAH,Gene
3798,PFAS,Gene
3799,PGCP,Gene
3800,PSAT1,Gene
3801,SLC1A3,Gene
3802,SLC1A6,Gene
3803,SLC1A7,Gene
3804,SLC25A18,Gene
3805,SLC25A22,Gene
3806,TAT,Gene
3807,L-glutamine,Chemical Compound
3808,L-leucine,Chemical Compound
3809,LARS,Gene
3810,LARS2,Gene
3811,LCMT1,Gene
3812,LCMT2,Gene
3813,L-lysine,Chemical Compound
3814,KARS,Gene
3815,SLC7A2,Gene
3816,L-methionine,Chemical Compound
3817,BHMT2,Gene
3818,MTR,Gene
3819,MTRR,Gene
3820,L-mimosine,Chemical Compound
3821,EIF5A,Gene
3822,L-monomethylarginine,Chemical Compound
3823,L-NAME,Chemical Compound
3824,L-NIL,Chemical Compound
3825,L-proline,Chemical Compound
3826,L3HYPDH,Gene
3827,P3H1,Gene
3828,P3H2,Gene
3829,P3H3,Gene
3830,P4HA1,Gene
3831,P4HA2,Gene
3832,PARS2,Gene
3833,PPIB,Gene
3834,PPIC,Gene
3835,PPIG,Gene
3836,PPIH,Gene
3837,PRODH,Gene
3838,PROSC,Gene
3839,PYCRL,Gene
3840,SLC6A14,Gene
3841,SLC6A7,Gene
3842,L-quisqualic-acid,Chemical Compound
3843,TARS,Gene
3844,L-threonine,Chemical Compound
3845,TARS2,Gene
3846,THNSL1,Gene
3847,L-152804,Chemical Compound
3848,L-161982,Chemical Compound
3849,L-165041,Chemical Compound
3850,GCGR,Gene
3851,L-168049,Chemical Compound
3852,L-365260,Chemical Compound
3853,L-368899,Chemical Compound
3854,"L-655,708",Chemical Compound
3855,PTGES,Gene
3856,L-655240,Chemical Compound
3857,L-689560,Chemical Compound
3858,IMPA1,Gene
3859,L-690330,Chemical Compound
3860,L-693403,Chemical Compound
3861,L-694247,Chemical Compound
3862,L-701252,Chemical Compound
3863,L-701324,Chemical Compound
3864,"L-732,138",Chemical Compound
3865,L-733060,Chemical Compound
3866,L-741742,Chemical Compound
3867,L-745870,Chemical Compound
3868,L-755507,Chemical Compound
3869,L-760735,Chemical Compound
3870,L-778123,Chemical Compound
3871,FNTB,Gene
3872,PGGT1B,Gene
3873,L-798106,Chemical Compound
3874,L-838417,Chemical Compound
3875,labetalol,Chemical Compound
3876,lacidipine,Chemical Compound
3877,lafutidine,Chemical Compound
3878,lamotrigine,Chemical Compound
3879,landiolol,Chemical Compound
3880,lansoprazole,Chemical Compound
3881,ATP4B,Gene
3882,lapatinib,Chemical Compound
3883,CXCL2,Gene
3884,laquinimod,Chemical Compound
3885,laropiprant,Chemical Compound
3886,larotrectinib,Chemical Compound
3887,lasofoxifene,Chemical Compound
3888,latanoprost,Chemical Compound
3889,latrepirdine,Chemical Compound
3890,ACTA1,Gene
3891,latrunculin-B,Chemical Compound
3892,MKL1,Gene
3893,SPIRE2,Gene
3894,GPR84,Gene
3895,lauric-acid,Chemical Compound
3896,HNF4A,Gene
3897,LY96,Gene
3898,lazabemide,Chemical Compound
3899,LCL-161,Chemical Compound
3900,LCQ908,Chemical Compound
3901,LDC1267,Chemical Compound
3902,LDN-209929,Chemical Compound
3903,LDN-212854,Chemical Compound
3904,RIPK2,Gene
3905,LDN-27219,Chemical Compound
3906,LDN193189,Chemical Compound
3907,LE-135,Chemical Compound
3908,leflunomide,Chemical Compound
3909,lemborexant,Chemical Compound
3910,lenalidomide,Chemical Compound
3911,lenvatinib,Chemical Compound
3912,lercanidipine,Chemical Compound
3913,lerisetron,Chemical Compound
3914,SLC22A12,Gene
3915,lesinurad,Chemical Compound
3916,lestaurtinib,Chemical Compound
3917,letrozole,Chemical Compound
3918,leucomethylene-blue,Chemical Compound
3919,leuprolide,Chemical Compound
3920,levalbuterol,Chemical Compound
3921,levallorphan,Chemical Compound
3922,ALPL,Gene
3923,levamisole,Chemical Compound
3924,levcromakalim,Chemical Compound
3925,levetiracetam,Chemical Compound
3926,SV2A,Gene
3927,levo-phencynonate,Chemical Compound
3928,levobetaxolol,Chemical Compound
3929,levobunolol,Chemical Compound
3930,levocabastine,Chemical Compound
3931,NTSR2,Gene
3932,levocarnitine,Chemical Compound
3933,CROT,Gene
3934,levocarnitine-propionate,Chemical Compound
3935,levocetirizine,Chemical Compound
3936,levodopa,Chemical Compound
3937,GPR143,Gene
3938,levofloxacin,Chemical Compound
3939,levomenthol,Chemical Compound
3940,TRPV3,Gene
3941,levomepromazine,Chemical Compound
3942,levomequitazine,Chemical Compound
3943,levonordefrin,Chemical Compound
3944,levonorgestrel,Chemical Compound
3945,levosimendan,Chemical Compound
3946,levosulpiride,Chemical Compound
3947,THRA,Gene
3948,levothyroxine,Chemical Compound
3949,THRB,Gene
3950,LFM-A13,Chemical Compound
3951,LGK-974,Chemical Compound
3952,LH846,Chemical Compound
3953,liarozole,Chemical Compound
3954,CYP26A1,Gene
3955,licarbazepine,Chemical Compound
3956,licochalcone-A,Chemical Compound
3957,licofelone,Chemical Compound
3958,lidocaine,Chemical Compound
3959,lidoflazine,Chemical Compound
3960,ligustilide,Chemical Compound
3961,limaprost-alfadex,Chemical Compound
3962,LIMKi-3,Chemical Compound
3963,GUCY2C,Gene
3964,linaclotide,Chemical Compound
3965,linagliptin,Chemical Compound
3966,lindane,Chemical Compound
3967,linezolid,Chemical Compound
3968,linifanib,Chemical Compound
3969,linoleic-acid,Chemical Compound
3970,linopirdine,Chemical Compound
3971,linsitinib,Chemical Compound
3972,INSRR,Gene
3973,liothyronine,Chemical Compound
3974,liraglutide,Chemical Compound
3975,lisinopril,Chemical Compound
3976,ACE2,Gene
3977,lisuride,Chemical Compound
3978,FAH,Gene
3979,lithium-acetoacetate,Chemical Compound
3980,lithocholic-acid,Chemical Compound
3981,litronesib,Chemical Compound
3982,lixivaptan,Chemical Compound
3983,LM-22A4,Chemical Compound
3984,SMN1,Gene
3985,LMI070,Chemical Compound
3986,LMK-235,Chemical Compound
3987,NGFR,Gene
3988,LM11A-31,Chemical Compound
3989,lobeline,Chemical Compound
3990,lofepramine,Chemical Compound
3991,lomeguatrib,Chemical Compound
3992,lomerizine,Chemical Compound
3993,GART,Gene
3994,lometrexol,Chemical Compound
3995,lomitapide,Chemical Compound
3996,lonafarnib,Chemical Compound
3997,NRAS,Gene
3998,lonidamine,Chemical Compound
3999,loperamide,Chemical Compound
4000,POMC,Gene
4001,loratadine,Chemical Compound
4002,loreclezole,Chemical Compound
4003,lorediplon,Chemical Compound
4004,lorglumide,Chemical Compound
4005,lorlatinib,Chemical Compound
4006,lornoxicam,Chemical Compound
4007,losartan,Chemical Compound
4008,losmapimod,Chemical Compound
4009,loteprednol,Chemical Compound
4010,lovastatin,Chemical Compound
4011,loxapine,Chemical Compound
4012,loxistatin-acid,Chemical Compound
4013,loxoprofen,Chemical Compound
4014,LPAR2,Gene
4015,LPA2-antagonist-1,Chemical Compound
4016,LRRK2-IN-1,Chemical Compound
4017,LSN-2463359,Chemical Compound
4018,LTB4R,Gene
4019,LTB4,Chemical Compound
4020,Lu-AA-47070,Chemical Compound
4021,lubiprostone,Chemical Compound
4022,APEX1,Gene
4023,lucanthone,Chemical Compound
4024,lucitanib,Chemical Compound
4025,LUF-5834,Chemical Compound
4026,lumacaftor,Chemical Compound
4027,lumateperone,Chemical Compound
4028,lumefantrine,Chemical Compound
4029,lumiracoxib,Chemical Compound
4030,lupanine,Chemical Compound
4031,lurasidone,Chemical Compound
4032,luteolin,Chemical Compound
4033,luzindole,Chemical Compound
4034,LXR-623,Chemical Compound
4035,LX1031,Chemical Compound
4036,LIMK2,Gene
4037,LX7101,Chemical Compound
4038,lylamine,Chemical Compound
4039,lypressin,Chemical Compound
4040,LY2090314,Chemical Compound
4041,LY2109761,Chemical Compound
4042,LY2140023,Chemical Compound
4043,LY215490,Chemical Compound
4044,LY2157299,Chemical Compound
4045,LY2183240,Chemical Compound
4046,LY2228820,Chemical Compound
4047,LY223982,Chemical Compound
4048,LY225910,Chemical Compound
4049,LY2365109,Chemical Compound
4050,LY2452473,Chemical Compound
4051,LY255283,Chemical Compound
4052,LY2584702,Chemical Compound
4053,LY2603618,Chemical Compound
4054,LY2606368,Chemical Compound
4055,LY2608204,Chemical Compound
4056,LY266097,Chemical Compound
4057,LY2784544,Chemical Compound
4058,LY2801653,Chemical Compound
4059,LY2811376,Chemical Compound
4060,LY2857785,Chemical Compound
4061,LY2874455,Chemical Compound
4062,LY288513,Chemical Compound
4063,LY2886721,Chemical Compound
4064,LY294002,Chemical Compound
4065,LY2979165,Chemical Compound
4066,LY3000328,Chemical Compound
4067,LY3009120,Chemical Compound
4068,LY3023414,Chemical Compound
4069,LY303511,Chemical Compound
4070,LY310762,Chemical Compound
4071,LY320135,Chemical Compound
4072,LY344864,Chemical Compound
4073,LY364947,Chemical Compound
4074,LY393558,Chemical Compound
4075,LY404187,Chemical Compound
4076,LY456236,Chemical Compound
4077,m-chlorophenylbiguanide,Chemical Compound
4078,M-14157,Chemical Compound
4079,M-25,Chemical Compound
4080,PLCB2,Gene
4081,m-3M3FBS,Chemical Compound
4082,PLCB3,Gene
4083,PLCD1,Gene
4084,PLCG1,Gene
4085,PLCG2,Gene
4086,M-344,Chemical Compound
4087,mabuterol,Chemical Compound
4088,macitentan,Chemical Compound
4089,mafenide,Chemical Compound
4090,magnolol,Chemical Compound
4091,malathion,Chemical Compound
4092,malic-acid,Chemical Compound
4093,manidipine,Chemical Compound
4094,maprotiline,Chemical Compound
4095,maraviroc,Chemical Compound
4096,maribavir,Chemical Compound
4097,marimastat,Chemical Compound
4098,MMP10,Gene
4099,MMP11,Gene
4100,MMP15,Gene
4101,MMP17,Gene
4102,MMP19,Gene
4103,MMP20,Gene
4104,MMP21,Gene
4105,MMP23A,Gene
4106,MMP24,Gene
4107,MMP26,Gene
4108,MMP27,Gene
4109,MMP28,Gene
4110,MMP7,Gene
4111,maropitant,Chemical Compound
4112,masitinib,Chemical Compound
4113,masoprocol,Chemical Compound
4114,matrine,Chemical Compound
4115,mavoglurant,Chemical Compound
4116,maxacalcitol,Chemical Compound
4117,MBX-2982,Chemical Compound
4118,MC-1,Chemical Compound
4119,GADL1,Gene
4120,HDC,Gene
4121,IGSF10,Gene
4122,MOCOS,Gene
4123,OAT,Gene
4124,PDXDC1,Gene
4125,PDXP,Gene
4126,PNPO,Gene
4127,PYGB,Gene
4128,SCLY,Gene
4129,SDS,Gene
4130,SDSL,Gene
4131,SEPSECS,Gene
4132,SGPL1,Gene
4133,SPTLC1,Gene
4134,SPTLC2,Gene
4135,SPTLC3,Gene
4136,SRR,Gene
4137,NLRP3,Gene
4138,MCC950,Chemical Compound
4139,MCOPPB,Chemical Compound
4140,mCPP,Chemical Compound
4141,MC1568,Chemical Compound
4142,AADACL2,Gene
4143,MD-920,Chemical Compound
4144,mdivi-1,Chemical Compound
4145,MDL-11939,Chemical Compound
4146,MDL-29951,Chemical Compound
4147,MDL-72832,Chemical Compound
4148,MDL-73005EF,Chemical Compound
4149,ME-0328,Chemical Compound
4150,mebendazole,Chemical Compound
4151,mebeverine,Chemical Compound
4152,mecamylamine,Chemical Compound
4153,NTSR1,Gene
4154,meclinertant,Chemical Compound
4155,meclizine,Chemical Compound
4156,meclofenamic-acid,Chemical Compound
4157,medetomidine,Chemical Compound
4158,medica-16,Chemical Compound
4159,medroxyprogesterone,Chemical Compound
4160,medroxyprogesterone-acetate,Chemical Compound
4161,medrysone,Chemical Compound
4162,mefenamic-acid,Chemical Compound
4163,megestrol-acetate,Chemical Compound
4164,meglitinide,Chemical Compound
4165,meglutol,Chemical Compound
4166,meisoindigo,Chemical Compound
4167,MEK1-2-inhibitor,Chemical Compound
4168,ASMT,Gene
4169,melatonin,Chemical Compound
4170,CALR,Gene
4171,EPX,Gene
4172,RORB,Gene
4173,BBOX1,Gene
4174,meldonium,Chemical Compound
4175,melevodopa,Chemical Compound
4176,meloxicam,Chemical Compound
4177,melperone,Chemical Compound
4178,melphalan-n-oxide,Chemical Compound
4179,menadione,Chemical Compound
4180,BGLAP,Gene
4181,F7,Gene
4182,F9,Gene
4183,PROC,Gene
4184,PROS1,Gene
4185,PROZ,Gene
4186,VKORC1L1,Gene
4187,menadione-bisulfite,Chemical Compound
4188,mepacrine,Chemical Compound
4189,MALT1,Gene
4190,mepazine,Chemical Compound
4191,mephentermine,Chemical Compound
4192,mephenytoin,Chemical Compound
4193,meprednisone,Chemical Compound
4194,meptazinol,Chemical Compound
4195,mepyramine,Chemical Compound
4196,mequinol,Chemical Compound
4197,merbarone,Chemical Compound
4198,mercaptopurine,Chemical Compound
4199,Merck60,Chemical Compound
4200,merimepodib,Chemical Compound
4201,mesalazine,Chemical Compound
4202,mesoridazine,Chemical Compound
4203,mestinon,Chemical Compound
4204,mestranol,Chemical Compound
4205,mesulergine,Chemical Compound
4206,metacresol,Chemical Compound
4207,metamizole,Chemical Compound
4208,metaproterenol,Chemical Compound
4209,metaraminol,Chemical Compound
4210,metatinib,Chemical Compound
4211,metazosin,Chemical Compound
4212,metenkephalin,Chemical Compound
4213,metergoline,Chemical Compound
4214,metformin,Chemical Compound
4215,methacholine,Chemical Compound
4216,methanesulfonyl-fluoride,Chemical Compound
4217,methantheline,Chemical Compound
4218,methapyrilene,Chemical Compound
4219,metharbital,Chemical Compound
4220,methazolamide,Chemical Compound
4221,methimazole,Chemical Compound
4222,methionine,Chemical Compound
4223,methiopril,Chemical Compound
4224,methocarbamol,Chemical Compound
4225,methotrexate,Chemical Compound
4226,methoxamine,Chemical Compound
4227,methoxsalen,Chemical Compound
4228,CYP2A13,Gene
4229,methoxyamine,Chemical Compound
4230,ATP2C1,Gene
4231,methoxyflurane,Chemical Compound
4232,ATP5D,Gene
4233,methscopolamine,Chemical Compound
4234,methsuximide,Chemical Compound
4235,methyclothiazide,Chemical Compound
4236,FCGR1A,Gene
4237,methyl-aminolevulinate,Chemical Compound
4238,methylatropine-nitrate,Chemical Compound
4239,methyldopa,Chemical Compound
4240,methylene-blue,Chemical Compound
4241,methylergometrine,Chemical Compound
4242,methyllycaconitine,Chemical Compound
4243,methylnaltrexone,Chemical Compound
4244,methylprednisolone,Chemical Compound
4245,methylprednisolone-aceponate,Chemical Compound
4246,methysergide,Chemical Compound
4247,TH,Gene
4248,metirosine,Chemical Compound
4249,metitepine,Chemical Compound
4250,metixene,Chemical Compound
4251,metoclopramide,Chemical Compound
4252,metocurine,Chemical Compound
4253,metolazone,Chemical Compound
4254,metoprolol,Chemical Compound
4255,metoxibutropate,Chemical Compound
4256,metrifonate,Chemical Compound
4257,metronidazole,Chemical Compound
4258,metyrapone,Chemical Compound
4259,mevastatin,Chemical Compound
4260,mexiletine,Chemical Compound
4261,ME0328,Chemical Compound
4262,MF-101,Chemical Compound
4263,MG-132,Chemical Compound
4264,MG-624,Chemical Compound
4265,MGCD-265,Chemical Compound
4266,PI4KB,Gene
4267,MI-14,Chemical Compound
4268,mianserin,Chemical Compound
4269,mibampator,Chemical Compound
4270,mibefradil,Chemical Compound
4271,miconazole,Chemical Compound
4272,midafotel,Chemical Compound
4273,midostaurin,Chemical Compound
4274,mifepristone,Chemical Compound
4275,mifobate,Chemical Compound
4276,miglitol,Chemical Compound
4277,GANAB,Gene
4278,GANC,Gene
4279,miglustat,Chemical Compound
4280,milacemide,Chemical Compound
4281,milnacipran,Chemical Compound
4282,milrinone,Chemical Compound
4283,miltefosine,Chemical Compound
4284,mimosine,Chemical Compound
4285,minaprine,Chemical Compound
4286,minodronic-acid,Chemical Compound
4287,GGPS1,Gene
4288,minoxidil,Chemical Compound
4289,mirabegron,Chemical Compound
4290,MRE11A,Gene
4291,mirin,Chemical Compound
4292,mirodenafil,Chemical Compound
4293,mirtazapine,Chemical Compound
4294,misoprostol,Chemical Compound
4295,mitiglinide,Chemical Compound
4296,VWF,Gene
4297,mitoflaxone,Chemical Compound
4298,mitotane,Chemical Compound
4299,mitoxantrone,Chemical Compound
4300,mivacurium,Chemical Compound
4301,mizolastine,Chemical Compound
4302,mizoribine,Chemical Compound
4303,MJ-15,Chemical Compound
4304,MK-0354,Chemical Compound
4305,MK-0773,Chemical Compound
4306,MK-0812,Chemical Compound
4307,MK-0893,Chemical Compound
4308,WEE1,Gene
4309,MK-1775,Chemical Compound
4310,MK-2206,Chemical Compound
4311,MK-2295,Chemical Compound
4312,MK-2461,Chemical Compound
4313,MK-2894,Chemical Compound
4314,MK-3207,Chemical Compound
4315,MK-3697,Chemical Compound
4316,BRS3,Gene
4317,MK-5046,Chemical Compound
4318,NMBR,Gene
4319,MK-5108,Chemical Compound
4320,MK-571,Chemical Compound
4321,MK-6096,Chemical Compound
4322,MK-8033,Chemical Compound
4323,MK-8245,Chemical Compound
4324,MK-8745,Chemical Compound
4325,MAPKAPK2,Gene
4326,MK2-IN-1,Chemical Compound
4327,MLN0128,Chemical Compound
4328,MLN1117,Chemical Compound
4329,MLN8054,Chemical Compound
4330,ML10302,Chemical Compound
4331,ML141,Chemical Compound
4332,CLK4,Gene
4333,ML167,Chemical Compound
4334,NR5A2,Gene
4335,ML179,Chemical Compound
4336,ML193,Chemical Compound
4337,TRPC4,Gene
4338,ML204,Chemical Compound
4339,ML213,Chemical Compound
4340,ML218,Chemical Compound
4341,ML228,Chemical Compound
4342,ML277,Chemical Compound
4343,STK33,Gene
4344,ML281,Chemical Compound
4345,KCNJ3,Gene
4346,ML297,Chemical Compound
4347,ML298,Chemical Compound
4348,ML314,Chemical Compound
4349,USP1,Gene
4350,ML323,Chemical Compound
4351,KDM4A,Gene
4352,ML324,Chemical Compound
4353,ML3403,Chemical Compound
4354,ML347,Chemical Compound
4355,LYPLA1,Gene
4356,ML348,Chemical Compound
4357,ML365,Chemical Compound
4358,ML786,Chemical Compound
4359,ML9,Chemical Compound
4360,MM-11253,Chemical Compound
4361,MM77,Chemical Compound
4362,MN-64,Chemical Compound
4363,mocetinostat,Chemical Compound
4364,moclobemide,Chemical Compound
4365,moexipril,Chemical Compound
4366,mofegiline,Chemical Compound
4367,mofezolac,Chemical Compound
4368,molidustat,Chemical Compound
4369,molindone,Chemical Compound
4370,molsidomine,Chemical Compound
4371,mometasone,Chemical Compound
4372,mometasone-furoate,Chemical Compound
4373,monastrol,Chemical Compound
4374,monobenzone,Chemical Compound
4375,montelukast,Chemical Compound
4376,moracizine,Chemical Compound
4377,morin,Chemical Compound
4378,morinidazole,Chemical Compound
4379,mosapride,Chemical Compound
4380,motesanib,Chemical Compound
4381,motolimod,Chemical Compound
4382,moxifloxacin,Chemical Compound
4383,moxonidine,Chemical Compound
4384,mozavaptan,Chemical Compound
4385,MPEP,Chemical Compound
4386,TTK,Gene
4387,MPI-0479605,Chemical Compound
4388,Mps-BAY-2a,Chemical Compound
4389,Mps1-IN-1,Chemical Compound
4390,MR-948,Chemical Compound
4391,MRK-016,Chemical Compound
4392,MRK-560,Chemical Compound
4393,MRS-1220,Chemical Compound
4394,MRS-1334,Chemical Compound
4395,P2RY6,Gene
4396,MRS-2578,Chemical Compound
4397,MRS-3777,Chemical Compound
4398,MSX-122,Chemical Compound
4399,MTPG,Chemical Compound
4400,mubritinib,Chemical Compound
4401,muscimol,Chemical Compound
4402,MY-5445,Chemical Compound
4403,mycophenolate-mofetil,Chemical Compound
4404,mycophenolic-acid,Chemical Compound
4405,myricetin,Chemical Compound
4406,myricitrin,Chemical Compound
4407,M8-B,Chemical Compound
4408,B4GALT1,Gene
4409,N-acetyl-D-glucosamine,Chemical Compound
4410,B4GALT2,Gene
4411,B4GALT3,Gene
4412,B4GALT4,Gene
4413,NAGK,Gene
4414,NAGLU,Gene
4415,NAGPA,Gene
4416,RENBP,Gene
4417,N-alpha-methylhistamine-dihydrochloride,Chemical Compound
4418,NAB-2,Chemical Compound
4419,nabumetone,Chemical Compound
4420,AHCY,Gene
4421,nadide,Chemical Compound
4422,DHPS,Gene
4423,GALE,Gene
4424,nadolol,Chemical Compound
4425,NADPH,Chemical Compound
4426,nafadotride,Chemical Compound
4427,nafamostat,Chemical Compound
4428,C1R,Gene
4429,nafcillin,Chemical Compound
4430,naftopidil,Chemical Compound
4431,nalbuphine,Chemical Compound
4432,nalfurafine,Chemical Compound
4433,nalmefene,Chemical Compound
4434,naloxegol,Chemical Compound
4435,naloxone,Chemical Compound
4436,naloxone-benzoylhydrazone,Chemical Compound
4437,naltrexone,Chemical Compound
4438,naltriben,Chemical Compound
4439,naltrindole,Chemical Compound
4440,NAN-190,Chemical Compound
4441,napabucasin,Chemical Compound
4442,naphazoline,Chemical Compound
4443,naproxen,Chemical Compound
4444,naratriptan,Chemical Compound
4445,naringenin,Chemical Compound
4446,naringeninic-acid,Chemical Compound
4447,PTGR1,Gene
4448,SLCO1A2,Gene
4449,naringin,Chemical Compound
4450,NAS-181,Chemical Compound
4451,nastorazepide,Chemical Compound
4452,nateglinide,Chemical Compound
4453,NAV-26,Chemical Compound
4454,navarixin,Chemical Compound
4455,navitoclax,Chemical Compound
4456,NBI-27914,Chemical Compound
4457,NBI-74330-(+/-),Chemical Compound
4458,NBQX,Chemical Compound
4459,NCS-382,Chemical Compound
4460,SLC52A2,Gene
4461,C5AR1,Gene
4462,NDT-9513727,Chemical Compound
4463,NE-100,Chemical Compound
4464,nebivolol,Chemical Compound
4465,nebracetam,Chemical Compound
4466,NECA,Chemical Compound
4467,RIPK1,Gene
4468,necrostatin-1,Chemical Compound
4469,necrostatin-2,Chemical Compound
4470,nedocromil,Chemical Compound
4471,CYSLTR2,Gene
4472,nefazodone,Chemical Compound
4473,nefiracetam,Chemical Compound
4474,nelarabine,Chemical Compound
4475,nelfinavir,Chemical Compound
4476,nemonapride,Chemical Compound
4477,nemorubicin,Chemical Compound
4478,neomycin,Chemical Compound
4479,neostigmine,Chemical Compound
4480,nepafenac,Chemical Compound
4481,nepicastat,Chemical Compound
4482,neratinib,Chemical Compound
4483,neridronic-acid,Chemical Compound
4484,netupitant,Chemical Compound
4485,BMP2,Gene
4486,neuropathiazol,Chemical Compound
4487,LIF,Gene
4488,nevirapine,Chemical Compound
4489,nexturastat-A,Chemical Compound
4490,NFKB-activation-inhibitor-II,Chemical Compound
4491,NG-nitro-arginine,Chemical Compound
4492,NGB-2904,Chemical Compound
4493,NGD-94-1,Chemical Compound
4494,NGD-98-2,Chemical Compound
4495,NHI-2,Chemical Compound
4496,BRD1,Gene
4497,NI-57,Chemical Compound
4498,BRPF1,Gene
4499,BRPF3,Gene
4500,DGAT2,Gene
4501,niacin,Chemical Compound
4502,NNMT,Gene
4503,QPRT,Gene
4504,nialamide,Chemical Compound
4505,nicardipine,Chemical Compound
4506,nicergoline,Chemical Compound
4507,niclosamide,Chemical Compound
4508,nicorandil,Chemical Compound
4509,BST1,Gene
4510,nicotinamide,Chemical Compound
4511,SIRT5,Gene
4512,CHAT,Gene
4513,nicotine,Chemical Compound
4514,NIDA-41020,Chemical Compound
4515,nifedipine,Chemical Compound
4516,nifenalol,Chemical Compound
4517,niflumic-acid,Chemical Compound
4518,CLCNKA,Gene
4519,CLCNKB,Gene
4520,UGT1A9,Gene
4521,niguldipine-(S)-(+),Chemical Compound
4522,nilotinib,Chemical Compound
4523,nilutamide,Chemical Compound
4524,nilvadipine,Chemical Compound
4525,nimesulide,Chemical Compound
4526,nimodipine,Chemical Compound
4527,nintedanib,Chemical Compound
4528,niraparib,Chemical Compound
4529,nisoldipine,Chemical Compound
4530,nisoxetine,Chemical Compound
4531,nitecapone,Chemical Compound
4532,nitrendipine,Chemical Compound
4533,nitrocaramiphen,Chemical Compound
4534,nitroxoline,Chemical Compound
4535,nizatidine,Chemical Compound
4536,NFE2L2,Gene
4537,NK-252,Chemical Compound
4538,NKY-80,Chemical Compound
4539,NLG919,Chemical Compound
4540,NMDA,Chemical Compound
4541,NMS-1286937,Chemical Compound
4542,NMS-873,Chemical Compound
4543,NN-DNJ,Chemical Compound
4544,NNC-05-2090,Chemical Compound
4545,NNC-55-0396,Chemical Compound
4546,NNC-63-0532,Chemical Compound
4547,NNC-711,Chemical Compound
4548,NO-ASA,Chemical Compound
4549,nobiletin,Chemical Compound
4550,nocodazole,Chemical Compound
4551,nolatrexed,Chemical Compound
4552,nomegestrol-acetate,Chemical Compound
4553,nomifensine,Chemical Compound
4554,nonivamide,Chemical Compound
4555,nor-binaltorphimine,Chemical Compound
4556,norelgestromin,Chemical Compound
4557,norepinephrine,Chemical Compound
4558,norethindrone,Chemical Compound
4559,norethindrone-acetate,Chemical Compound
4560,noretynodrel,Chemical Compound
4561,norfloxacin,Chemical Compound
4562,norfluoxetine,Chemical Compound
4563,norgestimate,Chemical Compound
4564,norgestrel,Chemical Compound
4565,nortriptyline,Chemical Compound
4566,noscapine,Chemical Compound
4567,NOV-002,Chemical Compound
4568,NPC-15199,Chemical Compound
4569,NPPB,Chemical Compound
4570,CLCN7,Gene
4571,NPS-2143,Chemical Compound
4572,NPY-5RA972,Chemical Compound
4573,NQDI-1,Chemical Compound
4574,NS-018,Chemical Compound
4575,NS-11021,Chemical Compound
4576,NS-1643,Chemical Compound
4577,NS-19504,Chemical Compound
4578,NS-309,Chemical Compound
4579,NS-3623,Chemical Compound
4580,NS-3861,Chemical Compound
4581,NS-5806,Chemical Compound
4582,NS-8,Chemical Compound
4583,NS-8593,Chemical Compound
4584,NS-9283,Chemical Compound
4585,NSC-3852,Chemical Compound
4586,NSC-405020,Chemical Compound
4587,NSC-4644,Chemical Compound
4588,NSC-5844,Chemical Compound
4589,NSC-625987,Chemical Compound
4590,SENP2,Gene
4591,NSC-632839,Chemical Compound
4592,USP2,Gene
4593,USP7,Gene
4594,NSC-636819,Chemical Compound
4595,KDM4B,Gene
4596,CDC25A,Gene
4597,NSC-663284,Chemical Compound
4598,CDC25C,Gene
4599,UBE2N,Gene
4600,NSC-697923,Chemical Compound
4601,NSC-95397,Chemical Compound
4602,NSC-9965,Chemical Compound
4603,NTNCB,Chemical Compound
4604,NTRC-824,Chemical Compound
4605,nTZDpa,Chemical Compound
4606,NT157,Chemical Compound
4607,NU-1025,Chemical Compound
4608,NU-2058,Chemical Compound
4609,NU-6027,Chemical Compound
4610,NU-7026,Chemical Compound
4611,NU-7441,Chemical Compound
4612,nutlin-3,Chemical Compound
4613,NVP-ADW742,Chemical Compound
4614,NVP-AEW541,Chemical Compound
4615,NVP-AUY922,Chemical Compound
4616,NVP-BEZ235,Chemical Compound
4617,NVP-BGJ398,Chemical Compound
4618,EPHB4,Gene
4619,NVP-BHG712,Chemical Compound
4620,NVP-BSK805,Chemical Compound
4621,NVP-BVU972,Chemical Compound
4622,NVP-DPP728,Chemical Compound
4623,NVP-HSP990,Chemical Compound
4624,NVP-TAE226,Chemical Compound
4625,NVP-TAE684,Chemical Compound
4626,NVP-TNKS656,Chemical Compound
4627,CERK,Gene
4628,NVP-231,Chemical Compound
4629,NVS-PAK1-1,Chemical Compound
4630,N6-cyclopentyladenosine,Chemical Compound
4631,N6022,Chemical Compound
4632,O-acetyl-L-serine,Chemical Compound
4633,POU5F1,Gene
4634,OAC2,Chemical Compound
4635,obatoclax,Chemical Compound
4636,obeticholic-acid,Chemical Compound
4637,obidoxime,Chemical Compound
4638,ochromycinone,Chemical Compound
4639,ocinaplon,Chemical Compound
4640,octopamine,Chemical Compound
4641,SSTR2,Gene
4642,octreotide,Chemical Compound
4643,SSTR3,Gene
4644,SSTR5,Gene
4645,OC000459,Chemical Compound
4646,odanacatib,Chemical Compound
4647,ODQ,Chemical Compound
4648,OF-1,Chemical Compound
4649,OG-L002,Chemical Compound
4650,WDR5,Gene
4651,OICR-9429,Chemical Compound
4652,olanzapine,Chemical Compound
4653,olaparib,Chemical Compound
4654,OLDA,Chemical Compound
4655,oleamide,Chemical Compound
4656,oleanolic-acid,Chemical Compound
4657,oleoylethanolamide,Chemical Compound
4658,oleuropein,Chemical Compound
4659,ATP5A1,Gene
4660,oligomycin-A,Chemical Compound
4661,olmesartan,Chemical Compound
4662,olmesartan-medoxomil,Chemical Compound
4663,olmutinib,Chemical Compound
4664,olomoucine,Chemical Compound
4665,olopatadine,Chemical Compound
4666,S100A1,Gene
4667,S100A2,Gene
4668,olprinone,Chemical Compound
4669,IFNG,Gene
4670,olsalazine,Chemical Compound
4671,TPMT,Gene
4672,oltipraz,Chemical Compound
4673,olvanil,Chemical Compound
4674,omapatrilat,Chemical Compound
4675,omarigliptin,Chemical Compound
4676,OMDM-2,Chemical Compound
4677,MYBPC3,Gene
4678,omecamtiv-mecarbil,Chemical Compound
4679,omeprazole,Chemical Compound
4680,omeprazole-magnesium,Chemical Compound
4681,TNFSF10,Gene
4682,ONC201,Chemical Compound
4683,ondansetron,Chemical Compound
4684,ONO-AE3-208,Chemical Compound
4685,ONO-4059,Chemical Compound
4686,ONO-4817,Chemical Compound
4687,ONO-8130,Chemical Compound
4688,ON123300,Chemical Compound
4689,OPC-21268,Chemical Compound
4690,opicapone,Chemical Compound
4691,OR-486,Chemical Compound
4692,orantinib,Chemical Compound
4693,ORE1001,Chemical Compound
4694,ORG-12962,Chemical Compound
4695,ORG-25543,Chemical Compound
4696,ORG-27569,Chemical Compound
4697,ORG-9768,Chemical Compound
4698,oridonin,Chemical Compound
4699,orlistat,Chemical Compound
4700,DAGLA,Gene
4701,DAGLB,Gene
4702,LIPF,Gene
4703,ornithine,Chemical Compound
4704,orotic-acid,Chemical Compound
4705,orphanin-fq,Chemical Compound
4706,orteronel,Chemical Compound
4707,ORY-1001,Chemical Compound
4708,oseltamivir-phosphate,Chemical Compound
4709,NEU1,Gene
4710,NEU2,Gene
4711,osemozotan,Chemical Compound
4712,OSI-027,Chemical Compound
4713,OSI-420,Chemical Compound
4714,OSI-930,Chemical Compound
4715,osimertinib,Chemical Compound
4716,ospemifene,Chemical Compound
4717,ostarine,Chemical Compound
4718,OT-R-antagonist-1,Chemical Compound
4719,otamixaban,Chemical Compound
4720,otenzepad,Chemical Compound
4721,otilonium,Chemical Compound
4722,MELK,Gene
4723,OTS167,Chemical Compound
4724,OTX015,Chemical Compound
4725,ouabain,Chemical Compound
4726,OXA-06,Chemical Compound
4727,oxaprozin,Chemical Compound
4728,oxatomide,Chemical Compound
4729,oxcarbazepine,Chemical Compound
4730,OXF-BD-02,Chemical Compound
4731,oxfenicine,Chemical Compound
4732,CPT1B,Gene
4733,oxibendazole,Chemical Compound
4734,oxotremorine-M,Chemical Compound
4735,oxotremorine-sesquifumarate,Chemical Compound
4736,oxprenolol,Chemical Compound
4737,oxybenzone,Chemical Compound
4738,oxybuprocaine,Chemical Compound
4739,oxybutynin,Chemical Compound
4740,oxymetazoline,Chemical Compound
4741,oxyphenonium,Chemical Compound
4742,oxypurinol,Chemical Compound
4743,oxyquinoline,Chemical Compound
4744,oxytocin,Chemical Compound
4745,ozagrel,Chemical Compound
4746,ozanimod,Chemical Compound
4747,O4I1,Chemical Compound
4748,O6-benzylguanine,Chemical Compound
4749,PA-452,Chemical Compound
4750,PAC-1,Chemical Compound
4751,paclitaxel,Chemical Compound
4752,PACOCF3,Chemical Compound
4753,pacritinib,Chemical Compound
4754,palbociclib,Chemical Compound
4755,paliperidone,Chemical Compound
4756,palmatine-chloride,Chemical Compound
4757,palmitoylethanolamide,Chemical Compound
4758,palomid-529,Chemical Compound
4759,palonosetron,Chemical Compound
4760,palosuran,Chemical Compound
4761,palovarotene,Chemical Compound
4762,pamidronate,Chemical Compound
4763,pancuronium,Chemical Compound
4764,panobinostat,Chemical Compound
4765,pantoprazole,Chemical Compound
4766,PAOPA,Chemical Compound
4767,papaverine,Chemical Compound
4768,para-toluenesulfonamide,Chemical Compound
4769,paracetamol,Chemical Compound
4770,paramethadione,Chemical Compound
4771,parbendazole,Chemical Compound
4772,pardoprunox,Chemical Compound
4773,parecoxib,Chemical Compound
4774,pargyline,Chemical Compound
4775,paricalcitol,Chemical Compound
4776,paroxetine,Chemical Compound
4777,parthenolide-(-),Chemical Compound
4778,parthenolide-(alternate-stereo),Chemical Compound
4779,SSTR1,Gene
4780,pasireotide,Chemical Compound
4781,pazopanib,Chemical Compound
4782,ITK,Gene
4783,SH2B3,Gene
4784,PCA-4248,Chemical Compound
4785,PCI-24781,Chemical Compound
4786,PCI-29732,Chemical Compound
4787,PCI-34051,Chemical Compound
4788,PCO-400,Chemical Compound
4789,PD-0325901,Chemical Compound
4790,PD-102807,Chemical Compound
4791,PD-118057,Chemical Compound
4792,PD-123319,Chemical Compound
4793,PD-128907,Chemical Compound
4794,PD-153035,Chemical Compound
4795,PD-156707,Chemical Compound
4796,PD-158780,Chemical Compound
4797,PD-160170,Chemical Compound
4798,PD-161570,Chemical Compound
4799,PD-166285,Chemical Compound
4800,PKMYT1,Gene
4801,PD-166793,Chemical Compound
4802,PD-168077,Chemical Compound
4803,PD-168393,Chemical Compound
4804,PD-168568,Chemical Compound
4805,PD-173074,Chemical Compound
4806,PD-173212,Chemical Compound
4807,PD-184352,Chemical Compound
4808,PD-198306,Chemical Compound
4809,PD-407824,Chemical Compound
4810,PD-81723,Chemical Compound
4811,PD-98059,Chemical Compound
4812,PDE10-IN-1,Chemical Compound
4813,PDP-EA,Chemical Compound
4814,CD274,Gene
4815,PD1-PDL-inhibitor-1,Chemical Compound
4816,peficitinib,Chemical Compound
4817,pefloxacin,Chemical Compound
4818,pelanserin,Chemical Compound
4819,pelitinib,Chemical Compound
4820,ATIC,Gene
4821,pemetrexed,Chemical Compound
4822,pemirolast,Chemical Compound
4823,penbutolol,Chemical Compound
4824,penfluridol,Chemical Compound
4825,pentagastrin,Chemical Compound
4826,TRDMT1,Gene
4827,pentamidine,Chemical Compound
4828,pentolinium,Chemical Compound
4829,pentostatin,Chemical Compound
4830,pentoxifylline,Chemical Compound
4831,NT5E,Gene
4832,pepstatin,Chemical Compound
4833,CTSD,Gene
4834,peretinoin,Chemical Compound
4835,pergolide,Chemical Compound
4836,perhexiline,Chemical Compound
4837,perifosine,Chemical Compound
4838,perillyl-alcohol,Chemical Compound
4839,perindopril,Chemical Compound
4840,perindoprilat,Chemical Compound
4841,perospirone,Chemical Compound
4842,perphenazine,Chemical Compound
4843,perzinfotel,Chemical Compound
4844,PETCM,Chemical Compound
4845,pevonedistat,Chemical Compound
4846,UBA3,Gene
4847,pexidartinib,Chemical Compound
4848,pexmetinib,Chemical Compound
4849,PF-02545920,Chemical Compound
4850,PF-03049423,Chemical Compound
4851,PF-03758309,Chemical Compound
4852,PF-03814735,Chemical Compound
4853,PF-04217903,Chemical Compound
4854,PF-04418948,Chemical Compound
4855,PF-04447943,Chemical Compound
4856,PF-04457845,Chemical Compound
4857,PF-04620110,Chemical Compound
4858,PF-04691502,Chemical Compound
4859,PF-04885614,Chemical Compound
4860,PF-04937319,Chemical Compound
4861,PF-05190457,Chemical Compound
4862,PF-05212384,Chemical Compound
4863,PF-06447475,Chemical Compound
4864,PF-06463922,Chemical Compound
4865,FES,Gene
4866,PF-3274167,Chemical Compound
4867,PF-3845,Chemical Compound
4868,MBTPS1,Gene
4869,PF-429242,Chemical Compound
4870,PF-431396,Chemical Compound
4871,PF-4708671,Chemical Compound
4872,PF-477736,Chemical Compound
4873,PF-4800567,Chemical Compound
4874,PF-4981517,Chemical Compound
4875,PF-5274857,Chemical Compound
4876,PF-562271,Chemical Compound
4877,PF-573228,Chemical Compound
4878,PF-670462,Chemical Compound
4879,PF-750,Chemical Compound
4880,PF-8380,Chemical Compound
4881,PF-915275,Chemical Compound
4882,PFI-1,Chemical Compound
4883,PBRM1,Gene
4884,PFI-3,Chemical Compound
4885,SMARCA4,Gene
4886,PFI-4,Chemical Compound
4887,PFKFB3,Gene
4888,PFK-015,Chemical Compound
4889,PFK-158,Chemical Compound
4890,MAPK10,Gene
4891,PGL5001,Chemical Compound
4892,MAPK9,Gene
4893,PH-797804,Chemical Compound
4894,PHA-568487,Chemical Compound
4895,PHA-665752,Chemical Compound
4896,PHA-680632,Chemical Compound
4897,PHA-767491,Chemical Compound
4898,PHA-793887,Chemical Compound
4899,PHA-848125,Chemical Compound
4900,PHCCC,Chemical Compound
4901,phenacemide,Chemical Compound
4902,phenacetin,Chemical Compound
4903,phenazone,Chemical Compound
4904,phenazopyridine,Chemical Compound
4905,phenelzine,Chemical Compound
4906,AOC3,Gene
4907,phenethyl-isothiocyanate,Chemical Compound
4908,phenformin,Chemical Compound
4909,phenindamine,Chemical Compound
4910,phenindione,Chemical Compound
4911,pheniramine,Chemical Compound
4912,phenol,Chemical Compound
4913,phenolphthalein,Chemical Compound
4914,phenoxybenzamine,Chemical Compound
4915,phenprocoumon,Chemical Compound
4916,phenserine,Chemical Compound
4917,phentolamine,Chemical Compound
4918,phenylbutazone,Chemical Compound
4919,phenylbutyrate,Chemical Compound
4920,phenylephrine,Chemical Compound
4921,phenytoin,Chemical Compound
4922,PhiKan-083,Chemical Compound
4923,AQP9,Gene
4924,phloretin,Chemical Compound
4925,CLCN3,Gene
4926,phlorizin,Chemical Compound
4927,SLC5A11,Gene
4928,SLC5A3,Gene
4929,phortress,Chemical Compound
4930,PHP-501,Chemical Compound
4931,PHT-427,Chemical Compound
4932,PHTPP,Chemical Compound
4933,physostigmine,Chemical Compound
4934,phytonadione,Chemical Compound
4935,PI-103,Chemical Compound
4936,piboserod,Chemical Compound
4937,picartamide,Chemical Compound
4938,piceatannol,Chemical Compound
4939,ATP5B,Gene
4940,ATP5C1,Gene
4941,IRF3,Gene
4942,piclamilast,Chemical Compound
4943,picotamide,Chemical Compound
4944,picrotin,Chemical Compound
4945,picrotoxinin,Chemical Compound
4946,pidolic-acid,Chemical Compound
4947,AMY1A,Gene
4948,AMY2B,Gene
4949,HCRT,Gene
4950,IGLC1,Gene
4951,KRTAP5-2,Gene
4952,TFF2,Gene
4953,VEGFA,Gene
4954,pifithrin-alpha,Chemical Compound
4955,pifithrin-cyclic,Chemical Compound
4956,pifithrin-mu,Chemical Compound
4957,PIK-293,Chemical Compound
4958,PIK-294,Chemical Compound
4959,PIK-75,Chemical Compound
4960,PIK-93,Chemical Compound
4961,PIK3C3,Gene
4962,pilocarpine,Chemical Compound
4963,pilsicainide,Chemical Compound
4964,PIM-1-Inhibitor-2,Chemical Compound
4965,pimavanserin,Chemical Compound
4966,pimobendan,Chemical Compound
4967,pimozide,Chemical Compound
4968,pinacidil,Chemical Compound
4969,pinaverium,Chemical Compound
4970,pindolol,Chemical Compound
4971,pindolol-(-),Chemical Compound
4972,pinocembrin,Chemical Compound
4973,pioglitazone,Chemical Compound
4974,pipamperone,Chemical Compound
4975,pipecuronium,Chemical Compound
4976,pipenzolate,Chemical Compound
4977,piperazine,Chemical Compound
4978,piperidolate,Chemical Compound
4979,piperine,Chemical Compound
4980,pipotiazine,Chemical Compound
4981,pipotiazine-palmitate,Chemical Compound
4982,piracetam,Chemical Compound
4983,pirarubicin,Chemical Compound
4984,pirenperone,Chemical Compound
4985,pirenzepine,Chemical Compound
4986,piretanide,Chemical Compound
4987,FURIN,Gene
4988,pirfenidone,Chemical Compound
4989,piribedil,Chemical Compound
4990,piricapiron,Chemical Compound
4991,pirinixic-acid,Chemical Compound
4992,pirlindole,Chemical Compound
4993,piroxicam,Chemical Compound
4994,piroximone,Chemical Compound
4995,PIT,Chemical Compound
4996,pitavastatin,Chemical Compound
4997,pitolisant,Chemical Compound
4998,pivagabine,Chemical Compound
4999,CRHR2,Gene
5000,pivanex,Chemical Compound
5001,pixantrone,Chemical Compound
5002,pizotifen,Chemical Compound
5003,PI4KIII-beta-inhibitor-1,Chemical Compound
5004,EEF2,Gene
5005,PJ-34,Chemical Compound
5006,PARP15,Gene
5007,PK-THPP,Chemical Compound
5008,PK-11195,Chemical Compound
5009,PK-44,Chemical Compound
5010,PKI-166,Chemical Compound
5011,PKI-179,Chemical Compound
5012,ACKR3,Gene
5013,plerixafor,Chemical Compound
5014,plovamer-acetate,Chemical Compound
5015,YARS,Gene
5016,YARS2,Gene
5017,plurisin-1,Chemical Compound
5018,PLX4720,Chemical Compound
5019,PLX647,Chemical Compound
5020,PLX8394,Chemical Compound
5021,PMPA,Chemical Compound
5022,PNU-120596,Chemical Compound
5023,PNU-142633,Chemical Compound
5024,PNU-177864,Chemical Compound
5025,PNU-22394,Chemical Compound
5026,PNU-282987,Chemical Compound
5027,PNU-74654,Chemical Compound
5028,PNU-89843,Chemical Compound
5029,podophyllotoxin,Chemical Compound
5030,polydatin,Chemical Compound
5031,polyinosine,Chemical Compound
5032,polythiazide,Chemical Compound
5033,ponatinib,Chemical Compound
5034,ponesimod,Chemical Compound
5035,posaconazole,Chemical Compound
5036,potassium-canrenoate,Chemical Compound
5037,pozanicline,Chemical Compound
5038,poziotinib,Chemical Compound
5039,PP-1,Chemical Compound
5040,PP-121,Chemical Compound
5041,PP-2,Chemical Compound
5042,PPT,Chemical Compound
5043,PPY-A,Chemical Compound
5044,PP242,Chemical Compound
5045,PASK,Gene
5046,PQ-401,Chemical Compound
5047,practolol,Chemical Compound
5048,pralatrexate,Chemical Compound
5049,pralidoxime,Chemical Compound
5050,pralidoxime-chloride,Chemical Compound
5051,pramipexole,Chemical Compound
5052,pranidipine,Chemical Compound
5053,pranlukast,Chemical Compound
5054,IL5,Gene
5055,MUC2,Gene
5056,prasugrel,Chemical Compound
5057,pravadoline,Chemical Compound
5058,pravastatin,Chemical Compound
5059,prazosin,Chemical Compound
5060,PRE-084,Chemical Compound
5061,preclamol,Chemical Compound
5062,prednicarbate,Chemical Compound
5063,prednisolone,Chemical Compound
5064,prednisolone-acetate,Chemical Compound
5065,prednisolone-hemisuccinate,Chemical Compound
5066,prednisolone-sodium-phosphate,Chemical Compound
5067,prednisone,Chemical Compound
5068,pregnenolone,Chemical Compound
5069,pregnenolone-succinate,Chemical Compound
5070,preladenant,Chemical Compound
5071,pretomanid,Chemical Compound
5072,prilocaine,Chemical Compound
5073,PRIMA1,Chemical Compound
5074,primidone,Chemical Compound
5075,prinaberel,Chemical Compound
5076,priralfinamide,Chemical Compound
5077,proadifen,Chemical Compound
5078,probenecid,Chemical Compound
5079,SLC22A11,Gene
5080,SLCO1C1,Gene
5081,probucol,Chemical Compound
5082,procainamide,Chemical Compound
5083,procaine,Chemical Compound
5084,KCNMB1,Gene
5085,KCNMB2,Gene
5086,KCNMB3,Gene
5087,KCNMB4,Gene
5088,procaterol,Chemical Compound
5089,prochlorperazine,Chemical Compound
5090,profenamine,Chemical Compound
5091,proflavine-hemisulfate,Chemical Compound
5092,progesterone,Chemical Compound
5093,proglumetacin,Chemical Compound
5094,proglumide,Chemical Compound
5095,proguanil,Chemical Compound
5096,promazine,Chemical Compound
5097,promestriene,Chemical Compound
5098,promethazine,Chemical Compound
5099,propacetamol,Chemical Compound
5100,propafenone,Chemical Compound
5101,propagermanium,Chemical Compound
5102,propantheline,Chemical Compound
5103,propentofylline,Chemical Compound
5104,propidium-iodide,Chemical Compound
5105,propiverine,Chemical Compound
5106,propofol,Chemical Compound
5107,propranolol,Chemical Compound
5108,propranolol-(R),Chemical Compound
5109,propranolol-(S),Chemical Compound
5110,DIO1,Gene
5111,propylthiouracil,Chemical Compound
5112,proquazone,Chemical Compound
5113,TRHR,Gene
5114,protirelin,Chemical Compound
5115,protoporphyrin-IX,Chemical Compound
5116,protriptyline,Chemical Compound
5117,proxyfan,Chemical Compound
5118,proxymetacaine,Chemical Compound
5119,PRT062070,Chemical Compound
5120,PRT062607,Chemical Compound
5121,PRC1,Gene
5122,PRT4165,Chemical Compound
5123,prucalopride,Chemical Compound
5124,pruvanserin,Chemical Compound
5125,PRX-08066,Chemical Compound
5126,ENTPD3,Gene
5127,PSB-06126,Chemical Compound
5128,PSB-11,Chemical Compound
5129,PSB-1115,Chemical Compound
5130,PSB-36,Chemical Compound
5131,PSB-603,Chemical Compound
5132,PSN-375963,Chemical Compound
5133,PSNCBAM-1,Chemical Compound
5134,psoralen,Chemical Compound
5135,PS178990,Chemical Compound
5136,EPAS1,Gene
5137,PT-2385,Chemical Compound
5138,pterostilbene,Chemical Compound
5139,PU-H71,Chemical Compound
5140,pumosetrag,Chemical Compound
5141,purmorphamine,Chemical Compound
5142,puromycin,Chemical Compound
5143,purvalanol-A,Chemical Compound
5144,CSNK1G3,Gene
5145,purvalanol-B,Chemical Compound
5146,AMD1,Gene
5147,putrescine,Chemical Compound
5148,PX-12,Chemical Compound
5149,pyrazinamide,Chemical Compound
5150,pyrazolanthrone,Chemical Compound
5151,MAPK8IP1,Gene
5152,pyrazoloacridine,Chemical Compound
5153,PDXK,Gene
5154,pyridoxal,Chemical Compound
5155,pyridoxine,Chemical Compound
5156,pyrimethamine,Chemical Compound
5157,pyrithione-zinc,Chemical Compound
5158,pyroxamide,Chemical Compound
5159,pyrrolidine-dithiocarbamate,Chemical Compound
5160,pyrvinium-pamoate,Chemical Compound
5161,P22077,Chemical Compound
5162,P276-00,Chemical Compound
5163,P5091,Chemical Compound
5164,P7C3,Chemical Compound
5165,quazinone,Chemical Compound
5166,quercetin,Chemical Compound
5167,HIBCH,Gene
5168,STK17B,Gene
5169,quetiapine,Chemical Compound
5170,quiflapon,Chemical Compound
5171,quinagolide,Chemical Compound
5172,quinapril,Chemical Compound
5173,quinaprilat,Chemical Compound
5174,quinelorane,Chemical Compound
5175,quinestrol,Chemical Compound
5176,quinidine,Chemical Compound
5177,KCNK1,Gene
5178,KCNK6,Gene
5179,GP9,Gene
5180,quinine,Chemical Compound
5181,quinpirol-(-),Chemical Compound
5182,quipazine,Chemical Compound
5183,quizartinib,Chemical Compound
5184,QX-314,Chemical Compound
5185,R-1485,Chemical Compound
5186,R-268712,Chemical Compound
5187,R-428,Chemical Compound
5188,DGKA,Gene
5189,R-59022,Chemical Compound
5190,R-96544,Chemical Compound
5191,rabeprazole,Chemical Compound
5192,rac-BHFF,Chemical Compound
5193,racecadotril,Chemical Compound
5194,raclopride,Chemical Compound
5195,radafaxine,Chemical Compound
5196,RAF265,Chemical Compound
5197,raloxifene,Chemical Compound
5198,raltitrexed,Chemical Compound
5199,ramatroban,Chemical Compound
5200,ramelteon,Chemical Compound
5201,ramipril,Chemical Compound
5202,ramosetron,Chemical Compound
5203,ranirestat,Chemical Compound
5204,ranitidine,Chemical Compound
5205,ranolazine,Chemical Compound
5206,rasagiline,Chemical Compound
5207,rauwolscine,Chemical Compound
5208,ravoxertinib,Chemical Compound
5209,RBC8,Chemical Compound
5210,rebamipide,Chemical Compound
5211,rebastinib,Chemical Compound
5212,reboxetine,Chemical Compound
5213,Rec-15/2615,Chemical Compound
5214,refametinib,Chemical Compound
5215,regadenoson,Chemical Compound
5216,regorafenib,Chemical Compound
5217,relcovaptan,Chemical Compound
5218,remacemide,Chemical Compound
5219,remimazolam,Chemical Compound
5220,NAT10,Gene
5221,remodelin,Chemical Compound
5222,remoxipride,Chemical Compound
5223,repaglinide,Chemical Compound
5224,reparixin,Chemical Compound
5225,repsox,Chemical Compound
5226,resatorvid,Chemical Compound
5227,reserpine,Chemical Compound
5228,resiquimod,Chemical Compound
5229,resminostat,Chemical Compound
5230,resorcinol,Chemical Compound
5231,resveratrol,Chemical Compound
5232,retaspimycin,Chemical Compound
5233,retinol,Chemical Compound
5234,DHRS3,Gene
5235,DHRS4,Gene
5236,LRAT,Gene
5237,NR2C2,Gene
5238,RBP3,Gene
5239,RDH11,Gene
5240,RDH12,Gene
5241,RDH13,Gene
5242,RDH14,Gene
5243,RDH8,Gene
5244,RETSAT,Gene
5245,RLBP1,Gene
5246,REV-5901,Chemical Compound
5247,revaprazan,Chemical Compound
5248,reversan,Chemical Compound
5249,reversine,Chemical Compound
5250,INCENP,Gene
5251,RGB-286638,Chemical Compound
5252,CDK3,Gene
5253,MAP3K7,Gene
5254,RGFP966,Chemical Compound
5255,RG108,Chemical Compound
5256,RG1530,Chemical Compound
5257,RG2833,Chemical Compound
5258,RG4733,Chemical Compound
5259,RG7112,Chemical Compound
5260,RHC-80267,Chemical Compound
5261,rhein,Chemical Compound
5262,rheochrysidin,Chemical Compound
5263,RAD51,Gene
5264,RI-1,Chemical Compound
5265,ribavirin,Chemical Compound
5266,ribociclib,Chemical Compound
5267,riboflavin,Chemical Compound
5268,RFK,Gene
5269,riboflavin-5-phosphate-sodium,Chemical Compound
5270,HAO1,Gene
5271,HAO2,Gene
5272,PPCDC,Gene
5273,RPS6KA4,Gene
5274,P4HB,Gene
5275,ribostamycin,Chemical Compound
5276,ricinoleic-acid,Chemical Compound
5277,rifampin,Chemical Compound
5278,rifamycin,Chemical Compound
5279,rifapentine,Chemical Compound
5280,rigosertib,Chemical Compound
5281,rilmenidine,Chemical Compound
5282,rilpivirine,Chemical Compound
5283,riluzole,Chemical Compound
5284,KCNK4,Gene
5285,rimcazole,Chemical Compound
5286,rimegepant,Chemical Compound
5287,rimexolone,Chemical Compound
5288,rimonabant,Chemical Compound
5289,riociguat,Chemical Compound
5290,ripasudil,Chemical Compound
5291,ripazepam,Chemical Compound
5292,risedronate,Chemical Compound
5293,risperidone,Chemical Compound
5294,RITA,Chemical Compound
5295,ritanserin,Chemical Compound
5296,ritonavir,Chemical Compound
5297,rivanicline,Chemical Compound
5298,rivaroxaban,Chemical Compound
5299,rivastigmine,Chemical Compound
5300,rizatriptan,Chemical Compound
5301,CDC42BPA,Gene
5302,RKI-1447,Chemical Compound
5303,DMPK,Gene
5304,PKN1,Gene
5305,RN-1,Chemical Compound
5306,RN-1734,Chemical Compound
5307,RN-1747,Chemical Compound
5308,Ro-04-5595,Chemical Compound
5309,NGF,Gene
5310,Ro-08-2750,Chemical Compound
5311,Ro-10-5824,Chemical Compound
5312,Ro-1138452,Chemical Compound
5313,Ro-15-4513,Chemical Compound
5314,Ro-19-4605,Chemical Compound
5315,Ro-20-1724,Chemical Compound
5316,Ro-25-6981,Chemical Compound
5317,Ro-28-1675,Chemical Compound
5318,Ro-3,Chemical Compound
5319,Ro-3306,Chemical Compound
5320,LSS,Gene
5321,Ro-48-8071,Chemical Compound
5322,Ro-4987655,Chemical Compound
5323,Ro-5126766,Chemical Compound
5324,Ro-60-0175,Chemical Compound
5325,KMO,Gene
5326,Ro-61-8048,Chemical Compound
5327,Ro-67-7476,Chemical Compound
5328,Ro-90-7501,Chemical Compound
5329,robalzotan,Chemical Compound
5330,rociletinib,Chemical Compound
5331,rocuronium,Chemical Compound
5332,ELN,Gene
5333,rofecoxib,Chemical Compound
5334,roflumilast,Chemical Compound
5335,romidepsin,Chemical Compound
5336,ropinirole,Chemical Compound
5337,ropivacaine,Chemical Compound
5338,roscovitine,Chemical Compound
5339,rosiglitazone,Chemical Compound
5340,rosmarinic-acid,Chemical Compound
5341,rostafuroxine,Chemical Compound
5342,rosuvastatin,Chemical Compound
5343,rotigotine,Chemical Compound
5344,rotundine,Chemical Compound
5345,roxatidine-acetate,Chemical Compound
5346,roxithromycin,Chemical Compound
5347,RP-001,Chemical Compound
5348,RQ-00203078,Chemical Compound
5349,RRx-001,Chemical Compound
5350,RS-100329,Chemical Compound
5351,RS-102221,Chemical Compound
5352,RS-102895,Chemical Compound
5353,RS-127445,Chemical Compound
5354,RS-17053,Chemical Compound
5355,RS-23597-190,Chemical Compound
5356,RS-39604,Chemical Compound
5357,RS-504393,Chemical Compound
5358,RS-56812,Chemical Compound
5359,RS-67333,Chemical Compound
5360,RS-67506,Chemical Compound
5361,RS-79948,Chemical Compound
5362,RTA-408,Chemical Compound
5363,HHAT,Gene
5364,RU-SKI-43,Chemical Compound
5365,RU-24969,Chemical Compound
5366,RU-28318,Chemical Compound
5367,RU-42173,Chemical Compound
5368,RU-58841,Chemical Compound
5369,rubitecan,Chemical Compound
5370,rucaparib,Chemical Compound
5371,rucinol,Chemical Compound
5372,rufinamide,Chemical Compound
5373,rupatadine,Chemical Compound
5374,rutaecarpine,Chemical Compound
5375,rutin,Chemical Compound
5376,ruxolitinib,Chemical Compound
5377,ruxolitinib-(S),Chemical Compound
5378,RWJ-21757,Chemical Compound
5379,RWJ-50271,Chemical Compound
5380,RWJ-67657,Chemical Compound
5381,RX-3117,Chemical Compound
5382,RX-821002,Chemical Compound
5383,ryuvidine,Chemical Compound
5384,R112,Chemical Compound
5385,R406,Chemical Compound
5386,R547,Chemical Compound
5387,S-isopropylisothiourea,Chemical Compound
5388,S-methylcysteine,Chemical Compound
5389,S-nitrosoglutathione,Chemical Compound
5390,S-07662,Chemical Compound
5391,S-111,Chemical Compound
5392,S-14506,Chemical Compound
5393,SA-47,Chemical Compound
5394,saccharin,Chemical Compound
5395,saclofen,Chemical Compound
5396,sacubitril,Chemical Compound
5397,safinamide,Chemical Compound
5398,safingol,Chemical Compound
5399,safranal,Chemical Compound
5400,SAG,Chemical Compound
5401,salicylic-acid,Chemical Compound
5402,salidroside,Chemical Compound
5403,salirasib,Chemical Compound
5404,salmeterol,Chemical Compound
5405,EIF2S1,Gene
5406,salubrinal,Chemical Compound
5407,salvianolic-acid-B,Chemical Compound
5408,salvinorin-A,Chemical Compound
5409,sal003,Chemical Compound
5410,sanguinarium-chloride,Chemical Compound
5411,SHH,Gene
5412,SANT-1,Chemical Compound
5413,SANT-2,Chemical Compound
5414,sapropterin,Chemical Compound
5415,saquinavir,Chemical Compound
5416,SAR-245409,Chemical Compound
5417,saracatinib,Chemical Compound
5418,sarcosine,Chemical Compound
5419,saroglitazar,Chemical Compound
5420,sarpogrelate,Chemical Compound
5421,SAR131675,Chemical Compound
5422,SAR405,Chemical Compound
5423,SAR405838,Chemical Compound
5424,SAR407899,Chemical Compound
5425,sasapyrine,Chemical Compound
5426,savolitinib,Chemical Compound
5427,saxagliptin,Chemical Compound
5428,SB-200646,Chemical Compound
5429,SB-202190,Chemical Compound
5430,SB-203186,Chemical Compound
5431,SB-203580,Chemical Compound
5432,GAK,Gene
5433,SB-205384,Chemical Compound
5434,SB-206553,Chemical Compound
5435,SB-216641,Chemical Compound
5436,SB-216763,Chemical Compound
5437,SB-218078,Chemical Compound
5438,TACR3,Gene
5439,SB-218795,Chemical Compound
5440,SB-221284,Chemical Compound
5441,SB-222200,Chemical Compound
5442,SB-225002,Chemical Compound
5443,SB-228357,Chemical Compound
5444,SB-2343,Chemical Compound
5445,SB-239063,Chemical Compound
5446,SB-242235,Chemical Compound
5447,SB-243213,Chemical Compound
5448,SB-258585,Chemical Compound
5449,SB-268262,Chemical Compound
5450,SB-269970,Chemical Compound
5451,SB-271046,Chemical Compound
5452,CCR3,Gene
5453,SB-297006,Chemical Compound
5454,SB-334867,Chemical Compound
5455,SB-366791,Chemical Compound
5456,SB-399885,Chemical Compound
5457,SB-408124,Chemical Compound
5458,SB-415286,Chemical Compound
5459,ACVR1C,Gene
5460,SB-431542,Chemical Compound
5461,SB-452533,Chemical Compound
5462,SB-505124,Chemical Compound
5463,SB-525334,Chemical Compound
5464,SB-590885,Chemical Compound
5465,SB-612111,Chemical Compound
5466,SB-657510,Chemical Compound
5467,SB-683698,Chemical Compound
5468,ITGB7,Gene
5469,SB-705498,Chemical Compound
5470,SB-706375,Chemical Compound
5471,SB-742457,Chemical Compound
5472,SB-743921,Chemical Compound
5473,SB-747651A,Chemical Compound
5474,RPS6KA5,Gene
5475,SB-756050,Chemical Compound
5476,SB-772077B,Chemical Compound
5477,SB-939,Chemical Compound
5478,SBE-13,Chemical Compound
5479,SBHA,Chemical Compound
5480,SC-10,Chemical Compound
5481,IL17A,Gene
5482,SC-12267,Chemical Compound
5483,SC-19220,Chemical Compound
5484,SC-236,Chemical Compound
5485,SC-51089,Chemical Compound
5486,SC-560,Chemical Compound
5487,SC-9,Chemical Compound
5488,SCH-202676,Chemical Compound
5489,SCH-221510,Chemical Compound
5490,SCH-23390,Chemical Compound
5491,KCNJ6,Gene
5492,SCH-28080,Chemical Compound
5493,SCH-51344,Chemical Compound
5494,SCH-58261,Chemical Compound
5495,SCH-900776,Chemical Compound
5496,schisandrin-B,Chemical Compound
5497,SCMC-Lys,Chemical Compound
5498,scopolamine,Chemical Compound
5499,SI,Gene
5500,scopolamine-N-oxide,Chemical Compound
5501,scriptaid,Chemical Compound
5502,SD-169,Chemical Compound
5503,SD-208,Chemical Compound
5504,SD-2590,Chemical Compound
5505,SDM25N,Chemical Compound
5506,SDZ-NKT-343,Chemical Compound
5507,SDZ-SER-082,Chemical Compound
5508,SDZ-WAG-994,Chemical Compound
5509,SDZ-205-557,Chemical Compound
5510,SDZ-21009,Chemical Compound
5511,SDZ-220-040,Chemical Compound
5512,SDZ-220-581,Chemical Compound
5513,secalciferol,Chemical Compound
5514,securinine,Chemical Compound
5515,segesterone-acetate,Chemical Compound
5516,selegiline,Chemical Compound
5517,selexipag,Chemical Compound
5518,selfotel,Chemical Compound
5519,selinexor,Chemical Compound
5520,selumetinib,Chemical Compound
5521,semagacestat,Chemical Compound
5522,semapimod,Chemical Compound
5523,semaxanib,Chemical Compound
5524,SEN-1269,Chemical Compound
5525,senicapoc,Chemical Compound
5526,seocalcitol,Chemical Compound
5527,SEP-227900,Chemical Compound
5528,seratrodast,Chemical Compound
5529,serdemetan,Chemical Compound
5530,serotonin,Chemical Compound
5531,sertindole,Chemical Compound
5532,sertraline,Chemical Compound
5533,setipiprant,Chemical Compound
5534,setiptiline,Chemical Compound
5535,sevoflurane,Chemical Compound
5536,SEW-2871,Chemical Compound
5537,MCOLN3,Gene
5538,SF-11,Chemical Compound
5539,SGC-CBP30,Chemical Compound
5540,PRMT3,Gene
5541,SGC-707,Chemical Compound
5542,SGI-1027,Chemical Compound
5543,SGI-1776,Chemical Compound
5544,SGS-742,Chemical Compound
5545,SGX523,Chemical Compound
5546,NPSR1,Gene
5547,SHA-68,Chemical Compound
5548,SHP099,Chemical Compound
5549,SIB-1553A,Chemical Compound
5550,SIB-1757,Chemical Compound
5551,SIB-1893,Chemical Compound
5552,NR5A1,Gene
5553,SID-7969543,Chemical Compound
5554,siguazodan,Chemical Compound
5555,sildenafil,Chemical Compound
5556,silibinin,Chemical Compound
5557,silodosin,Chemical Compound
5558,simeprevir,Chemical Compound
5559,simvastatin,Chemical Compound
5560,CARM1,Gene
5561,sinefungin,Chemical Compound
5562,sipatrigine,Chemical Compound
5563,siponimod,Chemical Compound
5564,siramesine,Chemical Compound
5565,sirolimus,Chemical Compound
5566,SirReal-2,Chemical Compound
5567,sirtinol,Chemical Compound
5568,SMAD3,Gene
5569,SIS3,Chemical Compound
5570,sitagliptin,Chemical Compound
5571,sitaxentan,Chemical Compound
5572,sivelestat,Chemical Compound
5573,MDM4,Gene
5574,SJ-172550,Chemical Compound
5575,SKF-10047-(+),Chemical Compound
5576,SKA-31,Chemical Compound
5577,skepinone-L,Chemical Compound
5578,SKF-38393,Chemical Compound
5579,SKF-77434,Chemical Compound
5580,SKF-81297,Chemical Compound
5581,SKF-83566,Chemical Compound
5582,SKF-86002,Chemical Compound
5583,SKF-89976A,Chemical Compound
5584,SKF-91488,Chemical Compound
5585,SKF-96365,Chemical Compound
5586,TRPC1,Gene
5587,SKI-II,Chemical Compound
5588,SKLB1002,Chemical Compound
5589,SLV-319-(+/-),Chemical Compound
5590,SLV-320,Chemical Compound
5591,SM-164,Chemical Compound
5592,SM-21,Chemical Compound
5593,SNCA,Gene
5594,SMER-28,Chemical Compound
5595,SMI-4a,Chemical Compound
5596,SN-2,Chemical Compound
5597,SN-38,Chemical Compound
5598,SNAP,Chemical Compound
5599,SNAP-5089,Chemical Compound
5600,SNAP-94847,Chemical Compound
5601,SNC-80,Chemical Compound
5602,SNG-1153,Chemical Compound
5603,SNS-314,Chemical Compound
5604,SNX-5422,Chemical Compound
5605,sobetirome,Chemical Compound
5606,sodium-butyrate,Chemical Compound
5607,sodium-dodecyl-sulfate,Chemical Compound
5608,sodium-monofluorophosphate,Chemical Compound
5609,PTPN6,Gene
5610,sodium-stibogluconate,Chemical Compound
5611,sodium-tetradecyl-sulfate,Chemical Compound
5612,CBR1,Gene
5613,sofalcone,Chemical Compound
5614,solcitinib,Chemical Compound
5615,solifenacin-succinate,Chemical Compound
5616,somatostatin,Chemical Compound
5617,SSTR4,Gene
5618,sonidegib,Chemical Compound
5619,sorafenib,Chemical Compound
5620,sorbinil,Chemical Compound
5621,sotagliflozin,Chemical Compound
5622,sotalol,Chemical Compound
5623,sotrastaurin,Chemical Compound
5624,PRKCH,Gene
5625,SP-100030,Chemical Compound
5626,SP-141,Chemical Compound
5627,spaglumic-acid,Chemical Compound
5628,sparfloxacin,Chemical Compound
5629,sparfosate,Chemical Compound
5630,USP10,Gene
5631,spautin-1,Chemical Compound
5632,USP13,Gene
5633,spermidine,Chemical Compound
5634,spermine,Chemical Compound
5635,SMOX,Gene
5636,SMS,Gene
5637,GPR12,Gene
5638,sphingosylphosphorylcholine,Chemical Compound
5639,spiperone,Chemical Compound
5640,spiradoline,Chemical Compound
5641,spironolactone,Chemical Compound
5642,CYP11B2,Gene
5643,SHBG,Gene
5644,spiroxatrine,Chemical Compound
5645,splitomycin,Chemical Compound
5646,SPP301,Chemical Compound
5647,SPP86,Chemical Compound
5648,FDFT1,Gene
5649,SQ-109,Chemical Compound
5650,SQ-22536,Chemical Compound
5651,SR-1078,Chemical Compound
5652,RORC,Gene
5653,SR-140333,Chemical Compound
5654,SR-1664,Chemical Compound
5655,SR-2211,Chemical Compound
5656,SR-2640,Chemical Compound
5657,SR-27897,Chemical Compound
5658,SR-3306,Chemical Compound
5659,SR-3576,Chemical Compound
5660,SR-3677,Chemical Compound
5661,SR-57227A,Chemical Compound
5662,SR-59230A,Chemical Compound
5663,SR-95639A,Chemical Compound
5664,SRC-kinase-inhibitor-I,Chemical Compound
5665,SRPK1,Gene
5666,SRPIN340,Chemical Compound
5667,SRT1720,Chemical Compound
5668,SRT2104,Chemical Compound
5669,SSR180711,Chemical Compound
5670,MYD88,Gene
5671,ST-2825,Chemical Compound
5672,STA-5326,Chemical Compound
5673,STAT3-inhibitor-VI,Chemical Compound
5674,stemregenin-1,Chemical Compound
5675,STF-083010,Chemical Compound
5676,STF-118804,Chemical Compound
5677,STF-31,Chemical Compound
5678,SLC2A1,Gene
5679,stiripentol,Chemical Compound
5680,stobadine,Chemical Compound
5681,strontium-ranelate,Chemical Compound
5682,strychnine,Chemical Compound
5683,substance-P,Chemical Compound
5684,succinic-acid,Chemical Compound
5685,HSD17B6,Gene
5686,OXCT1,Gene
5687,OXCT2,Gene
5688,PLOD1,Gene
5689,PLOD3,Gene
5690,SDHA,Gene
5691,SDHB,Gene
5692,SDHC,Gene
5693,SLC13A1,Gene
5694,SLC13A2,Gene
5695,SLC13A3,Gene
5696,SLC25A10,Gene
5697,SUCLA2,Gene
5698,SUCLG1,Gene
5699,SUCLG2,Gene
5700,SUCNR1,Gene
5701,TMLHE,Gene
5702,VCAM1,Gene
5703,succinobucol,Chemical Compound
5704,CHRFAM7A,Gene
5705,succinylcholine-chloride,Chemical Compound
5706,succinylsulfathiazole,Chemical Compound
5707,sucrose,Chemical Compound
5708,ATOX1,Gene
5709,C22orf28,Gene
5710,sulfameter,Chemical Compound
5711,sulfanilamide,Chemical Compound
5712,sulfaphenazole,Chemical Compound
5713,sulfasalazine,Chemical Compound
5714,sulfinpyrazone,Chemical Compound
5715,sulforaphane,Chemical Compound
5716,sulindac,Chemical Compound
5717,sulmetozine,Chemical Compound
5718,sultiame,Chemical Compound
5719,sumanirole,Chemical Compound
5720,sumatriptan,Chemical Compound
5721,CALCR,Gene
5722,SUN-B-8155,Chemical Compound
5723,SUN-11602,Chemical Compound
5724,sunitinib,Chemical Compound
5725,suprofen,Chemical Compound
5726,suramin,Chemical Compound
5727,FSHR,Gene
5728,suritozole,Chemical Compound
5729,SU014813,Chemical Compound
5730,SU11274,Chemical Compound
5731,SU16f,Chemical Compound
5732,SU3327,Chemical Compound
5733,SU4312,Chemical Compound
5734,SU9516,Chemical Compound
5735,swainsonine,Chemical Compound
5736,SX-011,Chemical Compound
5737,SYM-2081,Chemical Compound
5738,SYM-2206,Chemical Compound
5739,synephrine,Chemical Compound
5740,S1P1-agonist-III,Chemical Compound
5741,S18986,Chemical Compound
5742,S26948,Chemical Compound
5743,S4,Chemical Compound
5744,T-0070907,Chemical Compound
5745,T-0156,Chemical Compound
5746,T-0901317,Chemical Compound
5747,T-5224,Chemical Compound
5748,T-5601640,Chemical Compound
5749,T-62,Chemical Compound
5750,TA-01,Chemical Compound
5751,tabimorelin,Chemical Compound
5752,tacalcitol,Chemical Compound
5753,tacedinaline,Chemical Compound
5754,tacrine,Chemical Compound
5755,tacrolimus,Chemical Compound
5756,tadalafil,Chemical Compound
5757,TTR,Gene
5758,tafamidis-meglumine,Chemical Compound
5759,tafluprost,Chemical Compound
5760,tagatose,Chemical Compound
5761,TAK-063,Chemical Compound
5762,TAK-220,Chemical Compound
5763,TAK-285,Chemical Compound
5764,TAK-593,Chemical Compound
5765,TAK-632,Chemical Compound
5766,TAK-715,Chemical Compound
5767,TAK-733,Chemical Compound
5768,TAK-875,Chemical Compound
5769,TAK-901,Chemical Compound
5770,TAK-960,Chemical Compound
5771,talabostat,Chemical Compound
5772,taladegib,Chemical Compound
5773,talampanel,Chemical Compound
5774,talarozole,Chemical Compound
5775,talazoparib,Chemical Compound
5776,talinolol,Chemical Compound
5777,talipexole,Chemical Compound
5778,talmapimod,Chemical Compound
5779,talnetant,Chemical Compound
5780,talniflumate,Chemical Compound
5781,talopram,Chemical Compound
5782,taltirelin,Chemical Compound
5783,tamibarotene,Chemical Compound
5784,EBP,Gene
5785,tamoxifen,Chemical Compound
5786,tamsulosin,Chemical Compound
5787,tanaproget,Chemical Compound
5788,tandospirone,Chemical Compound
5789,tandutinib,Chemical Compound
5790,PDGFD,Gene
5791,tanespimycin,Chemical Compound
5792,tannic-acid,Chemical Compound
5793,tanshinone-I,Chemical Compound
5794,tanshinone-IIA,Chemical Compound
5795,taprenepag,Chemical Compound
5796,tarafenacin,Chemical Compound
5797,taranabant,Chemical Compound
5798,targinine,Chemical Compound
5799,tariquidar,Chemical Compound
5800,TAS-103,Chemical Compound
5801,taselisib,Chemical Compound
5802,tasimelteon,Chemical Compound
5803,tasquinimod,Chemical Compound
5804,CEL,Gene
5805,taurocholate,Chemical Compound
5806,taxifolin,Chemical Compound
5807,tazarotene,Chemical Compound
5808,tazemetostat,Chemical Compound
5809,TBOA-(DL),Chemical Compound
5810,TC-A-2317,Chemical Compound
5811,MAP3K5,Gene
5812,TC-ASK-10,Chemical Compound
5813,MAP3K6,Gene
5814,TC-E-5002,Chemical Compound
5815,KDM5A,Gene
5816,TC-E-5006,Chemical Compound
5817,TC-F-2,Chemical Compound
5818,FPR2,Gene
5819,TC-FPR-43,Chemical Compound
5820,TC-G-1000,Chemical Compound
5821,TC-G-1004,Chemical Compound
5822,TC-G-1005,Chemical Compound
5823,GPR39,Gene
5824,TC-G-1008,Chemical Compound
5825,TC-H-106,Chemical Compound
5826,TC-I-15,Chemical Compound
5827,TC-I-2000,Chemical Compound
5828,TC-I-2014,Chemical Compound
5829,LPAR5,Gene
5830,TC-LPA5-4,Chemical Compound
5831,TC-Mps1-12,Chemical Compound
5832,TC-N-1752,Chemical Compound
5833,TC-NTR1-17,Chemical Compound
5834,TC-O-9311,Chemical Compound
5835,TC-OT-39,Chemical Compound
5836,OXT,Gene
5837,TC-S-7003,Chemical Compound
5838,TC-S-7004,Chemical Compound
5839,TC-S-7005,Chemical Compound
5840,TC-S-7006,Chemical Compound
5841,TC-S-7009,Chemical Compound
5842,TC-SP-14,Chemical Compound
5843,TCN201,Chemical Compound
5844,TCN238,Chemical Compound
5845,TCS-HDAC6-20b,Chemical Compound
5846,TCS-OX2-29,Chemical Compound
5847,TCS-PIM-1-1,Chemical Compound
5848,TCS-2002,Chemical Compound
5849,TCS-21311,Chemical Compound
5850,TCS-2314,Chemical Compound
5851,TCS-3035,Chemical Compound
5852,TCS-359,Chemical Compound
5853,TCS-5861528,Chemical Compound
5854,TC1,Chemical Compound
5855,TC2559,Chemical Compound
5856,tebipenem,Chemical Compound
5857,tecadenoson,Chemical Compound
5858,tecalcet,Chemical Compound
5859,tecastemizole,Chemical Compound
5860,tegaserod,Chemical Compound
5861,teijin-compound-1,Chemical Compound
5862,telaprevir,Chemical Compound
5863,telatinib,Chemical Compound
5864,telcagepant,Chemical Compound
5865,telenzepine,Chemical Compound
5866,telithromycin,Chemical Compound
5867,telmisartan,Chemical Compound
5868,telotristat,Chemical Compound
5869,telotristat-ethyl,Chemical Compound
5870,temocapril,Chemical Compound
5871,temozolomide,Chemical Compound
5872,temsirolimus,Chemical Compound
5873,tenatoprazole,Chemical Compound
5874,teneligliptin,Chemical Compound
5875,tenidap,Chemical Compound
5876,teniposide,Chemical Compound
5877,tenofovir-disoproxil,Chemical Compound
5878,tenovin-1,Chemical Compound
5879,tenovin-6,Chemical Compound
5880,SIRT3,Gene
5881,tenoxicam,Chemical Compound
5882,tepoxalin,Chemical Compound
5883,PKM,Gene
5884,TEPP-46,Chemical Compound
5885,BIRC5,Gene
5886,terameprocol,Chemical Compound
5887,terazosin,Chemical Compound
5888,terbinafine,Chemical Compound
5889,terbutaline,Chemical Compound
5890,terfenadine,Chemical Compound
5891,terguride,Chemical Compound
5892,teriflunomide,Chemical Compound
5893,terlipressin,Chemical Compound
5894,terreic-acid-(-),Chemical Compound
5895,terutroban,Chemical Compound
5896,tesaglitazar,Chemical Compound
5897,tetomilast,Chemical Compound
5898,tetrabenazine,Chemical Compound
5899,tetracaine,Chemical Compound
5900,tetraethylenepentamine,Chemical Compound
5901,tetrahydrofolic-acid,Chemical Compound
5902,CDA,Gene
5903,tetrahydrouridine,Chemical Compound
5904,tetramisole,Chemical Compound
5905,tetrandrine,Chemical Compound
5906,tetrazol-5-yl-glycine-(RS),Chemical Compound
5907,tetrindole,Chemical Compound
5908,TFC-007,Chemical Compound
5909,TG-003,Chemical Compound
5910,TG-02,Chemical Compound
5911,TG-100572,Chemical Compound
5912,TG-100801,Chemical Compound
5913,TG-101209,Chemical Compound
5914,TGX-221,Chemical Compound
5915,TG100-115,Chemical Compound
5916,TH-588,Chemical Compound
5917,thalidomide,Chemical Compound
5918,theobromine,Chemical Compound
5919,MGEA5,Gene
5920,thiamet-g,Chemical Compound
5921,SLC19A2,Gene
5922,thiamine,Chemical Compound
5923,TPK1,Gene
5924,thiamylal,Chemical Compound
5925,thiethylperazine,Chemical Compound
5926,thiocolchicoside,Chemical Compound
5927,thioctic-acid,Chemical Compound
5928,thioguanine,Chemical Compound
5929,thiomersal,Chemical Compound
5930,thiopental,Chemical Compound
5931,thioperamide,Chemical Compound
5932,thioproperazine,Chemical Compound
5933,thioridazine,Chemical Compound
5934,thiorphan,Chemical Compound
5935,FOXM1,Gene
5936,thiostrepton,Chemical Compound
5937,thiotepa,Chemical Compound
5938,thiothixene,Chemical Compound
5939,thiram,Chemical Compound
5940,thymol,Chemical Compound
5941,THZ1,Chemical Compound
5942,THZ1-R,Chemical Compound
5943,THZ2,Chemical Compound
5944,tiagabine,Chemical Compound
5945,tianeptine,Chemical Compound
5946,tiapride,Chemical Compound
5947,tiaprofenic-acid,Chemical Compound
5948,tibolone,Chemical Compound
5949,ticagrelor,Chemical Compound
5950,ticlopidine,Chemical Compound
5951,TIC10,Chemical Compound
5952,tideglusib,Chemical Compound
5953,tienilic-acid,Chemical Compound
5954,tie2-kinase-inhibitor,Chemical Compound
5955,tifenazoxide,Chemical Compound
5956,tiludronate,Chemical Compound
5957,timofibrate,Chemical Compound
5958,timolol,Chemical Compound
5959,tiotidine,Chemical Compound
5960,tiotropium,Chemical Compound
5961,tioxolone,Chemical Compound
5962,tipifarnib,Chemical Compound
5963,SERPINE1,Gene
5964,tiplaxtinin,Chemical Compound
5965,tiprenolol,Chemical Compound
5966,tiracizine,Chemical Compound
5967,tiratricol,Chemical Compound
5968,tirofiban,Chemical Compound
5969,tivantinib,Chemical Compound
5970,tivozanib,Chemical Compound
5971,tizanidine,Chemical Compound
5972,TMN-355,Chemical Compound
5973,TNP-470,Chemical Compound
5974,tocainide,Chemical Compound
5975,toceranib,Chemical Compound
5976,tofacitinib,Chemical Compound
5977,tofisopam,Chemical Compound
5978,tofogliflozin,Chemical Compound
5979,tolamolol,Chemical Compound
5980,tolazamide,Chemical Compound
5981,tolazoline,Chemical Compound
5982,tolbutamide,Chemical Compound
5983,tolcapone,Chemical Compound
5984,tolimidone,Chemical Compound
5985,tolmetin,Chemical Compound
5986,tolonidine,Chemical Compound
5987,toloxatone,Chemical Compound
5988,tolperisone,Chemical Compound
5989,tolrestat,Chemical Compound
5990,AKR1B10,Gene
5991,tolterodine,Chemical Compound
5992,tolvaptan,Chemical Compound
5993,tomelukast,Chemical Compound
5994,topiramate,Chemical Compound
5995,topiroxostat,Chemical Compound
5996,topotecan,Chemical Compound
5997,torasemide,Chemical Compound
5998,torcetrapib,Chemical Compound
5999,torcitabine,Chemical Compound
6000,TK2,Gene
6001,toremifene,Chemical Compound
6002,torin-1,Chemical Compound
6003,torin-2,Chemical Compound
6004,tosedostat,Chemical Compound
6005,LAP3,Gene
6006,NPEPPS,Gene
6007,toyocamycin,Chemical Compound
6008,tozadenant,Chemical Compound
6009,tozasertib,Chemical Compound
6010,TP-003,Chemical Compound
6011,TP-0903,Chemical Compound
6012,TPCA-1,Chemical Compound
6013,tracazolate,Chemical Compound
6014,TRAM-34,Chemical Compound
6015,TRAM-39,Chemical Compound
6016,trametinib,Chemical Compound
6017,tramiprosate,Chemical Compound
6018,trandolapril,Chemical Compound
6019,tranexamic-acid,Chemical Compound
6020,tranilast,Chemical Compound
6021,tranylcypromine,Chemical Compound
6022,trap-101,Chemical Compound
6023,trapidil,Chemical Compound
6024,travoprost,Chemical Compound
6025,traxoprodil,Chemical Compound
6026,trazodone,Chemical Compound
6027,trelagliptin,Chemical Compound
6028,trepibutone,Chemical Compound
6029,treprostinil,Chemical Compound
6030,trequinsin,Chemical Compound
6031,tretazicar,Chemical Compound
6032,tretinoin,Chemical Compound
6033,GPRC5A,Gene
6034,RARRES1,Gene
6035,triamcinolone,Chemical Compound
6036,triamcinolone-acetonide,Chemical Compound
6037,triamterene,Chemical Compound
6038,triapine,Chemical Compound
6039,trichlormethiazide,Chemical Compound
6040,trichostatin-a,Chemical Compound
6041,triciribine,Chemical Compound
6042,triclabendazole,Chemical Compound
6043,triclosan,Chemical Compound
6044,trientine,Chemical Compound
6045,trifluoperazine,Chemical Compound
6046,S100A4,Gene
6047,triflupromazine,Chemical Compound
6048,trifluridine,Chemical Compound
6049,triflusal,Chemical Compound
6050,trihexyphenidyl,Chemical Compound
6051,trimebutine,Chemical Compound
6052,ACAA2,Gene
6053,trimetazidine,Chemical Compound
6054,trimethadione,Chemical Compound
6055,trimethobenzamide,Chemical Compound
6056,trimethoprim,Chemical Compound
6057,trimethoquinol,Chemical Compound
6058,trimetrexate,Chemical Compound
6059,trimipramine,Chemical Compound
6060,tripelennamine,Chemical Compound
6061,triprolidine,Chemical Compound
6062,triptan,Chemical Compound
6063,triptolide,Chemical Compound
6064,triptorelin,Chemical Compound
6065,trofinetide,Chemical Compound
6066,troglitazone,Chemical Compound
6067,trometamol,Chemical Compound
6068,CANT1,Gene
6069,DCN,Gene
6070,NEIL1,Gene
6071,"tropanyl-3,5-dimethylbenzoate",Chemical Compound
6072,tropesin,Chemical Compound
6073,tropicamide,Chemical Compound
6074,tropisetron,Chemical Compound
6075,trospium,Chemical Compound
6076,trovafloxacin,Chemical Compound
6077,TRV130,Chemical Compound
6078,tryptanthrin,Chemical Compound
6079,tryptophan,Chemical Compound
6080,WARS,Gene
6081,WARS2,Gene
6082,TTNPB,Chemical Compound
6083,TTP-22,Chemical Compound
6084,tubastatin-A,Chemical Compound
6085,tubocurarine,Chemical Compound
6086,ZACN,Gene
6087,tucatinib,Chemical Compound
6088,TUG-770,Chemical Compound
6089,TUG-891,Chemical Compound
6090,tulobuterol,Chemical Compound
6091,TW-37,Chemical Compound
6092,TWS-119,Chemical Compound
6093,MYC,Gene
6094,TY-52156,Chemical Compound
6095,tyrphostin-AG-1296,Chemical Compound
6096,tyrphostin-AG-1478,Chemical Compound
6097,tyrphostin-AG-18,Chemical Compound
6098,tyrphostin-AG-494,Chemical Compound
6099,tyrphostin-AG-825,Chemical Compound
6100,tyrphostin-AG-835,Chemical Compound
6101,tyrphostin-AG-879,Chemical Compound
6102,tyrphostin-AG-99,Chemical Compound
6103,U-0126,Chemical Compound
6104,MAP2K7,Gene
6105,U-0521,Chemical Compound
6106,U-104,Chemical Compound
6107,U-50488-(-),Chemical Compound
6108,U-54494A,Chemical Compound
6109,U-75799E,Chemical Compound
6110,U-99194,Chemical Compound
6111,UAMC-00039,Chemical Compound
6112,DPP7,Gene
6113,UB-165,Chemical Compound
6114,ubenimex,Chemical Compound
6115,RNPEP,Gene
6116,UBP-296,Chemical Compound
6117,UBP-302,Chemical Compound
6118,UBP-310,Chemical Compound
6119,UC-112,Chemical Compound
6120,UF-010,Chemical Compound
6121,ufenamate,Chemical Compound
6122,UH-232-(+),Chemical Compound
6123,UK-356618,Chemical Compound
6124,UK-383367,Chemical Compound
6125,UK-5099,Chemical Compound
6126,ulipristal,Chemical Compound
6127,umeclidinium,Chemical Compound
6128,UNC0224,Chemical Compound
6129,UNC0321,Chemical Compound
6130,UNC0631,Chemical Compound
6131,UNC0638,Chemical Compound
6132,UNC0642,Chemical Compound
6133,UNC0646,Chemical Compound
6134,UNC0737,Chemical Compound
6135,L3MBTL3,Gene
6136,UNC1215,Chemical Compound
6137,UNC1999,Chemical Compound
6138,UNC2025,Chemical Compound
6139,UNC2250,Chemical Compound
6140,UNC2327,Chemical Compound
6141,PIP5K1C,Gene
6142,UNC3230,Chemical Compound
6143,L3MBTL1,Gene
6144,UNC669,Chemical Compound
6145,UNC926,Chemical Compound
6146,UPF-1069,Chemical Compound
6147,uprosertib,Chemical Compound
6148,uracil,Chemical Compound
6149,UCKL1,Gene
6150,urapidil,Chemical Compound
6151,URB597,Chemical Compound
6152,FAAH2,Gene
6153,ARG1,Gene
6154,urea,Chemical Compound
6155,uric-acid,Chemical Compound
6156,uridine,Chemical Compound
6157,TYMP,Gene
6158,uridine-5'-triphosphate,Chemical Compound
6159,CDKL2,Gene
6160,URMC-099,Chemical Compound
6161,MAP3K10,Gene
6162,MAP3K11,Gene
6163,ursodiol,Chemical Compound
6164,ursolic-acid,Chemical Compound
6165,usniacin-(+),Chemical Compound
6166,valdecoxib,Chemical Compound
6167,valethamate,Chemical Compound
6168,valproic-acid,Chemical Compound
6169,ACADSB,Gene
6170,SCN1B,Gene
6171,SCN2B,Gene
6172,SCN3B,Gene
6173,SCN4B,Gene
6174,valrubicin,Chemical Compound
6175,valsartan,Chemical Compound
6176,valspodar,Chemical Compound
6177,vandetanib,Chemical Compound
6178,EPHA1,Gene
6179,EPHA10,Gene
6180,EPHA3,Gene
6181,EPHA4,Gene
6182,EPHA5,Gene
6183,EPHA6,Gene
6184,EPHA7,Gene
6185,EPHA8,Gene
6186,EPHB1,Gene
6187,EPHB2,Gene
6188,EPHB3,Gene
6189,EPHB6,Gene
6190,PTK6,Gene
6191,vanillin,Chemical Compound
6192,vanoxerine,Chemical Compound
6193,vardenafil,Chemical Compound
6194,varenicline,Chemical Compound
6195,varespladib,Chemical Compound
6196,vasopressin,Chemical Compound
6197,vatalanib,Chemical Compound
6198,VBY-825,Chemical Compound
6199,VE-821,Chemical Compound
6200,VE-822,Chemical Compound
6201,vecuronium,Chemical Compound
6202,vedaprofen,Chemical Compound
6203,veliflapon,Chemical Compound
6204,veliparib,Chemical Compound
6205,velneperit,Chemical Compound
6206,vemurafenib,Chemical Compound
6207,venetoclax,Chemical Compound
6208,venlafaxine,Chemical Compound
6209,VER-155008,Chemical Compound
6210,VER-49009,Chemical Compound
6211,verapamil,Chemical Compound
6212,NALCN,Gene
6213,CCR9,Gene
6214,vercirnon,Chemical Compound
6215,verinurad,Chemical Compound
6216,vernakalant,Chemical Compound
6217,verubulin,Chemical Compound
6218,SLC18A3,Gene
6219,vesamicol,Chemical Compound
6220,vesnarinone,Chemical Compound
6221,VGX-1027,Chemical Compound
6222,vicriviroc,Chemical Compound
6223,vidarabine,Chemical Compound
6224,vigabatrin,Chemical Compound
6225,vilanterol,Chemical Compound
6226,vilazodone,Chemical Compound
6227,vildagliptin,Chemical Compound
6228,viloxazine,Chemical Compound
6229,vinblastine,Chemical Compound
6230,TUBD1,Gene
6231,TUBE1,Gene
6232,TUBG1,Gene
6233,vinburnine,Chemical Compound
6234,vincamine,Chemical Compound
6235,vincristine,Chemical Compound
6236,vindesine,Chemical Compound
6237,vinorelbine,Chemical Compound
6238,vinpocetine,Chemical Compound
6239,vipadenant,Chemical Compound
6240,vismodegib,Chemical Compound
6241,vitamin-E,Chemical Compound
6242,PPP2CA,Gene
6243,PPP2CB,Gene
6244,SEC14L2,Gene
6245,SEC14L3,Gene
6246,SEC14L4,Gene
6247,VLX600,Chemical Compound
6248,voglibose,Chemical Compound
6249,volasertib,Chemical Compound
6250,volinanserin,Chemical Compound
6251,vonoprazan,Chemical Compound
6252,F2R,Gene
6253,vorapaxar,Chemical Compound
6254,voreloxin,Chemical Compound
6255,voriconazole,Chemical Compound
6256,vorinostat,Chemical Compound
6257,vortioxetine,Chemical Compound
6258,voxtalisib,Chemical Compound
6259,VP-20629,Chemical Compound
6260,VT-464,Chemical Compound
6261,VTP-27999,Chemical Compound
6262,VUF10166,Chemical Compound
6263,VUF10460,Chemical Compound
6264,VUF11207,Chemical Compound
6265,VU0155069,Chemical Compound
6266,VU0238429,Chemical Compound
6267,VU0240551,Chemical Compound
6268,VU0357121,Chemical Compound
6269,VU0360172,Chemical Compound
6270,VU0361737,Chemical Compound
6271,VU0364439,Chemical Compound
6272,VU0364739,Chemical Compound
6273,VU0364770,Chemical Compound
6274,VU0422288,Chemical Compound
6275,VU10010,Chemical Compound
6276,VU152100,Chemical Compound
6277,VU1545,Chemical Compound
6278,VU29,Chemical Compound
6279,VU591,Chemical Compound
6280,VX-11e,Chemical Compound
6281,VX-702,Chemical Compound
6282,VX-745,Chemical Compound
6283,VX-765,Chemical Compound
6284,W-54011,Chemical Compound
6285,warfarin,Chemical Compound
6286,WAY-100635,Chemical Compound
6287,WAY-161503,Chemical Compound
6288,WAY-170523,Chemical Compound
6289,WAY-200070,Chemical Compound
6290,WAY-207024,Chemical Compound
6291,WAY-208466,Chemical Compound
6292,WAY-213613,Chemical Compound
6293,SFRP1,Gene
6294,WAY-316606,Chemical Compound
6295,WAY-362450,Chemical Compound
6296,WAY-600,Chemical Compound
6297,WAY-629,Chemical Compound
6298,WB-4101,Chemical Compound
6299,WDR5-0103,Chemical Compound
6300,WH-4-023,Chemical Compound
6301,WHI-P154,Chemical Compound
6302,WIKI4,Chemical Compound
6303,WIN-18446,Chemical Compound
6304,WIN-64338,Chemical Compound
6305,WASL,Gene
6306,wiskostatin,Chemical Compound
6307,wnt-c59,Chemical Compound
6308,PI4KA,Gene
6309,wortmannin,Chemical Compound
6310,WP1066,Chemical Compound
6311,WP1130,Chemical Compound
6312,UCHL5,Gene
6313,USP9X,Gene
6314,WR99210,Chemical Compound
6315,CES3,Gene
6316,WWL-113,Chemical Compound
6317,ABHD6,Gene
6318,WWL-123,Chemical Compound
6319,WYE-125132,Chemical Compound
6320,WYE-354,Chemical Compound
6321,WYE-687,Chemical Compound
6322,WZ-3146,Chemical Compound
6323,WZ-4002,Chemical Compound
6324,WZ4003,Chemical Compound
6325,NUAK2,Gene
6326,WZ8040,Chemical Compound
6327,WZ811,Chemical Compound
6328,xaliproden,Chemical Compound
6329,xamoterol,Chemical Compound
6330,xanomeline,Chemical Compound
6331,XAV-939,Chemical Compound
6332,XBD173,Chemical Compound
6333,XD-14,Chemical Compound
6334,XE-991,Chemical Compound
6335,xipamide,Chemical Compound
6336,XL019,Chemical Compound
6337,XL147,Chemical Compound
6338,XL228,Chemical Compound
6339,XL388,Chemical Compound
6340,XL647,Chemical Compound
6341,XMD17-109,Chemical Compound
6342,DCLK2,Gene
6343,XMD8-92,Chemical Compound
6344,TNK1,Gene
6345,xylazine,Chemical Compound
6346,xylometazoline,Chemical Compound
6347,Y-11,Chemical Compound
6348,Y-134,Chemical Compound
6349,Y-26763,Chemical Compound
6350,Y-27152,Chemical Compound
6351,Y-27632,Chemical Compound
6352,PKN2,Gene
6353,Y-29794,Chemical Compound
6354,Y-320,Chemical Compound
6355,Y-39983,Chemical Compound
6356,YC-1,Chemical Compound
6357,YIL-781,Chemical Compound
6358,EWSR1,Gene
6359,YK-4-279,Chemical Compound
6360,FLI1,Gene
6361,YM-022,Chemical Compound
6362,YM-155,Chemical Compound
6363,YM-298198,Chemical Compound
6364,YM-298198-desmethyl,Chemical Compound
6365,YM-511,Chemical Compound
6366,YM-58483,Chemical Compound
6367,YM-750,Chemical Compound
6368,CSF2RB,Gene
6369,YM-90709,Chemical Compound
6370,IL5RA,Gene
6371,YM-976,Chemical Compound
6372,PIEZO1,Gene
6373,yoda-1,Chemical Compound
6374,yohimbine,Chemical Compound
6375,KCNJ14,Gene
6376,KCNJ15,Gene
6377,YZ9,Chemical Compound
6378,RHOA,Gene
6379,Y16,Chemical Compound
6380,zacopride,Chemical Compound
6381,zafirlukast,Chemical Compound
6382,zaldaride,Chemical Compound
6383,zaltidine,Chemical Compound
6384,zamifenacin,Chemical Compound
6385,zanamivir,Chemical Compound
6386,zaprinast,Chemical Compound
6387,zardaverine,Chemical Compound
6388,zatebradine,Chemical Compound
6389,HCN2,Gene
6390,ZCL-278,Chemical Compound
6391,ZD-2079,Chemical Compound
6392,ZD-7114,Chemical Compound
6393,ZD-7155,Chemical Compound
6394,ZD-7288,Chemical Compound
6395,zebularine,Chemical Compound
6396,zibotentan,Chemical Compound
6397,zidovudine,Chemical Compound
6398,zileuton,Chemical Compound
6399,zilpaterol,Chemical Compound
6400,zimelidine,Chemical Compound
6401,ziprasidone,Chemical Compound
6402,ZK-164015,Chemical Compound
6403,ZK-811752,Chemical Compound
6404,ZK-93423,Chemical Compound
6405,ZK-93426,Chemical Compound
6406,ZLN024,Chemical Compound
6407,ZM-241385,Chemical Compound
6408,ZM-306416,Chemical Compound
6409,ZM-323881,Chemical Compound
6410,ZM-336372,Chemical Compound
6411,ZM-39923,Chemical Compound
6412,ZM-447439,Chemical Compound
6413,zofenopril-calcium,Chemical Compound
6414,zoledronic-acid,Chemical Compound
6415,zolmitriptan,Chemical Compound
6416,zomepirac,Chemical Compound
6417,zoniporide,Chemical Compound
6418,zonisamide,Chemical Compound
6419,CA10,Gene
6420,CA11,Gene
6421,CA8,Gene
6422,zopolrestat,Chemical Compound
6423,zosuquidar,Chemical Compound
6424,ABCB4,Gene
6425,zotarolimus,Chemical Compound
6426,zotepine,Chemical Compound
6427,ZSTK-474,Chemical Compound
6428,zuclopenthixol,Chemical Compound
6429,Z160,Chemical Compound
6430,"1,2,3,4,5,6-hexabromocyclohexane",Chemical Compound
6431,"1,4-butanediol",Chemical Compound
6432,1-azakenpaullone,Chemical Compound
6433,1-deoxymannojirimycin,Chemical Compound
6434,1-EBIO,Chemical Compound
6435,1-hexadecanal,Chemical Compound
6436,1-naphthyl-PP1,Chemical Compound
6437,1-octanol,Chemical Compound
6438,1-phenylbiguanide,Chemical Compound
6439,10-DEBC,Chemical Compound
6440,10-hydroxycamptothecin,Chemical Compound
6441,KCNT2,Gene
6442,12-O-tetradecanoylphorbol-13-acetate,Chemical Compound
6443,1400W,Chemical Compound
6444,"16,16-dimethylprostaglandin-e2",Chemical Compound
6445,17-hydroxyprogesterone-caproate,Chemical Compound
6446,2'-MeCCPA,Chemical Compound
6447,"2,3-DCPE",Chemical Compound
6448,"2,4-dinitrochlorobenzene",Chemical Compound
6449,"2,4-dinitrophenol",Chemical Compound
6450,"2,5-furandimethanol",Chemical Compound
6451,2-(3-mercaptopropyl)pentanedioic-acid,Chemical Compound
6452,2-[1-(4-piperonyl)piperazinyl]benzothiazole,Chemical Compound
6453,2-aminobenzenesulfonamide,Chemical Compound
6454,2-APB,Chemical Compound
6455,TRPM6,Gene
6456,TRPV6,Gene
6457,2-BFI,Chemical Compound
6458,2-chloro-N6-cyclopentyladenosine,Chemical Compound
6459,2-chloroadenosine,Chemical Compound
6460,2-CMDO,Chemical Compound
6461,2-deoxyglucose,Chemical Compound
6462,SLC2A2,Gene
6463,SLC2A3,Gene
6464,SLC2A4,Gene
6465,2-fluoro-2-deoxy-D-galactose,Chemical Compound
6466,2-hydroxyflutamide,Chemical Compound
6467,2-hydroxysaclofen,Chemical Compound
6468,2-iminobiotin,Chemical Compound
6469,2-iodomelatonin,Chemical Compound
6470,2-methoxyestradiol,Chemical Compound
6471,2-methyl-5-hydroxytryptamine,Chemical Compound
6472,2-oleoylglycerol,Chemical Compound
6473,OXGR1,Gene
6474,2-oxoglutaric-acid,Chemical Compound
6475,2-oxopropanoate,Chemical Compound
6476,2-phenylmelatonin,Chemical Compound
6477,2-PMDQ,Chemical Compound
6478,2-pyridylethylamine,Chemical Compound
6479,ALOX12,Gene
6480,2-TEDC,Chemical Compound
6481,3'-fluorobenzylspiperone,Chemical Compound
6482,"3,3'-dichlorobenzaldazine",Chemical Compound
6483,"3,3'-diindolylmethane",Chemical Compound
6484,PI3,Gene
6485,"3,4-DCPG-(+/-)",Chemical Compound
6486,"3,4-DCPG-(S)",Chemical Compound
6487,"3,4-methylenedioxy-beta-nitrostyrene",Chemical Compound
6488,"3,5-DHPG-(S)",Chemical Compound
6489,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Chemical Compound
6490,HSD17B11,Gene
6491,3-alpha-hydroxy-5-beta-androstan-17-one,Chemical Compound
6492,IGHG2,Gene
6493,3-amino-benzamide,Chemical Compound
6494,3-AQC,Chemical Compound
6495,3-bromo-7-nitroindazole,Chemical Compound
6496,HK2,Gene
6497,3-bromopyruvate,Chemical Compound
6498,3-carboxy-4-hydroxyphenylglycine-(R),Chemical Compound
6499,3-carboxy-4-hydroxyphenylglycine-(S),Chemical Compound
6500,3-deazaadenosine,Chemical Compound
6501,3-deazaneplanocin-A,Chemical Compound
6502,B2M,Gene
6503,3-indolebutyric-acid,Chemical Compound
6504,HLA-A,Gene
6505,TRAC,Gene
6506,TRBC1,Gene
6507,3-MATIDA,Chemical Compound
6508,3-methyl-GABA,Chemical Compound
6509,3-methyladenine,Chemical Compound
6510,3-MPPI,Chemical Compound
6511,3PO,Chemical Compound
6512,"4,5,6,7-tetrabromobenzotriazole",Chemical Compound
6513,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Chemical Compound
6514,4-aminohippuric-acid,Chemical Compound
6515,4-carboxy-3-hydroxyphenylglycine-(RS),Chemical Compound
6516,4-carboxy-3-hydroxyphenylglycine-(S),Chemical Compound
6517,PLAUR,Gene
6518,4-chlorophenylguanidine,Chemical Compound
6519,4-CMTB,Chemical Compound
6520,4-DAMP,Chemical Compound
6521,4-HQN,Chemical Compound
6522,4-IBP,Chemical Compound
6523,4-iodo-L-phenylalanine,Chemical Compound
6524,4-iodo-6-phenylpyrimidine,Chemical Compound
6525,4-methylgenistein,Chemical Compound
6526,4-methylhistamine,Chemical Compound
6527,4-mu-8C,Chemical Compound
6528,4-P-PDOT,Chemical Compound
6529,4-PPBP,Chemical Compound
6530,4BP-TQS,Chemical Compound
6531,EIF4E,Gene
6532,4EGI-1,Chemical Compound
6533,4E1RCat,Chemical Compound
6534,EIF4G1,Gene
6535,4SC-202,Chemical Compound
6536,5'-chloro-5'-deoxy-ENBA-(+/-),Chemical Compound
6537,"5,7-dichlorokynurenic-acid",Chemical Compound
6538,"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",Chemical Compound
6539,ALAD,Gene
6540,5-aminolevulinic-acid,Chemical Compound
6541,P2RX4,Gene
6542,5-BDBD,Chemical Compound
6543,5-carboxamidotryptamine,Chemical Compound
6544,5-fluorouracil,Chemical Compound
6545,5-FP,Chemical Compound
6546,5-hydroxymethyl-tolterodine,Chemical Compound
6547,5-hydroxytryptophan,Chemical Compound
6548,SLC36A2,Gene
6549,5-methylfurmethiodide,Chemical Compound
6550,6-chloromelatonin,Chemical Compound
6551,6-iodo-nordihydrocapsaicin,Chemical Compound
6552,7-chlorokynurenic-acid,Chemical Compound
6553,7-hydroxy-DPAT,Chemical Compound
6554,7-hydroxy-PIPAT,Chemical Compound
6555,7-hydroxystaurosporine,Chemical Compound
6556,MARK1,Gene
6557,MARK3,Gene
6558,7-methoxytacrine,Chemical Compound
6559,7-nitroindazole,Chemical Compound
6560,8-bromo-cGMP,Chemical Compound
6561,8-hydroxy-DPAT,Chemical Compound
6562,8-hydroxy-PIPAT,Chemical Compound
6563,8-M-PDOT,Chemical Compound
6564,9-aminocamptothecin,Chemical Compound
6565,9-anthracenecarboxylic-acid,Chemical Compound
6566,FILIP1,Gene
6568,HIST1H2AH,Gene
6570,LY86,Gene
6572,BMP6,Gene
6574,CENPW,Gene
6576,UHRF1BP1,Gene
6578,AKTIP,Gene
6580,HMGA1,Gene
6582,C16orf55,Gene
6584,CORO7,Gene
6586,GPR126,Gene
6588,TFAP2B,Gene
6590,FTO,Gene
6594,GPRC5B,Gene
6596,SH2B1,Gene
6598,PARK2,Gene
6600,TDRG1,Gene
6602,C6orf106,Gene
6604,HIVEP1,Gene
6607,ADCY9,Gene
6609,SBK1,Gene
6612,STX1B2,Gene
6616,HIST1H2BF,Gene
6618,NUDT3,Gene
6622,intergenic,Gene
6624,MMS22L,Gene
6626,CBLN1,Gene
6628,PRMT7,Gene
6630,FOXO3,Gene
6632,KAT8,Gene
6635,IFNGR1,Gene
6637,DEFB112,Gene
6640,NR,Gene
6650,LRFN2,Gene
6651,WWOX,Gene
6654,NLRC3,Gene
6656,CAHM,Gene
6659,ZNF423,Gene
6661,HIST1H3G,Gene
6663,HIST1H2BH,Gene
6665,FOXO3A,Gene
6670,HCG22,Gene
6672,HLA-B,Gene
6673,MUC22,Gene
6674,RNF146,Gene
6676,RSPO3,Gene
6684,INO80E,Gene
6686,SLC22A2,Gene
6688,LINC00340,Gene
6690,MIR1538,Gene
6692,HLA-DQA2,Gene
6694,LOC285762,Gene
6696,LEMD2,Gene
6698,CDKAL1,Gene
6700,ANKRD6,Gene
6702,USP49,Gene
6704,HLA,Gene
6706,HLA-C,Gene
6707,TNFAIP3,Gene
6710,PRSS53,Gene
6712,FBXL19,Gene
6713,TRAF3IP2,Gene
6715,PRM3,Gene
6717,SOCS1,Gene
6720,MHC,Gene
6737,BTNL2,Gene
6740,CMIP,Gene
6742,HS3ST4,Gene
6744,C16orf82,Gene
6745,HLA-DRB1,Gene
6747,HLA-DQA1,Gene
6748,HLA-DQB1,Gene
6749,COG7,Gene
6751,LOC729993,Gene
6753,ERCC4,Gene
6754,LITAF,Gene
6756,MKL2,Gene
6758,CNOT1,Gene
6761,BACH2,Gene
6763,NKAIN2,Gene
6765,TAGAP,Gene
6767,TRIM31,Gene
6772,MICA,Gene
6776,CCR6,Gene
6795,HLA-DRA,Gene
6797,HLA-DRB,Gene
6799,HLA-DQB,Gene
6804,C4,Gene
6807,HPR,Gene
6809,HP,Gene
6810,DHX38,Gene
6811,ELOVL2,Gene
6815,ZFHX3,Gene
6817,ATG5,Gene
6821,ITGAM,Gene
6823,IRF8,Gene
6827,SLC22A3,Gene
6829,GAPDHP15,Gene
6831,RBBP4P4,Gene
6832,OFCC1,Gene
6834,RPL7AP36,Gene
6835,PEX6,Gene
6837,SOCS5P5,Gene
6839,MARCKS,Gene
6840,MTHFD1L,Gene
6842,AKAP12,Gene
6843,CPPED1,Gene
6845,SNX29,Gene
6846,FAM46A,Gene
6848,CDH13,Gene
6850,HERPU,Gene
6852,HERPUD1,Gene
6853,CET,Gene
6855,MAS1L,Gene
6857,TRIM39,Gene
6859,RPP21,Gene
6860,FLOT1,Gene
6862,MUC21,Gene
6864,CSNK2B,Gene
6866,MSH5,Gene
6867,MICB,Gene
6869,PSORS1C1,Gene
6871,ARID1B,Gene
6873,RMI2,Gene
6875,PRM2,Gene
6882,LOC728275,Gene
6884,QKI,Gene
6885,LOC644906,Gene
6887,MYLIP,Gene
6889,IER3,Gene
6892,HCP5,Gene
6893,NFKBIL1,Gene
6895,LTA,Gene
6896,NCR3,Gene
6897,BAT2,Gene
6899,HSPA1L,Gene
6900,CFB,Gene
6901,TNXB,Gene
6902,NOTCH4,Gene
6904,TAP2,Gene
6908,NCOA7,Gene
6910,HEY2,Gene
6911,HS3ST5,Gene
6916,SLC44A4,Gene
6917,3.8-1,Gene
6919,HCG26,Gene
6925,BCKDHB,Gene
6928,SLC35F1,Gene
6931,PMFBMP1,Gene
6934,IDDM8,Gene
6938,OLIG3,Gene
6940,NPRL3,Gene
6942,GMPR,Gene
6945,PLN,Gene
6950,HFE,Gene
6952,SLC17A3,Gene
6953,CCND3,Gene
6955,CCDC162P,Gene
6957,HBS1L,Gene
6959,CITED2,Gene
6961,LOC645434,Gene
6963,KIF22,Gene
6964,FAM38A,Gene
6966,CDC5L,Gene
6968,SUPT3H,Gene
6970,GPANK1,Gene
6975,SH3BGRL2,Gene
6977,CDH11,Gene
6979,SMIM13,Gene
6981,DSE,Gene
6984,HLA-DRB5,Gene
6987,MLN,Gene
6988,MIF1,Gene
6989,IP6K3,Gene
6990,RNASET2,Gene
6992,FGFR1OP,Gene
6993,MIR3939,Gene
6994,LOC100507489,Gene
6998,HLA region,Gene
7001,SLC2A12,Gene
7005,MAN1A1,Gene
7008,C6orf223,Gene
7010,PHACTR1,Gene
7012,CAP2,Gene
7014,REPS1,Gene
7016,PKD1L3,Gene
7023,LOC100130044,Gene
7025,NT5DC1,Gene
7030,TUSC1,Gene
7032,RBFOX1,Gene
7034,REEP3,Gene
7036,AK097143,Gene
7038,PCLO,Gene
7040,MIR548,Gene
7045,C6orf15,Gene
7051,LY86-AS1,Gene
7053,BAK1,Gene
7055,EYS,Gene
7067,TMC5,Gene
7069,PLLP,Gene
7072,COL21A1,Gene
7078,GP2,Gene
7080,ZFP1,Gene
7082,CTRB1,Gene
7083,CFDP1,Gene
7084,TMEM170A,Gene
7085,CHST6,Gene
7086,CHST5,Gene
7087,TMEM231,Gene
7088,GABARAPL2,Gene
7089,ADAT1,Gene
7090,TERF21P,Gene
7091,LDHD,Gene
7092,BCAR1,Gene
7093,CTRB2,Gene
7094,FA2H,Gene
7095,WDR59,Gene
7096,ZNFR1,Gene
7097,OR2B7P,Gene
7100,HACE1,Gene
7102,NECAB2,Gene
7106,MYB,Gene
7108,HLA-DOA,Gene
7116,HLA-DQB2,Gene
7118,HLA-DPA1,Gene
7120,HLA-DPB1,Gene
7123,TCF19,Gene
7125,HDGFL1,Gene
7131,LOC101928923,Gene
7134,SLC22A23,Gene
7138,RP1-239K6.1,Gene
7147,EXOC2,Gene
7149,IRF4,Gene
7155,C6orf37,Gene
7157,PLEKHG1,Gene
7163,HLA class II,Gene
7164,HLA class I,Gene
7165,STXBP5,Gene
7168,CASC15,Gene
7173,SRL,Gene
7175,FOXF2,Gene
7178,RSPH3,Gene
7179,EZR,Gene
7181,SLC17A4,Gene
7185,BYSL,Gene
7187,FRS3,Gene
7188,DST,Gene
7190,BEND6,Gene
7191,IMPG1,Gene
7193,SIM1,Gene
7195,MCHR2,Gene
7199,ASCC3,Gene
7200,LIN28B,Gene
7204,PTPRK,Gene
7208,FAM83B,Gene
7210,KCTD13,Gene
7212,TBX6,Gene
7214,COG4,Gene
7216,NFAT5,Gene
7218,WWP2,Gene
7223,SNX9,Gene
7226,SERAC1,Gene
7231,FNDC1,Gene
7235,AGPAT4,Gene
7237,SLC17A1,Gene
7239,HIST1H2AA,Gene
7242,LRRC16,Gene
7248,LOC100132735,Gene
7249,SYCP2L,Gene
7252,C6orf129,Gene
7254,FTSJD2,Gene
7255,FLJ45825,Gene
7257,COPS5P,Gene
7258,TSG1,Gene
7259,LOC729070,Gene
7261,LOC729076,Gene
7263,LOC729161,Gene
7265,LOC729177,Gene
7266,OR12D1P,Gene
7268,OR11A1,Gene
7270,THEMIS,Gene
7273,IL4R,Gene
7275,IL21R,Gene
7276,ATP2C2,Gene
7278,FGFR3P,Gene
7281,CCHCR1,Gene
7284,HYDIN,Gene
7286,RP1-23E21.2,Gene
7289,CCDC102A,Gene
7292,SYT17,Gene
7296,SPATA33,Gene
7300,RIMS1,Gene
7302,FUT9,Gene
7306,AK096023,Gene
7308,AY927499,Gene
7309,C6orf89,Gene
7310,CCDC167,Gene
7311,CPNE5,Gene
7312,FGD2,Gene
7313,MDGA1,Gene
7314,MIR4462,Gene
7315,MTCH1,Gene
7316,PI16,Gene
7317,PPIL1,Gene
7318,RNF8,Gene
7319,TBC1D22B,Gene
7320,TMEM217,Gene
7321,TRNA_Gln,Gene
7322,ZFAND3,Gene
7323,MBOAT1,Gene
7327,TRIM10,Gene
7328,PPP1R11,Gene
7329,TRIM40,Gene
7330,TRIM15,Gene
7331,HLA-A29.1,Gene
7332,TRIM26,Gene
7333,HCG9,Gene
7334,ZNRD1,Gene
7335,RNF39,Gene
7336,IYD,Gene
7348,LOC643623,Gene
7350,LOC100131869,Gene
7354,LINC00243,Gene
7355,LMBRD1,Gene
7357,LOC154449,Gene
7359,DLL1,Gene
7360,HLA-DPB2,Gene
7362,MON1B,Gene
7364,CNTNAP4,Gene
7365,SNRPC,Gene
7367,ZNF184,Gene
7369,C2,Gene
7374,NLRC5,Gene
7377,BCKDK,Gene
7379,STX1B,Gene
7383,SLC17A cluster,Gene
7385,NUP93,Gene
7388,YAP1P1,Gene
7392,NOD2,Gene
7394,AIF1,Gene
7396,LOC100129694,Gene
7400,DAAM2,Gene
7402,IRX5,Gene
7404,IRX6,Gene
7407,FOXF1-AS1,Gene
7409,RP11-436I24.1,Gene
7412,HAAO,Gene
7413,MTA3,Gene
7414,LAMA2,Gene
7419,MAF,Gene
7421,C6orf97,Gene
7423,FOXL1,Gene
7429,SALL1,Gene
7431,HSF2,Gene
7439,LOC100287612,Gene
7441,POU3F2,Gene
7443,MIR2113,Gene
7444,UMOD,Gene
7446,PDILT,Gene
7447,PDSS2,Gene
7451,ARHGAP18,Gene
7454,SEZ6L2,Gene
7457,PRDM1,Gene
7461,CLEC16A,Gene
7464,SLC38,Gene
7466,A8,Gene
7469,CDSN,Gene
7470,TREM2,Gene
7476,ATXN2L,Gene
7478,TUFM,Gene
7479,EIF3CL,Gene
7480,NFATC2IP,Gene
7481,NUPR1,Gene
7482,SPNS1,Gene
7483,LAT,Gene
7484,SULT1A1,Gene
7485,SULT1A2,Gene
7486,CCDC101,Gene
7495,SLC17A2,Gene
7498,N4BP1,Gene
7500,GPR31,Gene
7502,CBFA2T3,Gene
7504,PHACTR2,Gene
7507,CHD9,Gene
7509,CLEC3A,Gene
7511,WFDC1,Gene
7516,TOX3,Gene
7523,ZNF469,Gene
7527,A2BP1,Gene
7530,HMIP,Gene
7538,FAM86A,Gene
7541,PPIL4,Gene
7544,NFKBIE,Gene
7547,MIR4642,Gene
7552,CEP162,Gene
7554,TBX18,Gene
7555,RP1-90L14.1,Gene
7556,KIAA1009,Gene
7557,RP11-132M7.1,Gene
7564,LOC100508120,Gene
7566,NAA60,Gene
7570,ALDOA,Gene
7572,ASPHD1,Gene
7573,C16orf92,Gene
7574,DOC2A,Gene
7575,FAM57B,Gene
7576,GDPD3,Gene
7577,HIRIP3,Gene
7578,PPP4C,Gene
7579,TMEM219,Gene
7580,YPEL3,Gene
7582,SLC38A7,Gene
7583,ACD,Gene
7585,C16orf86,Gene
7586,CENPT,Gene
7587,CTRL,Gene
7588,DDX28,Gene
7589,DPEP2,Gene
7590,DPEP3,Gene
7591,DUS2L,Gene
7592,EDC4,Gene
7593,ENKD1,Gene
7594,ESRP2,Gene
7595,GFOD2,Gene
7596,LCAT,Gene
7597,NFATC3,Gene
7598,NRN1L,Gene
7599,NUTF2,Gene
7600,PARD6A,Gene
7601,PLA2G15,Gene
7602,PSKH1,Gene
7603,RANBP10,Gene
7604,SLC7A6,Gene
7605,SLC7A6OS,Gene
7606,THAP11,Gene
7607,TSNAXIP1,Gene
7610,LOC732275,Gene
7612,FOXF1,Gene
7620,C6orf118,Gene
7625,TXNDC11,Gene
7631,HCG27,Gene
7635,C6orf10,Gene
7637,NOTCh4,Gene
7641,EYA4,Gene
7645,Intergenic,Gene
7646,EPB41L2,Gene
7648,TMEM200A,Gene
7652,OR2D12,Gene
7654,OR2D13,Gene
7657,FLJ44180,Gene
7662,MCCD1,Gene
7664,BAT1,Gene
7665,LTB,Gene
7674,CYP21A2,Gene
7678,C6orf173,Gene
7682,MIR1275,Gene
7709,ITGAX,Gene
7715,TAP1,Gene
7726,IPCEF1,Gene
7731,KLHL32,Gene
7733,LINC00602,Gene
7742,HMGB3P18,Gene
7744,ATXN1,Gene
7753,HLA-DR,Gene
7758,IL20RA,Gene
7760,KCNK16,Gene
7764,RREB1,Gene
7766,SSR1,Gene
7771,TFAP2D,Gene
7778,LOC100506207,Gene
7784,PLAGL1,Gene
7787,RAB11FIP3,Gene
7790,APOBR,Gene
7793,GSE1,Gene
7795,ZFPM1,Gene
7798,HLA-B*38:02:01,Gene
7802,GMDS,Gene
7814,RP5-1120P11.1,Gene
7820,PERP,Gene
7821,LOC146513,Gene
7826,LA16c-OS12.2,Gene
7827,HBQ1,Gene
7828,Y_RNA,Gene
7829,LUC7L,Gene
7831,Z69890.1,Gene
7835,PIGQ,Gene
7837,NHLRC4,Gene
7841,RNF182,Gene
7846,C6orf183,Gene
7852,KHDRBS2,Gene
7855,EMC8,Gene
7857,RP11-542M13.2,Gene
7860,PRSS33,Gene
7863,RP11-396B14.2,Gene
7867,ZNF785,Gene
7872,ID4,Gene
7875,HCG23,Gene
7877,LINC01526,Gene
7878,SMOC2,Gene
7880,LINC01615,Gene
7882,EPM2A,Gene
7883,SNX20,Gene
7894,TEPP,Gene
7896,EDN1,Gene
7901,DNAAF1,Gene
7903,TAF1C,Gene
7908,MHC class III,Gene
7913,CIITA,Gene
7917,C6orf72,Gene
7919,KATNA1,Gene
7923,ADAMTS18,Gene
7925,AQP8,Gene
7937,HBZ,Gene
7939,HBM,Gene
7941,ITFG3,Gene
7944,CHTF18,Gene
7947,BTBD9,Gene
7950,HDDC2,Gene
7952,c16orf47,Gene
7955,CEP57L1,Gene
7956,CD164,Gene
7958,BAT5,Gene
7961,IL34,Gene
7964,LYPLA3,Gene
7970,SERPINB1,Gene
7978,HIST1H1T,Gene
7986,CDT1,Gene
7992,JPH3,Gene
7994,ZCCHC14,Gene
8013,C6orf99,Gene
8017,FOXC1,Gene
8020,HIST1H4E,Gene
8046,FKBP5,Gene
8048,TRERF1,Gene
8056,RP11-42I10.1,Gene
8058,RP3-416J7.4,Gene
8062,HCG4P8,Gene
8064,TRIM31-AS1,Gene
8067,XXbac-BPG248L24.10,Gene
8071,MRDS1,Gene
8102,WDR27,Gene
8106,ZNF318,Gene
8108,ABCC10,Gene
8109,LRRC16A,Gene
8112,HCG4B,Gene
8114,HLA-U,Gene
8118,C6orf48,Gene
8120,GGNBP1,Gene
8123,ETV7,Gene
8127,PAQR8,Gene
8131,DDO,Gene
8145,RP11-517H2.6,Gene
8173,THBS2,Gene
8175,AIG1,Gene
8177,HIST1H4L,Gene
8179,HIST1H3J,Gene
8180,CRIP3,Gene
8184,AP1G1,Gene
8186,SYNE1,Gene
8189,LRRC29,Gene
8193,HIST1H2BE,Gene
8195,C6orf1,Gene
8201,RBBP6,Gene
8203,TNRC6A,Gene
8204,RNA5SP427,Gene
8206,GLG1,Gene
8214,RP11-542M13.3,Gene
8225,UFL1,Gene
8226,MYH11,Gene
8230,GNAO1,Gene
8233,LOC283867,Gene
8236,SLC9A3R2,Gene
8238,PPL,Gene
8241,LINC00473,Gene
8242,DNAH3,Gene
8244,GCNT2,Gene
8248,RNU6-283P,Gene
8250,DDX39B,Gene
8255,C6ORF165,Gene
8257,C6orf165,Gene
8259,BEND3,Gene
8263,PHIP,Gene
8265,FHL5,Gene
8272,HIST1H2BL,Gene
8274,SAMD5,Gene
8276,SASH1,Gene
8281,CCDC170,Gene
8285,CLEC19A,Gene
8300,HLA-W,Gene
8303,USP8P1,Gene
8309,OARD1,Gene
8311,NFYA,Gene
8313,RP11-425D10.1,Gene
8316,AHI1,Gene
8321,PARN,Gene
8322,TNP2,Gene
8327,IL27,Gene
8331,SETD1A,Gene
8334,RP11-401P9.5,Gene
8340,FGFR3P1,Gene
8347,SERINC1,Gene
8354,HIST1H2BC,Gene
8356,RFX6,Gene
8358,VGLL2,Gene
8359,PKHD1,Gene
8362,SAYSD1,Gene
8364,KCNK5,Gene
8367,chr6mb117,Gene
8373,DCBLD1,Gene
8376,FRMD1,Gene
8383,chr16mb65,Gene
8386,chr6mb85,Gene
8389,chr16mb56,Gene
8393,FABP7,Gene
8398,CTU2,Gene
8400,PRPH2,Gene
8409,LINC00340/LOC729177,Gene
8411,MLIP,Gene
8416,CORO1A,Gene
8420,TCF25,Gene
8423,C6orf195,Gene
8424,RNF144B,Gene
8431,RP1-111C20.4,Gene
8433,ZBTB9,Gene
8437,CDK10,Gene
8438,AFG3L1P,Gene
8442,FOXC2,Gene
8445,chr6mb143,Gene
8450,chr6mb135,Gene
8457,VAC14,Gene
8464,LOC100505711,Gene
8469,SLC35B3,Gene
8475,PSMD7,Gene
8486,GLIS2,Gene
8488,TFAP4,Gene
8494,COL10A1,Gene
8495,PGBD1,Gene
8497,ZSCAN31,Gene
8504,COL12A1,Gene
8508,TRAP1,Gene
8510,TLDC1,Gene
8531,RP11-356I2.4,Gene
8545,MAZ,Gene
8552,FAM65B,Gene
8556,CDH8,Gene
8560,SOX4,Gene
8767,DHFRP2,Gene
8770,RP3-340B19.2,Gene
8773,MICD,Gene
8777,SEC14L5,Gene
8779,LOC100996634,Gene
8782,TAF8,Gene
8788,XXbac-BPG248L24.12,Gene
8792,ARMC12,Gene
8806,HCG20,Gene
8808,STX7,Gene
8813,HBA2,Gene
8815,Z84721.4,Gene
8816,SLC22A16,Gene
8819,CD2AP,Gene
8826,CTD-3088G3.8,Gene
8833,HCG18,Gene
8835,HCG17,Gene
8841,HBZP1,Gene
8846,RP1-209A6.1,Gene
8861,HIST1H4C,Gene
8863,LINC01149,Gene
8880,TEKT5,Gene
8885,DSP,Gene
8887,SCLC35F1,Gene
8889,ITGAD,Gene
8891,CDH3,Gene
8894,B3GAT2,Gene
8896,SMAP1,Gene
8897,LYPLA1P3,Gene
8898,RP1-92C4.2,Gene
8900,GAPDHP63,Gene
8901,RPL35AP18,Gene
8902,RP1-60O19.2,Gene
8904,QRSL1,Gene
8905,RPL21P65,Gene
8906,RTN4IP1,Gene
8908,FOXQ1,Gene
8914,NRN1,Gene
8916,F13A1,Gene
8917,PKMP5,Gene
8918,MIR5683,Gene
8919,RCC2P7,Gene
8922,RP1-27K12.2,Gene
8923,KLHL31,Gene
8924,ELOVL5,Gene
8925,METTL24,Gene
8927,CDC40,Gene
8928,HIVEP2,Gene
8931,ADTRP,Gene
8933,TMEM170B,Gene
8934,PRKRIRP5,Gene
8935,RPL13P,Gene
8937,ZNF90P2,Gene
8938,HCG14,Gene
8939,TRIM27,Gene
8940,C6orf100,Gene
8942,KRT18P1,Gene
8943,HCG15,Gene
8944,HCG16,Gene
8945,ZNF311,Gene
8946,XXbac-BCX196D17.5,Gene
8948,OR2N1P,Gene
8949,OR2J3,Gene
8950,OR2J1,Gene
8951,OR2J2,Gene
8952,OR2B3,Gene
8953,XXbac-BPG308J9.3,Gene
8955,OR2G1P,Gene
8956,OR2H4P,Gene
8957,OR2U1P,Gene
8958,OR2U2P,Gene
8959,KRASP1,Gene
8962,RNA5SP431,Gene
8965,RP1-80N2.3,Gene
8975,KIAA1609,Gene
8977,DEXI,Gene
8979,SLC25A51P1,Gene
8981,LOC441155,Gene
8983,PMFBP1,Gene
8985,ENPP3,Gene
8995,RP11-392A23.4,Gene
9001,RP5-1142A6.2,Gene
9010,NSMCE1,Gene
9012,FLJ21408,Gene
9013,KDM8,Gene
9019,BLIMP1,Gene
9021,ABCA3,Gene
9039,TRAM2,Gene
9045,ZDHHC14,Gene
9049,VWA7,Gene
9062,CTF1,Gene
9068,CLN3,Gene
9081,C6orf58,Gene
9084,RP3-522P13.3,Gene
9086,ZNF165,Gene
9090,BANP,Gene
9094,XXbac-BPG299F13.17,Gene
9098,VARS,Gene
9102,TREML2,Gene
9104,GPR116,Gene
9115,ZKSCAN3,Gene
9118,XXbac-BPG248L24.13,Gene
9304,LOC153910,Gene
9308,LST1,Gene
9312,ARMC2,Gene
9354,ADGRG6,Gene
9368,ANKRD11,Gene
9373,MIR4465,Gene
9375,RP11-354I13.2,Gene
9377,AC009081.1,Gene
9378,GNPATP,Gene
9380,EEF1A1P38,Gene
9384,UFL1-AS1,Gene
9385,KRT18P50,Gene
9388,RPS7P8,Gene
9390,GOPC,Gene
9391,RNA5SP214,Gene
9392,U95743.1,Gene
9394,RPS26P52,Gene
9397,MICF,Gene
9406,MESTP1,Gene
9407,EEF1DP5,Gene
9408,GLYR1,Gene
9410,ROGDI,Gene
9411,SEPT12,Gene
9412,UBN1,Gene
9413,ZNF500,Gene
9414,TCF21,Gene
9416,TBPL1,Gene
9417,HMGA1P7,Gene
9419,TPD52L1,Gene
9421,BMPR1APS1,Gene
9422,PRPF4B,Gene
9424,FAM217A,Gene
9425,C6orf201,Gene
9426,ECI2,Gene
9428,POLR2LP,Gene
9429,PSORS1C2,Gene
9431,MIR3182,Gene
9433,TRDN,Gene
9438,ATF7IP2,Gene
9440,IMPDH1P11,Gene
9445,RP3-340B19.3,Gene
9448,CEP85L,Gene
9460,TCEB2,Gene
9465,RP3-429O6.1,Gene
9475,SCML4,Gene
9480,HSBP1,Gene
9481,MLYCO,Gene
9482,OSGIN1,Gene
9483,SLC38A8,Gene
9484,RNA5SP432,Gene
9485,HSDL1,Gene
9486,ADAD2,Gene
9616,SUPT3H/RUNX1,Gene
9618,RUNX2,Gene
9619,XYLT1,Gene
9626,FOXP4,Gene
9649,LSM3P5,Gene
9650,LOC101928737,Gene
9651,LOC101928516,Gene
9653,MTHFSD,Gene
9656,FARS2,Gene
9658,MDN1,Gene
9660,TINAG,Gene
9662,RP11-146I2.1,Gene
9665,MRPL42P2,Gene
9667,RP1-13D10.3,Gene
9669,ZKSCAN8,Gene
9671,PPP1R10,Gene
9675,ATF6B,Gene
9676,RP11-513I15.6,Gene
9681,MED20,Gene
9687,SESN1,Gene
9689,SLC16A10,Gene
9701,KIAA0895L,Gene
9704,CDH1,Gene
9706,ATMIN,Gene
9708,SLC7A5,Gene
9712,SPATA2L,Gene
9721,BTF3P7,Gene
9723,RPI1-80N2.2,Gene
9737,HOGA1,Gene
9747,ZFP90,Gene
9864,OR1F12,Gene
9866,RP1-313I6.12,Gene
9881,TRNAR7,Gene
9883,ZNF204P,Gene
9885,TRNAS3,Gene
9910,ZNF778,Gene
9927,CLIC1,Gene
9929,PXT1,Gene
9932,EFHC1,Gene
9942,ATP6V1G2-DDX39B,Gene
9943,RP11-210H10__A.1,Gene
9952,MCHR2-AS1,Gene
9960,LINC01512,Gene
9961,LINC01625,Gene
9963,MIR588,Gene
9978,VARS2,Gene
9982,TPSB2,Gene
9984,PKD1L2,Gene
9986,PRRC2A,Gene
9993,NONE,Gene
9997,NDUFA5P9,Gene
9999,LOC100652960,Gene
10000,TNFRSF17,Gene
10002,LOC729978,Gene
10006,HIST1H1B,Gene
10015,GTF2H5,Gene
10017,RPGRIP1L,Gene
10029,BCKDHB/FAM46A,Gene
10032,CDH16,Gene
10034,HIST1H4A,Gene
10036,HIST1H3A,Gene
10038,ZDHHC7,Gene
10041,PHF3,Gene
10046,MPG,Gene
10048,TXNDC5,Gene
10050,RGS17,Gene
10054,LOC101927364,Gene
10055,LOC101928519,Gene
10058,VNN3,Gene
10061,IRX3,Gene
10065,ENPP5,Gene
10068,SMPDL3A,Gene
10080,CNEP1R1,Gene
10081,GPR114,Gene
10084,LOC102724152,Gene
10085,MEAT6,Gene
10086,CENPN,Gene
10098,PRSS16,Gene
10100,GPSM3,Gene
10102,RABEP2,Gene
10106,RNF5,Gene
10110,BTN3A2,Gene
10114,ZKSCAN4,Gene
10150,PEX3,Gene
10155,ABHD16A,Gene
10156,APOM,Gene
10157,ATP6V1G2,Gene
10158,BAG6,Gene
10159,C6orf25,Gene
10160,C6orf47,Gene
10161,HSPA1B,Gene
10162,LSM2,Gene
10163,LY6G5B,Gene
10164,LY6G5C,Gene
10165,LY6G6C,Gene
10166,LY6G6D,Gene
10167,LY6G6E,Gene
10168,LY6G6F,Gene
10169,MIR4646,Gene
10170,MIR6832,Gene
10171,MIR6891,Gene
10172,MSH5-SAPCD1,Gene
10173,PSORS1C3,Gene
10174,SAPCD1,Gene
10175,SNORA38,Gene
10176,SNORD48,Gene
10177,SNORD52,Gene
10178,SNORD84,Gene
10179,SNORD117,Gene
10181,UQCC2,Gene
10182,HLA-DOB,Gene
10185,LOC401242,Gene
10186,NKAPL,Gene
10187,OR2W1,Gene
10188,ZBED9,Gene
10189,ZSCAN12,Gene
10190,ZSCAN23,Gene
10191,ZSCAN26,Gene
10192,LOC100129636,Gene
10193,OR2H1,Gene
10195,OR5V1,Gene
10196,OR10C1,Gene
10197,OR12D2,Gene
10198,OR12D3,Gene
10199,OR14J1,Gene
10200,HIST1H2AI,Gene
10202,HIST1H2AJ,Gene
10203,HIST1H2AK,Gene
10204,HIST1H2AM,Gene
10205,HIST1H2BM,Gene
10206,HIST1H2BO,Gene
10207,HIST1H3H,Gene
10208,HIST1H3I,Gene
10209,HIST1H4J,Gene
10210,HIST1H4K,Gene
10211,LINC01012,Gene
10212,OR2B2,Gene
10213,OR2B6,Gene
10214,TOB2P1,Gene
10215,ZNF192P1,Gene
10216,ZSCAN9,Gene
10217,ZSCAN12P1,Gene
10218,ZSCAN16,Gene
10219,HIST1H2BN,Gene
10220,LOC100131289,Gene
10221,ZNF391,Gene
10222,ZSCAN16-AS1,Gene
10223,HIST1H2AL,Gene
10226,POM121L2,Gene
10227,VN1R10P,Gene
10231,HLA-DRB6,Gene
10233,AGPAT1,Gene
10234,EGFL8,Gene
10235,HLA-DMA,Gene
10236,HLA-DMB,Gene
10237,LOC100294145,Gene
10238,MIR6721,Gene
10239,MIR6833,Gene
10240,PBX2,Gene
10241,PPT2-EGFL8,Gene
10242,RNF5P1,Gene
10243,TAPSAR1,Gene
10245,C4A,Gene
10246,C4B,Gene
10247,C4B_2,Gene
10248,CYP21A1P,Gene
10249,DXO,Gene
10250,LOC102060414,Gene
10251,MIR1236,Gene
10252,NELFE,Gene
10253,SKIV2L,Gene
10254,STK19,Gene
10255,TNXA,Gene
10256,ZBTB12,Gene
10258,MIR4464,Gene
10268,CX3CL1,Gene
10272,CRISP2,Gene
10278,DEF8,Gene
10281,FANCA,Gene
10297,CHMP1A,Gene
10314,CALHM6,Gene
10316,FAM26F,Gene
10327,MDC1,Gene
10341,CYLD,Gene
10345,PDXDC2P,Gene
10361,MCM9,Gene
10374,LOC105377949,Gene
10376,LOC107986634,Gene
10380,LOC105378330,Gene
10382,DCTPP1,Gene
10384,FGF21,Gene
10388,MIR5093,Gene
10396,MT4,Gene
10398,PRSS35,Gene
10404,LOC105371069,Gene
10406,MRPS18A,Gene
10411,SPG7,Gene
10413,FAXC,Gene
10419,CD109,Gene
10423,LOC100132354,Gene
10425,MYLK4,Gene
10428,ABT1,Gene
10438,WFIKKN1,Gene
10440,ZNF281,Gene
10443,C16orf95,Gene
10445,GUCA1A,Gene
10448,CD83,Gene
10452,RP11-102N11.1,Gene
10454,SMLR1,Gene
10455,CTD-3037G24.3,Gene
10473,TMEM242,Gene
10475,SYTL3,Gene
10492,LOC595101,Gene
10630,STX11,Gene
10633,KIF25-AS1,Gene
10637,RP11-436D23.1,Gene
10643,RP11-240M16.1,Gene
10646,AL031390.1,Gene
10648,ZC3H12D,Gene
10660,LA16c-306E5.3,Gene
10662,CDIP1,Gene
10666,LYRM1,Gene
10671,RP11-44I10.3,Gene
10673,ADCY7,Gene
10676,CTCF,Gene
10678,RP11-615I2.1,Gene
10681,RP11-679B19.2,Gene
10683,RP11-345M22.1,Gene
10708,DCDC2,Gene
10710,SNORA48,Gene
10712,ENSG00000261584,Gene
10714,ENSG00000252399,Gene
10726,CASC16,Gene
10727,HIST1H1E,Gene
10729,HIST1H2BD,Gene
10730,HIST1H3PS1,Gene
10739,RP11-140K17.2,Gene
10742,LHFPL5,Gene
10745,ZNF292,Gene
10754,HLA-G,Gene
10774,ABCC6,Gene
10775,ORAI3,Gene
10777,AC135048.13,Gene
10783,TXNL4B,Gene
10790,NPIPB8,Gene
10793,ENSG00000242486,Gene
10795,BTN2A1,Gene
10798,ENSG00000264238,Gene
10843,LACE1,Gene
10846,MICC,Gene
10849,HMGN4,Gene
10851,RP11-44F14.2,Gene
10871,LOC100507477,Gene
10877,CLIC5,Gene
10903,NOB1,Gene
10905,DDX19B,Gene
10908,TTBK1,Gene
10924,BTN3A3,Gene
10929,FBXL16,Gene
10933,NPIPA8,Gene
10935,REV3L,Gene
10949,CDK19,Gene
10951,CALB2,Gene
10964,SSTR5-AS1,Gene
10966,NARFL,Gene
10968,TMEM244,Gene
10972,LOC440390,Gene
10974,LOC101928708,Gene
10981,KIF6,Gene
10984,STK38,Gene
10986,SRSF3,Gene
10988,SLC22A1,Gene
10994,LINC00917,Gene
10996,FENDRR,Gene
11007,NPW,Gene
11009,RP11-440G9.1,Gene
11011,EMP2,Gene
11028,KPNA5,Gene
11031,LOC107986540,Gene
11034,NHSL1,Gene
11036,LOC101928842,Gene
11041,HTRE1,Gene
11045,LRP11,Gene
11047,IGF2R,Gene
11049,DBNDD1,Gene
11066,LOC102723883,Gene
11068,ERVK13-1,Gene
11092,PRRT1,Gene
11098,NUS1,Gene
11101,AK127472,Gene
11103,TARID,Gene
11107,TERF2IP,Gene
11109,LOC101927998,Gene
11118,HIST1H2AC,Gene
11130,PPT2,Gene
11132,ADGRB3,Gene
11135,ZNF23,Gene
11148,LRRC1,Gene
11150,GFRAL,Gene
11152,HMGCLL1,Gene
11154,BMP5,Gene
11160,LINC01626,Gene
11162,LOC101928489,Gene
11166,UBE3D,Gene
11168,LOC101928820,Gene
11172,RNF217-AS1,Gene
11174,RP13-20L14.1,Gene
11184,RP11-505K9.4,Gene
11188,IST1,Gene
11194,MIR3668,Gene
11197,KCNK17,Gene
11206,COX6A1P2,Gene
11214,FIG4,Gene
11227,VASN,Gene
11228,PAM16,Gene
11229,NMRAL1,Gene
11230,DNAJA3,Gene
11235,TAPBP,Gene
11247,UBE2I,Gene
11249,TMEM188,Gene
11263,FUK,Gene
11284,TRAF7,Gene
11297,TIAM2,Gene
11302,TULP4,Gene
11305,LINC01558,Gene
11307,KIF25,Gene
11310,SRRM2,Gene
11314,SHISA9,Gene
11315,NTAN1,Gene
11340,HLA-L,Gene
11342,RBL2,Gene
11347,ENSG00000236920,Gene
11349,BTN2A2,Gene
11362,UBQLN1P1,Gene
11364,ENSG00000217379,Gene
11368,CLUAP1,Gene
11371,PAPD5,Gene
11377,RNU6-71P,Gene
11381,VTA1,Gene
11384,HIST1H2APS2,Gene
11390,PNPLA1,Gene
11405,MGRN1,Gene
11412,PRL,Gene
11421,ENSG00000246465,Gene
11434,RP4-662A9.2,Gene
11435,RP3-323P13.2,Gene
11440,RP5-1086L22.1,Gene
11481,GLIS2-AS1,Gene
11522,ENSG00000262801,Gene
11524,ENSG00000216915,Gene
11579,LINC02130,Gene
11581,LOC102724084,Gene
11585,LOC643714,Gene
11587,LOC644600/LOC644649,Gene
11595,TREM2-TREML2,Gene
11609,SNAI3-AS1,Gene
11613,novelD2,Gene
11617,CCL22,Gene
11623,ABCF1,Gene
11638,ENSG00000261241,Gene
11664,CRNDE,Gene
11665,COTL1,Gene
11727,IQCK,Gene
11733,ENSG00000252901,Gene
11746,UNGP1/LOC642659,Gene
11749,RP3-439I14.1,Gene
11752,CMAHP,Gene
11755,ENSG00000224605,Gene
11768,BAIAP3,Gene
11771,RP11-304L19.2,Gene
11773,RP11-166B2.1,Gene
11776,SLC9A5,Gene
11780,ATXN1L,Gene
11812,HIST1H4H,Gene
11815,RING1,Gene
11817,LOC101929285,Gene
11825,SCAF8,Gene
11847,GMDS-AS1,Gene
11854,HIST1H1C,Gene
11858,PDZD9,Gene
11864,MYCT1,Gene
11865,RP1-230L10.1,Gene
11887,PHLPP2,Gene
11911,HCG24,Gene
11913,SCUBE3,Gene
11946,UQCRHP1,Gene
11953,PPIL6,Gene
11978,BAI3,Gene
11989,MTCO3P1,Gene
11991,RPS10,Gene
11993,RPS10-NUDT3,Gene
12015,RFPL4B,Gene
12019,LOC100507501,Gene
12023,NPIPL1,Gene
12026,SERPINB6,Gene
12050,CORO7-PAM16,Gene
12052,GSPT1,Gene
12055,LINC01571;C16orf97,Gene
12058,SFTA2,Gene
12060,DPCR149,Gene
12061,HSPA1A46,Gene
12066,LINC0157144,Gene
12068,HCG2248,Gene
12069,HLA-DQB142,Gene
12119,HS3ST2,Gene
12154,TMEM181,Gene
12201,c6orf10,Gene
12208,BAT4,Gene
12213,DPCR1,Gene
12231,HLA-DQ,Gene
12234,ECHDC1,Gene
12237,RP11-157J24.1,Gene
12244,BAT3,Gene
12245,TRNAA-UGC,Gene
12247,CARD15,Gene
12253,GCM2,Gene
12271,HLA-F,Gene
12281,EIF3C,Gene
12292,AK026189,Gene
12296,ZNF323,Gene
12298,PPP1R14C,Gene
12300,MARVELD3,Gene
12313,C6orf12,Gene
12325,SLC22A,Gene
12327,LPAL2,Gene
12329,HIST1H2BJ,Gene
12331,BTN3A1,Gene
12332,HIST1H2AG,Gene
12339,LOC387103,Gene
12343,LOC389365,Gene
12346,C6orf204,Gene
12348,NDRG4,Gene
12370,TAB2,Gene
12372,PPIAP9,Gene
12373,HLA-B*5801,Gene
12374,other genes,Gene
12387,MRPL14,Gene
12390,CNKSR3,Gene
12392,RBM16,Gene
12402,LOC285735,Gene
12406,PDXC1,Gene
12407,C20:2,Gene
12408,C20:3,Gene
12409,LCA5,Gene
12411,DYNLRB2,Gene
12415,EGFL11,Gene
12421,RP11-252P19.1,Gene
12426,PRM1,Gene
12427,C16orf75,Gene
12428,SCGN,Gene
12432,JARID2,Gene
12439,AC009117.8,Gene
12442,AC092725.3,Gene
12444,AL353597.20,Gene
12448,FGFR10P,Gene
12449,RNASE2,Gene
12453,POL3S,Gene
12455,FLJ22536,Gene
12462,BCM01,Gene
12474,ZNF,Gene
12476,KIAA0174,Gene
12478,C16orf46,Gene
12484,TNFIP3,Gene
12497,Alpha-globin cluster,Gene
12504,T,Gene
12506,C6orf182,Gene
12509,GPLD1,Gene
12512,RGS11,Gene
12535,C6orf191,Gene
12553,AL139097.1,Gene
12556,HGC6.1.1,Gene
12558,MLLT4,Gene
12559,HGC6.3,Gene
12560,ULBP3,Gene
12568,BC087858,Gene
12570,DD413621,Gene
12574,AF086303,Gene
12581,ANKS1A,Gene
12594,LOC643174,Gene
12595,AL109920.3,Gene
12597,PRR18,Gene
12599,NTHL1,Gene
12602,KIAA0513,Gene
12605,9648,Gene
12609,IL22RA2,Gene
12621,RAB40C,Gene
12636,SOX8,Gene
12640,AL132875.2,Gene
12645,HUS1B,Gene
12648,MAP3K4,Gene
12656,HEATR3,Gene
12671,C6orf190,Gene
12675,PDE10,Gene
12683,DRB-DQB,Gene
12699,NCR2,Gene
12739,LOC442261,Gene
12742,LOC729251,Gene
12756,SLC22A7,Gene
12760,LOC642072,Gene
12764,RP11-406O16.1,Gene
12766,SYNJ2,Gene
12772,LOC100131680,Gene
12775,FAM50B,Gene
12779,MIR1972-2,Gene
12780,KIAA1752,Gene
12783,FLJ1111,Gene
12785,LOC729355,Gene
12787,C6orf167,Gene
12789,LOC92017,Gene
12794,RNGTT,Gene
12804,TCBA1,Gene
12814,CDYL,Gene
12819,LOC643281,Gene
12821,KLHL36,Gene
12826,UBR2,Gene
12830,UNC5CL,Gene
12834,ORC3,Gene
12836,SLC35A1,Gene
12837,RARS2,Gene
12841,SNRNP48,Gene
12843,TP53TG3B,Gene
12847,MYO6,Gene
12852,LOC646517,Gene
12855,MOXD1,Gene
12857,MPHOSPH6,Gene
12861,RPL15P3,Gene
12871,HLA-A*3101,Gene
12879,MT1X,Gene
12881,MT11P,Gene
12882,MT1H,Gene
12883,MT1G,Gene
12884,MT1B,Gene
12885,MT1F,Gene
12888,LOC441750,Gene
12893,KU-MEL-3,Gene
12895,PECI,Gene
12902,NUP153,Gene
12903,GLULD1,Gene
12911,LOC442232,Gene
12913,JMJD5,Gene
12915,OR2I1P,Gene
12920,NUDT7,Gene
12923,CUL9,Gene
12925,RPL21P119,Gene
12935,LOC401864,Gene
12939,C6orf105,Gene
12942,KIAA1900,Gene
12951,C16orf38,Gene
12954,C6orf205,Gene
12962,PRKCB1,Gene
12968,LOC440389,Gene
12971,CAPNS2,Gene
12973,LPCAT2,Gene
12978,TSC2,Gene
12985,FLJ45256,Gene
12987,VAT1L,Gene
12989,GSG1L,Gene
12997,RANBP9,Gene
12999,CDYL2,Gene
13005,C16orf96,Gene
13007,LOC342346,Gene
13011,E2F3,Gene
13013,LOC644649,Gene
13019,NRSN1,Gene
13024,MAP1LC3B,Gene
13026,FBXO31,Gene
13027,ENSG00000102921,Gene
13029,ASIP,Gene
13033,MHC region,Gene
13048,BF,Gene
13053,TMC7,Gene
13055,C6orf214,Gene
13064,DQB1,Gene
13065,HLA-DQA/B,Gene
13071,LOC729792,Gene
13072,HLA-DRB9,Gene
13079,BC034767,Gene
13081,HLA-DRB1-DQB1,Gene
13095,GAPDHL19,Gene
13098,LOC100131805,Gene
13102,LOC728727,Gene
13111,AC009063.8,Gene
13113,RP11-538A16.1,Gene
13115,XXbac-BPG250I8.13,Gene
13117,MUTED,Gene
13120,EEF1E1,Gene
13122,LOC100652953,Gene
13124,ALDH8A1,Gene
13128,C6orf170,Gene
13131,IL17F,Gene
13135,LOC441506,Gene
13137,RBM24,Gene
13141,LOC100131899,Gene
13145,ALG1,Gene
13157,LINC0022,Gene
13158,LINC00222,Gene
13160,FBXO5,Gene
13161,MTRF1L,Gene
13163,DOM3Z,Gene
13164,FKBPL,Gene
13165,LOC10029,Gene
13166,LOC100293534,Gene
13167,LOC100507547,Gene
13168,PPT2-EGF,Gene
13169,RDBP,Gene
13170,LOC10050,Gene
13172,HLA-DP,Gene
13173,DACT2,Gene
13180,ULBP6,Gene
13181,DQA1,Gene
13186,LYRM4,Gene
13190,UBD,Gene
13192,MOG,Gene
13193,HLA-H,Gene
13194,NKD1,Gene
13196,RP11-100A16.1,Gene
13201,DRB1,Gene
13203,DPB1,Gene
13207,COL19A1,Gene
13209,LOC729105,Gene
13218,ACTBP8,Gene
13219,LOC644119,Gene
13221,LOC283904,Gene
13222,LOC729464,Gene
13230,HAL-DQB2,Gene
13233,RUNDC2A,Gene
13239,HIST1H3C,Gene
13240,AC087190.5-2,Gene
13242,AL391500.13,Gene
13244,RP11-707M13.1,Gene
13245,IL32,Gene
13247,NEDD9,Gene
13254,C6orf64,Gene
13256,LOC389370,Gene
13259,LOC729635,Gene
13261,LOC729217,Gene
13263,LOC727977,Gene
13264,ZNF213,Gene
13266,LOC100129158,Gene
13269,ZBTB24,Gene
13277,CTU2/GALNS,Gene
13279,PPARD/FANCE,Gene
13281,Histone cluster,Gene
13287,HLA locus,Gene
13289,SENP6,Gene
13291,SUPT3H/RUNX2,Gene
13293,CASKIN1,Gene
13302,CYB5B,Gene
13306,FLJ32790,Gene
13309,BRD7,Gene
13319,APOB48R,Gene
13321,AC138894.2,Gene
13327,MDF1,Gene
13333,HERV,Gene
13335,FRD,Gene
13343,C6orf120,Gene
13344,PHF10,Gene
13345,TCTE3,Gene
13346,C6orf208,Gene
13347,FAM120B,Gene
13348,TBP,Gene
13349,PCD2,Gene
13370,LAMA4,Gene
13379,HLA-DR3,Gene
13382,AIM1,Gene
13403,MAP3K7IP2,Gene
13406,Unknown,Gene
13424,IBTK,Gene
13429,ZHP1,Gene
13430,CTRB1/2,Gene
13431,ZNRF1,Gene
13434,SEC5L1,Gene
13439,KIAA0350,Gene
13442,DCTN5,Gene
13444,PALB2,Gene
13462,C6orf71,Gene
13467,B3GALT4,Gene
13472,HLA_DRB1,Gene
13474,HLA_DQA1,Gene
13481,AC130454.2,Gene
13483,AC130454.1,Gene
13485,AL161904.1,Gene
13487,AL133264.1,Gene
13489,RP3-369A17.4,Gene
13490,ANKS1,Gene
13492,TREM,Gene
13501,LOC644502,Gene
13510,RPS12,Gene
13517,BTN1A1,Gene
13520,TRIM38,Gene
13522,WTAP,Gene
13525,HIST1H1D,Gene
13532,HAS3,Gene
13541,DKFZp779M0311,Gene
13542,BVES,Gene
13543,POPDC3,Gene
13544,E3 ubiquitin protein ligase 1,Gene
13551,GLYATL3,Gene
13560,TNFRSF21,Gene
13565,IDOL,Gene
13573,TNRC9,Gene
13576,SPACA1,Gene
13580,hCG_1820801,Gene
13593,BCMO1,Gene
13595,NUBP2,Gene
13597,IGFALS,Gene
13602,HLA-DR-DQ,Gene
13612,PDRM1,Gene
13614,RAB32,Gene
13618,RP11-330A16.1,Gene
13620,BTLN2,Gene
13635,C16orf47,Gene
13654,STG,Gene
13655,PSORS1,Gene
13658,TFEB,Gene
13669,PPP1R1,Gene
13671,FANCE,Gene
13686,LOC729200,Gene
13687,LOC100131413,Gene
13689,LOC100131080,Gene
13692,AC109462.1,Gene
13713,CD19,Gene
13719,GTF2H4,Gene
13723,SAMD3,Gene
13725,KIF13A,Gene
13726,HLA class III,Gene
13729,CRISPLD2,Gene
13731,SMPD2,Gene
13732,MNICAL1,Gene
13734,LBH,Gene
13736,TCP11,Gene
13737,ZNF76,Gene
13738,DEF6,Gene
13739,Histone class 1,Gene
13740,Butyrophilin genes,Gene
13742,ACSM1,Gene
13760,C6orf57,Gene
13766,KIAA1005,Gene
13770,ACSM5,Gene
13772,KIAA0319,Gene
13774,ULBP1,Gene
13781,PRMT8,Gene
13784,SNN,Gene
13785,ZC3H7A,Gene
13786,GINS3,Gene
13787,c6orf204,Gene
13788,ASF1A,Gene
13789,AKD2,Gene
13802,POLR3K,Gene
13803,LUCL7,Gene
13804,RPL2B,Gene
13805,NME4,Gene
13806,DECR,Gene
13808,RHOT2,Gene
13809,LMF1,Gene
13810,WDR90,Gene
13812,TULP1,Gene
13820,NEFL,Gene
13825,FBX031,Gene
13828,GPR110,Gene
13831,FAM18A,Gene
13833,CREBL1,Gene
13835,BUCS1,Gene
13836,COL11A2,Gene
13839,C16orf68,Gene
13843,GPR6,Gene
13846,FLJ11151,Gene
13850,CDKAL,Gene
13852,HLADRB1,Gene
13856,SNAP91,Gene
13874,GMNN,Gene
13881,UST,Gene
13885,TFAP2A,Gene
13890,SLC25A27,Gene
13900,TSPYL4,Gene
13902,C6orf132,Gene
13905,KIAA0182,Gene
13907,ABCC12,Gene
13911,TRMT11,Gene
13912,PRDM13,Gene
13915,LOC651503,Gene
13916,OR214J1,Gene
13928,C6orf155,Gene
13939,TJAP1,Gene
13947,RFWD3,Gene
13949,MLKL,Gene
13950,C6orf151,Gene
13956,SLIC1,Gene
13958,MIR16,Gene
13959,RLBP1L2,Gene
13967,DEK,Gene
13973,TGFB1I1,Gene
13979,LOC340156,Gene
13982,TREML1,Gene
14009,MGC45491,Gene
14011,VEGF,Gene
14014,C6orf60,Gene
14024,SFRS18,Gene
14029,HLA-DPB1*04,Gene
14030,TFB1M,Gene
14043,FBXL4,Gene
14046,NOX3,Gene
14071,IRAK1BP1,Gene
14073,MAS1,Gene
14080,C6orf148,Gene
14085,ZBTB2,Gene
14086,RMND1,Gene
14087,C6orf211,Gene
14089,GNG13,Gene
14092,TSC1,Gene
14093,TBC1D7,Gene
14103,FAM54A,Gene
14108,TREML4,Gene
14129,BXDC1,Gene
14138,ACSM2B,Gene
14141,KIAA1919,Gene
14153,AL357060.1,Gene
14158,AC136285.1,Gene
14166,BAI3 LMBRD1,Gene
14187,MED23,Gene
14192,HMGN3,Gene
14196,PMM2,Gene
14203,NPIP,Gene
14215,LOC728792,Gene
14217,TMEM14A,Gene
14221,HLA-DPA3,Gene
14230,KIAA1244,Gene
14237,GAN,Gene
14238,C16orf45,Gene
14239,KIAA0430,Gene
14240,NDEI,Gene
14241,RRN3,Gene
14242,PTCRA,Gene
14244,RPL7L1,Gene
14245,C6orf138,Gene
14254,PRIM2,Gene
14258,C6orf117,Gene
14271,FAM184A,Gene
14333,LOC101927480,Gene
14335,LINC02140,Gene
14391,PEX7,Gene
14393,SLC35D3,Gene
14448,AL589740.1,Gene
14450,SPSB3,Gene
14454,LINC01082,Gene
14458,LOC101927686,Gene
14468,RCAN2,Gene
14503,PDIA2,Gene
14508,TMEM8A,Gene
14511,CAPN15,Gene
14513,LA16c-366D1.3,Gene
14517,LA16c-366D3.1,Gene
14562,RP1-155D22.1,Gene
14601,MHC-region,Gene
14614,RP11-95M15.1,Gene
14617,XPO6,Gene
14640,RP11-95P2.1,Gene
14644,RP11-452L6.7,Gene
14646,VN1R64P,Gene
14648,SIAH1,Gene
14649,E2F4,Gene
14651,MIR328,Gene
14652,AC040160.1,Gene
14654,AGRP,Gene
14659,ZNF276,Gene
14684,RSPRY1,Gene
14696,XXbac-BPG254F23.7,Gene
14711,RP11-456H18.1,Gene
14714,RP11-239H6.2,Gene
14732,RPS4XP7,Gene
14736,HLA-S,Gene
14745,RPL31P28,Gene
14750,RNU4-76P,Gene
14762,LOC653786,Gene
14774,ARHGAP17,Gene
14778,RP5-894D12.3,Gene
14780,MUSP1,Gene
14795,GTF3C1,Gene
14811,LRRC36,Gene
14847,PRR14,Gene
14849,FAM65A,Gene
14851,RLTPR,Gene
14852,RP11-296I10.5,Gene
14854,AC009060.1,Gene
14879,SLX4,Gene
14917,ZC3H18,Gene
14920,ZFP57,Gene
14936,POLR3E,Gene
14940,LOC101927978,Gene
14941,KRT18P18,Gene
14942,RNU7-71P,Gene
14944,GAPDHP72,Gene
14955,RP3-359N14.2,Gene
14964,ACSM2A,Gene
14966,RP11-302L19.3,Gene
14968,RP11-437L7.1,Gene
14973,JB175072,Gene
14975,UBE2MP1,Gene
15031,RHAG,Gene
15108,CNGB1,Gene
15128,RP11-304L19.1,Gene
15129,RP11-304L19.3,Gene
15132,RP11-876N24.2,Gene
15160,HLA-V,Gene
15163,MOCS1,Gene
15166,NRC3,Gene
15184,PKIB,Gene
15191,ZKSCAN2,Gene
15194,RP11-452L6.1,Gene
15209,C16orf58,Gene
15210,RP11-297D21.4,Gene
15223,RP1-80N2.2,Gene
15226,RP1-190J20.2,Gene
15230,HIST1H1PS2,Gene
15241,RP1-302G2.5,Gene
15244,RP1-152L7.1,Gene
15312,GCLET,Gene
15315,DUSP22,Gene
15323,PACSIN1,Gene
15325,MIR193B,Gene
15332,BOLA2B,Gene
15333,SLX1A,Gene
15334,SULT1A3,Gene
15335,CD2BP2,Gene
15336,TBC1D10B,Gene
15337,MYLPF,Gene
15338,ZNF48,Gene
15339,SEPT1,Gene
15345,HIST1H1A,Gene
15346,HIST1H4B,Gene
15347,HIST1H3B,Gene
15348,HIST1H2AB,Gene
15349,HIST1H2BB,Gene
15350,HIST1H4D,Gene
15351,HIST1H3D,Gene
15352,HIST1H2AD,Gene
15353,HIST1H2BI,Gene
15354,ZNF322,Gene
15355,HIST1H2BK,Gene
15356,HIST1H4I,Gene
15357,SCAND3,Gene
15358,OR2H2,Gene
15359,CPNE7,Gene
15361,RP11-368I7.4,Gene
15362,VPS9D1,Gene
15363,CENPBD1,Gene
15364,GAS8,Gene
15365,C16orf3,Gene
15366,PRDM7,Gene
15399,TANGO6,Gene
15401,CHTF8,Gene
15402,CIRH1A,Gene
15403,SNTB2,Gene
15404,RP11-343C2.11,Gene
15405,VPS4A,Gene
15406,COG8,Gene
15407,TERF2,Gene
15417,GINM1,Gene
15418,LATS1,Gene
15419,NUP43,Gene
15420,PCMT1,Gene
15421,RAET1E,Gene
15422,RAET1G,Gene
15428,DNASE1,Gene
15439,RP11-178L8.4,Gene
15444,NPIPB6,Gene
15445,NPIPB7,Gene
15446,NPIPB9,Gene
15466,RALGPS2,Gene
15467,ANGPTL1,Gene
15468,CRB1,Gene
15469,DENND1B,Gene
15470,AL162431.1,Gene
15472,STX6,Gene
15473,MR1,Gene
15474,IER5,Gene
15475,C1orf106,Gene
15477,KIF21B,Gene
15478,CNTN2,Gene
15479,TMEM81,Gene
15480,RBBP5,Gene
15481,DSTYK,Gene
15482,TMCC2,Gene
15484,TFPI,Gene
15485,ANKRD44,Gene
15487,SF3B1,Gene
15488,COQ10B,Gene
15489,HSPD1,Gene
15490,HSPE1,Gene
15491,HSPE1-MOB4,Gene
15492,MOB4,Gene
15493,RFTN2,Gene
15494,AC011997.1,Gene
15495,MARS2,Gene
15496,BOLL,Gene
15497,PLCL1,Gene
15499,COL3A1,Gene
15500,COL5A2,Gene
15501,WDR75,Gene
15505,NPM1,Gene
15506,FGF18,Gene
15507,FAM117B,Gene
15508,ICA1L,Gene
15509,WDR12,Gene
15510,CARF,Gene
15511,NBEAL1,Gene
15512,CYP20A1,Gene
15513,ABI2,Gene
15515,MARCH4,Gene
15517,SMARCAL1,Gene
15518,RPL37A,Gene
15519,POGK,Gene
15521,TADA1,Gene
15522,ILDR2,Gene
15523,MAEL,Gene
15560,TBC1D7-LOC100130357,Gene
15562,GFOD1,Gene
15565,LOC101929705,Gene
15604,IFT140,Gene
15606,TMEM204,Gene
15611,LINC02189,Gene
15613,LOC105374972,Gene
15616,LOC100506188,Gene
15632,GSTA9P,Gene
15633,LOC105371348,Gene
15635,LOC105371349,Gene
15651,RP11-420G6.4,Gene
15662,XXbac-BPG32J3.20,Gene
15665,AL033381.1,Gene
15669,RP11-361F15.2,Gene
15674,SNORA70,Gene
15676,RP5-991C6.2,Gene
15677,RP1-72A23.1,Gene
15679,RNU2-61P,Gene
15730,AK024998,Gene
15733,SRSF12,Gene
15735,PM20D2,Gene
15742,UNC93A,Gene
15755,AX747287,Gene
15758,MIR548AE2,Gene
15764,BC031657,Gene
15777,MRPS18B,Gene
15783,B,Gene
15785,DPA1,Gene
15811,DPYSL3,Gene
15813,NOSTRIN,Gene
15814,SPC25,Gene
15816,TNIK,Gene
15817,TSC22D2,Gene
15819,DEPDC1B,Gene
15820,ELOVL7,Gene
15821,ERCC8,Gene
15822,NDUFAF2,Gene
15823,AC008498.1,Gene
15824,SMIM15,Gene
15825,ZSWIM6,Gene
15827,ZIC4,Gene
15828,ZIC1,Gene
15829,THADA,Gene
15831,ZFP36L2,Gene
15832,PLEKHH2,Gene
15834,TFDP2,Gene
15837,SLC35F6,Gene
15838,CENPA,Gene
15839,DPYSL5,Gene
15840,MAPRE3,Gene
15841,TMEM214,Gene
15842,AGBL5,Gene
15843,OST4,Gene
15844,EMILIN1,Gene
15845,CGREF1,Gene
15846,ABHD1,Gene
15847,PREB,Gene
15848,C2orf53,Gene
15849,TCF23,Gene
15850,CDC42EP3,Gene
15851,VIT,Gene
15852,AC007382.1,Gene
15853,STRN,Gene
15854,HEATR5B,Gene
15856,PKDCC,Gene
15862,FBXL7,Gene
15866,SETD9,Gene
15867,MIER3,Gene
15868,PDGFC,Gene
15869,ADAMTS6,Gene
15870,CENPK,Gene
15871,PPWD1,Gene
15872,TRIM23,Gene
15873,TRAPPC13,Gene
15874,CTC-534A2.2,Gene
15875,SGTB,Gene
15876,NLN,Gene
15877,ISL1,Gene
15879,TANK,Gene
15881,PSMD14,Gene
15882,TBR1,Gene
15883,RP11-215A19.2,Gene
15885,LIMD1,Gene
15886,SACM1L,Gene
15887,SLC6A20,Gene
15888,VANGL2,Gene
15889,TAGLN2,Gene
15890,IGSF9,Gene
15891,ZNF589,Gene
15892,NME6,Gene
15893,SPINK8,Gene
15894,FBXW12,Gene
15895,PLXNB1,Gene
15896,CCDC51,Gene
15897,TMA7,Gene
15898,ATRIP,Gene
15899,TREX1,Gene
15900,SHISA5,Gene
15901,PFKFB4,Gene
15902,UCN2,Gene
15903,COL7A1,Gene
15904,UQCRC1,Gene
15905,TMEM89,Gene
15906,SLC26A6,Gene
15907,CELSR3,Gene
15908,NCKIPSD,Gene
15909,IP6K2,Gene
15910,PRKAR2A,Gene
15911,SLC25A20,Gene
15912,ARIH2OS,Gene
15913,ARIH2,Gene
15914,P4HTM,Gene
15915,WDR6,Gene
15916,DALRD3,Gene
15917,NDUFAF3,Gene
15918,QRICH1,Gene
15919,QARS,Gene
15920,USP19,Gene
15921,LAMB2,Gene
15922,CCDC71,Gene
15923,KLHDC8B,Gene
15924,C3orf84,Gene
15925,CCDC36,Gene
15926,RP11-3B7.1,Gene
15927,C3orf62,Gene
15928,USP4,Gene
15929,TCTA,Gene
15930,NICN1,Gene
15931,DAG1,Gene
15932,BSN,Gene
15933,APEH,Gene
15934,MST1,Gene
15935,RNF123,Gene
15936,AMIGO3,Gene
15937,GMPPB,Gene
15938,IP6K1,Gene
15939,CDHR4,Gene
15940,FAM212A,Gene
15941,UBA7,Gene
15942,TRAIP,Gene
15943,CAMKV,Gene
15944,CTD-2330K9.3,Gene
15945,MON1A,Gene
15946,RBM6,Gene
15947,RBM5,Gene
15948,SEMA3F,Gene
15949,GNAT1,Gene
15950,GNAI2,Gene
15951,LSMEM2,Gene
15952,IFRD2,Gene
15953,HYAL2,Gene
15954,TUSC2,Gene
15955,RASSF1,Gene
15956,ZMYND10,Gene
15957,NPRL2,Gene
15958,CYB561D2,Gene
15959,XXcos-LUCA11.5,Gene
15960,TMEM115,Gene
15961,CISH,Gene
15962,MAPKAPK3,Gene
15963,DOCK3,Gene
15964,MOBP,Gene
15966,TBC1D5,Gene
15967,STIL,Gene
15968,FOXE3,Gene
15969,FOXD2,Gene
15976,PEAR1,Gene
15978,LRRC71,Gene
15979,ARHGEF11,Gene
15980,ETV3L,Gene
15981,C1orf54,Gene
15982,C1orf51,Gene
15983,MRPS21,Gene
15984,PRPF3,Gene
15985,RPRD2,Gene
15986,ECM1,Gene
15987,ADAMTSL4,Gene
15988,AL356356.1,Gene
15989,TBX15,Gene
16010,ZNRD1-AS1,Gene
16014,C16orf62,Gene
16021,RP1-281E18.1,Gene
16024,RP11-486E2.1,Gene
16028,RP11-63E9.1,Gene
16030,AC009080.1,Gene
16034,RP11-491F9.2,Gene
16040,AC009035.1,Gene
16042,RP11-716O23.1,Gene
16051,LOC645157,Gene
16055,MTRNR2L9,Gene
16057,LOC101927026,Gene
16065,FTHP1,Gene
16082,LOC105371270,Gene
16092,AC010547.9,Gene
16094,RP11-467I17.1,Gene
16101,RP1-159M24.1,Gene
16116,RP11-331F4.1,Gene
16127,CYCSL1,Gene
16138,C6OF10,Gene
16139,HLA- DQA1,Gene
16165,HLA-DRADQA2,Gene
16169,HLA-DRADQA1,Gene
16190,HLA-DRB3,Gene
16232,MAK,Gene
16237,C16orf72,Gene
16239,BCAR4,Gene
16250,CATX-11,Gene
16251,RSL1D1,Gene
16252,AF086132,Gene
16254,AY383626,Gene
16255,C6orf227,Gene
16259,ZNF771,Gene
16276,HCG4,Gene
16278,HCG8,Gene
16279,HLA-J,Gene
16280,LOC554223,Gene
16301,RNU6-1259P,Gene
16304,GSTA7P,Gene
16310,RP11-420N3.2,Gene
16312,RP11-420N3.3,Gene
16313,RNU6-214P,Gene
16319,RP11-883G14.1,Gene
16385,GUSBP2,Gene
16386,IFITM4P,Gene
16388,TRIM39-RPP21,Gene
16390,HLA-E,Gene
16405,LINC01623,Gene
16406,LINC01556,Gene
16414,GNL1,Gene
16428,TFAP2A-AS1,Gene
16435,MIR3143,Gene
16450,AC134300.1,Gene
16453,RP1-34B20.21,Gene
16458,MIR3144,Gene
16463,RP11-420L9.4,Gene
16485,C2-AS1,Gene
16486,SAPCD1-AS1,Gene
16490,MIR6780B,Gene
16492,LINC00240,Gene
16493,LOC100270746,Gene
16497,HIST1H2AE,Gene
16498,HIST1H2APS1,Gene
16499,HIST1H2BA,Gene
16500,HIST1H2BG,Gene
16501,HIST1H3E,Gene
16502,HIST1H3F,Gene
16503,HIST1H4F,Gene
16504,HIST1H4G,Gene
16506,MIR3135B,Gene
16507,PSMB8-AS1,Gene
16509,ATAT1,Gene
16510,C6orf136,Gene
16511,DHX16,Gene
16512,HLA-F-AS1,Gene
16513,LINC01015,Gene
16514,MDC1-AS1,Gene
16515,MIR4640,Gene
16516,MIR877,Gene
16517,NRM,Gene
16518,PPP1R18,Gene
16519,PRR3,Gene
16520,SNORD32B,Gene
16524,RPS3AP23,Gene
16526,AC093515.1,Gene
16529,RP11-135M8__A.1,Gene
16539,CCDC113,Gene
16541,FAM234A,Gene
16713,MPV17L,Gene
16741,DAXX,Gene
16743,KIFC1,Gene
16745,SNHG5,Gene
16747,AK9,Gene
16750,MIR1202,Gene
16760,RP1-253B10.1,Gene
16773,SETD6,Gene
16774,SNORA46,Gene
16775,SNORA76A,Gene
16782,BTN2A3P,Gene
16783,HCG11,Gene
16784,LOC285819,Gene
16794,CLDN20,Gene
16796,ADGRF5,Gene
16798,PRCAT47,Gene
16800,RP11-293N14.1,Gene
16802,RP11-437J19.1,Gene
16805,RP11-397G17.1,Gene
16807,RNA5SP430,Gene
16913,AC004158.3,Gene
16915,LINC01572,Gene
16916,PGP,Gene
16919,SPDEF,Gene
16928,CUTA,Gene
16929,LINC00336,Gene
16930,MIR1234,Gene
16931,MIR5004,Gene
16932,MIR6834,Gene
16933,MIR6873,Gene
16934,PFDN6,Gene
16935,PHF1,Gene
16936,RGL2,Gene
16937,SYNGAP1,Gene
16938,WDR46,Gene
16939,ZBTB22,Gene
17005,LINC00922,Gene
17007,C16orf78,Gene
17010,LOC101928880,Gene
17013,PACRG,Gene
17019,MAP7,Gene
17022,CASC6,Gene
17056,LOC105374928,Gene
17057,SLC17A1-4,Gene
17112,RP11-830F9.6,Gene
17121,BC041459,Gene
17125,PYCARD,Gene
17131,USP31,Gene
17136,FLYWCH1,Gene
17144,C6ORF97,Gene
17148,RP11-77K12.8,Gene
17152,POLR1C,Gene
17155,AMFR,Gene
17163,SUMO4,Gene
17165,COQ7,Gene
17171,ZNF646,Gene
17176,ATP2A1-AS1,Gene
17184,ADGB,Gene
17187,DTNBP1,Gene
17199,ENSG00000271623,Gene
17205,ENSG00000251417,Gene
17213,ENSG00000207514,Gene
17215,ZNF19,Gene
17222,HGC18,Gene
17229,HGMA1,Gene
17240,LOC101929163,Gene
17243,GPR63,Gene
17252,LOC100129195,Gene
17254,LOC442181,Gene
17257,OR2B3P,Gene
17259,LOC729653,Gene
17268,OTOA,Gene
17270,METTL9,Gene
17271,IGSF6,Gene
17277,ZNF75A,Gene
17279,OR2C1,Gene
17281,ARMT1,Gene
17291,NDE1,Gene
17306,ENSG00000271608,Gene
17310,MEI4,Gene
17319,LOC441178,Gene
17323,PLEKHG4,Gene
17326,LOC101928614,Gene
17333,MIR5095,Gene
17339,LINC01571,Gene
17341,C16orf97,Gene
17342,LOC101927334,Gene
17347,CASP8AP2,Gene
17356,HIST1A2AC,Gene
17361,ATP6V0D1,Gene
17382,ENSG00000260853,Gene
17384,RNU6-633P,Gene
17388,ENSG00000234816,Gene
17396,VN1R11P,Gene
17409,ENSG00000242753,Gene
17411,STMND1,Gene
17433,LOC100506172,Gene
17438,STX4,Gene
17439,ZNF668,Gene
17443,RHBDF1,Gene
17446,MRPL28,Gene
17457,MLST8,Gene
17461,XXbac-BPG154L12.5,Gene
17479,RNU6-200P,Gene
17517,KCTD19,Gene
17529,TMEM14C,Gene
17551,ZDHHC1,Gene
17558,TARiD,Gene
17560,XXbac-BPG116M5.17,Gene
17597,CCNF,Gene
17603,MYST1,Gene
17627,LINC00326,Gene
17641,PTK7,Gene
17650,DMA,Gene
17655,FOXCUT,Gene
17671,PANDAR,Gene
17678,EYA4-AS1,Gene
17680,LINC01312,Gene
17702,LINC01229,Gene
17715,LOC101929057,Gene
17716,LYRM2,Gene
17729,BCL7C,Gene
17748,SYCP2L / MAK,Gene
17750,MSH5 / HLA,Gene
17790,ABBA-1,Gene
17798,ZHFX3,Gene
17818,LINC01081,Gene
17870,ARL2BP,Gene
17905,BC035400,Gene
17912,RP11-264B17.4,Gene
17913,RP11-24N18.1,Gene
17916,AL592429.2,Gene
18046,KCNQ5-AS2,Gene
18070,SLC7A5P1,Gene
18082,RP11-207F8.1,Gene
18088,ACTG1P9,Gene
18103,CTGF,Gene
18159,CCL17,Gene
18208,GPR56,Gene
18210,RP11-510J16.5,Gene
18268,RNF217,Gene
18272,C16orf80,Gene
18276,TUBB4Q,Gene
18290,TRNA_Ser,Gene
18294,CAGE1,Gene
18376,MEI,Gene
18405,LINC02571,Gene
18408,MPIG6B,Gene
18412,LOC105371345,Gene
18424,C5orf15,Gene
18432,RP1-261G23.5,Gene
18438,BLOC1S5,Gene
18439,TMEM14B,Gene
18441,RN7SKP211,Gene
18537,APOOP5,Gene
18539,LINC00271,Gene
18545,ZG16B,Gene
18547,DLK2,Gene
18555,LINC02183,Gene
18671,ELMO3,Gene
18674,ADMTS18,Gene
18687,TAAR8,Gene
18689,TAAR6,Gene
18714,RNU6-1114P,Gene
18716,RNU6-603P,Gene
18728,C6orf203,Gene
18731,TUBBP9,Gene
18739,ABRACL,Gene
18742,ATP5F1P6,Gene
18750,TREM1,Gene
18756,RP3-359N14.1,Gene
18766,BLOC1S5-TXNDC5,Gene
18768,GLTSCR1L,Gene
18770,OGFRL1,Gene
18771,SLC17A5,Gene
18774,CCNC,Gene
18776,GTF3C6,Gene
18778,TSPYL1,Gene
18779,TRAPPC3L,Gene
18780,CLVS2,Gene
18786,OSTCP1,Gene
18804,DNAH8,Gene
18807,LOC100507173,Gene
18843,SOGA3,Gene
18849,FUS,Gene
18852,FAM92B,Gene
18875,DECR2,Gene
18933,OR2E1P,Gene
18940,TPSD1,Gene
18941,UNKL,Gene
18942,CCDC154,Gene
18944,RPS15A,Gene
18946,ARL6IP1,Gene
18947,SMG1,Gene
18949,TPPP3,Gene
18950,SMPD3,Gene
19031,RP11-461O7.1,Gene
19064,ABCC11,Gene
19117,XXbac-BPG154L12.4,Gene
19168,RNU7-152P,Gene
19182,CARMIL1,Gene
19186,MSLN,Gene
19198,LOC100130476,Gene
19224,FLJ38122,Gene
19234,RNU6-793P,Gene
19243,FUCA2,Gene
19245,LOC101928304,Gene
19247,LOC105377865,Gene
19257,LOC101928277,Gene
19333,VN1R12P,Gene
19338,SEPHS2,Gene
19340,CTF2P,Gene
19342,DUS2,Gene
19348,RPSAP2,Gene
19361,NPIPL1-CLN3,Gene
19385,SEC63,Gene
19398,MT1A,Gene
19413,PTX4,Gene
19415,CNPY3,Gene
19436,PDP2,Gene
19442,LOC107986519,Gene
19462,AL590867.1,Gene
19489,FAM192A,Gene
19536,TMEM114,Gene
19542,CLPS,Gene
19558,LINC00577,Gene
19560,LOC101928540,Gene
19564,WISP3,Gene
19571,RP11-437L7.1a,Gene
19577,CLEC18C,Gene
19583,ZFP57a,Gene
19588,RP1-309H15.2,Gene
19595,snoU13,Gene
19597,RN7SKP190,Gene
19607,RP11-679B17.2,Gene
19611,AC007347.1,Gene
19617,RN7SL841P,Gene
19620,MIR3925,Gene
19640,MLYCD,Gene
19646,LINC01567,Gene
19653,LINC00311,Gene
19655,GINS2,Gene
19665,RPS4XP9,Gene
19667,PPP1R14BP5,Gene
19686,KLC4,Gene
19692,XPO5,Gene
19714,intergenicN1L,Gene
19717,CUL9:RP3-330M21.5,Gene
19722,RAB44,Gene
19735,MIC-A,Gene
19769,LINC01622,Gene
19793,CES4A,Gene
19796,ZintergenicD1,Gene
19801,EXOC3L1,Gene
19817,RSL24D1P1,Gene
19821,LOC100129697,Gene
19822,TRAPPC2L,Gene
19848,EEF2K,Gene
19852,ZNF689,Gene
19884,RP11-343C2.9,Gene
19934,LITAFy,Gene
19952,PRDM1-ATG5,Gene
19987,LINC00581,Gene
19994,SRCAP,Gene
20000,AK097694,Gene
20007,LIN28B-AS1,Gene
20009,SOBP,Gene
20028,TXLNB,Gene
20030,LOC100507557,Gene
20041,PRSS8,Gene
20042,PRSS36,Gene
20060,LOC101929504,Gene
20092,LINC01569,Gene
20098,AK093002,Gene
20118,HAGHL,Gene
20135,PNRC1,Gene
20161,C6orf107,Gene
20167,EIF3C-1,Gene
20168,EIF3C-2,Gene
20169,EIF3CL-1,Gene
20170,EIF3CL-2,Gene
20171,LOC390688-1,Gene
20172,LOC390688-2,Gene
20173,LOC440350-1,Gene
20174,LOC440350-2,Gene
20175,LOC440350-3,Gene
20176,LOC440350-4,Gene
20177,CCDC95,Gene
20178,FLJ25404,Gene
20196,ITPRIPL2,Gene
20203,LOC101929541,Gene
20205,OSTM1-AS1,Gene
20208,KLF8P1,Gene
20231,RN7SK,Gene
20232,ICK,Gene
20233,RN7SL244,Gene
20234,FBXO9,Gene
20237,LOC102723649,Gene
20239,LOC442263,Gene
20256,PNLDC1,Gene
20258,LPL2,Gene
20264,PACRG-AS1,Gene
20274,GCN20,Gene
20280,ACSM3,Gene
20286,FTO-IT1,Gene
20295,GALNS,Gene
20296,IL17C,Gene
20297,LOC339059,Gene
20298,LOC100289580,Gene
20299,MIR4722,Gene
20300,MIR5189,Gene
20301,MVD,Gene
20302,PABPN1L,Gene
20303,RNF166,Gene
20304,SNAI3,Gene
20331,ZNF204,Gene
20333,SLC34A1,Gene
20336,PMSP,Gene
20345,PRSS54,Gene
20349,PRSS8/MYST1,Gene
20361,LOC388210,Gene
20377,NCRNA00171,Gene
20389,LOC389369,Gene
20393,C6orf26,Gene
20400,DQ141194,Gene
20401,C16orf74,Gene
20403,ADH5P4,Gene
20418,GCM1,Gene
20425,OX2R,Gene
20426,VIP,Gene
20433,C6ORF183,Gene
20449,ZDHHC20P2,Gene
20451,HCG25,Gene
20452,HLA-X,Gene
20462,LOC729159,Gene
20505,C6orf163,Gene
20507,TRAF3IP2-AS1,Gene
20514,KIAA0408,Gene
20529,HLA-area,Gene
20560,ITGAX-ITGAM,Gene
20568,AK123889,Gene
20580,FOPNL,Gene
20594,TDP2,Gene
20597,ECT2L,Gene
20610,HS3ST6,Gene
20612,MSRB1,Gene
20613,LOC154092,Gene
20634,MC1R-R,Gene
20635,MC1R-All,Gene
20671,TBC1D32,Gene
20673,CRAMP1L,Gene
20675,HN1L,Gene
20716,LOC100507254,Gene
20732,LOC102724704,Gene
20738,LOC101928047,Gene
20741,FAM26D,Gene
20743,ANKS4B,Gene
20745,ZP2,Gene
20746,CRYM,Gene
20747,MHC_Class II,Gene
20750,MIR4643,Gene
20753,MHC_Class III,Gene
20765,TSPO2,Gene
20771,HLA-B*38:02,Gene
20775,HLA-DRB1*08:03,Gene
20790,BTBD9-AS1,Gene
20800,FN3K,Gene
20837,RP5-973N23.4,Gene
20843,ENPP4,Gene
20845,OPN5,Gene
20847,CENPQ,Gene
20873,LOC101928035,Gene
20878,MDFI,Gene
20894,LINC02537,Gene
20900,LA16c-306A4.1,Gene
20929,RP1-287H17.1,Gene
20954,PRR25,Gene
20965,MANEA-AS1,Gene
20968,GUSBP4-LINC00680,Gene
20994,RP11-616M22.7,Gene
21004,C6orf103,Gene
21007,RPL31P56,Gene
21014,EHMT2-AS1,Gene
21016,HLA-DQB1-AS1,Gene
21059,ECI1,Gene
21098,LINC02542,Gene
21122,PSMG4,Gene
21153,RP11-960L18.1,Gene
21157,RP11-46C24.5,Gene
21164,RP11,Gene
21166,302L19.1,Gene
21169,RP1,Gene
21170,97D16.1,Gene
21172,88C11.7,Gene
21173,RPL3P2,Gene
21180,439H9.1,Gene
21187,HIST1,Gene
21189,H4PS1,Gene
21192,457M11.5,Gene
21207,RP11-69I8.3,Gene
21216,HINT3,Gene
21227,RP11-467J12.2/RP11-467J12.3,Gene
21230,LOC101928096,Gene
21231,AC126763.1,Gene
21236,HLADRB1,Gene
21237,HLADQA1,Gene
21244,DNAJA2,Gene
21260,RN7SL353P,Gene
21268,KCTD20,Gene
21272,C6orf226,Gene
21275,RP11-439L18.2,Gene
21293,AC009133.14,Gene
21294,AC009133.20,Gene
21319,MANEA,Gene
21327,RP11-278J20.2,Gene
21331,RPL5P18,Gene
21361,RP11-12A2.3,Gene
21367,AL360007.1,Gene
21372,RP3-344J20.1,Gene
21379,RP11-527F13.1,Gene
21395,RP11-44F14.8,Gene
21406,RP11-391L3.5,Gene
21421,RP1-167F1.2,Gene
21452,RNU6-1133P,Gene
21468,XXbac-BPG299F13.16,Gene
21484,XXbac-BPG308K3.6,Gene
21488,DDX6P1,Gene
21494,UBDP1,Gene
21500,ZDHHC20P1,Gene
21506,MICE,Gene
21507,HLA-P,Gene
21515,RP3-470L22.1,Gene
21534,RP11-457M11.5,Gene
21538,RP11-209A2.1,Gene
21548,RP5-1186N24.3,Gene
21550,OR2P1P,Gene
21557,RP11-7O14.1,Gene
21559,RP11-44F14.1,Gene
21568,AL671883.1,Gene
21584,LA16c-313D11.9,Gene
21586,LA16c-380A1.1,Gene
21603,CSNK2B-LY6G5B-1181,Gene
21616,RNU1-61P,Gene
21625,XXbac-BPG254F23.6,Gene
21633,XXbac-BPG181B23.7,Gene
21654,RP11-344J7.2,Gene
21659,RP1-92C4.1,Gene
21665,RP11-11L12.2,Gene
21667,RPL17P25,Gene
21670,TPSP2,Gene
21675,MVP,Gene
21678,RRAD,Gene
21680,FHOD1,Gene
21684,RP11-252E2.2,Gene
21691,CTC-786C10.1,Gene
21693,COX6CP16,Gene
21697,XXbac-BPG34I8.3,Gene
21699,AL662890.3,Gene
21702,AL669914.1,Gene
21705,DDR1-AS1,Gene
21726,COL21A1-DST,Gene
21738,LOC100507406,Gene
21821,ENSG00000224849,Gene
21830,LOC101927691,Gene
21832,LOC105378068,Gene
21869,GTPBP2,Gene
21894,MIR548H5,Gene
21909,RP11-523L20.2,Gene
21916,ENSG00000225879,Gene
21921,RP3-522P13.2,Gene
21965,RP1-8B1.4,Gene
21972,RP3-388E23.2,Gene
21986,CA5AP1,Gene
21991,RP11-77K12.1,Gene
21993,RP11-77K12.3,Gene
21996,RP11-345M22.2,Gene
22016,KRT18P9,Gene
22021,GPR111,Gene
22030,LOC100128588,Gene
22068,DDX39B-AS1,Gene
22070,VAC14-AS1,Gene
22071,MTSS1L,Gene
22072,SF3B3,Gene
22073,SNORD111,Gene
22074,SNORD111B,Gene
22075,ST3GAL2,Gene
22076,DDX19A,Gene
22077,LOC100506083,Gene
22078,EXOSC6,Gene
22085,RP11-472M19.2,Gene
22093,CCDC78,Gene
22105,LOC101928417,Gene
22110,CAPN11,Gene
22116,RP11-428F8.2,Gene
22152,HCG4P5,Gene
22158,CYCSP55,Gene
22180,ACSF3,Gene
22241,PEX6/MEA1/RP3-475N16.1/RPL24P4,Gene
22243,BMERB1,Gene
22272,ACSM3andERI2,Gene
22280,CTRB1/BCAR1,Gene
22287,C6orf168,Gene
22289,AC002485.1,Gene
22369,RIOK1,Gene
22471,FLJ23152,Gene
22484,RP11-252K23.2,Gene
22502,LOC100422737,Gene
22504,LOC101928663,Gene
22535,FCF1P10,Gene
22537,IL21R-AS1,Gene
22552,MAFTRR,Gene
22591,BPHL,Gene
22599,C6orf218,Gene
22637,LOC100131303,Gene
22638,MIR6773,Gene
22639,xMHC,Gene
22646,SPRK1,Gene
22677,CLEC18B,Gene
22683,DNPH1,Gene
22694,RP11-345J4.8,Gene
22700,HCCAT5,Gene
22710,LOC101927293,Gene
22725,LOC101928140,Gene
22801,SERPINB9,Gene
22839,RP11-345M22.3,Gene
22840,RP11-148M9.1,Gene
22845,FTH1P5,Gene
22849,ENSG00000223811,Gene
22860,LOC100507362,Gene
22863,COX11P1,Gene
22864,TRNAS17,Gene
22873,SUMO2P1,Gene
22943,FTSJD1,Gene
22948,MEFV,Gene
22982,AKD1,Gene
22988,MICAL1,Gene
23108,XXbac-BPG308K3.5,Gene
23116,XXbac-BPG170G13.31,Gene
23126,RN7SKP186,Gene
23129,HCG21,Gene
23138,WASF5P,Gene
23178,PPP1R2P1,Gene
23251,XXbac-BPGBPG24O18.1,Gene
23254,RP1-97D16.1,Gene
23267,XXbac-BPG16N22.5,Gene
23291,RPL13,Gene
23350,TPBG,Gene
23360,AS1,Gene
23361,LINC02188,Gene
23362,LINC02181,Gene
23364,CMTR2,Gene
23372,BC108660,Gene
23374,AK126539,Gene
23378,AK024736,Gene
23381,PTP4A1,Gene
23389,SMIM29,Gene
23416,AL354740.1,Gene
23441,TBC1D24,Gene
23486,RPL35P2,Gene
23558,RANP1,Gene
23560,XXbac-BPG27H4.8,Gene
23575,AL662890.1,Gene
23664,XXbac-BPG181B23.6,Gene
23883,ZNF747,Gene
23885,AL589935.1,Gene
23891,AC092378.1,Gene
23903,AL139807.1,Gene
23905,FAM135A,Gene
23933,ILRUN,Gene
23951,AC007491.1,Gene
23957,CDR2,Gene
23959,AC012322.1,Gene
23965,HIST1H2APS4,Gene
23978,LINC00533,Gene
24072,MICG,Gene
24084,RP11-624M8.1,Gene
24090,VIMP1,Gene
24094,PRELID1P1,Gene
24100,RP11-66H6.3,Gene
24105,RP11-250B2.5,Gene
24107,RP11-250B2.3,Gene
24120,PRDX2P4,Gene
24150,RP1-177A13.1,Gene
24160,RP11-15H7.2,Gene
24163,RNA5SP224,Gene
24175,XXbac-BPG300A18.13,Gene
24216,RP11-321N4.5,Gene
24224,HLA-DQA,Gene
24228,RNU6,Gene
24235,HLA-DQ1,Gene
24238,DPCR,Gene
24245,RP11-805I24.1,Gene
24250,RP11-863P13.1,Gene
24254,HLA-B*27,Gene
24255,HLA-A*0201,Gene
24258,ERAP1,Gene
24261,U91319.1,Gene
24264,RP11-1348G14.1,Gene
24265,RP11-1348G14.4,Gene
24266,RP11-58C22.1,Gene
24268,CTD-2336H13.2,Gene
24322,MEGT1,Gene
24323,AL645922.1,Gene
24356,SNAS1,Gene
24389,RAET1L,Gene
24413,OSTM1,Gene
24467,LOC101927314,Gene
24489,ACOT13,Gene
24505,ARPC3P5,Gene
24529,RSPH9,Gene
24530,MRPL4,Gene
24531,SLC35B2,Gene
24532,ABC10,Gene
24533,POLH,Gene
24534,TMEM63B,Gene
24535,TCTE1,Gene
24536,LRRC73,Gene
24537,MAD2L1BP,Gene
24538,YIPF3,Gene
24539,RSPO3-RNF146,Gene
24542,MIR4647,Gene
24544,HECA,Gene
24545,LOC643802,Gene
24546,BL2,Gene
24547,RPGRIP1,Gene
24549,AIRN,Gene
24550,LOC729603,Gene
24573,FBRS,Gene
24575,RNF40,Gene
24589,CMC2,Gene
24590,MIR4720,Gene
24591,LOC100129617,Gene
24691,RPS18,Gene
24692,VPS52,Gene
24709,RP3-495K2.1,Gene
24715,RP11-532F6.5,Gene
24743,MTCO2P33,Gene
24745,RP11-274H24.1,Gene
24747,RNU6-153P,Gene
24749,RP1-130G2.1,Gene
24757,C16orf59,Gene
24769,SPATS1,Gene
24793,LOC100507584,Gene
24810,RP1-72A23.3,Gene
24813,MTND4LP25,Gene
24817,RP11-14K2.1,Gene
24847,DDX11L10,Gene
24848,SNRNP25,Gene
24849,ARHGDIG,Gene
24850,LINC00235,Gene
24851,SOLH,Gene
24852,MIR5587,Gene
24853,MIR3176,Gene
24854,FAM195A,Gene
24855,RHBDL1,Gene
24856,MIR662,Gene
24857,RPUSD1,Gene
24858,PDF,Gene
24859,NIP7,Gene
24860,TMED6,Gene
24861,MIR140,Gene
24862,CLEC18A,Gene
24863,RNU6-48,Gene
24864,MNF1,Gene
24876,NHLRC1,Gene
24893,RP11-514O12.4,Gene
25007,C6orf123,Gene
25020,LOC285766,Gene
25046,BX105115,Gene
25048,RP1-140K8.2,Gene
25049,CTD-2535I10.1b,Gene
25076,RPL3L,Gene
25080,CGA,Gene
25093,AKAP7,Gene
25100,RP11-428J1.2,Gene
25104,RP1-168P16.2,Gene
25108,RN7SKP240,Gene
25119,RRAGD,Gene
25147,NOMO2,Gene
25150,MCART3P,Gene
25157,WDR24,Gene
25162,DDX43,Gene
25165,KDM1B,Gene
25185,RP11-436d23.1,Gene
25189,LOC105375010,Gene
25224,RUNDC2C,Gene
25233,PLA2G10,Gene
25239,LOC105377992LOC105377989,Gene
25248,LOC105371261,Gene
25251,LOC105377992,Gene
25252,LOC105377989,Gene
25256,GNPTG,Gene
25277,MIR365A,Gene
25279,LOC728012,Gene
25285,ERG,Gene
25287,RAET1M,Gene
25324,C6ORF118,Gene
25334,NPIPB11,Gene
25348,CARHSP1,Gene
25373,RPF2,Gene
25374,CDC2L6,Gene
25375,CCDC189,Gene
25378,MIR219A1,Gene
25385,C16orf48,Gene
25386,CTD-2012K14.1,Gene
25411,LINC01016,Gene
25451,PDCD2,Gene
25495,OXA1L,Gene
25507,HLA-DRAB5,Gene
25523,SYCE1L,Gene
25538,FAM162B,Gene
25541,MRAP2,Gene
25543,ZNF259P1,Gene
25560,PRSS22,Gene
25574,M19,Gene
25611,FKBP1C,Gene
25613,RP1-60O19.1,Gene
25620,6M1-18,Gene
25623,AK098012,Gene
25633,TEAD3,Gene
25666,AK097853,Gene
25668,AKAP7-MED23,Gene
25678,RP11-410D17.2,Gene
25683,AK093513,Gene
25731,KIAA0556,Gene
25734,RP3-335N17.2,Gene
25736,RP11-439L18.3,Gene
25747,RN7SL493P,Gene
25763,MIR548A1,Gene
25773,LOC105375065,Gene
25775,ASS1P1,Gene
25777,NUP50P2,Gene
25779,C1QTNF8,Gene
25780,KLHDC4,Gene
25781,RBMXP1,Gene
25783,RNU7-65P,Gene
25784,RPL34P16,Gene
25786,RPL31P32,Gene
25788,KRT18P30,Gene
25794,LOC105377991,Gene
25796,LOC105377990,Gene
25804,MGC34034,Gene
25812,HMGB1P39,Gene
25813,MIR4463,Gene
25815,NUBP1,Gene
25817,VN2R10P,Gene
25821,LOC105378114,Gene
25830,LOC100507203,Gene
25834,COQ3,Gene
25843,AFDN,Gene
25881,RP3-330M21.5,Gene
25883,SLC26A8,Gene
25885,AL162718.1,Gene
25930,METRN,Gene
25952,AC087564.1,Gene
25954,CYB5R4,Gene
25959,MIR8065,Gene
25975,RP1-39J2.1,Gene
26020,MIR6511B1,Gene
26025,TREML3P,Gene
26031,LINC02541,Gene
26034,AL158198.1,Gene
26037,AC125793.1,Gene
26056,RP3-329A5.8,Gene
26057,MKRNP2,Gene
26060,RP11-250B2.6,Gene
26080,AL035530.2,Gene
26082,RP11-304L19.4,Gene
26085,ANKS3,Gene
26087,RP11-883G14.4,Gene
26089,RP11-254F19.3,Gene
26108,MLIP-AS1,Gene
26109,NBAT1,Gene
26120,M2,Gene
26140,RP11-73O6.3,Gene
26159,RP11-427E4.1,Gene
26173,RP11-556O15.1,Gene
26185,TPI1P3,Gene
26188,AC079412.1,Gene
26196,LINC02133,Gene
26198,LOC101929243,Gene
26199,GNG5P1,Gene
26203,CTAGE9,Gene
26205,SYNJ2-IT1,Gene
26215,RIPOR2,Gene
26220,AL355312.5,Gene
26226,AL365259.1,Gene
26228,FILNC1,Gene
26232,AC005736.1,Gene
26240,AL050338.1,Gene
26242,STXBP5-AS1,Gene
26248,PRR35,Gene
26304,RP3-375P9.2,Gene
26326,RP11-415D17.4,Gene
26341,RPL32P1,Gene
26359,MTCYBP4,Gene
26379,RP11-137J7.2,Gene
26382,RP11-753B14.1,Gene
26393,RP1-67K17.3,Gene
26404,FOXF2-FOXCUT,Gene
26405,TFAP2B-PKHD1,Gene
26414,C6ORF106,Gene
26416,HLA-DQB3,Gene
26424,TAAR5,Gene
26436,CHP2,Gene
26438,CES5A,Gene
26459,LINC00574,Gene
26460,LOC102724511,Gene
26493,LOC105371082,Gene
26503,C6orf15-PSORS1C1,Gene
26505,DQB1.DRB1,Gene
26506,DPA1.DPB2,Gene
26556,LAP3P2,Gene
26570,LOC101929614,Gene
26571,LOC105378153,Gene
26576,DNAJA1P4,Gene
26578,HCG4P4,Gene
26589,HCG19P,Gene
26607,XXbacBPG299F13.15,Gene
26613,XXbacBPG248L24.13,Gene
26649,LOC107984137,Gene
26668,LOC107986598,Gene
26684,AL022068.1,Gene
26687,AL354740,Gene
26690,AC009065.8,Gene
26692,LOC107983965,Gene
26697,LOC101929006,Gene
26699,LOC105375005,Gene
26703,HLAB,Gene
26754,Y RNA,Gene
26760,XXbacBPG154L12.4,Gene
26779,USP45,Gene
26789,MIR548A1HG,Gene
26794,RPS15AP34,Gene
26796,OR2B8P,Gene
26798,RPL21P68,Gene
26801,UMOD-PDILT,Gene
26824,XXbac,Gene
26825,BPG248L24.12,Gene
26826,BPG300A18.13,Gene
26860,TSBP1,Gene
26882,AC127459.2,Gene
26888,LOC441167,Gene
26897,LOC105378031,Gene
26901,LOC102724168,Gene
26916,BPGBPG34I8.1,Gene
26919,BPG248L24.13,Gene
26921,440G9.1,Gene
26943,16q23,Gene
26945,420N3.2,Gene
26954,FAM157C,Gene
26957,HLA-DPA2,Gene
26973,RP11-420N3.2:RBFOX1,Gene
26975,RNU6-1286P,Gene
26977,RP3-399J4.4,Gene
26980,RP11-53L24.1,Gene
26985,MLIP:MLIP-AS1,Gene
27000,BNC2,Gene
27034,AK057218,Gene
27036,LOC100996860,Gene
27046,RP1-81D8.4,Gene
27071,TRNAI28P,Gene
27083,ADAT2,Gene
27092,RP11-510H23.1,Gene
27095,RP11-50O21.1,Gene
27114,RP11-2C24.5,Gene
27132,TTLL2,Gene
27134,TCP10,Gene
27151,RHBDL1STUB1,Gene
27161,GUSBP4,Gene
27168,TELO2,Gene
27169,RP11-1166P10.6,Gene
27171,CR1L,Gene
27178,HERC2,Gene
27180,SKOR2,Gene
27210,CUL7,Gene
27217,TENT5A,Gene
27224,AL356534.1,Gene
27229,AL078590.3,Gene
27240,AL109924.1,Gene
27259,CIAO3,Gene
27292,BRICD5,Gene
27293,E4F1,Gene
27313,AC138512.1,Gene
27319,TPR3,Gene
27321,P6K3,Gene
27347,CYP51A1P3,Gene
27350,AC004158.2,Gene
27365,RP11-95P2.3,Gene
27413,NHEG1,Gene
27436,ULBP2,Gene
27462,ENSG00000233908,Gene
27464,ENSG00000253194,Gene
27497,PGC,Gene
27502,RPL7AP7,Gene
27521,ENSG00000262267,Gene
27525,ENSG00000260364,Gene
27541,MIR193BHG,Gene
27557,GPC6,Gene
27600,RP11-146F11.1,Gene
27610,RP1NR23E21.2,Gene
27707,H2BC4,Gene
27709,UBALD1,Gene
27712,RP11-485G7.5,Gene
27716,RP11-21B21.4,Gene
27719,LA16c-313D11.12,Gene
27746,RP11-302L19.1,Gene
27806,RP11-370P15.2,Gene
27808,RP11-281J9.2,Gene
27816,PSORSIC1,Gene
27831,RP11-297M9.1,Gene
27862,WRNIP1,Gene
27887,MIR7159,Gene
27894,AC009120.4,Gene
27929,CTD-2349B8.1,Gene
27931,RP11-455F5.3,Gene
27937,RP11-432I5.2,Gene
27949,RP11-65J21.4,Gene
27966,U4,Gene
27988,LINC02182,Gene
27999,RP11-73O6.4,Gene
28012,PTCHD3P3,Gene
28016,AC140912.1,Gene
28047,TRX-CAT1-7,Gene
28050,LOC105375012,Gene
28061,MCM3,Gene
28088,ZNF629,Gene
28182,CRYBG1,Gene
28239,LOC100506281,Gene
28252,RAB23,Gene
28254,ZFP901,Gene
28259,PPARD1,Gene
28263,NUFIP1P,Gene
28268,MICA/HLA-B,Gene
28269,MAPK8IP3,Gene
28288,AY927475,Gene
28298,MIR548AI,Gene
28310,MIR4426,Gene
28337,FAM8A1,Gene
28340,RP11-481J2.2,Gene
28411,RP11-503C24.3,Gene
28412,RP11-503C24.2,Gene
28414,ZC2HC1B,Gene
28420,LOC101928945,Gene
28488,7SK,Gene
28494,RP11-429K17.1,Gene
28496,PPP2R5D,Gene
28497,LINC02532,Gene
28510,RP3-404K8.2,Gene
28517,AC012181.1,Gene
28525,RP11-631F7.1,Gene
28526,RN5S431,Gene
28531,RP1-167A14.2,Gene
28538,RP1-67M12.2,Gene
28546,NSMCE,Gene
28581,TAF11,Gene
28589,RP1-179N16.6,Gene
28592,RPL15P4,Gene
28645,RP11-69L16.4,Gene
28654,TRIM26BP,Gene
28677,STUB1,Gene
28678,JMJD8,Gene
28683,MIR940,Gene
28692,CTA-276F8.2,Gene
28693,RP11-65J21.3,Gene
28697,RNF151,Gene
28711,HNRNPA1P2,Gene
28740,RP3-391O22.3,Gene
28754,PRICKLE4,Gene
28756,TOMM6,Gene
28789,RP11-474L11.3,Gene
28811,LTBP2,Gene
29006,Hip circumference adjusted for BMI,Disease
29007,Waist circumference,Disease
29008,Waist-hip ratio,Disease
29009,Body mass index,Disease
29010,Hip circumference,Disease
29011,Response to Homoharringtonine (cytotoxicity),Disease
29012,Thrombomodulin levels in ischemic stroke,Disease
29013,Creatinine levels in ischemic stroke,Disease
29014,Prothrombin fragments F1+2 levels in ischemic stroke,Disease
29015,Clozapine-induced cytotoxicity,Disease
29016,Waist circumference adjusted for body mass index,Disease
29017,Trans fatty acid levels,Disease
29018,Response to inhaled glucocorticoid treatment in asthma (change in FEV1),Disease
29019,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),Disease
29020,Subcortical brain region volumes,Disease
29021,Bipolar disorder,Disease
29022,Cutaneous psoriasis,Disease
29023,Psoriasis vulgaris,Disease
29024,Psoriatic arthritis,Disease
29025,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Disease
29026,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Disease
29027,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Disease
29028,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Disease
29029,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Disease
29030,Delta-5 desaturase activity,Disease
29031,Waist-to-hip ratio adjusted for body mass index,Disease
29032,Verbal declarative memory,Disease
29033,Peanut allergy,Disease
29034,Egg allergy,Disease
29035,QT interval,Disease
29036,Celiac disease,Disease
29037,Beta-2 microglubulin plasma levels,Disease
29038,Rheumatoid arthritis,Disease
29039,Asymmetrical dimethylarginine levels,Disease
29040,Symmetrical dimethylarginine levels,Disease
29041,Serum dimethylarginine levels (asymmetric/symetric ratio),Disease
29042,Lipid metabolism phenotypes,Disease
29043,Type 2 diabetes,Disease
29044,Complement C3 and C4 levels,Disease
29045,Metabolite levels,Disease
29046,Systemic lupus erythematosus and Systemic sclerosis,Disease
29047,Colorectal cancer,Disease
29048,Alzheimer's disease (APOE e4 interaction),Disease
29049,Alzheimer's disease in APOE e4+ carriers,Disease
29050,Antibody level in response to infection,Disease
29051,Maximal oxygen uptake response,Disease
29052,HDL Cholesterol in HIV-infection,Disease
29053,Magnesium levels,Disease
29054,Cutaneous lupus erythematosus,Disease
29055,Vein graft stenosis in coronary artery bypass grafting,Disease
29056,Sasang constitutional medicine type (So-Eum),Disease
29057,Psoriasis,Disease
29058,Diisocyanate-induced asthma,Disease
29059,Type 1 diabetes and autoimmune thyroid diseases,Disease
29060,Leishmaniasis (visceral),Disease
29061,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)",Disease
29062,Brugada syndrome,Disease
29063,Obesity (early onset extreme),Disease
29064,Gray matter volume (schizophrenia interaction),Disease
29065,Chronic hepatitis C infection,Disease
29066,Ulcerative colitis,Disease
29067,Plasma plasminogen levels,Disease
29068,Mammographic density,Disease
29069,Thiazide-induced adverse metabolic effects in hypertensive patients,Disease
29070,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),Disease
29071,Sickle cell anemia (haemolysis),Disease
29072,Red blood cell traits,Disease
29073,Stroke (ischemic),Disease
29074,Febrile seizures (MMR vaccine-related),Disease
29075,Rheumatoid arthritis (ACPA-negative),Disease
29076,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",Disease
29077,Very long-chain saturated fatty acid levels (fatty acid 20:0),Disease
29078,Heschl's gyrus morphology,Disease
29079,Crohn's disease,Disease
29080,Age-related nuclear cataracts,Disease
29081,Pulmonary function in asthmatics,Disease
29082,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),Disease
29083,Schizophrenia (inflammation and infection response interaction),Disease
29084,Nonsyndromic cleft lip with or without cleft palate,Disease
29085,Number of pregnancies,Disease
29086,Spontaneous preterm birth (preterm birth),Disease
29087,Psychotic symptoms and prion disease,Disease
29088,Behavioral disturbance or psychiatric symptoms in prion disease,Disease
29089,Response to serotonin reuptake inhibitors in major depressive disorder,Disease
29090,Prostate cancer,Disease
29091,Serum total protein levels,Disease
29092,Dental caries,Disease
29093,Iron status biomarkers (ferritin levels),Disease
29094,Iron status biomarkers (transferrin saturation),Disease
29095,Iron status biomarkers (iron levels),Disease
29096,Iron status biomarkers (transferrin levels),Disease
29097,Vogt-Koyanagi-Harada syndrome,Disease
29098,Nasopharyngeal carcinoma (SNP x SNP interaction),Disease
29099,Gastritis,Disease
29100,Platelet count,Disease
29101,Melanoma,Disease
29102,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),Disease
29103,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),Disease
29104,Sleep time,Disease
29105,Sleep quality,Disease
29106,Sleep duration,Disease
29107,Allergic sensitization,Disease
29108,Pancreatic cancer,Disease
29109,Cardiac Troponin-T levels,Disease
29110,Multiple sclerosis,Disease
29111,Body mass index (change over time),Disease
29112,Hodgkin's lymphoma,Disease
29113,Follicular lymphoma,Disease
29114,Red wine liking,Disease
29115,White wine liking,Disease
29116,Chronic hepatitis B infection,Disease
29117,Number of children (6+ vs. 0 or 1),Disease
29118,Number of children,Disease
29119,Survival in microsatellite instability low/stable colorectal cancer,Disease
29120,Survival in rectal cancer,Disease
29121,Sitting height ratio,Disease
29122,Information processing speed,Disease
29123,Polychlorinated biphenyl levels,Disease
29124,Myeloproliferative neoplasms,Disease
29125,Blood pressure,Disease
29126,Food antigen IgG levels,Disease
29127,Diffuse large B cell lymphoma,Disease
29128,Plasma plasminogen activator levels,Disease
29129,Hepatitis,Disease
29130,Bladder cancer (smoking interaction),Disease
29131,Telomere length,Disease
29132,Carotid intima media thickness,Disease
29133,Cytomegalovirus antibody response,Disease
29134,Sarcoidosis,Disease
29135,Menarche (age at onset),Disease
29136,Lipoprotein (a) - cholesterol levels,Disease
29137,Urate levels in lean individuals,Disease
29138,Urate levels in overweight individuals,Disease
29139,ADAMTS13 activity,Disease
29140,Recalcitrant atopic dermatitis,Disease
29141,Serum IgE levels,Disease
29142,Chronic obstructive pulmonary disease-related biomarkers,Disease
29143,Cataracts in type 2 diabetes,Disease
29144,Coronary heart disease,Disease
29145,Alcohol dependence,Disease
29146,Facial pigmentation,Disease
29147,Schizophrenia,Disease
29148,Behavioural disinhibition (generation interaction),Disease
29149,Lipid traits,Disease
29150,Acne (severe),Disease
29151,Anger,Disease
29152,Adiponectin levels,Disease
29153,Chronic lymphocytic leukemia,Disease
29154,Preschool internalizing problems,Disease
29155,Glycated hemoglobin levels,Disease
29156,Endometrial cancer,Disease
29157,Antinuclear antibody levels,Disease
29158,Interferon alpha levels in systemic lupus erythematosus,Disease
29159,Thyroid peroxidase antibody positivity,Disease
29160,Immune response to measles-mumps-rubella vaccine,Disease
29161,Systemic lupus erythematosus,Disease
29162,General cognitive ability,Disease
29163,Enteric fever,Disease
29164,Parkinson's disease,Disease
29165,Breast cancer (menopausal hormone therapy interaction),Disease
29166,Political ideology,Disease
29167,Serum uric acid levels,Disease
29168,Birth weight,Disease
29169,HDL cholesterol,Disease
29170,Bronchopulmonary dysplasia,Disease
29171,Puberty onset (genital enlargement),Disease
29172,Puberty onset (breast development),Disease
29173,Puberty onset,Disease
29174,Response to statins (LDL cholesterol change),Disease
29175,Tourette's syndrome or obsessive-compulsive disorder,Disease
29176,Chemerin levels,Disease
29177,Hypospadias,Disease
29178,Breastfeeding duration,Disease
29179,Hyperopia,Disease
29180,Myopia,Disease
29181,Iron status biomarkers,Disease
29182,Serum thyroid-stimulating hormone levels,Disease
29183,Bone mineral density,Disease
29184,Vitiligo,Disease
29185,Vertical cup-disc ratio,Disease
29186,Bipolar disorder (body mass index interaction),Disease
29187,Kidney function decline traits,Disease
29188,Airway responsiveness in chronic obstructive pulmonary disease,Disease
29189,Cognitive function,Disease
29190,Cervical artery dissection,Disease
29191,Non-alcoholic fatty liver disease histology (other),Disease
29192,Multiple myeloma,Disease
29193,Alzheimer's disease,Disease
29194,Educational attainment,Disease
29195,Acute anterior uveitis (with or without ankylosing spondylitis),Disease
29196,Acute anterior uveitis in ankylosing spondylitis,Disease
29197,Refractive astigmatism,Disease
29198,Social autistic-like traits,Disease
29199,Lung Cancer (DNA repair capacity),Disease
29200,Fibrinogen,Disease
29201,Systolic blood pressure (alcohol consumption interaction),Disease
29202,Autoimmune hepatitis type-1,Disease
29203,Mitochondrial DNA levels,Disease
29204,Breast cancer,Disease
29205,Breast cancer (early onset),Disease
29206,Plasma homocysteine levels (post-methionine load test),Disease
29207,Cholesterol,Disease
29208,Central corneal thickness,Disease
29209,Periodontal disease-related phenotype (Socransky),Disease
29210,Response to inhaled corticosteroid treatment in asthma (change in FEV1),Disease
29211,Response to antipsychotic therapy (extrapyramidal side effects),Disease
29212,Fetal hemoglobin levels in sickle cell anemia,Disease
29213,Methotrexate pharmacokinetics (acute lymphoblastic leukemia),Disease
29214,Glaucoma,Disease
29215,Ossification of the posterior longitudinal ligament of the spine,Disease
29216,Schizophrenia or bipolar disorder,Disease
29217,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,Disease
29218,Diabetic retinopathy in type 2 diabetes,Disease
29219,Asthma and hay fever,Disease
29220,Cervical cancer,Disease
29221,Tuberculosis,Disease
29222,Laryngeal squamous cell carcinoma,Disease
29223,Breast cancer (survival),Disease
29224,Electroencephalogram traits,Disease
29225,Obesity-related traits,Disease
29226,Illicit drug use,Disease
29227,Non-substance related behavioral disinhibition,Disease
29228,Asthma (sex interaction),Disease
29229,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),Disease
29230,Lupus nephritis in systemic lupus erythematosus,Disease
29231,"Bone mineral density (paediatric, upper limb)",Disease
29232,"Bone mineral density (paediatric, skull)",Disease
29233,"Bone mineral density (paediatric, total body less head)",Disease
29234,Reading disability or specific language impairment (pleiotropy),Disease
29235,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy),Disease
29236,Colorectal cancer (calcium intake interaction),Disease
29237,Psychosis (atypical),Disease
29238,Height adjusted BMI,Disease
29239,Response to cytadine analogues (cytosine arabinoside),Disease
29240,Barrett's esophagus,Disease
29241,Neuroblastoma,Disease
29242,C-reactive protein,Disease
29243,AIDS progression,Disease
29244,Smoking quantity,Disease
29245,Smoking initiation,Disease
29246,C-reactive protein levels,Disease
29247,Hypertension,Disease
29248,Birth length,Disease
29249,Infant length,Disease
29250,Systolic blood pressure,Disease
29251,Diastolic blood pressure,Disease
29252,Alzheimer's disease (age of onset),Disease
29253,Age-related hearing impairment (SNP x SNP interaction),Disease
29254,Age-related hearing impairment,Disease
29255,IgE levels,Disease
29256,IgA nephropathy,Disease
29257,Thyroid peroxidase antibody levels,Disease
29258,Response to taxane treatment (paclitaxel),Disease
29259,Response to antipsychotic treatment,Disease
29260,Myopia (pathological),Disease
29261,Resting heart rate,Disease
29262,Asthma,Disease
29263,Amyotrophic lateral sclerosis,Disease
29264,Narcolepsy (onset before 2009 H1N1 influenza pandemic),Disease
29265,Narcolepsy (age of onset),Disease
29266,IgE levels in asthmatics (D.f. specific),Disease
29267,Hepatitis B vaccine response,Disease
29268,Lung function (forced vital capacity),Disease
29269,Endometriosis,Disease
29270,Mammographic density (dense area),Disease
29271,Mammographic density (non-dense area),Disease
29272,Overweight status,Disease
29273,Educational attainment (years of education),Disease
29274,Educational attainment (college completion),Disease
29275,Nonsyndromic cleft lip with cleft palate,Disease
29276,Post bronchodilator FEV1/FVC ratio,Disease
29277,Antithyroid drug-induced agranulocytosis,Disease
29278,Hematocrit,Disease
29279,Mean corpuscular hemoglobin concentration,Disease
29280,Presence of antiphospholipid antibodies,Disease
29281,Eosinophil counts,Disease
29282,Loneliness (multivariate analysis),Disease
29283,Loneliness,Disease
29284,Loneliness (linear analysis),Disease
29285,Inflammatory bowel disease,Disease
29286,Drug-induced liver injury,Disease
29287,Spherical equivalent (joint analysis main effects and education interaction),Disease
29288,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder,Disease
29289,Aggressiveness in attention deficit hyperactivity disorder,Disease
29290,Diastolic blood pressure response to hydrochlorothiazide in hypertension,Disease
29291,Systolic blood pressure response to hydrochlorothiazide in hypertension,Disease
29292,Lung cancer,Disease
29293,Smoking status (current vs former),Disease
29294,Bone mineral density (Ward's triangle area),Disease
29295,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,Disease
29296,Eosinophil percentage of white cells,Disease
29297,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50),Disease
29298,Glaucoma (primary open-angle),Disease
29299,Mean corpuscular volume,Disease
29300,Midgestational circulating levels of PCBs (fetal genetic effect),Disease
29301,Midgestational circulating levels of PBDEs,Disease
29302,Midgestational circulating levels of PBDEs (fetal genetic effect),Disease
29303,Midgestational circulating levels of PCBs,Disease
29304,Cerebrospinal P-tau181p levels,Disease
29305,C-reactive protein levels or HDL-cholesterol levels (pleiotropy),Disease
29306,C-reactive protein levels or LDL-cholesterol levels (pleiotropy),Disease
29307,C-reactive protein levels or total cholesterol levels (pleiotropy),Disease
29308,Cerebrospinal fluid AB1-42 levels,Disease
29309,C-reactive protein levels or triglyceride levels (pleiotropy),Disease
29310,Red blood cell count,Disease
29311,Hemoglobin levels,Disease
29312,Ischemic stroke,Disease
29313,Small vessel stroke,Disease
29314,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)",Disease
29315,Neuroticism,Disease
29316,Non-response to antidepressants and depression,Disease
29317,Response to citalopram or escitalopram in depression,Disease
29318,Non-response to citalopram or escitalopram and depression,Disease
29319,Gout,Disease
29320,Renal underexcretion gout,Disease
29321,Core binding factor acute myeloid leukemia,Disease
29322,Sleep traits (multi-trait analysis),Disease
29323,Insomnia,Disease
29324,Monocyte count,Disease
29325,Mathematical ability,Disease
29326,Cerebrospinal T-tau levels,Disease
29327,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",Disease
29328,Mean corpuscular hemoglobin,Disease
29329,Optic cup area,Disease
29330,Granulocyte percentage of myeloid white cells,Disease
29331,Pulse pressure,Disease
29332,Post bronchodilator FEV1,Disease
29333,"Cholesterol, total",Disease
29334,Body fat percentage,Disease
29335,Height,Disease
29336,Bortezomib-induced peripheral neuropathy in multiple myeloma,Disease
29337,Monocyte percentage of white cells,Disease
29338,Migraine,Disease
29339,Hypothyroidism,Disease
29340,Breast size,Disease
29341,Monobrow,Disease
29342,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase,Disease
29343,Antineutrophil cytoplasmic antibody-associated vasculitis,Disease
29344,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),Disease
29345,White blood cell count,Disease
29346,Male-pattern baldness,Disease
29347,Plateletcrit,Disease
29348,Venous thromboembolism adjusted for sickle cell variant rs77121243-T,Disease
29349,Carotid plaque burden,Disease
29350,Clopidogrel active metabolite levels,Disease
29351,Tonsillectomy,Disease
29352,Age at voice drop,Disease
29353,Optic disc area,Disease
29354,Sepsis in extremely premature infants,Disease
29355,Allergy,Disease
29356,Photic sneeze reflex,Disease
29357,Childhood ear infection,Disease
29358,Chin dimples,Disease
29359,Prostate-specific antigen levels,Disease
29360,Nose size,Disease
29361,Joint mobility (Beighton score),Disease
29362,Prostate-specific antigen levels (conditioned on lead SNPs),Disease
29363,Response to paliperidone in schizophrenia (positive Marder score),Disease
29365,Response to paliperidone in schizophrenia (negative Marder score),Disease
29368,Parental longevity (mother's age at death),Disease
29369,Parental longevity (combined parental age at death),Disease
29370,Cannabis dependence symptom count,Disease
29371,Anti-thyroid drug induced agranulocytosis,Disease
29372,Non-chemotherapy drug induced agranulocytosis,Disease
29373,Celiac disease and Rheumatoid arthritis,Disease
29374,Liver fibrosis severity in HIV/hepatitis C co-infection,Disease
29375,Collagenous colitis,Disease
29376,Migraine without aura,Disease
29377,Endometrial endometrioid carcinoma,Disease
29378,Response to antidepressants and depression,Disease
29379,Posterior cortical atrophy and Alzheimer's disease,Disease
29380,Cancer (pleiotropy),Disease
29381,Cancer,Disease
29382,HDL cholesterol levels,Disease
29383,Platelet distribution width,Disease
29384,Eosinophil percentage of granulocytes,Disease
29385,Atrial fibrillation,Disease
29386,White blood cell count (basophil),Disease
29387,Reticulocyte fraction of red cells,Disease
29388,Sum basophil neutrophil counts,Disease
29389,Isovolumetric relaxation time,Disease
29390,Aortic root size,Disease
29391,Left atrial antero-posterior diameter,Disease
29392,Left ventricle wall thickness,Disease
29393,Red cell distribution width,Disease
29394,Left ventricular fractional shortening,Disease
29395,Essential tremor,Disease
29396,Liver injury in anti-tuberculosis drug treatment,Disease
29397,Daytime sleep phenotypes,Disease
29399,Night sleep phenotypes,Disease
29400,High light scatter reticulocyte count,Disease
29401,Response to paliperidone in schizophrenia (CGI-S score),Disease
29403,Gut microbiota (beta diversity),Disease
29404,Sum neutrophil eosinophil counts,Disease
29405,Exhaled nitric oxide output,Disease
29406,Exhaled nitric oxide levels,Disease
29407,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease,Disease
29408,Body mass index (change over time) in lung cancer,Disease
29409,Body mass index (change over time) in cancer,Disease
29410,Granulocyte count,Disease
29411,Skin pigmentation,Disease
29412,"Age-related diseases, mortality and associated endophenotypes",Disease
29413,Age-related diseases and mortality,Disease
29414,Incident atrial fibrillation,Disease
29415,Age-related disease endophenotypes,Disease
29416,Hemoglobin concentration,Disease
29417,Prevalent atrial fibrillation,Disease
29423,Response to paliperidone in schizophrenia (PANSS score),Disease
29424,Immune response to measles vaccine (measles-induced IFN gamma),Disease
29425,Gut microbiota (bacterial taxa),Disease
29426,Gut microbiota (functional units),Disease
29427,Systemic sclerosis,Disease
29428,RR interval (tricyclic/tetracyclic antidepressant use interaction),Disease
29429,High light scatter reticulocyte percentage of red cells,Disease
29430,Total cholesterol levels,Disease
29431,LDL cholesterol levels,Disease
29432,Triglyceride levels,Disease
29433,Sum eosinophil basophil counts,Disease
29434,Otitis media,Disease
29435,Otitis media (recurrent),Disease
29436,Hepcidin/ferritin ratio,Disease
29437,Lung function (FVC),Disease
29438,Myeloid white cell count,Disease
29439,Lung function (FEV1),Disease
29440,Lung function (FEV1/FVC),Disease
29441,Chronic obstructive pulmonary disease,Disease
29442,Lymphocyte count,Disease
29443,Reticulocyte count,Disease
29444,Pre-treatment pain in head and neck squamous cell carcinoma,Disease
29445,Neutrophil percentage of granulocytes,Disease
29446,QRS duration,Disease
29447,QRS complex (Cornell),Disease
29448,QRS complex (Sokolow-Lyon),Disease
29449,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes,Disease
29450,QRS complex (12-leadsum),Disease
29451,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,Disease
29452,Immature fraction of reticulocytes,Disease
29453,HIV progression (CD4 and viral load),Disease
29454,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),Disease
29455,Acute-on-chronic liver failure in hepatitis B,Disease
29456,Neutrophil count,Disease
29457,LDL cholesterol,Disease
29458,Response to fenofibrate (HDL cholesterol levels),Disease
29459,Parental extreme longevity (95 years and older),Disease
29460,middle facial morphology traits (quantitative measurement),Disease
29461,facial morphology traits (multivariate analysis),Disease
29462,Pathological gambling,Disease
29463,Gestational age at birth (maternal effect),Disease
29464,Gestational age at birth in labor-initiated deliveries (child effect),Disease
29465,Gestational age at birth in labor-initiated deliveries (maternal effect),Disease
29466,EGFR mutation-positive lung adenocarcinoma,Disease
29467,Alcohol consumption (heavy vs. light/non-drinkers),Disease
29468,Extraversion,Disease
29469,Positive affect,Disease
29470,Depression,Disease
29471,Subjective well-being,Disease
29472,Life satisfaction,Disease
29473,Systemic juvenile idiopathic arthritis,Disease
29474,JT interval (sulfonylurea treatment interaction),Disease
29475,QRS interval (sulfonylurea treatment interaction),Disease
29476,Bone mineral density (spine),Disease
29477,Age at first birth,Disease
29478,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder,Disease
29479,Bipolar disorder or attention deficit hyperactivity disorder,Disease
29480,Excessive daytime sleepiness,Disease
29481,Childhood body mass index,Disease
29482,Membranous nephropathy,Disease
29483,Triglycerides,Disease
29484,Stroke,Disease
29485,Gastroesophageal reflux disease,Disease
29486,Severity of facial solar lentigines,Disease
29487,Subcutaneous adipose tissue,Disease
29488,Visceral adipose tissue adjusted for BMI,Disease
29489,Visceral adipose tissue/subcutaneous adipose tissue ratio,Disease
29490,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,Disease
29491,Coronary artery disease,Disease
29492,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),Disease
29493,Visceral adipose tissue attenuation (Hounslow unit scale),Disease
29494,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),Disease
29495,Developmental language disorder,Disease
29496,Developmental language disorder (linguistic errors),Disease
29497,Breast cancer (estrogen-receptor negative),Disease
29498,Protein C levels,Disease
29499,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",Disease
29500,Takotsubo syndrome,Disease
29501,Plasma t-tau levels,Disease
29502,Fibrinogen levels,Disease
29503,Methadone dose in opioid dependence,Disease
29504,Basophil percentage of white cells,Disease
29505,Lymphocyte percentage of white cells,Disease
29506,Neutrophil percentage of white cells,Disease
29507,Pediatric bone mineral density (spine),Disease
29508,Pediatric bone mineral content (femoral neck),Disease
29509,Pediatric bone mineral density (femoral neck),Disease
29510,Pediatric bone mineral density (hip),Disease
29511,Pediatric bone mineral content (radius),Disease
29512,Pediatric bone mineral content (spine),Disease
29513,Basophil percentage of granulocytes,Disease
29514,Mean platelet volume,Disease
29515,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Disease
29516,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Disease
29517,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Disease
29518,Longevity,Disease
29519,Parental longevity (father's age at death),Disease
29520,Microalbuminuria in type 1 diabetes,Disease
29521,"Dental caries (decayed, missing and filled teeth)",Disease
29522,Dental caries (decayed and filled deciduous tooth surfaces),Disease
29523,"Dental caries (decayed, missing and filled tooth surfaces)",Disease
29524,Blood protein levels,Disease
29525,Resistant hypertension,Disease
29526,Heel bone mineral density,Disease
29532,Epigenetic age acceleration in alcohol use disorder,Disease
29533,Phenylephrine infusion rate during anesthesia,Disease
29534,High density lipoprotein cholesterol levels,Disease
29535,Low density lipoprotein cholesterol levels,Disease
29536,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis),Disease
29537,Plasma anti-thyroglobulin levels,Disease
29538,Plasma anti-thyroid peroxidase levels,Disease
29539,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Disease
29540,Adolescent idiopathic scoliosis,Disease
29541,Waist-to-hip ratio adjusted for BMI,Disease
29542,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Disease
29543,Stress sensitivity (neuroticism score x major depressive disorder status interaction),Disease
29544,Peripheral artery disease,Disease
29545,Minimum anklebrachial index,Disease
29546,Age-related cognitive decline (memory) (slope of z-scores),Disease
29547,Age-related cognitive decline (visuospatial skill) (slope of z-scores),Disease
29548,Age-related cognitive decline (attention/processing speed) (slope of z-scores),Disease
29549,Age-related cognitive decline (language) (slope of z-scores),Disease
29550,End-stage kidney disease,Disease
29551,Mild to moderate chronic kidney disease,Disease
29552,Predicted visceral adipose tissue,Disease
29553,Mosaic loss of chromosome Y (Y chromosome dosage),Disease
29554,Serum platinum levels after completion of cisplatin chemotherapy,Disease
29555,T wave morphology restitution during exercise (MTAG),Disease
29556,T wave morphology restitution during exercise,Disease
29557,Microalbuminuria,Disease
29558,Urinary albumin-to-creatinine ratio,Disease
29559,Basal metabolic rate,Disease
29560,Post-traumatic stress disorder,Disease
29561,Metabolic syndrome,Disease
29576,Skin aging measurement,Disease
29577,Asthma (childhood onset),Disease
29578,Asthma and attention deficit hyperactivity disorder,Disease
29579,Asthma and major depressive disorder,Disease
29580,Corneal resistance factor,Disease
29581,Corneal hysteresis,Disease
29582,Cytokine levels,Disease
29583,Cytokine network levels (multivariate analysis),Disease
29584,Rate of ventricular enlargement,Disease
29585,Response to ketamine in bipolar disorder or major depression (antidepressant effects),Disease
29586,Red vs. brown/black hair color,Disease
29587,Blond vs. brown/black hair color,Disease
29588,Childhood steroid-sensitive nephrotic syndrome,Disease
29589,Longevity (age >90th survival percentile),Disease
29590,Gut microbiota relative abundance (bacterial taxa),Disease
29591,Parental longevity (father's age at death or father's attained age),Disease
29592,Asthma (time to onset),Disease
29593,Cognitive performance (processing speed),Disease
29594,Parental longevity (mother's age at death or mother's attained age),Disease
29595,Working memory,Disease
29596,Lung adenocarcinoma,Disease
29597,Non-small cell lung cancer,Disease
29598,High chromosomal aberration frequency (chromosome type),Disease
29599,Chromosomal aberration frequency (chromosome type),Disease
29600,High chromosomal aberration frequency (total),Disease
29601,High chromosomal aberration frequency (chromatid type),Disease
29627,Gestational age at birth (child effect),Disease
29629,Pulmonary arterial hypertension,Disease
29630,Right planum temporale grey matter volume,Disease
29631,Urinary sodium excretion,Disease
29632,Urinary potassium excretion,Disease
29633,Non-lobar intracerebral hemorrhage (MTAG),Disease
29634,Emotional recognition,Disease
29635,Face memory,Disease
29636,Abstraction and mental flexibility,Disease
29637,Spatial memory,Disease
29638,Joint damage in rheumatoid arthritis,Disease
29646,White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure),Disease
29647,White coat effect (clinic diastolic blood pressure minus ambulatory diastolic blood pressure),Disease
29648,Maximum retinal arteriolar tortuosity,Disease
29649,Uveal melanoma,Disease
29651,Uveal melanoma with any chromosomal aberration,Disease
29652,Hydrolysed wheat protein allergy,Disease
29653,Recurrence of mild malaria attacks,Disease
29654,Body fat percentage variance,Disease
29655,Body mass index variance,Disease
29656,Waist circumference variance,Disease
29657,Basal metabolic rate variance,Disease
29658,Hip circumference variance,Disease
29659,Heel bone mineral density variance,Disease
29660,Chronic lymphocytic leukemia or multiple sclerosis,Disease
29661,Marginal zone lymphoma or rheumatoid arthritis,Disease
29662,Marginal zone lymphoma or systemic lupus erythematosus,Disease
29663,Prepulse inhibition of the startle response,Disease
29664,Degraded stimulus continuous performance test score,Disease
29665,Spatial processing,Disease
29666,California verbal learning test score,Disease
29667,Antisaccade task score,Disease
29668,Neuroblastoma or malignant cutaneous melanoma,Disease
29685,Suicide,Disease
29686,Numerical cognitive ability,Disease
29687,Figural/spatial cognitive ability,Disease
29688,Tendinopathy,Disease
29689,Ankle-brachial index,Disease
29690,Peripheral artery disease (borderline),Disease
29699,"Number of decayed, missing and filled tooth surfaces or use of dentures",Disease
29700,Dentures,Disease
29701,Nicotine dependence symptom count,Disease
29725,White matter microstructure (radial diusivities),Disease
29726,Spontaneous adipocyte lipolysis,Disease
29727,Stimulated adipocyte lipolysis,Disease
29728,Cortical surface area,Disease
29729,White matter microstructure (mode of anisotropy),Disease
29730,Modic changes,Disease
29731,Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis,Disease
29732,Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis,Disease
29747,Pelvic organ prolapse,Disease
29748,Follicle stimulating hormone levels,Disease
29749,Follicle stimulating hormone in healthy women,Disease
29750,Luteinizing hormone levels in healthy women,Disease
29751,White matter microstructure (fractional anisotropy),Disease
29752,White matter microstructure (axial diusivities),Disease
29753,Behcet's disease,Disease
29757,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Disease
29758,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Disease
29759,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Disease
29760,Breast cancer (estrogen-receptor positive),Disease
29769,Lean mass index,Disease
29771,Cortical thickness,Disease
29772,Ocular sarcoidosis,Disease
29773,Brown vs. black hair color,Disease
29774,Factor VIII levels,Disease
29775,vWF levels,Disease
29776,Automobile speeding propensity,Disease
29777,Alcohol consumption (drinks per week),Disease
29778,Fat-free mass,Disease
29779,Smoking status (ever vs never smokers),Disease
29780,Risk-taking tendency (4-domain principal component model),Disease
29781,General risk tolerance (MTAG),Disease
29782,Brain region volumes,Disease
29783,Vertical cup-disc ratio (adjusted for vertical disc diameter),Disease
29784,Vertical cup-disc ratio (multi-trait analysis),Disease
29785,Intraocular pressure,Disease
29786,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Disease
29787,Gut microbiota (alpha diversity),Disease
29788,Accommodative esotropia,Disease
29789,Amblyopia,Disease
29799,Early cardiac repolarization,Disease
29801,Moderate-to-late spontaneous preterm birth,Disease
29802,Spontaneous preterm birth with premature rupture of membranes,Disease
29803,Spontaneous preterm birth without premature rupture of membranes,Disease
29804,Uterine fibroids,Disease
29805,Subpleural-predominant interstitial lung abnormalities,Disease
29806,Interstitial lung abnormalities,Disease
29807,Adventurousness,Disease
29808,Thoracic aortic calcification levels,Disease
29809,Cocaine use disorder x household tobacco use interaction,Disease
29811,Apolipoprotein B levels,Disease
29812,OTU97_108 (Phascolarctobacterium) abundance,Disease
29814,OTU97_117 (Ruminococcus) abundance,Disease
29815,OTU97_101 (Sutterella) abundance,Disease
29817,OTU97_17 (Parabacteroides) abundance,Disease
29820,OTU97_150 (Bacteroides) abundance,Disease
29822,OTU97_126 (Prevotella) abundance,Disease
29824,Age at adiposity rebound,Disease
29825,C_Clostridia abundance,Disease
29827,F_Lachnospiraceae abundance,Disease
29829,Heart failure,Disease
29830,OTU97_23 (Faecalibacterium) abundance,Disease
29832,G_Bacteroidetes abundance,Disease
29834,G_Barnesiella abundance,Disease
29836,OTU97_51 (Barnesiella) abundance,Disease
29837,OTU97_354 (Alloprevotella) abundance,Disease
29839,OTU97_39 (Proteobacteria) abundance,Disease
29842,OTU99_34 (Holdemanella) abundance,Disease
29845,OTU99_40 (Proteobacteria) abundance,Disease
29846,OTU99_45 (Faecalibacterium) abundance,Disease
29848,OTU99_54 (Holdemanella) abundance,Disease
29850,Type 2 diabetes (adjusted for BMI),Disease
29851,G_Parasutterella abundance,Disease
29853,Anxiety,Disease
29854,G_Ruminococcus abundance,Disease
29856,O_Clostridiales abundance,Disease
29857,G_Prevotella abundance,Disease
29859,G_Sutterella abundance,Disease
29861,OTU99_2 (Bacteroides) prevalence,Disease
29863,OTU99_23 (Faecalibacterium) prevalence,Disease
29865,OTU99_40 (Proteobacteria) prevalence,Disease
29867,OTU99_45 (Faecalibacterium) prevalence,Disease
29869,OTU99_39 (Alphaproteobacteria) prevalence,Disease
29871,OTU99_558 (Bacteroidales) prevalence,Disease
29873,OTU99_47 (Prevotella) prevalence,Disease
29875,TestASV_12 (Bacteroides) prevalence,Disease
29877,TestASV_14 (Lachnospiraceae) prevalence,Disease
29879,OTU99_65 (Sutterellaceae) prevalence,Disease
29881,Gamma glutamyl transferase levels in excessive alcohol consumption,Disease
29882,Alanine aminotransferase levels in excessive alcohol consumption,Disease
29883,Erectile dysfunction,Disease
29884,Gamma glutamyl transferase levels in low alcohol consumption,Disease
29885,Hepatitis C (spontaneous viral clearance),Disease
29886,Number of sexual partners,Disease
29887,TestASV_15 (Bacteroides) prevalence,Disease
29889,Crohn's disease (time to progression),Disease
29890,Crohn's disease (time to first abdominal surgery),Disease
29891,Intracranial volume,Disease
29892,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy),Disease
29900,Peak expiratory flow,Disease
29901,Hemoglobin,Disease
29907,FEV1,Disease
29908,Serum urea levels,Disease
29909,Morningness,Disease
29918,Crohn's disease or systemic sclerosis,Disease
29923,Autism spectrum disorder,Disease
29925,Autism and major depressive disorder (MTAG),Disease
29926,Autism and schizophrenia (MTAG),Disease
29927,Autism and educational attainment (MTAG),Disease
29928,Thiopurine-induced myelosuppression in inflammatory bowel disease,Disease
29945,Daytime nap,Disease
29946,Ease of getting up in the morning,Disease
29950,Snoring,Disease
29955,IgG N-glycosylation phenotypes (multivariate analysis),Disease
29956,Intracranial aneurysm,Disease
29957,Insomnia symptoms (never/rarely vs. sometimes/usually),Disease
29958,Triiodothyronine levels,Disease
29959,Creativity,Disease
29960,Calcific aortic valve stenosis,Disease
29967,Tourette syndrome,Disease
29996,Carotid intima media thickness x smoking interaction,Disease
29997,Bladder cancer,Disease
29998,Polycystic ovary syndrome,Disease
30012,Alzheimer's disease (late onset),Disease
30017,Insomnia symptoms (never/rarely vs. usually),Disease
30018,Weight gain in amisulpride-treated first-episode psychosis,Disease
30019,Endometriosis or migraine,Disease
30020,Adverse response to inhaled corticosteroid treatment x age interaction in asthma,Disease
30021,Venous thromboembolism,Disease
30023,Trauma exposure in major depressive disorder-negative individuals,Disease
30024,Trauma exposure,Disease
30025,Trauma exposure in major depressive disorder,Disease
30026,Postoperative acute renal failure after cardiac surgery,Disease
30027,Spontaneous coronary artery dissection,Disease
30041,Attention deficit hyperactivity disorder,Disease
30042,Attention deficit hyperactivity disorder (persistent),Disease
30043,Attention deficit hyperactivity disorder (childhood),Disease
30044,Lactate dehydrogenase levels,Disease
30050,Major depressive disorder in trauma exposed individuals,Disease
30051,Major depressive disorder in trauma-unexposed individuals,Disease
30052,Major depressive disorder,Disease
30053,Drug-induced liver injury (flucloxacillin),Disease
30054,Recurrence of Clostridium difficile infection x bezlotuxumab treatment interaction (2df test),Disease
30056,Chronic rhinosinusitis,Disease
30057,Nasal polyps,Disease
30058,Obese vs. thin,Disease
30059,Obesity (extreme),Disease
30093,Essential hypertension (time to event),Disease
30094,Hyperlipidemia (time to event),Disease
30095,Asthma (time to event),Disease
30096,Cataract (time to event),Disease
30112,Chronotype (sMEQ score),Disease
30113,Evening vs. morning chronotype (sMEQ score),Disease
30114,Evening vs. morning chronotype (self-assessed),Disease
30121,Brain amyloid deposition (PET imaging),Disease
30122,"Gut microbiota (bacterial taxa, hurdle binary method)",Disease
30123,Depressive symptoms x herpes simplex 1 infection interaction,Disease
30124,Depression x herpes simplex 1 infection interaction,Disease
30125,Idiopathic membranous nephropathy,Disease
30126,Immunoglobulin A,Disease
30127,Hepatocellular carcinoma,Disease
30128,Caudate nucleus volume,Disease
30129,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy,Disease
30130,Lipoprotein-associated phospholipase A2 activity and mass,Disease
30131,Response to hepatitis C treatment,Disease
30132,Hepatitis C induced liver cirrhosis,Disease
30133,Menopause (age at onset),Disease
30134,Waist circumference and related phenotypes,Disease
30135,Infantile hypertrophic pyloric stenosis,Disease
30136,Menarche and menopause (age at onset),Disease
30137,Bone mineral density (hip),Disease
30138,Response to citalopram treatment,Disease
30139,Primary biliary cholangitis,Disease
30140,Warfarin maintenance dose,Disease
30141,Nasopharyngeal carcinoma,Disease
30142,Type 1 diabetes,Disease
30143,Inflammatory bowel disease (early onset),Disease
30144,Lumiracoxib-related liver injury,Disease
30145,Bipolar disorder or major depressive disorder,Disease
30146,Response to statin therapy,Disease
30147,Pulmonary function,Disease
30148,Malaria,Disease
30149,Heart rate,Disease
30150,HIV-1 control,Disease
30151,Monocyte early outgrowth colony forming units,Disease
30152,Major depressive disorder (broad),Disease
30153,Platelet aggregation,Disease
30154,Renal cell carcinoma,Disease
30155,Electrocardiographic traits,Disease
30156,Calcium levels,Disease
30157,Response to treatment for acute lymphoblastic leukemia,Disease
30158,Smoking behavior,Disease
30159,Age-related macular degeneration,Disease
30160,Dupuytren's disease,Disease
30161,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN),Disease
30162,Bipolar disorder and schizophrenia,Disease
30163,Renal function-related traits (BUN),Disease
30164,Renal function-related traits (sCR),Disease
30165,Renal function-related traits (eGRFcrea),Disease
30166,Renal function-related traits (urea),Disease
30167,Lentiform nucleus volume,Disease
30168,End-stage coagulation,Disease
30169,Pit-and-Fissure caries,Disease
30170,Circulating vasoactive peptide levels,Disease
30171,Refractive error,Disease
30172,Blood trace element (Se levels),Disease
30173,Blood trace element (Cu levels),Disease
30174,Acute lymphoblastic leukemia (childhood),Disease
30175,Obesity,Disease
30176,Uric acid levels,Disease
30177,Hematological parameters,Disease
30178,Ovarian reserve,Disease
30179,Apolipoprotein A1 levels,Disease
30180,Cognitive performance,Disease
30181,Ileal carcinoids,Disease
30182,Ankylosing spondylitis,Disease
30183,Protein quantitative trait loci,Disease
30184,IgE grass sensitization,Disease
30185,Allergic rhinitis,Disease
30186,Pubertal anthropometrics,Disease
30187,Attention deficit hyperactivity disorder and conduct disorder,Disease
30188,Response to TNF antagonist treatment,Disease
30189,Response to anti-TNF alpha therapy in inflammatory bowel disease,Disease
30190,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction),Disease
30191,Conduct disorder (maternal expressed emotions interaction),Disease
30192,Black vs. blond hair color,Disease
30193,Black vs. red hair color,Disease
30194,Cardiovascular disease risk factors,Disease
30195,Interstitial lung disease,Disease
30196,Hematology traits,Disease
30197,Relative hand skill in reading disability,Disease
30198,Hematological and biochemical traits,Disease
30199,Response to dabigatran etexilate treatment,Disease
30200,Ulcerative colitis or Crohn's disease,Disease
30201,Immune response to anthrax vaccine,Disease
30202,Activated partial thromboplastin time,Disease
30203,Electroencephalographic traits in alcoholism,Disease
30204,Basal cell carcinoma,Disease
30205,Depression (quantitative trait),Disease
30206,Response to antipsychotic treatment in schizophrenia (working memory),Disease
30207,Response to antipsychotic treatment in schizophrenia (reasoning),Disease
30208,Renal sinus fat,Disease
30209,Airflow obstruction,Disease
30210,Femoral neck bone geometry,Disease
30211,Nodular sclerosis Hodgkin lymphoma,Disease
30212,Clozapine-induced agranulocytosis,Disease
30213,Homocysteine levels,Disease
30214,Axial length,Disease
30215,Body mass index in non-asthmatics,Disease
30216,Metabolite levels (HVA),Disease
30217,Metabolite levels (5-HIAA),Disease
30218,Metabolite levels (HVA-5-HIAA Factor score),Disease
30219,Metabolite levels (HVA/5-HIAA ratio),Disease
30220,Metabolite levels (HVA/MHPG ratio),Disease
30221,Metabolite levels (MHPG),Disease
30222,Metabolite levels (5-HIAA/ MHPG Ratio),Disease
30223,Response to fenofibrate (adiponectin levels),Disease
30224,Obsessive-compulsive disorder,Disease
30225,Breast cancer (male),Disease
30226,Orofacial clefts,Disease
30227,Disc degeneration (lumbar),Disease
30228,Partial epilepsies,Disease
30229,Non-obstructive azoospermia,Disease
30230,HPV seropositivity,Disease
30231,Progressive supranuclear palsy,Disease
30232,Aging,Disease
30233,Neonatal lupus,Disease
30234,Autism,Disease
30235,Chronic kidney disease and serum creatinine levels,Disease
30236,Testicular germ cell tumor,Disease
30237,PR interval,Disease
30238,Breast Cancer in BRCA1 mutation carriers,Disease
30239,Response to fenofibrate,Disease
30240,Sunburns,Disease
30241,Hair color,Disease
30242,Non-melanoma skin cancer,Disease
30243,Tanning,Disease
30244,Periodontal microbiota,Disease
30245,Caffeine consumption,Disease
30246,Circulating myeloperoxidase levels (serum),Disease
30247,Dengue shock syndrome,Disease
30248,Liver enzyme levels (alkaline phosphatase),Disease
30249,Liver enzyme levels (gamma-glutamyl transferase),Disease
30250,White blood cell types,Disease
30251,Brain connectivity,Disease
30252,Sex hormone-binding globulin levels,Disease
30253,Hepatocellular carcinoma in hepatitis B infection,Disease
30254,Periodontitis,Disease
30255,QT interval (drug interaction),Disease
30256,Attention deficit hyperactivity disorder (combined symptoms),Disease
30257,Attention deficit hyperactivity disorder (inattention symptoms),Disease
30258,HbA2 levels,Disease
30259,Atopic dermatitis,Disease
30260,Venous thromboembolism (SNP x SNP interaction),Disease
30261,Response to amphetamines,Disease
30262,Urate levels,Disease
30263,Adiposity,Disease
30264,Lung cancer (asbestos exposure interaction),Disease
30265,Cannabis use (initiation),Disease
30266,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),Disease
30267,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide),Disease
30268,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs),Disease
30269,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel),Disease
30270,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel),Disease
30271,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),Disease
30272,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin),Disease
30273,Preeclampsia,Disease
30274,Type 2 diabetes (dietary heme iron intake interaction),Disease
30275,Palmitic acid (16:0) levels,Disease
30276,Palmitoleic acid (16:1n-7) levels,Disease
30277,Oleic acid (18:1n-9) levels,Disease
30278,Visceral fat,Disease
30279,Age-related macular degeneration (choroidal neovascularisation),Disease
30280,Age-related macular degeneration (geographic atrophy),Disease
30281,Esophageal cancer (squamous cell),Disease
30282,Lifetime average cigarettes per day in chronic obstructive pulmonary disease,Disease
30283,Sexual dysfunction (female),Disease
30284,Age at smoking initiation in chronic obstructive pulmonary disease,Disease
30285,Capecitabine sensitivity,Disease
30286,Esophageal cancer,Disease
30287,Aspirin exacerbated respiratory disease in asthmatics,Disease
30288,Cystic fibrosis severity,Disease
30289,Hypertension (SNP x SNP interaction),Disease
30290,Scoliosis,Disease
30291,Response to anti-depressant treatment in major depressive disorder,Disease
30292,Adverse response to carbamazepine,Disease
30293,Gambling,Disease
30294,Molar-incisor hypomineralization,Disease
30295,Epstein-Barr virus immune response (EBNA-1),Disease
30296,Myasthenia gravis,Disease
30297,Anxiety in major depressive disorder,Disease
30298,Anxiety and major depressive disorder,Disease
30299,Multiple sclerosis (OCB status),Disease
30300,Femoral neck bone mineral density,Disease
30301,Lumbar spine bone mineral density,Disease
30302,Alcohol and nicotine co-dependence,Disease
30303,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),Disease
30304,C-reactive protein and white blood cell count,Disease
30305,Thyroid hormone levels,Disease
30306,Retinopathy in non-diabetics,Disease
30307,Alzheimer's disease (cognitive decline),Disease
30308,Periodontitis (Mean PAL),Disease
30309,Periodontitis (PAL4Q3),Disease
30310,Periodontitis (CDC/AAP),Disease
30311,Response to tocilizumab in rheumatoid arthritis,Disease
30312,Thyroid function,Disease
30313,Thyroid peroxidase autoantibody levels in type 1 diabetes,Disease
30314,Bilirubin levels,Disease
30315,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",Disease
30316,Electrocardiographic conduction measures,Disease
30317,Economic and political preferences,Disease
30318,Economic and political preferences (environmentalism),Disease
30319,Crohn's disease and celiac disease,Disease
30320,Response to angiotensin II receptor blocker therapy,Disease
30321,Economic and political preferences (immigration/crime),Disease
30322,Nephropathy,Disease
30323,White matter integrity,Disease
30324,Hepatitis B (viral clearance),Disease
30325,Dietary macronutrient intake,Disease
30326,Haptoglobin levels,Disease
30327,Restless legs syndrome,Disease
30328,Drug-induced liver injury (amoxicillin-clavulanate),Disease
30329,Dialysis-related mortality,Disease
30330,Antipsychotic drug-induced QTc interval prolongation,Disease
30331,Metabolic traits,Disease
30332,Immune reponse to smallpox (secreted IL-2),Disease
30333,Immune reponse to smallpox (secreted IL-10),Disease
30334,Immune reponse to smallpox (secreted IL-12p40),Disease
30335,Immune response to smallpox vaccine (IL-6),Disease
30336,Immune reponse to smallpox (secreted IFN-alpha),Disease
30337,Response to mTOR inhibitor (everolimus),Disease
30338,Response to mTOR inhibitor (rapamycin),Disease
30339,Primary tooth development (number of teeth),Disease
30340,Primary tooth development (time to first tooth eruption),Disease
30341,Coronary artery calcification,Disease
30342,Response to gemcitabine in pancreatic cancer,Disease
30343,Crohn's disease and psoriasis,Disease
30344,Treatment response for severe sepsis,Disease
30345,Osteoarthritis,Disease
30346,Phospholipid levels (plasma),Disease
30347,Sphingolipid levels,Disease
30348,Response to TNF-alpha inhibitors in rheumatoid arthritis,Disease
30349,Lp (a) levels,Disease
30350,Paget's disease,Disease
30351,Weight loss (gastric bypass surgery),Disease
30352,Sexual dimorphism in anthropometric traits,Disease
30353,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),Disease
30354,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel),Disease
30355,Kawasaki disease,Disease
30356,vWF and FVIII levels,Disease
30357,Alopecia areata,Disease
30358,Hepatitis B,Disease
30359,Nevirapine-induced rash,Disease
30360,HIV-1 viral setpoint,Disease
30361,Graves' disease,Disease
30362,Multiple myeloma (IgH translocation),Disease
30363,HIV-1 susceptibility,Disease
30364,Bulimia nervosa,Disease
30365,Anorexia nervosa,Disease
30366,Eating disorders,Disease
30367,Metabolite levels (Pyroglutamine),Disease
30368,Metabolite levels  (X-11787),Disease
30369,Metabolite levels (Dihydroxy docosatrienoic acid),Disease
30370,Tetralogy of Fallot,Disease
30371,D-dimer levels,Disease
30372,Erectile dysfunction in type 1 diabetes,Disease
30373,Corneal astigmatism,Disease
30374,Homeostasis model assessment of beta-cell function (dietary factor interaction),Disease
30375,Fasting insulin (dietary factor interaction),Disease
30376,Homeostasis model assessment of insulin resistance (dietary factor interaction),Disease
30377,Liver enzyme levels (alanine transaminase),Disease
30378,Insulin resistance/response,Disease
30379,Orthostatic hypotension,Disease
30380,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Disease
30381,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Disease
30382,Fasting blood insulin (BMI interaction),Disease
30383,Fasting blood glucose (BMI interaction),Disease
30384,Fasting blood insulin,Disease
30385,Fasting blood glucose,Disease
30386,Retinal vascular caliber,Disease
30387,IgG glycosylation,Disease
30388,Hemostatic factors and hematological phenotypes,Disease
30389,Arthritis (juvenile idiopathic),Disease
30390,Brain structure (hippocampal volume),Disease
30391,Corneal structure,Disease
30392,Crohn's disease (time to surgery),Disease
30393,F-cell distribution,Disease
30394,Select biomarker traits,Disease
30395,Skin sensitivity to sun,Disease
30396,Red vs non-red hair color,Disease
30397,Freckles,Disease
30398,Blond vs. brown hair color,Disease
30399,Diabetes (gestational),Disease
30400,Metabolic syndrome (bivariate traits),Disease
30401,HDL Cholesterol - Triglycerides (HDLC-TG),Disease
30402,Other erythrocyte phenotypes,Disease
30403,Prostate cancer (SNP x SNP interaction),Disease
30404,Anthropometric traits,Disease
30405,Non-alcoholic fatty liver disease histology (AST),Disease
30406,RR interval (heart rate),Disease
30407,Alcoholism (alcohol use disorder factor score),Disease
30408,Alcoholism (alcohol dependence factor score),Disease
30409,Alzheimer's disease biomarkers,Disease
30410,F-cell distribution in sickle cell anaemia,Disease
30411,Freckling,Disease
30412,Common traits (Other),Disease
30413,Eye color,Disease
30414,Biomedical quantitative traits,Disease
30415,Liver enzyme levels,Disease
30416,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction),Disease
30417,Quantitative traits,Disease
30418,Type 2 diabetes nephropathy,Disease
30419,Optic disc parameters,Disease
30420,Inattentive symptoms,Disease
30421,Hyperactive-impulsive symptoms,Disease
30422,Age-related macular degeneration (smoking status interaction),Disease
30423,Age-related macular degeneration (extreme sampling),Disease
30424,Brain structure,Disease
30425,Attention deficit hyperactivity disorder (time to onset),Disease
30426,Beta thalassemia/hemoglobin E disease,Disease
30427,Response to interferon beta therapy,Disease
30428,Panic disorder,Disease
30429,Folate pathway vitamin levels,Disease
30431,Cognitive test performance,Disease
30432,Echocardiographic traits,Disease
30433,Optic nerve measurement (rim area),Disease
30434,Smooth-surface caries,Disease
30435,Carotenoid and tocopherol levels,Disease
30436,Insulin-like growth factors,Disease
30437,Thyroid stimulating hormone levels,Disease
30438,Major CVD,Disease
30439,Leprosy,Disease
30440,Hip geometry,Disease
30441,Tonometry,Disease
30442,Lymphoma,Disease
30443,Myocardial infarction (early onset),Disease
30444,Brain lesion load,Disease
30445,Multiple sclerosis (severity),Disease
30446,Normalized brain volume,Disease
30447,Weight,Disease
30448,Morbidity-free survival,Disease
30449,Hearing impairment,Disease
30450,Cardiovascular risk factors,Disease
30451,Cardiac structure and function,Disease
30452,Osteosarcoma,Disease
30453,Pulmonary function (smoking interaction),Disease
30454,Diabetic retinopathy,Disease
30455,Biochemical measures,Disease
30456,Sudden cardiac arrest,Disease
30457,Orofacial clefts (maternal alcohol consumption interaction),Disease
30458,Alcohol consumption (transferrin glycosylation),Disease
30459,Body mass in chronic obstructive pulmonary disease,Disease
30460,Cardiac hypertrophy,Disease
30461,Vitiligo (non-segmental),Disease
30462,Chronic kidney disease,Disease
30463,Radiation response,Disease
30464,Hoarding,Disease
30465,Anti-cyclic Citrullinated Peptide Antibody,Disease
30466,Systolic blood pressure in sickle cell anemia,Disease
30467,Hepatitis C induced liver fibrosis,Disease
30468,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy),Disease
30469,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),Disease
30470,Sjgren's syndrome,Disease
30471,Electrodermal activity,Disease
30472,Bone properties (heel),Disease
30473,Serum metabolite levels,Disease
30474,Esophageal squamous cell carcinoma,Disease
30475,Urinary uromodulin levels,Disease
30476,Bipolar disorder with mood-incongruent psychosis,Disease
30477,Hashimoto thyroiditis versus Graves' disease,Disease
30478,Marginal zone lymphoma,Disease
30479,Sensory disturbances after bilateral sagittal split ramus osteotomy,Disease
30480,Amyotrophic lateral sclerosis (sporadic),Disease
30481,Social communication problems,Disease
30482,"Schizophrenia, schizoaffective disorder or bipolar disorder",Disease
30483,Large artery stroke,Disease
30484,Coronary artery disease or ischemic stroke,Disease
30485,Coronary artery disease or large artery stroke,Disease
30486,PR interval in Tripanosoma cruzi seropositivity,Disease
30487,QT interval in Tripanosoma cruzi seropositivity,Disease
30488,Ejection fraction in Tripanosoma cruzi seropositivity,Disease
30489,Self-reported allergy,Disease
30490,Aortic-valve calcification,Disease
30491,Narcolepsy,Disease
30492,Body mass index  (smoking years interaction),Disease
30493,Thyroid volume,Disease
30494,Epilepsy (remission after treatment),Disease
30495,Migraine - clinic-based,Disease
30496,Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer,Disease
30497,Job-related exhaustion,Disease
30498,Body mass index (SNP x SNP interaction),Disease
30499,Vascular endothelial growth factor levels,Disease
30500,Response to platinum-based agents,Disease
30501,Eosinophilic esophagitis (pediatric),Disease
30502,Wegener's granulomatosis,Disease
30503,Hepcidin levels,Disease
30504,Creatinine levels,Disease
30505,Digit length ratio,Disease
30506,Personality dimensions,Disease
30507,Knee osteoarthritis,Disease
30508,QRS duration in Tripanosoma cruzi seropositivity,Disease
30509,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity,Disease
30510,Antibody status in Tripanosoma cruzi seropositivity,Disease
30511,Parasitemia in Tripanosoma cruzi seropositivity,Disease
30512,Blood pressure measurement (high sodium and potassium intervention),Disease
30513,Blood pressure measurement (low sodium intervention),Disease
30514,Blood pressure measurement (high sodium intervention),Disease
30515,Chronic myeloid leukemia,Disease
30516,Glycemic traits,Disease
30517,Migraine with aura,Disease
30518,Word reading,Disease
30519,Reading and spelling,Disease
30520,Non-word repetition,Disease
30521,Phosphorus levels,Disease
30522,Response to platinum-based chemotherapy (carboplatin),Disease
30523,Response to platinum-based chemotherapy (cisplatin),Disease
30524,Response to antidepressants,Disease
30525,Inflammatory skin disease,Disease
30526,Blood pressure (smoking interaction),Disease
30527,Response to Dalcetrapib treatment in acute coronary syndrome,Disease
30528,Congenital left-sided heart lesions,Disease
30529,Epithelial ovarian cancer,Disease
30530,Allergic rhinitis in non-asthmatics,Disease
30531,Red blood cell fatty acid levels,Disease
30532,Frontotemporal dementia,Disease
30533,L-arginine levels,Disease
30534,Shingles,Disease
30535,Glucose homeostasis traits,Disease
30536,Glaucoma (high intraocular pressure),Disease
30537,White matter microstructure (global fractional anisotropy),Disease
30538,Conduct disorder (symptom count),Disease
30539,Renal function and chronic kidney disease,Disease
30540,Asthma (corticosteroid response),Disease
30541,Esophageal adenocarcinoma,Disease
30542,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),Disease
30543,Response to radiotherapy in cancer (late toxicity),Disease
30544,Autism spectrum disorder-related traits,Disease
30545,CD4:CD8 lymphocyte ratio,Disease
30546,CD8-positive T-lymphocyte count,Disease
30547,Fasting plasma glucose,Disease
30548,Longevity (90 years and older),Disease
30549,Age-related cataracts,Disease
30550,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Disease
30551,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Disease
30552,Sepsis from pneumonia (survival),Disease
30553,White matter hyperintensity volume (adjusted for hypertension),Disease
30554,Parkinson's disease progression (composite),Disease
30555,Response to selenium supplementation (change in plasma selenium concentration),Disease
30565,Nonalcoholic fatty liver disease,Disease
30566,Percent liver fat,Disease
30567,Liver fibrosis and steatohepatitis severity (MRI cT1 measure),Disease
30568,Problematic alcohol use (MTAG),Disease
30569,Diffuse plaques (SNP x SNP interaction),Disease
30570,Schizophrenia (MTAG),Disease
30571,Bipolar disorder (MTAG),Disease
30572,Homeostasis model assessment of insulin resistance,Disease
30573,Fasting glucose,Disease
30574,Parental lifespan,Disease
30575,Caffeine consumption from coffee,Disease
30576,Caffeine consumption from tea,Disease
30577,Caffeine consumption from coffee or tea,Disease
30578,Septic shock,Disease
30579,Autism spectrum disorder (MTAG),Disease
30580,Depressive symptoms (MTAG),Disease
30591,White matter hyperintensity volume,Disease
30603,Help-seeking from a GP,Disease
30604,Help-seeking from a psychiatrist,Disease
30605,Help-seeking from a GP (without major depressive disorder symptoms),Disease
30606,Major depressive disorder (lifetime),Disease
30607,Alcohol use disorder,Disease
30608,Response to antiepileptic mood-stabilizing treatment in bipolar disorder,Disease
30609,"Gut microbiota (bacterial taxa, rank normal transformation method)",Disease
30610,Parent of origin effect on receptive language ability (paternal),Disease
30611,Parent of origin effect on receptive language ability (maternal),Disease
30612,Preeclampsia (maternal genotype effect),Disease
30614,Triglyceride levels in HIV infection,Disease
30615,Macrovascular complications in type 2 diabetes,Disease
30619,Neuritic plaques (SNP x SNP interaction),Disease
30620,Problematic alcohol use,Disease
30637,Alcohol consumption (drinks per week) (MTAG),Disease
30638,Attention deficit hyperactivity disorder (MTAG),Disease
30639,Depressive symptoms,Disease
30641,Rate of cognitive decline in Alzheimer's disease,Disease
30670,LDL cholesterol levels in HIV infection,Disease
30671,Peak hip bone mineral content,Disease
30673,"CV-A6-associated hand, foot, and mouth disease (severe vs mild)",Disease
30674,Migraine with aura and/or diastolic blood pressure,Disease
30675,Migraine with aura and/or systolic blood pressure,Disease
30676,Migraine with aura and/or pulse pressure,Disease
30677,Migraine without aura and/or diastolic blood pressure,Disease
30678,Migraine without aura and/or systolic blood pressure,Disease
30679,Migraine without aura and/or pulse pressure,Disease
30680,Migraine and/or diastolic blood pressure,Disease
30681,Migraine and/or pulse pressure,Disease
30682,Migraine and/or systolic blood pressure,Disease
30683,Deliberate self-harm,Disease
30684,Thrombosis in response to liver transplant,Disease
30685,Autoimmune thyroid disease,Disease
30686,Cognitive function in depression,Disease
30688,Tumor necrosis factor beta levels,Disease
30689,Rheumatic heart disease,Disease
30690,Response to radiotherapy in nasopharyngeal carcinoma (acute oral mucositis),Disease
30715,Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms),Disease
30716,Estrogen level change in anastrozole-treated breast cancer,Disease
30719,Sepsis (hospital admission),Disease
30720,Sepsis (90-day mortality),Disease
30721,L-selectin levels,Disease
30724,Cardiovascular death or myocardial infarction in response to clopidogrel treatment,Disease
30725,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment",Disease
30726,Stent thrombosis in response to clopidogrel treatment,Disease
30728,Platelet reactivity in response to clopidogrel treatment,Disease
30729,Nontraumatic osteonecrosis of the femoral head,Disease
30730,White matter hyperintensity volume x hypertension interaction (2df),Disease
30731,HDL cholesterol levels in HIV infection,Disease
30732,Periventricular white matter hyperintensities,Disease
30733,Total PHF-tau (SNP x SNP interaction),Disease
30734,Autoimmune traits,Disease
30737,Cardiovascular disease,Disease
30740,Tumor necrosis factor levels,Disease
30742,Pancreatic beta-cell glucose sensitivity,Disease
30743,Myocardial fractal dimension (slice 5),Disease
30744,Myocardial fractal dimension (slice 7),Disease
30745,Myocardial fractal dimension (slice 6),Disease
30746,Myocardial fractal dimension (slice 4),Disease
30747,Myocardial fractal dimension (slice 8),Disease
30748,Shoulder impingement syndrome,Disease
30755,Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer,Disease
30756,Leukoderma in response to rhododendrol,Disease
30767,Eczema,Disease
30770,Mastocytosis,Disease
30771,Systemic mastocytosis,Disease
30772,Cutaneous mastocytosis,Disease
30773,Facial morphology traits (59 NSCL/P endophenotypic segments),Disease
30785,Residual cognitive resilience,Disease
30786,Combined resilience (covariance of educational attainment with residual cognitive resilience),Disease
30787,Vaginal microbiome composition (Shannon diversity index),Disease
30807,Gastric cancer,Disease
30808,Neonatal white matter microstructure,Disease
30809,Adult onset asthma or type 2 diabetes,Disease
30810,Adult onset asthma and/or BMI,Disease
30811,Nonatopic asthma and/or BMI,Disease
30812,Asthma (adult onset),Disease
30815,"Aging traits (healthspan, parental lifespan or longevity) (multivariate analysis)",Disease
30816,Electrocardiographic traits (multivariate),Disease
30817,Brain morphology (MOSTest),Disease
30818,Motor fluctuations in levodopa treated Parkinson's disease,Disease
30819,Levodopa-induced dyskinesia in levodopa treated Parkinson's disease,Disease
30820,Response to esketamine in treatment resistant depression,Disease
30821,Response to esketamine (responder status) in treatment resistant depression,Disease
30824,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels,Disease
30827,Cortical thickness (MOSTest),Disease
30828,Subcortical volume (MOSTest),Disease
30831,Arterial stiffness (brachial-femoral pulse wave velocity),Disease
30832,Total carotid plaque area (excess vs minimal atherosclerosis),Disease
30833,circulating leptin levels adjusted for BMI,Disease
30834,circulating leptin levels,Disease
30835,Glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia,Disease
30859,Percent mammographic density,Disease
30860,Cerebrospinal fluid t-tau:AB1-42 ratio,Disease
30861,Restless legs syndrome in migraine without aura,Disease
30863,Deep white matter hyperintensities,Disease
30868,Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism,Disease
30873,Respiratory diseases,Disease
30900,Age at menopause,Disease
30913,Neuroblastoma (pediatric),Disease
30919,"Allergic disease (asthma, hay fever and/or eczema) (age of onset)",Disease
30920,"Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)",Disease
30937,Brain morphology (min-P),Disease
30938,Cortical surface area (MOSTest),Disease
30968,Cortical surface area (min-P),Disease
30969,Subcortical volume (min-P),Disease
30970,Cortical thickness (min-P),Disease
30975,Oral cavity cancer,Disease
30976,Oropharynx cancer,Disease
30977,Head and neck squamous cell carcinoma,Disease
30978,Ceramide levels (C24:0),Disease
30979,Ceramide levels (C22:0),Disease
30980,Waist-to-hip ratio adjusted for BMI in non-smokers,Disease
30981,Body fat mass,Disease
30982,Skin aging (microtopography measurement),Disease
30983,Dehydroepiandrosterone sulphate levels,Disease
30984,Chronic periodontitis (mean interproximal clinical attachment level),Disease
30985,Barrett's esophagus  or Esophageal adenocarcinoma,Disease
30986,Survival in pancreatic cancer,Disease
30987,Glomerular filtration rate,Disease
30988,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),Disease
30989,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,Disease
30990,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,Disease
30991,Body mass index (joint analysis main effects and physical activity interaction),Disease
30992,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),Disease
30993,Psychosis proneness (hypomanic personality scale),Disease
30994,Psychosis proneness (perceptual aberration scale),Disease
30995,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale),Disease
30996,Acute graft versus host disease in bone marrow transplantation (recipient effect),Disease
30997,Acute graft versus host disease in bone marrow transplantation (donor effect),Disease
30998,Response to statins (HDL cholesterol change),Disease
30999,Early onset atrial fibrillation,Disease
31000,Alcoholic chronic pancreatitis,Disease
31001,Left ventricular obstructive tract defect (inherited effect),Disease
31002,Left ventricular obstructive tract defect (maternal effect),Disease
31003,Congenital heart disease (inherited effect),Disease
31004,Congenital heart disease (maternal effect),Disease
31005,Conotruncal heart defects (maternal effects),Disease
31006,Appendicular lean mass,Disease
31007,Lean body mass,Disease
31008,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),Disease
31009,Plantar warts,Disease
31010,Bacterial meningitis,Disease
31011,Fear of minor pain,Disease
31012,Fear of medical pain (dental),Disease
31013,Fear of pain,Disease
31014,IgG galactosylation phenotypes (multivariate analysis),Disease
31015,Rubella,Disease
31016,Mononucleosis,Disease
31017,Insomnia complaints,Disease
31018,Peripheral arterial disease (traffic-related air pollution interaction),Disease
31019,Facial morphology (factor 16),Disease
31020,"Facial morphology (factor 17, height of vermillion upper lip)",Disease
31021,"Facial morphology (factor 15, philtrum width)",Disease
31022,Autism spectrum disorder or schizophrenia,Disease
31023,Urinary tract infection frequency,Disease
31024,Chronic sinus infection,Disease
31025,Number of common colds,Disease
31026,Hepatitis A,Disease
31027,Rheumatic fever,Disease
31028,Pneumonia,Disease
31029,Scarlet fever,Disease
31030,Small cell lung carcinoma,Disease
31031,Squamous cell lung carcinoma,Disease
31032,"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)",Disease
31033,"Facial morphology (factor 4, facial height related to vertical position of gnathion)",Disease
31034,"Facial morphology (factor 9, facial height related to vertical position of nasion)",Disease
31035,"Facial morphology (factor 7, width of cartilaginous portion of nose)",Disease
31036,"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)",Disease
31037,"Facial morphology (factor 6, height of vermillion lower lip)",Disease
31038,"Facial morphology (factor 11, projection of the nose)",Disease
31039,Obstetric antiphospholipid syndrome,Disease
31040,Chickenpox,Disease
31041,Cold sores,Disease
31042,Mumps,Disease
31043,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms,Disease
31044,Lipoprotein (a) levels,Disease
31045,Lung cancer in ever smokers,Disease
31046,Lung cancer in never smokers,Disease
31047,"Facial morphology (factor 2, vertical position of orbits relative to midface)",Disease
31048,Facial morphology (factor 18),Disease
31049,Facial morphology (factor 19),Disease
31050,Trunk fat mass,Disease
31051,Verbal memory performance (immediate recall change),Disease
31052,Verbal memory performance (residualized delayed recall level),Disease
31053,Hepatocellular carcinoma in hepatitis C infection,Disease
31054,Strep throat,Disease
31055,Subjective well-being (MTAG),Disease
31056,Neuroticism (MTAG),Disease
31057,Cerebral blood flow,Disease
31058,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous),Disease
31059,Red blood cell density in sickle cell anemia,Disease
31060,Heart rate variability traits (SDNN),Disease
31061,Heart rate variability traits (RMSSD),Disease
31062,Heart rate variability traits (pvRSA/HF),Disease
31063,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),Disease
31064,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),Disease
31065,Monocyte chemoattractant protein-1 levels,Disease
31066,Interleukin-12p70 levels,Disease
31067,RANTES levels,Disease
31068,Platelet-derived growth factor BB levels,Disease
31069,Stem cell factor levels,Disease
31070,Macrophage inflammatory protein 1b levels,Disease
31071,Prudent dietary pattern,Disease
31072,Western dietary pattern,Disease
31073,Primary vesicoureteric reflux,Disease
31074,Anti-saccade response,Disease
31075,Pursuit maintenance gain,Disease
31076,Initial pursuit acceleration in psychotic disorders,Disease
31077,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,Disease
31078,Macrophage inflammatory protein 1a levels,Disease
31079,Monokine induced by gamma interferon levels,Disease
31080,Macrophage colony stimulating factor levels,Disease
31081,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),Disease
31082,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),Disease
31083,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),Disease
31084,Post bronchodilator FEV1/FVC ratio in COPD,Disease
31085,ACPA-positive rheumatoid arthritis (smoking interaction),Disease
31086,Milk allergy (maternal genetic effects),Disease
31087,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),Disease
31088,Limited cutaneous systemic scleroderma,Disease
31089,Blood osmolality (transformed sodium),Disease
31090,Neuritic plaques or neurofibrillary tangles (pleiotropy),Disease
31091,Initial pursuit acceleration,Disease
31092,Cleft palate,Disease
31093,Primary sclerosing cholangitis,Disease
31094,Multiple system atrophy,Disease
31095,Ovarian disease with few adhesions,Disease
31096,Deep ovarian and/or rectovaginal disease with dense adhesions,Disease
31097,Opioid dependence,Disease
31098,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),Disease
31099,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,Disease
31100,Diarrhoea in darapladib-treated cardiovascular disease (time to event),Disease
31101,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),Disease
31102,Lipoprotein phospholipase A2 activity in cardiovascular disease,Disease
31103,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),Disease
31104,GLP-1 levels in response to oral glucose tolerance test (fasting),Disease
31105,GIP levels in response to oral glucose tolerance test (120 minutes),Disease
31106,Nicotine dependence,Disease
31107,Mean arterial pressure,Disease
31110,Obsessive-compulsive disorder or autism spectrum disorder,Disease
31111,Huntington's disease progression,Disease
31112,Immunoglobulin A vasculitis,Disease
31113,Intelligence (MTAG),Disease
31114,Adult asthma,Disease
31115,Coenzyme Q10 levels,Disease
31116,Plasma kynurenine levels in major depressive disorder,Disease
31117,Follicle stimulating hormone levels in polycystic ovary syndrome,Disease
31118,Testosterone levels in polycystic ovary syndrome,Disease
31119,Sarcoidosis (non-Lofgren's syndrome),Disease
31120,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations),Disease
31121,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome),Disease
31122,Thrombin-activatable fibrinolysis inhibitor activation peptide,Disease
31123,Sarcoidosis (Lofgren's syndrome),Disease
31124,Epstein-Barr virus copy number in lymphoblastoid cell lines,Disease
31125,Serum uric acid levels in response to allopurinol in gout,Disease
31126,Lower body strength,Disease
31127,Brain volume in infants (white matter),Disease
31128,Brain volume in infants (cerebrospinal fluid),Disease
31129,Brain volume in infants (grey matter),Disease
31130,Opioid requirements during laparoscopic-assisted colectomy,Disease
31131,Total cholesterol levels in HDL,Disease
31132,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,Disease
31133,Recurrent major depressive disorder,Disease
31134,Disease progression in age-related macular degeneration,Disease
31135,Disease progression to choroidal neovascularization form in age-related macular degeneration,Disease
31136,Disease progression in age-related macular degeneration (adjusted for baseline),Disease
31137,"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",Disease
31138,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),Disease
31139,Response to metformin (IC50),Disease
31140,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),Disease
31141,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),Disease
31142,Nevirapine-induced hypersensitivity in HIV,Disease
31143,Itch intensity from mosquito bite,Disease
31144,Itch intensity from mosquito bite adjusted by bite size,Disease
31145,Tenofovir clearance in HIV infection,Disease
31146,Blood pressure traits (multi-trait analysis),Disease
31147,Waist circumference adjusted for BMI (adjusted for smoking behaviour),Disease
31148,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),Disease
31149,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),Disease
31150,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),Disease
31151,Body mass index (adult),Disease
31152,Intelligence,Disease
31153,Mosquito bite size,Disease
31154,Perceived unattractiveness to mosquitoes,Disease
31155,BMI (adjusted for smoking behaviour),Disease
31156,Body mass index (joint analysis main effects and smoking interaction),Disease
31157,Pre bronchodilator FEV1/FVC ratio in never-smokers,Disease
31158,Late-onset Alzheimer's disease,Disease
31159,Dermatomyositis,Disease
31160,Hip minimal joint space width,Disease
31161,Insulin levels,Disease
31162,Insulin levels adjusted for BMI,Disease
31163,Insulin disposition index,Disease
31164,Incremental insulin,Disease
31165,Corrected insulin response,Disease
31166,Corrected insulin response adjusted for insulin sensitivity index,Disease
31167,Bipolar disorder lithium response (continuous) or schizophrenia,Disease
31168,Bipolar disorder lithium response (categorical) or schizophrenia,Disease
31169,Response to mepolizumab in severe asthma,Disease
31170,Moyamoya disease,Disease
31171,Alcohol dependence symptom count,Disease
31172,Selective IgA deficiency,Disease
31173,Thiopurine S-methyltransferase activity,Disease
31174,Oral cavity and pharyngeal cancer,Disease
31175,Mortality in sepsis,Disease
31176,Food addiction,Disease
31177,Depression in response to interferon-based therapy in chronic hepatitis C,Disease
31178,Inhibitory control,Disease
31179,Dementia with Lewy bodies,Disease
31180,Chronic rhinosinusitis with nasal polyps,Disease
31181,Sulfasalazine-induced agranulocytosis,Disease
31182,Heart rate response to exercise,Disease
31183,Heart rate response to recovery post exercise,Disease
31184,Systemic sclerosis (anti-centromere-positive),Disease
31185,Diffuse cutaneous systemic sclerosis,Disease
31186,Systemic sclerosis (anti-topoisomerase-positive),Disease
31187,Total body bone mineral density,Disease
31188,Epstein Barr virus nuclear antigen 1 IgG levels,Disease
31189,Epstein Barr virus nuclear antigen 1 IgG seropositivity,Disease
31190,Epstein-Barr virus immune response (multivariate analysis),Disease
31191,Giant cell arteritis,Disease
31192,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),Disease
31193,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),Disease
31194,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),Disease
31195,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),Disease
31196,Total body bone mineral density (age 30-45),Disease
31197,Total body bone mineral density (age 45-60),Disease
31198,Total body bone mineral density (age over 60),Disease
31199,Alzheimer's disease or family history of Alzheimer's disease,Disease
31200,Stimulated C-peptide levels in type I diabetes,Disease
31201,Random C-peptide levels in type I diabetes,Disease
31202,C-peptide levels in type I diabetes,Disease
31203,Low tan response,Disease
31204,Neuromyelitis optica,Disease
31205,Neuromyelitis optica (AQP4-IgG-positive),Disease
31206,Spherical equivalent or myopia (age of diagnosis),Disease
31207,Myopia (age of diagnosis),Disease
31208,"Allergic disease (asthma, hay fever or eczema)",Disease
31209,Thyroid autoantibody positivity (anti-thyroglobulin (TgAb) and/or anti-thyroid peroxidase  (TPOAb) levels),Disease
31210,Optic disc size,Disease
31211,Bone mineral density (total hip),Disease
31212,Menstruation quality of life impact (loss of concentration),Disease
31213,Vaginal discharge (itching),Disease
31229,Exacerbations requiring hospitalisation in asthma,Disease
31230,Cannabis use (age at onset),Disease
31231,Reaction time,Disease
31232,Coronary artery disease in diabetes,Disease
31233,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease,Disease
31234,Executive function in ADHD,Disease
31236,Spherical equivalent,Disease
31237,Optic nerve head parameters (multi-trait analysis),Disease
31238,Cognitive decline (age-related),Disease
31241,Behavioural changes in frontotemporal lobe dementia,Disease
31242,Anti-chlamydia trachomatis IgG seropositivity,Disease
31243,Blood glucose levels,Disease
31244,Myocardial infarction,Disease
31245,Coffee consumption,Disease
31246,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Disease
31247,Cervical cancer (MTAG),Disease
31248,Gynecologic disease (multivariate analysis),Disease
31250,Atopic asthma,Disease
31252,Dermatomyositis or juvenile dermatomyositis,Disease
31253,Polymyositis,Disease
31254,Idiopathic inflammatory myopathy,Disease
31255,Age at loss of ambulation in Duchenne muscular dystrophy,Disease
31256,Non-glioblastoma glioma,Disease
31257,Glioma,Disease
31258,Worry,Disease
31259,Rosacea symptom severity,Disease
31260,"Obstructive sleep apnea trait (apnea hypopnea index, change over time)",Disease
31261,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement,Disease
31262,End stage renal disease x APOL1 genotype interaction,Disease
31263,Menstruation quality of life impact (dysmenorrhea),Disease
31264,Menstruation quality of life impact (acne),Disease
31265,Menstruation quality of life impact (fever),Disease
31266,Blood protein levels in cardiovascular risk,Disease
31267,Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome,Disease
31268,Longitudinal brain connectivity change (Louvain modularity),Disease
31269,Serum 25-Hydroxyvitamin D levels,Disease
31270,Nonatopic asthma,Disease
31271,Response to ketogenic dietary therapies in epilepsy,Disease
31272,Depressed affect,Disease
31274,Response to (pegylated) interferon in HBeAg-negative hepatitis B,Disease
31275,Response to (pegylated) interferon in HBeAG-positive hepatitis B,Disease
31276,Intrinsic epigenetic age acceleration,Disease
31277,Total body bone mineral density (MTAG),Disease
31278,Heel bone mineral density (MTAG),Disease
31279,Gynecologic disease,Disease
31280,Ovarian cancer (MTAG),Disease
31281,Alcohol-associated liver disease in light drinkers,Disease
31283,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 2),Disease
31285,Rapidly progressive Alzheimer's disease (typical) (case-control set 2),Disease
31287,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs typical) (case-control set 3),Disease
31290,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),Disease
31292,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 1),Disease
31293,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),Disease
31296,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),Disease
31297,Prostate cancer (early onset),Disease
31298,Diabetes mellitus,Disease
31299,Non-del(5q) myelodysplastic syndromes,Disease
31300,Bone mineral content,Disease
31301,Maternal nondisjunction of chromosome 21 (mothers vs fathers),Disease
31302,Maternal nondisjunction of chromosome 21 (MI error vs fathers),Disease
31303,Cryptosporidiosis,Disease
31304,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Disease
31305,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Disease
31306,Severe aplastic anemia,Disease
31307,Uterine fibroids (MTAG),Disease
31308,Endometrial cancer (MTAG),Disease
31309,Ovarian cancer,Disease
31310,Red blood cell traits (multivariate analysis),Disease
31330,NASH resolution in nonalcoholic steatohepatitis,Disease
31331,Cutaneous squamous cell carcinoma,Disease
31332,Response to statins (LDL cholesterol percent change),Disease
31333,Low density lipoprotein cholesterol levels (on statin treatment),Disease
31334,Alcohol-associated liver disease in non drinkers,Disease
31373,Maximum cranial length,Disease
31374,Prostate cancer (advanced),Disease
31375,Cerebellum growth,Disease
31376,Cardioembolic stroke (CCSp classification),Disease
31377,Cardioembolic stroke (TOAST classification),Disease
31378,Cardioembolic stroke (CCS and TOAST classification),Disease
31379,Cardioembolic stroke (CCS or TOAST classification),Disease
31380,Cardioembolic stroke (CCSc classification),Disease
31381,Lipoprotein (a) levels in response to niacin in statin-treated individuals,Disease
31382,HDL cholesterol change in response to niacin in statin-treated individuals,Disease
31383,Gastrointestinal infection,Disease
31384,Glycosuria in pregnancy (maternal genotype effect),Disease
31385,Glycosuria in pregnancy (offspring genotype effect),Disease
31386,Glycosuria in pregnancy (maternal and offspring genotype effect),Disease
31387,Neck pain or shoulder pain,Disease
31388,Hallux valgus,Disease
31389,Gout (normal type),Disease
31391,Externalizing behaviour score,Disease
31392,Parkinson's disease or first degree relation to individual with Parkinson's disease,Disease
31393,Occipital lobe volume,Disease
31394,Lung function in never smokers (high FEV1 vs average FEV1),Disease
31395,Lung function in never smokers (low FEV1 vs average FEV1),Disease
31396,Smoking status (heavy vs never),Disease
31397,Lung function (low FEV1 vs high FEV1),Disease
31398,Lung function in never smokers (low FEV1 vs high FEV1),Disease
31399,Lung function (low FEV1 vs high FEV1) x smoking interaction,Disease
31400,Cerebrospinal fluid sTREM-2 levels,Disease
31420,HDL cholesterol levels x long total sleep time interaction (2df test),Disease
31421,Idiopathic pulmonary fibrosis,Disease
31422,Hospital contact for infections,Disease
31443,TestASV_38 (Ruminococcus) abundance,Disease
31444,OTU97_31 (Prevotella) prevalence,Disease
31446,OTU97_2 (Bacteroides) prevalence,Disease
31447,OTU97_21 (Parasutterella) prevalence,Disease
31449,OTU97_354 (Alloprevotella) prevalence,Disease
31451,OTU97_38 (Alphaproteobacteria) prevalence,Disease
31453,OTU99_124 (Paraprevotella) prevalence,Disease
31455,OTU99_132 (Bacteroidales) prevalence,Disease
31458,Urinary metabolite levels in chronic kidney disease,Disease
31459,Fish- and plant-related diet,Disease
31460,Oily fish consumption,Disease
31461,Non-oily fish consumption,Disease
31462,Lamb consumption,Disease
31463,Beef consumption,Disease
31464,HDL cholesterol levels x short total sleep time interaction (2df test),Disease
31465,Kidney stones,Disease
31487,Trunk fat mass adjusted for trunk lean mass,Disease
31488,Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass,Disease
31489,Serum alkaline phosphatase levels,Disease
31492,Hemoglobin A1c levels,Disease
31495,Parkinson's disease (age of onset),Disease
31496,Birth weight (MTAG),Disease
31497,Birth length (MTAG),Disease
31498,Infant head circumference (MTAG),Disease
31499,Skin pigmentation (conditioned on rs1426654 and rs35397),Disease
31508,Facial morphology,Disease
31509,Serum metabolite levels (CMS),Disease
31510,Caf-au-lait macule number in neurofibromatosis type1,Disease
31511,Basophil count,Disease
31515,Household income (MTAG),Disease
31516,Excessive sweating,Disease
31518,Self-reported risk-taking behaviour,Disease
31521,Mucinous adenocarcinoma in colorectal cancer,Disease
31522,Cerebrospinal fluid -synuclein levels,Disease
31526,Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect),Disease
31527,Type 1 diabetes in high risk HLA genotype individuals (time to event),Disease
31528,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),Disease
31529,White matter microstructure (mean diusivities),Disease
31530,Leukocyte telomere length,Disease
31531,Serum cancer antigen 125 (CA 125) levels,Disease
31532,Osteoarthritis of the hand,Disease
31533,Household income,Disease
31534,Osteoporosis-related phenotypes (MTAG),Disease
31535,Urinary calcium excretion,Disease
31536,Urinary magnesium excretion,Disease
31537,Urinary volume,Disease
31542,Hay fever and/or eczema,Disease
31557,Insulin-related traits (multivariate analysis),Disease
31592,Clozapine-induced myocarditis in schizophrenia,Disease
31636,TestASV_33 (Paraprevotella) prevalence,Disease
31638,TestASV_30 (Paraprevotella) prevalence,Disease
31640,TestASV_48 (Sutterella) abundance,Disease
31642,TestASV_42 (Alphaproteobacteria) abundance,Disease
31643,TestASV_39 (Bacteroides) abundance,Disease
31645,TestASV_44 (Parasutterella) abundance,Disease
31647,TestASV_46 (Sutterella) abundance,Disease
31649,Bipolar disorder or body mass index,Disease
31650,OTU97_58 (Sutterellaceae) prevalence,Disease
31651,OTU97_6 (Sutterella) prevalence,Disease
31653,OTU97_39 (Proteobacteria) prevalence,Disease
31654,OTU97_51 (Barnesiella) prevalence,Disease
31656,TestASV_6 (Subdoligranulum) prevalence,Disease
31658,TestASV_47 (Parasutterella) prevalence,Disease
31659,Low HDL-cholesterol levels,Disease
31660,Graft survival time in renal transplantation (donor effect),Disease
31661,Graft survival time in renal transplantation (donor effect) x APOL1 genotype interaction,Disease
31662,Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker,Disease
31663,Fruit consumption,Disease
31664,Fractures,Disease
31665,TestASV_2 (Bacteroides) abundance,Disease
31667,TestASV_20 (Phascolarctobacterium) abundance,Disease
31669,TestASV_21 (Ruminococcaceae) abundance,Disease
31671,TestASV_24 (Bacteroides) abundance,Disease
31672,OTU97_80 (Ruminococcus) prevalence,Disease
31674,OTU99_106 (Barnesiella) prevalence,Disease
31676,OTU99_108 (Cytophagales) prevalence,Disease
31678,OTU97_95 (Cytophagales) prevalence,Disease
31679,Survival in breast cancer (estrogen-receptor positive),Disease
31680,Suicidal or self-harm ideation,Disease
31681,Compulsion score in obsessive compulsive disorder,Disease
31682,Meat-related diet,Disease
31683,Pork consumption,Disease
31684,Coronary artery disease in type 1 diabetes,Disease
31685,TestASV_10 (Parabacteroides) abundance,Disease
31687,OTU99_92 (Ruminococcus) abundance,Disease
31689,TestASV_16 (Bacteroides) abundance,Disease
31691,OTU99_84 (Prevotella) abundance,Disease
31693,G_Coprococcus prevalence,Disease
31696,G_Parasutterella prevalence,Disease
31698,G_Prevotella prevalence,Disease
31699,G_Bacteroidales prevalence,Disease
31701,G_Catenibacterium prevalence,Disease
31703,OTU97_137 (Catenibacterium) prevalence,Disease
31704,OTU97_138 (Oscillibacter) prevalence,Disease
31706,OTU97_150 (Bacteroides) prevalence,Disease
31708,OTU97_16 (Faecalibacterium) prevalence,Disease
31710,OTU97_13 (Subdoligranulum) prevalence,Disease
31712,Lung function,Disease
31713,Hypertriglyceridemia,Disease
31714,Urinary metabolite modules (eigenmetabolites) in chronic kidney disease,Disease
31715,Serum immune biomarker levels,Disease
31716,Cerebrospinal fluid immune biomarker levels,Disease
31717,Epilepsy,Disease
31718,Juvenile myoclonic epilepsy,Disease
31719,Focal epilepsy (with hippocampal sclerosis),Disease
31720,Generalized epilepsy,Disease
31721,Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome,Disease
31722,Aspartate aminotransferase levels in low alcohol consumption,Disease
31723,Blood metabolite levels,Disease
31724,Youthful appearance (self-reported),Disease
31725,White matter hyperintensities,Disease
31726,White matter integrity (fractional anisotropy),Disease
31727,White matter integrity (mean diffusivity),Disease
31728,Cutaneous malignant melanoma,Disease
31729,Cutaneous melanoma or hair colour,Disease
31730,Nevus count or cutaneous melanoma,Disease
31733,Neuropathologic traits (pleiotropy),Disease
31734,Microscopic brain infarct,Disease
31735,Macroscopic brain infarct,Disease
31738,Neuritic plaque,Disease
31741,Diffuse plaques,Disease
31743,Neurofibrillary tangles,Disease
31744,COVID-19 (critical illness vs population),Disease
31746,JT interval,Disease
31747,Sleep (1/2-day periodicity),Disease
31748,Sleep activity levels,Disease
31749,Sleep start time,Disease
31750,LDL cholesterol levels x short total sleep time interaction (2df test),Disease
31751,Triglyceride levels x long total sleep time interaction (2df test),Disease
31752,Triglyceride levels x short total sleep time interaction (2df test),Disease
31753,LDL cholesterol levels x short total sleep time interaction (1df test),Disease
31754,LDL cholesterol levels x loop diuretics use interaction,Disease
31755,Triglyceride levels x loop diuretics use interaction,Disease
31756,Brainstem volume,Disease
31757,Putamen volume,Disease
31758,Cortical surface area (visual PC2),Disease
31759,Cortical surface area (global PC1),Disease
31760,Response to lamotrigine and valproic acid in genetic generalized epilepsy,Disease
31761,Leisure sedentary behaviour (television watching),Disease
31762,Bone mineral density (hip) and hip bone size,Disease
31763,Leisure sedentary behaviour (computer use),Disease
31764,Complement factor H binding to malondialdehyde,Disease
31765,LDL cholesterol levels x long total sleep time interaction (2df test),Disease
31766,Circulating leptin levels in high cardiovascular risk,Disease
31806,MHC class I polypeptide-related sequence A levels,Disease
31807,CCL19 levels,Disease
31808,Protein level change in low calorie diet obesity intervention,Disease
31809,Protein levels in obesity,Disease
31832,High myopia,Disease
31833,Retinal detachment or retinal break,Disease
31834,Cataracts (operation),Disease
31835,Buruli ulcer (age at onset),Disease
31836,Hip bone size,Disease
31837,Primary biliary cirrhosis,Disease
31838,Adipose morphology,Disease
31839,Vascular endothelial growth factor levels in major depressive disorder,Disease
31840,Glaucoma (multi-trait analysis),Disease
31841,Relative fat intake,Disease
31842,Relative carbohydrate intake,Disease
31843,Relative sugar intake,Disease
31844,Carotid intima media thickness (mean),Disease
31845,Carotid intima media thickness (mean-maximum),Disease
31846,Ebbinghaus illusion (underestimation),Disease
31847,Ebbinghaus illusion (overestimation),Disease
31848,OTU97_86 (Phascolarctobacterium) abundance,Disease
31850,TPE interval (resting),Disease
31851,OTU99_116 (Sutterella) abundance,Disease
31853,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),Disease
31854,Pepsinogen I/II ratio,Disease
31855,Eosinophilic esophagitis,Disease
31856,Lifetime smoking index,Disease
31861,OTU99_23 (Faecalibacterium) abundance,Disease
31863,OTU99_132 (Bacteroidales) abundance,Disease
31865,OTU99_137 (Ruminococcus) abundance,Disease
31866,OTU99_150 (Prevotella) abundance,Disease
31867,Childhood obesity,Disease
31868,Proliferative diabetic retinopathy,Disease
31869,Bipolar I disorder,Disease
31870,Age-related hearing impairment (high frequency),Disease
31874,Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive),Disease
31875,Eosinophilic granulomatosis with polyangiitis (ANCA negative),Disease
31876,Eosinophilic granulomatosis with polyangiitis,Disease
31877,Smoking status (current vs never),Disease
31880,BMI in adult survivors of childhood acute lymphoblastic leukemia,Disease
31881,Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders),Disease
31882,Response to antidepressants (non-treatment-resistant vs treatment-resistant depression),Disease
31883,Mastocytosis (KIT D816V positive),Disease
31884,Fasting insulin,Disease
31885,Plasma free amino acid levels (adjusted for twenty other PFAAs),Disease
31886,Eye color (brightness),Disease
31887,Plasma free amino acid levels (adjusted for one other PFAA),Disease
31888,"Skin, hair and eye pigmentation (multivariate analysis)",Disease
31889,Plasma free amino acid levels,Disease
31890,Body fat distribution (arm fat ratio),Disease
31891,Glucagon levels in response to oral glucose tolerance test (30 minutes),Disease
31892,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes),Disease
31893,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes),Disease
31894,Glucagon levels in response to oral glucose tolerance test (fasting),Disease
31895,Glucagon levels in response to oral glucose tolerance test (120 minutes),Disease
31896,Body fat distribution (leg fat ratio),Disease
31897,HDL cholesterol x physical activity interaction (2df test),Disease
31898,LDL cholesterol x physical activity interaction (2df test),Disease
31899,Triglycerides x physical activity interaction (2df test),Disease
31900,Body fat distribution (trunk fat ratio),Disease
31901,Staphylococcus aureus nasal carriage (intermittent),Disease
31902,Pediatric autoimmune diseases,Disease
31903,Postoperative atrial fibrillation in coronary artery bypass grafting surgery,Disease
31904,Rotator cuff tears,Disease
31905,Influenza A (H1N1) infection,Disease
31906,Mild influenza (H1N1) infection,Disease
31907,Severe influenza A (H1N1) infection,Disease
31908,Urinary metabolites,Disease
31909,Bone mineral density (hip) and age at menarche,Disease
31910,Scalp hair shape,Disease
31911,Eyebrow thickness,Disease
31912,Monobrow thickness,Disease
31913,Beard thickness,Disease
31914,Hair greying,Disease
31915,Gut microbiome composition (winter),Disease
31916,Gut microbiome composition (summer),Disease
31917,Thrombosis,Disease
31918,Squamous cell carcinoma,Disease
31919,Low high density lipoprotein cholesterol levels,Disease
31920,Advanced age-related macular degeneration,Disease
31921,Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging),Disease
31922,Cognitive decline rate in late mild cognitive impairment,Disease
31923,Glomerular filtration rate in non diabetics (creatinine),Disease
31924,Glomerular filtration rate in diabetics (creatinine),Disease
31925,Glomerular filtration rate (creatinine),Disease
31926,Myositis,Disease
31927,Parkinson disease and lewy body pathology,Disease
31928,Oligoclonal band status in multiple sclerosis,Disease
31929,Immunoglobulin G index levels in multiple sclerosis,Disease
31930,Motion sickness,Disease
31931,Depressive symptoms (SSRI exposure interaction),Disease
31932,Exudative age-related macular degeneration,Disease
31933,Takayasu arteritis,Disease
31934,Adenocarcinoma,Disease
31935,Ischemic stroke (cardioembolic),Disease
31936,Ischemic stroke (undetermined subtype),Disease
31937,Cerebral amyloid deposition (PET imaging),Disease
31938,antipsychotic drug dosage in schizophrenia or schizoaffective disorder,Disease
31939,Alzheimer disease and age of onset,Disease
31940,Morning vs. evening chronotype,Disease
31941,Chronotype,Disease
31942,Obstructive sleep apnea (average oxygen saturation during sleep),Disease
31943,Obstructive sleep apnea trait (average respiratory event duration),Disease
31944,Post bronchodilator FEV1 in COPD,Disease
31945,Gut microbiome composition (summer and winter),Disease
31946,Bone mineral density (femoral neck),Disease
31947,Entorhinal cortical volume,Disease
31948,Total ventricular volume,Disease
31949,Entorhinal cortical volume (Alzheimer's disease interaction),Disease
31950,Body mass index (age interaction),Disease
31951,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length),Disease
31952,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations),Disease
31953,Exploratory eye movement dysfunction in schizophrenia (responsive search score),Disease
31954,Early childhood aggressive behavior,Disease
31955,Childhood and early adolescence aggressive behavior,Disease
31956,Exploratory eye movement dysfunction in schizophrenia (cognitive search score),Disease
31957,Systolic blood pressure (cigarette smoking interaction),Disease
31958,Response to anti-TNF therapy in rheumatoid arthritis,Disease
31959,Manic episodes in bipolar disorder,Disease
31960,Depressive episodes in bipolar disorder,Disease
31961,Depressive and manic episodes in bipolar disorder,Disease
31962,Glucocorticoid-induced osteonecrosis,Disease
31963,Incident coronary heart disease,Disease
31964,Incident myocardial infarction,Disease
31965,Urinary albumin-to-creatinine ratio in non-diabetics,Disease
31966,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),Disease
31967,Emphysema imaging phenotypes,Disease
31968,Percentage gas trapping,Disease
31969,Hippocampal sclerosis,Disease
31970,Cerebral amyloid angiopathy,Disease
31971,Narcolepsy with cataplexy,Disease
31972,3-hydroxypropylmercapturic acid levels in smokers,Disease
31973,Asparaginase hypersensitivity in acute lymphoblastic leukemia,Disease
31974,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,Disease
31975,Multiple myeloma and monoclonal gammopathy,Disease
31976,Sex hormone levels,Disease
31977,Response to simvastatin treatment (PCSK9 protein level change),Disease
31978,Yu-Zhi constitution type in type 2 diabetes,Disease
31979,Multiple myeloma (survival),Disease
31980,Colorectal or endometrial cancer,Disease
31981,Glomerular filtration rate in chronic kidney disease,Disease
31982,Proteinuria in chronic kidney disease,Disease
31983,Dementia and core Alzheimer's disease neuropathologic changes,Disease
31984,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis,Disease
31985,Skin colour saturation,Disease
31986,Perceived skin darkness,Disease
31987,Forced expiratory volume in 1 second (occupational environmental exposures interaction),Disease
31988,Classic bladder exstrophy,Disease
31989,Response to zileuton treatment in asthma (FEV1 change interaction),Disease
31990,Bone mineral accretion in asthma (oral corticosteroid dose interaction),Disease
31991,Erythema nodosum in inflammatory bowel disease,Disease
31992,Peak creatinine levels in vancomycin therapy,Disease
31993,Epilepsy and lamotrigine-induced maculopapular eruptions,Disease
31994,Blond vs non-blond hair color,Disease
31995,Brown vs. non-brown hair color,Disease
31996,Light vs. dark hair color,Disease
31997,Black vs. non-black hair color,Disease
31998,Trichloroethylene-induced hypersensitivity syndrome,Disease
31999,Attention function in attention deficit hyperactive disorder,Disease
32000,Postprandial triglyceride response to high fat diet meal,Disease
32001,Left superior temporal gyrus thickness (schizophrenia interaction),Disease
32002,Diabetic kidney disease,Disease
32003,Mitral valve prolapse,Disease
32004,Antipsychotic drug-induced weight gain,Disease
32005,Antipsychotic drug-induced weight gain (time interaction),Disease
32006,White matter lesion progression (adjusted for white matter lesion burden at baseline),Disease
32007,Eating disorder in bipolar disorder,Disease
32008,Bipolar disorder and eating disorder,Disease
32009,Lung disease severity in cystic fibrosis,Disease
32010,Staphylococcus aureus infection,Disease
32011,Skin and soft tissue Staphylococcus aureus infection,Disease
32012,Soluble receptor for advanced glycation end-product levels,Disease
32013,Ear morphology,Disease
32014,Lobe size,Disease
32015,Lobe attachment,Disease
32016,Cerebrospinal fluid clusterin levels,Disease
32017,Plasma clusterin levels,Disease
32018,Response to Pazopanib in cancer (hepatotoxicity),Disease
32019,Cardiovascular disease in hypertension (calcium channel blocker interaction),Disease
32020,Atopic march,Disease
32021,Setpoint viral load in HIV-1 infection,Disease
32022,Pelvic organ prolapse (moderate/severe),Disease
32023,Late-onset myasthenia gravis,Disease
32024,LDL peak particle diameter (total fat intake interaction),Disease
32025,Dysphagia,Disease
32026,Plasma homocysteine levels,Disease
32027,Non-cardia gastric cancer,Disease
32028,Thionamide-induced agranulocytosis in Graves' disease,Disease
32029,Response to lithium treatment in bipolar disorder (dichotomous phenotype),Disease
32030,Survival in colorectal cancer (distant metastatic),Disease
32031,Sense of smell,Disease
32032,Osteoarthritis (hip),Disease
32033,Tetanus toxoid IgG concentrations post childhood immunization,Disease
32035,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention),Disease
32036,Osteoarthritis of the hip or knee,Disease
32037,3-Indolepropionic acid to L-Valine ratio in coronary artery disease,Disease
32039,3-Indolepropionic acid levels in coronary artery disease,Disease
32041,L-Histidine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32043,3-Indolepropionic acid to LysoPC 16:0 ratio in coronary artery disease,Disease
32044,3-Indolepropionic acid to LysoPC 18:1 ratio in coronary artery disease,Disease
32045,L-Thyroxine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32046,Hydrocinnamic acid levels in coronary artery disease,Disease
32047,3-Indolepropionic acid to Trimethylamine N-oxide ratio in coronary artery disease,Disease
32048,3-Indolepropionic acid to Sarcosine ratio in coronary artery disease,Disease
32049,3-Indolepropionic acid to L-Lysine ratio in coronary artery disease,Disease
32050,L-Glutamic acid to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32051,3-Indolepropionic acid to Adenine ratio in coronary artery disease,Disease
32052,3-Indolepropionic acid to L-Methionine ratio in coronary artery disease,Disease
32053,L-Phenylalanine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32054,3-Indolepropionic acid to L-Tyrosine ratio in coronary artery disease,Disease
32055,3-Indolepropionic acid to Phenylpyruvic acid ratio in coronary artery disease,Disease
32056,3-Indolepropionic acid to L-Ornithine ratio in coronary artery disease,Disease
32057,L-Glutamine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32058,3-Indolepropionic acid to Taurocholic acid sodium salt hydrate ratio in coronary artery disease,Disease
32059,Asp-phe to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32061,"3-Indolepropionic acid to 3,3',5-Triiodo-L-thyronine ratio in coronary artery disease",Disease
32062,D-Arabinose to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32063,L-Threonine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32064,3-Indolepropionic acid to N6-Acetyl-L-lysine ratio in coronary artery disease,Disease
32065,L-Aspartic acid to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32066,3-Indolepropionic acid to Uric acid ratio in coronary artery disease,Disease
32067,3-Indolepropionic acid to D-Fructose ratio in coronary artery disease,Disease
32068,L-Tryptophan to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32069,3-Indolepropionic acid to Choline ratio in coronary artery disease,Disease
32070,3-Indolepropionic acid to Uridine ratio in coronary artery disease,Disease
32071,L-Serine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32072,3-Indolepropionic acid to S-(5-Adenosy) -L-homocysteine ratio in coronary artery disease,Disease
32073,3-Indolepropionic acid to D-2-Aminobutyric acid ratio in coronary artery disease,Disease
32074,3-Indolepropionic acid to LysoPC 16:1 ratio in coronary artery disease,Disease
32075,3-Indolepropionic acid to Hippuric acid ratio in coronary artery disease,Disease
32076,3-Indolepropionic acid to Pipecolinic acid ratio in coronary artery disease,Disease
32077,L-Citrulline to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32078,Response to treatment in irritable bowel syndrome (symptom severity),Disease
32080,Asthma (moderate or severe),Disease
32082,Protein quantitative trait loci (liver),Disease
32083,Circulating fibroblast growth factor 23 levels,Disease
32085,Amygdala volume change rate x age interaction (1df),Disease
32087,Cerebellum cortex volume change rate x age interaction (1df),Disease
32089,Lateral ventricle volume change rate x age interaction (1df),Disease
32091,Cerebellum white matter volume change rate x age interaction (1df),Disease
32093,Cerebral white matter volume change rate x age interaction (1df),Disease
32096,Cortex volume change rate x age interaction (1df),Disease
32098,Brain surface area change rate x age interaction (1df),Disease
32100,Thalamus volume change rate x age interaction (1df),Disease
32102,Thalamus volume change rate,Disease
32104,Total brain volume change rate,Disease
32105,Putamen volume change rate,Disease
32107,Pallidum volume change rate x age interaction (1df),Disease
32109,Putamen volume change rate x age interaction (1df),Disease
32111,Gut microbiota alpha diversity (Shannon index),Disease
32112,Carbamazepine-induced serious cutaneous adverse reaction,Disease
32116,Total amyloid (SNP x SNP interaction),Disease
32117,Neurofibrillary tangles (SNP x SNP interaction),Disease
32139,Mean spheric corpuscular volume,Disease
32146,Corneal endothelial cell size variation coefficient,Disease
32147,Impulsivity (non-planning),Disease
32148,Lack of premeditation,Disease
32149,Negative urgency,Disease
32150,Sweet beverage consumption,Disease
32151,Sugar-sweetened beverage consumption,Disease
32152,Artificially sweetened beverage consumption,Disease
32153,Pure non-grapefruit juice consumption,Disease
32154,Tea consumption,Disease
32155,Grapefruit juice consumption,Disease
32156,Lack of perseverance,Disease
32157,Impulsivity (attentional),Disease
32158,Aspartate aminotransferase levels in non-alcoholic fatty liver disease,Disease
32159,Alanine aminotransferase levels in non-alcoholic fatty liver disease,Disease
32160,Priapism in sickle cell disease,Disease
32161,Cerebellum white matter volume change rate x age interaction (2df),Disease
32163,Cerebral white matter volume change rate x age interaction (2df),Disease
32164,Cortical thickness change rate x age interaction (2df),Disease
32166,Short-term memory (digit-span task),Disease
32167,Rapid automised naming of digits,Disease
32168,Rapid automised naming of pictures,Disease
32188,Post-traumatic stress disorder (re-experiencing symptoms),Disease
32189,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),Disease
32194,Percentage of invited food questionnaires completed,Disease
32195,Acceptance of an invitation to participate in a mental health questionnaire,Disease
32196,Blood cell traits (multivariate analysis),Disease
32197,Emphysema annual change measurement in smokers (adjusted lung density),Disease
32198,Emphysema annual change measurement in smokers (percent low attenuation area),Disease
32199,Bitter non-alcoholic beverage consumption,Disease
32200,Bitter alcoholic beverage consumption,Disease
32204,Estimated glomerular filtration rate,Disease
32205,Response to treatment in irritable bowel syndrome (pain frequency),Disease
32208,Response to treatment in irritable bowel syndrome (pain severity),Disease
32213,3-Indolepropionic acid to L-Pipecolic acid ratio in coronary artery disease,Disease
32214,3-Indolepropionic acid to 3-Hydroxybutyrate ratio in coronary artery disease,Disease
32215,3-Indolepropionic acid to (S)-(-)-2-Hydroxyisocaproic acid ratio in coronary artery disease,Disease
32216,3-Indolepropionic acid to Creatinine ratio in coronary artery disease,Disease
32217,L-Pyroglutamic acid to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32218,3-Indolepropionic acid to gamma-Linolenic acid (C18:3n6) ratio in coronary artery disease,Disease
32219,"3-Indolepropionic acid to N,N-Dimethylglycine ratio in coronary artery disease",Disease
32220,3-Indolepropionic acid to SubericAcid ratio in coronary artery disease,Disease
32221,3-Indolepropionic acid to 2-(dimethylamino) guanosine ratio in coronary artery disease,Disease
32222,3-Indolepropionic acid to LysoPC 14:0 ratio in coronary artery disease,Disease
32223,3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio in coronary artery disease,Disease
32224,3-Indolepropionic acid to Azelaic acid ratio in coronary artery disease,Disease
32225,"3-Indolepropionic acid to cis-5,8,11,14,17-Eicosapentaenoic acid (C20:5n3) ratio in coronary artery disease",Disease
32226,3-Indolepropionic acid to Hypoxanthine ratio in coronary artery disease,Disease
32227,L-Proline to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32228,D-Trehalose to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32229,3-Indolepropionic acid to Methylmalonic acid ratio in coronary artery disease,Disease
32230,3-Indolepropionic acid to alpha-Linolenic acid (C18:3n3) ratio in coronary artery disease,Disease
32231,3-Indolepropionic acid to S-Sulfo-L-cysteine ratio in coronary artery disease,Disease
32232,3-Indolepropionic acid to LysoPC 20:0 ratio in coronary artery disease,Disease
32233,3-Indolepropionic acid to beta-Pseudouridine ratio in coronary artery disease,Disease
32234,Dulcitol to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32235,3-Indolepropionic acid to 4-Nitrophenol ratio in coronary artery disease,Disease
32236,3-Indolepropionic acid to Indole-5-carboxylic acid ratio in coronary artery disease,Disease
32237,Pantothenate to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32238,3-Indolepropionic acid to L-Saccharopine ratio in coronary artery disease,Disease
32239,3-Indolepropionic acid to 5-oxoproline ratio in coronary artery disease,Disease
32240,L-Asparagine Anhydrous to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32241,3-Indolepropionic acid to Kinurenine ratio in coronary artery disease,Disease
32242,3-Indolepropionic acid to LysoPC 18:0 ratio in coronary artery disease,Disease
32243,3-Indolepropionic acid to L-2-Aminobutyric acid ratio in coronary artery disease,Disease
32244,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease,Disease
32245,3-Indolepropionic acid to 2-Methylsuccinic acid ratio in coronary artery disease,Disease
32246,3-Indolepropionic acid to LysoPC 20:2 ratio in coronary artery disease,Disease
32247,3-Indolepropionic acid to 4-Guanidinobutyric acid ratio in coronary artery disease,Disease
32248,3-Indolepropionic acid to Isonicotinamide ratio in coronary artery disease,Disease
32249,5-Methyluridine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32250,3-Indolepropionic acid to N-acetylglycine ratio in coronary artery disease,Disease
32251,3-Indolepropionic acid to N-Acetyl-L-tyrosine ratio in coronary artery disease,Disease
32252,L-Cystine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32253,3-Indolepropionic acid to Cyclic AMP ratio in coronary artery disease,Disease
32254,3-Indolepropionic acid to L-Carnitine ratio in coronary artery disease,Disease
32255,"3-Indolepropionic acid to 1,4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide ratio in coronary artery disease",Disease
32256,3-Indolepropionic acid to Creatine ratio in coronary artery disease,Disease
32257,3-Indolepropionic acid to Dodecanedioic aicd ratio in coronary artery disease,Disease
32258,3-Indolepropionic acid to LysoPC 20:1 ratio in coronary artery disease,Disease
32259,3-Indolepropionic acid to L-Arginine ratio in coronary artery disease,Disease
32260,3-Indolepropionic acid to Kynurenic acid ratio in coronary artery disease,Disease
32261,3-Indolepropionic acid to 2-Hydroxyisocaproic acid ratio in coronary artery disease,Disease
32262,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease,Disease
32263,3-Indolepropionic acid to Lauric acid/Dodecanoic acid (C12:0) ratio in coronary artery disease,Disease
32264,3-Indolepropionic acid to Homovanillic acid ratio in coronary artery disease,Disease
32265,N-acetyl-l-leucine to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32266,3-Indolepropionic acid to Myoinositol ratio in coronary artery disease,Disease
32267,3-Indolepropionic acid to Urocanic acid ratio in coronary artery disease,Disease
32268,Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32269,3-Indolepropionic acid to Maltose ratio in coronary artery disease,Disease
32270,D-Malic acid to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32271,D-Sucrose to 3-Indolepropionic acid ratio in coronary artery disease,Disease
32272,Caudate volume change rate,Disease
32275,Lateral ventricle volume change rate,Disease
32277,Pallidum volume change rate,Disease
32280,Cortex volume change rate,Disease
32282,Cortical thickness change rate,Disease
32284,Thalamus volume change rate x age interaction (2df),Disease
32286,Lateral ventricle volume change rate x age interaction (2df),Disease
32287,Pallidum volume change rate x age interaction (2df),Disease
32290,Putamen volume change rate x age interaction (2df),Disease
32292,Mortality in COVID-19,Disease
32305,Alanine aminotransferase levels,Disease
32306,Corneal curvature,Disease
32309,Gut microbiota relative abundance (Sutterella),Disease
32310,Gut microbiota relative abundance (Faecalibacterium),Disease
32311,Gut microbiota relative abundance (Oscillospira),Disease
32312,Gut microbiota relative abundance (Eubacterium belonging to family Erysipelotrichaceae),Disease
32313,Gut microbiota alpha diversity (Chao1 index),Disease
32314,Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae),Disease
32317,Cognitive function (generalized correlation coefficient),Disease
32318,Body mass index and systolic blood pressure (bivariate analysis),Disease
32319,Body mass index and diastolic blood pressure (bivariate analysis),Disease
32320,Systolic blood pressure and diastolic blood pressure (bivariate analysis),Disease
32321,Mean reticulocyte volume,Disease
32324,Gut microbiota relative abundance (Prevotella),Disease
32325,Gut microbiota relative abundance (Streptococcus),Disease
32327,Atorvastatin-induced myopathy,Disease
32328,Self-rated health,Disease
32329,Bone mineral density or leg lean mass (pleiotropy),Disease
32330,Leg lean mass,Disease
32331,Anorectal malformation,Disease
32333,Iron status biomarkers (total iron binding capacity),Disease
32355,First fracture in long-term childhood cancer survivors (time to event),Disease
32356,Cortical volume,Disease
32357,Helicobacter pylori OMP antibody levels,Disease
32358,Chlamydia trachomatis PorB antibody levels,Disease
32359,Epstein-Barr virus EA-D antibody levels,Disease
32360,Epstein-Barr virus VCA p18 antibody levels,Disease
32361,Epstein-Barr virus ZEBRA antibody levels,Disease
32362,Merkel cell polyomavirus VP1 antibody levels,Disease
32363,Anti-human herpesvirus6IE1A IgGseropositivity,Disease
32364,Human herpes virus6 IE1Aantibodylevels,Disease
32365,Varicella zoster virus glycoproteins E and I antibody levels,Disease
32366,Helicobacter pylori UREA antibody levels,Disease
32367,Anti-polyomavirus 2 IgG seropositivity,Disease
32368,Polyomavirus 2  JC VP1 antibody levels,Disease
32369,Epstein-Barr virus EBNA-1 antibody levels,Disease
32370,Anti-Merkel cell polyomavirus IgG seropositivity,Disease
32371,Human herpesvirus7 U14antibodylevels,Disease
32372,Anti-varicella zoster virus IgG seropositivity,Disease
32373,Opioid use disorder,Disease
32374,Gut microbiota relative abundance (unclassified genus belonging to family Lachnospiraceae),Disease
32375,Gut microbiota relative abundance (Blautia),Disease
32376,Gut microbiota relative abundance (unclassified genus belonging to family Ruminococcaceae),Disease
32377,Gut microbiota relative abundance (Dorea),Disease
32395,Urolithiasis,Disease
32396,Arrhythmia,Disease
32404,Simvastatin-induced myopathy,Disease
32416,Chronic kidney disease x type 2 diabetes interaction,Disease
32417,Obsessive-compulsive traits,Disease
32418,Interleukin-6 levels,Disease
32423,Mitochondrial DNA copy number,Disease
32424,Mitochondrial DNA copy number (white blood cells),Disease
32425,Factor VII activity,Disease
32436,Lean nonalcoholic fatty liver disease,Disease
32437,Nonsyndromic cleft palate,Disease
32447,Differentiated thyroid cancer,Disease
32448,Aspartate aminotransferase levels,Disease
32452,Beta-2-microglobulin levels,Disease
32453,C-C motif chemokine 22 levels,Disease
32455,C-C motif chemokine 17 levels,Disease
32457,Ubiquitin-conjugating enzyme E2 G2 levels,Disease
32462,Ubiquitin carboxyl-terminal hydrolase 25 levels,Disease
32470,Post-traumatic stress disorder (MTAG),Disease
32472,Non-HDL cholesterol levels,Disease
32497,Tryptase beta-2 levels,Disease
32510,GDNF family receptor alpha-1 levels,Disease
32512,Heparin cofactor 2 levels,Disease
32515,Thrombospondin-2 levels,Disease
32548,Hazardous alcohol drinking,Disease
32555,Rectal cancer,Disease
32558,Colorectal cancer vs inflammatory bowel disease,Disease
32561,Colorectal cancer vs inflammatory bowel disease or controls,Disease
32565,Right colon cancer,Disease
32567,Left colon cancer,Disease
32575,HDL cholesterol levels in type 2 diabetes,Disease
32576,Total cholesterol levels in chylomicrons and extremely large VLDL,Disease
32578,Cholesteryl esters to total lipids ratio in medium VLDL,Disease
32579,Free cholesterol to total lipids ratio in medium VLDL,Disease
32581,Free cholesterol in medium VLDL,Disease
32583,Cholesterol esters in medium VLDL,Disease
32584,Total cholesterol levels in small HDL,Disease
32585,Total cholesterol to total lipids ratio in small HDL,Disease
32587,Ratio of saturated fatty acids to total fatty acids,Disease
32588,Saturated fatty acids,Disease
32592,Serum total triglyceride levels,Disease
32593,Free cholesterol to total lipids ratio in small LDL,Disease
32595,Concentration of small LDL particles,Disease
32597,Total lipids in small LDL,Disease
32601,Ischemic stroke (large artery atherosclerosis),Disease
32602,Ischemic stroke (small-vessel),Disease
32603,Apolipoprotein A-I levels,Disease
32605,Systolic blood pressure (BMI adjusted),Disease
32608,Systolic blood pressure (BMI unadjusted),Disease
32611,Total cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Disease
32613,Cholesteryl ester levels in chylomicrons and extremely large VLDL,Disease
32614,Triglycerides to total lipids ratio in very small VLDL,Disease
32615,Triglycerides in very small VLDL,Disease
32616,Phospholipids in very small VLDL,Disease
32626,Serum total cholesterol levels,Disease
32628,Polyunsaturated fatty acids,Disease
32629,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",Disease
32631,Ratio of polyunsaturated fatty acids to total fatty acids,Disease
32633,Pyruvate levels,Disease
32635,Phenylalanine levels,Disease
32638,Cholesterol esters in small LDL,Disease
32640,Total cholesterol to total lipids ratio in small LDL,Disease
32642,Total Cholesterol in small LDL,Disease
32643,Hashimoto thyroiditis,Disease
32645,Ratio of apolipoprotein B to apolipoprotein A1 levels,Disease
32646,Diastolic blood pressure (BMI unadjusted),Disease
32651,Coronary artery disease or von Willebrand factor levels (pleiotropy),Disease
32652,Coronary artery disease or factor XI levels (pleiotropy),Disease
32659,Unstable angina pectoris,Disease
32661,acne vulgaris,Disease
32662,Breast cancer subtype (triple negative vs luminal A-like),Disease
32663,Serum albumin levels,Disease
32668,Ratio of triglycerides to phosphoglycerides,Disease
32670,Triglycerides to total lipids ratio in small VLDL,Disease
32672,Triglycerides in small VLDL,Disease
32673,Acute radiotoxicity in head and neck cancer,Disease
32675,Acute radiotoxicity in lung cancer,Disease
32686,Phospholipids in very large VLDL,Disease
32691,Neovascular age-related macular degeneration,Disease
32695,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,Disease
32696,Free cholesterol levels in chylomicrons and extremely large VLDL,Disease
32697,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Disease
32698,Total lipid levels in chylomicrons and extremely large VLDL,Disease
32699,Phospholipid levels in chylomicrons and extremely large VLDL,Disease
32700,Phospholipids to total lipids ratio in medium LDL,Disease
32702,Concentration of chylomicrons and extremely large VLDL particles,Disease
32703,Cholesterol esters in small HDL,Disease
32704,Cholesteryl esters to total lipids ratio in small HDL,Disease
32705,Free cholesterol to total lipids ratio in small HDL,Disease
32706,Free cholesterol in small HDL,Disease
32709,Total lipids in small HDL,Disease
32711,Waist-hip index,Disease
32712,Phospholipids to total lipids ratio in small LDL,Disease
32713,Phospholipids in small LDL,Disease
32714,Triglycerides in small LDL,Disease
32718,3-Hydroxybutyrate levels,Disease
32719,Conjugated linoleic acid,Disease
32724,Diastolic blood pressure (BMI adjusted),Disease
32727,Nonalcoholic fatty liver disease (imputed),Disease
32732,Uterine prolapse,Disease
32733,Uveitis,Disease
32735,Coronary artery disease or fibrinogen levels (pleiotropy),Disease
32746,Varicose veins,Disease
32763,Dry eye disease,Disease
32780,Phospholipids to total lipids ratio in very large HDL,Disease
32781,Phospholipids in very large HDL,Disease
32787,Severe COVID-19 infection (severe vs non-severe),Disease
32789,Free cholesterol to total lipids ratio in very small VLDL,Disease
32791,Free cholesterol in very small VLDL,Disease
32792,Concentration of very small VLDL particles,Disease
32793,Total lipids in very small VLDL,Disease
32794,Total fatty acids,Disease
32795,Total phosphoglycerides levels,Disease
32798,Tyrosine levels,Disease
32800,Estimated degree of unsaturation,Disease
32801,Total cholines levels,Disease
32803,Cholesterol esters in very small VLDL,Disease
32805,Total cholesterol to total lipids ratio in very small VLDL,Disease
32806,Cholesteryl esters to total lipids ratio in very small VLDL,Disease
32807,Triglycerides to total lipids ratio in very large VLDL,Disease
32808,Triglycerides in very large VLDL,Disease
32809,Total cholesterol in very small VLDL,Disease
32810,Triglycerides to total lipids ratio in medium LDL,Disease
32812,Triglycerides in medium LDL,Disease
32813,"Monounsaturated fatty acids (16:1, 18:1) levels",Disease
32814,Ratio of monounsaturated fatty acids to total fatty acids,Disease
32817,Triglycerides to total lipids ratio in medium VLDL,Disease
32818,Phospholipids to total lipids ratio in medium VLDL,Disease
32819,Triglycerides in medium VLDL,Disease
32820,Phosphatidylcholine and other choline levels,Disease
32821,Phospholipids in medium VLDL,Disease
32822,Cholesteryl esters to total lipids ratio in small LDL,Disease
32823,Free cholesterol in small LDL,Disease
32824,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,Disease
32826,Triglyceride levels in chylomicrons and extremely large VLDL,Disease
32828,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,Disease
32829,Acetate levels,Disease
32831,Total cholesterol in small VLDL,Disease
32832,Alanine levels,Disease
32837,Omega-3 fatty acids levels,Disease
32838,Ratio of omega-3 fatty acids to total fatty acids,Disease
32839,Omega-6 fatty acids levels,Disease
32841,Mean arterial pressure (BMI adjusted),Disease
32842,Coronary artery disease or factor VII levels (pleiotropy),Disease
32843,Coronary artery disease or tissue plasminogen activator levels (pleiotropy),Disease
32856,Total cholesterol in very large VLDL,Disease
32857,Cholesterol esters in very large VLDL,Disease
32858,Total cholesterol to total lipids ratio in very large VLDL,Disease
32859,Cholesteryl esters to total lipids ratio in very large VLDL,Disease
32860,Free cholesterol in very large VLDL,Disease
32878,Angina,Disease
32881,Ratio of omega-6 fatty acids to total fatty acids,Disease
32882,Glucose levels,Disease
32883,Retinal venular tortuosity,Disease
32885,Retinal venular width,Disease
32897,Electrocardiogram morphology (amplitude at temporal datapoints),Disease
32898,Urine heptanoylglutamine levels in chronic kidney disease,Disease
32899,Plasma hexanoylglutamine levels in chronic kidney disease,Disease
32901,Urine gamma-CEHC sulfate levels in chronic kidney disease,Disease
32902,Plasma butyrylcarnitine (C4) levels in chronic kidney disease,Disease
32903,Plasma carotene diol (1) levels in chronic kidney disease,Disease
32905,Plasma carotene diol (2) levels in chronic kidney disease,Disease
32906,Plasma carotene diol (3) levels in chronic kidney disease,Disease
32907,Plasma cerotoylcarnitine (C26)* levels in chronic kidney disease,Disease
32908,Plasma ethylmalonate levels in chronic kidney disease,Disease
32910,Urine ethylmalonate levels in chronic kidney disease,Disease
32911,Plasma ferulic acid 4-sulfate levels in chronic kidney disease,Disease
32912,Urine ferulic acid 4-sulfate levels in chronic kidney disease,Disease
32913,Plasma furaneol sulfate levels in chronic kidney disease,Disease
32914,Urine furaneol sulfate levels in chronic kidney disease,Disease
32915,Urine hexanoylglutamine levels in chronic kidney disease,Disease
32916,Plasma ergothioneine levels in chronic kidney disease,Disease
32918,Autoimmune neurological syndromes with anti-GAD65 autoantibodies,Disease
32925,Vertex-wise cortical thickness,Disease
32926,Urinary uromodulin levels (raw),Disease
32935,Urinary uromodulin levels (indexed to creatinine),Disease
32939,Fasting plasma glucose change,Disease
32942,COVID-19 (critical illness vs population or mild symptoms),Disease
32946,Estimated glomerular filtration rate (creatinine),Disease
32948,Predicted developmental stuttering,Disease
32958,Vaginal microbiome MetaCyc pathway (P163-PWY|L-lysine fermentation to acetate and butanoate),Disease
32961,Vaginal microbiome MetaCyc pathway (P562-PWY|myo-inositol degradation I),Disease
32965,Vaginal microbiome MetaCyc pathway (POLYAMSYN-PWY|superpathway of polyamine biosynthesis I),Disease
32967,Vaginal microbiome MetaCyc pathway (PPGPPMET-PWY|ppGpp biosynthesis),Disease
32969,Vaginal microbiome MetaCyc pathway (P381-PWY|adenosylcobalamin biosynthesis II (late cobalt incorporation)),Disease
32973,Vaginal microbiome MetaCyc pathway (P164-PWY|purine nucleobases degradation I (anaerobic)),Disease
32976,Vaginal microbiome MetaCyc pathway (P221-PWY|octane oxidation),Disease
32979,Vertex-wise cortical surface area,Disease
32980,Vertex-wise sulcal depth,Disease
32990,Orofacial cleft x maternal vitamin supplementation interaction (2df),Disease
32993,Plasma ascorbic acid 2-sulfate levels in chronic kidney disease,Disease
32995,Plasma ascorbic acid 3-sulfate* levels in chronic kidney disease,Disease
32997,Urine azelate (C9-DC) levels in chronic kidney disease,Disease
32998,Plasma 5-methylthioadenosine (MTA) levels in chronic kidney disease,Disease
33000,Plasma acisoga levels in chronic kidney disease,Disease
33001,Urine glutamine conjugate of C10H16O2 (2)* levels in chronic kidney disease,Disease
33002,Urine glutamine conjugate of C8H12O2 (3)* levels in chronic kidney disease,Disease
33004,Urine glutamine conjugate of C8H12O4 (1)* levels in chronic kidney disease,Disease
33005,Urine glutamine conjugate of C9H16O2 (1)* levels in chronic kidney disease,Disease
33006,Plasma glutarylcarnitine (C5-DC) levels in chronic kidney disease,Disease
33007,Urine glutarylcarnitine (C5-DC) levels in chronic kidney disease,Disease
33008,Urine alpha-CEHC sulfate levels in chronic kidney disease,Disease
33009,Plasma arachidonoylcarnitine (C20:4) levels in chronic kidney disease,Disease
33010,Plasma argininate* levels in chronic kidney disease,Disease
33011,Urine argininate* levels in chronic kidney disease,Disease
33012,Urine acisoga levels in chronic kidney disease,Disease
33013,"Urine adenosine 3',5'-cyclic monophosphate (cAMP) levels in chronic kidney disease",Disease
33015,Urine adenosine levels in chronic kidney disease,Disease
33016,Plasma adipoylcarnitine (C6-DC) levels in chronic kidney disease,Disease
33017,Urine adipoylcarnitine (C6-DC) levels in chronic kidney disease,Disease
33046,Vaginal microbiome MetaCyc pathway (PWY-5121|superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)),Disease
33048,Vaginal microbiome MetaCyc pathway (PWY-5177|glutaryl-CoA degradation),Disease
33051,Vaginal microbiome MetaCyc pathway (PWY-5182|toluene degradation II (aerobic) (via 4-methylcatechol)),Disease
33055,Vaginal microbiome MetaCyc pathway (PWY-5180|toluene degradation I (aerobic) (via o-cresol)),Disease
33064,Urine 3-formylindole levels in chronic kidney disease,Disease
33066,Urine 3-hydroxycinnamate sulfate levels in chronic kidney disease,Disease
33067,Plasma 3-hydroxydecanoylcarnitine levels in chronic kidney disease,Disease
33069,Urine 3-hydroxydodecanedioate* levels in chronic kidney disease,Disease
33071,Plasma 3-hydroxyhexanoate levels in chronic kidney disease,Disease
33073,Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease,Disease
33075,Plasma 3-hydroxyoctanoylcarnitine (1) levels in chronic kidney disease,Disease
33076,Plasma 3-hydroxyoctanoylcarnitine (2) levels in chronic kidney disease,Disease
33077,Urine 3-hydroxysebacate levels in chronic kidney disease,Disease
33079,Urine 21-hydroxypregnenolone disulfate levels in chronic kidney disease,Disease
33080,Urine 3-(3-hydroxyphenyl)propionate levels in chronic kidney disease,Disease
33081,Plasma 3-decenoylcarnitine levels in chronic kidney disease,Disease
33083,Urine 4-hydroxycinnamate sulfate levels in chronic kidney disease,Disease
33084,Urine 4-hydroxyphenylacetylglutamine levels in chronic kidney disease,Disease
33086,Urine 4-hydroxyphenylpyruvate levels in chronic kidney disease,Disease
33087,Urine 4-methylhexanoylglutamine levels in chronic kidney disease,Disease
33089,Urine 5-hydroxyindole sulfate levels in chronic kidney disease,Disease
33131,Vaginal microbiome MetaCyc pathway (P124-PWY|Bifidobacterium shunt),Disease
33133,Vaginal microbiome MetaCyc pathway (NAD-BIOSYNTHESIS-II|NAD salvage pathway II),Disease
33136,Vaginal microbiome MetaCyc pathway (METH-ACETATE-PWY|methanogenesis from acetate),Disease
33141,"Vaginal microbiome MetaCyc pathway (P125-PWY|superpathway of (R,R)-butanediol biosynthesis)",Disease
33151,Urine 2-hydroxysebacate levels in chronic kidney disease,Disease
33152,"Plasma 2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA)* levels in chronic kidney disease",Disease
33153,Plasma phenylacetylglutamate levels in chronic kidney disease,Disease
33155,Urine phenylacetylglutamate levels in chronic kidney disease,Disease
33156,Plasma phenyllactate (PLA) levels in chronic kidney disease,Disease
33158,Urine phenyllactate (PLA) levels in chronic kidney disease,Disease
33159,Plasma picolinate levels in chronic kidney disease,Disease
33160,"Plasma 1,2-dipalmitoyl-GPC (16:0/16:0) levels in chronic kidney disease",Disease
33161,Urine pterin levels in chronic kidney disease,Disease
33162,Urine pyridoxal levels in chronic kidney disease,Disease
33163,Plasma S-adenosylhomocysteine (SAH) levels in chronic kidney disease,Disease
33164,Urine S-adenosylhomocysteine (SAH) levels in chronic kidney disease,Disease
33166,Urine sebacate (C10-DC) levels in chronic kidney disease,Disease
33168,Urine picolinate levels in chronic kidney disease,Disease
33169,Plasma picolinoylglycine levels in chronic kidney disease,Disease
33170,Plasma pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease,Disease
33171,Urine pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease,Disease
33172,Urine pregnenediol disulfate (C21H34O8S2)* levels in chronic kidney disease,Disease
33173,Urine prolylglycine levels in chronic kidney disease,Disease
33175,Plasma propionylcarnitine (C3) levels in chronic kidney disease,Disease
33176,Plasma stearoylcarnitine (C18) levels in chronic kidney disease,Disease
33177,Urine suberate (C8-DC) levels in chronic kidney disease,Disease
33179,Plasma suberoylcarnitine (C8-DC) levels in chronic kidney disease,Disease
33188,Fasting plasma glucose in prediabetes,Disease
33190,Body mass index in prediabetes,Disease
33198,Vaginal microbiome MetaCyc pathway (PWY-1861|formaldehyde assimilation II (RuMP Cycle)),Disease
33200,Vaginal microbiome MetaCyc pathway (PWY-4984|urea cycle),Disease
33202,Vaginal microbiome MetaCyc pathway (PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY|protocatechuate degradation II (ortho-cleavage pathway)),Disease
33204,Vaginal microbiome MetaCyc pathway (PWY-1622|formaldehyde assimilation I (serine pathway)),Disease
33224,Breast cancer or lung cancer (pleiotropy),Disease
33227,Lung cancer or head/neck cancer (pleiotropy),Disease
33229,Breast cancer or ovarian cancer (pleiotropy),Disease
33231,Retinal arteriolar tortuosity,Disease
33237,Urine nicotinamide riboside levels in chronic kidney disease,Disease
33238,Plasma oleoylcarnitine (C18:1) levels in chronic kidney disease,Disease
33239,Plasma palmitoylcarnitine (C16) levels in chronic kidney disease,Disease
33240,Plasma X-11381 levels in chronic kidney disease,Disease
33241,Plasma X-11470 levels in chronic kidney disease,Disease
33243,Urine X-11470 levels in chronic kidney disease,Disease
33244,Plasma X-11478 levels in chronic kidney disease,Disease
33245,Urine X-12097 levels in chronic kidney disease,Disease
33247,Plasma X-12100 levels in chronic kidney disease,Disease
33249,Urine X-12100 levels in chronic kidney disease,Disease
33251,Urine X-12124 levels in chronic kidney disease,Disease
33253,Plasma X-12689 levels in chronic kidney disease,Disease
33255,Urine X-12704 levels in chronic kidney disease,Disease
33256,Urine X-12707 levels in chronic kidney disease,Disease
33275,Central serous chorioretinopathy,Disease
33286,Vaginal microbiome MetaCyc pathway (FASYN-INITIAL-PWY|superpathway of fatty acid biosynthesis initiation (E. coli)),Disease
33289,Vaginal microbiome MetaCyc pathway (FUC-RHAMCAT-PWY|superpathway of fucose and rhamnose degradation),Disease
33291,Vaginal microbiome MetaCyc pathway (CENTFERM-PWY|pyruvate fermentation to butanoate),Disease
33296,Vaginal microbiome MetaCyc pathway (ENTBACSYN-PWY|enterobactin biosynthesis),Disease
33299,Vaginal microbiome MetaCyc pathway (FUCCAT-PWY|fucose degradation),Disease
33304,Vaginal microbiome MetaCyc pathway (FAO-PWY|fatty acid beta;-oxidation I),Disease
33322,Plasma 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* levels in chronic kidney disease,Disease
33323,Plasma 1-methylnicotinamide levels in chronic kidney disease,Disease
33324,Age at menarche,Disease
33325,Urine diacetylspermidine* levels in chronic kidney disease,Disease
33326,Plasma dihomo-linolenoylcarnitine (C20:3n3 or 6)* levels in chronic kidney disease,Disease
33327,Plasma dihomo-linoleoylcarnitine (C20:2)* levels in chronic kidney disease,Disease
33328,Urine dihydroferulic acid sulfate levels in chronic kidney disease,Disease
33329,Urine isoxanthopterin levels in chronic kidney disease,Disease
33330,Plasma kynurenine levels in chronic kidney disease,Disease
33331,Urine kynurenine levels in chronic kidney disease,Disease
33333,Plasma levulinoylcarnitine levels in chronic kidney disease,Disease
33334,Plasma linolenoylcarnitine (C18:3)* levels in chronic kidney disease,Disease
33335,Plasma linoleoylcarnitine (C18:2)* levels in chronic kidney disease,Disease
33336,Plasma lysine levels in chronic kidney disease,Disease
33337,Urine cyclo(leu-asp)* levels in chronic kidney disease,Disease
33338,"Plasma cys-gly, oxidized levels in chronic kidney disease",Disease
33340,Plasma cysteinylglycine disulfide* levels in chronic kidney disease,Disease
33342,Urine cysteinylglycine disulfide* levels in chronic kidney disease,Disease
33343,Plasma cysteinylglycine levels in chronic kidney disease,Disease
33344,Urine cysteinylglycine levels in chronic kidney disease,Disease
33345,Urine glucuronide of C10H18O2 (10)* levels in chronic kidney disease,Disease
33347,Plasma imidazole lactate levels in chronic kidney disease,Disease
33349,Urine imidazole lactate levels in chronic kidney disease,Disease
33350,Plasma indoleacetoylcarnitine* levels in chronic kidney disease,Disease
33351,Urine indoleacetoylcarnitine* levels in chronic kidney disease,Disease
33352,Plasma indoleacetylglutamine levels in chronic kidney disease,Disease
33353,Urine indoleacetylglutamine levels in chronic kidney disease,Disease
33354,Urine indoleacetylglycine levels in chronic kidney disease,Disease
33355,Urine indolelactate levels in chronic kidney disease,Disease
33356,Plasma indolepropionate levels in chronic kidney disease,Disease
33357,Plasma isobutyrylcarnitine (C4) levels in chronic kidney disease,Disease
33358,Urine isobutyrylcarnitine (C4) levels in chronic kidney disease,Disease
33359,Urine isocaproylglutamine levels in chronic kidney disease,Disease
33360,Plasma 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)* levels in chronic kidney disease,Disease
33361,Total bilirubin levels,Disease
33366,Chronic sputum production,Disease
33379,Vaginal microbiome MetaCyc pathway (ARG+POLYAMINE-SYN|superpathway of arginine and polyamine biosynthesis),Disease
33381,Vaginal microbiome MetaCyc pathway (CATECHOL-ORTHO-CLEAVAGE-PWY|catechol degradation to beta;-ketoadipate),Disease
33386,Vaginal microbiome MetaCyc pathway (ALL-CHORISMATE-PWY|superpathway of chorismate metabolism),Disease
33393,Triglycerides (54:7)B levels,Disease
33396,Phosphatidylcholines (42:5) levels,Disease
33398,Fornix volume,Disease
33400,Brain age (difference between predicted and chronological age),Disease
33401,Plasma methylsuccinoylcarnitine levels in chronic kidney disease,Disease
33403,Urine methylsuccinoylcarnitine levels in chronic kidney disease,Disease
33404,Urine myo-inositol levels in chronic kidney disease,Disease
33405,Urine N-lactoyl leucine levels in chronic kidney disease,Disease
33407,Urine N-lactoyl phenylalanine levels in chronic kidney disease,Disease
33408,Urine N-lactoyl tyrosine levels in chronic kidney disease,Disease
33410,Urine N-lactoyl valine levels in chronic kidney disease,Disease
33411,Urine N-octanoylglutamine levels in chronic kidney disease,Disease
33412,Urine suberoylcarnitine (C8-DC) levels in chronic kidney disease,Disease
33413,Plasma maltol sulfate levels in chronic kidney disease,Disease
33414,Urine maltol sulfate levels in chronic kidney disease,Disease
33415,Plasma N-acetyl-isoputreanine levels in chronic kidney disease,Disease
33416,Urine N-acetyl-met-phe levels in chronic kidney disease,Disease
33417,Plasma N-acetylcarnosine levels in chronic kidney disease,Disease
33419,Urine N-acetylcarnosine levels in chronic kidney disease,Disease
33420,Plasma N-acetylphenylalanine levels in chronic kidney disease,Disease
33421,Plasma N-acetyltryptophan levels in chronic kidney disease,Disease
33423,Plasma N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease,Disease
33425,Urine N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease,Disease
33426,Plasma N-acetylglucosaminylasparagine levels in chronic kidney disease,Disease
33427,Urine N-acetylglucosaminylasparagine levels in chronic kidney disease,Disease
33428,Plasma N-acetylkynurenine (2) levels in chronic kidney disease,Disease
33436,Phosphatidylcholines (38:2) levels,Disease
33447,Urine X-21829 levels in chronic kidney disease,Disease
33448,Urine X-21841 levels in chronic kidney disease,Disease
33449,Urine X-23518 levels in chronic kidney disease,Disease
33450,Plasma X-24422 levels in chronic kidney disease,Disease
33451,Urine X-24470 levels in chronic kidney disease,Disease
33455,Urine X-17328 levels in chronic kidney disease,Disease
33456,Urine X-17674 levels in chronic kidney disease,Disease
33457,Urine X-18888 levels in chronic kidney disease,Disease
33458,Urine X-13837 levels in chronic kidney disease,Disease
33459,Plasma X-13846 levels in chronic kidney disease,Disease
33460,Urine X-13846 levels in chronic kidney disease,Disease
33461,Plasma X-13866 levels in chronic kidney disease,Disease
33463,Urine X-13866 levels in chronic kidney disease,Disease
33464,Urine X-13874 levels in chronic kidney disease,Disease
33465,Urine X-15806 levels in chronic kidney disease,Disease
33466,Plasma X-17304 levels in chronic kidney disease,Disease
33467,Plasma X-17323 levels in chronic kidney disease,Disease
33468,Urine X-17323 levels in chronic kidney disease,Disease
33469,Plasma X-19141 levels in chronic kidney disease,Disease
33470,Urine X-24515 levels in chronic kidney disease,Disease
33471,Plasma X-24556 levels in chronic kidney disease,Disease
33472,Urine X-12714 levels in chronic kidney disease,Disease
33473,Plasma X-12798 levels in chronic kidney disease,Disease
33475,Plasma X-12822 levels in chronic kidney disease,Disease
33476,Urine X-12822 levels in chronic kidney disease,Disease
33478,Urine X-12839 levels in chronic kidney disease,Disease
33479,Plasma X-13684 levels in chronic kidney disease,Disease
33481,Urine X-13684 levels in chronic kidney disease,Disease
33482,Urine X-23787 levels in chronic kidney disease,Disease
33484,Plasma X-23983 levels in chronic kidney disease,Disease
33486,Urine X-24339 levels in chronic kidney disease,Disease
33488,Urine X-24345 levels in chronic kidney disease,Disease
33493,Cardiovascular delta age (difference between ECG-predicted and chronological age),Disease
33501,Blood urea nitrogen levels,Disease
33505,Vaginal microbiome MetaCyc pathway (GLUCOSE1PMETAB-PWY|glucose and glucose-1-phosphate degradation),Disease
33507,Vaginal microbiome MetaCyc pathway (GLUCUROCAT-PWY|superpathway of beta;-D-glucuronide and D-glucuronate degradation),Disease
33509,Vaginal microbiome MetaCyc pathway (HISDEG-PWY|L-histidine degradation I),Disease
33513,Vaginal microbiome MetaCyc pathway (GALACT-GLUCUROCAT-PWY|superpathway of hexuronide and hexuronate degradation),Disease
33514,Vaginal microbiome MetaCyc pathway (KDO-NAGLIPASYN-PWY|superpathway of (Kdo)2-lipid A biosynthesis),Disease
33518,Vaginal microbiome MetaCyc pathway (PWY-5265|peptidoglycan biosynthesis II (staphylococci)),Disease
33521,Ascending thoracic aortic diameter,Disease
33526,Rheumatoid arthritis or multiple sclerosis,Disease
33529,Rheumatoid arthritis or irritable bowel disease,Disease
33542,Rheumatoid arthritis or type 1 diabetes,Disease
33557,Orange juice liking,Disease
33559,Oranges liking,Disease
33560,Plum liking,Disease
33564,F-meat liking (derived food-liking factor),Disease
33565,Milky sweets liking,Disease
33567,F-oily fish liking (derived food-liking factor),Disease
33569,Liver liking,Disease
33570,Salad dressing liking,Disease
33572,Salami liking,Disease
33573,Mackerel liking,Disease
33575,Porridge liking,Disease
33576,Raw carrot liking,Disease
33577,Red meat liking,Disease
33578,F-acquired taste liking (derived food-liking factor),Disease
33580,F-fatty food liking (derived food-liking factor),Disease
33581,F-fish liking (derived food-liking factor),Disease
33582,F-chocolate/coffee liking (derived food-liking factor),Disease
33584,F-coffee/alcohol liking (derived food-liking factor),Disease
33585,F-cooking vegetables liking (derived food-liking factor),Disease
33587,Coriander liking,Disease
33589,Crisps liking,Disease
33591,Coffee difference liking,Disease
33593,Coffee max liking,Disease
33594,F-cooking flavour liking (derived food-liking factor),Disease
33596,Croissant liking,Disease
33598,Curry liking,Disease
33599,F-deep fried food liking (derived food-liking factor),Disease
33602,Fruit liking,Disease
33603,Dried fruit liking,Disease
33604,F-fatty/salty food liking (derived food-liking factor),Disease
33605,Capers liking,Disease
33606,F-capsicum liking (derived food-liking factor),Disease
33607,F-cheese liking (derived food-liking factor),Disease
33675,F-fruit liking (derived food-liking factor),Disease
33676,Fruit juice liking,Disease
33677,Globe artichoke liking,Disease
33678,Serum uromodulin concentration,Disease
33743,Small intestine neuroendocrine tumor,Disease
33787,F-vegetarian liking (derived food-liking factor),Disease
33788,White bread liking,Disease
33790,F-whole food liking (derived food-liking factor),Disease
33792,Whole grain cereal liking,Disease
33793,F-strong vegetable liking (derived food-liking factor),Disease
33794,Smoked fish liking,Disease
33795,F-sodas liking (derived food-liking factor),Disease
33796,Soft cheese liking,Disease
33798,Soy sauce liking,Disease
33800,Soya milk liking,Disease
33802,Spicy food liking,Disease
33804,Strawberries liking,Disease
33806,F-sweet food liking (derived food-liking factor),Disease
33808,Tea difference liking,Disease
33809,Tea with sugar liking,Disease
33812,F-strong flavour liking (derived food-liking factor),Disease
33815,Alcohol liking,Disease
33817,Aniseed liking,Disease
33820,Apple juice liking,Disease
33828,Longitudinal peak diastolic strain rate,Disease
33829,Radial peak diastolic strain rate,Disease
33863,Phosphatidylethanolamine (36:2) levels,Disease
33869,Plasma X-25244 levels in chronic kidney disease,Disease
33870,Plasma X-25371 levels in chronic kidney disease,Disease
33872,Plasma xanthurenate levels in chronic kidney disease,Disease
33873,Plasma ximenoylcarnitine (C26:1)* levels in chronic kidney disease,Disease
33884,Vaginal microbiome beta diversity (Unweighted Unifrac),Disease
33886,Vaginal microbiome beta diversity (Bray-curtis Dissimilarity),Disease
33888,Vaginal microbiome dominance (s_Lactobacillus iners),Disease
33890,Vaginal microbiome MetaCyc pathway (1CMET2-PWY|N10-formyl-tetrahydrofolate biosynthesis),Disease
33894,Descending thoracic aortic diameter,Disease
33901,Malignant vs benign glioma,Disease
33925,Haddock liking,Disease
33926,F-healthy food liking (derived food-liking factor),Disease
33927,F-healthy breakfast food liking (derived food-liking factor),Disease
33928,Goat cheese liking,Disease
33935,Herring liking,Disease
33940,F-highly palatable foods liking (derived food-liking factor),Disease
33941,Kiwi liking,Disease
33943,Lager liking,Disease
33945,Horseradish liking,Disease
33947,Honey liking,Disease
33948,F-bitter food liking (derived food-liking factor),Disease
33949,Broad bean liking,Disease
33953,Beans liking,Disease
33955,Beef/steak liking,Disease
33956,Beetroot liking,Disease
33958,F-caffeinated/sweet liking (derived food-liking factor),Disease
33959,F-cake/biscuits liking (derived food-liking factor),Disease
33960,Avocado liking,Disease
33963,Baked/steamed fish liking,Disease
33964,Butternut squash liking,Disease
33969,Obstructive heart defect,Disease
33971,Obstructive heart defect (maternal genotype effect),Disease
33978,Hormone-sensitive cancer,Disease
33990,Vaginal microbiome MetaCyc pathway (PWY-6507|4-deoxy-L-threo-hex-4-enopyranuronate degradation),Disease
33991,Vaginal microbiome MetaCyc pathway (PWY-6519|8-amino-7-oxononanoate biosynthesis I),Disease
33994,"Vaginal microbiome MetaCyc pathway (PWY-6383|mono-trans, poly-cis decaprenyl phosphate biosynthesis)",Disease
33996,Vaginal microbiome MetaCyc pathway (PWY-6562|norspermidine biosynthesis),Disease
33998,Vaginal microbiome relative abundance (f_Mycoplasmataceae),Disease
34001,Vaginal microbiome relative abundance (o_Bacteroidales),Disease
34002,Vaginal microbiome relative abundance (g_Dialister),Disease
34006,Vaginal microbiome relative abundance (g_Megasphaera),Disease
34008,Vaginal microbiome relative abundance (g_Anaerococcus),Disease
34010,Vaginal microbiome relative abundance (o_Campylobacterales),Disease
34013,Vaginal microbiome relative abundance (g_Peptoniphilus),Disease
34016,Vaginal microbiome relative abundance (g_Prevotella),Disease
34017,Vaginal microbiome relative abundance (g_Streptococcus),Disease
34019,Vaginal microbiome relative abundance (p_Proteobacteria),Disease
34021,Medication use (vasodilators used in cardiac diseases),Disease
34024,Medication use (antihypertensives),Disease
34026,Medication use (antithrombotic agents),Disease
34029,Medication use (beta blocking agents),Disease
34035,Medication use (diuretics),Disease
34040,Actinic keratosis,Disease
34072,Vaginal microbiome MetaCyc pathway (PWY-6708|ubiquinol-8 biosynthesis (prokaryotic)),Disease
34073,Vaginal microbiome MetaCyc pathway (PWY-6749|CMP-legionaminate biosynthesis I),Disease
34076,Vaginal microbiome MetaCyc pathway (PWY-6590|superpathway of Clostridium acetobutylicum acidogenic fermentation),Disease
34077,Vaginal microbiome MetaCyc pathway (PWY-6608|guanosine nucleotides degradation III),Disease
34099,Vaginal microbiome MetaCyc pathway (PWY-6609|adenine and adenosine salvage III),Disease
34100,Vaginal microbiome relative abundance (s_Lactobacillus crispatus),Disease
34102,Vaginal microbiome relative abundance (s_Lactobacillus jensenii),Disease
34105,Vaginal microbiome relative abundance (s_Dialister micraerophilus),Disease
34106,Vaginal microbiome relative abundance (s_Dialister propionicifaciens),Disease
34108,Vaginal microbiome relative abundance (s_Aerococcus christensenii),Disease
34115,Vaginal microbiome relative abundance (s_Lactobacillus reuteri),Disease
34120,Facial skin hydration,Disease
34123,Facial wrinkles,Disease
34125,Serum creatinine levels,Disease
34136,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Disease
34137,Medication use (drugs used in diabetes),Disease
34139,BMI at 8 months old,Disease
34141,BMI at 1 year old,Disease
34147,BMI at 2 years old,Disease
34148,BMI at 3 years old,Disease
34149,BMI at 7 years old,Disease
34150,BMI at 1.5 years old,Disease
34151,BMI at 8 years old,Disease
34152,Medication use (immunosuppressants),Disease
34155,"Medication use (anti-inflammatory and antirheumatic products, non-steroids)",Disease
34156,Medication use (drugs affecting bone structure and mineralization),Disease
34158,Medication use (salicylic acid and derivatives),Disease
34161,Medication use (anilides),Disease
34162,Medication use (antimigraine preparations),Disease
34165,Medication use (thyroid preparations),Disease
34168,Executive function (longitudinal),Disease
34170,Executive function,Disease
34175,Cognitive performance (visuoconstruction) (longitudinal),Disease
34179,Cognitive performance (visuoconstruction),Disease
34190,Vaginal microbiome MetaCyc pathway (PWY-5507|adenosylcobalamin biosynthesis I (early cobalt insertion)),Disease
34192,Vaginal microbiome MetaCyc pathway (PWY-5856|ubiquinol-9 biosynthesis (prokaryotic)),Disease
34194,Vaginal microbiome MetaCyc pathway (PWY-5857|ubiquinol-10 biosynthesis (prokaryotic)),Disease
34195,Vaginal microbiome MetaCyc pathway (PWY-5415|catechol degradation I (meta-cleavage pathway)),Disease
34201,Vaginal microbiome MetaCyc pathway (PWY-5705|allantoin degradation to glyoxylate III),Disease
34205,Vaginal microbiome MetaCyc pathway (PWY-5741|ethylmalonyl-CoA pathway),Disease
34208,Vaginal microbiome MetaCyc pathway (PWY-5860|superpathway of demethylmenaquinol-6 biosynthesis I),Disease
34209,Vaginal microbiome MetaCyc pathway (PWY-5861|superpathway of demethylmenaquinol-8 biosynthesis),Disease
34210,Vaginal microbiome MetaCyc pathway (PWY-5845|superpathway of menaquinol-9 biosynthesis),Disease
34212,Vaginal microbiome MetaCyc pathway (PWY-5850|superpathway of menaquinol-6 biosynthesis I),Disease
34213,Vaginal microbiome MetaCyc pathway (PWY-5855|ubiquinol-7 biosynthesis (prokaryotic)),Disease
34214,Vaginal microbiome MetaCyc pathway (PWY-5862|superpathway of demethylmenaquinol-9 biosynthesis),Disease
34215,Estimated glomerular filtration rate (cystatin c),Disease
34217,Vaginal microbiome MetaCyc pathway (PWY0-1241|ADP-L-glycero-beta;-D-manno-heptose biosynthesis),Disease
34219,Vaginal microbiome MetaCyc pathway (PWY0-1261|anhydromuropeptides recycling),Disease
34220,Vaginal microbiome MetaCyc pathway (PWY0-1298|superpathway of pyrimidine deoxyribonucleosides degradation),Disease
34221,Vaginal microbiome MetaCyc pathway (PWY0-1533|methylphosphonate degradation I),Disease
34222,Vaginal microbiome MetaCyc pathway (PWY0-162|superpathway of pyrimidine ribonucleotides de novo biosynthesis),Disease
34224,Vaginal microbiome MetaCyc pathway (PWY0-166|superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E. coli)),Disease
34229,Vaginal microbiome MetaCyc pathway (PWY0-1479|tRNA processing),Disease
34244,Vaginal microbiome relative abundance (s_Megasphaera genomosp type 1),Disease
34247,Vaginal microbiome relative abundance (s_Prevotella bivia),Disease
34248,Vaginal microbiome relative abundance (s_Peptoniphilus vaginalis),Disease
34250,Vaginal microbiome relative abundance (pleiotropy),Disease
34252,BMI at 6 months old,Disease
34260,BMI at birth,Disease
34261,BMI at 3 months old,Disease
34262,Myalgic encephalomyelitis / chronic fatigue syndrome,Disease
34264,Log white blood cell count in acute lymphoblastic leukemia,Disease
34266,Spline residuals of log white blood cell count in acute lymphoblastic leukemia,Disease
34269,Cognitive performance (attention) (longitudinal),Disease
34273,Medication use (HMG CoA reductase inhibitors),Disease
34287,Breast cancer x TP53 mutation interaction,Disease
34289,Breast cancer x TP53 gain of function mutation interaction,Disease
34299,Depression (age of onset),Disease
34302,"Vaginal microbiome MetaCyc pathway (PWY-7159|chlorophyllide a biosynthesis III (aerobic, light independent))",Disease
34303,"Vaginal microbiome MetaCyc pathway (PWY-7013|L-1,2-propanediol degradation)",Disease
34305,Vaginal microbiome MetaCyc pathway (PWY-7094|fatty acid salvage),Disease
34306,Vaginal microbiome MetaCyc pathway (TEICHOICACID-PWY|teichoic acid (poly-glycerol) biosynthesis),Disease
34307,Vaginal microbiome MetaCyc pathway (RUMP-PWY|formaldehyde oxidation I),Disease
34309,Vaginal microbiome MetaCyc pathway (PYRIDOXSYN-PWY|pyridoxal 5'-phosphate biosynthesis I),Disease
34311,Cutaneous melanoma (MTAG),Disease
34318,Medication use (agents acting on the renin-angiotensin system),Disease
34349,Regional cortical thickness (medialorbitofrontal),Disease
34350,Regional cortical thickness (parahippocampal),Disease
34351,Regional cortical thickness (inferiorparietal),Disease
34353,Regional cortical thickness (lingual),Disease
34354,Regional cortical thickness (lateraloccipital),Disease
34355,Vaginal microbiome MetaCyc pathway (PWY-6151|S-adenosyl-L-methionine cycle I),Disease
34357,Vaginal microbiome MetaCyc pathway (PWY-621|sucrose degradation III (sucrose invertase)),Disease
34358,Vaginal microbiome MetaCyc pathway (PWY-6123|inosine-5'-phosphate biosynthesis I),Disease
34360,Vaginal microbiome MetaCyc pathway (PWY-6125|superpathway of guanosine nucleotides de novo biosynthesis II),Disease
34361,Vaginal microbiome MetaCyc pathway (PWY-6700|queuosine biosynthesis),Disease
34362,Vaginal microbiome MetaCyc pathway (PWY-6277|superpathway of 5-aminoimidazole ribonucleotide biosynthesis),Disease
34364,Vaginal microbiome MetaCyc pathway (PWY-5863|superpathway of phylloquinol biosynthesis),Disease
34366,Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis),Disease
34367,Vaginal microbiome MetaCyc pathway (PWY-5897|superpathway of menaquinol-11 biosynthesis),Disease
34368,Vaginal microbiome MetaCyc pathway (PWY-5899|superpathway of menaquinol-13 biosynthesis),Disease
34369,Vaginal microbiome MetaCyc pathway (PWY490-3|nitrate reduction VI (assimilatory)),Disease
34371,Vaginal microbiome MetaCyc pathway (PYRIDNUCSAL-PWY|NAD salvage pathway I),Disease
34372,Vaginal microbiome MetaCyc pathway (PYRIDNUCSYN-PWY|NAD biosynthesis I (from aspartate)),Disease
34373,Vaginal microbiome MetaCyc pathway (PWY0-321|phenylacetate degradation I (aerobic)),Disease
34385,Vaginal microbiome MetaCyc pathway (PWY0-42|2-methylcitrate cycle I),Disease
34387,Vaginal microbiome MetaCyc pathway (PWY0-862|(5Z)-dodec-5-enoate biosynthesis),Disease
34389,Vaginal microbiome MetaCyc pathway (PWY1G-0|mycothiol biosynthesis),Disease
34392,Pseudouridine levels,Disease
34394,Medication use (calcium channel blockers),Disease
34400,High-density lipoprotein mediated cholesterol efflux capacity,Disease
34401,White matter lesions (Fazekas score),Disease
34404,Left hippocampal volume,Disease
34407,Global cognition (Mini Mental State Examination) (longitudinal),Disease
34418,Facial wrinkles (under eye),Disease
34421,Sib-shared facial trait 757; Facial segment 37; 3D morphology of the philtrium,Disease
34423,Sib-shared facial trait 782; Facial segment 40; 3D morphology of the nose sides,Disease
34425,Sib-shared facial trait 788; Facial segment 42; 3D morphology of the nose sides,Disease
34426,Sib-shared facial trait 823; Facial segment 44; 3D morphology of the nose apex,Disease
34428,Sib-shared facial trait 835; Facial segment 45; 3D morphology of the nose alae,Disease
34430,Sib-shared facial trait 869; Facial segment 50; 3D morphology of the cheeks,Disease
34432,Inosine levels,Disease
34433,Isobutyrylcarnitine (c4) levels,Disease
34434,Ornithine levels (Metabolon platform),Disease
34436,Regional cortical thickness (frontalpole),Disease
34438,Regional cortical thickness (insula),Disease
34439,"Vaginal microbiome MetaCyc pathway (PWY-5837|1,4-dihydroxy-2-naphthoate biosynthesis I)",Disease
34441,Vaginal microbiome MetaCyc pathway (PWY-5838|superpathway of menaquinol-8 biosynthesis I),Disease
34445,Vaginal microbiome MetaCyc pathway (PWY-5840|superpathway of menaquinol-7 biosynthesis),Disease
34450,Vaginal microbiome MetaCyc pathway (PWY-5747|2-methylcitrate cycle II),Disease
34452,Vaginal microbiome MetaCyc pathway (PWY-5695|urate biosynthesis/inosine 5'-phosphate degradation),Disease
34458,Vaginal microbiome MetaCyc pathway (PWY-7539|6-hydroxymethyl-dihydropterin diphosphate biosynthesis III (Chlamydia)),Disease
34460,Vaginal microbiome MetaCyc pathway (PWY-7664|oleate biosynthesis IV (anaerobic)),Disease
34462,Vaginal microbiome MetaCyc pathway (PWY-7373|superpathway of demethylmenaquinol-6 biosynthesis II),Disease
34471,"Medication use (adrenergics, inhalants)",Disease
34474,Cognitive performance (language ability) (longitudinal),Disease
34477,Medication use (antihistamines for systemic use),Disease
34478,Medication use (antiglaucoma preparations and miotics),Disease
34479,Cognitive function (delayed memory) (longitudinal),Disease
34481,Cognitive function (delayed memory),Disease
34485,Cognitive function (immediate memory),Disease
34490,Medication use (glucocorticoids),Disease
34501,Regional cortical thickness (entorhinal),Disease
34502,Regional cortical thickness (fusiform),Disease
34503,Regional cortical thickness (caudalmiddlefrontal),Disease
34505,Global cortical thickness (GlobalMeanMean),Disease
34507,Tyrosine levels (Biocrates platform),Disease
34509,Threonine levels (Metabolon platform),Disease
34511,Oleoylcarnitine levels (Metabolon platform),Disease
34513,1-palmitoleoylglycerophosphocholine levels (Metabolon platform),Disease
34515,X-11469 levels,Disease
34517,X-12798 levels,Disease
34518,X-13435 levels,Disease
34520,X-14086 levels,Disease
34522,Sib-shared facial trait 891; Facial segment 52; 3D morphology of the outer cheeks,Disease
34524,Sib-shared facial trait 920; Facial segment 56; 3D morphology of the middle forehead,Disease
34526,Sib-shared facial trait 1000; Facial segment 60; 3D morphology of the eye sockets,Disease
34528,Elevated alanine aminotransferase and aspartate aminotransferase levels in acute lymphoblastic leukemia,Disease
34545,Vaginal microbiome MetaCyc pathway (PWY-7328|superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis),Disease
34547,"Vaginal microbiome MetaCyc pathway (PWY-7237|myo-, chiro- and scillo-inositol degradation)",Disease
34549,Vaginal microbiome MetaCyc pathway (PWY-7242|D-fructuronate degradation),Disease
34550,Vaginal microbiome MetaCyc pathway (PWY-7219|adenosine ribonucleotides de novo biosynthesis),Disease
34552,Vaginal microbiome MetaCyc pathway (PWY-7220|adenosine deoxyribonucleotides de novo biosynthesis II),Disease
34554,Vaginal microbiome MetaCyc pathway (PWY-7222|guanosine deoxyribonucleotides de novo biosynthesis II),Disease
34555,"Vaginal microbiome MetaCyc pathway (PWY-7371|1,4-dihydroxy-6-naphthoate biosynthesis II)",Disease
34559,Vaginal microbiome MetaCyc pathway (UBISYN-PWY|superpathway of ubiquinol-8 biosynthesis (prokaryotic)),Disease
34560,Vaginal microbiome presence (c_Actinobacteria),Disease
34563,Vaginal microbiome presence (s_Dialister micraerophilus),Disease
34564,Vaginal microbiome presence (s_Lactobacillus mulieris),Disease
34566,Vaginal microbiome presence (f_Mycoplasmataceae),Disease
34567,Vaginal microbiome presence (g_Dialister),Disease
34568,Vaginal microbiome presence (g_Megasphaera),Disease
34569,Vaginal microbiome presence (p_Proteobacteria),Disease
34570,Vaginal microbiome presence (s_Aerococcus christensenii),Disease
34572,Vaginal microbiome relative abundance (f_Lachnospiraceae),Disease
34576,Vaginal microbiome relative abundance (c_Gammaproteobacteria),Disease
34577,Vaginal microbiome relative abundance (f_Aerococcaceae),Disease
34578,Facial skin elasticity,Disease
34581,Facial skin melanin,Disease
34583,Facial skin gloss,Disease
34589,Biological age (PhenoAge),Disease
34598,Global cognition (Mini Mental State Examination),Disease
34603,Cognitive function (immediate memory) (longitudinal),Disease
34621,Regional cortical thickness (superiorfrontal),Disease
34622,Sib-shared facial trait 524; Facial segment 18; 3D morphology of the philtrium,Disease
34624,Sib-shared facial trait 528; Facial segment 18; 3D morphology of the philtrium,Disease
34626,Sib-shared facial trait 232; Facial segment 5; 3D morphology of the nose,Disease
34628,Sib-shared facial trait 25; Facial segment 1; 3D morphology of the full face,Disease
34630,Sib-shared facial trait 247; Facial segment 6; 3D morphology of the lower face,Disease
34632,Sib-shared facial trait 263; Facial segment 6; 3D morphology of the lower face,Disease
34634,Sib-shared facial trait 283; Facial segment 7; 3D morphology of the upper face,Disease
34636,Sib-shared facial trait 347; Facial segment 9; 3D morphology of the upper lip,Disease
34638,"Sib-shared facial trait 159; Facial segment 3; 3D morphology of the upper and lower face, excluding the nose",Disease
34640,Sib-shared facial trait 84; Facial segment 1; 3D morphology of the full face,Disease
34642,Sib-shared facial trait 290; Facial segment 7; 3D morphology of the upper face,Disease
34644,Regional cortical thickness (superiorparietal),Disease
34645,Sib-shared facial trait 531; Facial segment 19; 3D morphology of the upper vermillion,Disease
34648,Regional cortical thickness (rostralanteriorcingulate),Disease
34650,Regional cortical thickness (rostralmiddlefrontal),Disease
34651,Regional cortical thickness (superiortemporal),Disease
34653,Regional cortical thickness (supramarginal),Disease
34654,Regional cortical thickness (precentral),Disease
34655,Regional cortical thickness (precuneus),Disease
34656,Acid sphingomyelinase-like phosphodiesterase 3a levels,Disease
34658,"Vascular endothelial growth factor A, isoform 121 levels",Disease
34659,alpha-2-macroglobulin receptor-associated protein levels,Disease
34671,Oxaliplatin-induced peripheral sensory neuropathy in colon cancer,Disease
34673,Time to recovery from peripheral sensory neuropathy in colon cancer,Disease
34676,Oxaliplatin-induced allergic reactions in colon cancer,Disease
34684,Intracranial germ cell tumors,Disease
34693,"Advanced glycosylation end product-specific receptor, soluble levels",Disease
34695,Complement factor B levels,Disease
34697,Cation-independent mannose-6-phosphate receptor levels,Disease
34704,Plasminogen levels,Disease
34709,ICD10 K44: Diaphragmatic hernia,Disease
34711,Time to colon cancer recurrence,Disease
34719,Retinoic acid receptor responder protein 2 levels,Disease
34736,Stem Cell Growth Factor-alpha levels,Disease
34738,Brain-specific serine protease 4 levels,Disease
34741,Complement C4 levels,Disease
34764,CD109 antigen levels,Disease
34778,Glycine levels,Disease
34780,Glycoprotein acetyls (mainly a1-acid glycoprotein),Disease
34781,Mean diameter of VLDL particles,Disease
34786,Decenoylcarnitine levels,Disease
34788,Decanoylcarnitine levels,Disease
34790,Butyrylcarnitine levels,Disease
34791,Sarcosine levels,Disease
34793,Dodecanoylcarnitine levels,Disease
34796,Octanoylcarnitine levels,Disease
34797,Propionylcarnitine levels,Disease
34798,Dodecenoylcarnitine levels,Disease
34799,Tetradecenoylcarnitine levels,Disease
34800,QTc interval,Disease
34815,F-savour/caloric food liking (derived food-liking factor),Disease
34816,F-seafood liking (derived food-liking factor),Disease
34831,F-savoury food liking (derived food-liking factor),Disease
34833,Salmon liking,Disease
34834,Sardines liking,Disease
34841,F-sharp flavour liking (derived food-liking factor),Disease
34842,F-small fish liking (derived food-liking factor),Disease
34845,Shellfish liking,Disease
34870,Oral corticosteroid burst in asthma,Disease
34879,Asthma exacerbations in inhaled corticosteroid treatment,Disease
34888,Germline telomere length in neuroblastoma,Disease
34890,Serum uromodulin levels (antibody-based assay),Disease
34892,Serum uromodulin levels (aptamer-based assay),Disease
34904,COVID-19 (hospitalized vs population),Disease
34905,SARS-CoV-2 infection,Disease
34907,Environmental pollutants exposure (AC50 low),Disease
34910,Environmental pollutants exposure (AC50 high),Disease
34913,Cadmium chloride levels,Disease
34914,Chlorpyrifos levels,Disease
34915,Di-n-butyl phthalate levels,Disease
34916,Diazinon levels,Disease
34917,Nickel levels,Disease
34918,Pentachlorophenol levels,Disease
34919,Parathion levels,Disease
34921,Ideal cardiovascular health score (clinical and behavioral),Disease
34923,Ideal cardiovascular health (clinical and behavioral),Disease
34924,alpha-Aminoadipic acid levels,Disease
34928,Environmental pollutants exposure (POD high),Disease
34929,Environmental pollutants exposure (POD low),Disease
34935,Environmental pollutants exposure (Expo high),Disease
34936,Endrin levels,Disease
34937,Ethion levels,Disease
34938,Endosulfan levels,Disease
34943,Heptachlor levels,Disease
34945,Environmental pollutants exposure (Expo low),Disease
34948,Lithium clearance,Disease
34950,Heptachlor epoxide levels,Disease
34951,Mercuric chloride levels,Disease
34952,Methoxychlor levels,Disease
34953,Mercuric chloride-2 levels,Disease
34954,Cardioembolic stroke (MTAG),Disease
34957,"2,4,5-trichlorophenol levels",Disease
34960,Aldrin levels,Disease
34961,Azinphos methyl levels,Disease
34963,DDT metabolite (DDD p-p') levels,Disease
34964,DDT metabolite (DDT o-p') levels,Disease
34965,DDT metabolite (DDT p-p') levels,Disease
34968,"4,6-dinitro-o-cresol levels",Disease
34969,"2,4,5-trichlorophenol-2 levels",Disease
34973,Cobalt levels,Disease
34975,Disulfoton levels,Disease
34976,Dieldrin levels,Disease
34977,Dicofol levels,Disease
34984,Potassium chromate levels,Disease
34985,Atrial fibrillation (MTAG),Disease
34989,Environmental pollutants exposure (RfD high),Disease
34990,Environmental pollutants exposure (RfD low),Disease
35006,A body shape index,Disease
35008,Sex hormone-binding globulin levels adjusted for BMI,Disease
35009,Coffee consumption (cups per day),Disease
35010,"Gastroesophageal reflux disease, peptic ulcer disease and/or corresponding medications and treatment",Disease
35011,Irritable bowel syndrome,Disease
35012,Mouth ulcers,Disease
35020,Total testosterone levels,Disease
35023,Digit length ratio (right hand),Disease
35024,Digit length ratio (left hand),Disease
35025,Cerebrospinal fluid p-Tau181p:AB1-42 ratio,Disease
35026,Adult body size,Disease
35027,IgM levels,Disease
35028,IgG levels,Disease
35029,Diverticular disease,Disease
35030,Anti-sp100 seropositivity in primary biliary cholangitis,Disease
35031,Cognitive function in longevity,Disease
35032,Systolic blood pressure (baseline),Disease
35033,Systolic blood pressure change trajectory,Disease
35034,Autoimmune pulmonary alveolar proteinosis,Disease
35036,Well-being spectrum (multivariate analysis),Disease
35037,Triiodothyronine levels and thyroxine levels,Disease
35038,Carpal tunnel syndrome,Disease
35039,Hand grip strength,Disease
35040,Cognitive impairment test score,Disease
35042,Diastolic blood pressure change trajectory,Disease
35043,Academic attainment (maths),Disease
35044,Cirrhosis (alcohol related),Disease
35046,Diastolic blood pressure (long-term average),Disease
35047,Academic attainment (science),Disease
35049,Metabolically unhealthy in obesity,Disease
35050,Metabolically unhealthy in normal weight,Disease
35051,Cutaneous leishmaniasis,Disease
35061,joint destruction in rheumatoid arthritis (rapid vs slow),Disease
35062,Hypertrophic cardiomyopathy,Disease
35063,Lack of behavioral control,Disease
35064,Frontal fibrosing alopecia,Disease
35066,Alcohol use disorder (consumption score),Disease
35067,Serum urate levels in chronic kidney disease,Disease
35070,Ferritin levels,Disease
35071,Declining hemoglobin trajectory in blood donors,Disease
35080,BRCA1/2-negative high-risk breast cancer,Disease
35081,Hip shape (DXA scan),Disease
35082,Addison's disease,Disease
35085,Vesicoureteral reflux,Disease
35086,Early age-related macular degeneration,Disease
35088,Facial pigmentation measurement (UV light),Disease
35089,Facial pigmentation measurement (polar light),Disease
35090,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)(time to event),Disease
35091,Response to tofacitinib treatment in psoriasis (herpes zoster)(time to event),Disease
35092,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster),Disease
35093,Response to tofacitinib treatment in psoriasis (herpes zoster),Disease
35094,Response to tofacitinib treatment (herpes zoster)(time to event),Disease
35095,Response to tofacitinib treatment (herpes zoster),Disease
35096,Ulna and radius bone mineral density,Disease
35097,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma,Disease
35099,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,Disease
35100,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy",Disease
35101,Asthma with severe exacerbations,Disease
35102,Diverticulitis,Disease
35103,Bipolar disorder or ulcerative colitis (MTAG),Disease
35106,Bipolar disorder or inflammatory bowel disease (MTAG),Disease
35108,2-hydroxyadipate levels,Disease
35110,Eukaryotic elongation factor 2 kinase levels,Disease
35112,Tapasin levels,Disease
35114,Proteasome subunit beta type-1 levels,Disease
35116,"NAD-dependent protein deacylase sirtuin-5, mitochondrial levels",Disease
35121,Chloride intracellular channel protein 5 levels,Disease
35123,Integrin beta-2 levels,Disease
35124,Histone deacetylase complex subunit SAP30 levels,Disease
35133,Migraine with aura (age at onset),Disease
35135,Interleukin-17B (analyte X3499.77) levels,Disease
35139,Epididymis-specific alpha-mannosidase levels,Disease
35140,Triggering receptor expressed on myeloid cells 1 levels,Disease
35142,Cation-independent mannose-6-phosphate receptor (analyte X3676.15) levels,Disease
35143,Membrane frizzled-related protein levels,Disease
35146,Butyrophilin subfamily 2 member A1 levels,Disease
35148,N-acetylglucosamine-6-sulfatase (analyte X3616.3) levels,Disease
35151,Lymphocyte antigen 86 levels,Disease
35155,SLAM family member 5 (analyte X3642.4) levels,Disease
35157,Thrombospondin-2 (analyte X3339.33) levels,Disease
35159,Tryptase beta-2 (analyte X3403.1) levels,Disease
35161,Granzyme A (analyte X3440.7) levels,Disease
35163,Severe coronary stenosis (family history of CAD interaction),Disease
35164,Severe coronary stenosis,Disease
35166,Lung adenocarcinoma (conditioned on cigarettes per day),Disease
35167,Squamous cell lung carcinoma (conditioned on cigarettes per day),Disease
35168,Lung cancer (conditioned on cigarettes per day),Disease
35170,Methazolamide-induced Stevens-Johnson syndrome / toxic epidermal necrolysis,Disease
35181,FAD-linked sulfhydryl oxidase ALR levels,Disease
35183,Otoraplin levels,Disease
35185,"Neuregulin-1, sensory and motor neuron-derived factor isoform levels",Disease
35186,5'-Nucleotidase (analyte X15452.5) levels,Disease
35188,T-cell surface glycoprotein CD8 alpha chain (analyte X15462.28) levels,Disease
35189,Collagen alpha-1(IX) chain (analyte X15466.30) levels,Disease
35191,Low-density lipoprotein receptor-related protein 11 (analyte X15472.16) levels,Disease
35193,Vascular non-inflammatory molecule 2 (analyte X15480.2) levels,Disease
35195,Cation-independent mannose-6-phosphate receptor (analyte X16057.6) levels,Disease
35197,Nidogen-2 (analyte X16060.99) levels,Disease
35199,Triggering receptor expressed on myeloid cells 2 (analyte X16300.4) levels,Disease
35200,Syndecan-3 levels,Disease
35202,Ephrin type-A receptor 7 (analyte X15580.2) levels,Disease
35204,Myelin-oligodendrocyte glycoprotein levels,Disease
35205,Prostasin (analyte X15513.108) levels,Disease
35207,M.tuberculosis induced TNF-a level,Disease
35209,S.typhi induced IL-10 level,Disease
35212,S.typhi induced IL-1B level,Disease
35214,S.pneumoniae induced IL-1B level,Disease
35216,S.pneumoniae induced IL-6 level,Disease
35218,S.pneumoniae induced TNF-a level,Disease
35220,LPS induced IL-1B level,Disease
35222,S.enteritidis induced IFN-G level,Disease
35224,Protein disulfide-isomerase A3 (analyte X7832.181) levels,Disease
35226,S-arrestin levels,Disease
35228,Double C2-like domain-containing protein beta levels,Disease
35230,"Glycoprotein endo-alpha-1,2-mannosidase levels",Disease
35232,"Ferritin, mitochondrial levels",Disease
35233,N-acetylated-alpha-linked acidic dipeptidase 2 levels,Disease
35234,Chronic obstructive pulmonary disease in non-current smokers,Disease
35235,Schizophrenia vs bipolar disorder (ordinary least squares (OLS)),Disease
35237,Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Disease
35239,Neuferricin levels,Disease
35240,"39S ribosomal protein L55, mitochondrial levels",Disease
35242,P-selectin glycoprotein ligand 1:Extracellular domain levels,Disease
35245,Collagen alpha-2(XI) chain levels,Disease
35247,Cyclic AMP-responsive element-binding protein 3-like protein 4 levels,Disease
35251,Cyclic AMP-dependent transcription factor ATF-6 beta levels,Disease
35253,Hepatitis A virus cellular receptor 2 (analyte X11481.25) levels,Disease
35255,"Signal peptide, CUB and EGF-like domain-containing protein 3 levels",Disease
35257,Sphingomyelin phosphodiesterase levels,Disease
35259,Secretagogin (analyte X10894.25) levels,Disease
35261,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels,Disease
35262,Thioredoxin domain-containing protein 5 levels,Disease
35264,Zymogen granule protein 16 homolog B levels,Disease
35266,Low-density lipoprotein receptor-related protein 11 (analyte X8330.1) levels,Disease
35267,Uronyl 2-sulfotransferase levels,Disease
35269,Allograft inflammatory factor 1 levels,Disease
35270,Olfactomedin-like protein 3 (analyte X8660.33) levels,Disease
35272,Dipeptidase 1 (analyte X8794.13) levels,Disease
35274,Myeloid cell surface antigen CD33 levels,Disease
35276,Natural cytotoxicity triggering receptor 3 levels,Disease
35277,Agouti-related protein levels,Disease
35279,Delta-like protein 1 (analyte X8264.43) levels,Disease
35281,Alpha-L-iduronidase levels,Disease
35282,Lysosomal protective protein levels,Disease
35283,Complement C2 levels,Disease
35285,"WAP, kazal, immunoglobulin, kunitz and NTR domain-containing protein 1 levels",Disease
35287,melanoma-derived growth regulatory protein levels,Disease
35289,NKG2D ligand 3 levels,Disease
35293,Inguinal hernia,Disease
35295,Bipolar disorder or Crohn's disease (MTAG),Disease
35301,Intestinal permeability measurement,Disease
35302,Creutzfeldt-Jakob disease (sporadic),Disease
35303,Schizophrenia vs autism spectrum disorder (ordinary least squares (OLS)),Disease
35304,Diphosphomevalonate decarboxylase (analyte X19748.3) levels,Disease
35306,"Acylpyruvase FAHD1, mitochondrial levels",Disease
35308,Charged multivesicular body protein 1a levels,Disease
35309,"Hydroxyacylglutathione hydrolase, mitochondrial levels",Disease
35311,"Enoyl-CoA delta isomerase 1, mitochondrial levels",Disease
35313,Retinoic acid early transcript 1L protein (analyte X20526.3) levels,Disease
35315,Nuclear apoptosis-inducing factor 1 levels,Disease
35317,Desmoglein-2 (analyte X20517.1) levels,Disease
35318,Gastric intrinsic factor levels,Disease
35320,Tripeptidyl-peptidase 1 levels,Disease
35322,Butyrophilin subfamily 3 member A3 (analyte X17692.2) levels,Disease
35324,Microtubule-associated proteins 1A/1B light chain 3A levels,Disease
35325,"Succinate-semialdehyde dehydrogenase, mitochondrial levels",Disease
35327,Phosphomannomutase 2 levels,Disease
35329,Valacyclovir hydrolase levels,Disease
35331,Glycerol-3-phosphate phosphatase levels,Disease
35332,Promotilin levels,Disease
35334,Triggering receptor expressed on myeloid cells 2 (analyte X5635.66) levels,Disease
35335,Chymotrypsinogen B2 levels,Disease
35338,Endophilin-A3 (analyte X23029.3) levels,Disease
35339,AN1-type zinc finger protein 2B levels,Disease
35340,Vasorin levels,Disease
35341,Cysteine-rich secretory protein LCCL domain-containing 2 levels,Disease
35343,Tenascin-X levels,Disease
35345,Trem-like transcript 2 protein levels,Disease
35346,Colipase levels,Disease
35348,T-cell surface glycoprotein CD8 alpha chain (analyte X5992.50) levels,Disease
35349,Paraneoplastic antigen Ma2 levels,Disease
35356,Glutathione S-transferase A2 levels,Disease
35380,Suicide attempt severity in mood disorders,Disease
35381,Suicidality in mood disorders,Disease
35386,Serpin B9 levels,Disease
35388,Alpha-L-fucoside fucohydrolase levels,Disease
35389,L-dopachrome tautomerase levels,Disease
35390,Shadow of prion protein levels,Disease
35392,Killer cell immunoglobulin-like receptor 2DS2 levels,Disease
35394,Apolipoprotein M (analyte X10445.20) levels,Disease
35396,Interleukin-18 receptor accessory protein (analyte X10457.3) levels,Disease
35398,Splicing factor U2AF 65 kDa subunit levels,Disease
35400,Rac GTPase-activating protein 1 levels,Disease
35403,Plexin domain-containing protein 2:Extracellular domain levels,Disease
35405,Retinoic acid early transcript 1L protein (analyte X10589.7) levels,Disease
35407,Protein Mdm4 levels,Disease
35409,N-acetylglucosamine-1-phosphotransferase subunit gamma levels,Disease
35411,Leukocyte elastase inhibitor levels,Disease
35416,Immunoglobulin D levels,Disease
35417,Neuropeptide W levels,Disease
35419,Protein FAM110A (analyte X22371.46) levels,Disease
35421,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X4771.10) levels,Disease
35422,CD83 antigen levels,Disease
35424,MHC class I polypeptide-related sequence B levels,Disease
35429,Reticulon-4 receptor levels,Disease
35430,Platelet-activating factor acetylhydrolase levels,Disease
35432,Lactoylglutathione lyase levels,Disease
35434,Peptidyl-prolyl cis-trans isomerase-like 1 levels,Disease
35435,Unconventional myosin-VI levels,Disease
35437,Complement C4b levels,Disease
35440,Ras association domain-containing protein 2 levels,Disease
35442,Delta-like protein 1 (analyte X5349.69) levels,Disease
35446,Bipolar disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Disease
35447,Anorexia nervosa vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Disease
35448,Autism spectrum disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Disease
35449,ADHD vs anorexia nervosa (ordinary least squares (OLS)),Disease
35451,Ultradistal forearm bone mineral density,Disease
35452,Laminin-2 levels,Disease
35454,C4a anaphylatoxin levels,Disease
35458,Interleukin-17B (analyte X14022.17) levels,Disease
35459,Fibroblast growth factor 7 (analyte X14031.18) levels,Disease
35460,Interleukin-15 receptor subunit alpha (analyte X14054.17) levels,Disease
35461,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X14086.11) levels,Disease
35463,Thrombospondin-2 (analyte X14111.15) levels,Disease
35465,Tumor necrosis factor receptor superfamily member 10D levels,Disease
35467,Apolipoprotein M (analyte X14125.5) levels,Disease
35469,Interleukin-36 alpha levels,Disease
35472,Homeobox protein SIX6 levels,Disease
35473,Uncharacterized metallophosphoesterase CSTP1 levels,Disease
35475,Adhesion G-protein coupled receptor G1 levels,Disease
35477,Tryptase beta-2 (analyte X14696.45) levels,Disease
35479,Secretagogin (analyte X15305.7) levels,Disease
35481,Thioredoxin-like protein 4B levels,Disease
35482,Prolyl endopeptidase levels,Disease
35484,Ras-related protein Rab-14 levels,Disease
35485,Stromal cell-derived factor 2-like protein 1 levels,Disease
35488,"Protein G6b:Isoform A, Extracellular domain levels",Disease
35492,IGF-like family receptor 1 levels,Disease
35494,Protein-methionine sulfoxide oxidase MICAL1 levels,Disease
35495,Nodal modulator 2 levels,Disease
35497,"HLA class II histocompatibility antigen, DQ alpha 2 chain levels",Disease
35501,DnaJ homolog subfamily B member 11 levels,Disease
35503,C->U-editing enzyme APOBEC-2 levels,Disease
35504,Inactive pancreatic lipase-related protein 1 levels,Disease
35506,Low-density lipoprotein receptor-related protein 11 (analyte X6713.4) levels,Disease
35508,Hemoglobin subunit zeta levels,Disease
35510,GDNF family receptor alpha-like levels,Disease
35512,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 levels",Disease
35513,Hepatitis A virus cellular receptor 2 (analyte X7152.5) levels,Disease
35514,GDH/6PGL endoplasmic bifunctional protein levels,Disease
35517,Liver carboxylesterase 1 (analyte X7182.1) levels,Disease
35518,Leucine-rich repeat and fibronectin type-III domain-containing protein 2 levels,Disease
35520,Tuberoinfundibular peptide of 39 residues levels,Disease
35521,Cadherin-1 (analyte X2501.51) levels,Disease
35523,NADP-dependent malic enzyme levels,Disease
35535,Sun-seeking behavior,Disease
35536,Crohn's disease vs rheumatoid arthritis (ordinary least squares (OLS)),Disease
35537,"Acetyl-CoA acetyltransferase, cytosolic levels",Disease
35539,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 levels,Disease
35541,Killer cell immunoglobulin-like receptor 2DL3 levels,Disease
35543,Lysosome-associated membrane glycoprotein 1 levels,Disease
35544,Ribonuclease T2 levels,Disease
35546,GMP reductase 1 levels,Disease
35548,Daily alcohol intake x rs671 interaction (2df),Disease
35549,Alcohol drinking status x rs671 interaction (2df),Disease
35550,Butyrophilin subfamily 3 member A2 levels,Disease
35556,Transcription initiation factor IIA subunit 2 levels,Disease
35557,Butyrophilin subfamily 3 member A3 (analyte X22950.6) levels,Disease
35561,NKG2D ligand 2 (analyte X22583.47) levels,Disease
35562,Butyrophilin subfamily 2 member A2 levels,Disease
35566,N-acetylgalactosamine-6-sulfatase levels,Disease
35568,Glutamate carboxypeptidase 2 (analyte X5478.50) levels,Disease
35570,Clinical depression,Disease
35578,Angiostatin levels,Disease
35579,Heat shock 70 kDa protein 1A (analyte X4124.24) levels,Disease
35581,Methyltransferase-like protein 24 levels,Disease
35583,Desmoglein-2 (analyte X9484.75) levels,Disease
35586,72 kDa type IV collagenase levels,Disease
35588,Cysteine-rich secretory protein 2 levels,Disease
35591,Peptidyl-prolyl cis-trans isomerase FKBP7 levels,Disease
35595,Fibroblast growth factor 7 (analyte X4487.1) levels,Disease
35596,Interleukin-34 levels,Disease
35598,Carbohydrate sulfotransferase 6 levels,Disease
35600,Ribosyldihydronicotinamide dehydrogenase [quinone] levels,Disease
35602,WAP four-disulfide core domain protein 1 levels,Disease
35604,Protein eyes shut homolog levels,Disease
35606,Tryptase beta-1 levels,Disease
35607,NAD(P)H dehydrogenase [quinone] 1 levels,Disease
35610,HLA-C levels,Disease
35616,Crohn's disease vs ulcerative colitis (ordinary least squares (OLS)),Disease
35617,Major depressive disorder vs ADHD (ordinary least squares (OLS)),Disease
35619,Psoriasis or type 2 diabetes (trans-disease meta-analysis),Disease
35620,Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect),Disease
35621,Childhood aggressive behavior,Disease
35625,"Stomatin-like protein 2, mitochondrial levels",Disease
35627,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels,Disease
35629,Tolloid-like protein 1 levels,Disease
35631,UPF0705 protein C11orf49 (analyte X23767.1) levels,Disease
35632,"Aspartate aminotransferase, mitochondrial (analyte X23903.3) levels",Disease
35634,SH2 domain-containing adapter protein D levels,Disease
35636,Prosaposin levels,Disease
35637,Adhesion G protein-coupled receptor F5 levels,Disease
35639,Prenylcysteine oxidase 1 levels,Disease
35641,Leukocyte immunoglobulin-like receptor subfamily B member 4 levels,Disease
35663,Symptomatic extra- and intra-cranial atherosclerotic stenosis,Disease
35666,Phosphatidylcholine-O_18:0_[M+H]1+/Lysophosphatidylethanolamine_21:0_[M+H]1+ levels,Disease
35668,Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels,Disease
35670,Gamma glutamyl transferase levels,Disease
35673,Phosphatidylcholine(36:3)_[M+H]1+/Phosphatidylethanolamine(39:3)_[M+H]1+/Phosphatidate(41:4)_[M+NH4]1+ levels,Disease
35675,Node-level brain connectivity (multivariate analysis),Disease
35679,Serum urate levels,Disease
35718,Phosphatidylcholine_38:3_[M+H]1+/Phosphatidylethanolamine_41:3_[M+H]1+/Phosphatidate_43:4_[M+NH4]1+ levels,Disease
35725,Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels,Disease
35751,Serum phosphate levels,Disease
35779,Gut bacterial pathway abundance (GLYCOCAT.PWY..glycogen.degradation.I..bacterial.),Disease
35781,Gut bacterial pathway abundance (PWY.5088..L.glutamate.degradation.VIII..to.propanoate.),Disease
35815,Phosphatidylcholine(38:3)_[M+H]1+/Phosphatidylethanolamine(41:3)_[M+H]1+/Phosphatidate(43:4)_[M+NH4]1+ levels,Disease
35823,White blood cell count (neutrophil),Disease
35826,Phosphatidylcholine(38:3)_[M+OAc]1-/Phosphatidylserine(42:2)_[M-H]1- levels,Disease
35837,Phosphatidylethanolamine(40:2)_[M-H]1- levels,Disease
35856,Phosphatidylcholine_40:6_[M+H]1+/Phosphatidylethanolamine_43:6_[M+H]1+ levels,Disease
35871,Insulin-like growth factor 1 levels,Disease
35872,Phosphatidylcholine(38:2)_[M+H]1+/Phosphatidylethanolamine(41:2)_[M+H]1+ levels,Disease
35873,Heel bone mineral density T score,Disease
35875,Direct bilirubin levels,Disease
35877,12-lead ECG morphology phenotype,Disease
35883,Depressive symptoms x dependent stressful life events interaction (1df test),Disease
35885,Depressive symptoms x independent stressful life events interaction (2df test),Disease
35887,Depressive symptoms x dependent stressful life events interaction (2df test),Disease
35888,Depressive symptoms x stressful life events interaction (1df test),Disease
35889,Depressive symptoms x stressful life events interaction (2df test),Disease
35890,Depressive symptoms x independent stressful life events interaction (1df test),Disease
35906,Edge-level brain connectivity (multivariate analysis),Disease
35910,Schizophrenia or breast cancer (pleiotropy),Disease
35911,Schizophrenia or ER positive breast cancer (pleiotropy),Disease
35916,White blood cell count (lymphocyte),Disease
35919,White blood cell count (monocyte),Disease
35942,Phosphatidylcholine_37:3_[M+OAc]1-/Phosphatidylserine_41:2_[M-H]1- levels,Disease
35943,Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels,Disease
35944,Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels,Disease
35947,Lung function (FVC) and body mass index,Disease
35953,Mean sphered cell volume,Disease
35963,Phosphatidylcholine(40:6)_[M+H]1+/Phosphatidylethanolamine(43:6)_[M+H]1+ levels,Disease
35965,Phosphatidylethanolamine_38:3_[M-H]1- levels,Disease
35972,Risky substance use,Disease
35974,Phosphatidylcholine_36:3_[M+H]1+/Phosphatidylethanolamine_39:3_[M+H]1+/Phosphatidate_41:4_[M+NH4]1+ levels,Disease
35975,Phosphatidylcholine-O(34:3)_[M+H]1+/Phosphatidylethanolamine-P(37:2)_[M+H]1+ levels,Disease
35998,Lung function (FEV1) and body mass index,Disease
36000,Cystatin C levels,Disease
36007,Phosphatidylcholine(38:6)_[M+H]1+/Phosphatidylethanolamine(41:6)_[M+H]1+ levels,Disease
36052,Cholesteryl ester(20:3)_[M+NH4]1+ levels,Disease
36092,Early-onset myasthenia gravis,Disease
36094,Diacylglycerol_38:5_[M+H-H2O]1+ levels,Disease
36108,Phosphatidylcholine_38:2_[M+H]1+/Phosphatidylethanolamine_41:2_[M+H]1+ levels,Disease
36111,Go reaction time variability,Disease
36138,Cholesteryl ester_18:3_[M+NH4]1+ levels,Disease
36139,Cholesteryl ester_20:3_[M+NH4]1+ levels,Disease
36141,Cholesteryl ester_22:6_[M+NH4]1+ levels,Disease
36142,Phosphatidylethanolamine_38:5_[M-H]1- levels,Disease
36153,Fatty acid(20:3)_[M-H]1- levels,Disease
36170,Acute myeloid leukemia or myelodysplastic syndrome (pleiotropy),Disease
36188,Externalizing behaviour (multivariate analysis),Disease
36197,Osteoarthritis of the hip or knee (with total joint replacement),Disease
36218,Body mass index and bone mineral density (pleiotropy),Disease
36248,Kidney cancer,Disease
36256,Response to erlotinib,Disease
36258,Response to trametinib,Disease
36261,Response to arsenic trioxide,Disease
36264,Response to vemurafenib,Disease
36266,Response to paclitaxel and epirubicin,Disease
36269,Response to vinblastine,Disease
36271,Hydroxycholesterol_[M+H-2H2O]1+ levels,Disease
36273,Lysophosphatidylcholine_16:0_[M+H]1+/Lysophosphatidylethanolamine_19:0_[M+H]1+ levels,Disease
36281,Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels,Disease
36305,Clear cell renal cell carcinoma,Disease
36312,Osteoarthritis (with total hip replacement),Disease
36316,Finger osteoarthritis,Disease
36320,Change in high-sensitivity cardiac troponin I concentration,Disease
36322,High-sensitivity cardiac troponin I concentration,Disease
36336,Phosphatidylinositol(40:6)_[M-H]1- levels,Disease
36347,Delayed neurodevelopment,Disease
36378,Sleepwalking,Disease
36383,Idiopathic achalasia,Disease
36387,Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels,Disease
36388,Phosphatidylcholine_34:1_[M+H]1+/Phosphatidylethanolamine_37:1_[M+H]1+/Phosphatidate_39:2_[M+NH4]1+ levels,Disease
36389,Phosphatidylcholine_34:0_[M+H]1+/Phosphatidylethanolamine_37:0_[M+H]1+/Phosphatidate_39:1_[M+NH4]1+ levels,Disease
36401,Physical activity,Disease
36404,Suicide attempt,Disease
36408,Cardiorespiratory fitness (vo2 max),Disease
36411,Vitamin D-binding protein levels (adjusted for GC haplotype),Disease
36415,Lysophosphatidylethanolamine_18:0_[M-H]1- levels,Disease
36416,Lysophosphatidylethanolamine_20:0_[M-H]1- levels,Disease
36417,Phosphatidylcholine_35:2_[M+H]1+/Phosphatidylethanolamine_38:2_[M+H]1+/Phosphatidate_40:3_[M+NH4]1+ levels,Disease
36418,Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels,Disease
36438,Human papilloma virus 16 negative oropharyngeal cancer,Disease
36440,Human papilloma virus 16 positive oropharyngeal cancer,Disease
36444,Oropharynx cancer and human papilloma virus 16 negative oropharyngeal cancer,Disease
36454,Breast cancer and/or colorectal cancer,Disease
36455,Educational attainment (MTAG),Disease
36456,Pre-treatment viral load in HIV-1 infection,Disease
36457,Velopharyngeal dysfunction,Disease
36458,Cognitive empathy,Disease
36463,"Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)",Disease
36464,Hypertrophic cardiomyopathy (sarcomere positive),Disease
36465,Hypertrophic cardiomyopathy (sarcomere negative),Disease
36466,Self-reported math ability (MTAG),Disease
36467,T cell lymphocyte profile difference,Disease
36468,Childhood body fatness,Disease
36469,Self-reported math ability,Disease
36470,Aerodigestive squamous cell cancer (pleiotropy),Disease
36471,Shigella-associated diarrhea,Disease
36472,Systolic blood pressure (education interaction),Disease
36473,Diastolic blood pressure (education interaction),Disease
36474,Adverse response to benznidazole in Chagas disease,Disease
36475,BMI x environmental factors (including physical activity) interaction,Disease
36476,BMI x  environmental factors (excluding physical activity) interaction,Disease
36477,Fever in mesalamine-treated irritable bowel disease,Disease
36478,Fever and diarrhea in mesalamine-treated irritable bowel disease,Disease
36479,Macular thickness,Disease
36480,Childhood onset ulcerative colitis,Disease
36481,Fulminant type 1 diabetes,Disease
36482,Facial morphology traits (63 three-dimensional facial segments),Disease
36483,B cell lymphocyte profile difference,Disease
36484,Cognitive performance (MTAG),Disease
36485,Sum of carotid plaque area,Disease
36486,Carotid plaque maximum area,Disease
36487,Mean area of carotid plaque,Disease
36488,Maximum stenosis,Disease
36489,Mean degree of stenosis,Disease
36490,Adiponectin levels x Mediterranean diet adherence interaction,Disease
36491,Post-traumatic stress disorder (mental health questionnaire or predicted),Disease
36494,Generalized anxiety disorder (phenotype risk score),Disease
36496,Post-traumatic stress disorder (phenotype risk score),Disease
36498,Autoimmune traits (pleiotropy),Disease
36499,Left-handedness,Disease
36500,Breast cancer in BRCA2 mutation carriers,Disease
36501,Extranodal natural killer T-cell lymphoma (nasal type),Disease
36502,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event),Disease
36503,Cellular nuclear factor (erythroid-derived 2)-like 2 levels,Disease
36504,Heart rate in heart failure with reduced ejection fraction,Disease
36505,Sero-negative rheumatoid arthritis,Disease
36506,Carotid plaque,Disease
36507,Sum of stenosis,Disease
36508,Urinary albumin excretion,Disease
36509,Poor prognosis in Crohn's disease,Disease
36510,Macular telangiectasia type 2,Disease
36511,Cannabis smoking or cigarette smoking or schizophrenia,Disease
36514,Hypo-HDL-cholesterolemia,Disease
36515,BMI at 5 years old,Disease
36516,Adult hearing difficulty,Disease
36517,Alzheimer's disease with memory domain impairment,Disease
36518,Alzheimer's disease with visuospatial domain impairment,Disease
36519,Alzheimer's disease with multiple cognitive domain impairments,Disease
36520,Alzheimer's disease with no specific cognitive domain impairment,Disease
36521,Health literacy,Disease
36522,Response to cognitive-behavioural therapy in anxiety disorder,Disease
36523,Response to cognitive-behavioural therapy in major depressive disorder,Disease
36524,Aromatic antiseizure medication-induced Stevens-Johnson syndrome or toxic epidermal necrolysis in HLA-B*15:02 non-carriers,Disease
36526,Candidemia,Disease
36527,Response to hepatitis B vaccine,Disease
36528,Sensitivity to environmental stress and adversity,Disease
36529,Sleep (number of episodes),Disease
36536,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,Disease
36562,Major depressive episode treated with electroconvulsive therapy,Disease
36563,Major depressive disorder and major depressive episode treated with electroconvulsive therapy,Disease
36564,Carotenoid levels,Disease
36565,Lipid or lipoprotein levels,Disease
36566,IgA levels,Disease
36567,Composite immunoglobulin trait (IgA/IgG),Disease
36568,Composite immunoglobulin trait (IgA/IgM),Disease
36569,Composite immunoglobulin trait (IgA x IgG x IgM),Disease
36570,Left ventricular mass to end-diastolic volume ratio,Disease
36571,Left ventricular global circumferential strain,Disease
36572,Dilated cardiomyopathy (MTAG),Disease
36573,Left ventricular global radial strain,Disease
36574,Left ventricular global longitudinal strain,Disease
36575,Hypertrophic cardiomyopathy (MTAG),Disease
36576,Sleep duration (short sleep),Disease
36577,Sleep duration (long sleep),Disease
36587,Latent autoimmune diabetes,Disease
36588,Latent autoimmune diabetes vs. type 2 diabetes,Disease
36589,Latent autoimmune diabetes vs. type 1 diabetes,Disease
36590,Seasonality and depression,Disease
36593,HDL cholesterol and triglyceride levels (pleiotropy),Disease
36594,Delayed reward discounting,Disease
36595,Plasma renin activity levels,Disease
36596,Diffusing capacity of the lung for carbon monoxide traits,Disease
36597,Upper eyelid sagging severity,Disease
36598,Initial alcohol sensitivity,Disease
36610,Waist-to-hip ratio adjusted for BMI (additive genetic model),Disease
36611,Morning person,Disease
36612,Smoking behaviour (cigarettes smoked per day),Disease
36613,Smoking cessation,Disease
36614,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,Disease
36615,Age of smoking initiation (MTAG),Disease
36616,Smoking initiation (ever regular vs never regular) (MTAG),Disease
36617,Thyroglobulin plasma levels,Disease
36618,Postoperative survival time in hepatocellular carcinoma,Disease
36619,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy),Disease
36620,Lumbar spine bone mineral density (trabecular),Disease
36621,Lumbar spine bone mineral density (integral),Disease
36622,Depression in smokers,Disease
36623,Cerebral amyloid angiopathy in APOEe4 non-carrier Alzheimers disease,Disease
36624,Cerebral amyloid angiopathy x sex interaction in Alzheimers disease,Disease
36625,Cerebral amyloid angiopathy x APOEe4 status interaction in Alzheimers disease,Disease
36626,Cerebral amyloid angiopathy in Alzheimers disease,Disease
36657,Major adverse cardiovascular events in response to aspirin and clopidogrel treatment,Disease
36671,Lymphocyte-to-monocyte ratio,Disease
36674,Neutrophil-to-lymphocyte ratio,Disease
36680,Platelet-to-lymphocyte ratio,Disease
36687,Corneal resistance factor (MTAG),Disease
36690,Central corneal thickness (MTAG),Disease
36694,Kawasaki disease or immunoglobulin A vasculitis (pleiotropy),Disease
36742,Liver stiffness changes at sustained virological response following antiviral therapy in HCV infection,Disease
36763,Intracerebral hemorrhage stroke,Disease
36765,Subcortical intracerebral hemorrhage,Disease
36767,Triglyceride to HDL cholesterol ratio,Disease
36769,Sensation seeking (measured by UPPS at 28 years),Disease
36781,Trunk lean mass,Disease
36782,Gynoid fat mass,Disease
36784,Android bone mass,Disease
36786,Right unilateral cleft lip,Disease
36787,Left unilateral cleft lip,Disease
36788,Right unilateral cleft lip and palate,Disease
36789,Left unilateral cleft lip and palate,Disease
36790,Idiopathic central precocious puberty,Disease
36793,Frailty index,Disease
36794,Nasal protrusion,Disease
36796,Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis),Disease
36799,Thoracic aortic aneurysms,Disease
36801,Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis),Disease
36808,Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis),Disease
36809,Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis),Disease
36810,Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis),Disease
36815,Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis),Disease
36816,Childhood asthma x sex interaction,Disease
36818,Recurrence-free survival in non-muscle-invasive bladder cancer,Disease
36820,Progression-free survival in non-muscle-invasive bladder cancer,Disease
36823,Hearing function,Disease
36826,Hearing function (left/right asymmetry),Disease
36856,Opioid dependence (time to event),Disease
36857,HTLV-1 associated myelopathy,Disease
36864,Wheat-dependent exercise-induced anaphylaxis,Disease
36866,Complement factor H-like 1 protein levels,Disease
36869,Complement factor H measurement,Disease
36872,Complement factor H-related protein 1 levels,Disease
36875,Complement factor H-related protein 3 levels,Disease
36878,Complement factor H-related protein 2 levels,Disease
36888,Pulmonary mycobacterium avium complex disease,Disease
36903,Complement factor H-related protein 4 levels,Disease
36913,Complement factor H-related protein 5 levels,Disease
36919,Switch to non-stimulant treatment in ADHD,Disease
36926,"Tinnitus (chronic, bothersome)",Disease
36928,Total cerebellar volume (excluding Crus I vermis),Disease
36933,Body fat percentage or coronary artery disease (MTAG),Disease
36934,Body fat percentage or heart failure (MTAG),Disease
36960,Warfarin dose variability,Disease
36971,Progesterone levels,Disease
36989,Testosterone to estradiol ratio,Disease
36991,"Schizophrenia, bipolar disorder or recurrent major depressive disorder",Disease
36992,"Schizophrenia, bipolar disorder or recurrent major depressive disorder x sex interaction (3df)",Disease
36993,"Schizophrenia, bipolar disorder or major depressive disorder",Disease
36994,"Schizophrenia, bipolar disorder or major depressive disorder x sex interaction (3df)",Disease
36995,Response to antipsychotic treatment in schizophrenia,Disease
37003,Lipoprotein-associated phospholipase A2 mass,Disease
37005,Bisphosphonate-related osteonecrosis of the jaw,Disease
37009,Language functional connectivity,Disease
37024,Schizophrenia x sex interaction,Disease
37025,Bipolar disorder x sex interaction,Disease
37026,Major depressive disorder x sex interaction,Disease
37033,Lipoprotein-associated phospholipase A2 activity,Disease
37054,Vertigo,Disease
37116,Copper levels,Disease
37128,Negative urgency (measured by UPPS at 28 years),Disease
37132,Sensation seeking (measured by UPPS at 26 years),Disease
37155,Metabolic biomarkers (multivariate analysis),Disease
37160,Cognitive processing speed,Disease
37163,Cognitive processing accuracy,Disease
37166,DNA methylation-estimated plasminogen activator inhibitor-1 levels,Disease
37167,DNA methylation PhenoAge acceleration,Disease
37168,Hemorrhagic fever with renal syndrome,Disease
37171,Hemorrhagic fever with renal syndrome (severe vs mild),Disease
37178,Random glucose levels,Disease
37180,Systolic blood pressure (MTAG),Disease
37187,DNA methylation GrimAge acceleration,Disease
37188,Non-albumin protein levels,Disease
37189,Lipoprotein A levels (UKB data field 30790),Disease
37197,Alkaline phosphatase (UKB data field 30610),Disease
37199,Ocular disease,Disease
37201,Severe insulin-resistant type 2 diabetes,Disease
37202,Severe insulin-deficient type 2 diabetes,Disease
37203,Mild obesity-related type 2 diabetes,Disease
37204,Mild age-related type 2 diabetes,Disease
37205,Severe autoimmune type 2 diabetes,Disease
37213,Response to levetiracetam in focal epilepsy,Disease
37215,Response to phenytoin in focal epilepsy,Disease
37218,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node1),Disease
37219,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node25),Disease
37221,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node26),Disease
37223,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node27),Disease
37225,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node29),Disease
37227,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node42),Disease
37229,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node2),Disease
37230,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node3),Disease
37232,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node5),Disease
37233,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node17),Disease
37234,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node9),Disease
37236,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node11),Disease
37237,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node14),Disease
37238,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node20),Disease
37239,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node21),Disease
37240,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node44),Disease
37241,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node48),Disease
37243,DNA methylation Hannum age acceleration,Disease
37244,Wellbeing index,Disease
37246,Childhood maltreatment,Disease
37272,Testosterone levels,Disease
37275,Type 2 diabetes or polycystic ovary syndrome (pleiotropy),Disease
37276,Type 2 diabetes (adjusted for BMI) or polycystic ovary syndrome (pleiotropy),Disease
37278,Fasting insulin (adjusted for BMI) or polycystic ovary syndrome (pleiotropy),Disease
37280,HbA1c or polycystic ovary syndrome (pleiotropy),Disease
37289,Stimulant dependence,Disease
37292,Ascending aorta diameter,Disease
37294,Neonatal abstinence syndrome,Disease
37298,Bisoprolol clearance in non-ST elevation acute coronary syndrome,Disease
37303,Epigenetic age acceleration (Hannum) in childhood cancer survivors,Disease
37335,Response to levetiracetam in epilepsy,Disease
37337,Clostridioides difficle infection,Disease
37364,Primary dental caries (decayed and filled teeth),Disease
37366,Permanent dental caries (decayed and filled teeth),Disease
37374,Albuminuria,Disease
37375,Dyslipidemia,Disease
37377,Osteoporosis,Disease
37380,Carotid artery intima-media thickness in type 2 diabetes,Disease
37382,Coronary artery calcification in type 2 diabetes (excluding prevalent cardiovascular disease),Disease
37385,Femur bone mineral density x serum urate levels interaction,Disease
37386,Aspartate aminotransferase to alanine aminotransferase ratio,Disease
37387,Mean platelet volume during first trimester of pregnancy,Disease
37400,Total protein levels x insomnia interaction,Disease
37402,Mean platelet volume during the postpartum period,Disease
37405,Mean platelet volume at delivery,Disease
37409,Fasting total lipids in very small VLDL,Disease
37410,Fasting very small VLDL particle concentration,Disease
37411,Fasting phospholipid levels in very large HDL,Disease
37412,Fasting total cholesterol in very small VLDL,Disease
37413,Fasting cholesterol esters in very small VLDL,Disease
37414,Fasting total cholesterol in very large HDL,Disease
37415,Fasting cholesterol esters in very large HDL,Disease
37416,Parkinson's disease motor subtype (tremor dominant vs postural instability/gait difficulty),Disease
37417,Parkinson's disease motor subtype (tremor to postural instability/gait difficulty score ratio),Disease
37418,Fasting tyrosine,Disease
37422,Fasting free cholesterol in very large HDL,Disease
37423,Fasting total lipids in very large HDL,Disease
37424,Fasting very large HDL particle concentration,Disease
37425,Coprococcus comes,Disease
37427,Chronic widespread musculoskeletal pain,Disease
37428,Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel,Disease
37429,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,Disease
37430,Progression free survival in serous epithelial ovarian cancer,Disease
37431,Pancreas volume,Disease
37432,Kidney volume,Disease
37433,Visceral adipose tissue volume,Disease
37434,Abdominal subcutaneous adipose tissue volume,Disease
37435,Liver iron content,Disease
37436,Lung volume,Disease
37437,Pancreas fat,Disease
37438,JC polyomavirus VP1 antibody levels,Disease
37442,Human polyomavirus 6 VP1 antibody levels,Disease
37444,Anti-JC polyomavirus IgG seropositivity,Disease
37446,COVID-19 (severe respiratory symptoms vs population),Disease
37448,COVID-19 (covid respiratory support vs population),Disease
37451,Mean platelet volume during third trimester of pregnancy,Disease
37464,Postprandial total cholesterol in very large HDL,Disease
37465,Postprandial cholesterol esters in very large HDL,Disease
37466,Postprandial free cholesterol in very large HDL,Disease
37467,Postprandial cholesterol esters in small VLDL,Disease
37468,Postprandial total cholesterol in very small VLDL,Disease
37469,Postprandial cholesterol esters in very small VLDL,Disease
37470,Postprandial total lipids in very small VLDL,Disease
37471,Postprandial very small VLDL particle concentration,Disease
37472,Postprandial total lipids in very large HDL,Disease
37473,Postprandial very large HDL particle concentration,Disease
37474,Postprandial phospholipid levels in very large HDL,Disease
37475,Postprandial tyrosine,Disease
37480,25(OH)D3 levels in prediabetes,Disease
37549,Hearing function (0.5 kHz),Disease
37551,Hearing function (1 kHz),Disease
37553,Hearing function (4 kHz),Disease
37555,Hearing function (8 kHz),Disease
37559,Accelerated cognitive decline,Disease
37563,Decaffeinated coffee consumption or major depression disorder,Disease
37565,Decaffeinated coffee consumption and/or neuroticism,Disease
37573,Cholesteryl ester levels in large HDL,Disease
37577,Free cholesterol levels in large HDL,Disease
37580,Concentration of large HDL particles,Disease
37582,Gestational diabetes,Disease
37585,Phospholipids to total lipids ratio in large HDL,Disease
37587,Triglyceride levels in large HDL,Disease
37593,Alanine aminotransferase levels x vegetarianism interaction,Disease
37595,Albumin levels x vegetarianism interaction,Disease
37598,Alkaline phosphatase levels x vegetarianism interaction,Disease
37600,Apolipoprotein B levels x vegetarianism interaction,Disease
37602,Free cholesterol levels in large LDL,Disease
37605,Aspartate aminotransferase levels x vegetarianism interaction,Disease
37607,C reactive protein levels x vegetarianism interaction,Disease
37610,Calcium levels x vegetarianism interaction,Disease
37612,Cholesterol levels x vegetarianism interaction,Disease
37615,HbA1c levels (adjusted for BMI) x vegetarianism interaction,Disease
37618,Cystatin C levels (adjusted for BMI) x vegetarianism interaction,Disease
37621,Gamma glutamyltransferase levels (adjusted for BMI) x vegetarianism interaction,Disease
37624,Insulin-like growth factor 1 levels (adjusted for BMI) x vegetarianism interaction,Disease
37626,Direct low density lipoprotein cholesterol levels (adjusted for BMI) x vegetarianism interaction,Disease
37628,Concentration of large LDL particles,Disease
37633,Cholesterol levels in large VLDL,Disease
37642,Hip index,Disease
37643,Phospholipid levels in large VLDL,Disease
37644,Concentration of large VLDL particles,Disease
37645,Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),Disease
37649,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels (ENPP5.6556.5.3),Disease
37653,Cholesteryl ester levels in HDL,Disease
37656,Carotid Intima-media thickness (mean of the maximum cIMT),Disease
37664,Fractalkine levels (CX3CL1.2827.23.2),Disease
37670,Ubiquitin-like protein ISG15 levels (ISG15.14151.4.3),Disease
37672,UDP-N-acetylhexosamine pyrophosphorylase levels (UAP1.13580.2.3),Disease
37673,Phospholipid levels in HDL,Disease
37676,Ubiquitin carboxyl-terminal hydrolase 25 levels (USP25.9215.117.3),Disease
37690,Concentration of HDL particles,Disease
37691,Cholesterol levels in IDL,Disease
37695,Phospholipid levels in IDL,Disease
37697,Melanocyte protein PMEL levels (PMEL.6472.40.3),Disease
37699,NAD(P)H dehydrogenase [quinone] 1 levels (NQO1.9837.60.3),Disease
37702,Natural cytotoxicity triggering receptor 3 levels (NCR3.3003.29.2),Disease
37704,MHC class I polypeptide-related sequence B levels (MICB.5102.55.3),Disease
37711,Vesicle-fusing ATPase levels (NSF.13992.12.3),Disease
37713,Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3),Disease
37715,N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3),Disease
37716,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels (NAGPA.11208.15.3),Disease
37717,Cyclic AMP-dependent transcription factor ATF-6 alpha levels (ATF6.11277.23.3),Disease
37718,Polypeptide N-acetylgalactosaminyltransferase 1 levels (GALNT1.7090.17.3),Disease
37722,"Glycoprotein endo-alpha-1,2-mannosidase levels (MANEA.8014.359.3)",Disease
37726,Carotid intima media thickness (maximum),Disease
37728,Glutathione S-transferase A1 levels (GSTA1.12446.49.3),Disease
37730,Glycine N-methyltransferase levels (GNMT.14006.36.3),Disease
37735,Free cholesterol to total lipids ratio in IDL,Disease
37748,Cholesterol to total lipids ratio in large HDL,Disease
37753,Phospholipid levels in large HDL,Disease
37766,Cholesterol to total lipids ratio in large LDL,Disease
37769,Albumin levels (adjusted for BMI) x vegetarianism interaction,Disease
37770,Total lipid levels in large LDL,Disease
37772,Free cholesterol to total lipids ratio in large LDL,Disease
37774,Estimated glomerular filtration rate x vegetarianism interaction,Disease
37775,Urea levels x vegetarianism interaction,Disease
37777,Vitamin D levels x vegetarianism interaction,Disease
37779,Triglycerides to total lipids ratio in large LDL,Disease
37782,Total lipid levels in large VLDL,Disease
37783,Free cholesterol to total lipids ratio in large VLDL,Disease
37787,Cholesteryl esters to total lipids ratio in large HDL,Disease
37797,HbA1c levels x vegetarianism interaction,Disease
37802,Direct low density lipoprotein cholesterol levels x vegetarianism interaction,Disease
37803,Phosphate levels x vegetarianism interaction,Disease
37805,Testosterone levels (adjusted for BMI) x vegetarianism interaction,Disease
37808,Total bilirubin levels (adjusted for BMI) x vegetarianism interaction,Disease
37811,Lipoprotein A levels (adjusted for BMI) x vegetarianism interaction,Disease
37814,Phosphate levels (adjusted for BMI) x vegetarianism interaction,Disease
37815,Phospholipid levels in large LDL,Disease
37816,Cholesterol to total lipids ratio in large VLDL,Disease
37826,Total lipid levels in large HDL,Disease
37827,Insomnia or psoriasis (pleiotropy),Disease
37853,Cholesteryl ester levels in large LDL,Disease
37855,Cholesteryl esters to total lipids ratio in large LDL,Disease
37868,Free cholesterol levels in large VLDL,Disease
37870,Cholesterol levels in large HDL,Disease
37871,Free cholesterol to total lipids ratio in large HDL,Disease
37888,Cholesterol levels in large LDL,Disease
37889,Triglycerides to total lipids ratio in large HDL,Disease
37891,Cholesterol levels (adjusted for BMI) x vegetarianism interaction,Disease
37892,Aspartate aminotransferase levels (adjusted for BMI) x vegetarianism interaction,Disease
37894,C reactive protein levels (adjusted for BMI) x vegetarianism interaction,Disease
37896,Calcium levels (adjusted for BMI) x vegetarianism interaction,Disease
37897,Phospholipids to total lipids ratio in large LDL,Disease
37903,Estimated glomerular filtration rate (adjusted for BMI) x vegetarianism interaction,Disease
37904,Urea levels (adjusted for BMI) x vegetarianism interaction,Disease
37906,Cholesteryl esters to total lipids ratio in large VLDL,Disease
37934,Testosterone levels x vegetarianism interaction,Disease
37935,Total bilirubin levels x vegetarianism interaction,Disease
37936,Triglyceride levels x vegetarianism interaction,Disease
37941,Triglyceride levels in large LDL,Disease
37942,Cholesteryl ester levels in large VLDL,Disease
37943,Free cholesterol levels in LDL,Disease
37944,"Pediatric dental caries (decayed, missing and filled teeth >5)",Disease
37946,Cholesteryl ester levels in medium HDL,Disease
37949,Cholesterol to total lipids ratio in medium HDL,Disease
37950,Total lipid levels in medium HDL,Disease
37955,Depression severity  x hours spent watching television interaction,Disease
37958,Cigarette consumption x playing computer games interaction,Disease
37959,Alcohol consumption x playing computer games interaction,Disease
37962,Anxiety severity x hours spent watching television interaction,Disease
37966,Cholesterol levels in medium LDL,Disease
37967,Cholesterol to total lipids ratio in medium LDL,Disease
37972,Phospholipid levels in medium LDL,Disease
37977,Testosterone levels in premenopausal women,Disease
37979,Omega-3 fatty acid levels,Disease
37982,Ferritin levels (FTH1.FTL.3031.66.1),Disease
37983,ER membrane protein complex subunit 4 levels (EMC4.13516.46.3),Disease
37985,Carotid intima media thickness (minimum),Disease
37986,Cholesteryl esters to total lipids ratio in IDL,Disease
37988,Chronic elevation of alanine aminotransferase (cALT) levels,Disease
37990,Triglyceride levels in IDL,Disease
37995,Mitogen-activated protein kinase 13 levels (MAPK13.5006.71.1),Disease
38003,Osteocalcin levels (BGLAP.11067.13.3),Disease
38005,NmrA-like family domain-containing protein 1 levels (NMRAL1.13988.67.3),Disease
38007,Neural cell adhesion molecule 2 levels (NCAM2.6507.16.3),Disease
38009,Neuropeptide W levels (NPW.9986.14.3),Disease
38011,Neutrophil collagenase levels (MMP8.2954.56.2),Disease
38015,SPARC-like protein 1 levels (SPARCL1.4467.49.2),Disease
38016,Granulysin levels (GNLY.3195.50.2),Disease
38018,Gremlin-1 levels (GREM1.4449.67.3),Disease
38023,Stromal membrane-associated protein 1 levels (SMAP1.11649.3.3),Disease
38025,Killer cell immunoglobulin-like receptor 2DS2 levels (KIR2DS2.10428.1.3),Disease
38029,Triglyceride levels in HDL,Disease
38031,Average diameter for HDL particles,Disease
38033,Free cholesterol levels in IDL,Disease
38034,Phospholipids to total lipids ratio in IDL,Disease
38039,Vascular endothelial growth factor A levels (VEGFA.2597.8.3),Disease
38040,"Vascular endothelial growth factor A, isoform 121 levels (VEGFA.14032.2.3)",Disease
38043,Promotilin levels (MLN.5631.83.3),Disease
38046,T-cell surface protein tactile levels (CD96.9735.44.3),Disease
38048,Tapasin levels (TAPBP.12378.71.3),Disease
38050,Tapasin-related protein levels (TAPBPL.6364.7.3),Disease
38051,"HLA class II histocompatibility antigen, DQ alpha 2 chain levels (HLA.DQA2.7757.5.3)",Disease
38057,Tenascin-X levels (TNXB.5698.60.3),Disease
38063,Cholesterol to total lipids ratio in IDL,Disease
38069,Total lipid levels in IDL,Disease
38070,Concentration of IDL particles,Disease
38072,Triglycerides to total lipids ratio in IDL,Disease
38073,Thioredoxin domain-containing protein 5 levels (TXNDC5.11212.7.3),Disease
38074,Thrombospondin-2 levels (THBS2.3339.33.1),Disease
38078,Inactive pancreatic lipase-related protein 1 levels (PNLIPRP1.6627.25.3),Disease
38080,Inducible T-cell costimulator levels (ICOS.14084.191.3),Disease
38082,Total lipid levels in HDL,Disease
38086,Cholesteryl ester levels in IDL,Disease
38087,radiation-induced toxicity (physician-rated acute dysphagia),Disease
38089,radiation-induced toxicity (patient-rated acute xerostomia),Disease
38090,radiation-induced toxicity (physician-rated acute xerostomia),Disease
38093,radiation-induced toxicity (patient-rated acute sticky saliva),Disease
38095,radiation-induced toxicity (standardized total average toxicity_patient),Disease
38097,Free cholesterol levels in small HDL,Disease
38099,Phospholipids to total lipids ratio in small HDL,Disease
38105,Cholesterol levels in small LDL,Disease
38106,Primary open angle glaucoma (multi-trait analysis),Disease
38117,Cholesterol to total lipids ratio in small LDL,Disease
38119,Cholesteryl ester levels in small VLDL,Disease
38121,Cholesterol to total lipids ratio in small VLDL,Disease
38124,Annual frequency of asthma exacerbations in non-smokers,Disease
38126,Annual frequency of asthma exacerbations in smokers,Disease
38128,Cholesteryl esters to total lipids ratio in small VLDL,Disease
38131,Saturated fatty acid levels,Disease
38135,Total lipid levels in lipoprotein particles,Disease
38136,Total concentration of lipoprotein particles,Disease
38137,Total fatty acid levels,Disease
38138,Anti-hepatitis E antibody seropositivity,Disease
38141,Free cholesterol levels in VLDL,Disease
38142,Total lipid levels in VLDL,Disease
38143,Triglyceride levels in VLDL,Disease
38144,Cholesterol levels in very large HDL,Disease
38148,Cholesteryl ester levels in very large HDL,Disease
38149,Cholesteryl esters to total lipids ratio in very large HDL,Disease
38154,Free cholesterol levels in very large HDL,Disease
38157,Free cholesterol to total lipids ratio in very large HDL,Disease
38158,Total lipid levels in very large HDL,Disease
38159,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; all treatment preparations),Disease
38161,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFN-1b subcutaneous),Disease
38164,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFN-1a subcutaneous and intramuscular),Disease
38167,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFN-1a subcutaneous),Disease
38169,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; all treatment preparations),Disease
38174,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFN-1b subcutaneous),Disease
38176,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFN-1a subcutaneous and intramuscular),Disease
38178,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFN-1a subcutaneous),Disease
38180,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; all treatment preparations),Disease
38181,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFN-1b subcutaneous),Disease
38183,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFN-1a subcutaneous and intramuscular),Disease
38185,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFN-1a subcutaneous),Disease
38187,Phospholipid levels in very large HDL,Disease
38194,Triglycerides to total lipids ratio in very large HDL,Disease
38195,Cholesterol levels in very large VLDL,Disease
38196,Cholesterol to total lipids ratio in very large VLDL,Disease
38201,Whole brain restricted isotropic diffusion (multivariate analysis),Disease
38204,Cholesteryl ester levels in very large VLDL,Disease
38207,Concentration of medium HDL particles,Disease
38209,Hunner-type interstitial cystitis,Disease
38210,Psycho-cardiometabolic multimorbidity (multivariate analysis),Disease
38217,Total lipid levels in small HDL,Disease
38218,Concentration of small HDL particles,Disease
38221,Free cholesterol levels in small LDL,Disease
38224,Phospholipid levels in small LDL,Disease
38225,Extraintestinal manifestations in inflammatory bowel disease (ankylosing spondylitis and sacroiliitis),Disease
38228,Extraintestinal manifestations in inflammatory bowel disease (ocular manifestations),Disease
38231,Extraintestinal manifestations in inflammatory bowel disease (primary sclerosing cholangitis),Disease
38237,Extraintestinal manifestations in inflammatory bowel disease (any of 6 phenotypes),Disease
38239,Free cholesterol levels in small VLDL,Disease
38240,Phospholipids to total lipids ratio in small VLDL,Disease
38242,Sphingomyelin levels,Disease
38244,Total triglycerides levels,Disease
38245,Tanner 3 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model),Disease
38248,Tanner 2 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model),Disease
38252,Phospholipid levels in VLDL,Disease
38253,Concentration of VLDL particles,Disease
38257,Triglyceride levels in small HDL,Disease
38260,Triglyceride levels in small LDL,Disease
38262,Free cholesterol to total lipids ratio in small VLDL,Disease
38265,Cardiorespiratory fitness,Disease
38268,Phospholipid levels in small VLDL,Disease
38269,Total phospholipid levels in lipoprotein particles,Disease
38271,Cholesterol to total lipids ratio in very large HDL,Disease
38274,High general stress,Disease
38278,Concentration of very large HDL particles,Disease
38282,Triglyceride levels in very large HDL,Disease
38293,Acetoacetate levels,Disease
38297,Acetone levels,Disease
38300,Clinical LDL cholesterol levels,Disease
38303,Potassium levels,Disease
38308,Glycoprotein acetyls levels,Disease
38318,Cholesterol levels in medium HDL,Disease
38319,Polyunsaturated fatty acid levels,Disease
38328,Alpha-hydroxyisovalerate levels in elite athletes,Disease
38333,Argininate levels in elite athletes,Disease
38335,Beta-citrylglutamate levels in elite athletes,Disease
38338,Betaine levels in elite athletes,Disease
38341,1-methylhistidine levels in elite athletes,Disease
38344,"Periodontal pocket (adjusted for age, sex and smoking status)",Disease
38346,"Periodontal pocket (adjusted for age, sex, smoking status  and plaque)",Disease
38347,Perfluorooctanesulfonic acid (PFOS) levels in elite athletes,Disease
38349,Ursodeoxycholate levels in elite athletes,Disease
38353,Tyrosine levels in elite athletes,Disease
38355,N-methylpipecolate levels in elite athletes,Disease
38357,Methyl glucopyranoside (alpha + beta) levels in elite athletes,Disease
38359,Tryptophan betaine levels in elite athletes,Disease
38361,Tryptophan levels in elite athletes,Disease
38362,N-(2-furoyl)glycine levels in elite athletes,Disease
38364,Tartronate (hydroxymalonate) levels in elite athletes,Disease
38367,"Bilirubin (Z,Z) levels in elite athletes",Disease
38369,Gulonate levels in elite athletes,Disease
38371,Ribonate levels in elite athletes,Disease
38373,Xylose levels in elite athletes,Disease
38375,Alpha-ketoglutarate levels in elite athletes,Disease
38377,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) levels in elite athletes,Disease
38379,Galactonate levels in elite athletes,Disease
38381,Tyramine O-sulfate levels in elite athletes,Disease
38383,Urea levels in elite athletes,Disease
38385,1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) levels in elite athletes,Disease
38387,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels in elite athletes,Disease
38389,1-palmitoyl-2-oleoyl-GPC (16:0/18:1) levels in elite athletes,Disease
38391,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels in elite athletes,Disease
38398,5-oxoproline levels in elite athletes,Disease
38400,1-stearoyl-GPC (18:0) levels in elite athletes,Disease
38404,1-stearoyl-GPE (18:0) levels in elite athletes,Disease
38405,1-palmitoyl-GPI (16:0) levels in elite athletes,Disease
38407,1-stearoyl-2-linoleoyl-GPC (18:0/18:2) levels in elite athletes,Disease
38409,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels in elite athletes,Disease
38411,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels in elite athletes,Disease
38413,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels in elite athletes,Disease
38416,1-palmitoyl-2-stearoyl-GPC (16:0/18:0) levels in elite athletes,Disease
38417,1-palmitoyl-GPC (16:0) levels in elite athletes,Disease
38418,1-palmitoyl-GPE (16:0) levels in elite athletes,Disease
38420,5-HETE levels in elite athletes,Disease
38422,Cysteine levels in elite athletes,Disease
38428,Cystathionine levels in elite athletes,Disease
38430,5-HEPE levels in elite athletes,Disease
38432,4-HDoHE levels in elite athletes,Disease
38434,Cortisone levels in elite athletes,Disease
38436,3-hydroxyoctanoate levels in elite athletes,Disease
38438,Chenodeoxycholate levels in elite athletes,Disease
38444,Dehydroisoandrosterone sulfate (DHEA-S) levels in elite athletes,Disease
38446,Deoxycholate levels in elite athletes,Disease
38449,Dihomo-linoleate (20:2n6) levels in elite athletes,Disease
38451,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Disease
38453,Dimethylglycine levels in elite athletes,Disease
38455,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Disease
38457,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Disease
38459,Adipoylcarnitine (C6-DC) levels in elite athletes,Disease
38461,Andro steroid monosulfate C19H28O6S (1) levels in elite athletes,Disease
38463,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels in elite athletes",Disease
38466,Atopic dermatitis (moderate to severe),Disease
38470,Glutamine levels,Disease
38473,Docosahexaenoic acid levels,Disease
38475,Histidine levels,Disease
38477,Isoleucine levels,Disease
38478,Lactate levels,Disease
38479,Linoleic acid levels,Disease
38486,Total free cholesterol levels,Disease
38487,4-hydroxyphenylpyruvate levels in elite athletes,Disease
38489,2-oxoarginine levels in elite athletes,Disease
38491,3-hydroxy-2-ethylpropionate levels in elite athletes,Disease
38495,3-methylglutaconate levels in elite athletes,Disease
38500,2-hydroxy-3-methylvalerate levels in elite athletes,Disease
38502,1-methylimidazoleacetate levels in elite athletes,Disease
38504,5-bromotryptophan levels in elite athletes,Disease
38507,2-hydroxybutyrate/2-hydroxyisobutyrate levels in elite athletes,Disease
38509,2-methylbutyrylcarnitine (C5) levels in elite athletes,Disease
38512,2-methylbutyrylglycine levels in elite athletes,Disease
38516,Taurolithocholate 3-sulfate levels in elite athletes,Disease
38518,Tetradecanedioate levels in elite athletes,Disease
38520,Theobromine levels in elite athletes,Disease
38522,Cinnamoylglycine levels in elite athletes,Disease
38524,5-acetylamino-6-amino-3-methyluracil levels in elite athletes,Disease
38526,5-acetylamino-6-formylamino-3-methyluracil levels in elite athletes,Disease
38529,6-hydroxyindole sulfate levels in elite athletes,Disease
38531,Acesulfame levels in elite athletes,Disease
38533,Gluconate levels in elite athletes,Disease
38536,Stearoylcarnitine (C18) levels in elite athletes,Disease
38537,Dihydroferulic acid levels in elite athletes,Disease
38539,Taurochenodeoxycholate levels in elite athletes,Disease
38543,S-methylmethionine levels in elite athletes,Disease
38545,"1,3,7-trimethylurate levels in elite athletes",Disease
38547,"1,5-anhydroglucitol (1,5-AG) levels in elite athletes",Disease
38549,"1,7-dimethylurate levels in elite athletes",Disease
38551,Spermidine levels in elite athletes,Disease
38553,Tiglylcarnitine (C5:1-DC) levels in elite athletes,Disease
38555,N-formylphenylalanine levels in elite athletes,Disease
38557,N-trimethyl 5-aminovalerate levels in elite athletes,Disease
38559,N-acetyltryptophan levels in elite athletes,Disease
38560,N-acetylproline levels in elite athletes,Disease
38563,3-ureidopropionate levels in elite athletes,Disease
38565,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels in elite athletes,Disease
38567,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) levels in elite athletes,Disease
38569,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels in elite athletes,Disease
38571,1-palmitoleoyl-GPC (16:1) levels in elite athletes,Disease
38573,1-palmitoleoylglycerol (16:1) levels in elite athletes,Disease
38575,1-oleoyl-GPE (18:1) levels in elite athletes,Disease
38576,1-oleoyl-GPI (18:1) levels in elite athletes,Disease
38580,Carnitine levels in elite athletes,Disease
38582,Biliverdin levels in elite athletes,Disease
38584,2-aminooctanoate levels in elite athletes,Disease
38586,Arginine levels in elite athletes,Disease
38588,Aspartate levels in elite athletes,Disease
38590,2-hydroxyadipate levels in elite athletes,Disease
38592,Caffeic acid sulfate levels in elite athletes,Disease
38594,21-hydroxypregnenolone disulfate levels in elite athletes,Disease
38596,3-hydroxy-3-methylglutarate levels in elite athletes,Disease
38598,2-hydroxyoctanoate levels in elite athletes,Disease
38599,2-linoleoylglycerol (18:2) levels in elite athletes,Disease
38601,2-oleoylglycerol (18:1) levels in elite athletes,Disease
38603,2-palmitoleoyl-GPC (16:1) levels in elite athletes,Disease
38606,3-hydroxyhexanoate levels in elite athletes,Disease
38608,3-hydroxymyristate levels in elite athletes,Disease
38610,Gamma glutamyl transpeptidase,Disease
38623,Citrate levels,Disease
38641,Leucine levels,Disease
38643,Total esterified cholesterol levels,Disease
38651,Dopamine 3-O-sulfate levels in elite athletes,Disease
38653,Isobutyrylcarnitine (C4) levels in elite athletes,Disease
38655,4-hydroxychlorothalonil levels in elite athletes,Disease
38657,4-methylcatechol sulfate levels in elite athletes,Disease
38660,Stachydrine levels in elite athletes,Disease
38662,3-hydroxyhippurate levels in elite athletes,Disease
38664,3-methoxycatechol sulfate (2) levels in elite athletes,Disease
38666,3-methyl catechol sulfate (1) levels in elite athletes,Disease
38668,4-acetylphenol sulfate levels in elite athletes,Disease
38670,4-allylphenol sulfate levels in elite athletes,Disease
38673,Guanidinosuccinate levels in elite athletes,Disease
38675,Imidazole lactate levels in elite athletes,Disease
38677,Imidazole propionate levels in elite athletes,Disease
38682,Thioproline levels in elite athletes,Disease
38684,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels in elite athletes,Disease
38685,1-(1-enyl-palmitoyl)-GPC (P-16:0) levels in elite athletes,Disease
38687,1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) levels in elite athletes,Disease
38688,3-(4-hydroxyphenyl)lactate levels in elite athletes,Disease
38690,3-aminoisobutyrate levels in elite athletes,Disease
38692,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) levels in elite athletes,Disease
38694,1-(1-enyl-stearoyl)-GPE (P-18:0) levels in elite athletes,Disease
38696,1-arachidonoyl-GPA (20:4) levels in elite athletes,Disease
38700,1-linoleoyl-GPC (18:2) levels in elite athletes,Disease
38702,1-arachidonoyl-GPI (20:4) levels in elite athletes,Disease
38704,1-dihomo-linolenylglycerol (20:3) levels in elite athletes,Disease
38707,1-lignoceroyl-GPC (24:0) levels in elite athletes,Disease
38709,1-linolenoyl-GPC (18:3) levels in elite athletes,Disease
38711,"12,13-DiHOME levels in elite athletes",Disease
38713,14-HDoHE/17-HDoHE levels in elite athletes,Disease
38717,1-stearoyl-GPG (18:0) levels in elite athletes,Disease
38719,Adrenate (22:4n6) levels in elite athletes,Disease
38721,Arabinose levels in elite athletes,Disease
38722,2-aminoheptanoate levels in elite athletes,Disease
38724,15-methylpalmitate levels in elite athletes,Disease
38726,"1,2-dipalmitoyl-GPE (16:0/16:0) levels in elite athletes",Disease
38730,10-undecenoate (11:1n1) levels in elite athletes,Disease
38737,Erythronate levels in elite athletes,Disease
38738,Eicosapentaenoate (EPA; 20:5n3) levels in elite athletes,Disease
38739,"Androstenediol (3beta,17beta) monosulfate (1) levels in elite athletes",Disease
38741,Gamma-glutamylglutamate levels in elite athletes,Disease
38743,Dodecanedioate levels in elite athletes,Disease
38747,"Androstenediol (3alpha, 17alpha) monosulfate (3) levels in elite athletes",Disease
38749,Azelate (nonanedioate) levels in elite athletes,Disease
38751,Behenoyl sphingomyelin (d18:1/22:0) levels in elite athletes,Disease
38753,Arachidonoylcarnitine (C20:4) levels in elite athletes,Disease
38756,Gamma-glutamylisoleucine levels in elite athletes,Disease
38758,Gamma-glutamylleucine levels in elite athletes,Disease
38760,"Ceramide (d18:1/14:0, d16:1/16:0) levels in elite athletes",Disease
38762,"Ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0) levels in elite athletes",Disease
38764,"Ceramide (d16:1/24:1, d18:1/22:1) levels in elite athletes",Disease
38766,Gamma-glutamyltyrosine levels in elite athletes,Disease
38768,Glutamine levels in elite athletes,Disease
38770,Glycerate levels in elite athletes,Disease
38772,Free cholesterol to total lipids ratio in very large VLDL,Disease
38773,Total lipid levels in very large VLDL,Disease
38774,Concentration of very large VLDL particles,Disease
38779,Phospholipids to total lipids ratio in very large VLDL,Disease
38781,Phospholipid levels in very large VLDL,Disease
38782,Triglyceride levels in very large VLDL,Disease
38789,Cholesterol to total lipids ratio in very small VLDL,Disease
38790,Ascending aorta maximum area,Disease
38791,Peripheral artery disease in non diabetes,Disease
38792,Ascending aorta minimum area,Disease
38796,Whole brain restricted directional diffusion (multivariate analysis),Disease
38800,Cholesteryl ester levels in very small VLDL,Disease
38808,Gastric polyp,Disease
38812,Hepatic cancer,Disease
38817,Triglyceride levels in very small VLDL,Disease
38822,Cholesterol levels in chylomicrons and extremely large VLDL,Disease
38840,Free cholesterol levels in very large VLDL,Disease
38852,Free cholesterol levels in very small VLDL,Disease
38856,Cirrhosis,Disease
38857,Angina pectoris,Disease
38861,Chronic sinusitis,Disease
38863,Autoimmune hepatitis,Disease
38866,Cytomegalovirus infection after allogeneic hematopoietic cell transplantation (recipients),Disease
38868,Cytomegalovirus high-level reactivation after allogeneic hematopoietic cell transplantation (donors),Disease
38870,Phospholipids to total lipids ratio in very small VLDL,Disease
38872,Phospholipid levels in very small VLDL,Disease
38873,Facial morphology (segment 7),Disease
38874,Facial morphology (segment 9),Disease
38875,Facial morphology (segment 21),Disease
38877,Facial morphology (segment 22),Disease
38879,Facial morphology (segment 53),Disease
38881,Facial morphology (segment 59),Disease
38883,Facial morphology (segment 2),Disease
38885,Atrial fibrillation/atrial flutter,Disease
38891,Facial morphology (segment 62),Disease
38893,Whole brain free water diffusion (multivariate analysis),Disease
38907,Peripheral artery disease in ever smokers,Disease
38909,Facial morphology (segment 11),Disease
38911,Facial morphology (segment 19),Disease
38913,Facial morphology (segment 23),Disease
38915,Facial morphology (segment 28),Disease
38916,Facial morphology (segment 1),Disease
38922,Substance dependence,Disease
38928,Retinitis pigmentosa,Disease
38930,Pulmonary tuberculosis,Disease
38932,Pollinosis,Disease
38935,Stable angina pectoris,Disease
38949,Cholesterol levels in very small VLDL,Disease
38951,Total lipid levels in very small VLDL,Disease
38952,Nephrotic syndrome,Disease
38959,Iritis,Disease
38970,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Disease
38991,Neuropathic pain,Disease
38996,Brain-specific serine protease 4 levels (PRSS22.4534.10.2),Disease
38998,Beta-defensin 119 levels (DEFB119.13455.10.3),Disease
39001,C-C motif chemokine 17 levels (CCL17.3519.3.2),Disease
39003,C-C motif chemokine 19 levels (CCL19.4922.13.1),Disease
39004,C-C motif chemokine 21 levels (CCL21.2516.57.3),Disease
39006,C-C motif chemokine 22 levels (CCL22.3508.78.3),Disease
39016,Acid sphingomyelinase-like phosphodiesterase 3a levels (SMPDL3A.14086.11.3),Disease
39018,Adhesion G protein-coupled receptor F5 levels (ADGRF5.6409.57.3),Disease
39021,"Advanced glycosylation end product-specific receptor, soluble levels (AGER.4125.52.2)",Disease
39022,Agouti-related protein levels (AGRP.2813.11.2),Disease
39024,alpha-2-macroglobulin receptor-associated protein levels (LRPAP1.3640.14.3),Disease
39028,"Amelogenin, X isoform levels (AMELX.8578.45.3)",Disease
39030,Angiostatin levels (PLG.3710.49.2),Disease
39032,Cerebellin-1 levels (CBLN1.9313.27.3),Disease
39037,Chloride intracellular channel protein 5 levels (CLIC5.12475.48.3),Disease
39039,Chymotrypsinogen B levels (CTRB1.5671.1.3),Disease
39042,ATP-dependent RNA helicase DHX8 levels (DHX8.11601.26.3),Disease
39043,Colipase levels (CLPS.5749.53.3),Disease
39047,Apolipoprotein L1 levels (APOL1.9506.10.3),Disease
39048,Apolipoprotein M levels (APOM.10445.20.3),Disease
39050,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D levels (PDE4D.5255.22.3)",Disease
39054,Cation-independent mannose-6-phosphate receptor levels (IGF2R.3676.15.3),Disease
39057,CD109 antigen levels (CD109.3290.50.2),Disease
39059,Carboxypeptidase B levels (CPB1.6356.3.3),Disease
39062,Intracerebral hemorrhage,Disease
39066,Iron deficiency anemia,Disease
39068,Juvenile rheumatoid arthritis,Disease
39073,Streptacidiphilus abundance in stool,Disease
39075,Treponema D abundance in stool,Disease
39077,Treponemataceae abundance in stool,Disease
39079,RUG472 sp900319345 abundance in stool,Disease
39081,RUG472 abundance in stool,Disease
39082,Succinivibrio abundance in stool,Disease
39084,UBA1066 sp900317515 abundance in stool,Disease
39086,UBA11471 sp000434215 abundance in stool,Disease
39088,UBA11471 abundance in stool,Disease
39089,UBA1206 sp000433115 abundance in stool,Disease
39091,UBA1448 sp002329405 abundance in stool,Disease
39093,UBA1448 abundance in stool,Disease
39094,UBA1777 sp900319835 abundance in stool,Disease
39095,UBA2922 sp900313925 abundance in stool,Disease
39097,UBA6398 sp002451695 abundance in stool,Disease
39099,UBA7182 sp002491115 abundance in stool,Disease
39102,Acidobacteriales abundance in stool,Disease
39104,Agathobacter sp000434275 abundance in stool,Disease
39106,Anaeromassilibacillus sp001305115 abundance in stool,Disease
39108,UBA7748 sp900314535 abundance in stool,Disease
39110,UBA8517 abundance in stool,Disease
39112,Achromobacter abundance in stool,Disease
39114,Borreliaceae abundance in stool,Disease
39116,Borreliales abundance in stool,Disease
39119,Neuropathic bladder,Disease
39121,Malignant lymphoma,Disease
39124,Meniere's disease,Disease
39126,Bacillus AY abundance in stool,Disease
39128,Bifidobacterium angulatum abundance in stool,Disease
39130,CAG-349 abundance in stool,Disease
39132,CAG-448 sp000433415 abundance in stool,Disease
39134,CAG-170 sp003516765 abundance in stool,Disease
39136,CAG-177 sp002438685 abundance in stool,Disease
39138,CAG-177 sp002451755 abundance in stool,Disease
39139,CAG-177 sp003514385 abundance in stool,Disease
39140,CAG-177 sp003538135 abundance in stool,Disease
39141,CAG-177 abundance in stool,Disease
39142,CAG-180 sp000432435 abundance in stool,Disease
39143,CAG-269 sp001915995 abundance in stool,Disease
39145,CAG-81 sp000435795 abundance in stool,Disease
39147,CAG-841 sp002479075 abundance in stool,Disease
39149,CAG-882 sp003486385 abundance in stool,Disease
39155,CAG-977 abundance in stool,Disease
39157,Clostridium tertium abundance in stool,Disease
39159,Desulfovibrio piger abundance in stool,Disease
39162,Cholesterol to total lipids ratio in small HDL,Disease
39164,Cholesteryl ester levels in small HDL,Disease
39165,Phospholipid levels in small HDL,Disease
39166,Triglycerides to total lipids ratio in small HDL,Disease
39167,Total lipid levels in small LDL,Disease
39168,Triglycerides to total lipids ratio in small LDL,Disease
39170,Total lipid levels in small VLDL,Disease
39171,Triglyceride levels in small VLDL,Disease
39174,Resilience score,Disease
39176,VLDL cholesterol levels,Disease
39177,Valine levels,Disease
39184,Saliva microbiota abundance (Order Actinomycetales),Disease
39187,Total concentration of branched-chain amino acids (leucine + isoleucine + valine),Disease
39190,Cholesteryl ester levels in VLDL,Disease
39205,Cholesteryl ester levels in small LDL,Disease
39206,Cholesterol levels in small VLDL,Disease
39207,Pulmonary tuberculosis resistance,Disease
39209,Concentration of small VLDL particles,Disease
39211,Anti-hepatitis E antibody levels,Disease
39218,Degree of unsaturation,Disease
39226,Average diameter for VLDL particles,Disease
39232,Lignoceroylcarnitine (C24) levels in elite athletes,Disease
39235,Maleate levels in elite athletes,Disease
39237,Linoleoylcarnitine (C18:2) levels in elite athletes,Disease
39238,Mannose levels in elite athletes,Disease
39242,Linoleoyl ethanolamide levels in elite athletes,Disease
39245,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels in elite athletes,Disease
39247,Tonsillitis,Disease
39252,N-acetylmethionine levels in elite athletes,Disease
39254,N-acetyltaurine levels in elite athletes,Disease
39256,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels in elite athletes,Disease
39258,Palmitoyl ethanolamide levels in elite athletes,Disease
39259,Palmitoyl-oleoyl-glycerol (16:0/18:1) [1] levels in elite athletes,Disease
39262,Viral variant GAG242N carrier status in HIV infection,Disease
39264,Cerebrospinal fluid metabolite X-24728 levels,Disease
39265,Cerebrospinal fluid metabolite X-25948 levels,Disease
39267,Cerebrospinal fluid adenine levels,Disease
39269,Oleoylcarnitine (C18:1) levels in elite athletes,Disease
39270,"Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) levels in elite athletes",Disease
39272,"Sphingomyelin (d18:2/24:1, d18:1/24:2) levels in elite athletes",Disease
39277,Brain 2-hydroxystearate levels,Disease
39279,Sphingomyelin (d18:2/24:2) levels in elite athletes,Disease
39281,Sphingosine 1-phosphate levels in elite athletes,Disease
39282,Stearoylcholine levels in elite athletes,Disease
39285,Chronic heart failure,Disease
39290,Bronchiectasis,Disease
39296,Dihydroorotate levels in elite athletes,Disease
39298,Pro-hydroxy-pro levels in elite athletes,Disease
39300,Pyridoxate levels in elite athletes,Disease
39303,Pipecolate levels in elite athletes,Disease
39305,2'-O-methyluridine levels in elite athletes,Disease
39307,N1-methylinosine levels in elite athletes,Disease
39309,N6-carbamoylthreonyladenosine levels in elite athletes,Disease
39310,Orotidine levels in elite athletes,Disease
39313,Pyruvate levels in elite athletes,Disease
39316,Cataracts,Disease
39320,Phenylacetylglutamate levels in elite athletes,Disease
39322,Valylglutamine levels in elite athletes,Disease
39324,Valylglycine levels in elite athletes,Disease
39326,"1,2,3-benzenetriol sulfate (2) levels in elite athletes",Disease
39328,"2,3-dihydroxyisovalerate levels in elite athletes",Disease
39329,3-(3-hydroxyphenyl)propionate sulfate levels in elite athletes,Disease
39332,Esophageal varix,Disease
39334,Bell's palsy,Disease
39340,Homostachydrine levels in elite athletes,Disease
39343,HWESASXX levels in elite athletes,Disease
39345,Hypoxanthine levels in elite athletes,Disease
39347,Glycolithocholate sulfate levels in elite athletes,Disease
39349,"Glycosyl ceramide (d18:1/23:1, d17:1/24:1) levels in elite athletes",Disease
39352,Inosine levels in elite athletes,Disease
39357,Chiro-inositol levels in elite athletes,Disease
39360,Eicosenoate (20:1) levels in elite athletes,Disease
39361,Etiocholanolone glucuronide levels in elite athletes,Disease
39364,Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes,Disease
39366,Dihomo-linoleoylcarnitine (C20:2) levels in elite athletes,Disease
39367,Docosadienoate (22:2n6) levels in elite athletes,Disease
39372,Leucine levels in elite athletes,Disease
39381,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels in elite athletes,Disease
39383,Kynurenine levels in elite athletes,Disease
39386,"Glycosyl ceramide (d18:2/24:1, d18:1/24:2) levels in elite athletes",Disease
39387,Isoleucine levels in elite athletes,Disease
39389,Lactosyl-N-behenoyl-sphingosine (d18:1/22:0) levels in elite athletes,Disease
39392,N-acetyl-beta-alanine levels in elite athletes,Disease
39394,N-palmitoyltaurine levels in elite athletes,Disease
39398,N-acetylarginine levels in elite athletes,Disease
39400,Margaroylcarnitine levels in elite athletes,Disease
39402,Methionine sulfoxide levels in elite athletes,Disease
39404,Myristoylcarnitine (C14) levels in elite athletes,Disease
39405,Octanoylcarnitine (C8) levels in elite athletes,Disease
39408,Oleoyl ethanolamide levels in elite athletes,Disease
39410,N-palmitoyl-sphingadienine (d18:2/16:0) levels in elite athletes,Disease
39412,"Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0) levels in elite athletes",Disease
39415,"Sphingomyelin (d18:2/21:0, d16:2/23:0) levels in elite athletes",Disease
39417,Nonadecanoate (19:0) levels in elite athletes,Disease
39418,"Sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2) levels in elite athletes",Disease
39420,Octadecanedioate levels in elite athletes,Disease
39422,Sebacate (decanedioate) levels in elite athletes,Disease
39424,Pregnanediol-3-glucuronide levels in elite athletes,Disease
39426,Pregnanolone/allopregnanolone sulfate levels in elite athletes,Disease
39428,Pregnen-diol disulfate C21H34O8S2 levels in elite athletes,Disease
39430,"Sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1) levels in elite athletes",Disease
39432,Brain 2-hydroxyglutarate levels,Disease
39434,Cerebrospinal fluid imidazole lactate levels,Disease
39435,Cerebrospinal fluid xanthosine levels,Disease
39437,Cerebrospinal fluid phenyllactate (PLA) levels,Disease
39439,Phenylacetate levels in elite athletes,Disease
39441,Phenyllactate (PLA) levels in elite athletes,Disease
39443,Phenol sulfate levels in elite athletes,Disease
39445,Cerebrospinal fluid ethylmalonate levels,Disease
39447,Cerebrospinal fluid 5-methylthioadenosine (MTA) levels,Disease
39449,Cerebrospinal fluid 3-(4-hydroxyphenyl)lactate levels,Disease
39451,Cerebrospinal fluid inosine levels,Disease
39452,Cerebrospinal fluid methylmalonate (MMA) levels,Disease
39456,Cerebrospinal fluid isobutyrylcarnitine (C4) levels,Disease
39457,Leucylalanine levels in elite athletes,Disease
39459,Serine levels in elite athletes,Disease
39462,Gamma-glutamyltryptophan levels in elite athletes,Disease
39464,Quinate levels in elite athletes,Disease
39465,4-hydroxyphenylacetylglutamine levels in elite athletes,Disease
39466,Chronic glomerulonephritis,Disease
39468,Chronic renal failure,Disease
39470,Chronic bronchitis,Disease
39473,Colon polyp,Disease
39475,Cystitis,Disease
39477,Cholelithiasis,Disease
39479,"Hearing loss, difficulty in hearing",Disease
39482,Hyperthyroidism,Disease
39486,Goiter,Disease
39496,Body mass index in physically active individuals,Disease
39497,Waist circumference adjusted for BMI in active individuals,Disease
39498,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),Disease
39499,Sporadic neuroblastoma,Disease
39500,Body mass index in physically inactive individuals,Disease
39501,Waist circumference adjusted for BMI in inactive individuals,Disease
39502,Waist-to-hip ratio adjusted for BMI in active individuals,Disease
39503,Foot ulcer in diabetes and neuropathy,Disease
39504,Foot ulcer and neuropathy in diabetes,Disease
39505,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,Disease
39506,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale),Disease
39507,Ankylosing spondylitis (SNP x SNP interaction),Disease
39508,Plasma trimethylamine N-oxide levels,Disease
39509,Obstructive sleep apnea trait (apnea hypopnea index),Disease
39510,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,Disease
39511,Diastolic blood pressure x sodium interaction (1df test),Disease
39512,Diastolic blood pressure x sodium interaction (2df test),Disease
39513,Colonoscopy-negative controls vs population controls,Disease
39514,Paclitaxel disposition in epithelial ovarian cancer,Disease
39515,Carboplatin disposition in epthelial ovarian cancer,Disease
39516,Hepatocyte growth factor levels,Disease
39517,Interleukin-1-receptor antagonist levels,Disease
39518,Interferon gamma levels,Disease
39519,Interleukin-1-beta levels,Disease
39520,Interleukin-2 receptor antagonist levels,Disease
39521,Interleukin-4 levels,Disease
39522,Interleukin-2 levels,Disease
39523,Stromal-cell-derived factor 1 alpha levels,Disease
39524,Tumor necrosis factor alpha levels,Disease
39525,Stem cell growth factor beta levels,Disease
39526,Idiopathic osteonecrosis of the femoral head,Disease
39527,Glioblastoma,Disease
39528,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),Disease
39529,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),Disease
39530,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),Disease
39531,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),Disease
39532,Lobe attachment (rater-scored or self-reported),Disease
39533,Iris color (L* coordinate),Disease
39534,Iris color (a* coordinate),Disease
39535,Cognitive ability (MTAG),Disease
39536,Cognitive ability,Disease
39537,Lobe attachment (rater scored),Disease
39538,P wave terminal force,Disease
39539,Caudate volume in trauma-exposed individuals,Disease
39540,Nucleus accumbens volume in trauma-exposed individuals,Disease
39541,Cardiometabolic and hematological traits,Disease
39542,Branched-chain amino acid levels (Isoleucine),Disease
39543,Branched-chain amino acid levels (Valine),Disease
39544,High altitude adaptation,Disease
39545,Common carotid intima-media thickness in HIV negative individuals,Disease
39546,Common carotid intima-media thickness,Disease
39547,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),Disease
39548,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,Disease
39549,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,Disease
39550,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,Disease
39551,Low vWF levels,Disease
39552,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,Disease
39553,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)",Disease
39554,Objective response to lithium treatment in bipolar disorder,Disease
39555,Interleukin-10 levels,Disease
39556,Fibroblast growth factor basic levels,Disease
39557,Growth-regulated protein alpha levels,Disease
39558,Eotaxin levels,Disease
39559,Rheumatoid arthritis (ACPA-positive),Disease
39560,Waist-to-hip ratio adjusted for BMI (age <50),Disease
39561,Waist-to-hip ratio adjusted for BMI (age >50),Disease
39562,Body mass index (age <50),Disease
39563,Body mass index (age>50),Disease
39564,Interferon gamma-induced protein 10 levels,Disease
39565,Macrophage Migration Inhibitory Factor levels,Disease
39566,Interleukin-18 levels,Disease
39567,Interleukin-17 levels,Disease
39568,Immunoglobulin light chain (AL) amyloidosis,Disease
39569,TRAIL levels,Disease
39570,Plasma thyroid-stimulating hormone levels,Disease
39571,Heart rate response to beta blockers (atenolol add-on therapy),Disease
39572,Heart rate response to beta blockers,Disease
39573,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),Disease
39574,Waist-to-hip ratio adjusted for BMI x sex interaction,Disease
39575,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),Disease
39576,Yeast infection,Disease
39577,Myringotomy,Disease
39578,Measles,Disease
39579,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),Disease
39580,Neuroblastoma (1p deletion),Disease
39581,Neuroblastoma (MYCN amplification),Disease
39582,Borderline personality disorder,Disease
39583,Facial morphology (factor 22),Disease
39584,Facial morphology (factor 23),Disease
39585,"Facial morphology (factor 14, intercanthal width)",Disease
39586,"Facial morphology (factor 21, depth of nasal alae)",Disease
39587,Prevalent type 2 diabetes,Disease
39588,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),Disease
39589,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks),Disease
39590,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks),Disease
39591,Waist circumference adjusted for BMI (smoking interaction),Disease
39592,Energy expenditure (24h),Disease
39593,Bone ultrasound measurement (velocity of sound),Disease
39594,Bone ultrasound measurement (broadband ultrasound attenuation),Disease
39595,Waist circumference adjusted for BMI in non-smokers,Disease
39596,Peak insulin response,Disease
39597,Acute insulin response,Disease
39598,Insulin secretion rate,Disease
39599,BMI in non-smokers,Disease
39600,Waist circumference adjusted for BMI in smokers,Disease
39601,BMI in smokers,Disease
39602,Interleukin-9 levels,Disease
39603,Interleukin-13 levels,Disease
39604,Alcohol consumption over the past year,Disease
39605,Severe malaria (adjusted for sickle cell variant rs334),Disease
39606,Mixed cellularity Hodgkin lymphoma,Disease
39607,Severe malaria,Disease
39608,Colorectal adenoma (advanced),Disease
39609,Interleukin-8 levels,Disease
39610,Interleukin-7 levels,Disease
39611,Interleukin-5 levels,Disease
39612,CTACK levels,Disease
39613,beta-nerve growth factor levels,Disease
39614,Diastolic blood pressure (cigarette smoking interaction),Disease
39615,Major depression and alcohol dependence,Disease
39616,Facial emotion recognition (angry faces),Disease
39617,Facial emotion recognition (fearful faces),Disease
39618,Alcohol consumption (max-drinks),Disease
39619,Response to alcohol consumption (flushing response),Disease
39620,Body mass index x sex x age interaction (4df test),Disease
39621,Peanut allergy (parent-of-origin effect),Disease
39622,Peanut allergy (maternal genetic effects),Disease
39623,Idiopathic dilated cardiomyopathy,Disease
39624,Heart rate response to recovery post exercise (20 sec),Disease
39625,Decline in glucose metabolism in posterior cingulate cortex,Disease
39626,Caudate activity during reward,Disease
39627,Creatine kinase levels,Disease
39628,Response to haloperidol in schizophrenia,Disease
39629,Irritable mood,Disease
39630,Feeling miserable,Disease
39631,Systemic lupus erythematosus or rheumatoid arthritis,Disease
39632,Carotid artery external diameter,Disease
39633,Carotid artery internal diameter,Disease
39634,Antipsychotic drug-induced QTc interval change in schizophrenia,Disease
39635,Thiopurine-induced alopecia in inflammatory bowel disease,Disease
39636,Virologic severity in Herpes simplex virus type 2 infection,Disease
39637,Plantar fascial disorders,Disease
39638,Serum metabolite concentrations in chronic kidney disease,Disease
39639,Serum metabolite ratios in chronic kidney disease,Disease
39640,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,Disease
39641,Family history of Alzheimer's disease,Disease
39642,Fractional excretion of metabolites in chronic kidney disease,Disease
39643,Asthma or allergic disease (pleiotropy),Disease
39644,Erosive tooth wear (severe vs non-severe),Disease
39645,Nonsyndromic cleft lip,Disease
39647,Keratinocyte cancer (MTAG),Disease
39648,17-hydroxyprogesterone (17-OHP) levels,Disease
39649,DHEAS levels,Disease
39650,Smoking initiation (ever regular vs never regular),Disease
39651,Lysophosphatidylcholine levels,Disease
39652,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,Disease
39653,Suicide attempts in major depressive disorder,Disease
39654,Mood instability,Disease
39655,Maximum habitual alcohol consumption,Disease
39663,Phosphatidylcholine-ether levels,Disease
39665,Balding type 1,Disease
39694,Alzheimer's disease in hypertension,Disease
39698,Smoking behaviour (cigarette pack-years),Disease
39699,Subscapular skin fold thickness,Disease
39701,Cholesteryl ester levels,Disease
39706,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia,Disease
39719,Chronic central serous retinopathy,Disease
39720,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded),Disease
39721,Benign prostatic hyperplasia and lower urinary tract symptoms,Disease
39722,Fasting glucose change (long-term),Disease
39723,Fasting glucose change (short-term),Disease
39729,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils),Disease
39730,Walking difficulty in Charcot-Marie-Tooth disease 1A,Disease
39733,Diabetic retinopathy (all NPDR and PDR),Disease
39734,Proliferative diabetic retinopathy (vs no DR),Disease
39735,Free thyroxine concentration,Disease
39736,Nevus count,Disease
39737,"Infant, child and juvenile death (proportion of children died <15 years)",Disease
39738,Brain glucose metabolism (fluorodeoxyglucose uptake),Disease
39739,Suicidality (suicidal ideation/attempts),Disease
39740,Vitiligo (late onset),Disease
39741,Vitiligo (early onset),Disease
39742,Suicide attempts in schizophrenia,Disease
39743,Suicide attempts in bipolar disorder or schizophrenia,Disease
39744,Estradiol levels,Disease
39745,Albumin-globulin ratio,Disease
39746,Feeling worry,Disease
39747,Feeling hurt,Disease
39748,Feeling nervous,Disease
39749,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Disease
39750,Plasma trimethyllysine levels,Disease
39751,Urinary haptoglobin levels in type 2 diabetes,Disease
39752,Plasma haptoglobin levels in type 2 diabetes,Disease
39753,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,Disease
39754,Serum bilirubin levels x sex interaction in metabolic syndrome,Disease
39755,Cisplatin-induced ototoxicity,Disease
39759,LDL cholesterol levels in current drinkers,Disease
39760,Response to interferon treatment in hepatitis C virus genotype 3,Disease
39761,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3,Disease
39762,Thiopurine-induced leukopenia in inflammatory bowel disease,Disease
39763,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,Disease
39764,Neurociticism,Disease
39765,Autoimmune hepatitis in primary sclerosing cholangitis,Disease
39766,Liver transplant-free survival in primary sclerosing cholangitis (time to event),Disease
39767,Feeling tense,Disease
39768,Persistent hepatitis B virus infection,Disease
39769,Breast milk fatty acid composition (maternal genotype effect),Disease
39770,Breast milk fatty acid composition (infant genotype effect),Disease
39771,Aortic valve stenosis,Disease
39772,Age at first sexual intercourse,Disease
39773,Empathy quotient,Disease
39774,Nicotine withdrawal,Disease
39775,Coronary artery aneurysm in Kawasaki disease,Disease
39776,Normal facial asymmetry (angle of surface orientation score),Disease
39777,Fast beta electroencephalogram,Disease
39778,Cerebrospinal fluid biomarker levels,Disease
39779,Possible neuropathic pain in post total joint replacement surgery for osteoarthritis,Disease
39780,Moderate to vigorous physical activity levels,Disease
39781,Vigorous physical activity,Disease
39782,Strenuous sports or other exercises,Disease
39783,Blood sugar levels,Disease
39784,Alanine transaminase levels,Disease
39785,Sodium levels,Disease
39786,Chloride levels,Disease
39787,Osteoarthritis (self-reported),Disease
39788,Broad depression or major depressive disorder (self-reported),Disease
39789,Broad depression or schizophrenia,Disease
39790,Angiotensin-converting enzyme inhibitor intolerance,Disease
39791,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),Disease
39792,Cortisol levels (saliva),Disease
39793,Feeling fed-up,Disease
39794,Feeling guilty,Disease
39795,Experiencing mood swings,Disease
39796,Worry too long after an embarrassing experience,Disease
39797,Smoking behaviour (maximum cigarettes in a 24 hour period),Disease
39798,Surgical necrotising enterocolitis in extremely premature birth,Disease
39799,Nonobstructive coronary artery disease,Disease
39800,Barrett's esophagus x pack-years of smoking exposure interaction,Disease
39801,Multiple sclerosis and systolic blood pressure (pleiotropy),Disease
39802,Multiple sclerosis and body mass index (pleiotropy),Disease
39803,Multiple sclerosis and waist-to-hip-ratio (pleiotropy),Disease
39804,Multiple sclerosis and type 2 diabetes (pleiotropy),Disease
39805,Type 2 diabetes (age of onset),Disease
39806,Cough in response to angiotensin-converting enzyme inhibitor drugs,Disease
39807,Liver disease severity in Alagille syndrome,Disease
39808,Ankle injury,Disease
39809,Eye morphology,Disease
39810,Headache,Disease
39811,Binge eating behaviour and bipolar disorder,Disease
39812,Multiple keratinocyte cancers,Disease
39813,Gait speed in old age,Disease
39822,Rostral middle frontal gyrus volume,Disease
39823,Superior frontal gyrus volume,Disease
39824,Superior parietal cortex volume,Disease
39825,Pericalcarine cortex volume,Disease
39826,Lateral orbital frontal cortex volume,Disease
39827,Middle temporal gyrus volume,Disease
39828,Parahippocampal gyrus volume,Disease
39829,Precuneus cortex volume,Disease
39830,Pars triangularis volume,Disease
39831,Paracentral lobule volume,Disease
39832,Pars opercularis volume,Disease
39833,Medial orbital frontal cortex volume,Disease
39834,Cortex volume,Disease
39835,Cerebral white matter volume,Disease
39836,Intake of sweets,Disease
39837,Perceived intensity of neohesperidin dihydrochalcone,Disease
39838,Sub-cortical grey matter volume,Disease
39839,Estimated glomerular filtration rate in diabetes,Disease
39840,Perceived intensity of sweet substances,Disease
39841,Perceived sweetness of sucrose,Disease
39842,Colorectal cancer or advanced adenoma,Disease
39843,Familial lung adenocarcinoma,Disease
39844,Familial lung cancer,Disease
39846,Response to antidepressants (symptom remission),Disease
39847,Adverse response to drug,Disease
39848,Pneumococcal meningitis,Disease
39850,Corpus callosum central volume,Disease
39851,Corpus callosum mid-anterior volume,Disease
39852,Lateral ventricle volume,Disease
39853,Lateral ventricle temporal horn volume,Disease
39854,Third ventricle volume,Disease
39857,Estimated glomerular filtration rate in non-diabetics,Disease
39858,Familial squamous cell lung carcinoma,Disease
39859,Metabolite risk score for predicting weight gain,Disease
39863,Caudal anterior-cingulate cortex volume,Disease
39864,Caudal middle frontal gyrus volume,Disease
39865,Cuneus cortex volume,Disease
39867,Inferior parietal cortex volume,Disease
39868,Isthmus-cingulate cortex volume,Disease
39869,Lateral occipital cortex volume,Disease
39871,Systemising,Disease
39872,Nucleus accumbens volume,Disease
39873,Choroid plexus volume,Disease
39874,Frontal pole volume,Disease
39875,Temporal pole volume,Disease
39876,Insular cortex volume,Disease
39877,Pallidum volume,Disease
39878,Hippocampal volume,Disease
39879,Amygdala volume,Disease
39880,Thalamus volume,Disease
39881,Cerebellum white matter volume,Disease
39882,Whole brain grey matter density,Disease
39883,Intake of total sugars,Disease
39884,Perceived intensity of glucose,Disease
39885,Superior temporal sulcus banks volume,Disease
39889,Subjective response to placebo treatment in childhood asthma (change in cough/wheeze),Disease
39890,Response to placebo treatment in childhood asthma (FVC change),Disease
39891,Handedness (non-right-handed vs right-handed),Disease
39892,Nose morphology,Disease
39893,Upper eyelid morphology,Disease
39894,Verbal intelligence quotient (cesarean section interaction),Disease
39895,Performance intelligence quotient (cesarean section interaction),Disease
39896,Full scale intelligence quotient (cesarean section interaction),Disease
39897,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),Disease
39899,Bone mineral density (femoral neck) in inflammatory bowel disease,Disease
39900,Systolic blood pressure x alcohol consumption interaction (2df test),Disease
39901,Cerebrospinal fluid p-tau levels in normal cognition,Disease
39902,Logical memory (immediate recall) in normal cognition,Disease
39903,Hippocampal volume in mild cognitive impairment,Disease
39905,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,Disease
39906,Hippocampal volume in Alzheimer's disease dementia,Disease
39907,Parental longevity (mother's attained age),Disease
39908,Parental longevity (father's attained age),Disease
39909,Pulse pressure x alcohol consumption interaction (2df test),Disease
39910,Mean arterial pressure x alcohol consumption interaction (2df test),Disease
39911,Diastolic blood pressure x alcohol consumption interaction (2df test),Disease
39912,Obsessive-compulsive disorder x sex interaction,Disease
39914,Childhood dental caries in permanent teeth,Disease
39915,"Parental longevity (combined parental attained age, Martingale residuals)",Disease
39916,Parental longevity (both parents in top 10%),Disease
39917,Cerebrospinal AB1-42 levels in normal cognition,Disease
39918,Logical memory (delayed recall) in normal cognition,Disease
39919,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),Disease
39920,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),Disease
39945,Fatty acid desaturase activity (serum),Disease
39946,Asthma x Hispanic interaction (2df),Disease
39949,HDL cholesterol levels in current drinkers,Disease
39950,Regular attendance at a gym or sports club,Disease
39951,Regular attendance at a pub or social club,Disease
39952,Regular attendance at a religious group,Disease
39953,Loneliness (MTAG),Disease
39954,Pemphigus,Disease
39955,Pemphigus vulgaris,Disease
39956,Triglyceride levels in current drinkers,Disease
39957,Diabetic maculopathy in type 2 diabetes,Disease
39958,Mental health study participation (provided email address),Disease
39959,Mental health study participation (completed survey),Disease
39960,Number of alcoholic drinks required to feel an effect (long-term average),Disease
39961,Alzheimer's disease or gastroesophageal reflux disease,Disease
39963,Urea levels,Disease
39964,Diastolic blood pressure (MTAG),Disease
39992,PCSK9 levels,Disease
39998,body mass index x pumpkin consumption interaction,Disease
40003,Seropositivity for rhinovirus b peptide (twist_47860),Disease
40004,Seropositivity for enterovirus peptide (agilent_11510),Disease
40008,Seropositivity for enterovirus peptide (agilent_6487),Disease
40010,Seropositivity for enterovirus b peptide (twist_28808),Disease
40011,Seropositivity for enterovirus peptide (agilent_6423),Disease
40013,Seropositivity for escherichia coli O157:H7 str. EDL933 peptide (agilent_231281),Disease
40015,Seropositivity for human adenovirus 12 peptide (twist_43231),Disease
40020,Seropositivity for human adenovirus 12 peptide (twist_55551),Disease
40023,Seropositivity for human adenovirus c peptide (agilent_42),Disease
40025,Seropositivity for human adenovirus c peptide (agilent_2749),Disease
40026,Seropositivity for aegilops tauschii (tausch's goatgrass) peptide (twist_22888),Disease
40027,Familial combined hyperlipidemia defined by Mexico criteria,Disease
40029,Seropositivity for firmicutes peptide (agilent_150014),Disease
40031,Seropositivity for haemophilus influenzae peptide (agilent_223654),Disease
40033,Seropositivity for haemophilus influenzae peptide (agilent_229777),Disease
40037,Seropositivity for haemophilus influenzae nontypable strain 3179b peptide (agilent_223905),Disease
40039,Seropositivity for haemophilus influenzae peptide (agilent_228606),Disease
40040,Seropositivity for enterobacteria phage peptide (twist_92147),Disease
40042,Seropositivity for enterobacteria phage peptide (twist_65044),Disease
40044,Seropositivity for enterobacteria phage phi1 peptide (twist_87290),Disease
40047,Seropositivity for enterobacteria phage phi1 peptide (twist_60834),Disease
40048,Seropositivity for enterobacteriaceae peptide (agilent_241053),Disease
40050,Seropositivity for enterococcus faecalis v583 peptide (agilent_219731),Disease
40052,Seropositivity for enterococcus faecalis v583 peptide (agilent_140151),Disease
40054,Seropositivity for enterovirus b peptide (twist_28803),Disease
40056,Seropositivity for rhinovirus b peptide (twist_28813),Disease
40057,Seropositivity for enterovirus peptide (agilent_4843),Disease
40059,Seropositivity for dorea formicigenerans (agilent_160727),Disease
40060,Seropositivity for escherichia coli O157:H7 str. sakai peptide (agilent_90858),Disease
40064,Seropositivity for eubacterium peptide (agilent_101119),Disease
40066,Seropositivity for eubacterium rectale (agilent_212176),Disease
40067,Seropositivity for eubacterium rectale (agilent_108406),Disease
40068,Seropositivity for eubacterium rectale (agilent_79020),Disease
40070,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_199016),Disease
40073,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_194982),Disease
40076,Alzheimer's disease or gastroesophageal reflux disease and/or peptic ulcer disease,Disease
40079,Neurofilament light chain levels,Disease
40084,Thyroid peroxidase antibody positivity in pregnancy,Disease
40098,Cisplatin-induced nephrotoxicity (increased serum creatinine AKI-CTCAE),Disease
40100,Cisplatin-induced nephrotoxicity (decreased eGFR),Disease
40149,Retinal vascular fractal density,Disease
40154,Lysophosphatidylcholine(15:0) levels,Disease
40166,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Disease
40168,Coronary artery disease (MTAG),Disease
40172,Stroke (MTAG),Disease
40174,Alzheimer's disease (MTAG),Disease
40175,Carotid intima-media thickness (MTAG),Disease
40181,Familial combined hyperlipidemia defined by Brunzell criteria,Disease
40182,Acute encephalopathy with biphasic seizures and late reduced diffusion,Disease
40184,"Hair colour (natural, before greying): Blonde (UKB data field 1747_1)",Disease
40205,"Hair colour (natural, before greying): Red (UKB data field 1747_2)",Disease
40223,"Hair colour (natural, before greying): Light brown (UKB data field 1747_3)",Disease
40247,"Hair colour (natural, before greying): Dark brown (UKB data field 1747_4)",Disease
40301,Cognitive function (processing speed) x major depressive disorder interaction (1df),Disease
40303,Cognitive function (processing speed) x major depressive disorder interaction (2df),Disease
40332,Long-chain dicarboxylacylcarnitines levels (dominant genetic model),Disease
40338,Short-chain dicarboxylacylcarnitine levels (dominant genetic model),Disease
40342,Age related hearing loss-related regional glucose metabolism (Cochlear nucleus),Disease
40347,Thyroid peroxidase antibody levels in pregnancy,Disease
40348,Age related hearing loss-related regional glucose metabolism (Inferior colliculus),Disease
40350,Free thyroxine levels within normal range in pregnancy,Disease
40352,Subclinical hypothyroidism in pregnancy,Disease
40353,Isolated hypothyroxinemia  in pregnancy,Disease
40355,Subclinical hyperthyroidism in pregnancy,Disease
40357,Overt hyperthyroidism in pregnancy,Disease
40363,Thyroid stimulating hormone levels within normal range in pregnancy,Disease
40366,Vitamin D levels,Disease
40376,Steroid induced osteonecrosis of the femoral head and systemic lupus erythematosus,Disease
40378,Bone mineral density T score in postmenopausal osteoporosis,Disease
40380,Low hand grip strength,Disease
40382,Retinal vascular fractal dimension,Disease
40402,Occupational attainment,Disease
40404,Lifetime smoking,Disease
40412,Immunoglobulin N-glycan 10 levels,Disease
40414,Immunoglobulin N-glycan 19 levels,Disease
40416,lung cancer x sex interaction,Disease
40418,Lifetime smoking (without educational attainment),Disease
40419,Granulocyte telomere length,Disease
40421,Lymphocyte telomere length,Disease
40423,B-cell telomere length,Disease
40426,Type ii diabetes,Disease
40434,Response to gabapentin in female chronic pelvic pain,Disease
40438,Response to gabapentin in female chronic pelvic pain (side-effect burden),Disease
40446,Alzheimer's disease or peptic ulcer disease,Disease
40449,Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044),Disease
40450,Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10),Disease
40451,Hearing difficulty/problems: No (UKB data field 2247_0),Disease
40453,Hearing difficulty/problems: Yes (UKB data field 2247_1),Disease
40454,"Hair colour (natural, before greying): Black (UKB data field 1747_5)",Disease
40458,Disorders of iron metabolism (PheCode 275.1),Disease
40460,Treatment or medication use - insulin product (UKB data field 20003_1140883066),Disease
40463,Treatment or medication use - sulfasalazine (UKB data field 20003_1140909702),Disease
40465,Treatment or medication use - atorvastatin (UKB data field 20003_1141146234),Disease
40486,Cognitive function (executive function) x major depressive disorder interaction (1df),Disease
40489,Cognitive function (executive function) x major depressive disorder interaction (2df),Disease
40491,Crohn's disease or Leprosy (opposite effect),Disease
40499,Seropositivity for streptococcus pneumoniae peptide (agilent_223208),Disease
40503,Seropositivity for streptococcus pneumoniae peptide (agilent_227833),Disease
40510,Seropositivity for streptococcus pneumoniae peptide (agilent_241214),Disease
40513,Seropositivity for streptococcus pneumoniae peptide (agilent_243228),Disease
40514,Seropositivity for streptococcus pneumoniae peptide (agilent_235513),Disease
40515,Seropositivity for streptococcus pneumoniae peptide (agilent_236127),Disease
40517,Seropositivity for streptococcus pneumoniae peptide (agilent_243958),Disease
40519,Seropositivity for streptococcus pneumoniae peptide (agilent_220951),Disease
40520,Seropositivity for streptococcus pneumoniae peptide (agilent_220184),Disease
40523,Seropositivity for streptococcus pneumoniae peptide (agilent_223641),Disease
40525,Seropositivity for streptococcus pneumoniae peptide (agilent_226792),Disease
40526,Seropositivity for streptococcus pneumoniae peptide (agilent_225587),Disease
40529,Seropositivity for streptococcus pneumoniae peptide (agilent_231039),Disease
40530,Seropositivity for streptococcus pneumoniae peptide (twist_48171),Disease
40532,Seropositivity for streptococcus pneumoniae peptide (agilent_220672),Disease
40538,Seropositivity for streptococcus pneumoniae peptide (agilent_220944),Disease
40541,Seropositivity for staphylococcus aureus peptide (twist_34337),Disease
40545,Seropositivity for staphylococcus aureus peptide (twist_39975),Disease
40550,Seropositivity for staphylococcus aureus peptide (agilent_236148),Disease
40553,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204518),Disease
40555,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_134645),Disease
40558,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_26654),Disease
40561,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205649),Disease
40562,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_20117),Disease
40564,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_69388),Disease
40565,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_236929),Disease
40567,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_237201),Disease
40570,Seropositivity for staphylococcus aureus subsp. aureus strain newman peptide (agilent_239239),Disease
40573,Seropositivity for staphylococcus peptide (agilent_237677),Disease
40575,Seropositivity for staphylococcus aureus peptide (agilent_222726),Disease
40578,Seropositivity for staphylococcus aureus peptide (agilent_226247),Disease
40579,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217424),Disease
40582,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_105317),Disease
40584,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188119),Disease
40587,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_92408),Disease
40588,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_81159),Disease
40590,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204624),Disease
40591,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15915),Disease
40600,Seropositivity for staphylococcus aureus peptide (agilent_241121),Disease
40604,Seropositivity for staphylococcus aureus peptide (agilent_222381),Disease
40606,Coronary vascular stenosis,Disease
40609,Brain vascular stenosis,Disease
40611,Lifetime major depressive disorder (AutoComplete Impute),Disease
40614,Total adipose tissue,Disease
40617,Sinus bradycardia,Disease
40619,Skeletal muscle mass,Disease
40620,Seropositivity for streptococcus pyogenes peptide (agilent_241884),Disease
40621,Seropositivity for streptococcus pyogenes peptide (agilent_235068),Disease
40637,Seropositivity for streptococcus pyogenes peptide (agilent_221984),Disease
40638,Seropositivity for streptococcus pyogenes peptide (agilent_220658),Disease
40659,Seropositivity for vibrio cholerae AM-19226 peptide (agilent_188248),Disease
40660,Seropositivity for vibrio vulnificus peptide (agilent_157295),Disease
40662,Seropositivity for neisseria meningitidis peptide (agilent_223729),Disease
40664,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_28164),Disease
40666,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_30726),Disease
40674,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_1603),Disease
40676,Seropositivity for staphylococcus aureus peptide (twist_2995),Disease
40678,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_84757),Disease
40688,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187024),Disease
40690,Seropositivity for lactobacillus reuteri peptide (agilent_204160),Disease
40692,Seropositivity for root peptide (agilent_156552),Disease
40693,Seropositivity for root peptide (agilent_184788),Disease
40694,Seropositivity for struthio camelus (ostrich) peptide (twist_5109),Disease
40703,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_21920),Disease
40706,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_23359),Disease
40708,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_39688),Disease
40711,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_180726),Disease
40712,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_53453),Disease
40714,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_80555),Disease
40717,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198635),Disease
40718,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205647),Disease
40720,Lifetime major depressive disorder (MTAG),Disease
40721,Lifetime major depressive disorder (AutoComplete Impute and observed),Disease
40723,Drusen,Disease
40725,Forced vital capacity (FVC) (%),Disease
40727,Forced expiratory volume in 1 second (FEV1) (litres),Disease
40729,FEV1/FVC ratio,Disease
40732,Urine pH measurement,Disease
40734,Lifetime major depressive disorder (SoftImpute),Disease
40735,Lifetime major depressive disorder (SoftImpute and observed),Disease
40736,Seropositivity for streptococcus agalactiae peptide (agilent_241118),Disease
40738,Seropositivity for streptococcus pneumoniae peptide (agilent_243291),Disease
40739,Seropositivity for streptococcus pneumoniae peptide (agilent_241401),Disease
40741,Seropositivity for streptococcus pneumoniae peptide (agilent_223189),Disease
40743,Seropositivity for streptococcus pneumoniae peptide (agilent_223825),Disease
40747,Seropositivity for streptococcus pneumoniae peptide (agilent_223466),Disease
40748,Seropositivity for streptococcus pneumoniae peptide (agilent_221413),Disease
40750,Seropositivity for streptococcus pneumoniae peptide (agilent_233612),Disease
40755,Seropositivity for staphylococcus aureus peptide (agilent_221466),Disease
40758,Seropositivity for staphylococcus aureus peptide (agilent_237594),Disease
40761,Seropositivity for staphylococcus aureus peptide (agilent_236695),Disease
40762,Seropositivity for staphylococcus aureus peptide (agilent_222756),Disease
40764,Seropositivity for influenza a virus peptide (twist_59245),Disease
40766,Seropositivity for lachnospiraceae peptide (agilent_193943),Disease
40767,Seropositivity for lachnospiraceae peptide (agilent_141373),Disease
40769,Seropositivity for lactobacillus acidophilus peptide (agilent_24672),Disease
40770,Seropositivity for lactobacillus acidophilus peptide (agilent_189058),Disease
40772,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_13363),Disease
40773,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187025),Disease
40775,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_193278),Disease
40776,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_167634),Disease
40777,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_103772),Disease
40779,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_78561),Disease
40780,Seropositivity for staphylococcus aureus peptide (agilent_236333),Disease
40781,Seropositivity for staphylococcus aureus peptide (agilent_227810),Disease
40783,Seropositivity for staphylococcus aureus peptide (agilent_241827),Disease
40784,Seropositivity for staphylococcus aureus peptide (agilent_240086),Disease
40786,Seropositivity for staphylococcus aureus peptide (agilent_233907),Disease
40787,Seropositivity for staphylococcus aureus peptide (agilent_223217),Disease
40799,Seropositivity for staphylococcus aureus peptide (agilent_228814),Disease
40800,Seropositivity for staphylococcus aureus peptide (agilent_222322),Disease
40803,Bone density,Disease
40805,Spondylolisthesis,Disease
40808,Seropositivity for aix galericulata (mandarin duck) peptide (twist_23200),Disease
40812,Seropositivity for hordeum vulgare (barley) peptide (twist_15602),Disease
40816,Seropositivity for hordeum vulgare (barley) peptide (twist_7301),Disease
40817,Seropositivity for bifidobacterium longum 35624 peptide (agilent_29665),Disease
40819,Seropositivity for blautia obeum (agilent_133371),Disease
40821,Seropositivity for blautia producta peptide (agilent_74695),Disease
40822,Seropositivity for blautia producta peptide (agilent_122181),Disease
40824,Seropositivity for blautia producta peptide (agilent_172699),Disease
40826,Seropositivity for streptococcus agalactiae peptide (agilent_234887),Disease
40831,Seropositivity for streptococcus pneumoniae peptide (agilent_6216),Disease
40835,Seropositivity for streptococcus pneumoniae peptide (twist_15509),Disease
40837,Seropositivity for streptococcus peptide (agilent_235929),Disease
40838,Seropositivity for streptococcus peptide (agilent_223589),Disease
40839,Seropositivity for streptococcus pneumoniae peptide (agilent_242450),Disease
40841,Seropositivity for streptococcus pneumoniae peptide (agilent_229734),Disease
40843,Seropositivity for streptococcus pneumoniae peptide (agilent_221864),Disease
40847,Seropositivity for streptococcus pneumoniae peptide (agilent_229757),Disease
40851,Seropositivity for streptococcus pneumoniae peptide (agilent_224401),Disease
40853,Seropositivity for streptococcus pneumoniae peptide (agilent_231226),Disease
40859,Seropositivity for streptococcus pneumoniae peptide (agilent_243229),Disease
40861,Seropositivity for streptococcus pneumoniae peptide (agilent_226736),Disease
40867,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27538),Disease
40869,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_1075),Disease
40871,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_318),Disease
40872,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32586),Disease
40874,Seropositivity for bacteria peptide (agilent_240518),Disease
40876,Seropositivity for bubalus bubalis (buffalo) peptide (twist_22083),Disease
40878,Seropositivity for escherichia virus p1 peptide (twist_92719),Disease
40879,Seropositivity for euarchontoglires peptide (agilent_7767),Disease
40881,Seropositivity for gallus peptide (twist_24274),Disease
40882,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52109),Disease
40883,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_9904),Disease
40885,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_212),Disease
40887,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46426),Disease
40889,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27552),Disease
40890,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6936),Disease
40892,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_8059),Disease
40893,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31240),Disease
40894,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_129),Disease
40896,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_35320),Disease
40898,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7302),Disease
40900,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32108),Disease
40902,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_3328),Disease
40905,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27540),Disease
40906,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_321),Disease
40908,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34377),Disease
40909,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52019),Disease
40911,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7435),Disease
40912,Seropositivity for shigella sonnei 53g peptide (agilent_75769),Disease
40913,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27904),Disease
40914,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_54751),Disease
40916,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46937),Disease
40918,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43249),Disease
40919,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31993),Disease
40920,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_56934),Disease
40922,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6942),Disease
40924,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_4834),Disease
40926,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34869),Disease
40928,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52249),Disease
40929,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6000),Disease
40930,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7167),Disease
40931,Seropositivity for shigella sonnei 53g peptide (agilent_197679),Disease
40932,Seropositivity for lactobacillus phage (twist_95165),Disease
40933,Seropositivity for lactobacillus phage LFEINF peptide (twist_99693),Disease
40934,Seropositivity for lactobacillus phage LFEINF peptide (twist_88894),Disease
40937,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_235512),Disease
40939,Seropositivity for streptococcus pneumoniae peptide (twist_39967),Disease
40941,Seropositivity for streptococcus pneumoniae peptide (agilent_6963),Disease
40944,Seropositivity for streptococcus pneumoniae peptide (twist_34196),Disease
40946,Seropositivity for streptococcus pneumoniae peptide (twist_54623),Disease
40951,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_142700),Disease
40953,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171284),Disease
40955,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15630),Disease
40958,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_16154),Disease
40960,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188441),Disease
40965,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_79076),Disease
40968,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_90420),Disease
40971,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_62056),Disease
40974,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_96214),Disease
40975,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_49012),Disease
40976,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198671),Disease
40978,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217792),Disease
40980,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_202443),Disease
40981,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_24484),Disease
40982,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_174905),Disease
40983,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171144),Disease
40987,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_88528),Disease
40989,Seropositivity for human peptide (twist_18247),Disease
40991,Seropositivity for human huntingtin peptide (twist_34234),Disease
40992,Seropositivity for human twist-related protein 1 peptide (twist_46270),Disease
40994,Seropositivity for human peptide (twist_55461),Disease
40996,Seropositivity for ruminococcus bromii peptide (agilent_106172),Disease
40998,Seropositivity for ruminococcus torques (agilent_153754),Disease
40999,Seropositivity for secale cereale (rye) peptide (twist_23370),Disease
41000,Seropositivity for salmonella phage felixo1 peptide (twist_85996),Disease
41002,Seropositivity for shigella flexneri 2a str. 301 peptide (agilent_182601),Disease
41005,"Seropositivity (peptide co-occurrence module 19: pathobion, phages)",Disease
41008,Seropositivity (peptide co-occurrence module 21: plant thionins),Disease
41010,"Seropositivity (peptide co-occurrence module 22: bacteria, phage, allergen)",Disease
41012,Seropositivity for haemophilus influenzae peptide (agilent_224288),Disease
41014,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_32597),Disease
41017,Seropositivity for root peptide (agilent_201897),Disease
41019,Seropositivity for triticum aestivum wheat peptide (twist_41103),Disease
41020,Seropositivity for triticum aestivum (common wheat) peptide (twist_14325),Disease
41022,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_11627),Disease
41025,Seropositivity for triticum monococcum (einkorn wheat) peptide (twist_2100),Disease
41026,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_12614),Disease
41028,"Seropositivity (peptide co-occurrence module 1: CMV, (others))",Disease
41030,"Seropositivity (peptide co-occurrence module 5: bacteria, phage, autoantigens)",Disease
41031,"Seropositivity (peptide co-occurrence module 12: H. pylori, for phages))",Disease
41033,"Seropositivity (peptide co-occurrence module 13: ABC transporters , ATP-binding proteins)",Disease
41034,Seropositivity (peptide co-occurrence module 14: Enterovirus),Disease
41035,Seropositivity for meleagris gallopavo (turkey) peptide (twist_3824),Disease
41037,Seropositivity for oryza sativa (rice) peptide (twist_19685),Disease
41039,Seropositivity for ovis aries (sheep) peptide (twist_23154),Disease
41041,Seropositivity for staphylococcus aureus peptide (twist_30077),Disease
41042,Seropositivity for staphylococcus aureus peptide (twist_26858),Disease
41043,Seropositivity for staphylococcus aureus peptide (agilent_7803),Disease
41044,Seropositivity for staphylococcus aureus peptide (twist_42091),Disease
41045,Seropositivity for staphylococcus aureus clumping factor b peptide (agilent_6129),Disease
41046,Seropositivity for staphylococcaceae peptide (agilent_7434),Disease
41047,Seropositivity for staphylococcus aureus peptide (twist_34104),Disease
41048,Seropositivity for staphylococcus aureus peptide (twist_26221),Disease
41050,Seropositivity for japanese encephalitis virus peptide (agilent_9991),Disease
41051,Seropositivity for japanese encephalitis virus peptide (twist_57308),Disease
41052,Seropositivity for klebsiella phage peptide (twist_64561),Disease
41053,Seropositivity for meleagris gallopavo (turkey) peptide (twist_1792),Disease
41057,Seropositivity for staphylococcus aureus peptide (twist_35030),Disease
41059,Seropositivity for staphylococcus aureus peptide (twist_44831),Disease
41060,Seropositivity for staphylococcus aureus peptide (twist_46764),Disease
41062,Seropositivity for staphylococcus aureus peptide (twist_38332),Disease
41063,Seropositivity for staphylococcus aureus peptide (twist_38683),Disease
41067,Seropositivity for staphylococcus aureus peptide (twist_27464),Disease
41069,Seropositivity for staphylococcaceae peptide (agilent_4825),Disease
41070,Seropositivity for staphylococcaceae peptide (agilent_11147),Disease
41071,Seropositivity for staphylococcaceae peptide (agilent_1726),Disease
41074,Seropositivity for plasmodium falciparum peptide (twist_49209),Disease
41075,Seropositivity for human poliovirus peptide (twist_51547),Disease
41077,Seropositivity for porphyromonas gingivalis peptide (twist_38172),Disease
41079,Seropositivity for human alphaherpesvirus 2 peptide (twist_42886),Disease
41080,Seropositivity for human herpesvirus 1 peptide (agilent_3614),Disease
41081,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_36146),Disease
41083,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_35647),Disease
41084,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_26954),Disease
41086,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43798),Disease
41087,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_38776),Disease
41089,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_58154),Disease
41090,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_2111),Disease
41092,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27988),Disease
41094,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32572),Disease
41095,Seropositivity for bos taurus peptide (twist_36969),Disease
41096,Seropositivity for bacteria peptide (agilent_8927),Disease
41097,Seropositivity for bacteria peptide (agilent_6224),Disease
41100,Seropositivity for lactobacillus phage LFEINF peptide (twist_64023),Disease
41112,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_36361),Disease
41115,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_53018),Disease
41117,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27542),Disease
41121,Seropositivity for bacteria peptide (agilent_9701),Disease
41122,Seropositivity for human mastadenovirus peptide (agilent_9680),Disease
41123,Seropositivity for human mastadenovirus peptide (agilent_329),Disease
41126,Seropositivity for mycobacterium tuberculosis peptide (agilent_2469),Disease
41127,Seropositivity for mycobacterium tuberculosis peptide (twist_52112),Disease
41129,Seropositivity for mycobacterium tuberculosis peptide (agilent_10341),Disease
41131,Seropositivity for bos taurus peptide (twist_33039),Disease
41133,Seropositivity for bacteria peptide (agilent_240644),Disease
41134,Seropositivity for bacteria peptide (agilent_225414),Disease
41135,Seropositivity for bacteria peptide (agilent_220708),Disease
41137,Seropositivity for bacteria peptide (agilent_241029),Disease
41138,Seropositivity for lactobacillus phage phig1e peptide (twist_69609),Disease
41140,Seropositivity for lactococcus phage BIL285 peptide (twist_64633),Disease
41142,Seropositivity for listeria monocytogenes peptide (agilent_169153),Disease
41143,Seropositivity for listeria monocytogenes peptide (twist_41490),Disease
41144,Seropositivity for listeria monocytogenes peptide (agilent_118201),Disease
41145,Seropositivity for listeria phage 2389 peptide (twist_76871),Disease
41147,Glutamic oxaloacetic transaminase levels,Disease
41150,COVID-19 (covid pneumonia vs population),Disease
41152,COVID-19 (covid vs negative),Disease
41154,COVID-19 (hospitalized covid vs population),Disease
41162,Human milk oligosaccharide concentration (lacto-N-fucopentaose III),Disease
41165,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in non-secretors,Disease
41168,Platelet count during  first trimester of pregnancy,Disease
41185,Postprandial total cholesterol in HDL2,Disease
41186,Postprandial total cholesterol in HDL3,Disease
41187,Postprandial total cholesterol in HDL,Disease
41188,Postprandial apolipoprotein A-I,Disease
41189,Postprandial mean diameter of HDL particles,Disease
41190,Low testosterone levels,Disease
41191,Mean platelet volume during second trimester of pregnancy,Disease
41200,Motor coordination,Disease
41201,Perceptual and visual search speed (trail making test A),Disease
41204,Disability level (impaired activities of daily living),Disease
41206,Global cognition (Clinical Dementia Rating Scale Sum of Boxes),Disease
41212,Cognitive impairment level,Disease
41214,Postprandial serum total triglycerides,Disease
41216,Progression free survival in epithelial ovarian cancer,Disease
41227,Platelet count during  third trimester of pregnancy,Disease
41230,Platelet count at delivery,Disease
41231,Platelet count during  postpartum period,Disease
41240,Gestational thrombocytopenia,Disease
41254,Response to buprenorphine in opioid use disorder,Disease
41256,Postprandial total cholesterol in large VLDL,Disease
41257,Postprandial mean diameter of LDL particles,Disease
41258,Postprandial total cholesterol in large HDL,Disease
41259,Postprandial cholesterol esters in large HDL,Disease
41260,Postprandial cholesterol esters in medium HDL,Disease
41261,Postprandial free cholesterol in medium HDL,Disease
41262,Postprandial total lipids in medium HDL,Disease
41263,Postprandial medium HDL particle concentration,Disease
41264,Postprandial phospholipid levels in medium HDL,Disease
41265,Postprandial triglycerides levels in medium HDL,Disease
41266,Postprandial free cholesterol in large VLDL,Disease
41267,Postprandial total lipids in large VLDL,Disease
41268,Postprandial large VLDL particle concentration,Disease
41269,Postprandial phospholipid levels in large VLDL,Disease
41270,Postprandial total cholesterol in medium HDL,Disease
41271,Postprandial free cholesterol in large HDL,Disease
41272,Postprandial total lipids in large HDL,Disease
41273,Postprandial large HDL particle concentration,Disease
41274,Postprandial phospholipid levels in large HDL,Disease
41275,Postprandial triglycerides levels in large HDL,Disease
41276,Postprandial free cholesterol in medium VLDL,Disease
41277,Anxious temperament,Disease
41279,Hyperthymic temperament,Disease
41281,Platelet count during  second trimester of pregnancy,Disease
41296,Fasting total cholesterol in small VLDL,Disease
41297,Fasting cholesterol esters in small VLDL,Disease
41298,Fasting triglycerides levels in small HDL,Disease
41299,Conotruncal heart defects with normally related great vessels in 22q.11.2 deletion syndrome,Disease
41301,Conotruncal heart defects with normally related great vessels (without 22q.11.2 deletion syndrome),Disease
41309,Conotruncal heart defects with normally related great vessels,Disease
41312,Liver volume,Disease
41313,Spleen volume,Disease
41326,Postprandial triglycerides levels in chylomicrons and extremely large VLDL,Disease
41328,Fasting apolipoprotein A-I,Disease
41329,Postprandial total cholesterol in chylomicrons and extremely large VLDL,Disease
41330,Postprandial free cholesterol in chylomicrons and extremely large VLDL,Disease
41331,Postprandial total lipids in chylomicrons and extremely large VLDL,Disease
41332,Postprandial chylomicrons and extremely large VLDL particle concentration,Disease
41333,Postprandial phospholipid levels in chylomicrons and extremely large VLDL,Disease
41334,Fasting total cholesterol in HDL2,Disease
41335,Fasting total cholesterol in HDL3,Disease
41336,Fasting total cholesterol in HDL,Disease
41337,Fasting mean diameter of HDL particles,Disease
41338,Left atrial active emptying fraction,Disease
41340,Psychosis in Alzheimer's disease,Disease
41349,Cluster headache,Disease
41350,Fasting lactate,Disease
41352,Fasting total cholesterol in large HDL,Disease
41353,Fasting cholesterol esters in large HDL,Disease
41354,Fasting free cholesterol in large HDL,Disease
41355,Fasting total lipids in large HDL,Disease
41356,Fasting large HDL particle concentration,Disease
41357,Relative brain age,Disease
41363,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in secretors,Disease
41365,Fasting phospholipid levels in large HDL,Disease
41366,Fasting triglycerides levels in large HDL,Disease
41367,Fasting phospholipid levels in medium HDL,Disease
41368,Fasting triglycerides levels in medium HDL,Disease
41369,Fasting total cholesterol in medium HDL,Disease
41370,Fasting cholesterol esters in medium HDL,Disease
41371,Fasting free cholesterol in medium HDL,Disease
41372,Fasting total lipids in medium HDL,Disease
41373,Fasting medium HDL particle concentration,Disease
41374,Urgency urinary incontinence,Disease
41383,Oral glucose tolerance test-1h,Disease
41385,Gestational diabetes mellitus,Disease
41386,Oral glucose tolerance test-0h,Disease
41388,Oral glucose tolerance test-2h,Disease
41409,Glycated hemoglobin HbA1c levels,Disease
41411,hemolysis of donated blood (osmotic),Disease
41412,Bullous pemphigoid,Disease
41413,Intralaminar thalamic nuclei volume,Disease
41414,Medial thalamic nuclei volume,Disease
41415,Posterior thalamic nuclei volume,Disease
41416,Lateral thalamic nuclei volume,Disease
41435,Hemoglobin levels in non-alcoholic fatty liver disease x mastiha supplementation interaction,Disease
41436,Interleukin-10 levels in non-alcoholic fatty liver disease x mastiha supplementation interaction,Disease
41437,Heel bone mineral density x serum urate levels interaction,Disease
41438,Major depressive disorder (MTAG),Disease
41443,L1-L4 bone mineral density x serum urate levels interaction,Disease
41452,Body size (confirmatory factor analysis Factor 21),Disease
41462,Basal ganglia structure,Disease
41469,FEV1 or inflammatory bowel disease (pleiotropy),Disease
41472,FEV1 or irritable bowel syndrome (pleiotropy),Disease
41477,FVC or peptic ulcer disease (pleiotropy),Disease
41479,FVC or inflammatory bowel disease (pleiotropy),Disease
41481,FVC or irritable bowel syndrome (pleiotropy),Disease
41483,FVC or gastro-oesophageal reflux disease (pleiotropy),Disease
41485,FEV1/FVC or irritable bowel syndrome (pleiotropy),Disease
41496,Alkaline phosphatase levels,Disease
41519,Phosphate levels,Disease
41528,Anxiety disorder,Disease
41531,FEV1 or gastro-oesophageal reflux disease (pleiotropy),Disease
41532,FEV1 or peptic ulcer disease (pleiotropy),Disease
41539,FEV1/FVC or peptic ulcer disease (pleiotropy),Disease
41542,FEV1/FVC or gastro-oesophageal reflux disease (pleiotropy),Disease
41545,FEV1/FVC or inflammatory bowel disease (pleiotropy),Disease
41556,Erythrocyte sedimentation rate,Disease
41569,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (truncated),Disease
41570,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (peptide),Disease
41573,Cerebrospinal fluid soluble TREM2 levels,Disease
41583,Serum potassium levels,Disease
41584,Serum sodium levels,Disease
41586,T4 levels,Disease
41587,Total protein levels,Disease
41589,Myocardial infarction (PheCode 411.2),Disease
41590,Coronary atherosclerosis (PheCode 411.4),Disease
41591,Ulcerative colitis (PheCode 555.2),Disease
41592,Celiac disease (PheCode 557.1),Disease
41595,Platelet response to aspirin,Disease
41611,Seropositivity for bacteroides peptide (agilent_153971),Disease
41613,Seropositivity for anser anser (greylag goose) peptide (twist_23199),Disease
41615,Familial combined hyperlipidemia defined by Consensus criteria,Disease
41617,Seropositivity for klebsiella phage peptide (twist_73875),Disease
41619,Familial combined hyperlipidemia defined by Dutch criteria,Disease
41620,Seropositivity for bacteroides peptide (agilent_161799),Disease
41621,Seropositivity for bacteroides peptide (agilent_170659),Disease
41624,Seropositivity for bacilli peptide (agilent_5601),Disease
41625,Seropositivity for bacilli peptide (agilent_236678),Disease
41627,Seropositivity for streptococcus phage peptide (twist_76831),Disease
41629,Seropositivity for capra hircus (goat) peptide (twist_20844),Disease
41630,Seropositivity for clostridiales peptide (agilent_205050),Disease
41633,Seropositivity for clostridium perfringens (agilent_61837),Disease
41635,Seropositivity for clostridiales peptide (agilent_68956),Disease
41639,Seropositivity for clostridium perfringens peptide (agilent_231580),Disease
41641,Seropositivity for clostridium perfringens (agilent_107181),Disease
41642,Seropositivity for clostridium perfringens (agilent_167207),Disease
41644,Seropositivity for coxsackievirus peptide (twist_47443),Disease
41646,Seropositivity for dorea formicigenerans (agilent_198014),Disease
41648,Seropositivity for clostridiales peptide (agilent_56881),Disease
41650,Gallbladder cholecystitis,Disease
41660,Two-hour glucose,Disease
41663,Hypertension (confirmatory factor analysis Factor 12),Disease
41672,Telangiectasia (>= grade 1) in breast cancer treated with radiotherapy,Disease
41675,Joint pain (confirmatory factor analysis Factor 14),Disease
41681,Coronary artery disease (confirmatory factor analysis Factor 16),Disease
41682,Chronic pain (confirmatory factor analysis Factor 18),Disease
41683,Bone density (confirmatory factor analysis Factor 19),Disease
41696,Fasting insulin z-score (<15th percentile),Disease
41698,Fasting insulin z-score (<25th percentile),Disease
41702,Fasting insulin z-score (>50th percentile),Disease
41704,Fasting insulin z-score (>85th percentile),Disease
41707,"Placental weight (fetal genotype, adjusted for sex and gestational age)",Disease
41715,Dementia,Disease
41721,Handedness (left-handed vs. right-handed),Disease
41741,"Placental weight (fetal genotype, adjusted for sex)",Disease
41750,Vitamin B12 levels,Disease
41755,Intraocular pressure (confirmatory factor analysis Factor 26),Disease
41756,Age-related eyesight deterioration (confirmatory factor analysis Factor 27),Disease
41762,Diabetes (confirmatory factor analysis Factor 28),Disease
41765,Comfortable retirement (confirmatory factor analysis Factor 29),Disease
41767,Inflammatory markers and poor diet (confirmatory factor analysis Factor 30),Disease
41771,Endometriosis or asthma (pleiotropy),Disease
41776,Gastrointestinal issues (confirmatory factor analysis Factor 31),Disease
41779,Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35),Disease
41781,Cognition and processing speed (confirmatory factor analysis Factor 34),Disease
41784,Hearing (confirmatory factor analysis Factor 32),Disease
41796,Vitamin D insufficiency,Disease
41800,Physical activity (confirmatory factor analysis Factor 23),Disease
41802,Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24),Disease
41818,Esophageal atresia with or without tracheoesophageal fistula,Disease
41820,Vascular dementia,Disease
41824,Urbanicity (confirmatory factor analysis Factor 4),Disease
41826,Occupation and workplace environment (confirmatory factor analysis Factor 5),Disease
41828,Smoking and associated risk behaviours (confirmatory factor analysis Factor 6),Disease
41831,BMI and adiposity (confirmatory factor analysis Factor 7),Disease
41843,Trauma (confirmatory factor analysis Factor 9),Disease
41844,Educational attainment (confirmatory factor analysis Factor 10),Disease
41846,Respiratory disease (confirmatory factor analysis Factor 11),Disease
41867,Amyloid beta standardized uptake value ratio (adjusted for APOE E4 count),Disease
41890,Alcohol consumption x experiences in childhood (felt loved by family member) interaction,Disease
41892,Alcohol consumption x traumatic event in childhood (felt hated by family member) interaction,Disease
41895,Smoking x experiences in childhood (felt loved by family member) interaction,Disease
41897,Smoking x traumatic event in childhood (felt hated by family member) interaction,Disease
41898,Smoking x traumatic event in childhood (sexually molested) interaction,Disease
41902,Reduction in HbA1c levels in response to sulfonylureas treatment in type 2 diabetes,Disease
41905,Physical activity (Total log acceleration 12am-2am),Disease
41906,Physical activity (Total log acceleration 2am-4am),Disease
41907,Physical activity (Total log acceleration 10pm-12am),Disease
41908,Major depressive disorder or stress-related disorder,Disease
41962,Thrombin generation parameter (endogenous thrombin potential),Disease
41964,Bevacizumab-induced composite toxicity (either hypertension or proteinuria),Disease
41967,Sociability score,Disease
41968,Phospholipids in IDL,Disease
41971,Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG),Disease
41972,Bipolar disorder or glomerular filtration rate estimated from cystatin (MTAG),Disease
41975,Bipolar disorder or urinary albumin-to-creatinine ratio (MTAG),Disease
41977,Major depressive disorder or blood urea nitrogen levels (MTAG),Disease
41978,Triglyceride levels in LDL,Disease
41979,Mean diameter of LDL particles,Disease
41984,Stable warfarin dose,Disease
41996,Triglycerides to total lipids ratio in large VLDL,Disease
41997,Phospholipids in large VLDL,Disease
41998,Phospholipids to total lipids ratio in large VLDL,Disease
41999,Triglycerides in large VLDL,Disease
42003,Cholesteryl esters to total lipids ratio in medium LDL,Disease
42004,Free cholesterol in medium LDL,Disease
42005,Cholesterol esters in medium LDL,Disease
42006,Concentration of medium LDL particles,Disease
42014,STAMBP protein levels,Disease
42016,LTA protein levels,Disease
42018,MMP10 protein levels,Disease
42020,CXCL8 protein levels,Disease
42022,SULT1A1 protein levels,Disease
42025,SIRT2 protein levels,Disease
42026,VEGFA protein levels,Disease
42027,BMI x meat diet interaction,Disease
42028,HDL-C x sedentary time interaction,Disease
42036,Left atrial diameter,Disease
42039,High-sensitivity cardiac troponin T levels,Disease
42049,High-density lipoprotein 3 cholesterol levels,Disease
42050,Clonal hematopoiesis (mutational barcode method),Disease
42065,NT5E protein levels,Disease
42068,TXLNA protein levels,Disease
42069,MSLN protein levels,Disease
42071,MICA-MICB heterodimer protein levels,Disease
42079,RSPO3 protein levels,Disease
42081,Raynaud's syndrome,Disease
42093,Acute myeloid leukemia (normal cytogenetics),Disease
42094,Seroconversion induced by one dose of COVID-19 vaccine,Disease
42095,Seroconversion induced by two doses of COVID-19 vaccine,Disease
42112,Total lipid levels in medium LDL,Disease
42118,ASCVD risk score (Systematic Coronary Risk Evaluation 2-Older People-Lipid scores),Disease
42129,Parkinson's disease (age of onset) x smoking interaction,Disease
42133,Phospholipids in medium LDL,Disease
42144,GLO1 protein levels,Disease
42151,HAVCR1 protein levels,Disease
42153,CBLIF protein levels,Disease
42155,CA5A protein levels,Disease
42157,THBS2 protein levels,Disease
42159,Type 2 diabetes mellitus adjusted for BMI or coronary artery disease (pleiotropy),Disease
42193,Education attainment or attention deficit hyperactivity disorder,Disease
42195,Education attainment or autism spectrum disorders,Disease
42196,Education attainment or alcohol use disorders,Disease
42197,Education attainment or bipolar disorder,Disease
42198,Education attainment or cannabis use disorder,Disease
42199,Education attainment or tourettes syndrome,Disease
42203,Type 2 diabetes mellitus or coronary artery disease (pleiotropy),Disease
42218,High-sensitivity cardiac troponin T levels (MTAG),Disease
42220,High-sensitivity cardiac troponin I concentration (MTAG),Disease
42221,Serum aluminum levels,Disease
42223,Serum arsenic levels,Disease
42225,Serum barium levels,Disease
42230,Serum calcium levels,Disease
42235,Total cholesterol in HDL3,Disease
42236,Cholesterol esters in IDL,Disease
42237,Total cholesterol to total lipids ratio in IDL,Disease
42241,Free cholesterol in IDL,Disease
42243,Free cholesterol in large HDL,Disease
42248,Phospholipids in large LDL,Disease
42257,Triglycerides in large LDL,Disease
42258,Total cholesterol in HDL2,Disease
42264,Total Cholesterol in IDL,Disease
42265,Total cholesterol in large HDL,Disease
42268,Triglycerides in large HDL,Disease
42269,Phospholipids in large HDL,Disease
42271,Intestinal Behcet's disease,Disease
42274,Cholesterol esters in large VLDL,Disease
42275,Total cholesterol to total lipids ratio in large VLDL,Disease
42276,Free cholesterol in large VLDL,Disease
42281,Triglycerides to total lipids ratio in medium HDL,Disease
42282,Phospholipids to total lipids ratio in medium HDL,Disease
42283,Phospholipids in medium HDL,Disease
42286,Triglycerides in medium HDL,Disease
42293,Rectum and left colon stage I/II/IV colorectal cancer (metastasis vs no metastasis),Disease
42295,Triglycerides in IDL,Disease
42298,Major depressive disorder or glomerular filtration rate estimated from creatine (MTAG),Disease
42303,Major depressive disorder or glomerular filtration rate estimated from cystatin (MTAG),Disease
42323,Total lipids in large VLDL,Disease
42324,Total cholesterol to total lipids ratio in medium LDL,Disease
42325,Total cholesterol in medium LDL,Disease
42330,Free cholesterol levels,Disease
42332,Glycoprotein acetylation,Disease
42342,Total lipids in large HDL,Disease
42343,Mosaic loss of chromosome X,Disease
42368,Total Cholesterol in large VLDL,Disease
42370,Free cholesterol to total lipids ratio in medium HDL,Disease
42371,Total lipids in medium HDL,Disease
42372,Free cholesterol in medium HDL,Disease
42385,Total lipids in IDL,Disease
42388,Cholesterol esters in large HDL,Disease
42389,Total cholesterol to total lipids ratio in large HDL,Disease
42406,Cholesterol esters in large LDL,Disease
42407,Free cholesterol in large LDL,Disease
42408,Total lipids in large LDL,Disease
42412,Mean diameter of HDL particles,Disease
42414,Total cholesterol levels in LDL,Disease
42415,Ratio of 18:2 linoleic acid to total fatty acids,Disease
42417,Linoleic acid (18:2) levels,Disease
42425,Total cholesterol in large LDL,Disease
42426,Total cholesterol to total lipids ratio in large LDL,Disease
42435,Total cholesterol levels in medium HDL,Disease
42436,Total cholesterol to total lipids ratio in medium HDL,Disease
42439,Cholesterol esters in medium HDL,Disease
42440,Cholesteryl esters to total lipids ratio in medium HDL,Disease
42442,Plasma factor V levels (parent of origin effect) x rs75463553 interaction,Disease
42446,Free cholesterol to total lipids ratio in medium LDL,Disease
42447,Coronary artery disease or factor VIII levels (pleiotropy),Disease
42455,Skeletal age,Disease
42459,Free cholesterol in very large HDL,Disease
42460,Total lipids in very large HDL,Disease
42471,Urticaria,Disease
42477,Phospholipids in small VLDL,Disease
42478,Acute radiotoxicity in cancer (adjusted for clinical covariates),Disease
42480,Acute radiotoxicity in prostate cancer,Disease
42486,Total lipids in very large VLDL,Disease
42488,Coronary artery disease or plasminogen activator inhibitor 1 levels (pleiotropy),Disease
42491,Ischemic stroke or factor VII levels (pleiotropy),Disease
42492,Ischemic stroke or factor VIII levels (pleiotropy),Disease
42493,Ischemic stroke or von Willebrand factor levels (pleiotropy),Disease
42495,Free cholesterol in small VLDL,Disease
42496,Total lipids in small VLDL,Disease
42497,Melanoma x citrus consumption interaction (2df),Disease
42499,Total cholesterol levels in very large HDL,Disease
42501,Total cholesterol to total lipids ratio in very large HDL,Disease
42502,Cholesterol esters in very large HDL,Disease
42523,Fibrinogen levels or plasminogen activator inhibitor 1 levels (pleiotropy),Disease
42526,Fibrinogen levels or factor VII levels or factor XI levels or tissue plasminogen activator levels (pleiotropy),Disease
42527,Fibrinogen levels or tissue plasminogen activator levels (pleiotropy),Disease
42528,Venous thromboembolism or factor VII levels (pleiotropy),Disease
42532,Cholesterol esters in small VLDL,Disease
42533,Age of onset of type 1 diabetes,Disease
42534,Ischemic stroke or factor XI levels (pleiotropy),Disease
42535,Ischemic stroke or fibrinogen levels (pleiotropy),Disease
42537,Ischemic stroke or tissue plasminogen activator levels (pleiotropy),Disease
42538,Ischemic stroke or plasminogen activator inhibitor 1 levels (pleiotropy),Disease
42539,Factor VIII levels or von Willebrand factor levels (pleiotropy),Disease
42541,Fibrinogen levels or factor VII levels (pleiotropy),Disease
42550,Acute radiotoxicity in cancer,Disease
42555,Triglycerides in very large HDL,Disease
42576,Total bone mineral density x gut microbiota (genus Dialister) interaction,Disease
42578,Femur total bone mineral density x gut microbiota (genus Lactococcus) interaction,Disease
42598,Total cholesterol to total lipids ratio in small VLDL,Disease
42603,Total cholesterol levels in VLDL,Disease
42607,"gp41 C34 peptide, HIV levels",Disease
42610,Granzyme A levels,Disease
42615,Plasma titanium levels,Disease
42617,Plasma vanadium levels,Disease
42622,Phosphatidylcholine diacyl C40:6 levels,Disease
42623,Phosphatidylcholine diacyl C42:5 levels,Disease
42625,Phosphatidylcholine acyl-alkyl C34:1 levels,Disease
42626,Phosphatidylcholine acyl-alkyl C34:3 levels,Disease
42627,Phosphatidylcholine diacyl C36:3 levels,Disease
42628,Phosphatidylcholine diacyl C36:4 levels,Disease
42629,Phosphatidylcholine acyl-alkyl C38:5 levels,Disease
42630,Phosphatidylcholine acyl-alkyl C38:6 levels,Disease
42631,Phosphatidylcholine acyl-alkyl C42:1 levels,Disease
42632,Phosphatidylcholine diacyl C38:3 levels,Disease
42633,Phosphatidylcholine diacyl C38:4 levels,Disease
42634,Phosphatidylcholine diacyl C38:5 levels,Disease
42635,Phosphatidylcholine diacyl C38:6 levels,Disease
42636,Phosphatidylcholine acyl-alkyl C42:3 levels,Disease
42638,Phosphatidylcholine acyl-alkyl C42:5 levels,Disease
42640,Phosphatidylcholine acyl-alkyl C36:3 levels,Disease
42641,Phosphatidylcholine acyl-alkyl C36:4 levels,Disease
42642,Phosphatidylcholine acyl-alkyl C36:5 levels,Disease
42643,Phosphatidylcholine acyl-alkyl C32:2 levels,Disease
42644,Phosphatidylcholine diacyl C42:6 levels,Disease
42645,Phosphatidylcholine acyl-alkyl C34:2 levels,Disease
42646,Phosphatidylcholine acyl-alkyl C32:1 levels,Disease
42647,Alkylphosphatidylcholine (O-18:1/18:2) levels,Disease
42649,Alkenylphosphatidylcholine (P-16:0/20:5) levels,Disease
42651,Alkylphosphatidylcholine (O-16:0/22:6) levels,Disease
42654,Alkenylphosphatidylethanolamine (P-20:1/20:4) levels,Disease
42656,Phosphatidylglycerol (36:1) levels,Disease
42658,Phosphatidylinositol (18:0_20:3) (b) levels,Disease
42659,Phosphatidylinositol (18:0_22:4) levels,Disease
42660,Alkenylphosphatidylethanolamine (P-19:0/20:4) (a) levels,Disease
42662,Phosphatidylinositol (18:0_18:1) levels,Disease
42667,Alkenylphosphatidylethanolamine (P-18:1/20:5) (b) levels,Disease
42669,Diacylglycerol (18:1_20:3) levels,Disease
42671,Dehydrocholesteryl ester (16:0) levels,Disease
42673,Dehydrocholesteryl ester (18:1) levels,Disease
42675,C-C motif chemokine 19 levels,Disease
42680,Plasma manganese levels,Disease
42682,Plasma rubidium levels,Disease
42684,Plasma selenium levels,Disease
42686,Plasma nickel levels,Disease
42688,Plasma lead levels,Disease
42693,Revision surgery after total joint arthroplasty,Disease
42695,Revision surgery due to aseptic loosening after total hip arthroplasty,Disease
42707,Sphingomyeline C18:0 levels,Disease
42708,Tetradecadienylcarnitine levels,Disease
42709,Tetradecanoylcarnitine levels,Disease
42711,Threonine levels,Disease
42714,Pimelylcarnitine levels,Disease
42717,Sphingomyeline C16:0 levels,Disease
42719,Tryptophan levels,Disease
42721,Number of clonal hematopoiesis mutations,Disease
42723,Phosphatidylinositol (18:0_22:5) (n6) levels,Disease
42724,Phosphatidylinositol (34:1) levels,Disease
42725,Acylcarnitine (12:0) levels,Disease
42732,Acylcarnitine (16:0) levels,Disease
42740,Acylcarnitine (16:1) levels,Disease
42742,Acylcarnitine (17:0) (a) levels,Disease
42743,Acylcarnitine (17:0) (b) levels,Disease
42744,Acylcarnitine (18:0) levels,Disease
42749,Acylcarnitine (14:0) levels,Disease
42750,Acylcarnitine (15:0) (a) levels,Disease
42751,Acylcarnitine (15:0) (b) levels,Disease
42752,Acylcarnitine (18:1) levels,Disease
42755,Acylcarnitine (18:2) levels,Disease
42760,Monohexosylceramide (d16:1/20:0) levels,Disease
42767,Phosphatidylserine (36:2) levels,Disease
42769,Sphingomyelin (d18:1/20:0) levels/Sphingomyelin (d16:1/22:0) levels,Disease
42785,Serum copper levels,Disease
42788,Serum iron levels,Disease
42791,Serum magnesium levels,Disease
42792,Serum manganese levels,Disease
42795,Serum molybdenum levels,Disease
42797,Serum nickel levels,Disease
42800,Serum cobalt levels,Disease
42802,Serum chromium levels,Disease
42805,Cleft lip (with or without cleft palate) or cleft palate,Disease
42825,Mediator of RNA polymerase II transcription subunit 1 levels,Disease
42835,Carnitine levels,Disease
42837,Arginine levels,Disease
42839,Acetylcarnitine levels,Disease
42840,Venous thromboembolism in pregnancy,Disease
42842,Alkylphosphatidylcholine (O-16:0/16:0) levels,Disease
42844,Phosphatidylcholine (40:7) (a) levels,Disease
42846,Phosphatidylcholine (38:4) (b) levels,Disease
42847,Phosphatidylcholine (38:5) (a) levels,Disease
42848,Phosphatidylcholine (38:5) (b) levels,Disease
42849,Phosphatidylcholine (38:7) (c) levels,Disease
42850,Phosphatidylcholine (18:1_20:3) levels,Disease
42853,Phosphatidylcholine (39:5) (b) levels,Disease
42854,Alkenylphosphatidylethanolamine (P-18:0/22:6) levels,Disease
42856,Alkenylphosphatidylethanolamine (P-16:0/20:3) (a) levels,Disease
42858,Alkenylphosphatidylethanolamine (P-16:0/22:5) (n3) levels,Disease
42860,Alkenylphosphatidylethanolamine (P-16:0/22:6) levels,Disease
42862,Alkenylphosphatidylethanolamine (P-18:0/20:3) (b) levels,Disease
42863,Diacylglycerol (16:0_22:6) levels,Disease
42866,Dehydrocholesteryl ester (18:2) levels,Disease
42868,Ceramide (d19:1/26:0) levels,Disease
42870,Ceramide (d19:1/24:0) levels,Disease
42872,Phosphatidylcholine (16:0_20:3) (a) levels,Disease
42875,Phosphatidylcholine (17:0_20:4) levels,Disease
42877,Phosphatidylcholine (16:0_18:2) levels,Disease
42879,Phosphatidylcholine (15:0_20:4) levels,Disease
42880,Phosphatidylcholine (16:0_20:4) levels,Disease
42881,Phosphatidylcholine (16:0_22:6) levels,Disease
42886,Trefoil factor 3 levels,Disease
42889,Neutrophil collagenase levels,Disease
42892,Plasminogen activator inhibitor 1 levels,Disease
42897,Serum strontium levels,Disease
42900,Serum lead levels,Disease
42902,Serum rubidium levels,Disease
42904,Serum selenium levels,Disease
42907,Serum titanium levels,Disease
42910,Serum vanadium levels,Disease
42915,Cleft lip with or without cleft palate,Disease
42920,Phosphatidylcholine (18:0_20:3) levels,Disease
42923,Phosphatidylcholine (18:0_20:4) levels,Disease
42924,Phosphatidylcholine (18:0_22:5) (n3) levels/Phosphatidylcholine (20:1_20:4) levels,Disease
42926,Phosphatidylcholine (18:0_22:5) (n6) levels,Disease
42928,Phosphatidylcholine (18:0_22:6) levels,Disease
42938,Alkylphosphatidylethanolamine (O-16:0/22:6) levels,Disease
42940,Alkylphosphatidylethanolamine (O-18:0/22:6) levels,Disease
42941,Alkenylphosphatidylethanolamine (P-15:0/22:6) (a) levels,Disease
42943,Alkenylphosphatidylethanolamine (P-16:0/18:1) levels,Disease
42945,Phosphatidylethanolamine (18:0_22:5) (n3) levels,Disease
42947,Phosphatidylethanolamine (18:0_20:3) (a) levels,Disease
42953,Ceramide (d18:2/16:0) levels,Disease
42955,Ceramide (d18:2/22:0) levels,Disease
42957,Lysophosphatidylinositol (18:1) [sn1] levels,Disease
42959,Lysophosphatidylcholine (22:5) [sn2] (n3) levels,Disease
42961,Lysophosphatidylethanolamine (16:0) [sn1] levels,Disease
42962,Lysophosphatidylethanolamine (16:0) [sn2] levels,Disease
42967,Plasma copper levels,Disease
42970,Plasma iron levels,Disease
42972,Plasma cadmium levels,Disease
42974,Plasma calcium levels,Disease
42978,Revision surgery after total hip arthroplasty,Disease
42979,Revision surgery after total knee arthroplasty,Disease
42982,Kynurenine levels,Disease
42984,Lysine levels,Disease
42987,Ornithine levels,Disease
42988,Phosphatidylcholine diacyl C32:0 levels,Disease
42989,lysoPhosphatidylcholine acyl C20:3 levels,Disease
42990,lysoPhosphatidylcholine acyl C20:4 levels,Disease
42991,lysoPhosphatidylcholine acyl C26:0 levels,Disease
42992,Hexadecanoylcarnitine levels,Disease
42993,Hexadecenoylcarnitine levels,Disease
42994,Methylglutarylcarnitine levels,Disease
42995,Octadecandienylcarnitine levels,Disease
42996,Octadecanoylcarnitine levels,Disease
42997,Octadecenoylcarnitine levels,Disease
43001,Cholesteryl ester (16:0) levels,Disease
43002,Cholesteryl ester (16:2) levels,Disease
43004,Cholesteryl ester (18:0) levels,Disease
43005,Cholesteryl ester (18:3) levels,Disease
43006,Cholesteryl ester (20:3) levels,Disease
43008,Cholesteryl ester (20:5) levels,Disease
43010,Cholesteryl ester (24:5) levels,Disease
43017,Cholesteryl ester (24:6) levels,Disease
43018,Lysophosphatidylcholine (15-MHDA) [sn1] levels /Lysophosphatidylcholine (17:0) [sn2] levels,Disease
43020,Lysophosphatidylcholine (15-MHDA) [sn2] levels,Disease
43022,Lysophosphatidylcholine (18:2) [sn2] levels,Disease
43024,Lysophosphatidylcholine (20:1) [sn1] levels,Disease
43026,Lysophosphatidylcholine (20:2) [sn1] levels,Disease
43027,Lysophosphatidylcholine (22:5) [sn1] (n3) levels/Lysophosphatidylcholine (22:5) [sn2] (n6) levels,Disease
43029,Lysophosphatidylcholine (22:5) [sn1] (n6) levels,Disease
43031,Lysophosphatidylcholine (20:3) [sn1] levels,Disease
43034,Lysophosphatidylcholine (20:3) [sn2] levels,Disease
43037,Lysophosphatidylcholine (15:0) [sn1] levels,Disease
43039,Lysophosphatidylcholine (15:0) [sn2] levels,Disease
43040,Lysophosphatidylcholine (15-MHDA) [sn1]  [104_sn1] levels,Disease
43041,Monohexosylceramide (d18:1/24:1) levels,Disease
43043,Monohexosylceramide (d18:1/22:0) levels,Disease
43045,Triacylglycerol (50:2) [NL-18:2] levels,Disease
43048,Triacylglycerol (51:1) [NL-18:1] levels,Disease
43050,Triacylglycerol (54:1) [NL-18:1] levels,Disease
43051,Triacylglycerol (50:0) [NL-18:0] levels,Disease
43052,Triacylglycerol (50:1) [NL-18:1] levels,Disease
43054,Total cholesterol to total lipids ratio in medium VLDL,Disease
43055,Total cholesterol in medium VLDL,Disease
43064,Concentration of medium VLDL particles,Disease
43065,Total lipids in medium VLDL,Disease
43074,Triglycerides in small HDL,Disease
43075,Phospholipids in small HDL,Disease
43076,Sphingomyelins levels,Disease
43089,Ratio of 22:6 docosahexaenoic acid to total fatty acids,Disease
43090,Diacylglycerol levels,Disease
43091,Ratio of diacylglycerol to triglycerides,Disease
43092,Docosahexaenoic acid (22:6) levels,Disease
43099,Pulse pressure (BMI unadjusted),Disease
43102,Pulse pressure (BMI adjusted),Disease
43104,Esterified cholesterol levels,Disease
43105,Estimated description of fatty acid chain length not actual carbon number,Disease
43106,Mean arterial pressure (BMI unadjusted),Disease
43107,Total Phosphatidylserine levels,Disease
43109,Total Alkyldiacylglycerol levels,Disease
43111,Alkylphosphatidylcholine (O-34:1) levels,Disease
43112,Alkenylphosphatidylcholine (P-16:0/22:6) levels,Disease
43118,Glycated haemoglobin HbA1c levels adjusted for BMI,Disease
43160,White matter fractional anisotropy x age interaction (2df),Disease
43166,Enorma massiliensis abundance in stool,Disease
43168,Eubacterium I ramulus A abundance in stool,Disease
43169,Ezakiellaceae abundance in stool,Disease
43171,Faecalicatena glycyrrhizinilyticum abundance in stool,Disease
43173,Pediatric asthma,Disease
43175,Enteroscipio abundance in stool,Disease
43179,Geobacteraceae abundance in stool,Disease
43181,Holdemania sp900120005 abundance in stool,Disease
43183,Firmicutes E abundance in stool,Disease
43189,Klebsiella A abundance in stool,Disease
43191,Klebsiella pneumoniae abundance in stool,Disease
43193,Klebsiella abundance in stool,Disease
43195,Paraglaciecola abundance in stool,Disease
43197,Megamonas funiformis abundance in stool,Disease
43199,Methanobacterium B abundance in stool,Disease
43204,Negativibacillus massiliensis abundance in stool,Disease
43206,Sleep apnea syndrome,Disease
43213,Skin cancer,Disease
43217,Spinal canal stenosis,Disease
43219,Venous thromboembolism or factor VIII levels (pleiotropy),Disease
43220,Venous thromboembolism or von Willebrand factor levels (pleiotropy),Disease
43223,Venous thromboembolism or factor XI levels (pleiotropy),Disease
43224,Venous thromboembolism or fibrinogen levels (pleiotropy),Disease
43225,Venous thromboembolism or tissue plasminogen activator levels (pleiotropy),Disease
43226,Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy),Disease
43245,Triacylglycerol (54:4) [NL-18:0] levels,Disease
43247,Triacylglycerol (54:5) [NL-18:1] levels,Disease
43248,Triacylglycerol (56:6) [NL-20:4] levels,Disease
43250,Total Phosphatidylcholine levels,Disease
43252,Alkylphosphatidylcholine (O-32:1) levels,Disease
43253,Total Phosphatidylinositol levels,Disease
43255,Sphingomyelin (d19:1/24:1) levels,Disease
43257,Sulfatide (d18:1/16:0) levels,Disease
43259,Total Triacylglycerol levels,Disease
43261,Alkyldiacylglycerol (O-50:1) [NL-16:0] levels,Disease
43262,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels,Disease
43263,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels,Disease
43264,Total Acylcarnitine levels,Disease
43265,Total Cholesteryl ester levels,Disease
43267,Total Dehydrocholesteryl ester levels,Disease
43270,Alkenylphosphatidylcholine (P-16:0/16:0) levels,Disease
43273,Asthma-COPD overlap syndrome,Disease
43287,Vascular endothelial growth factor A level in Chronic kidney disease with hypertension and no diabetes (2597_8),Disease
43289,Adhesion G protein-coupled receptor F5 level in Chronic kidney disease with hypertension and no diabetes (6409_57),Disease
43291,Tenascin-X level in Chronic kidney disease with hypertension and no diabetes (5698_60),Disease
43293,Retinoic acid early transcript 1L protein level in Chronic kidney disease with hypertension and no diabetes (20526_3),Disease
43295,Izumo sperm-egg fusion protein 4 level in Chronic kidney disease with hypertension and no diabetes (20549_1),Disease
43296,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (5992_50),Disease
43298,Protein Mdm4 level in Chronic kidney disease with hypertension and no diabetes (13229_20),Disease
43301,Interleukin-36 alpha level in Chronic kidney disease with hypertension and no diabetes (14150_7),Disease
43303,Prolyl endopeptidase level in Chronic kidney disease with hypertension and no diabetes (14273_19),Disease
43304,Butyrophilin subfamily 3 member A2 level in Chronic kidney disease with hypertension and no diabetes (21433_3),Disease
43306,MTSS1-like protein level in Chronic kidney disease with hypertension and no diabetes (25252_29),Disease
43308,Interleukin-21 level in Chronic kidney disease with hypertension and no diabetes (7124_18),Disease
43310,Uncharacterized metallophosphoesterase CSTP1 level in Chronic kidney disease with hypertension and no diabetes (21108_5),Disease
43312,MHC class I polypeptide-related sequence A level in Chronic kidney disease with hypertension and no diabetes (2730_58),Disease
43314,"Vascular endothelial growth factor A, isoform 121 level in Chronic kidney disease with hypertension and no diabetes (14032_2)",Disease
43315,Alpha-L-fucoside fucohydrolase level in Chronic kidney disease with hypertension and no diabetes (21384_2),Disease
43316,Neutrophil collagenase level in Chronic kidney disease with hypertension and no diabetes (2954_56),Disease
43317,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 level in Chronic kidney disease with hypertension and no diabetes (6556_5),Disease
43318,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (6713_4),Disease
43320,Hemoglobin subunit zeta level in Chronic kidney disease with hypertension and no diabetes (6919_3),Disease
43322,Haptoglobin level in Chronic kidney disease with hypertension and no diabetes (3054_3),Disease
43323,Sialidase-1 level in Chronic kidney disease with hypertension and no diabetes (15426_5),Disease
43325,N-sulphoglucosamine sulphohydrolase level in Chronic kidney disease with hypertension and no diabetes (21766_50),Disease
43327,HLA-C level in Chronic kidney disease with hypertension and no diabetes (21797_4),Disease
43328,"Neuregulin-1, sensory and motor neuron-derived factor isoform level in Chronic kidney disease with hypertension and no diabetes (15446_25)",Disease
43329,5'-Nucleotidase level in Chronic kidney disease with hypertension and no diabetes (15452_5),Disease
43331,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (15462_28),Disease
43333,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (15472_16),Disease
43335,Vascular non-inflammatory molecule 2 level in Chronic kidney disease with hypertension and no diabetes (15480_2),Disease
43337,Glutamate receptor 4 level in Chronic kidney disease with hypertension and no diabetes (10760_107),Disease
43339,Cerebellin-2 level in Chronic kidney disease with hypertension and no diabetes (21887_2),Disease
43341,Apolipoprotein M level in Chronic kidney disease with hypertension and no diabetes (10445_20),Disease
43343,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (14696_45),Disease
43345,Coiled-coil domain-containing protein 134 level in Chronic kidney disease with hypertension and no diabetes (15300_66),Disease
43346,Thioredoxin-like protein 4B level in Chronic kidney disease with hypertension and no diabetes (15316_262),Disease
43348,Stromal cell-derived factor 2 level in Chronic kidney disease with hypertension and no diabetes (15333_11),Disease
43350,alpha-2-macroglobulin receptor-associated protein level in Chronic kidney disease with hypertension and no diabetes (3640_14),Disease
43351,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (3676_15),Disease
43352,Spermatogenesis-associated protein 20 level in Chronic kidney disease with hypertension and no diabetes (11117_2),Disease
43355,CD109 antigen level in Chronic kidney disease with hypertension and no diabetes (3290_50),Disease
43357,Heparin cofactor 2 level in Chronic kidney disease with hypertension and no diabetes (3316_58),Disease
43358,Complement C4b level in Chronic kidney disease with hypertension and no diabetes (2182_54),Disease
43359,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (3403_1),Disease
43361,Calsequestrin-1 level in Chronic kidney disease with hypertension and no diabetes (11263_57),Disease
43362,Cyclic AMP-responsive element-binding protein 3-like protein 4 level in Chronic kidney disease with hypertension and no diabetes (11308_8),Disease
43363,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 level in Chronic kidney disease with hypertension and no diabetes (16900_29),Disease
43365,"Alanine--tRNA ligase, cytoplasmic level in Chronic kidney disease with hypertension and no diabetes (12340_17)",Disease
43367,"Aspartate aminotransferase, mitochondrial level in Chronic kidney disease with hypertension and no diabetes (18233_10)",Disease
43369,Ermin level in Chronic kidney disease with hypertension and no diabetes (23425_19),Disease
43370,Methyltransferase-like protein 2B level in Chronic kidney disease with hypertension and no diabetes (23558_33),Disease
43371,Coiled-coil domain-containing protein 94 level in Chronic kidney disease with hypertension and no diabetes (23571_93),Disease
43372,GATA zinc finger domain-containing protein 1 level in Chronic kidney disease with hypertension and no diabetes (22154_37),Disease
43373,Complement factor B level in Chronic kidney disease with hypertension and no diabetes (4129_72),Disease
43375,Butyrophilin subfamily 2 member A2 level in Chronic kidney disease with hypertension and no diabetes (22586_24),Disease
43376,Collagen alpha-1(X) chain level in Chronic kidney disease with hypertension and no diabetes (15653_9),Disease
43378,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (16057_6),Disease
43379,Triggering receptor expressed on myeloid cells 2 level in Chronic kidney disease with hypertension and no diabetes (16300_4),Disease
43381,"Vascular endothelial growth factor A, isoform 121 level in Chronic kidney disease with hypertension and no diabetes (4867_15)",Disease
43382,Apolipoprotein L1 level in Chronic kidney disease with hypertension and no diabetes (11510_31),Disease
43384,Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Disease
43385,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (17692_2),Disease
43386,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (22950_6),Disease
43388,Endophilin-A3 level in Chronic kidney disease with hypertension and no diabetes (23029_3),Disease
43389,Tapasin level in Chronic kidney disease with hypertension and no diabetes (12378_71),Disease
43391,Dipeptidase 1 level in Chronic kidney disease with hypertension and no diabetes (8794_13),Disease
43393,Dipeptidase 2 level in Chronic kidney disease with hypertension and no diabetes (8327_26),Disease
43395,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (8330_1),Disease
43397,Zymogen granule membrane protein 16 level in Chronic kidney disease with hypertension and no diabetes (8219_14),Disease
43401,Triggering receptor expressed on myeloid cells 1 level in Chronic kidney disease with hypertension and no diabetes (9266_1),Disease
43403,Cysteine-rich secretory protein 2 level in Chronic kidney disease with hypertension and no diabetes (9282_12),Disease
43405,Cerebellin-1 level in Chronic kidney disease with hypertension and no diabetes (9313_27),Disease
43406,WAP four-disulfide core domain protein 1 level in Chronic kidney disease with hypertension and no diabetes (9316_67),Disease
43407,Trimeric intracellular cation channel type B level in Chronic kidney disease with hypertension and no diabetes (9509_4),Disease
43408,"HLA class II histocompatibility antigen, DQ alpha 2 chain level in Chronic kidney disease with hypertension and no diabetes (7757_5)",Disease
43409,Haptoglobin isoform 2 level in Chronic kidney disease with hypertension and no diabetes (7905_30),Disease
43410,"Glycoprotein endo-alpha-1,2-mannosidase level in Chronic kidney disease with hypertension and no diabetes (8014_359)",Disease
43412,DnaJ homolog subfamily C member 4 level in Chronic kidney disease with hypertension and no diabetes (8016_19),Disease
43413,"Ferritin, mitochondrial level in Chronic kidney disease with hypertension and no diabetes (8048_9)",Disease
43414,Cadherin-11 level in Chronic kidney disease with hypertension and no diabetes (9604_14),Disease
43416,T-cell surface protein tactile level in Chronic kidney disease with hypertension and no diabetes (9735_44),Disease
43417,NAD(P)H dehydrogenase [quinone] 1 level in Chronic kidney disease with hypertension and no diabetes (9837_60),Disease
43427,Suicide attempts,Disease
43429,Circulating levels of total-tau,Disease
43435,Overall survival in advanced colorectal cancer,Disease
43448,Fasting insulin adjusted for BMI,Disease
43458,Acute graft-versus-host disease (stage 2 to 4) (donor effect),Disease
43460,Acute graft-versus-host disease (stage 2b to 4) (donor effect),Disease
43462,Acute graft-versus-host disease (gut) (donor effect),Disease
43464,Chronic graft-versus-host disease (recipient effect),Disease
43489,Guanylate-binding protein 2 level in Chronic kidney disease with hypertension and no diabetes (18891_98),Disease
43490,Katanin p60 ATPase-containing subunit A-like 1 level in Chronic kidney disease with hypertension and no diabetes (24494_67),Disease
43492,MHC class I polypeptide-related sequence B level in Chronic kidney disease with hypertension and no diabetes (5102_55),Disease
43493,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D level in Chronic kidney disease with hypertension and no diabetes (5255_22)",Disease
43494,Histone deacetylase complex subunit SAP30 level in Chronic kidney disease with hypertension and no diabetes (12888_18),Disease
43495,Isoform L-VEGF165 level in Chronic kidney disease with hypertension and no diabetes (19437_61),Disease
43497,Chymotrypsinogen B2 level in Chronic kidney disease with hypertension and no diabetes (5648_28),Disease
43513,Glaucoma (low intraocular pressure),Disease
43514,CD127 on CD28+ CD45RA+ CD8+ T cell,Disease
43516,CD127 on CD28- CD8+ T cell,Disease
43518,CD127 on CD4+ T cell,Disease
43520,CD45 on CD4+ T cell,Disease
43522,CD127 on CD45RA+ CD4+ T cell,Disease
43524,CD45 on HLA DR+ T cell,Disease
43526,CCR7 on naive CD8+ T cell,Disease
43529,CD45 on HLA DR+ CD4+ T cell,Disease
43531,CD127 on CD28+ CD4+ T cell,Disease
43532,CD127 on CD28+ CD4-CD8- T cell,Disease
43534,CD4 on monocyte,Disease
43535,CD4 on HLA DR+ CD4+ T cell,Disease
43537,HippSubfield lh volume subiculum-head,Disease
43539,CD16-CD56 on Natural Killer T,Disease
43540,CD28 on CD45RA+ CD4+ T cell,Disease
43541,CD34 on Hematopoietic Stem Cell,Disease
43543,HVEM on naive CD8+ T cell,Disease
43545,CD28 on CD28+ CD4+ T cell,Disease
43546,CD28 on CD28+ CD4-CD8- T cell,Disease
43547,CD28 on CD28+ CD45RA+ CD8+ T cell,Disease
43549,CD28 on CD4+ T cell,Disease
43550,CD28 on resting CD4 regulatory T cell,Disease
43551,aseg rh volume choroid-plexus,Disease
43552,aseg rh volume Lateral-Ventricle,Disease
43553,CCR7 on naive CD4+ T cell,Disease
43554,HLA DR on CD14- CD16+ monocyte,Disease
43556,HLA DR on plasmacytoid Dendritic Cell,Disease
43557,HLA DR on Dendritic Cell,Disease
43560,HLA DR on Hematopoietic Stem Cell,Disease
43562,HLA DR on CD33+ HLA DR+ CD14-,Disease
43565,HLA DR on CD33+ HLA DR+ CD14dim,Disease
43566,HLA DR on CD33dim HLA DR+ CD11b+,Disease
43570,HLA DR on CD33dim HLA DR+ CD11b-,Disease
43572,HLA DR on CD33- HLA DR+,Disease
43573,CD11c on myeloid Dendritic Cell,Disease
43577,CD11c on CD62L+ myeloid Dendritic Cell,Disease
43579,CD11c on monocyte,Disease
43581,CD11c on granulocyte,Disease
43583,HLA DR on HLA DR+ T cell,Disease
43585,HLA DR on HLA DR+ CD4+ T cell,Disease
43586,HLA DR on B cell,Disease
43589,HLA DR on HLA DR+ Natural Killer,Disease
43592,CD8 on CD28+ CD45RA- CD8+ T cell,Disease
43594,CD8 on CD28+ CD45RA+ CD8+ T cell,Disease
43596,CD8 on CD28- CD8+ T cell,Disease
43597,CD8 on CD39+ CD8+ T cell,Disease
43599,IDP SWI T2star left putamen,Disease
43600,IDP SWI T2star right putamen,Disease
43602,HLA DR on myeloid Dendritic Cell,Disease
43611,IDP dMRI ProbtrackX L2 unc r,Disease
43612,IDP dMRI ProbtrackX L1 unc r,Disease
43613,IDP dMRI ProbtrackX L2 ifo l,Disease
43614,IDP dMRI ProbtrackX L1 unc l,Disease
43616,aparc-pial rh area TotalSurface,Disease
43617,aparc-pial rh area caudalmiddlefrontal,Disease
43618,aparc-pial rh area cuneus,Disease
43619,aparc-pial rh area lateraloccipital,Disease
43620,aparc-pial rh area lateralorbitofrontal,Disease
43622,aparc-pial lh area caudalmiddlefrontal,Disease
43623,aparc-pial lh area lateralorbitofrontal,Disease
43624,aparc-pial lh area pericalcarine,Disease
43626,aparc-a2009s rh area Pole-occipital,Disease
43628,aparc-a2009s rh area G-cuneus,Disease
43629,IDP dMRI TBSS ISOVF Posterior corona radiata L,Disease
43630,IDP dMRI TBSS ISOVF Posterior thalamic radiation L,Disease
43631,IDP dMRI TBSS ISOVF Sagittal stratum R,Disease
43632,IDP dMRI TBSS ISOVF Sagittal stratum L,Disease
43633,IDP dMRI TBSS ISOVF External capsule R,Disease
43635,IDP dMRI TBSS ISOVF External capsule L,Disease
43636,IDP dMRI TBSS ISOVF Cingulum cingulate gyrus R,Disease
43637,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus R,Disease
43638,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus L,Disease
43639,IDP dMRI ProbtrackX ISOVF ar r,Disease
43640,IDP T1 FAST ROIs R mid front gyrus,Disease
43641,IDP dMRI ProbtrackX ISOVF slf l,Disease
43642,IDP dMRI ProbtrackX ISOVF slf r,Disease
43644,IDP dMRI ProbtrackX ISOVF str l,Disease
43645,IDP dMRI ProbtrackX ISOVF str r,Disease
43646,IDP dMRI ProbtrackX ISOVF unc l,Disease
43647,IDP dMRI ProbtrackX ISOVF unc r,Disease
43648,IDP dMRI ProbtrackX ISOVF cgc l,Disease
43649,IDP dMRI ProbtrackX ISOVF cgc r,Disease
43650,IDP dMRI ProbtrackX ISOVF fmi,Disease
43652,IDP dMRI ProbtrackX ISOVF ifo l,Disease
43653,IDP dMRI ProbtrackX ISOVF ifo r,Disease
43654,IDP dMRI ProbtrackX ISOVF ilf l,Disease
43655,IDP dMRI ProbtrackX ISOVF ilf r,Disease
43656,IDP T1 SIENAX CSF normalised volume,Disease
43657,IDP T1 SIENAX CSF unnormalised volume,Disease
43658,aseg lh intensity Cerebellum-Cortex,Disease
43659,aseg lh intensity Thalamus-Proper,Disease
43661,aseg lh intensity Putamen,Disease
43663,wg lh intensity-contrast lateraloccipital,Disease
43665,wg lh intensity-contrast lateralorbitofrontal,Disease
43667,wg lh intensity-contrast medialorbitofrontal,Disease
43669,aseg rh intensity Cerebellum-Cortex,Disease
43670,aseg rh intensity Thalamus-Proper,Disease
43671,aseg rh intensity Putamen,Disease
43672,wg lh intensity-contrast fusiform,Disease
43674,wg lh intensity-contrast inferiorparietal,Disease
43675,wg lh intensity-contrast inferiortemporal,Disease
43676,wg lh intensity-contrast isthmuscingulate,Disease
43677,wg lh intensity-contrast bankssts,Disease
43679,Highest math class taken (MTAG),Disease
43680,Rotator cuff injury,Disease
43681,Body fat percentage and type 2 diabetes (pairwise),Disease
43682,Body mass index and HDL-C (pairwise),Disease
43683,Body mass index and LDL-C (pairwise),Disease
43684,Body mass index and triglycerides (pairwise),Disease
43685,Adipsin levels,Disease
43687,Adipsin levels in overweight individuals,Disease
43688,Adipsin levels in type 2 diabetes,Disease
43692,ghrelin levels in lean individuals,Disease
43694,ghrelin levels in overweight individuals,Disease
43696,Chronic lymphocytic leukemia (time to first treatment),Disease
43697,Gastrointestinal event in colchicine-treated recent myocardial infarction (time to event),Disease
43698,Podoconiosis,Disease
43700,HLA DR++ monocyte %monocyte,Disease
43702,HLA DR++ monocyte %leukocyte,Disease
43703,HLA DR++ monocyte Absolute Count,Disease
43705,CD4+/CD8+ T cell,Disease
43707,CD4+ T cell %T cell,Disease
43708,CD8+ T cell Absolute Count,Disease
43710,CD8+ T cell %T cell,Disease
43711,CD8dim T cell Absolute Count,Disease
43712,CD8dim T cell %T cell,Disease
43713,CD4-CD8- T cell Absolute Count,Disease
43714,CD4-CD8- T cell %T cell,Disease
43715,Lymphocyte Absolute Count,Disease
43717,T cell Absolute Count,Disease
43718,CD4+ T cell %leukocyte,Disease
43719,CD8+ T cell %leukocyte,Disease
43720,CD4+ CD8dim T cell Absolute Count,Disease
43722,CD4+ CD8dim T cell %lymphocyte,Disease
43724,CD4+ CD8dim T cell %leukocyte,Disease
43725,CD8dim T cell %leukocyte,Disease
43726,CD4-CD8- T cell %leukocyte,Disease
43727,CD8+ and CD8dim T cell %leukocyte,Disease
43728,TCRgd T cell Absolute Count,Disease
43730,TCRgd T cell %lymphocyte,Disease
43732,HLA DR+ T cell Absolute Count,Disease
43735,HLA DR+ T cell%T cell,Disease
43736,HLA DR+ T cell%lymphocyte,Disease
43738,Natural Killer T Absolute Count,Disease
43739,Natural Killer T %T cell,Disease
43740,Natural Killer T %lymphocyte,Disease
43741,HLA DR+ CD4+ T cell Absolute Count,Disease
43742,HLA DR+ CD4+ T cell %T cell,Disease
43744,HLA DR+ CD4+ T cell %lymphocyte,Disease
43745,HLA DR+ CD8+ T cell Absolute Count,Disease
43746,HLA DR+ CD8+ T cell %T cell,Disease
43747,HLA DR+ CD8+ T cell %lymphocyte,Disease
43748,CD8+ Natural Killer T Absolute Count,Disease
43750,CD8dim Natural Killer T Absolute Count,Disease
43751,CD25 on CD28+ CD4+ T cell,Disease
43753,FSC-A on plasmacytoid Dendritic Cell,Disease
43754,FSC-A on CD4+ T cell,Disease
43756,IDP dMRI ProbtrackX FA str l,Disease
43758,Brainstem global volume Whole-brainstem,Disease
43760,aparc-Desikan lh volume caudalmiddlefrontal,Disease
43761,aparc-Desikan lh volume pericalcarine,Disease
43762,Brainstem global volume Pons,Disease
43764,Brainstem global volume Medulla,Disease
43766,IDP dMRI ProbtrackX MD unc r,Disease
43767,aparc-Desikan rh area caudalmiddlefrontal,Disease
43768,aparc-Desikan rh area cuneus,Disease
43769,IDP dMRI ProbtrackX ICVF ar l,Disease
43770,IDP dMRI ProbtrackX ICVF ar r,Disease
43771,IDP dMRI ProbtrackX ICVF ifo r,Disease
43772,IDP dMRI ProbtrackX ICVF cst r,Disease
43774,IDP dMRI ProbtrackX ICVF ilf r,Disease
43775,IDP dMRI ProbtrackX ICVF ptr l,Disease
43776,IDP dMRI ProbtrackX ICVF ptr r,Disease
43777,IDP dMRI ProbtrackX ICVF slf l,Disease
43778,Keratoconus,Disease
43779,Age-related hearing impairment (MTAG),Disease
43782,Myeloperoxidase-DNA complexes,Disease
43783,Odorant perception,Disease
43784,Low hand grip strength (60 years and older) (EWGSOP),Disease
43785,Low hand grip strength (60 years and older) (FNIH),Disease
43786,Highest math class taken,Disease
43787,CD33dim HLA DR+ CD11b- Absolute Count,Disease
43789,Monocytic Myeloid-Derived Suppressor Cells Absolute Count,Disease
43790,CD28- CD4-CD8- T cell %T cell,Disease
43791,CD20 on IgD- CD38dim B cell,Disease
43793,CD20 on memory B cell,Disease
43796,CD20 on naive-mature B cell,Disease
43799,CD20 on unswitched memory B cell,Disease
43802,CD20 on switched memory B cell,Disease
43804,CD20 on IgD+ B cell,Disease
43805,CD20 on IgD+ CD38+ B cell,Disease
43808,CD20 on IgD+ CD38dim B cell,Disease
43810,CD20 on IgD- CD24- B cell,Disease
43812,CD20 on IgD- CD27- B cell,Disease
43814,CD20 on IgD- CD38- B cell,Disease
43816,CD19 on switched memory B cell,Disease
43817,CD19 on transitional B cell,Disease
43819,CD20 on B cell,Disease
43821,CD20 on CD24+ CD27+ B cell,Disease
43822,CD20 on IgD+ CD24+ B cell,Disease
43823,CD20 on IgD+ CD24- B cell,Disease
43824,CD20 on IgD+ CD38- B cell,Disease
43825,CD19 on IgD+ CD24+ B cell,Disease
43827,CD19 on IgD+ CD24- B cell,Disease
43829,CD19 on IgD+ CD38+ B cell,Disease
43830,CD19 on IgD+ CD38dim B cell,Disease
43831,CD19 on IgD- CD27- B cell,Disease
43832,CD19 on IgD- CD38- B cell,Disease
43833,CD19 on IgD- CD38dim B cell,Disease
43834,CD19 on unswitched memory B cell,Disease
43835,CD64 on CD14+ CD16- monocyte,Disease
43837,HLA DR on CD14+ CD16- monocyte,Disease
43839,CD40 on CD14- CD16+ monocyte,Disease
43841,HLA DR on CD14+ monocyte,Disease
43842,CCR2 on CD14+ CD16+ monocyte,Disease
43844,HLA DR on CD14- CD16-,Disease
43846,HLA DR on monocyte,Disease
43847,CD64 on CD14+ CD16+ monocyte,Disease
43848,CD4 on CD4+ T cell,Disease
43850,CD4 on Central Memory CD4+ T cell,Disease
43851,CD4 on naive CD4+ T cell,Disease
43853,CD4 on Effector Memory CD4+ T cell,Disease
43855,CD4 on CD45RA+ CD4+ T cell,Disease
43856,CD19 on B cell,Disease
43857,CD64 on CD14- CD16-,Disease
43859,CD64 on monocyte,Disease
43860,HLA DR on CD14+ CD16+ monocyte,Disease
43861,ThalamNuclei lh volume L-Sg,Disease
43863,wg rh intensity-contrast precuneus,Disease
43864,wg rh intensity-contrast rostralanteriorcingulate,Disease
43866,wg rh intensity-contrast rostralmiddlefrontal,Disease
43867,wg rh intensity-contrast superiorfrontal,Disease
43869,IDP dMRI TBSS MD Sagittal stratum R,Disease
43870,IDP dMRI TBSS MD Sagittal stratum L,Disease
43871,aparc-DKTatlas rh volume lingual,Disease
43872,IDP dMRI TBSS MD Corticospinal tract R,Disease
43874,aparc-DKTatlas rh volume pericalcarine,Disease
43875,IDP dMRI TBSS MD Posterior thalamic radiation R,Disease
43876,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule R,Disease
43877,aparc-DKTatlas rh area caudalmiddlefrontal,Disease
43878,aparc-DKTatlas rh area cuneus,Disease
43879,aparc-DKTatlas lh area pericalcarine,Disease
43880,IDP dMRI TBSS ICVF Posterior thalamic radiation R,Disease
43881,IDP dMRI TBSS ICVF Posterior thalamic radiation L,Disease
43882,IDP dMRI TBSS ICVF Sagittal stratum R,Disease
43883,BA-exvivo lh area BA6,Disease
43884,BA-exvivo lh area V1,Disease
43885,BA-exvivo lh area V2,Disease
43886,BA-exvivo rh area V1,Disease
43887,BA-exvivo rh area perirhinal,Disease
43889,BA-exvivo rh area entorhinal,Disease
43890,aparc-DKTatlas lh area caudalmiddlefrontal,Disease
43891,IDP dMRI TBSS ICVF Superior corona radiata R,Disease
43892,IDP dMRI TBSS ICVF Posterior corona radiata L,Disease
43893,wg rh intensity-contrast parsopercularis,Disease
43894,wg rh intensity-contrast parsorbitalis,Disease
43895,wg rh intensity-contrast parstriangularis,Disease
43896,IDP T1 FAST ROIs L intracalc cortex,Disease
43897,wg rh intensity-contrast medialorbitofrontal,Disease
43899,wg rh intensity-contrast middletemporal,Disease
43900,wg rh intensity-contrast inferiortemporal,Disease
43901,wg rh intensity-contrast lateraloccipital,Disease
43902,wg rh intensity-contrast lateralorbitofrontal,Disease
43904,IDP T1 FAST ROIs R intracalc cortex,Disease
43905,IDP T1 FAST ROIs R planum temporale,Disease
43906,IDP T1 FAST ROIs L occ pole,Disease
43908,IDP T1 FAST ROIs R cerebellum crus I,Disease
43910,IDP T1 FAST ROIs R occ pole,Disease
43911,IDP T1 FAST ROIs L caudate,Disease
43912,IDP T1 FAST ROIs L putamen,Disease
43913,IDP T1 FAST ROIs R putamen,Disease
43914,Leftright brain asymmetry,Disease
43917,Chronic pain,Disease
43918,Dilated cardiomyopathy,Disease
43919,Childhood asthma exacerbations in long-acting beta2-agonist treatment,Disease
43920,aparc-a2009s rh volume Pole-occipital,Disease
43921,aparc-Desikan lh area caudalmiddlefrontal,Disease
43922,aparc-Desikan lh area pericalcarine,Disease
43923,IDP dMRI TBSS L3 Posterior thalamic radiation L,Disease
43925,IDP dMRI TBSS L3 Sagittal stratum R,Disease
43926,IDP dMRI TBSS ICVF Superior longitudinal fasciculus R,Disease
43927,IDP dMRI TBSS ICVF Superior longitudinal fasciculus L,Disease
43928,IDP dMRI TBSS ICVF Sagittal stratum L,Disease
43938,Pancreatic ductal adenocarcinoma x smoking interaction,Disease
43939,Sick sinus syndrome,Disease
43940,Plasma Blast-Plasma Cell %lymphocyte,Disease
43942,CD8dim Natural Killer T %T cell,Disease
43943,CD8dim Natural Killer T %lymphocyte,Disease
43944,CD4-CD8- Natural Killer T Absolute Count,Disease
43945,CD4-CD8- Natural Killer T %T cell,Disease
43946,CD4-CD8- Natural Killer T %lymphocyte,Disease
43947,IgD+ CD38- B cell %B cell,Disease
43949,IgD on unswitched memory B cell,Disease
43952,IgD on transitional B cell,Disease
43954,CD3 on naive CD8+ T cell,Disease
43956,IgD on IgD+ CD24+ B cell,Disease
43958,IgD on IgD+ CD38+ B cell,Disease
43960,CD25 on IgD- CD24- B cell,Disease
43961,CD20 on transitional B cell,Disease
43963,CD24 on CD24+ CD27+ B cell,Disease
43966,CD24 on IgD+ CD24+ B cell,Disease
43970,CD24 on IgD+ CD38- B cell,Disease
43971,CD24 on IgD+ CD38+ B cell,Disease
43973,CD24 on IgD- CD38- B cell,Disease
43974,CD24 on IgD- CD38dim B cell,Disease
43975,CD24 on memory B cell,Disease
43976,CD24 on unswitched memory B cell,Disease
43977,CD24 on switched memory B cell,Disease
43978,CD24 on transitional B cell,Disease
43980,CD3 on HLA DR+ T cell,Disease
43982,CD3 on Natural Killer T,Disease
43983,CD3 on Naive CD4+ T cell,Disease
43985,CD3 on CD45RA+ CD4+ T cell,Disease
43986,IDP dMRI TBSS MO Retrolenticular part of internal capsule R,Disease
43987,IDP dMRI TBSS MO Superior corona radiata R,Disease
43989,IDP dMRI TBSS MO Superior corona radiata L,Disease
43991,IDP dMRI TBSS MO Posterior corona radiata R,Disease
43992,IDP dMRI ProbtrackX MO str l,Disease
43994,IDP dMRI ProbtrackX MO str r,Disease
43996,IDP dMRI TBSS MO Body of corpus callosum,Disease
43997,IDP dMRI TBSS MO Fornix,Disease
43998,aparc-Desikan rh volume lingual,Disease
43999,aparc-DKTatlas lh volume pericalcarine,Disease
44000,BA-exvivo rh volume V1,Disease
44001,BA-exvivo rh volume V2,Disease
44002,aparc-DKTatlas lh volume caudalanteriorcingulate,Disease
44003,aparc-DKTatlas lh volume caudalmiddlefrontal,Disease
44004,aparc-Desikan rh volume pericalcarine,Disease
44005,BA-exvivo lh volume V2,Disease
44006,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule L,Disease
44008,aparc-pial rh area pericalcarine,Disease
44009,IDP dMRI ProbtrackX L3 unc r,Disease
44010,IDP dMRI TBSS ICVF Fornix,Disease
44011,IDP dMRI TBSS ICVF Cerebral peduncle R,Disease
44012,IDP dMRI TBSS ICVF Cerebral peduncle L,Disease
44013,wg lh intensity-contrast posteriorcingulate,Disease
44015,wg lh intensity-contrast rostralanteriorcingulate,Disease
44016,wg lh intensity-contrast rostralmiddlefrontal,Disease
44017,wg lh intensity-contrast superiorfrontal,Disease
44018,wg rh intensity-contrast fusiform,Disease
44019,wg rh intensity-contrast inferiorparietal,Disease
44020,wg lh intensity-contrast frontalpole,Disease
44021,wg lh intensity-contrast temporalpole,Disease
44024,wg lh intensity-contrast superiorparietal,Disease
44025,wg lh intensity-contrast superiortemporal,Disease
44026,wg lh intensity-contrast supramarginal,Disease
44027,wg lh intensity-contrast middletemporal,Disease
44029,wg lh intensity-contrast parsopercularis,Disease
44030,wg lh intensity-contrast parsorbitalis,Disease
44032,wg lh intensity-contrast parstriangularis,Disease
44034,Rapid response to perioperative phenylephrine (change in diastolic blood pressure),Disease
44035,Liver fibrogenesis (alpha smooth muscle actin levels),Disease
44036,Liver fibrosis (total hepatic collagen content),Disease
44037,Body fat percentage and HDL-C (pairwise),Disease
44038,Body fat percentage and LDL-C (pairwise),Disease
44039,Body fat percentage and triglycerides (pairwise),Disease
44040,Interleukin-6 levels in overweight individuals,Disease
44042,Insulin levels in lean individuals,Disease
44046,Glucagon levels,Disease
44048,Glucagon levels in overweight individuals,Disease
44055,CD28- CD25++ CD8+ T cell Absolute Count,Disease
44056,CD127- CD8+ T cell Absolute Count,Disease
44057,CD28- CD8+ T cell %T cell,Disease
44059,CD28- CD8+ T cell %CD8+ T cell,Disease
44061,CD28- CD8+ T cell Absolute Count,Disease
44062,CD28+ CD45RA+ CD8+ T cell %T cell,Disease
44064,CD28+ CD45RA+ CD8+ T cell Absolute Count,Disease
44066,CD28+ CD45RA- CD8+ T cell %CD8+ T cell,Disease
44068,Naive CD4+ T cell Absolute Count,Disease
44069,Naive CD4+ T cell %CD4+ T cell,Disease
44070,Effector Memory CD4+ T cell %CD4+ T cell,Disease
44072,Effector Memory CD4+ T cell %T cell,Disease
44073,Terminally Differentiated CD4+ T cell Absolute Count,Disease
44075,Terminally Differentiated CD4+ T cell %CD4+ T cell,Disease
44076,Terminally Differentiated CD4+ T cell %T cell,Disease
44077,Naive CD8+ T cell Absolute Count,Disease
44079,Naive CD8+ T cell %T cell,Disease
44080,Effector Memory CD8+ T cell Absolute Count,Disease
44081,Terminally Differentiated CD4-CD8- T cell %T cell,Disease
44083,CD28- CD4-CD8- T cell Absolute Count,Disease
44085,CD28- CD8dim T cell %T cell,Disease
44086,CD45RA+ CD8+ T cell Absolute Count,Disease
44087,CD45RA+ CD8+ T cell %T cell,Disease
44089,Naive CD4-CD8- T cell %T cell,Disease
44090,Effector Memory CD4-CD8- T cell Absolute Count,Disease
44091,Effector Memory CD4-CD8- T cell %T cell,Disease
44092,Terminally Differentiated CD4-CD8- T cell Absolute Count,Disease
44094,CD28- CD8dim T cell Absolute Count,Disease
44095,CD28+ CD45RA+ CD8dim T cell %T cell,Disease
44097,CD28+ CD45RA+ CD8dim T cell %CD8dim T cell,Disease
44098,CD28- CD127- CD25++ CD8+ T cell Absolute Count,Disease
44100,CD25++ CD4+ T cell %T cell,Disease
44101,CD25++ CD45RA- CD4 not regulatory T cell Absolute Count,Disease
44102,CD25++ CD45RA- CD4 not regulatory T cell %T cell,Disease
44103,CD45RA- CD4+ T cell %T cell,Disease
44104,wg rh intensity-contrast temporalpole,Disease
44107,IDP T2 FLAIR BIANCA WMH volume,Disease
44108,IDP SWI T2star left thalamus,Disease
44109,CD4 on activated CD4 regulatory T cell,Disease
44111,CD4 on CD39+ secreting CD4 regulatory T cell,Disease
44112,CD45 on CD33- HLA DR+,Disease
44114,CD8 on Central Memory CD8+ T cell,Disease
44118,CD8 on naive CD8+ T cell,Disease
44119,CD8 on Effector Memory CD8+ T cell,Disease
44121,CD8 on CD8+ T cell,Disease
44122,SSC-A on CD4+ T cell,Disease
44123,SSC-A on HLA DR+ T cell,Disease
44124,CD80 on myeloid Dendritic Cell,Disease
44126,CD80 on CD62L+ myeloid Dendritic Cell,Disease
44128,CD8 on Natural Killer T,Disease
44129,CD4 on CD28+ CD4+ T cell,Disease
44130,CD4 on CD39+ activated CD4 regulatory T cell,Disease
44131,wg rh intensity-contrast superiorparietal,Disease
44132,wg rh intensity-contrast supramarginal,Disease
44133,wg rh intensity-contrast frontalpole,Disease
44134,IDP SWI T2star left caudate,Disease
44135,IDP SWI T2star right caudate,Disease
44136,SSC-A on myeloid Dendritic Cell,Disease
44138,IDP dMRI TBSS L1 Superior longitudinal fasciculus L,Disease
44139,IDP dMRI TBSS L2 Corticospinal tract R,Disease
44141,IDP dMRI TBSS L1 Corticospinal tract R,Disease
44142,IDP dMRI TBSS L1 Superior corona radiata L,Disease
44144,IDP dMRI TBSS L1 Sagittal stratum R,Disease
44145,aparc-a2009s lh area S-orbital-med-olfact,Disease
44146,IDP dMRI TBSS OD Body of corpus callosum,Disease
44147,IDP dMRI TBSS OD Superior corona radiata L,Disease
44148,IDP dMRI TBSS OD Posterior corona radiata R,Disease
44149,aparc-DKTatlas rh area insula,Disease
44151,aparc-a2009s lh area G-cuneus,Disease
44152,aparc-a2009s lh area S-calcarine,Disease
44153,IDP dMRI ProbtrackX OD str l,Disease
44154,IDP dMRI ProbtrackX OD str r,Disease
44155,IDP dMRI TBSS ISOVF Corticospinal tract R,Disease
44156,IDP dMRI TBSS ISOVF Anterior corona radiata R,Disease
44158,IDP dMRI TBSS ISOVF Anterior corona radiata L,Disease
44159,IDP dMRI TBSS ISOVF Posterior corona radiata R,Disease
44161,QC T2 FLAIR-to-T1 linear alignment discrepancy,Disease
44162,aseg lh volume VentralDC,Disease
44163,aseg lh volume choroid-plexus,Disease
44164,aseg lh volume CerebralWhiteMatter,Disease
44165,aseg global volume VentricleChoroid,Disease
44167,aseg global volume 4th-Ventricle,Disease
44168,aseg global volume WM-hypointensities,Disease
44169,IDP T1 FAST ROIs L cerebellum VIIIa,Disease
44171,IDP T1 FAST ROIs V cerebellum VIIIa,Disease
44172,IDP T1 FAST ROIs L cerebellum VIIIb,Disease
44173,IDP T1 FAST ROIs V cerebellum VIIIb,Disease
44175,IDP T1 FAST ROIs V cerebellum IX,Disease
44176,Body mass index and fasting glucose (pairwise),Disease
44177,Body mass index and systole blood pressure (pairwise),Disease
44178,Body mass index and coronary artery disease (pairwise),Disease
44179,Waist-hip ratio and HDL-C (pairwise),Disease
44180,Waist-hip ratio and systolic blood pressure (pairwise),Disease
44181,Visfatin levels in type 2 diabetes,Disease
44183,Glucose-dependent insulinotropic peptide levels,Disease
44185,Glucagon-like peptide-1 levels in overweight individuals,Disease
44187,ghrelin levels,Disease
44190,Glucose-dependent insulinotropic peptide levels in lean individuals,Disease
44192,Fibrosis-4 index in high alcohol intake,Disease
44195,Aspartate transaminase levels in high alcohol intake,Disease
44196,Forns index in high alcohol intake,Disease
44199,Hair morphology traits,Disease
44200,Depression (broad),Disease
44204,Nicotine dependence and major depression (severity of comorbidity),Disease
44205,Lateral ventricular volume in normal aging,Disease
44206,Offspring birth weight,Disease
44207,Cholesteryl ester transfer protein levels,Disease
44208,Response to opioid analgesics in cancer (pain decrease),Disease
44221,Anti-rubella virus IgG levels,Disease
44222,Subiculum volume (corrected for total hippocampal volume),Disease
44223,Ewing sarcoma,Disease
44224,Hip bone mineral density and total body fat mass (bivariate analysis),Disease
44225,Falling risk,Disease
44226,Eye color traits,Disease
44227,Anthropometric traits (multi-trait analysis),Disease
44228,Skin pigmentation traits,Disease
44229,Endometrial cancer (Non-endometrioid histology),Disease
44230,Endometrial cancer (endometrioid histology),Disease
44231,Extremely high intelligence,Disease
44247,Anorexia nervosa or obsessive-compulsive disorder,Disease
44248,Postburn scar pliability,Disease
44249,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),Disease
44250,Eudaimonic well-being,Disease
44251,Lung cancer (SNP x SNP interaction),Disease
44252,Relative amplitude of rest-activity cycles,Disease
44253,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles),Disease
44284,Adrenomedullin levels,Disease
44286,Growth differentiation factor-15 levels,Disease
44288,C-C motif chemokine 20 levels,Disease
44289,Ovarian cancer-related tumor marker CA 125 levels,Disease
44292,Cathepsin L1 levels,Disease
44296,CX3CL1 levels,Disease
44299,"Estimated glomerular filtration rate (creatinine, Rapid3)",Disease
44300,"Estimated glomerular filtration rate (creatinine, CKDi25)",Disease
44301,Stool frequency,Disease
44303,Body composition traits,Disease
44305,Gut microbiota alpha diversity (Simpson index),Disease
44307,Gut microbiota alpha diversity (Inverse Simpson index),Disease
44313,Verbal-numerical reasoning,Disease
44314,Low myopia vs hyperopia,Disease
44315,CD99L2/RARRES2 protein level ratio,Disease
44316,CD84/SDC4 protein level ratio,Disease
44318,CD84/TREML2 protein level ratio,Disease
44319,CD93/CLEC14A protein level ratio,Disease
44320,GP1BA/SDC4 protein level ratio,Disease
44322,CD79B/TNFRSF13B protein level ratio,Disease
44324,CD79B/TNFRSF4 protein level ratio,Disease
44326,CD83/HAVCR2 protein level ratio,Disease
44328,CD83/IL12A_IL12B protein level ratio,Disease
44330,CD83/LAMP3 protein level ratio,Disease
44332,CD83/TNFRSF4 protein level ratio,Disease
44334,CD83/TREM2 protein level ratio,Disease
44335,CD74/JAM2 protein level ratio,Disease
44337,CD74/LILRB4 protein level ratio,Disease
44338,CD74/NPDC1 protein level ratio,Disease
44340,CD74/TIMD4 protein level ratio,Disease
44341,CD74/TNFRSF21 protein level ratio,Disease
44343,CD79B/FCRL1 protein level ratio,Disease
44345,CD79B/FCRL2 protein level ratio,Disease
44348,CD79B/ICAM3 protein level ratio,Disease
44349,CD84/CDKN1A protein level ratio,Disease
44350,CDC37/SNX9 protein level ratio,Disease
44351,CDCP1/IL18BP protein level ratio,Disease
44353,CDCP1/MSR1 protein level ratio,Disease
44354,CDH17/GALNT3 protein level ratio,Disease
44355,GOPC/PLXNA4 protein level ratio,Disease
44356,GP1BA/HBEGF protein level ratio,Disease
44357,CD69/TXNDC5 protein level ratio,Disease
44358,CD74/DLL1 protein level ratio,Disease
44360,CD74/IL18BP protein level ratio,Disease
44362,HSPA1A/MITD1 protein level ratio,Disease
44364,HSPA1A/STIP1 protein level ratio,Disease
44367,HSPA1A/WWP2 protein level ratio,Disease
44370,HSPB1/KYAT1 protein level ratio,Disease
44371,HSPB1/PLIN3 protein level ratio,Disease
44372,HSPB1/QDPR protein level ratio,Disease
44373,HSPG2/SMOC2 protein level ratio,Disease
44374,HSPG2/VASN protein level ratio,Disease
44375,HYOU1/PTPRF protein level ratio,Disease
44376,ICAM2/IL7R protein level ratio,Disease
44377,ICAM3/LY9 protein level ratio,Disease
44380,ICAM3/NOTCH1 protein level ratio,Disease
44381,IDS/SMPDL3A protein level ratio,Disease
44382,IFNGR1/LTBR protein level ratio,Disease
44384,IGF2R/LGMN protein level ratio,Disease
44386,IGFBP6/SMOC2 protein level ratio,Disease
44387,IGSF8/NECTIN2 protein level ratio,Disease
44388,IL18BP/THBD protein level ratio,Disease
44389,IL1R2/MEGF9 protein level ratio,Disease
44391,IKBKG/TJAP1 protein level ratio,Disease
44393,IL12A_IL12B/LAG3 protein level ratio,Disease
44395,HYOU1/THBD protein level ratio,Disease
44397,HPCAL1/PLA2G4A protein level ratio,Disease
44398,HSPA1A/MGLL protein level ratio,Disease
44399,CEACAM8/PGLYRP1 protein level ratio,Disease
44401,CELA3A/CPA1 protein level ratio,Disease
44403,CELA3A/CPB1 protein level ratio,Disease
44405,CELA3A/CTRB1 protein level ratio,Disease
44407,CELA3A/CTRC protein level ratio,Disease
44408,CELA3A/KIRREL2 protein level ratio,Disease
44410,CELA3A/PLA2G1B protein level ratio,Disease
44411,CEP20/LBR protein level ratio,Disease
44413,CEP20/MED18 protein level ratio,Disease
44414,CEP20/PRKRA protein level ratio,Disease
44416,CDKN2D/TBL1X protein level ratio,Disease
44417,CDSN/KLK8 protein level ratio,Disease
44418,CDSN/LY6D protein level ratio,Disease
44419,CDSN/NECTIN4 protein level ratio,Disease
44420,CEACAM8/MMP9 protein level ratio,Disease
44421,CEP43/MPHOSPH8 protein level ratio,Disease
44422,CEP43/PLXNB3 protein level ratio,Disease
44423,IPCEF1/TXLNA protein level ratio,Disease
44425,IRAG2/WASF1 protein level ratio,Disease
44427,Type 1 diabetes (age at diagnosis),Disease
44428,Gut microbiota presence (family Pseudomonadaceae id.3718),Disease
44430,Gut microbiota abundance (order Gastranaerophilales id.1591),Disease
44432,Gut microbiota abundance (unknown family id.1000001214),Disease
44433,Episodic memory (pairs-matching),Disease
44436,Theta electroencephalogram power,Disease
44437,Ischemic stroke in hypertension,Disease
44439,Cardio-cerebrovascular disease in diabetes mellitus,Disease
44441,Coronary artery disease in hypertension,Disease
44443,Cardio-cerebrovascular disease in dyslipidemia,Disease
44446,Ischemic stroke in diabetes mellitus,Disease
44452,CD63/EDAR protein level ratio,Disease
44454,CD69/CHMP1A protein level ratio,Disease
44455,CD69/EDAR protein level ratio,Disease
44456,CD69/PLXNA4 protein level ratio,Disease
44457,HOMA-B (corrected for HOMA-IR),Disease
44458,GZMH/KLRD1 protein level ratio,Disease
44460,HAGH/HBQ1 protein level ratio,Disease
44463,HAGH/HMBS protein level ratio,Disease
44465,HAGH/PKLR protein level ratio,Disease
44466,HAGH/PSMD9 protein level ratio,Disease
44467,HAGH/UBAC1 protein level ratio,Disease
44468,HARS1/RWDD1 protein level ratio,Disease
44470,HARS1/SERPINB1 protein level ratio,Disease
44472,HAVCR2/LRRC25 protein level ratio,Disease
44473,HAVCR2/PILRA protein level ratio,Disease
44474,HAVCR2/TNFRSF1B protein level ratio,Disease
44476,HBEGF/LAT2 protein level ratio,Disease
44477,STAMBP/WWP2 protein level ratio,Disease
44479,GYS1/USP8 protein level ratio,Disease
44481,GYS1/WASF1 protein level ratio,Disease
44482,GZMA/GZMB protein level ratio,Disease
44483,GZMA/IL12A_IL12B protein level ratio,Disease
44484,GZMA/ITGB7 protein level ratio,Disease
44485,GZMA/KIR2DL3 protein level ratio,Disease
44487,GZMA/LTA protein level ratio,Disease
44488,GZMA/TNFRSF4 protein level ratio,Disease
44490,GZMA/TNFRSF8 protein level ratio,Disease
44491,GZMB/IL15 protein level ratio,Disease
44492,GP6/MANF protein level ratio,Disease
44493,GP6/SERPINB1 protein level ratio,Disease
44494,GSTA1/PBLD protein level ratio,Disease
44496,GSTA1/RBP5 protein level ratio,Disease
44497,GSTA1/SULT2A1 protein level ratio,Disease
44498,GSTA3/KRT18 protein level ratio,Disease
44499,GYS1/ITGB1BP2 protein level ratio,Disease
44500,GYS1/PPP1R2 protein level ratio,Disease
44501,GYS1/STK11 protein level ratio,Disease
44502,GYS1/SUSD1 protein level ratio,Disease
44504,GSTA1/KRT18 protein level ratio,Disease
44505,AMBP/EFEMP1 protein level ratio,Disease
44507,AMBP/HYOU1 protein level ratio,Disease
44508,ALCAM/CDH5 protein level ratio,Disease
44511,ALCAM/CNTN1 protein level ratio,Disease
44512,ALCAM/ICAM3 protein level ratio,Disease
44513,ALCAM/LRRC25 protein level ratio,Disease
44515,ALCAM/NOTCH1 protein level ratio,Disease
44517,ALCAM/SPINT1 protein level ratio,Disease
44518,ALDH1A1/CA2 protein level ratio,Disease
44519,ALDH1A1/PTS protein level ratio,Disease
44520,ANPEP/NT5E protein level ratio,Disease
44522,ANXA11/NT5C3A protein level ratio,Disease
44524,IMPA1/TBCC protein level ratio,Disease
44526,ANGPT1/CCN2 protein level ratio,Disease
44528,ANGPT1/CPXM1 protein level ratio,Disease
44530,INPP1/TBCC protein level ratio,Disease
44531,IPCEF1/SMAD1 protein level ratio,Disease
44532,ANGPT1/PDGFB protein level ratio,Disease
44533,IPCEF1/SPARC protein level ratio,Disease
44535,IPCEF1/TBCB protein level ratio,Disease
44536,IPCEF1/TBCC protein level ratio,Disease
44538,ITGA5/VCAM1 protein level ratio,Disease
44539,ITGA6/THPO protein level ratio,Disease
44540,ITGAM/ITGAV protein level ratio,Disease
44542,ITGB1BP2/LAT2 protein level ratio,Disease
44543,ITGA5/ITGB7 protein level ratio,Disease
44544,ITGB1BP2/USP8 protein level ratio,Disease
44545,ITGB1BP2/WASF1 protein level ratio,Disease
44546,ITGB1/ITGB2 protein level ratio,Disease
44548,ITGB1/MCAM protein level ratio,Disease
44550,ITGB1/VASN protein level ratio,Disease
44552,ITGB1BP2/MED18 protein level ratio,Disease
44553,ITGB1BP2/MITD1 protein level ratio,Disease
44554,ITGB1BP2/PDLIM7 protein level ratio,Disease
44555,ITGB1BP2/PLXNA4 protein level ratio,Disease
44556,ITGB1BP2/TIA1 protein level ratio,Disease
44557,ITGB1BP2/SKAP2 protein level ratio,Disease
44558,ITGB1BP2/STAT5B protein level ratio,Disease
44559,ITGB1BP2/STK11 protein level ratio,Disease
44560,ITGB1BP2/PPP1R12A protein level ratio,Disease
44561,ITGB1BP2/PTPN6 protein level ratio,Disease
44562,CD40 ligand levels,Disease
44565,Proheparin-binding EGF-like growth factor levels,Disease
44566,C-C motif chemokine 3 levels,Disease
44568,C-X-C motif chemokine 16 levels,Disease
44570,Receptor for advanced glycosylation end products levels,Disease
44574,Matrix metalloproteinase-10 levels,Disease
44576,Kidney injury molecule 1 levels,Disease
44577,Dickkopf-related protein 1 levels,Disease
44578,Galanin peptide levels,Disease
44581,Gut microbiota abundance (unknown genus id.1000001215),Disease
44582,Gut microbiota abundance (family Oxalobacteraceae id.2966),Disease
44584,Gut microbiota abundance (class Actinobacteria id.419),Disease
44586,Cognitive traits (MTAG),Disease
44589,Tuberculosis susceptibility in HIV infection,Disease
44590,Coronary artery disease in dyslipidemia,Disease
44592,Ischemic stroke in dyslipidemia,Disease
44597,Lacunar stroke,Disease
44598,CDKN2D/MANF protein level ratio,Disease
44600,CDKN2D/ITGB1BP2 protein level ratio,Disease
44601,CDKN2D/CHMP1A protein level ratio,Disease
44602,CDKN2D/CNPY4 protein level ratio,Disease
44605,CDKN2D/TACC3 protein level ratio,Disease
44606,CDKN1A/TBL1X protein level ratio,Disease
44607,CDKN1A/TMSB10 protein level ratio,Disease
44608,CDKN1A/TXLNA protein level ratio,Disease
44609,CDKN1A/YES1 protein level ratio,Disease
44610,Tumor necrosis factor receptor 2 levels,Disease
44611,Resistin levels,Disease
44614,Tumor necrosis factor receptor superfamily member 6 levels,Disease
44615,Angiopoietin-1 receptor levels,Disease
44618,Heat shock 27 kDa protein levels,Disease
44620,Myeloperoxidase levels,Disease
44621,Lectin-like oxidized LDL receptor 1 levels,Disease
44624,Tissue factor levels,Disease
44626,Type 2 diabetes or prostate cancer (pleiotropy),Disease
44627,TNF/TNFRSF1B protein level ratio,Disease
44628,TRAF2/WWP2 protein level ratio,Disease
44629,USP8/WASF1 protein level ratio,Disease
44630,HBEGF/PDGFA protein level ratio,Disease
44631,TNFRSF1A/TNFRSF1B protein level ratio,Disease
44632,TNFRSF4/TNFRSF9 protein level ratio,Disease
44633,TBCC/TXLNA protein level ratio,Disease
44634,TBCC/WWP2 protein level ratio,Disease
44635,TCL1A/TNFRSF13C protein level ratio,Disease
44636,TGFBI/VASN protein level ratio,Disease
44637,TGFBR2/THBD protein level ratio,Disease
44639,STAT5B/WASF1 protein level ratio,Disease
44640,STK4/VTA1 protein level ratio,Disease
44641,SUGT1/TBL1X protein level ratio,Disease
44642,SULT1A1/VTA1 protein level ratio,Disease
44643,SUSD1/THPO protein level ratio,Disease
44644,TNFRSF13B/TNFRSF9 protein level ratio,Disease
44645,TACC3/TBC1D23 protein level ratio,Disease
44646,TACC3/TRIAP1 protein level ratio,Disease
44647,TBCB/TBCC protein level ratio,Disease
44648,CDH5/PTPRM protein level ratio,Disease
44649,CDH5/TEK protein level ratio,Disease
44651,CDKN1A/CDKN2D protein level ratio,Disease
44652,CDKN1A/DAB2 protein level ratio,Disease
44653,CDH17/SPINT1 protein level ratio,Disease
44654,CDH3/NECTIN4 protein level ratio,Disease
44655,CDH3/TNFRSF21 protein level ratio,Disease
44656,CDH5/ENG protein level ratio,Disease
44657,CDH5/NOTCH1 protein level ratio,Disease
44658,ANXA3/EDAR protein level ratio,Disease
44659,ANXA3/RWDD1 protein level ratio,Disease
44660,ANXA3/SERPINB1 protein level ratio,Disease
44661,ANXA4/HSPB1 protein level ratio,Disease
44662,CDKN1A/TACC3 protein level ratio,Disease
44663,CDKN1A/TBC1D23 protein level ratio,Disease
44664,CDKN1A/FXN protein level ratio,Disease
44665,CDKN1A/HBEGF protein level ratio,Disease
44666,CDKN1A/NCK2 protein level ratio,Disease
44667,CDKN1A/PLA2G4A protein level ratio,Disease
44668,CDKN1A/DNAJB1 protein level ratio,Disease
44669,CDKN1A/ENO2 protein level ratio,Disease
44670,CDKN1A/FOXO1 protein level ratio,Disease
44671,Aspartate aminotransferase platelet ratio index in high alcohol intake,Disease
44674,Ondansetron-induced QT prolongation,Disease
44675,Carotid artery stenosis,Disease
44676,Gut microbiota presence (family Bacteroidales S24 7group id.11173),Disease
44677,Gut microbiota presence (genus Lachnospiraceae UCG 010 id.11330),Disease
44679,Gut microbiota presence (genus Anaerostipes id.1991),Disease
44682,Alzheimer's disease or LDL levels (pleiotropy),Disease
44683,Tinnitus,Disease
44684,Low myopia,Disease
44685,Mitochondrial heteroplasmy measurement,Disease
44686,LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Disease
44687,Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Disease
44688,Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Disease
44689,LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder,Disease
44690,HDL levels x fish oil supplementation interaction (2df),Disease
44691,HDL levels x fish oil supplementation interaction (1df),Disease
44692,Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder,Disease
44693,HLAE/LILRB1 protein level ratio,Disease
44695,HMBS/PKLR protein level ratio,Disease
44696,HMBS/PSMG3 protein level ratio,Disease
44698,HMBS/TGM2 protein level ratio,Disease
44699,HBEGF/PFKFB2 protein level ratio,Disease
44700,HBEGF/PLXNA4 protein level ratio,Disease
44701,HBEGF/SDC4 protein level ratio,Disease
44702,HBEGF/WWP2 protein level ratio,Disease
44703,HBEGF/YES1 protein level ratio,Disease
44704,HBQ1/HMBS protein level ratio,Disease
44707,HBEGF/PDGFB protein level ratio,Disease
44708,HEXIM1/IKBKG protein level ratio,Disease
44709,HEXIM1/STK11 protein level ratio,Disease
44710,HEXIM1/IPCEF1 protein level ratio,Disease
44711,HEXIM1/SRPK2 protein level ratio,Disease
44712,JAM2/TGFBR2 protein level ratio,Disease
44713,JAM2/TNFRSF21 protein level ratio,Disease
44715,KIRREL2/PLA2G1B protein level ratio,Disease
44717,KLK6/MOG protein level ratio,Disease
44718,KLRB1/KLRD1 protein level ratio,Disease
44720,CHMP1A/VASH1 protein level ratio,Disease
44721,CHRDL1/SMOC2 protein level ratio,Disease
44722,CIAPIN1/MSRA protein level ratio,Disease
44724,CIAPIN1/PARK7 protein level ratio,Disease
44726,CIAPIN1/PLA2G4A protein level ratio,Disease
44727,CIAPIN1/PLPBP protein level ratio,Disease
44729,CIAPIN1/SNX9 protein level ratio,Disease
44730,KIFBP/TACC3 protein level ratio,Disease
44731,CHAC2/GMPR protein level ratio,Disease
44732,Monoclonal gammopathy of undetermined significance,Disease
44746,Energy expenditure,Disease
44750,Skin reflectance (Melanin index),Disease
44751,Pemphigus foliaceus,Disease
44755,Iris color (b* coordinate),Disease
44756,Anxiety/tension (special factor of neuroticism),Disease
44757,3-month functional outcome in ischaemic stroke (modified Rankin score),Disease
44758,3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score),Disease
44770,General factor of neuroticism,Disease
44781,Post bronchodilator FEV1/FVC ratio in smoking,Disease
44786,Obesity without metabolic disease,Disease
44792,Bronchopulmonary dysplasia in preterm infants,Disease
44793,Plasma parathyroid hormone levels,Disease
44794,Cannabis use,Disease
44795,Abdominal aortic aneurysm,Disease
44796,Response to antidepressants (symptom improvement),Disease
44797,Remission after antidepressant treatment in major depression,Disease
44798,Alpha synuclein levels (MTAG),Disease
44799,Response to lurasidone in schizophrenia,Disease
44800,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma,Disease
44801,High IL-1beta levels in gingival crevicular fluid,Disease
44802,Uterine fibroid number (single vs multiple),Disease
44803,Uterine fibroid size (maximum dimension),Disease
44804,Uterine fibroid size (maximum volume),Disease
44817,Iris heterochromicity,Disease
44821,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer,Disease
44834,MED18/ZBTB16 protein level ratio,Disease
44835,COL6A3/SMOC2 protein level ratio,Disease
44836,COLEC12/LAIR1 protein level ratio,Disease
44837,MANF/NCK2 protein level ratio,Disease
44839,MANF/PDGFB protein level ratio,Disease
44841,MANF/PLA2G4A protein level ratio,Disease
44842,MANF/PMVK protein level ratio,Disease
44843,MCAM/NCAM1 protein level ratio,Disease
44844,MCAM/NTRK3 protein level ratio,Disease
44845,MCFD2/TXNDC5 protein level ratio,Disease
44846,MED18/SH2B3 protein level ratio,Disease
44848,MED18/TACC3 protein level ratio,Disease
44849,MED18/TBL1X protein level ratio,Disease
44850,MAP3K5/ZBTB16 protein level ratio,Disease
44852,MAP4K5/TBCC protein level ratio,Disease
44853,MANF/PTPN6 protein level ratio,Disease
44854,MANF/TXNDC5 protein level ratio,Disease
44856,MAP3K5/MAVS protein level ratio,Disease
44857,Brain shape (segment 117),Disease
44859,Brain shape (segment 140),Disease
44860,Brain shape (segment 199),Disease
44862,Brain shape (segment 204),Disease
44864,Brain shape (segment 116),Disease
44866,CTSO/IGF2R protein level ratio,Disease
44867,CTSZ/SMPDL3A protein level ratio,Disease
44868,CX3CL1/EPHB6 protein level ratio,Disease
44870,CX3CL1/LAYN protein level ratio,Disease
44871,CX3CL1/RGMB protein level ratio,Disease
44873,CSF1/SEMA3F protein level ratio,Disease
44874,CST3/DEFA1_DEFA1B protein level ratio,Disease
44876,CST3/RARRES2 protein level ratio,Disease
44877,CST3/RETN protein level ratio,Disease
44878,CST3/TFF3 protein level ratio,Disease
44879,CTF1/ITGB1BP2 protein level ratio,Disease
44880,CTRB1/KIRREL2 protein level ratio,Disease
44882,CTRB1/PLA2G1B protein level ratio,Disease
44883,CTRB1/PRSS2 protein level ratio,Disease
44884,CTRC/KIRREL2 protein level ratio,Disease
44885,CTRC/PLA2G1B protein level ratio,Disease
44886,CTSF/SMPDL3A protein level ratio,Disease
44887,CRTAM/PDCD1 protein level ratio,Disease
44889,CRTAM/TNFRSF9 protein level ratio,Disease
44890,CRTAM/VCAM1 protein level ratio,Disease
44891,DAG1/F2R protein level ratio,Disease
44893,DAG1/HBEGF protein level ratio,Disease
44894,DAG1/MGLL protein level ratio,Disease
44895,Thymus and reactivation regulated chemokine levels,Disease
44896,Vascular endothelial growth factor A levels,Disease
44897,PDCD1/TNFRSF4 protein level ratio,Disease
44899,PDCD1/TNFRSF8 protein level ratio,Disease
44901,PDCD1/TNFRSF9 protein level ratio,Disease
44903,PDGFB/SNAP29 protein level ratio,Disease
44904,DEFA1_DEFA1B/LCN2 protein level ratio,Disease
44907,DFFA/SIRT2 protein level ratio,Disease
44909,DKK1/VEGFC protein level ratio,Disease
44910,PKLR/TGM2 protein level ratio,Disease
44911,PKLR/UBAC1 protein level ratio,Disease
44912,PLA2G15/PRCP protein level ratio,Disease
44913,DKK1/IPCEF1 protein level ratio,Disease
44914,DKK1/SDC4 protein level ratio,Disease
44916,DKK1/VEGFA protein level ratio,Disease
44917,DSG3/DSG4 protein level ratio,Disease
44919,DNMBP/STX4 protein level ratio,Disease
44921,DNMBP/TBC1D5 protein level ratio,Disease
44922,DNMBP/TBCC protein level ratio,Disease
44923,DNMBP/TJAP1 protein level ratio,Disease
44924,DNMBP/WWP2 protein level ratio,Disease
44925,DNPH1/EIF4EBP1 protein level ratio,Disease
44927,DNPH1/GLOD4 protein level ratio,Disease
44928,DNPH1/LHPP protein level ratio,Disease
44930,DNPH1/NSFL1C protein level ratio,Disease
44931,DLL1/EFEMP1 protein level ratio,Disease
44933,DLL1/IL18BP protein level ratio,Disease
44935,DLL1/NBL1 protein level ratio,Disease
44937,DLL1/NECTIN4 protein level ratio,Disease
44938,DLL1/NOTCH1 protein level ratio,Disease
44939,DLL1/TGFBR2 protein level ratio,Disease
44941,DNAJA2/FIS1 protein level ratio,Disease
44942,DNPH1/PKLR protein level ratio,Disease
44943,DNPH1/PSMG3 protein level ratio,Disease
44945,DRG2/INPP1 protein level ratio,Disease
44946,DRG2/SEMA4D protein level ratio,Disease
44947,DNAJB1/SIRT2 protein level ratio,Disease
44948,DNMBP/FKBP5 protein level ratio,Disease
44950,DNMBP/PTPN1 protein level ratio,Disease
44951,DPP6/SEZ6L protein level ratio,Disease
44952,EIF4G1/HEXIM1 protein level ratio,Disease
44953,EFNA1/TNFRSF1A protein level ratio,Disease
44955,EFNA4/LAYN protein level ratio,Disease
44956,EIF4B/RWDD1 protein level ratio,Disease
44957,EIF4B/TBCC protein level ratio,Disease
44958,EIF4EBP1/GLRX protein level ratio,Disease
44959,EIF4EBP1/PSMG3 protein level ratio,Disease
44960,EIF4G1/FKBP5 protein level ratio,Disease
44961,SDC4/SELP protein level ratio,Disease
44962,EFNA4/SCARB2 protein level ratio,Disease
44963,EFNA4/TNFRSF10A protein level ratio,Disease
44965,EFNA4/TNFRSF10B protein level ratio,Disease
44966,EFNA4/TNFRSF9 protein level ratio,Disease
44967,EGF/MANF protein level ratio,Disease
44968,EIF4B/IPCEF1 protein level ratio,Disease
44969,EIF4B/METAP2 protein level ratio,Disease
44970,EGF/MGLL protein level ratio,Disease
44972,EGF/PPIB protein level ratio,Disease
44973,CC2D1A/CDKN1A protein level ratio,Disease
44974,CC2D1A/TBCC protein level ratio,Disease
44975,CC2D1A/WWP2 protein level ratio,Disease
44977,CCL13/CCL17 protein level ratio,Disease
44979,CCL17/CCL22 protein level ratio,Disease
44981,CCL5/CXCL3 protein level ratio,Disease
44983,CCL5/CXCL5 protein level ratio,Disease
44984,F2R/ITGB1BP2 protein level ratio,Disease
44985,CASP8/SERPINB1 protein level ratio,Disease
44986,CC2D1A/CD2AP protein level ratio,Disease
44988,CASP3/SULT1A1 protein level ratio,Disease
44989,CASP8/CIAPIN1 protein level ratio,Disease
44990,CCL17/PDGFB protein level ratio,Disease
44992,CCL17/THPO protein level ratio,Disease
44993,CCL17/CCL5 protein level ratio,Disease
44995,CCL17/CD69 protein level ratio,Disease
44997,CCL17/CXCL3 protein level ratio,Disease
44998,CCL17/F2R protein level ratio,Disease
44999,CD46/TIMP1 protein level ratio,Disease
45001,CD48/CRTAM protein level ratio,Disease
45002,CD48/FCRL6 protein level ratio,Disease
45004,CD48/ITGB7 protein level ratio,Disease
45005,CD4/LILRB4 protein level ratio,Disease
45006,CD58/IFNGR1 protein level ratio,Disease
45008,CD58/MCAM protein level ratio,Disease
45009,CD5/IL16 protein level ratio,Disease
45010,CD5/TNFRSF9 protein level ratio,Disease
45011,CD38/IL12A_IL12B protein level ratio,Disease
45012,CD40/FIS1 protein level ratio,Disease
45013,CD40/VSIR protein level ratio,Disease
45014,Retinal nerve fibre layer (RNFL) thickness,Disease
45015,Abdominal fat cell number,Disease
45019,Ganglion cell inner plexiform layer (GCIPL) thickness,Disease
45026,Retinal nerve fibre layer thickness or ganglion cell inner plexiform layer thickness (MTAG),Disease
45027,QT dynamics during exercise,Disease
45029,Endometriosis or depression (pleiotropy),Disease
45037,SSRI response to core syndromal factor measured by HAM-D-21 in major depressive disorder,Disease
45038,SSRI response to anorexia syndromal factor measured by HAM-D-21 in major depressive disorder,Disease
45040,SSRI response to total HAM-D-21 score in major depressive disorder,Disease
45041,Cardiometabolic multimorbidity,Disease
45042,Multisite chronic pain,Disease
45043,Haemorrhoidal disease,Disease
45044,Hair curvature (quantitative),Disease
45045,Hair curvature (observational),Disease
45049,Opioid use disorder vs exposed controls,Disease
45050,Age at natural menopause,Disease
45064,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics,Disease
45065,Biological sex,Disease
45069,Congenital heart disease (anomalies of thoracic arteries and veins),Disease
45076,Vitamin C levels,Disease
45077,Phoneme awareness,Disease
45078,Word spelling,Disease
45079,Reading ability (multivariate),Disease
45080,Rapid automised naming of letters,Disease
45081,Non-word reading,Disease
45085,Smoking status,Disease
45090,Adverse response to chemotherapy (amenorrhea) in breast cancer,Disease
45091,Alcohol consumption,Disease
45092,Participation in an health questionnaire (not invited vs invited),Disease
45093,Glucosuria (moderate to severe),Disease
45094,Glucosuria (mild),Disease
45095,Glucosuria,Disease
45111,Liver fibrosis in non-alcoholic fatty liver disease,Disease
45112,Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease,Disease
45113,Neurological blood protein biomarker levels,Disease
45117,Annualised percent change of cerebrospinal fluid AB1-42 levels,Disease
45118,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)",Disease
45119,Anti-anoctamin 2 antibody levels,Disease
45120,Airway obstruction (FEV1/FVC<70%) in never smokers,Disease
45122,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,Disease
45138,Glomerular filtration rate in type 2 diabetes,Disease
45139,Glomerular filtration rate in diabetes,Disease
45140,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),Disease
45141,Early diabetic kidney disease in type 2 diabetes,Disease
45142,Diabetic kidney disease in type 2 diabetes,Disease
45143,Central cerebrospinal fluid amyloid beta 42 to 40 ratio,Disease
45145,Contamination dimension in obsessive compulsive disorder,Disease
45149,Type 2 diabetes nephropathy including microalbuminuria,Disease
45163,Facial morphology (forehead protrusion 1),Disease
45165,Facial morphology (brow ridge protrusion 1),Disease
45167,Facial morphology (lower lip protrusion),Disease
45169,Facial morphology (lip protrusion),Disease
45170,Facial morphology (brow ridge protrusion 2),Disease
45171,Facial morphology (upper face flatness),Disease
45172,Tuberculosis (SNP x SNP interaction),Disease
45173,Psychological distress,Disease
45174,Fish intake frequency,Disease
45175,LAG3/VCAM1 protein level ratio,Disease
45177,LAYN/ULBP2 protein level ratio,Disease
45179,LBR/RWDD1 protein level ratio,Disease
45180,LBR/SERPINB1 protein level ratio,Disease
45181,KLRD1/LY9 protein level ratio,Disease
45182,CEP43/USP8 protein level ratio,Disease
45183,CEP43/WASF1 protein level ratio,Disease
45184,LAMA4/NID1 protein level ratio,Disease
45186,LAMP3/MSLN protein level ratio,Disease
45188,LAT2/MANF protein level ratio,Disease
45189,LAT2/SERPINB1 protein level ratio,Disease
45190,LAT2/YES1 protein level ratio,Disease
45191,CHAC2/TPMT protein level ratio,Disease
45193,CHGB/MOG protein level ratio,Disease
45195,CHGB/PTPRN2 protein level ratio,Disease
45196,CHMP1A/CRADD protein level ratio,Disease
45197,CHMP1A/DCTN1 protein level ratio,Disease
45198,CHMP1A/EIF4B protein level ratio,Disease
45199,CHMP1A/EREG protein level ratio,Disease
45200,CHMP1A/HPCAL1 protein level ratio,Disease
45201,CHMP1A/MITD1 protein level ratio,Disease
45202,CHMP1A/PLA2G4A protein level ratio,Disease
45203,CHMP1A/PTPN6 protein level ratio,Disease
45204,CHMP1A/RHOC protein level ratio,Disease
45205,CHMP1A/SNAP23 protein level ratio,Disease
45206,CHMP1A/SNAP29 protein level ratio,Disease
45207,CHMP1A/STAMBP protein level ratio,Disease
45208,CHMP1A/STK11 protein level ratio,Disease
45209,CHMP1A/SUGT1 protein level ratio,Disease
45210,CHMP1A/TBCB protein level ratio,Disease
45211,CHMP1A/USP8 protein level ratio,Disease
45212,CLEC1B/EGF protein level ratio,Disease
45213,CLEC1B/HBEGF protein level ratio,Disease
45214,CLEC1B/HEXIM1 protein level ratio,Disease
45215,MPI/SIRT2 protein level ratio,Disease
45216,MPI/TACC3 protein level ratio,Disease
45217,MPO/PRTN3 protein level ratio,Disease
45218,MOG/PTPRN2 protein level ratio,Disease
45219,MOG/RTBDN protein level ratio,Disease
45220,MOG/SEZ6L protein level ratio,Disease
45221,CRELD2/SUMF2 protein level ratio,Disease
45223,CRELD2/TXNDC5 protein level ratio,Disease
45224,CRIM1/NRP2 protein level ratio,Disease
45226,CRKL/SERPINB1 protein level ratio,Disease
45227,CRTAM/FCRL6 protein level ratio,Disease
45229,CRTAM/GZMA protein level ratio,Disease
45230,CRTAM/ICAM3 protein level ratio,Disease
45231,CRTAM/KLRD1 protein level ratio,Disease
45233,CRKL/MANF protein level ratio,Disease
45234,CRKL/MGLL protein level ratio,Disease
45235,MPHOSPH8/WASF1 protein level ratio,Disease
45236,MPIG6B/PLXNA4 protein level ratio,Disease
45238,MSRA/SERPINB1 protein level ratio,Disease
45239,Obstructive sleep apnea,Disease
45240,Brain shape (segment 1),Disease
45243,NID1/SORT1 protein level ratio,Disease
45245,NOTCH1/TIE1 protein level ratio,Disease
45247,MSRA/SNX9 protein level ratio,Disease
45248,MSRA/TJAP1 protein level ratio,Disease
45249,MVK/SHMT1 protein level ratio,Disease
45251,NFATC1/TJAP1 protein level ratio,Disease
45252,NSFL1C/PSMG3 protein level ratio,Disease
45253,NSFL1C/RWDD1 protein level ratio,Disease
45254,NUCB2/TXNDC5 protein level ratio,Disease
45255,NUDT5/RWDD1 protein level ratio,Disease
45256,NUDT5/SERPINB1 protein level ratio,Disease
45257,OLR1/OSM protein level ratio,Disease
45259,DAPP1/ITGB1BP2 protein level ratio,Disease
45260,PIK3IP1/TNFRSF1A protein level ratio,Disease
45261,PIK3IP1/TNFRSF1B protein level ratio,Disease
45263,APP/HBEGF protein level ratio,Disease
45265,PEAR1/TREML2 protein level ratio,Disease
45266,PFKFB2/SERPINB1 protein level ratio,Disease
45267,PIK3AP1/PSMG3 protein level ratio,Disease
45268,Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Disease
45270,PPP1R2/TBL1X protein level ratio,Disease
45271,AXIN1/CALCOCO1 protein level ratio,Disease
45273,AXIN1/CDKN1A protein level ratio,Disease
45274,AXIN1/CLIP2 protein level ratio,Disease
45275,AXIN1/DAPP1 protein level ratio,Disease
45276,PPP1R2/TACC3 protein level ratio,Disease
45277,PRKAR1A/SNAP23 protein level ratio,Disease
45278,AXIN1/BACH1 protein level ratio,Disease
45279,AXIN1/BANK1 protein level ratio,Disease
45280,AXIN1/DOK2 protein level ratio,Disease
45281,AXIN1/GOPC protein level ratio,Disease
45282,AXIN1/HEXIM1 protein level ratio,Disease
45283,ROBO2/SCARF2 protein level ratio,Disease
45284,ROBO2/SFTPD protein level ratio,Disease
45286,RWDD1/SERPINB6 protein level ratio,Disease
45289,RWDD1/STAMBP protein level ratio,Disease
45290,RWDD1/SULT1A1 protein level ratio,Disease
45291,BLVRB/HAGH protein level ratio,Disease
45292,BLVRB/HBQ1 protein level ratio,Disease
45293,BLVRB/HMBS protein level ratio,Disease
45294,BCAN/MOG protein level ratio,Disease
45296,RWDD1/TXNDC5 protein level ratio,Disease
45297,RWDD1/VTA1 protein level ratio,Disease
45299,S100A4/SNX9 protein level ratio,Disease
45300,BCR/ITGB1BP2 protein level ratio,Disease
45301,BCR/PLXNA4 protein level ratio,Disease
45302,BIN2/TJAP1 protein level ratio,Disease
45303,BLVRB/CA2 protein level ratio,Disease
45304,BIN2/CORO1A protein level ratio,Disease
45305,CANT1/GSTA1 protein level ratio,Disease
45306,CARHSP1/HMBS protein level ratio,Disease
45308,CARHSP1/TBC1D17 protein level ratio,Disease
45309,ENG/NCAM2 protein level ratio,Disease
45310,CA3/HMBS protein level ratio,Disease
45311,CA5A/GRPEL1 protein level ratio,Disease
45313,CA5A/GSTA1 protein level ratio,Disease
45314,CA5A/KRT18 protein level ratio,Disease
45315,CA5A/SULT2A1 protein level ratio,Disease
45316,CA9/CBLIF protein level ratio,Disease
45318,ENO1/FIS1 protein level ratio,Disease
45319,ENO1/RWDD1 protein level ratio,Disease
45320,ENO1/SERPINB6 protein level ratio,Disease
45321,ENO1/SULT1A1 protein level ratio,Disease
45322,ENO1/VTA1 protein level ratio,Disease
45323,CA1/CA2 protein level ratio,Disease
45324,CA1/HMBS protein level ratio,Disease
45325,CA1/TGM2 protein level ratio,Disease
45326,CA2/CA3 protein level ratio,Disease
45327,CA2/DNPH1 protein level ratio,Disease
45328,CA2/HAGH protein level ratio,Disease
45329,CA2/HMBS protein level ratio,Disease
45330,CA2/PSMG3 protein level ratio,Disease
45331,CALCOCO1/MAP3K5 protein level ratio,Disease
45332,CALCOCO1/TJAP1 protein level ratio,Disease
45333,CD209/GP2 protein level ratio,Disease
45334,CD22/CD79B protein level ratio,Disease
45336,CD22/FCER2 protein level ratio,Disease
45338,CD22/FCRL1 protein level ratio,Disease
45339,CD22/FOLR2 protein level ratio,Disease
45340,CD22/SEMA7A protein level ratio,Disease
45341,FCRL5/MZB1 protein level ratio,Disease
45342,FCRL6/GZMA protein level ratio,Disease
45344,FCRL6/KLRD1 protein level ratio,Disease
45346,CD22/TNFRSF13C protein level ratio,Disease
45347,CD244/CRTAM protein level ratio,Disease
45349,CD244/TREML2 protein level ratio,Disease
45351,CD109/CNTN4 protein level ratio,Disease
45353,CD160/IL15 protein level ratio,Disease
45354,CD160/KIR2DL3 protein level ratio,Disease
45355,CD160/KLRB1 protein level ratio,Disease
45356,CD160/NCR1 protein level ratio,Disease
45358,FIS1/HSPA1A protein level ratio,Disease
45359,FIS1/HTRA2 protein level ratio,Disease
45360,CD163/MSR1 protein level ratio,Disease
45361,CD163/SIGLEC1 protein level ratio,Disease
45362,CD164/CD99 protein level ratio,Disease
45364,CD1C/CD207 protein level ratio,Disease
45365,CD27/ICAM3 protein level ratio,Disease
45366,CD27/TNFRSF13B protein level ratio,Disease
45368,CD2AP/CD40 protein level ratio,Disease
45369,CD2AP/EIF4EBP1 protein level ratio,Disease
45370,CD2AP/PLPBP protein level ratio,Disease
45371,CD2AP/SNX9 protein level ratio,Disease
45373,CD2AP/TRAF2 protein level ratio,Disease
45374,CD2AP/VSIR protein level ratio,Disease
45375,FCRL2/LY9 protein level ratio,Disease
45378,FCRL2/SEMA7A protein level ratio,Disease
45379,FCRL2/TNFRSF13B protein level ratio,Disease
45381,AHSP/HMBS protein level ratio,Disease
45384,AIF1/TPMT protein level ratio,Disease
45386,AK1/DNPH1 protein level ratio,Disease
45387,AGXT/CA5A protein level ratio,Disease
45388,AGXT/GSTA1 protein level ratio,Disease
45389,AHCY/HSPA1A protein level ratio,Disease
45390,AHSP/BLVRB protein level ratio,Disease
45392,AHSP/CA2 protein level ratio,Disease
45394,AHSP/HBQ1 protein level ratio,Disease
45396,AARSD1/PIK3AP1 protein level ratio,Disease
45397,AARSD1/PSMG3 protein level ratio,Disease
45398,AARSD1/RWDD1 protein level ratio,Disease
45399,ABHD14B/APRT protein level ratio,Disease
45401,ABHD14B/CCS protein level ratio,Disease
45402,ADH4/CA5A protein level ratio,Disease
45403,ADH4/GSTA1 protein level ratio,Disease
45404,ADH4/KRT18 protein level ratio,Disease
45406,AGRN/BTN2A1 protein level ratio,Disease
45408,Longevity (100 years and older),Disease
45409,Facial wrinkles (frown lines),Disease
45411,LBR/TXNDC5 protein level ratio,Disease
45412,LCN2/PGLYRP1 protein level ratio,Disease
45413,LCN2/RETN protein level ratio,Disease
45414,LDLR/MEGF9 protein level ratio,Disease
45415,MANF/MESD protein level ratio,Disease
45416,MANF/MPIG6B protein level ratio,Disease
45417,LYN/TACC3 protein level ratio,Disease
45418,COL18A1/RETN protein level ratio,Disease
45419,CNPY4/SIRT2 protein level ratio,Disease
45422,CNPY4/TBC1D23 protein level ratio,Disease
45424,CNST/ITGB1BP2 protein level ratio,Disease
45425,CNTN1/EGFR protein level ratio,Disease
45426,CNPY4/INPP1 protein level ratio,Disease
45427,CNPY4/KIFBP protein level ratio,Disease
45428,CNPY4/MANF protein level ratio,Disease
45429,CNPY4/MESD protein level ratio,Disease
45431,CNPY4/MPI protein level ratio,Disease
45434,CLPS/CTRB1 protein level ratio,Disease
45436,CLPS/PLA2G1B protein level ratio,Disease
45437,CLPS/PRSS2 protein level ratio,Disease
45438,CNPY4/ERBIN protein level ratio,Disease
45440,CLIP2/PDLIM7 protein level ratio,Disease
45441,CPB1/PRSS2 protein level ratio,Disease
45442,CPB1/REG1A protein level ratio,Disease
45443,CPPED1/PPCDC protein level ratio,Disease
45445,CPXM1/DKK1 protein level ratio,Disease
45446,CPXM1/HBEGF protein level ratio,Disease
45448,COLEC12/TGFBR2 protein level ratio,Disease
45449,CRADD/STAMBP protein level ratio,Disease
45450,CRADD/TBCC protein level ratio,Disease
45451,CREG1/GUSB protein level ratio,Disease
45452,CPB1/CTRB1 protein level ratio,Disease
45453,CPB1/CTRC protein level ratio,Disease
45454,CPB1/KIRREL2 protein level ratio,Disease
45455,CRADD/EDAR protein level ratio,Disease
45456,CRADD/FADD protein level ratio,Disease
45457,CRADD/HSPA1A protein level ratio,Disease
45458,CRADD/SIRT2 protein level ratio,Disease
45459,COMT/ITGB1BP2 protein level ratio,Disease
45460,CORO1A/SNX9 protein level ratio,Disease
45461,CORO1A/TBC1D5 protein level ratio,Disease
45463,CPXM1/LGMN protein level ratio,Disease
45464,CPXM1/MDK protein level ratio,Disease
45465,CPXM1/SPARC protein level ratio,Disease
45466,CPXM1/VEGFC protein level ratio,Disease
45467,CR2/TNFRSF13B protein level ratio,Disease
45468,CRACR2A/DNMBP protein level ratio,Disease
45470,CPA1/CTRB1 protein level ratio,Disease
45471,CPA1/CTRC protein level ratio,Disease
45472,CRACR2A/MAP3K5 protein level ratio,Disease
45473,CRADD/DARS1 protein level ratio,Disease
45474,Brain shape (segment 3),Disease
45475,Brain shape (segment 5),Disease
45477,Brain shape (segment 2),Disease
45480,APOM/ERBB3 protein level ratio,Disease
45482,NSFL1C/SERPINB1 protein level ratio,Disease
45483,NSFL1C/STIP1 protein level ratio,Disease
45484,NSFL1C/TXNDC5 protein level ratio,Disease
45485,NT5C3A/RWDD1 protein level ratio,Disease
45486,OSCAR/TNFRSF14 protein level ratio,Disease
45487,PARK7/S100A4 protein level ratio,Disease
45489,PARK7/STIP1 protein level ratio,Disease
45490,PARK7/TXNDC5 protein level ratio,Disease
45491,PCDH17/THBD protein level ratio,Disease
45492,Adiponectin levels (BMI-adjusted),Disease
45494,ARG1/HMBS protein level ratio,Disease
45495,ARG1/PKLR protein level ratio,Disease
45497,ARHGAP1/RAD23B protein level ratio,Disease
45498,ARHGEF12/AXIN1 protein level ratio,Disease
45499,ARHGEF12/BANK1 protein level ratio,Disease
45500,ART3/RGMA protein level ratio,Disease
45501,ART3/RGMB protein level ratio,Disease
45502,ARG1/HAGH protein level ratio,Disease
45503,PLAUR/PRSS8 protein level ratio,Disease
45505,PLAUR/TREM2 protein level ratio,Disease
45506,PLPBP/RWDD1 protein level ratio,Disease
45507,PLPBP/SERPINB1 protein level ratio,Disease
45508,PLPBP/SNX9 protein level ratio,Disease
45509,PMVK/RHOC protein level ratio,Disease
45511,PPCDC/RWDD1 protein level ratio,Disease
45512,PLA2G15/SMPD1 protein level ratio,Disease
45514,PLA2G15/SMPDL3A protein level ratio,Disease
45515,PLXNA4/VASH1 protein level ratio,Disease
45516,PLA2G4A/SNX9 protein level ratio,Disease
45517,PLA2G4A/TBL1X protein level ratio,Disease
45518,PLXNA4/SNAP29 protein level ratio,Disease
45520,PLXNA4/SRPK2 protein level ratio,Disease
45522,PLXNA4/USP8 protein level ratio,Disease
45523,PPP1R12A/TXNDC5 protein level ratio,Disease
45525,QPCT/RNASET2 protein level ratio,Disease
45526,RARRES2/TFPI protein level ratio,Disease
45528,RHOC/TIA1 protein level ratio,Disease
45529,RILP/RWDD1 protein level ratio,Disease
45530,RNF41/WWP2 protein level ratio,Disease
45531,RGMB/SMOC2 protein level ratio,Disease
45532,RGMB/TNFRSF21 protein level ratio,Disease
45533,RHOC/TBCB protein level ratio,Disease
45534,RHOC/TBCC protein level ratio,Disease
45535,REG1A/TFF3 protein level ratio,Disease
45536,RETN/RNASET2 protein level ratio,Disease
45537,EBAG9/FKBP5 protein level ratio,Disease
45538,PSMD9/UBAC1 protein level ratio,Disease
45539,PSME2/PSMG3 protein level ratio,Disease
45540,PSME2/RBKS protein level ratio,Disease
45541,PTPN1/WWP2 protein level ratio,Disease
45542,PTPN6/SULT1A1 protein level ratio,Disease
45543,PTPN6/TXNDC5 protein level ratio,Disease
45544,EPHB6/TNFRSF9 protein level ratio,Disease
45545,EPO/TFRC protein level ratio,Disease
45546,ESAM/LAMA4 protein level ratio,Disease
45548,ESAM/THPO protein level ratio,Disease
45549,ENO2/RWDD1 protein level ratio,Disease
45550,ENO2/SULT1A1 protein level ratio,Disease
45551,ENO2/TXNDC5 protein level ratio,Disease
45552,ERBB2/PTPRF protein level ratio,Disease
45553,ERBB3/IL1R2 protein level ratio,Disease
45554,ERBB4/UMOD protein level ratio,Disease
45555,ERBIN/LAT2 protein level ratio,Disease
45556,EREG/HBEGF protein level ratio,Disease
45558,EREG/ITGB1BP2 protein level ratio,Disease
45559,ERP44/SUMF2 protein level ratio,Disease
45560,ENO2/ITGB1BP2 protein level ratio,Disease
45561,ENO2/MGLL protein level ratio,Disease
45562,CASP3/SERPINB1 protein level ratio,Disease
45563,Neck circumference,Disease
45564,FKBP4/RWDD1 protein level ratio,Disease
45565,FKBP4/WWP2 protein level ratio,Disease
45566,FKBP5/MAP4K5 protein level ratio,Disease
45567,FKBP5/MITD1 protein level ratio,Disease
45568,FKBP5/MPIG6B protein level ratio,Disease
45569,FKBP5/PTPN1 protein level ratio,Disease
45570,FOLR1/MSLN protein level ratio,Disease
45571,FOLR2/HAVCR2 protein level ratio,Disease
45572,FOLR2/MSR1 protein level ratio,Disease
45573,FOLR2/THY1 protein level ratio,Disease
45575,CD300E/CXCL10 protein level ratio,Disease
45577,CD300E/LILRA5 protein level ratio,Disease
45579,FLI1/TBL1X protein level ratio,Disease
45580,FLT1/VEGFA protein level ratio,Disease
45581,FLT4/ICAM2 protein level ratio,Disease
45583,CD300C/CLEC14A protein level ratio,Disease
45584,CD300C/GOLM2 protein level ratio,Disease
45585,CD300C/HAVCR2 protein level ratio,Disease
45586,FIS1/MGLL protein level ratio,Disease
45587,FIS1/MPIG6B protein level ratio,Disease
45588,FIS1/SKAP2 protein level ratio,Disease
45589,FKBP4/FKBP5 protein level ratio,Disease
45590,FOXO1/MAP3K5 protein level ratio,Disease
45591,FKBP5/RHOC protein level ratio,Disease
45592,FKBP5/TBCB protein level ratio,Disease
45593,FKBP5/TBCC protein level ratio,Disease
45594,FKBP5/ZBTB16 protein level ratio,Disease
45595,FLI1/IPCEF1 protein level ratio,Disease
45596,ACE2/GGT1 protein level ratio,Disease
45597,ACVRL1/EFNA4 protein level ratio,Disease
45599,ACVRL1/TNFRSF9 protein level ratio,Disease
45600,ACY1/GSTA1 protein level ratio,Disease
45601,LTA/LTBR protein level ratio,Disease
45602,LTBP2/PDGFRA protein level ratio,Disease
45604,LGMN/SPINT2 protein level ratio,Disease
45605,LHPP/PKLR protein level ratio,Disease
45606,LRP11/NECTIN2 protein level ratio,Disease
45608,LRP11/ROR1 protein level ratio,Disease
45609,CKAP4/IL4R protein level ratio,Disease
45611,CKAP4/TNFRSF4 protein level ratio,Disease
45612,CLEC14A/EPHB4 protein level ratio,Disease
45613,CLEC14A/PIK3IP1 protein level ratio,Disease
45615,CLEC14A/TNFRSF21 protein level ratio,Disease
45616,CLEC4D/MMP9 protein level ratio,Disease
45617,CLEC4D/OSM protein level ratio,Disease
45618,CLEC4D/TGFA protein level ratio,Disease
45619,LDLR/PCSK9 protein level ratio,Disease
45620,LGALS8/RWDD1 protein level ratio,Disease
45621,LGALS8/SERPINB6 protein level ratio,Disease
45622,LGALS8/TXNDC5 protein level ratio,Disease
45623,CLEC1B/TXNDC5 protein level ratio,Disease
45624,CLEC4G/MERTK protein level ratio,Disease
45626,Clostridioides difficle infection in antibiotics-users,Disease
45627,MITD1/TBCC protein level ratio,Disease
45628,MLN/TNFRSF12A protein level ratio,Disease
45630,MMP8/MMP9 protein level ratio,Disease
45631,MMP8/PGLYRP1 protein level ratio,Disease
45633,MMP9/OLR1 protein level ratio,Disease
45635,MMP9/PGLYRP1 protein level ratio,Disease
45637,MGLL/PTPN6 protein level ratio,Disease
45638,MGLL/SHMT1 protein level ratio,Disease
45639,MGLL/STK4 protein level ratio,Disease
45640,MGLL/VTA1 protein level ratio,Disease
45641,MICB_MICA/TEK protein level ratio,Disease
45643,MIF/SERPINB1 protein level ratio,Disease
45644,MITD1/SNX9 protein level ratio,Disease
45645,MGLL/MITD1 protein level ratio,Disease
45646,MGLL/MPIG6B protein level ratio,Disease
45647,MGLL/PLA2G4A protein level ratio,Disease
45648,METAP2/PLPBP protein level ratio,Disease
45649,CREG1/PLA2G15 protein level ratio,Disease
45650,CREG1/SMPDL3A protein level ratio,Disease
45651,MESD/SERPINB1 protein level ratio,Disease
45652,Brain shape (segment 62),Disease
45654,Brain shape (segment 81),Disease
45656,Brain shape (segment 86),Disease
45658,Brain shape (segment 31),Disease
45660,Brain shape (segment 20),Disease
45661,Brain shape (segment 21),Disease
45662,Brain shape (segment 7),Disease
45664,CXCL3/CXCL5 protein level ratio,Disease
45665,CXCL3/MGLL protein level ratio,Disease
45666,CXCL3/PTPN6 protein level ratio,Disease
45667,APP/DKK1 protein level ratio,Disease
45668,CXCL10/CXCL9 protein level ratio,Disease
45669,CXCL10/WARS protein level ratio,Disease
45670,CXCL11/CXCL13 protein level ratio,Disease
45671,CXCL11/ITGB1BP2 protein level ratio,Disease
45672,CXCL11/SDC4 protein level ratio,Disease
45673,CXCL5/CXCL6 protein level ratio,Disease
45674,CXCL5/EDAR protein level ratio,Disease
45675,CXCL5/MESD protein level ratio,Disease
45678,Brain shape (segment 276),Disease
45680,Brain shape (segment 285),Disease
45681,CXCL5/SERPINE1 protein level ratio,Disease
45682,DAB2/NCK2 protein level ratio,Disease
45683,DAB2/FKBP5 protein level ratio,Disease
45684,DAB2/GRAP2 protein level ratio,Disease
45685,CXCL5/PLXNA4 protein level ratio,Disease
45686,CXCL5/PPIB protein level ratio,Disease
45687,Brain shape (segment 51),Disease
45688,Brain shape (segment 60),Disease
45690,ATG4A/TPMT protein level ratio,Disease
45691,ATOX1/GYS1 protein level ratio,Disease
45692,DCTN1/RWDD1 protein level ratio,Disease
45693,DCXR/GSTA1 protein level ratio,Disease
45694,DBNL/EDAR protein level ratio,Disease
45695,DBNL/HEXIM1 protein level ratio,Disease
45696,DBNL/HSPA1A protein level ratio,Disease
45697,DBNL/RWDD1 protein level ratio,Disease
45698,DBI/STIP1 protein level ratio,Disease
45699,DDR1/SFTPD protein level ratio,Disease
45700,ATP5IF1/HSPA1A protein level ratio,Disease
45701,AXL/MSR1 protein level ratio,Disease
45702,BCAM/CDH5 protein level ratio,Disease
45703,BCAM/EPO protein level ratio,Disease
45704,BAG6/WASF1 protein level ratio,Disease
45705,BANK1/HEXIM1 protein level ratio,Disease
45706,B4GALT1/LRP11 protein level ratio,Disease
45707,B4GALT1/SMOC2 protein level ratio,Disease
45708,BACH1/CD2AP protein level ratio,Disease
45709,AXIN1/NFATC1 protein level ratio,Disease
45710,AXIN1/PLXNA4 protein level ratio,Disease
45711,AXIN1/SRPK2 protein level ratio,Disease
45712,AXL/IL18BP protein level ratio,Disease
45714,AXL/MCAM protein level ratio,Disease
45715,AXIN1/ITGB1BP2 protein level ratio,Disease
45716,AXIN1/MAP2K6 protein level ratio,Disease
45717,AXIN1/MAVS protein level ratio,Disease
45718,AXIN1/IKBKG protein level ratio,Disease
45719,AXIN1/INPPL1 protein level ratio,Disease
45720,AXIN1/IRAK4 protein level ratio,Disease
45721,BACH1/SNX9 protein level ratio,Disease
45722,BMP6/SPINT2 protein level ratio,Disease
45724,BPIFB1/GLRX protein level ratio,Disease
45725,BTN2A1/BTN3A2 protein level ratio,Disease
45727,BTN2A1/CSF1 protein level ratio,Disease
45730,BTN2A1/EPHA1 protein level ratio,Disease
45732,BTN2A1/IFNGR1 protein level ratio,Disease
45734,BTN2A1/IL10RB protein level ratio,Disease
45735,BTN2A1/IL18BP protein level ratio,Disease
45736,BTN2A1/LILRB4 protein level ratio,Disease
45737,BTN2A1/PIK3IP1 protein level ratio,Disease
45738,BTN2A1/SMOC2 protein level ratio,Disease
45739,C2/LILRB4 protein level ratio,Disease
45740,C2/SSC5D protein level ratio,Disease
45741,EBAG9/HBEGF protein level ratio,Disease
45742,EBAG9/TBCC protein level ratio,Disease
45743,EDAR/SERPINB1 protein level ratio,Disease
45744,EDAR/SNAP23 protein level ratio,Disease
45745,EDAR/TMSB10 protein level ratio,Disease
45746,EDAR/TXNDC5 protein level ratio,Disease
45747,EDAR/ENO2 protein level ratio,Disease
45748,EDAR/F2R protein level ratio,Disease
45749,EDAR/PRDX5 protein level ratio,Disease
45750,EDAR/SDC4 protein level ratio,Disease
45751,EDAR/IRAK4 protein level ratio,Disease
45752,EDAR/ITGB1BP2 protein level ratio,Disease
45753,SRC/SULT1A1 protein level ratio,Disease
45754,C4BPB/ENTPD5 protein level ratio,Disease
45755,SNX9/VTA1 protein level ratio,Disease
45756,SNX9/WWP2 protein level ratio,Disease
45757,SORT1/VSIR protein level ratio,Disease
45758,SLAMF7/TXNDC15 protein level ratio,Disease
45759,SMAD1/ZBTB16 protein level ratio,Disease
45760,SEZ6L/SEZ6L2 protein level ratio,Disease
45761,SH2B3/TBL1X protein level ratio,Disease
45762,SEMA4D/TREML2 protein level ratio,Disease
45763,SEMA4D/TXNDC5 protein level ratio,Disease
45764,SERPINB1/SERPINB6 protein level ratio,Disease
45765,SERPINB1/SERPINB9 protein level ratio,Disease
45766,SERPINB1/STAT5B protein level ratio,Disease
45767,SERPINB1/STIP1 protein level ratio,Disease
45768,SERPINB1/TMSB10 protein level ratio,Disease
45769,SERPINB6/SOD1 protein level ratio,Disease
45770,SERPINB6/TXNDC5 protein level ratio,Disease
45771,SMPD1/SMPDL3A protein level ratio,Disease
45772,SNAP23/TBL1X protein level ratio,Disease
45773,SNAP23/ZBTB16 protein level ratio,Disease
45774,SNAP29/SNX9 protein level ratio,Disease
45775,SNAP29/TJAP1 protein level ratio,Disease
45776,SNX9/STAMBP protein level ratio,Disease
45777,SNX9/STIP1 protein level ratio,Disease
45778,SNX9/STK4 protein level ratio,Disease
45779,SNX9/VASH1 protein level ratio,Disease
45781,Early-onset schizophrenia,Disease
45782,FBP1/GSTA1 protein level ratio,Disease
45783,FCER2/FCRL1 protein level ratio,Disease
45786,FCER2/TCL1A protein level ratio,Disease
45787,FCER2/TNFRSF9 protein level ratio,Disease
45790,FAM3B/GUCA2A protein level ratio,Disease
45791,CCN2/HBEGF protein level ratio,Disease
45792,FCRL1/TNFRSF13C protein level ratio,Disease
45795,FCRL1/TREML2 protein level ratio,Disease
45796,CCN2/DKK1 protein level ratio,Disease
45799,CCN2/SPINT2 protein level ratio,Disease
45800,CCN2/TPP1 protein level ratio,Disease
45801,CCN2/VEGFC protein level ratio,Disease
45803,CCN3/FAP protein level ratio,Disease
45805,FADD/MGLL protein level ratio,Disease
45806,F2R/SNX9 protein level ratio,Disease
45807,GFER/RRM2B protein level ratio,Disease
45809,GFER/TRIAP1 protein level ratio,Disease
45811,GFRA1/TNFRSF1A protein level ratio,Disease
45812,GFRA3/LAYN protein level ratio,Disease
45813,GLRX/QDPR protein level ratio,Disease
45814,GMPR/NSFL1C protein level ratio,Disease
45815,GMPR/PSMG3 protein level ratio,Disease
45816,GNLY/GZMA protein level ratio,Disease
45818,GNLY/KIR2DL3 protein level ratio,Disease
45819,GOLM2/ITGA5 protein level ratio,Disease
45820,ADA2/COMP protein level ratio,Disease
45821,ADA2/VCAM1 protein level ratio,Disease
45822,GLO1/GLOD4 protein level ratio,Disease
45823,GLO1/S100A4 protein level ratio,Disease
45824,GLOD4/GMPR protein level ratio,Disease
45825,GLOD4/HSPA1A protein level ratio,Disease
45826,ADGRE5/ITGB2 protein level ratio,Disease
45827,ADGRE5/VCAM1 protein level ratio,Disease
45828,ADAM23/BSG protein level ratio,Disease
45829,ADAMTS15/CLMP protein level ratio,Disease
45830,ADGRE2/B4GALT1 protein level ratio,Disease
45832,ADGRE2/CRIM1 protein level ratio,Disease
45833,ADGRE2/IFNGR1 protein level ratio,Disease
45834,ADGRE2/SIGLEC1 protein level ratio,Disease
45835,Parkinson's disease progression (cognitive),Disease
45836,Serum levels of protein APOA1,Disease
45837,Serum levels of protein ADGRE5,Disease
45838,Serum levels of protein ADGRF5,Disease
45841,Serum levels of protein APOA5,Disease
45842,Serum levels of protein AGER,Disease
45843,Serum levels of protein AGRP,Disease
45846,Serum levels of protein AHSA1,Disease
45847,Serum levels of protein RAB17,Disease
45848,Serum levels of protein PTPN1,Disease
45849,Serum levels of protein RAB5C,Disease
45850,Serum levels of protein RACGAP1,Disease
45853,Serum levels of protein RAD51,Disease
45854,Serum levels of protein NAALAD2,Disease
45855,Serum levels of protein NCR3,Disease
45857,Serum levels of protein NDUFB4,Disease
45858,Serum levels of protein EPO,Disease
45859,Serum levels of protein ERP29,Disease
45861,Serum levels of protein ENPP5,Disease
45862,Serum levels of protein ENTPD3,Disease
45864,Serum levels of protein NAGPA,Disease
45866,Serum levels of protein NBL1,Disease
45867,Serum levels of protein NCAM2,Disease
45869,Serum levels of protein PTN,Disease
45871,Bilateral cleft lip,Disease
45872,Serum levels of protein FAS,Disease
45873,Serum levels of protein FCER1A,Disease
45874,Serum levels of protein PCDHA4,Disease
45876,Serum levels of protein PCDHB14,Disease
45877,Serum levels of protein PCDHB4,Disease
45878,Serum levels of protein PCDHGA11,Disease
45880,Serum levels of protein PCDHGB4,Disease
45881,Serum levels of protein NRXN3,Disease
45882,Serum levels of protein NPTX1,Disease
45883,Serum levels of protein NPW,Disease
45885,Serum levels of protein NQO1,Disease
45886,Serum levels of protein NQO2,Disease
45888,Bilateral cleft lip and palate,Disease
45889,Unilateral cleft lip,Disease
45890,Serum levels of protein ATF6,Disease
45892,Serum levels of protein ATF6B,Disease
45893,Serum levels of protein IFNAR1,Disease
45894,Serum levels of protein PIGA,Disease
45895,Serum levels of protein PIK3CG,Disease
45896,Serum levels of protein PILRA,Disease
45897,Serum levels of protein C2,Disease
45899,Serum levels of protein C2orf40,Disease
45900,Serum levels of protein C4A;C4B,Disease
45906,Serum levels of protein CBLN1,Disease
45908,Serum levels of protein C6orf25,Disease
45910,Serum levels of protein CA4,Disease
45911,Serum levels of protein IL15,Disease
45913,Serum levels of protein IL21,Disease
45914,Serum levels of protein IL34,Disease
45916,Serum levels of protein IL36A,Disease
45918,Serum levels of protein IL18R1,Disease
45919,Serum levels of protein IL18RAP,Disease
45921,Serum levels of protein CLPS,Disease
45926,Serum levels of protein CMPK1,Disease
45927,Noncognitive aspects of educational attainment,Disease
45928,Serum levels of protein CLIC5,Disease
45929,Serum levels of protein KIR2DS2,Disease
45930,Serum levels of protein KLK12,Disease
45931,Serum levels of protein CLEC12B,Disease
45932,Serum levels of protein KCNE2,Disease
45933,Serum levels of protein LAYN,Disease
45934,Serum levels of protein KLK6,Disease
45935,Serum levels of protein KLRC3,Disease
45936,Serum levels of protein LDLRAD4,Disease
45937,Serum levels of protein CPB1,Disease
45938,Serum levels of protein CPXM1,Disease
45940,Serum levels of protein CRABP1,Disease
45941,Serum levels of protein CREB3L4,Disease
45942,Serum levels of protein COL11A2,Disease
45946,Serum levels of protein CRISP2,Disease
45951,Serum levels of protein CRISPLD2,Disease
45954,Serum levels of protein CNTN1,Disease
45955,Serum levels of protein MICA,Disease
45958,Serum levels of protein MICB,Disease
45962,Serum levels of protein PPIL1,Disease
45964,Serum levels of protein METTL24,Disease
45967,Serum levels of protein PLXDC2,Disease
45968,Serum levels of protein PNLIPRP1,Disease
45969,Serum levels of protein GPC3,Disease
45971,Serum levels of protein GRAMD1C,Disease
45974,Serum levels of protein MLN,Disease
45976,Serum levels of protein POLR1C,Disease
45977,Serum levels of protein POMC,Disease
45978,Serum levels of protein EEF2K,Disease
45979,Serum levels of protein MOCS3,Disease
45980,Serum levels of protein MPG,Disease
45982,Serum levels of protein PRSS2,Disease
45983,Serum levels of protein PRSS22,Disease
45985,Serum levels of protein PRSS57,Disease
45987,Serum levels of protein PSMB1,Disease
45989,Serum levels of protein MMP7,Disease
45990,Serum levels of protein MRPL55,Disease
45991,Serum levels of protein MST1R,Disease
45992,Serum levels of protein PRSS8,Disease
45994,Serum levels of protein PRTN3,Disease
45995,Serum levels of protein PSMD11,Disease
45996,Serum levels of protein HPSE,Disease
45998,Serum levels of protein HSPA1A,Disease
45999,Serum levels of protein ANTXR1,Disease
46000,Serum levels of protein ANXA10,Disease
46001,Serum levels of protein HNF4A,Disease
46002,Serum levels of protein HP,Disease
46004,Serum levels of protein AIF1,Disease
46006,Serum levels of protein AKT3,Disease
46007,Serum levels of protein ALB,Disease
46009,Serum levels of protein RGS8,Disease
46010,Serum levels of protein RBM19,Disease
46011,Serum levels of protein OSM,Disease
46012,Serum levels of protein P4HB,Disease
46014,Serum levels of protein F13B,Disease
46016,Serum levels of protein PCSK7,Disease
46018,Serum levels of protein RSPO3,Disease
46021,Serum levels of protein RNF43,Disease
46022,Serum levels of protein RPL30,Disease
46023,Serum levels of protein RPS10,Disease
46024,Serum levels of protein PDIA3,Disease
46026,Serum levels of protein PDIA5,Disease
46028,Serum levels of protein PDILT,Disease
46030,Serum levels of protein APOL1,Disease
46031,Serum levels of protein APOM,Disease
46034,Unilateral cleft lip and palate,Disease
46035,Serum levels of protein BGLAP,Disease
46036,Serum levels of protein BGN,Disease
46039,Serum levels of protein BMP7,Disease
46041,Serum levels of protein IL10RA,Disease
46042,Serum levels of protein BAGE3,Disease
46043,Serum levels of protein BCL2L1,Disease
46044,Serum levels of protein BCL2L10,Disease
46045,Serum levels of protein AZGP1,Disease
46046,Serum levels of protein B2M,Disease
46048,Serum levels of protein IGF2R,Disease
46052,Serum levels of protein IGFBP6,Disease
46053,Serum levels of protein IGFBPL1,Disease
46055,Serum levels of protein IGFL3,Disease
46056,Serum levels of protein C11orf87,Disease
46058,Serum levels of protein FN1,Disease
46059,Serum levels of protein CCL17,Disease
46061,Serum levels of protein CCL19,Disease
46063,Serum levels of protein CCL22,Disease
46064,Cervical intraepithelial neoplasia grade 3,Disease
46065,Cervical intraepithelial neoplasia grade 3 and invasive cervical cancer,Disease
46066,Serum levels of protein CCL1,Disease
46067,Serum levels of protein CD109,Disease
46071,Serum levels of protein CD8A,Disease
46072,Serum levels of protein CFB,Disease
46074,Serum levels of protein ISG15,Disease
46076,Serum levels of protein CDH7,Disease
46077,Serum levels of protein CDK5;CDK5R1,Disease
46078,Serum levels of protein CFP,Disease
46079,Serum levels of protein CFTR,Disease
46080,Serum levels of protein CGA;TSHB,Disease
46082,Serum levels of protein CDH11,Disease
46085,Serum levels of protein LILRB1,Disease
46087,Serum levels of protein FRS2,Disease
46089,Serum levels of protein LIPA,Disease
46090,Serum levels of protein LPO,Disease
46092,Serum levels of protein LRP11,Disease
46095,Serum levels of protein LRPAP1,Disease
46100,Serum levels of protein FRZB,Disease
46101,Serum levels of protein CTGF,Disease
46104,Serum levels of protein CTRB2,Disease
46106,Serum levels of protein GFRAL,Disease
46109,Serum levels of protein GIP,Disease
46111,Serum levels of protein FTH1;FTL,Disease
46112,Serum levels of protein FTMT,Disease
46113,Serum levels of protein CX3CL1,Disease
46115,Serum levels of protein CXCL2;CXCL3,Disease
46117,Serum levels of protein GABARAPL2,Disease
46119,Serum levels of protein GBP6,Disease
46120,Serum levels of protein GCNT4,Disease
46121,Serum levels of protein DES,Disease
46122,Serum levels of protein DEFB119,Disease
46124,Serum levels of protein MAPK13,Disease
46126,Serum levels of protein DCUN1D5,Disease
46127,Serum levels of protein DDR1,Disease
46129,Serum levels of protein GNLY,Disease
46131,Serum levels of protein GNMT,Disease
46133,Serum levels of protein GNPTG,Disease
46135,Serum levels of protein MANEA,Disease
46137,Serum levels of protein PLG,Disease
46142,Serum levels of protein GLO1,Disease
46145,Cognitive aspects of educational attainment,Disease
46146,Serum levels of protein DLK2,Disease
46148,Serum levels of protein DNAJB11,Disease
46150,Serum levels of protein PREP,Disease
46152,Serum levels of protein HBZ,Disease
46154,Serum levels of protein GZMA,Disease
46155,Serum levels of protein GZMB,Disease
46157,Serum levels of protein H6PD,Disease
46158,Serum levels of protein HAVCR2,Disease
46162,Serum levels of protein DNAJC10,Disease
46164,Serum levels of protein DPEP1,Disease
46166,Serum levels of protein DSG1,Disease
46167,Serum levels of protein SERPIND1,Disease
46168,Serum levels of protein SERPINF2,Disease
46169,Serum levels of protein SEMA6C,Disease
46170,Serum levels of protein SIGLEC8,Disease
46171,Serum levels of protein SMPDL3A,Disease
46172,Primary central nervous system lymphoma,Disease
46173,Gallstone disease,Disease
46174,Arterial stiffness index,Disease
46175,Strabismus,Disease
46177,Invasive breast cancer,Disease
46178,Serum levels of protein TDO2,Disease
46179,Serum levels of protein TEK,Disease
46180,Serum levels of protein SYT11,Disease
46181,Serum levels of protein TAPBP,Disease
46183,Serum levels of protein TAPBPL,Disease
46185,Serum levels of protein SPARCL1,Disease
46186,Serum levels of protein SPAG11B,Disease
46188,Serum levels of protein SULT4A1,Disease
46189,Serum levels of protein SURF1,Disease
46190,Serum levels of protein SYNCRIP,Disease
46191,Serum levels of protein SRL,Disease
46193,Breast cancer (triple negative or BRCA1-positive),Disease
46195,Serum levels of protein TMX3,Disease
46197,Serum levels of protein TF,Disease
46198,Serum levels of protein TFF3,Disease
46199,Serum levels of protein TGM3,Disease
46200,Serum levels of protein THBS2,Disease
46201,Serum levels of protein TMCC3,Disease
46202,Serum levels of protein TMEM52B,Disease
46203,Serum levels of protein TREM2,Disease
46205,Serum levels of protein TREML1,Disease
46207,Serum levels of protein TRIL,Disease
46208,Serum levels of protein TXNDC15,Disease
46209,Serum levels of protein USP25,Disease
46210,Serum levels of protein UST,Disease
46211,Serum levels of protein UTS2,Disease
46212,Serum levels of protein UXS1,Disease
46214,Serum levels of protein VEGFA,Disease
46215,Serum levels of protein VEGFB,Disease
46216,Serum levels of protein TXNDC5,Disease
46218,Serum levels of protein TYK2,Disease
46219,Serum levels of protein UBC,Disease
46220,Serum levels of protein TPM2,Disease
46221,Serum levels of protein TPPP2,Disease
46223,Serum levels of protein TPSB2,Disease
46226,Serum levels of protein TNXB,Disease
46227,Serum levels of protein TPSB2;TPSAB1,Disease
46233,Serum levels of protein TREM1,Disease
46238,Serum levels of protein VOPP1,Disease
46239,Serum levels of protein ZAP70,Disease
46240,Serum levels of protein ZG16B,Disease
46241,Serum levels of protein WFDC1,Disease
46242,Serum levels of protein WFIKKN1,Disease
46245,Serum levels of protein WIF1,Disease
46246,Serum levels of protein ZNF276,Disease
46247,Chronic obstructive pulmonary disease x ever smoker interaction (2df),Disease
46248,Skin and soft tissue infections,Disease
46249,Chronic obstructive pulmonary disease in ever smokers,Disease
46250,Chronic obstructive pulmonary disease in never smokers,Disease
46251,Chronic obstructive pulmonary disease x ever smoker interaction (main effect),Disease
46252,Chronic obstructive pulmonary disease x current smoker interaction (2df),Disease
46253,Chronic obstructive pulmonary disease x current smoker interaction (main effect),Disease
46257,Bioavailable testosterone levels,Disease
46258,Spondylosis,Disease
46259,Body size at age 10,Disease
46260,Coronary artery disease in individuals without type 2 diabetes,Disease
46261,Childhood asthma with severe exacerbations,Disease
46262,Neuropsychiatric disorders,Disease
46264,Esophageal or stomach cancer,Disease
46269,Thyroid cancer,Disease
46271,Lymphocytic leukemia,Disease
46279,Walking pace,Disease
46285,Cancer (pleiotropy)(bidirectional),Disease
46291,interferon-related traits,Disease
46309,Non-tuberculous mycobacterial pulmonary disease,Disease
46310,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect),Disease
46311,"Type 2 diabetes (SNP x SNP interaction, 2df)",Disease
46312,"Type 2 diabetes (SNP x SNP interaction, 1df)",Disease
46313,Fasting blood glucose adjusted for BMI,Disease
46314,Benign prostatic hyperplasia,Disease
46315,Hyperuricemia,Disease
46316,Resting-state electroencephalogram vigilance,Disease
46317,Remission after SSRI treatment in MDD or openness,Disease
46318,Response to SSRI in MDD or openness,Disease
46327,Non-Hodgkin's lymphoma,Disease
46332,Thyrotoxic periodic paralysis,Disease
46333,Inflammatory biomarkers (multivariate analysis),Disease
46334,Cryptococcosis in HIV infection,Disease
46335,Hypertension in type 2 diabetes,Disease
46336,Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test),Disease
46337,Attention deficit hyperactivity disorder symptom score,Disease
46338,tricyclic pyrone compound response (IC50),Disease
46339,Shoulder impingement,Disease
46340,Plasma factor VII activating protease levels,Disease
46341,Cigarettes smoked per day (MTAG),Disease
46342,Asthma onset (childhood vs adult),Disease
46344,Handedness (Right-handed vs. non-right-handed),Disease
46345,Breast cancer specific mortality in breast cancer,Disease
46346,Breast cancer specific mortality in estrogen receptor negative breast cancer,Disease
46347,Smoking cessation (MTAG),Disease
46348,Breast cancer specific mortality in estrogen receptor positive breast cancer,Disease
46349,"Cortical brain region measurements (area, volume and thickness)",Disease
46351,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy),Disease
46352,Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy),Disease
46353,Spine bone size,Disease
46354,Thyrotoxic hypokalemic periodic paralysis and Graves disease,Disease
46355,Supraventricular ectopy,Disease
46356,Early chronic obstructive pulmonary disease in never smokers,Disease
46357,Early chronic obstructive pulmonary disease,Disease
46358,Nocturnal enuresis,Disease
46359,Idiopathic intracranial hypertension,Disease
46360,Global electrical heterogeneity phenotypes,Disease
46361,Clostridium difficile infection in multiple myeloma,Disease
46362,Lipid traits (pleiotropy) (HIPO component 2),Disease
46363,Social science traits (pleiotropy) (HIPO component 1),Disease
46364,Endometriosis or endometrial cancer (pleiotropy),Disease
46365,Warfarin-associated bleeding,Disease
46366,Antidepressant treatment resistance (> 2 drugs prescribed),Disease
46367,DNA methylation variation (age effect),Disease
46368,Diffusing capacity of carbon monoxide,Disease
46369,Cortical amyloid beta load,Disease
46370,Alzheimer's disease progression score,Disease
46371,Body mass index and waist-hip ratio (pleiotropy),Disease
46372,Cholesterol efflux capacity,Disease
46373,Cholesterol efflux capacity (cAMP stimulated assay),Disease
46374,Atypical femoral fracture in phosphonate treatment,Disease
46375,Bisphosphonate-associated atypical femoral fracture,Disease
46376,Asthma (age of onset),Disease
46377,Infliximab-induced mucosal healing in Crohn's disease,Disease
46378,Low susceptibility to hepatitis C infection,Disease
46379,Cocaine dependence,Disease
46380,Severity of nausea and vomiting of pregnancy,Disease
46419,Verbal learning,Disease
46421,Metabolite peak levels (QI15571),Disease
46423,Metabolite peak levels (QI9645),Disease
46425,Metabolite peak levels (QI7379),Disease
46426,Metabolite peak levels (QI7380),Disease
46427,Metabolite peak levels (QI7389),Disease
46429,Metabolite peak levels (QI7549),Disease
46431,Metabolite peak levels (QI8421),Disease
46434,Metabolite peak levels (QI8422),Disease
46436,Metabolite peak levels (QI843),Disease
46437,Metabolite peak levels (QI8774),Disease
46438,Metabolite peak levels (QI8814),Disease
46439,Metabolite peak levels (QI7090),Disease
46440,Metabolite peak levels (QI14245),Disease
46444,Peptidoglycan recognition protein 1 levels,Disease
46453,Cerebrospinal fluid p-tau levels,Disease
46468,Sterol ester (27:1/20:3) levels,Disease
46469,Phosphatidylcholine (15:0_18:2) levels,Disease
46470,Phosphatidylcholine (16:0_16:0) levels,Disease
46471,Phosphatidylcholine (16:0_18:3) levels,Disease
46472,Sterol ester (27:1/20:4) levels,Disease
46474,Sterol ester (27:1/16:0) levels,Disease
46475,Sterol ester (27:1/18:0) levels,Disease
46476,Sedentary behavior at work,Disease
46478,Leisure screen time (MTAG),Disease
46479,Moderate-to-vigorous intensity physical activity during leisure time (MTAG),Disease
46480,Phosphatidylinositol (18:0_20:3) levels,Disease
46482,Phosphatidylcholine (18:1_18:1) levels,Disease
46483,Phosphatidylcholine (18:1_18:2) levels,Disease
46484,Phosphatidylinositol (18:1_20:4) levels,Disease
46486,Apolipoprotein L1 levels,Disease
46488,Heat shock protein beta-1 levels,Disease
46490,Triacylglycerol (50:1) levels,Disease
46498,R-spondin-3 levels,Disease
46501,Apolipoprotein M levels,Disease
46564,"Complement component 1 Q subcomponent-binding protein, mitochondrial levels",Disease
46565,Endoplasmic reticulum resident protein 29 levels,Disease
46595,Gremlin-1 levels,Disease
46597,Interleukin-22 receptor subunit alpha-2 levels,Disease
46599,Contactin-1 levels,Disease
46602,Verbal short term memory,Disease
46611,Descending aorta maximum area,Disease
46612,Ascending aorta distensibility,Disease
46616,Ascending aorta distensibility (MTAG),Disease
46618,Descending aorta distensibility (MTAG),Disease
46621,Ascending aorta maximum area (MTAG),Disease
46623,Facial phenotypes (interpalpebral inferius length),Disease
46625,Facial phenotypes (nasion to pogonion),Disease
46628,Facial phenotypes (left palpebral fissure length),Disease
46630,Facial phenotypes (outercanthal width),Disease
46632,Facial phenotypes (midendocanthion to pogonion),Disease
46635,Descending aorta maximum area (MTAG),Disease
46636,Facial phenotypes (right palpebrale fissure height),Disease
46638,Facial phenotypes (midendocanthion to subnasale),Disease
46649,Descending aorta minimum area,Disease
46657,N4-acetylcytidine levels,Disease
46659,Metabolite peak levels (QI11461),Disease
46674,Metabolite peak levels (QI12750),Disease
46675,Metabolite peak levels (QI13644),Disease
46676,Xanthosine levels,Disease
46677,Metabolite peak levels (QI4584),Disease
46678,Metabolite peak levels (QI2718),Disease
46680,Metabolite peak levels (QI3783),Disease
46702,Metabolite peak levels (QI12380),Disease
46704,Protein Wnt-7a levels,Disease
46706,C34 gp41 HIV Fragment levels,Disease
46707,dCTP pyrophosphatase 1 levels,Disease
46740,Leisure screen time,Disease
46743,Moderate-to-vigorous intensity physical activity during leisure time,Disease
46749,Phosphatidylcholine (18:0_18:2) levels,Disease
46751,Phosphatidylcholine (O-18:2_18:2) levels,Disease
46752,Phosphatidylethanolamine (18:0_18:2) levels,Disease
46753,Phosphatidylcholine (O-16:0_16:1) levels,Disease
46754,Phosphatidylcholine (O-16:0_18:1) levels,Disease
46755,Phosphatidylcholine (O-16:0_18:2) levels,Disease
46756,Phosphatidylcholine (O-16:0_20:3) levels,Disease
46757,Phosphatidylcholine (O-16:1_18:2) levels,Disease
46758,Phosphatidylcholine (O-16:1_20:3) levels,Disease
46759,Phosphatidylcholine (O-17:0_17:1) levels,Disease
46760,Phosphatidylcholine (O-18:1_16:0) levels,Disease
46761,Phosphatidylcholine (O-18:1_20:3) levels,Disease
46762,Phosphatidylcholine (O-18:1_20:4) levels,Disease
46763,Phosphatidylcholine (O-18:2_16:0) levels,Disease
46764,Phosphatidylcholine (16:0_20:3) levels,Disease
46765,Phosphatidylcholine (16:1_18:2) levels,Disease
46766,Interleukin-17F levels,Disease
46769,Mitogen-activated protein kinase 3 levels,Disease
46772,Fractalkine levels,Disease
46773,Tumor necrosis factor receptor superfamily member EDAR levels,Disease
46776,Platelet-activating factor levels,Disease
46779,Stem Cell Growth Factor-beta levels,Disease
46784,Leukocyte immunoglobulin-like receptor subfamily B member 1 levels,Disease
46799,Non-receptor tyrosine-protein kinase TYK2 levels,Disease
46847,Total omega-3 fatty acid levels,Disease
46851,Total omega-6 fatty acid levels,Disease
46854,Perinatal depression,Disease
46857,Metabolonic lactone sulfate levels,Disease
46874,Age of onset of depression x felt loved as a child interaction,Disease
46880,von Willebrand factor levels,Disease
46883,Large artery stroke (MTAG),Disease
46884,Small vessel stroke (MTAG),Disease
46905,eGFR decline after treatment with platinum based chemotherapy,Disease
46915,Survival in coronary artery disease,Disease
46918,Circulating docosahexaenoic acid levels,Disease
46931,Chronic spontaneous urticaria,Disease
46944,"COVID-19 (hospitalized vs tested, not hospitalized)",Disease
46946,COVID-19 (hospitalized vs not hospitalized),Disease
46968,Facial morphology (multitrait analysis),Disease
46971,C-reactive protein levels (MTAG),Disease
46973,Drinks per week,Disease
46984,COVID-19 death (death vs tested and survived),Disease
46986,COVID-19 death (death vs population),Disease
47002,"COVID-19 (severe vs tested, not severe)",Disease
47006,COVID-19 (severe vs population),Disease
47025,Acute tubulointerstitial nephritis,Disease
47033,Episodic memory,Disease
47035,Language performance,Disease
47044,Visuospatial ability,Disease
47050,sarcopenia,Disease
47052,COVID-19 (severe vs non-severe with positive test),Disease
47065,School performance E-factor 1 (overall performance),Disease
47066,School performance E-factor 2 (language performance relative to maths),Disease
47067,School performance E-factor 3 (oral performance relative to written),Disease
47109,Pulmonary embolism,Disease
47134,Frequency of common cold infection,Disease
47136,Systemic infections,Disease
47153,COVID-19 hospitalization or rheumatoid arthritis (MTAG),Disease
47156,Severe COVID-19 or rheumatoid arthritis (MTAG),Disease
47187,Antipsychotic-induced metabolic syndrome in schizophrenia,Disease
47189,Chronic Chagas Cardiomyopathy in Chagas disease,Disease
47193,Free testosterone levels,Disease
47210,Nonsyndromic orofacial cleft x sex interaction,Disease
47230,Severe COVID-19 or systemic lupus erythematosus (inverse variance),Disease
47231,Premature atrial contraction frequency,Disease
47245,Albumin levels,Disease
47265,Risk-taking behavior (multivariate analysis),Disease
47280,Very low density lipoprotein cholesterol levels,Disease
47283,Smoking initiation (ever vs never),Disease
47285,Smoking cessation (current vs former),Disease
47287,Nonsyndromic orofacial cleft x sex interaction (2df),Disease
47290,Serum glutamic-oxaloacetic transaminase levels,Disease
47291,Urinary microalbumin levels,Disease
47295,Univariate microbial feature (genus: staphylococcus) at the forehead (sebaceous skin),Disease
47297,Univariate microbial feature (asv: asv004) at the forehead (sebaceous skin),Disease
47299,Univariate microbial feature (genus: anaerococcus) at the dorsal forearm (dry skin),Disease
47301,Univariate microbial feature (family: clostridiales) at the incertae (moist skin),Disease
47305,Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP),Disease
47312,Change in processing speed in pediatric CNS tumors treated with craniospinal irradiation,Disease
47315,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels,Disease
47316,21-hydroxypregnenolone disulfate levels,Disease
47317,3-methoxytyrosine levels,Disease
47318,3-phenylpropionate (hydrocinnamate) levels,Disease
47320,4-allylphenol sulfate levels,Disease
47324,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Disease
47325,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) levels,Disease
47327,"4-androsten-3beta,17beta-diol disulfate (2) levels",Disease
47329,"4-androsten-3beta,17beta-diol monosulfate (2) levels",Disease
47331,4-ethylphenylsulfate levels,Disease
47332,"5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels",Disease
47333,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels",Disease
47334,5-bromotryptophan levels,Disease
47337,Dihomo-linolenate (20:3n3 or n6) levels,Disease
47338,Dodecadienoate (12:2) (X-21343) levels,Disease
47340,Ethylmalonate levels,Disease
47341,Gamma-glutamyl-alpha-lysine levels,Disease
47343,Gamma-glutamyltyrosine levels,Disease
47347,Epiandrosterone sulfate levels,Disease
47348,Ergothioneine levels,Disease
47350,Hydroxy-cmpf (X-02269) levels,Disease
47351,Imidazole lactate levels,Disease
47354,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Disease
47356,1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) levels,Disease
47357,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,Disease
47358,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,Disease
47359,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels,Disease
47360,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels,Disease
47361,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels,Disease
47362,1-dihomo-linolenoyl-GPC (20:3n3 or 6) levels,Disease
47363,1-docosahexaenoyl-GPC (22:6) levels,Disease
47365,1-docosahexaenoyl-GPE (22:6) levels,Disease
47367,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels,Disease
47368,"1,2-dipalmitoyl-gpc (16:0/16:0) levels",Disease
47369,"1,3,7-trimethylurate levels",Disease
47371,Xanthurenate levels,Disease
47372,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Disease
47373,X-23749 levels,Disease
47377,Waist circumference (aged 40-50 years),Disease
47378,Migraine or type 2 diabetes,Disease
47381,Remission after antidepressant treatment in major depressive disorder,Disease
47382,Response to antidepressants (symptom improvement) in major depressive disorder,Disease
47385,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Disease
47386,1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) levels,Disease
47387,1-palmityl-2-stearoyl-GPC (O-16:0/18:0) levels,Disease
47388,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,Disease
47396,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Disease
47397,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,Disease
47400,Estimated glomerular filtration rate in type 2 diabetes,Disease
47402,Ascorbic acid 3-sulfate (X-12206) levels,Disease
47405,Beta-hydroxyisovalerate levels,Disease
47408,Betaine levels,Disease
47409,Cis-4-decenoyl carnitine levels,Disease
47411,Androsterone sulfate levels,Disease
47412,"Cys-gly, oxidized levels",Disease
47415,Cysteine s-sulfate levels,Disease
47417,Cysteinylglycine levels,Disease
47420,Cystine levels,Disease
47421,Cytidine levels,Disease
47422,Decadienedioic acid (c10:2-dc) (X-21792) levels,Disease
47425,Indolepropionate levels,Disease
47427,Isobutyrylcarnitine levels,Disease
47428,Isoleucylleucine/leucylisoleucine levels,Disease
47431,Laurylcarnitine levels,Disease
47433,Methionine sulfone levels,Disease
47434,Myristoylcarnitine levels,Disease
47435,N1-methyladenosine levels,Disease
47437,"N6,n6,n6-trimethyllysine levels",Disease
47448,N-acetylcarnosine levels,Disease
47449,N-acetylphenylalanine levels,Disease
47450,Linoleoylcarnitine levels,Disease
47452,N-acetylglucosamine/n-acetylgalactosamine levels,Disease
47454,N-acetylhistidine levels,Disease
47455,N-acetyl-isoputreanine (X-12688) levels,Disease
47458,Palmitoylcarnitine levels,Disease
47459,P-cresol-glucuronide levels,Disease
47461,Phenyllactate (pla) levels,Disease
47466,Orotate levels,Disease
47467,Palmitoleoylcarnitine levels,Disease
47468,Oleoylcarnitine levels,Disease
47469,Stearoylcarnitine levels,Disease
47470,Succinylcarnitine levels,Disease
47473,Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP),Disease
47479,X-11470 levels,Disease
47484,X-11478 levels,Disease
47486,X-12100 levels,Disease
47487,X-19141 levels,Disease
47489,X-21319 levels,Disease
47492,X-21364 levels,Disease
47493,X-21410 levels,Disease
47495,X-12847 levels,Disease
47497,X-13684 levels,Disease
47500,X-13866 levels,Disease
47503,X-15469 levels,Disease
47505,X-15486 levels,Disease
47506,X-11261 levels,Disease
47508,X-11381 levels,Disease
47510,X-17676 levels,Disease
47513,X-17690 levels,Disease
47515,X-18921 levels,Disease
47542,Posterior urethral valves,Disease
47582,Bone stiffness index,Disease
47590,Hip fracture,Disease
47597,Skin autofluorescence,Disease
47598,Skin reflectance,Disease
47605,Suicide behavior,Disease
47608,4-acetaminophen sulfate levels,Disease
47610,4-acetylphenol sulfate levels,Disease
47612,"4-androsten-3alpha,17alpha-diol monosulfate (2) levels",Disease
47615,"4-androsten-3beta,17beta-diol disulfate (1) levels",Disease
47618,"4-androsten-3beta,17beta-diol monosulfate (1) levels",Disease
47620,Triglyceride levels in type 2 diabetes,Disease
47621,Triglyceride levels in non-type 2 diabetes,Disease
47623,4-guanidinobutanoate levels,Disease
47624,4-hydroxycoumarin levels,Disease
47626,4-methylcatechol sulfate levels,Disease
47628,4-vinylguaiacol sulfate levels,Disease
47630,"5alpha-androstan-3alpha,17beta-diol monosulfate (2) levels",Disease
47632,"5alpha-androstan-3beta,17alpha-diol disulfate levels",Disease
47634,"5alpha-androstan-3beta,17beta-diol disulfate levels",Disease
47635,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Disease
47637,4-vinylphenol sulfate levels,Disease
47638,"5alpha-androstan-3alpha,17beta-diol disulfate levels",Disease
47641,5-methyluridine (ribothymidine) levels,Disease
47644,6-hydroxyindole sulfate levels,Disease
47646,Asparagine levels,Disease
47650,"Bilirubin (z,z) levels",Disease
47652,Cholate levels,Disease
47654,Alpha-hydroxyisovalerate levels,Disease
47656,Andro steroid monosulfate (1) levels,Disease
47657,Acisoga levels,Disease
47659,Adenine levels,Disease
47661,Adipoylcarnitine levels,Disease
47662,Docosahexaenoate (DHA; 22:6n3) levels,Disease
47664,Dodecanedioate levels,Disease
47667,dihydroferulic acid levels,Disease
47669,Cysteine-glutathione disulfide levels,Disease
47670,Dehydroisoandrosterone sulfate (dhea-s) levels,Disease
47677,Etiocholanolone glucuronide levels,Disease
47678,Ferulic acid 4-sulfate levels,Disease
47679,Gamma-CEHC levels,Disease
47680,Gamma-glutamylleucine levels,Disease
47682,Gamma-glutamylmethionine levels,Disease
47683,Gamma-glutamylphenylalanine levels,Disease
47686,Glutarylcarnitine (C5) levels,Disease
47689,Hexanoylcarnitine levels,Disease
47690,Glycodeoxycholate sulfate levels,Disease
47692,Glycolithocholate sulfate levels,Disease
47694,Gamma-glutamyl-2-aminobutyrate levels,Disease
47695,Gamma-glutamyl-epsilon-lysine levels,Disease
47697,Gamma-glutamylglutamate levels,Disease
47698,Gamma-glutamylglutamine levels,Disease
47699,Gamma-glutamylhistidine levels,Disease
47703,Glycocholenate sulfate levels,Disease
47705,Gluconic acid levels,Disease
47707,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,Disease
47709,1-palmitoyl-2-palmitoleoyl-gpc (16:0/16:1) levels,Disease
47710,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,Disease
47714,1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) levels,Disease
47716,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Disease
47718,Hydroquinone sulfate levels,Disease
47721,Hypotaurine levels,Disease
47723,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Disease
47725,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Disease
47726,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Disease
47728,1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels,Disease
47731,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) levels,Disease
47733,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,Disease
47734,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels,Disease
47736,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,Disease
47738,1-stearoyl-GPE (18:0) levels,Disease
47740,2-aminooctanoate levels,Disease
47742,Indolelactate levels,Disease
47744,Myo-inositol levels,Disease
47747,"N2,N5-diacetylornithine levels",Disease
47749,N6-carbamoylthreonyladenosine levels,Disease
47750,Mannitol/sorbitol levels,Disease
47753,Lactosyl-N-palmitoyl-sphingosine levels,Disease
47754,Indoleacetate levels,Disease
47755,Indoleacetylglutamine levels,Disease
47757,Indolin-2-one levels,Disease
47758,Isoeugenol sulfate levels,Disease
47761,Isovalerylcarnitine levels,Disease
47762,Kynurenate levels,Disease
47765,Interstitial lung diseases in rheumatoid arthritis,Disease
47767,N-acetylarginine levels,Disease
47768,N-acetyltryptophan levels,Disease
47769,N-delta-acetylornithine levels,Disease
47771,N-acetylkynurenine (2) levels,Disease
47772,N-acetylleucine levels,Disease
47774,N-acetylneuraminate levels,Disease
47775,N-acetylcitrulline levels,Disease
47777,N-acetylglycine levels,Disease
47779,Chronic obstructive pulmonary disease liability (machine learning-based score),Disease
47785,Resistance to COVID-19 infection (Exposed negative vs positive),Disease
47787,Low-density lipoprotein levels (MTAG),Disease
47804,Photoreceptor cell layer thickness phenotypes (MTAG),Disease
47813,Mitral valve annular diameter (left ventricle systole),Disease
47834,Childhood median systolic blood pressure percentile (0-3 years old),Disease
47837,Childhood median systolic blood pressure percentile,Disease
47840,Childhood median systolic blood pressure percentile (13-18 years old),Disease
47844,Age of onset of childhood onset asthma,Disease
47847,Age of onset of adult onset asthma,Disease
47849,BMI (standard GWA),Disease
47860,Triglyceride levels (MTAG),Disease
47861,Coffee intake (weighted GWA),Disease
47862,Depression/anxiety (standard GWA),Disease
47863,Diabetes (standard GWA),Disease
47865,Diabetes (weighted GWA),Disease
47866,Coffee intake (standard GWA),Disease
47874,Plasma myo-inositol levels,Disease
47876,Idiopathic knee osteoarthritis,Disease
47881,Age when finished full-time education (standard GWA),Disease
47900,Age when finished full-time education (weighted GWA),Disease
47909,Fruit intake (standard GWA),Disease
47936,Migraine (MTAG),Disease
47938,Cervical artery dissection (MTAG),Disease
47939,Migraine without aura (MTAG),Disease
47952,Height (standard GWA),Disease
47969,Gestational age (fetal effect),Disease
47971,Multisyllabic word repetition,Disease
47973,Hearing loss,Disease
47982,Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy),Disease
48012,Impulse control disorders in Parkinsons disease,Disease
48016,3-hydroxyhexanoate levels,Disease
48018,Myristoleoylcarnitine (C14:1) levels,Disease
48020,Suberoylcarnitine (C8-DC) levels,Disease
48021,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,Disease
48022,Adipoylcarnitine (C6-DC) levels,Disease
48023,Nonanoylcarnitine (C9) levels,Disease
48024,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,Disease
48043,N-acetylglucosaminylasparagine levels,Disease
48045,Flavin adenine dinucleotide (FAD) levels,Disease
48046,Succinylcarnitine (c4-dc) levels,Disease
48048,Palmitoylcarnitine (C16) levels,Disease
48050,Propionylcarnitine (c3) levels,Disease
48051,Octanoylcarnitine (c8) levels,Disease
48052,Decanoylcarnitine (C10) levels,Disease
48053,Laurylcarnitine (C12) levels,Disease
48054,Oleoylcarnitine (C18:1) levels,Disease
48055,Ascorbic acid 2-sulfate levels,Disease
48061,Carotene diol (1) levels,Disease
48063,Carotene diol (2) levels,Disease
48064,Carotene diol (3) levels,Disease
48065,Ascorbic acid 3-sulfate levels,Disease
48071,Alzheimers disease polygenic risk score (upper quantile vs lower quantile),Disease
48077,Dietary macronutrient intake (multi-trait analysis),Disease
48078,Widow's peak,Disease
48079,Earlobe attachment,Disease
48087,Late-onset Alzheimer's disease in high risk polygenic risk score,Disease
48089,CFTR mutation F508del heterozygosity in cystic fibrosis,Disease
48100,"Depression, cognition and memory (multivariate analysis)",Disease
48103,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,Disease
48105,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Disease
48106,Docosapentaenoylcarnitine (C22:5n3) levels,Disease
48107,N-acetyl-2-aminooctanoate levels,Disease
48109,Dodecadienoate (12:2) levels,Disease
48111,Arachidonoylcarnitine (C20:4) levels,Disease
48112,Eicosenoylcarnitine (C20:1) levels,Disease
48113,Dihomo-linoleoylcarnitine (C20:2) levels,Disease
48114,Dihomo-linolenoylcarnitine (C20:3n3 or 6) levels,Disease
48115,Linolenoylcarnitine (C18:3) levels,Disease
48116,Cerotoylcarnitine (C26) levels,Disease
48117,Ximenoylcarnitine (C26:1) levels,Disease
48118,Nisinate (24:6n3) levels,Disease
48120,Ceramide [N(26)S(19)] levels,Disease
48122,"3beta,7alpha-dihydroxy-5-cholestenoate levels",Disease
48124,Hexanoylglutamine levels,Disease
48126,"Androstenediol (3beta,17beta) disulfate (1) levels",Disease
48127,"Androstenediol (3beta,17beta) disulfate (2) levels",Disease
48128,"Androstenediol (3alpha, 17alpha) monosulfate (2) levels",Disease
48129,"Androstenediol (3beta,17beta) monosulfate (2) levels",Disease
48145,COVID-19 or hypertension (pleiotropy),Disease
48146,3-(3-hydroxyphenyl)propionate levels,Disease
48147,"3,4-methyleneheptanoate levels",Disease
48148,3-formylindole levels,Disease
48150,3-indoleglyoxylic acid levels,Disease
48152,Phenylacetate levels,Disease
48156,COVID-19 or obesity (pleiotropy),Disease
48158,Glutarylcarnitine (c5-dc) levels,Disease
48159,X-26054 levels,Disease
48161,X-24811 levels,Disease
48163,X-25371 levels,Disease
48164,Homoarginine levels,Disease
48186,Trigger finger,Disease
48190,Insomnia in migraine with aura,Disease
48194,"Alcohol consumption (drinks per month) (UKB data field 1578, 4424)",Disease
48199,Lamb or mutton consumption (UKB data field 1379),Disease
48201,Drink temperature,Disease
48206,Added salt consumption,Disease
48211,Cheese consumption,Disease
48218,Opioid use disorder (MTAG),Disease
48240,Triglyceride levels in medium HDL,Disease
48242,High-density lipoprotein 2 cholesterol levels,Disease
48258,HDL cholesterol levels adjusted for adiponectin levels,Disease
48259,Methylmalonate (mma) levels,Disease
48262,3-decenoylcarnitine levels,Disease
48263,3-hydroxydecanoylcarnitine levels,Disease
48264,Picolinoylglycine levels,Disease
48266,(2 or 3)-decenoate (10:1n7 or n8) levels,Disease
48268,Decadienedioic acid (C10:2-DC) levels,Disease
48269,Gamma-glutamyltryptophan levels,Disease
48270,Phenylalanylphenylalanine levels,Disease
48272,Isoleucylglycine levels,Disease
48273,Hypoxanthine levels,Disease
48275,Phenylacetylglutamate levels,Disease
48276,4-hydroxyphenylacetylglutamine levels,Disease
48279,X-07765 levels,Disease
48281,X-12216 levels,Disease
48283,X-12689 levels,Disease
48284,X-12707 levels,Disease
48285,X-12822 levels,Disease
48296,Dried fruit consumption,Disease
48297,Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428),Disease
48299,Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2),Disease
48300,Cooked vegetables consumption,Disease
48302,Raw vegetable consumption,Disease
48303,Fresh fruit consumption,Disease
48304,Healthy aging,Disease
48309,Principal component-derived dietary pattern 1,Disease
48310,Principal component-derived dietary pattern 13,Disease
48313,Principal component-derived dietary pattern 3,Disease
48317,Principal component-derived dietary pattern 5,Disease
48331,Glycerate levels,Disease
48333,N-acetyl-d-tryptophan levels,Disease
48335,Right ventricular end systolic volume,Disease
48336,Right ventricular stroke volume,Disease
48337,Right ventricular end diastolic volume,Disease
48339,Uterine leiomyoma or ER positive breast cancer (pleiotropy),Disease
48342,Uterine leiomyoma or breast cancer (pleiotropy),Disease
48350,Uterine leiomyoma or ER negative breast cancer (pleiotropy),Disease
48353,X-23787 levels,Disease
48355,X-24328 levels,Disease
48357,X-13553 levels,Disease
48359,X-13729 levels,Disease
48360,X-13844 levels,Disease
48363,X-24422 levels,Disease
48364,X-24556 levels,Disease
48365,X-16087 levels,Disease
48366,X-21285 levels,Disease
48368,X-21470 levels,Disease
48373,Linoleoylcarnitine (C18:2) levels,Disease
48374,1-dihomo-linolenoyl-GPE (20:3n3 or 6) levels,Disease
48375,Andro steroid monosulfate C19H28O6S (1) levels,Disease
48377,Cis-4-decenoylcarnitine (C10:1) levels,Disease
48378,16a-hydroxy DHEA 3-sulfate levels,Disease
48387,Insomnia in chronic migraine,Disease
48390,Never eat wheat vs no wheat restrictions (UKB data field 6144),Disease
48391,"Never eat sugar vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)",Disease
48392,Never eat sugar vs no sugar restrictions (UKB data field 6144),Disease
48394,Tea intake (UKB data field 1488),Disease
48396,"Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418)",Disease
48398,"Red wine consumption (glasses per month) (UKB data field 1578, 4419)",Disease
48399,Water consumption (glasses per day) (UKB data field 1528),Disease
48402,Bread type: White (UKB data field 1448_1),Disease
48404,"Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5)",Disease
48406,Cereal consumption (bowls per week) (UKB data field 1458),Disease
48407,Bread consumption (slices per week) (UKB data field 1438),Disease
48412,Principal component-derived dietary pattern 36,Disease
48414,Principal component-derived dietary pattern 43,Disease
48415,Principal component-derived dietary pattern 44,Disease
48417,Principal component-derived dietary pattern 54,Disease
48451,Argininate levels,Disease
48453,2-oxoarginine levels,Disease
48457,Indoleacetoylcarnitine levels,Disease
48459,2-ketocaprylate levels,Disease
48460,"Hydroxy-N6,N6,N6-trimethyllysine levels",Disease
48461,Picolinate levels,Disease
48462,"N,N,N-trimethyl-5-aminovalerate levels",Disease
48463,6-bromotryptophan levels,Disease
48469,Fructosyllysine levels,Disease
48470,3-methylglutarylcarnitine (2) levels,Disease
48472,Orbital telorism,Disease
48474,Oral microbiome alpha diversity (Shannon index) in oral squamous cell carcinoma,Disease
48476,Oral microbiome beta diversity (Bray-Curtis) in oral squamous cell carcinoma,Disease
48481,P-cresol glucuronide levels,Disease
48483,4-allylcatechol sulfate levels,Disease
48485,2-hydroxyfluorene sulfate levels,Disease
48487,3-ethylcatechol sulfate (1) levels,Disease
48489,Salicylate levels,Disease
48493,S-adenosylhomocysteine (SAH) levels,Disease
48497,5-methylthioadenosine (mta) levels,Disease
48499,2-hydroxyphenylacetate levels,Disease
48500,Phenylpyruvate levels,Disease
48539,Severe COVID-19 infection,Disease
48542,High-density lipoprotein levels (MTAG),Disease
48571,Minimum measurement of hepatic fat,Disease
48573,Maximum measurement of hepatic fat,Disease
48576,Medication use for hyperlipidemia (number of purchases),Disease
48579,Medication use for T2D (number of purchases),Disease
48581,Years ovulating,Disease
48608,COVID-19 infection or rheumatoid arthritis (MTAG),Disease
48610,COVID-19 hospitalization or systemic lupus erythematosus (MTAG),Disease
48613,Severe COVID-19 or systemic lupus erythematosus (MTAG),Disease
48621,Suicidal thoughts and behaviors,Disease
48627,Body composition (MOSTest),Disease
48629,Bone mineral density at right trochanter (model 2),Disease
48631,Bone mineral density at left trochanter (model 2),Disease
48649,COVID-19 infection or systemic lupus erythematosus (MTAG),Disease
48713,Systolic blood pressure x low social support interaction (2df test),Disease
48719,Systolic blood pressure x depressive symptoms interaction (2df test),Disease
48720,Diastolic blood pressure x depressive symptoms interaction (2df test),Disease
48722,Pulse pressure x anxiety symptoms interaction (2df test),Disease
48724,Pulse pressure x low social support interaction (2df test),Disease
48725,Pulse pressure x anxiety symptoms interaction (1df test),Disease
48734,Heart failure (multivariate analysis),Disease
48739,MSLN plasma levels,Disease
48741,Haptoglobin plasma levels,Disease
48742,Lp a plasma levels,Disease
48744,Early onset colorectal cancer,Disease
48745,Colorectal cancer (age of onset),Disease
48747,VEGF plasma levels,Disease
48749,Irritable bowel syndrome (MTAG),Disease
48752,Half-life of apixaban,Disease
48754,Time to peak concentration of apixaban,Disease
48756,anti-Xa activity of apixaban,Disease
48759,Concentration of apixaban (at 12h),Disease
48797,Interleukin-12 subunit beta levels,Disease
48799,TNF-beta levels,Disease
48801,CUB domain-containing protein 1 levels,Disease
48813,THP plasma levels,Disease
48814,TN X plasma levels,Disease
48816,Change in working memory in pediatric CNS tumors treated with craniospinal irradiation,Disease
48819,Change in intelligence quotient in pediatric CNS tumors treated with craniospinal irradiation,Disease
48830,High grade prostate cancer x metformin use interaction (simple model),Disease
48841,Nap duration in severe depression,Disease
48844,Response to antidepressants in major depressive disorder,Disease
48846,"1,2-dilinoleoyl-GPC (18:2/18:2) levels",Disease
48849,1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (p-18:0/20:4) levels,Disease
48850,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (p-18:0/22:6) levels,Disease
48851,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (p-18:0/22:6) levels,Disease
48852,Phenol sulfate levels,Disease
48853,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels,Disease
48854,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels,Disease
48855,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (p-16:0/22:6) levels,Disease
48856,1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels,Disease
48858,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Disease
48859,Pantothenate levels,Disease
48860,P-cresol sulfate levels,Disease
48863,Body surface area,Disease
48872,"Sphingomyelin (d18:1/20:1, d18:2/20:0) levels",Disease
48873,Suberate (octanedioate) levels,Disease
48876,Sarcosine (N-Methylglycine) levels,Disease
48878,Spermidine levels,Disease
48880,"Sphingomyelin (d18:1/20:0, d16:1/22:0) levels",Disease
48881,Sphingosine 1-phosphate levels,Disease
48883,"Sphingomyelin (d18:2/24:1, d18:1/24:2) levels",Disease
48891,Theophylline levels,Disease
48893,Threonate levels,Disease
48895,X-11429 levels,Disease
48897,X-11440 levels,Disease
48898,Vanillylmandelate (VMA) levels,Disease
48899,X-02249 levels,Disease
48901,X-02269 levels,Disease
48902,X-09789 levels,Disease
48904,X-11308 levels,Disease
48906,X-11334 levels,Disease
48907,X-22379 levels,Disease
48909,X-21736 levels,Disease
48911,X-21792 levels,Disease
48912,Alcohol dependence (codominant genetic model),Disease
48947,IgG antibody levels in response to SARS-CoV-2 vaccination,Disease
48949,Total antibody levels in response to SARS-CoV-2 vaccination,Disease
48951,Neutral antibody levels in response to SARS-CoV-2 vaccination,Disease
48953,Maximum habitual alcohol consumption (MTAG),Disease
48955,Opioid addiction,Disease
48965,Medication use for hypertension (number of purchases),Disease
48971,Abdominal subcutaneous adipose tissue normalized,Disease
48972,Posterior thigh muscle volume,Disease
48973,Anterior thigh muscle fat infiltration percentage,Disease
48975,Abdominal subcutaneous adipose tissue,Disease
48976,Anterior thigh muscle volume,Disease
48978,Posterior thigh muscle fat infiltration percentage,Disease
49012,Weight-to-muscle ratio,Disease
49013,Abdominal fat ratio,Disease
49032,Early-onset anorexia nervosa,Disease
49036,LDL (standard GWA),Disease
49039,BMI (weighted GWA),Disease
49042,Cancer (standard GWA),Disease
49048,Brain arteriolosclerosis,Disease
49050,LDL (weighted GWA),Disease
49059,Sleep health score,Disease
49062,Male infertility (Sertoli cell-only),Disease
49079,Early neurological instability after acute ischemic stroke,Disease
49110,Body shape (principal component analysis),Disease
49112,Anti-beta-casein IgG levels,Disease
49114,Anti-feline herpes IgG levels,Disease
49115,Fibromuscular dysplasia,Disease
49122,Opioid analgesic dose requirement in cancer pain treatment,Disease
49196,Red blood cell distribution width coefficient of variation,Disease
49197,Disruptive behavior (multivariate analysis),Disease
49207,Common executive function,Disease
49246,Nodal modulator 1 levels,Disease
49249,Low-density lipoprotein receptor-related protein 11 levels,Disease
49253,Matrix metalloproteinase-2 levels,Disease
49256,Serpin B6 levels,Disease
49259,Interleukin-4 receptor subunit alpha levels,Disease
49261,Serine protease 27 levels,Disease
49265,Pulmonary surfactant-associated protein D levels,Disease
49288,Early-onset ischemic stroke,Disease
49298,Pulse rate,Disease
49330,AFP levels,Disease
49336,Sialomucin core protein 24 levels,Disease
49338,Cadherin-5 levels,Disease
49340,"Carbonic anhydrase 5A,mitochondrial levels",Disease
49343,Carboxypeptidase A1 levels,Disease
49344,Carboxypeptidase B levels,Disease
49345,Cathepsin O levels,Disease
49349,Periodic limb movement in sleep,Disease
49350,Periodic limb movement index,Disease
49351,Early childhood caries,Disease
49353,Hand Osteoarthritis,Disease
49381,Dental development,Disease
49383,Oral cancer,Disease
49393,Pediatric steroid sensitive nephrotic syndrome,Disease
49403,Personality traits or cognitive traits (multivariate analysis),Disease
49409,Multi-trait sex score,Disease
49423,Mood disorder,Disease
49428,Noninflammatory bullous pemphigoid in response to dipeptidyl peptidase-4 inhibitors,Disease
49430,Conventional bullous pemphigoid,Disease
49432,Bullous pemphigoid (except dipeptidyl peptidase-4 inhibitor-induced noninflammatory),Disease
49438,Total cholesterol levels (MTAG),Disease
49453,Neutrophil perturbation response (side fluorescence standard deviation of neutrophil 4 in response to colchicine perturbation measured by WDF dye),Disease
49455,Breast area percent density,Disease
49470,Irritable bowel syndrome or major depressive disorder (pleiotropy),Disease
49473,AGRP levels,Disease
49488,Aging (eyeAgeAcceleration),Disease
49493,Multi-trait sum score,Disease
49496,COVID-19 with respiratory failure,Disease
49498,COVID-19 with respiratory failure requiring mechanical ventilation,Disease
49528,ICD10 M54: Dorsalgia,Disease
49529,ICD10 M51: Intervertebral disc disorder,Disease
49556,Time to osteonecrosis in systemic lupus erythematosus,Disease
49561,Persistence with methotrexate treatment at three years in early rheumatoid arthritis,Disease
49564,ICD10 C22: Malignant neoplasm of liver and intrahepatic bile ducts,Disease
49566,ICD10 C34: Malignant neoplasm of bronchus and lung,Disease
49568,Non-insulin-dependent diabetes mellitus (Union E11),Disease
49569,ICD10 E14: Unspecified diabetes mellitus,Disease
49570,ICD10 H40: Glaucoma,Disease
49572,ICD10 K74: Fibrosis and cirrhosis of liver,Disease
49574,ICD10 K81: Cholecystitis,Disease
49576,Treatment effectiveness of angiotensin II receptor blocker in hypertension,Disease
49579,Treatment effectiveness of beta blocker in hypertension,Disease
49581,Treatment effectiveness of angiotensin converting enzyme inhibitor in hypertension,Disease
49584,Treatment effectiveness of alpha blocker in hypertension,Disease
49586,Treatment effectiveness of alpha-beta blocker in hypertension,Disease
49588,Treatment effectiveness of calcium channel blocker-dihydropyridine in hypertension,Disease
49591,Treatment effectiveness of calcium channel blocker in hypertension,Disease
49594,Treatment effectiveness of calcium channel blocker-benzothiazepine in hypertension,Disease
49613,Periodontitis / loose teeth (MTAG),Disease
49629,Osteonecrosis in systemic lupus erythematosus,Disease
49635,Raynauds phenomenon disease,Disease
49636,Breast dense area,Disease
49663,Brain age gap,Disease
49670,Hearing problems,Disease
49674,Treatment effectiveness of anti-hypertensive diuretic in hypertension,Disease
49677,Resistance to antihypertensive treatment in hypertension,Disease
49679,CSF1 levels,Disease
49681,CXCL9 levels,Disease
49683,Breast area,Disease
49693,Pierre Robin Sequence endophenotypic score,Disease
49701,Inflammatory bowel disease or bipolar disorder (pleiotropy),Disease
49707,MIC-A levels,Disease
49714,TIE2 levels,Disease
49719,Gestational duration,Disease
49735,Annual healthcare cost,Disease
49741,Male puberty timing (late vs. average onset facial hair),Disease
49743,Male puberty timing (early vs. average onset voice breaking),Disease
49744,Male puberty timing (late vs. average onset voice breaking),Disease
49746,Male puberty timing (age at voice breaking MTAG),Disease
49758,Spontaneous dizygotic twinning,Disease
49781,Early onset non-small cell lung cancer,Disease
49783,Migraine or glucose levels,Disease
49784,Migraine or fasting glucose levels,Disease
49786,Headache or fasting glucose levels,Disease
49788,Migraine or fasting insulin levels,Disease
49791,Headache or fasting insulin levels,Disease
49792,Headache or HbA1c levels,Disease
49801,Cannabis use disorder,Disease
49804,Fracture of forearm,Disease
49807,Thromboembolic events in Sickle cell disease,Disease
49817,Pain,Disease
49833,Gastroesophageal reflux disease or bipolar disorder (pleiotropy),Disease
49834,COVID-19 severity,Disease
49844,Serum sclerostin levels,Disease
49849,Male puberty timing (early vs. average onset facial hair),Disease
49873,Childhood wheezing (pre-school remitting),Disease
49875,Childhood wheezing (late-onset),Disease
49878,S-6-hydroxywarfarin levels,Disease
49886,R-6-hydroxywarfarin levels,Disease
49929,Morbidity in COVID-19 (deceased vs asymptomatic),Disease
49931,COVID-19 (severe vs population) x cardiometabolic health status interaction (joint test),Disease
49933,COVID-19 (severe vs population) x cardiometabolic health status interaction,Disease
49935,COVID-19 (severe vs population) x sex interaction (joint test),Disease
49937,COVID-19 (severe vs population) x sex interaction,Disease
49938,S-6-hydroxywarfarin to S-warfarin ratio,Disease
49940,S-warfarin to R-warfarin ratio,Disease
49944,R-6-hydroxywarfarin to R-warfarin ratio,Disease
49951,"DHEA-S-to-4-androsten-3beta,17beta-diol disulfate 2 ratio",Disease
49952,Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,Disease
49953,Hexanoylcarnitine-to-octanoylcarnitine ratio,Disease
49954,Linoleate 18:2n6-to-dihomo-linolenate 20:3n3 or n6 ratio,Disease
49955,Lysine-to-glutaroyl carnitine ratio,Disease
49956,Phenyllactate-to-phenylalanine ratio,Disease
49958,X-11444-to-X-11470 ratio,Disease
49959,X-12798-to-phenylalanine ratio,Disease
49960,"4-androsten-3beta,17beta-diol disulfate 2 levels",Disease
49962,Cigarettes smoked per day,Disease
49975,Age of smoking initiation,Disease
49976,Visceral adipose tissue volumes,Disease
49977,Abdominal adipose tissue volumes,Disease
49979,Gluteofemoral adipose tissue volumes,Disease
49983,Visceral adipose tissue volumes (adjusted for BMI and height),Disease
49986,Visceral adipose tissue volumes to gluteofemoral adipose tissue volumes ratio,Disease
49988,Abdominal adipose tissue volumes to gluteofemoral adipose tissue volumes ratio,Disease
49990,Gluteofemoral adipose tissue volumes (adjusted for BMI and height),Disease
49991,Visceral adipose tissue volumes to abdominal adipose tissue volumes ratio,Disease
49997,Abdominal adipose tissue volumes (adjusted for BMI and height),Disease
49998,Colorectal cancer x menopausal hormone therapy interaction,Disease
50001,Colorectal cancer x menopausal hormone therapy interaction (2df test),Disease
50003,Colorectal cancer x menopausal hormone therapy interaction (3df test),Disease
50004,Colorectal cancer x estrogen-progesterone hormone therapy interaction,Disease
50006,R-warfarin levels,Disease
50017,RS-10-hydroxywarfarin to RS-warfarin ratio,Disease
50019,S-7-hydroxywarfarin to S-warfarin ratio,Disease
50023,Platelet factor 4/heparin antibody levels in heparin treatment,Disease
50031,Opioid use disorder (broad),Disease
50033,RS-warfarin levels,Disease
50035,Octadecadienylcarnitine levels,Disease
50057,X-11550 levels,Disease
50058,X-12038 levels,Disease
50059,X-12244--N-acetylcarnosine levels,Disease
50060,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Disease
50062,Glutaroyl carnitine levels,Disease
50063,Dihomo-linolenate 20:3n3 or n6 levels,Disease
50064,X-12556 levels,Disease
50066,X-12627 levels,Disease
50072,COVID-19,Disease
50075,Alanine aminotransferase level after methotrexate initiation in rheumatoid arthritis,Disease
50078,Alanine aminotransferase elevation after methotrexate initiation in rheumatoid arthritis (>1.5  ULN),Disease
50093,RS-6-hydroxywarfarin levels,Disease
50100,S-7-hydroxywarfarin levels,Disease
50112,3-phenylpropionate hydrocinnamate levels,Disease
50115,Scyllo-inositol levels,Disease
50172,COVID-19 (severe vs mild),Disease
50184,Adverse response to chemotherapy in breast cancer (grade 3/4 neutropenic or leukopenic events),Disease
50186,Alzheimer's disease in non-APOE e4 carriers,Disease
50202,Lifelong premature ejaculation,Disease
50206,Dementia in APOE e4+ carriers,Disease
50207,Dementia in non-APOE e4 carriers,Disease
50221,Colorectal cancer x estrogen hormone therapy interaction,Disease
50224,Colorectal cancer x estrogen-progesterone hormone therapy interaction (3df test),Disease
50235,HLA risk haplotype in IgA deficiency (homozygous HLA-DRB1*07:01 HLA-DQB1*02:02),Disease
50237,Colorectal cancer x estrogen-progesterone hormone therapy interaction (2df test),Disease
50238,S-warfarin levels,Disease
50246,RS-10-hydroxywarfarin levels,Disease
50313,Age-related macular degeneration or COVID-19 infection (MTAG),Disease
50315,COVID-19 critical illness or age-related macular degeneration (MTAG),Disease
50316,COVID-19 hospitalization or age-related macular degeneration (MTAG),Disease
50340,Asthma or chronic obstructive pulmonary disease (pleiotropy),Disease
50357,Age-related macular degeneration or COVID-19 hospitalization (MTAG),Disease
50358,Age-related macular degeneration or COVID-19 critical illness (MTAG),Disease
50373,Geographic atrophy within a central 5 mm circle (model 1),Disease
50375,Drusen area within a central 5 mm circle (model 1),Disease
50379,Drusen volume within a central 5 mm circle (model 1),Disease
50382,Drusen area within a central 3 mm circle (model 1),Disease
50383,Drusen area within a central 5 mm circle (model 2),Disease
50392,Uterine leiomyomata,Disease
50401,Juvenile dermatomyositis,Disease
50417,Crohn's disease x smoking status (never vs ever smoking) interaction,Disease
50419,Ulcerative colitis x smoking status (never vs ever smoking) interaction,Disease
50420,Inflammatory bowel disease x smoking status (never vs ever smoking) interaction,Disease
50421,Crohn's disease x smoking status (never vs current smoking) interaction,Disease
50424,Inflammatory bowel disease x smoking status (never vs current smoking) interaction,Disease
50425,Crohn's disease x smoking status (never vs former smoking) interaction,Disease
50427,Inflammatory bowel disease x smoking status (never vs former smoking) interaction,Disease
50433,Bone mineral density mean,Disease
50441,Whole body fat mass (UKB data field 23100),Disease
50474,Baseline memory in normal cognition,Disease
50477,Whole body fat free mass (UKB data field 23101),Disease
50482,Baseline memory in normal cognition x sex interaction,Disease
50485,Memory decline in impaired cognition,Disease
50488,Memory decline in normal cognition,Disease
50530,Bone mineral density variability,Disease
50540,Memory decline,Disease
50544,Memory decline in impaired cognition x sex interaction,Disease
50551,Memory decline in normal cognition x sex interaction,Disease
50607,Memory decline x sex interaction,Disease
50636,Gastroesophageal reflux disease (UKB data field 20002_1138),Disease
50637,Gastritis and duodenitis (UKB data field 20002_1143),Disease
50639,ICD10 K31.7: Polyp of stomach and duodenum,Disease
50641,ICD10 K70: Liver fibrosis and cirrhosis,Disease
50651,Diffuse gastric cancer in H. pylori positive individuals,Disease
50656,Posterior brain arterial diameters,Disease
50662,"ICD10 K50, K51: inflammatory bowel disease",Disease
50663,Colorectal polyp (UKB data field 20002_1460),Disease
50669,"Cancer code, self-reported: small intestinal cancer (UKB data field 20001_1019)",Disease
50670,Cholelithiasis (UKB data field 20002_1162),Disease
50673,alpha-Fetoprotein levels,Disease
50696,Bone density T-score,Disease
50705,Body fat rate,Disease
50712,Ischemic heart disease (PheCode 411),Disease
50715,Bone density Z-score,Disease
50744,Baseline memory x sex interaction,Disease
50747,Baseline memory in impaired cognition x sex interaction,Disease
50758,Telomere length (principal component 1),Disease
50773,"Estimated glomerular filtration rate (creatinine, cystatin c)",Disease
50780,Baseline memory in impaired cognition,Disease
50794,Baseline memory,Disease
50800,Hip shape mode 1,Disease
50803,Hip shape mode 2,Disease
50879,Ease of skin tanning,Disease
50883,Ease of sunburn,Disease
50885,Extensive white matter perivascular space burden,Disease
50888,Underweight,Disease
50891,"Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial levels",Disease
50892,Statherin levels,Disease
50894,Stromal interaction molecule 1 levels,Disease
50896,Serine/threonine-protein kinase 16 levels,Disease
50898,Adenylyltransferase and sulfurtransferase MOCS3 levels,Disease
50899,Matrix-remodeling-associated protein 8 levels,Disease
50900,Myeloblastin levels,Disease
50902,Myosin light chain 6B levels,Disease
50903,Myelin protein zero-like protein 1 levels,Disease
50904,Melanoregulin levels,Disease
50905,Methenyltetrahydrofolate synthase domain-containing protein levels,Disease
50907,Serine/threonine-protein kinase PAK 3 levels,Disease
50909,Serine/threonine-protein kinase PAK 5 levels,Disease
50911,Mucin-16 levels,Disease
50914,Mitochondrial ubiquitin ligase activator of NFKB 1 levels,Disease
50915,Neuroendocrine protein 7B2 levels,Disease
50918,E3 ubiquitin-protein ligase NEURL1 levels,Disease
50921,Magnesium transporter NIPA4 levels,Disease
50922,Neutrophil elastase levels,Disease
50924,NEDD8-activating enzyme E1 regulatory subunit levels,Disease
50926,Fc receptor-like protein 1 levels,Disease
50927,Zona pellucida-binding protein 1 levels,Disease
50928,Protein zwilch homolog levels,Disease
50929,Inhibin beta B chain (mixed) levels,Disease
50935,Fatty acid-binding protein 9 levels,Disease
50937,"Iron-sulfur cluster co-chaperone protein HscB, mitochondrial levels",Disease
50938,Fibroblast growth factor 8 isoform B levels,Disease
50941,"Poly(A) RNA polymerase, mitochondrial levels",Disease
50942,Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 levels,Disease
50943,Guanylate-binding protein 6 levels,Disease
50944,GTP cyclohydrolase 1 levels,Disease
50945,Melanocyte protein PMEL levels,Disease
50948,Insomnia (standard GWA),Disease
50950,Number of non-cancer illnesses (standard GWA),Disease
50952,Height (weighted GWA),Disease
50955,Body mass index (MTAG),Disease
50969,TNF receptor-associated factor 1 levels,Disease
50972,Triggering receptor expressed on myeloid cells 2 levels,Disease
50974,"Tryptophan 2,3-dioxygenase levels",Disease
50975,Thiopurine S-methyltransferase levels,Disease
50976,Transferrin receptor protein 1 levels,Disease
50977,Trypsin-1 levels,Disease
50979,Trypsin-2 levels,Disease
50980,Tubulin polymerization-promoting protein family member 2 levels,Disease
50985,Tapasin-related protein levels,Disease
50987,"Troponin T, fast skeletal muscle levels",Disease
50988,TOM1-like protein 2 levels,Disease
50989,TOMM20-like protein 1 levels,Disease
50990,Thioredoxin-related transmembrane protein 2 levels,Disease
50991,Protein disulfide-isomerase TMX3 levels,Disease
50993,Mitochondrial import inner membrane translocase subunit TIM14 levels,Disease
50995,T-cell immunoglobulin and mucin domain-containing protein 4 levels,Disease
50997,Transcription factor AP-1 levels,Disease
50998,Tumor necrosis factor alpha-induced protein 3 levels,Disease
51000,Tumor necrosis factor receptor superfamily member 21 levels,Disease
51002,Tumor necrosis factor receptor superfamily member 3 levels,Disease
51003,Tumor necrosis factor receptor superfamily member 8 levels,Disease
51005,Tumor necrosis factor ligand superfamily member 14 levels,Disease
51006,Tumor necrosis factor ligand superfamily member 18 levels,Disease
51008,Trimeric intracellular cation channel type B levels,Disease
51009,Tumor necrosis factor receptor superfamily member 17 levels,Disease
51010,Chronotype x daytime light exposure interaction,Disease
51012,"Alanine--tRNA ligase, cytoplasmic levels",Disease
51014,Paralemmin-1 levels,Disease
51015,"Peptide chain release factor 1-like, mitochondrial levels",Disease
51018,Proprotein convertase subtilisin/kexin type 7 levels,Disease
51020,Protein canopy homolog 3 levels,Disease
51022,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP] levels",Disease
51023,RBC levels of 15-HETE,Disease
51026,Beta-defensin 113 levels,Disease
51028,Beta-defensin 116 levels,Disease
51029,Beta-defensin 132 levels,Disease
51030,Biglycan levels,Disease
51032,"RBC levels of 9,10-diHOME",Disease
51034,RBC levels of acetyl-carnitine,Disease
51035,RBC levels of ADP,Disease
51037,RBC levels of 2-Oxoglutaramate,Disease
51039,RBC levels of 5-6-Dihydrothymine,Disease
51041,RBC levels of 8-HETE.1,Disease
51043,RBC levels of 11-HETE.1,Disease
51047,Left ventricular end diastolic mass,Disease
51049,Left ventricular end-diastolic volume,Disease
51050,Left ventricular ejection fraction,Disease
51053,Right ventricular peak ejection rate,Disease
51062,Left ventricular end diastolic mass end diastolic volume ratio,Disease
51065,Systolic blood pressure (standard GWA),Disease
51069,Smoking status (standard GWA),Disease
51071,Nuclear distribution protein nudE homolog 1 levels,Disease
51073,"Nucleoside diphosphate kinase, mitochondrial levels",Disease
51076,Protein NDRG4 levels,Disease
51080,"NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial levels",Disease
51081,Tight junction protein ZO-1 levels,Disease
51084,U6 snRNA-associated Sm-like protein LSm4 levels,Disease
51085,Neural cell adhesion molecule 2 levels,Disease
51087,Gamma-aminobutyric acid receptor-associated protein-like 2 levels,Disease
51089,Nuclear pore membrane glycoprotein 210-like levels,Disease
51091,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha levels,Disease
51092,Receptor-type tyrosine-protein kinase FLT3 levels,Disease
51093,G2/mitotic-specific cyclin-B2 levels,Disease
51094,Galactose-3-O-sulfotransferase 2 levels,Disease
51096,Glycerol-3-phosphate dehydrogenase 1-like protein levels,Disease
51099,Frizzled-10 levels,Disease
51100,Phospholipase A2 levels,Disease
51101,Prolyl 4-hydroxylase subunit alpha-2 levels,Disease
51103,Ferritin light chain levels,Disease
51104,Pancreatic triacylglycerol lipase levels,Disease
51107,Proto-oncogene tyrosine-protein kinase ROS levels,Disease
51108,Peroxisome proliferator-activated receptor alpha levels,Disease
51110,PH and SEC7 domain-containing protein 1 levels,Disease
51111,Pre-mRNA-processing factor 6 levels,Disease
51112,PR domain zinc finger protein 1 levels,Disease
51113,Prion-like protein doppel levels,Disease
51115,Proteasome subunit alpha type-2 levels,Disease
51116,Proteasome subunit alpha type-5 levels,Disease
51118,Proteasome subunit alpha type-7 levels,Disease
51121,Proteasome subunit beta type-2 levels,Disease
51125,Pro-opiomelanocortin levels,Disease
51127,Prostasin levels,Disease
51138,Reaction time (standard GWA),Disease
51139,Reaction time (weighted GWA),Disease
51140,Risk taking (standard GWA),Disease
51142,Risk taking (weighted GWA),Disease
51143,Alcohol frequency weekly (standard GWA),Disease
51155,Soluble CD163 levels,Disease
51158,Neuronal pentraxin-1 levels,Disease
51160,Neurexophilin-1 levels,Disease
51161,OCIA domain-containing protein 1 levels,Disease
51162,Opticin levels,Disease
51163,Oral cancer-overexpressed protein 1 levels,Disease
51164,Oncostatin-M levels,Disease
51165,Arsenite methyltransferase levels,Disease
51166,Histone chaperone ASF1A levels,Disease
51168,ATPase family AAA domain-containing protein 1 levels,Disease
51169,Cyclic AMP-dependent transcription factor ATF-6 alpha levels,Disease
51170,Armadillo repeat-containing protein 5 levels,Disease
51173,"ATP synthase subunit beta, mitochondrial levels",Disease
51174,ATP-dependent RNA helicase A levels,Disease
51175,Extracellular tyrosine-protein kinase PKDCC levels,Disease
51176,Plasmin levels,Disease
51179,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 levels",Disease
51180,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 levels",Disease
51182,Augurin levels,Disease
51183,Aurora kinase B levels,Disease
51194,Skin phototype score,Disease
51207,Skin color (Fitzpatrick scale),Disease
51210,Primary focal segmental glomerulosclerosis in chronic kidney disease,Disease
51218,Extrapulmonary tuberculosis,Disease
51220,Transcription initiation factor TFIID subunit 10 levels,Disease
51221,Tropomyosin beta chain levels,Disease
51222,Histone-lysine N-methyltransferase SUV420H2 levels,Disease
51223,T-cell surface glycoprotein CD1a levels,Disease
51224,Sulfatase-modifying factor 2 levels,Disease
51226,Synaptotagmin-11 levels,Disease
51228,Syntaxin-7 levels,Disease
51230,Suppressor of fused homolog levels,Disease
51231,TLR4 interactor with leucine rich repeats levels,Disease
51233,"Thymidine kinase, cytosolic levels",Disease
51234,"Thymidine kinase 2, mitochondrial levels",Disease
51236,Tachykinin-4 levels,Disease
51237,Transmembrane protein 9 levels,Disease
51238,Thyroid peroxidase levels,Disease
51239,Transmembrane protein C1orf162 levels,Disease
51240,Transmembrane protein 185A levels,Disease
51242,Ubiquitin D levels,Disease
51243,"Malignant lymphoma (Non-Hodgkin lymphoma, multiple myeloma, or Hodgkin lymphoma)",Disease
51246,Alanine aminotransferase 1 levels,Disease
51247,Anthrax toxin receptor 1 levels,Disease
51248,"Angiopoietin-1 receptor, soluble levels",Disease
51253,Cryptic phenotype that captures Alport syndrome severity,Disease
51254,Cryptic phenotype that captures autosomal dominant polycystic kidney disease severity,Disease
51255,Systolic blood pressure (weighted GWA),Disease
51267,"Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A levels",Disease
51268,Myc-associated zinc finger protein levels,Disease
51270,Mast cell-expressed membrane protein 1 levels,Disease
51271,"Malonyl-CoA decarboxylase, mitochondrial levels",Disease
51273,Homeobox protein MOX-2 levels,Disease
51275,MICAL-like protein 2 levels,Disease
51281,Matrix metalloproteinase-9 levels,Disease
51283,UDP-glucuronic acid decarboxylase 1 levels,Disease
51286,Valine--tRNA ligase levels,Disease
51287,Vesicle-associated membrane protein 8 levels,Disease
51288,Urotensin-2 levels,Disease
51291,Vascular endothelial growth factor B levels,Disease
51292,Vascular endothelial growth factor receptor 1 levels,Disease
51293,Uncharacterized protein C3orf18 levels,Disease
51294,Uncharacterized protein C4orf32 levels,Disease
51295,Sleep apnea (MTAG),Disease
51297,Protein disulfide-isomerase A4 levels,Disease
51298,Apolipoprotein A-V levels,Disease
51299,Protein delta homolog 1 levels,Disease
51300,Protein delta homolog 2 levels,Disease
51301,Apolipoprotein C-III levels,Disease
51307,ER membrane protein complex subunit 4 levels,Disease
51308,Chymotrypsin-like elastase family member 2A levels,Disease
51310,Histone-lysine N-methyltransferase EHMT2 levels,Disease
51311,Erythropoietin levels,Disease
51312,Epididymal-specific lipocalin-10 levels,Disease
51313,"Electron transfer flavoprotein subunit alpha, mitochondrial levels",Disease
51314,DNA excision repair protein ERCC-1 levels,Disease
51316,Protein FAM177A1 levels,Disease
51318,Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 levels,Disease
51320,Ectonucleoside triphosphate diphosphohydrolase 1 levels,Disease
51321,Ectonucleoside triphosphate diphosphohydrolase 3 levels,Disease
51322,Endothelin-2 levels,Disease
51325,OTU domain-containing protein 5 levels,Disease
51326,Activin receptor type-2A levels,Disease
51327,Aspartoacylase levels,Disease
51328,Acyl-coenzyme A thioesterase 13 levels,Disease
51330,"Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial levels",Disease
51331,14-3-3 protein family levels,Disease
51333,5-Nucleotidase levels,Disease
51336,Amiloride-sensitive amine oxidase [copper-containing] levels,Disease
51338,Prorelaxin H2 levels,Disease
51339,Prefoldin subunit 3 levels,Disease
51340,Platelet endothelial cell adhesion molecule levels,Disease
51341,Prolyl endopeptidase FAP levels,Disease
51342,Peptidyl-prolyl cis-trans isomerase G levels,Disease
51344,"Peroxisomal 2,4-dienoyl-CoA reductase levels",Disease
51363,Left ventricle sphericity index,Disease
51365,Left ventricle short axis,Disease
51368,Skin color,Disease
51370,Overweight,Disease
51372,Epstein-Barr virus seropositivity,Disease
51374,Colorectal cancer x cigarettes per day interaction (1df),Disease
51375,Colorectal cancer x cigarettes per day interaction (3df),Disease
51376,Pro-FMRFamide-related neuropeptide FF levels,Disease
51377,NKG2-E type II integral membrane protein levels,Disease
51378,NmrA-like family domain-containing protein 1 levels,Disease
51381,Vitamin K-dependent protein S levels,Disease
51383,Noggin levels,Disease
51384,B-cell lymphoma 6 protein levels,Disease
51385,Breast cancer anti-estrogen resistance protein 3 levels,Disease
51388,Left ventricular stroke volume,Disease
51396,Inclusion body myositis,Disease
51397,Idiopathic inflammatory myopathy with anti-Jo1 positive,Disease
51398,Thioredoxin domain-containing protein 15 levels,Disease
51400,Thioredoxin-interacting protein levels,Disease
51401,Trypsin-3 levels,Disease
51406,Thrombospondin-type laminin G domain and EAR repeat-containing protein levels,Disease
51409,"Tyrosine-protein kinase receptor Tie-1, soluble levels",Disease
51411,Tyrosine-protein kinase ZAP-70 levels,Disease
51412,Alpha angle,Disease
51414,Zinc finger protein 276 levels,Disease
51415,V-set and transmembrane domain-containing protein 4 levels,Disease
51416,Protein Wnt-11 levels,Disease
51419,WAP four-disulfide core domain protein 5 levels,Disease
51420,Protein Wnt-5a levels,Disease
51421,WW domain-containing oxidoreductase levels,Disease
51424,Very low-density lipoprotein receptor levels,Disease
51425,Vascular non-inflammatory molecule 2 levels,Disease
51430,"Vesicular, overexpressed in cancer, prosurvival protein 1 levels",Disease
51431,Vacuolar protein sorting-associated protein 28 homolog levels,Disease
51433,Zinc fingers and homeoboxes protein 3 levels,Disease
51434,Afamin levels,Disease
51442,25-hydroxyvitamin D levels (skin colour stratified),Disease
51443,25-Hydroxyvitamin D levels,Disease
51461,Soluble transferrin receptor concentration,Disease
51465,Hepcidin concentration,Disease
51484,Hip shape mode 4,Disease
51489,Hip shape mode 3,Disease
51491,Hip shape mode 6,Disease
51501,Serum O-methylascorbate levels  x sex interaction,Disease
51504,Serum ascorbic acid 2-sulfate levels x sex interaction,Disease
51521,Lactate levels in blood donors,Disease
51522,Phosphoenolpyruvate levels in blood donors,Disease
51557,FVC,Disease
51618,Pain intensity in opioid-treated advanced cancer,Disease
51659,Hip shape mode 8,Disease
51661,Hip shape mode 9,Disease
51670,Hip shape mode 10,Disease
51674,Fluid intelligence,Disease
51691,"2,3-Phospho-D-glycerate levels in blood donors",Disease
51693,ATP levels in blood donors,Disease
51694,D-Hexose-phosphate levels in blood donors,Disease
51695,Serum 25-Hydroxyvitamin D levels (conditioned on BMI),Disease
51697,Adhesion G protein-coupled receptor B3 levels,Disease
51699,Cadherin-15 levels,Disease
51705,Epithelial discoidin domain-containing receptor 1 levels,Disease
51707,Dipeptidase 1 levels,Disease
51709,Dipeptidase 2 levels,Disease
51756,Achondroplasia-like facial shape score,Disease
51796,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Disease
51797,Microalbumin urine,Disease
51802,Telomere length (principal component 2),Disease
51829,NKG2D ligand 2 levels,Disease
51835,SPARC-related modular calcium-binding protein 2 levels,Disease
51838,Interleukin-32 levels,Disease
51841,Group 10 secretory phospholipase A2 levels,Disease
51843,Tubulin polymerization-promoting protein family member 3 levels,Disease
51849,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386),Disease
51850,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386) x waist circumference interaction (2df),Disease
51867,Corpus callosum fractional anisotropy (body),Disease
51871,Corpus callosum fractional anisotropy (MOSTest),Disease
51875,Allergen component sensitization (Hevea brasiliensis 8),Disease
51899,Smoking initiation (MTAG),Disease
51904,Color vision defects (Tritan),Disease
51916,Major depressive disorder or hospitalized COVID-19 (pleiotropy),Disease
51917,Major depressive disorder or COVID-19 infection (pleiotropy),Disease
51921,Arthritis,Disease
51922,Cholesterol levels,Disease
51928,Biliary atresia,Disease
51930,Metabolite levels (gamma-glutamyllysine; gamma-glutamyl-epsilon-lysine),Disease
51931,Metabolite levels (propyl 4-hydroxybenzoate sulfate),Disease
51937,Metabolite levels (methyl-4-hydroxybenzoate sulfate),Disease
51939,Metabolite levels (indoleacetoylcarnitine),Disease
51941,"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",Disease
51942,Metabolite levels (N-acetylcarnosine),Disease
51944,Metabolite levels (butyrylcarnitine; butyrylcarnitine (C4); C4 carnitine; C4_carnitine),Disease
51945,"Metabolite levels (cys-gly, oxidized)",Disease
51948,Metabolite levels (linolenoylcarnitine (C18:3)),Disease
51950,Metabolite levels (tyrosine),Disease
51952,"Metabolite levels (4-androsten-3beta,17beta-diol disulfate (2); androstenediol (3beta,17beta) disulfate (2))",Disease
51973,Monocyte side fluorescence,Disease
51974,Basophil forward scatter distribution width,Disease
51975,Monocyte side scatter,Disease
51982,Pain (pleiotropy),Disease
52055,Metabolite levels (isobutyrylcarnitine; isobutyrylcarnitine (C4)),Disease
52056,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Disease
52057,Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6); C38:6 PC; C38_6_PC),Disease
52058,Metabolite levels (ornithine),Disease
52059,Metabolite levels (arachidonoylcarnitine (C20:4)),Disease
52060,Metabolite levels (azelaoyltaurine),Disease
52063,Metabolite levels (phenylacetate),Disease
52065,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6)),Disease
52066,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),Disease
52067,Metabolite levels (lysine),Disease
52068,Metabolite levels (serotonin (5HT); serotonin),Disease
52069,Metabolite levels (succinylcarnitine; succinylcarnitine (C4-DC)),Disease
52070,Metabolite levels (cysteinylglycine disulfide),Disease
52072,Metabolite levels (guanosine),Disease
52075,Metabolite levels (o-cresol sulfate),Disease
52076,Metabolite levels (oleoylcarnitine; oleoylcarnitine (C18:1); C18:1 carnitine; C18_1_carnitine),Disease
52077,Metabolite levels (21-hydroxypregnenolone disulfate),Disease
52078,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Disease
52079,Metabolite levels (inosine; cmh_inosine; Inosine),Disease
52082,Metabolite levels (phenyllactate (PLA); phenyllactate),Disease
52084,Metabolite levels (3-phenylpropionate (hydrocinnamate); hydrocinnamate),Disease
52085,Metabolite levels (propionylcarnitine; propionylcarnitine (C3); C3 carnitine; C3_carnitine),Disease
52086,ICD10 L50: Urticaria,Disease
52093,Common variable immunodeficiency,Disease
52108,Anterior uveitis,Disease
52110,Crohn's disease x sex interaction (2df),Disease
52116,Erythema nodosum in Behcet's disease,Disease
52117,Neurological involvement in Behcet's disease,Disease
52119,Absolute neutrophil count,Disease
52147,Antipsychotic-induced triglycerides change in schizophrenia (6-week),Disease
52149,Triglycerides level in antipsychotic-treated schizophrenia (6-week),Disease
52159,Genetic generalized epilepsy,Disease
52161,Red blood cell haemoglobin equivalent,Disease
52163,Red cell distribution width - standard deviation,Disease
52179,Reticulocyte haemoglobin equivalent,Disease
52181,Reticulocyte production index,Disease
52183,Low fluorescent percentage of reticulocytes,Disease
52184,Immature granulocyte percentage of white cells,Disease
52186,Neutrophil forward scatter distribution width,Disease
52188,Immature granulocyte count,Disease
52189,Neutrophil side scatter distribution width,Disease
52190,Neutrophil forward scatter,Disease
52193,Neutrophil side fluorescence,Disease
52196,Corpus callosum volume (MOSTest),Disease
52204,Response to high-intensity interval training in physically inactive (maximal oxygen uptake),Disease
52209,Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)),Disease
52210,Metabolite levels (gamma-glutamyl-alpha-lysine),Disease
52212,Metabolite levels (pterin),Disease
52215,Metabolite levels (N-acetylglucosamine/N-acetylgalactosamine),Disease
52216,Metabolite levels (N-acetylglucosaminylasparagine),Disease
52220,Metabolite levels (12-HETE),Disease
52221,Metabolite levels (hexanoylglutamine),Disease
52222,Metabolite levels (3-hydroxyhexanoate),Disease
52224,Metabolite levels (beta-hydroxyisovalerate),Disease
52226,Metabolite levels (carnitine),Disease
52227,Metabolite levels (arginine),Disease
52228,Metabolite levels (picolinate),Disease
52231,Metabolite levels (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)),Disease
52232,Metabolite levels (S-1-pyrroline-5-carboxylate),Disease
52234,Liver thiopurine methyltransferase levels,Disease
52245,Iron deficiency anaemia,Disease
52250,End-diastolic bi-ventricular shape (principal component 5),Disease
52251,End-diastolic bi-ventricular shape (principal component 9),Disease
52253,End-diastolic bi-ventricular shape (principal component 1),Disease
52255,End-diastolic bi-ventricular shape (principal component 3),Disease
52256,End-diastolic bi-ventricular shape (principal component 4),Disease
52259,Alcohol use frequency in adolescence,Disease
52266,Platelet forward scatter distribution width,Disease
52267,High fluorescence immature platelet fraction,Disease
52268,Platelet side fluorescence distribution width,Disease
52271,Platelet side scatter distribution width,Disease
52274,Reticulocyte forward scatter,Disease
52276,Reticulocyte side fluorescence,Disease
52280,Medium fluorescent percentage of reticulocytes,Disease
52281,High fluorescent percentage of reticulocytes,Disease
52283,Neutrophil side scatter,Disease
52284,Immature reticulocyte forward scatter,Disease
52308,Reactive lymphocyte percentage of white cells,Disease
52310,Lymphocyte side scatter distribution width,Disease
52312,Lymphocyte side fluorescence distribution width,Disease
52314,Reactive lymphocyte count,Disease
52316,Reactive percentage of lymphocytes,Disease
52318,Monocyte side fluorescence distribution width,Disease
52319,Lymphocyte side scatter,Disease
52322,Lymphocyte forward scatter,Disease
52326,Lymphocyte side fluorescence,Disease
52334,Cannabis use disorder (MTAG),Disease
52383,Alcohol use disorder (MTAG),Disease
52386,Allergen component sensitization (Mercurialis annua 1),Disease
52387,Allergen component sensitization (Phleum pratense 1),Disease
52397,Breast cancer or critical COVID-19 (pleiotropy),Disease
52399,Metabolite levels (xanthosine; Xanthosine),Disease
52400,Metabolite levels (carotene diol (1)),Disease
52402,Metabolite levels (carotene diol (2)),Disease
52403,Metabolite levels (cysteinylglycine),Disease
52404,Metabolite levels (imidazole lactate; imidazolelactate),Disease
52406,Metabolite levels (prolylglycine; pro-gly),Disease
52408,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),Disease
52410,Metabolite levels (indoleacetylglutamine),Disease
52411,Metabolite levels (indolebutyrate),Disease
52413,Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine),Disease
52414,Metabolite levels (3-methylglutarylcarnitine (2)),Disease
52415,"Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",Disease
52416,Metabolite levels (N-acetyltryptophan),Disease
52418,Metabolite levels (N-palmitoyltaurine),Disease
52422,Basophil side fluorescence,Disease
52426,Basophil side fluorescence distribution width,Disease
52427,Eosinophil forward scatter distribution width,Disease
52430,Eosinophil side scatter,Disease
52431,Eosinophil side fluorescence,Disease
52432,Eosinophil forward scatter,Disease
52434,Eosinophil side scatter distribution width,Disease
52438,Corpus callosum fractional anisotropy (splenium),Disease
52440,Corpus callosum posterior volume,Disease
52442,Corpus callosum volume,Disease
52448,Metabolite levels (glycine),Disease
52450,Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate),Disease
52451,Metabolite levels (glutarylcarnitine (C5); glutarylcarnitine (C5-DC); C5-DC carnitine; C5_DC_carnitine),Disease
52452,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Disease
52453,IL-6 response to bacterial stimulus (Fla),Disease
52455,IL-6 response to bacterial stimulus (LPA),Disease
52614,Asthma in any disease,Disease
52618,Asthma in gastrointestinal disease,Disease
52619,Asthma in muscoskeletal disease,Disease
52620,Asthma in cardiovascular disease,Disease
52624,Triamcinolone acetonide-induced ocular hypertension,Disease
52627,Dyslexia,Disease
52640,Opioid addiction (multi-trait analysis),Disease
52643,General pain factor,Disease
52651,Type 2 diabetes or schizophrenia (pleiotropy),Disease
52662,Hoarding symptoms,Disease
52665,Congenital solitary functioning kidney,Disease
52669,Serum neurofilament light levels,Disease
52675,Hippocampal subfield left CA3 volume (body),Disease
52677,Hippocampal subfield left CA1 volume (head),Disease
52679,Hippocampal subfield left CA4 volume (body),Disease
52681,Hippocampal left GC-ML-DG volume (body),Disease
52683,Hippocampal subfield left CA4 volume (head),Disease
52687,Orbitofrontal area (unadjusted for global measures),Disease
52689,Occipital area (unadjusted for global measures),Disease
52693,Hippocampal subfield right CA1 volume (head),Disease
52695,Right molecular layer hippocampal volume (head),Disease
52697,Right presubiculum volume (body),Disease
52699,Right presubiculum volume (head),Disease
52702,Right subiculum volume (body),Disease
52704,Right subiculum volume (head),Disease
52714,Occipital thickness (unadjusted for global measures),Disease
52717,Superior parietal thickness (unadjusted for global measures),Disease
52719,Perisylvian thickness (unadjusted for global measures),Disease
52720,Right hippocampal volume (body),Disease
52753,Triacylglycerol (52:4) levels,Disease
52755,Triacylglycerol (58:8) levels,Disease
52757,Inferior parietal area (unadjusted for global measures),Disease
52762,Motor premotor area (unadjusted for global measures),Disease
52767,Dorsomedial frontal area (unadjusted for global measures),Disease
52768,Hippocampal subfield right CA4 volume (head),Disease
52770,Hippocampal right GC-ML-DG volume (body),Disease
52772,Hippocampal right GC-ML-DG volume (head),Disease
52774,Hippocampal subfield right CA4 volume (body),Disease
52777,Right hippocampal volume (fissure),Disease
52778,Right hippocampal volume (head),Disease
52780,Inferior parietal thickness (unadjusted for global measures),Disease
52784,Post-traumatic stress disorder in combat exposure,Disease
52786,Post-traumatic stress disorder symptom severity (total),Disease
52796,O-methylcatechol sulfate levels,Disease
52797,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels,Disease
52798,Palmitoyl sphingomyelin (d18:1/16:0) levels,Disease
52799,2-oleoylglycerol (18:1) levels,Disease
52801,3-(3-hydroxyphenyl)propionate sulfate levels,Disease
52802,3-(4-hydroxyphenyl)lactate levels,Disease
52806,"3,7-dimethylurate levels",Disease
52807,3-hydroxyoctanoate levels,Disease
52809,3-indoxyl sulfate levels,Disease
52811,3-methyl catechol sulfate (1) levels,Disease
52812,X-23297 levels,Disease
52814,Orotidine levels,Disease
52816,Oxalate (ethanedioate) levels,Disease
52827,"Phosphatidylcholine (16:0/22:5n3, 18:1/20:4) levels",Disease
52828,1-methylnicotinamide levels,Disease
52829,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Disease
52830,Pregnenolone sulfate levels,Disease
52831,Proline levels,Disease
52833,Pipecolate levels,Disease
52835,Pregn steroid monosulfate levels,Disease
52837,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Disease
52838,Pregnanediol-3-glucuronide levels,Disease
52840,Pregnen-diol disulfate levels,Disease
52841,Pyridoxate levels,Disease
52843,Quinate levels,Disease
52846,X-11564 levels,Disease
52847,X-11593 levels,Disease
52849,X-12681 levels,Disease
52851,X-12688 levels,Disease
52853,X-12714 levels,Disease
52855,X-12715 levels,Disease
52857,X-12170 levels,Disease
52859,X-12206 levels,Disease
52863,X-12221 levels,Disease
52864,X-12231 levels,Disease
52865,X-12339 levels,Disease
52867,X-12462 levels,Disease
52868,X-12511 levels,Disease
52871,X-12007 levels,Disease
52873,X-12117 levels,Disease
52874,X-12824 levels,Disease
52875,X-11452 levels,Disease
52877,Alcohol dependence (allelic genetic model),Disease
52879,Spielberger Trait Anxiety Inventory in alcohol dependence (allelic genetic model),Disease
52880,Otosclerosis,Disease
52894,X-23369 levels,Disease
52896,X-23593 levels,Disease
52898,X-23997 levels,Disease
52900,X-24240 levels,Disease
52901,X-24452 levels,Disease
52902,X-24542 levels,Disease
52906,X-24544 levels,Disease
52908,X-24449 levels,Disease
52909,Refractive error (autorefraction measured),Disease
52911,1-dihomo-linoleoyl-GPC (20:2) levels,Disease
52912,1-linoleoyl-GPE (18:2) levels,Disease
52913,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Disease
52915,1-methylimidazoleacetate levels,Disease
52917,1-linolenoyl-GPC (18:3) levels,Disease
52919,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Disease
52921,1-linoleoyl-gpc (18:2) levels,Disease
52922,1-arachidonoyl-GPA (20:4) levels,Disease
52924,1-arachidonoyl-gpc (20:4n6) levels,Disease
52925,1-docosapentaenoyl-GPC (22:5n3) levels,Disease
52926,1-docosapentaenoyl-GPC (22:5n6) levels,Disease
52928,1-eicosapentaenoyl-GPC (20:5) levels,Disease
52930,1-eicosapentaenoyl-GPE (20:5) levels,Disease
52932,"1,5-anhydroglucitol (1,5-ag) levels",Disease
52937,X-16071 levels,Disease
52939,X-16570 levels,Disease
52941,X-16649 levels,Disease
52944,X-14056 levels,Disease
52946,X-16944 levels,Disease
52947,X-17337 levels,Disease
52949,X-12846 levels,Disease
52951,X-13431 levels,Disease
52952,X-14939 levels,Disease
52953,X-15503 levels,Disease
52956,X-17677 levels,Disease
52957,X-18922 levels,Disease
52960,X-21258 levels,Disease
52961,X-21286 levels,Disease
52962,X-21312 levels,Disease
52963,X-21339 levels,Disease
52964,X-21343 levels,Disease
52969,X-21365 levels,Disease
52972,X-21467 levels,Disease
52974,X-21411 levels,Disease
52976,X-21441 levels,Disease
52978,Basal cell carcinoma (MTAG),Disease
52982,Squamous cell carcinoma (MTAG),Disease
52984,Hiatus hernia,Disease
52986,Hernia (two or more subtypes),Disease
52987,Back pain,Disease
52989,Hernia (any subtypes),Disease
52990,Hernia,Disease
53008,Dietary Approaches to Stop Hypertension (DASH) diet,Disease
53022,Anteromedial temporal area (unadjusted for global measures),Disease
53023,Dorsolateral prefrontal area (unadjusted for global measures),Disease
53025,Hippocampal left GC-ML-DG volume (head),Disease
53027,Left hippocampal volume (body),Disease
53028,Left hippocampal volume (tail),Disease
53031,Left hippocampal volume (head),Disease
53034,Posterolateral temporal area (unadjusted for global measures),Disease
53037,Parsopercularis area (unadjusted for global measures),Disease
53038,Superior temporal area (unadjusted for global measures),Disease
53041,Superior parietal area (unadjusted for global measures),Disease
53042,Dorsolateral prefrontal thickness (unadjusted for global measures),Disease
53044,Primary aldosteronism,Disease
53046,Ventromedial occipital thickness (unadjusted for global measures),Disease
53047,Temporal pole thickness (unadjusted for global measures),Disease
53050,Ventral frontal thickness (unadjusted for global measures),Disease
53052,Vasculitis (pleiotropy),Disease
53057,Phosphatidylinositol (16:0_18:1) levels,Disease
53092,Developmental dysplasia of the hip,Disease
53094,Left subiculum volume (body),Disease
53095,Left subiculum volume (head),Disease
53096,Precuneus area (unadjusted for global measures),Disease
53099,Left molecular layer hippocampal volume (head),Disease
53100,Left parasubiculum volume,Disease
53103,Left presubiculum volume (body),Disease
53105,Left presubiculum volume (head),Disease
53109,Right hippocampal volume,Disease
53110,Right hippocampal volume (tail),Disease
53111,Medial prefrontal thickness (unadjusted for global measures),Disease
53114,Middle temporal thickness (unadjusted for global measures),Disease
53115,Motor premotor thickness (unadjusted for global measures),Disease
53117,Right molecular layer hippocampal volume (body),Disease
53119,Cognitive performance (memory) (longitudinal),Disease
53122,Cognitive performance (language) (longitudinal),Disease
53128,Cognitive performance (visuospatial function) (longitudinal),Disease
53130,Post-traumatic stress disorder symptom severity (avoidance),Disease
53131,"Non-response to survey questionnaires: ""I don't know"" item",Disease
53134,"Non-response to survey questionnaires: ""prefer not to answer"" item",Disease
53140,Genetically independent pain phenotypes (GIP2),Disease
53151,Tuberculosis x mycobacterium tuberculosis lineage interaction,Disease
53153,Tuberculosis (main host cluster) x mycobacterium tuberculosis lineage interaction,Disease
53154,Diffuse idiopathic skeletal hyperostosis flow score,Disease
53161,Endometriosis (stage 3 or 4),Disease
53162,Endometriosis (MTAG),Disease
53184,Preterm delivery,Disease
53186,Nonalcoholic fatty liver disease in lean individuals (BMI <25),Disease
53191,"Docosanoid osbond acid, all-cis-4,7,10,13,16-DPA, FFA Docosapentaenoic Acid levels",Disease
53192,"Docosanoid 14S-HDHA, Docosanoid 17R-HDHA levels",Disease
53194,"Eicosanoid 13-HpODE, Eicosanoid 9-HpODE b levels",Disease
53196,FFA Adrenic Acid a levels,Disease
53198,FFA Docosahexaenoic Acid levels,Disease
53199,FFA Eicosapentaenoic Acidc levels,Disease
53201,Sarcopenia in chronic obstructive pulmonary disease (fat-free mass index defined),Disease
53202,Fat-free mass index in chronic obstructive pulmonary disease,Disease
53203,Appendicular skeletal muscle index in chronic obstructive pulmonary disease,Disease
53204,Hand grip strength in chronic obstructive pulmonary disease,Disease
53206,Basal metabolic rate in chronic obstructive pulmonary disease,Disease
53229,Body mass index or knee osteoarthritis (pleiotropy),Disease
53233,Body mass index or osteoarthritis (pleiotropy),Disease
53238,Body mass index or hip osteoarthritis (pleiotropy),Disease
53244,Lung disease severity in cystic fibrosis with pancreatic insufficiency,Disease
53253,Problematic tobacco use,Disease
53256,Substance use disorder (pleiotropy),Disease
53258,Addiction risk factors,Disease
53300,Erosive hand osteoarthritis,Disease
53302,Cerebrospinal fluid amyloid beta 42 levels (12 month visit),Disease
53304,Amyloid (PET imaging) (24 month visit),Disease
53305,Cerebrospinal fluid p-tau levels (24 month visit),Disease
53307,Functional activities questionnaire (baseline),Disease
53459,Butyrophilin-like protein 9 levels,Disease
53461,S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels,Disease
53462,Baculoviral IAP repeat-containing protein 5 levels,Disease
53463,Bone morphogenetic protein 3 levels,Disease
53464,Bone morphogenetic protein 7 levels,Disease
53465,RBC levels of D-Rhamnose,Disease
53468,RBC levels of L-Carnitine.1,Disease
53469,RBC levels of LPC18:2,Disease
53471,RBC levels of Fumarate,Disease
53473,RBC levels of L-Carnitine,Disease
53474,RBC levels of Diphosphate,Disease
53476,RBC levels of Dopamine,Disease
53480,RBC levels of Pyruvate (uM),Disease
53486,DNA-directed RNA polymerases I and III subunit RPAC1 levels,Disease
53487,DNA-directed RNA polymerase III subunit RPC9 levels,Disease
53488,Rap guanine nucleotide exchange factor 5 levels,Disease
53493,Spatial QRS-T angle,Disease
53497,Kallikrein-6 levels,Disease
53499,Junctophilin-4 levels,Disease
53501,Killer cell immunoglobulin-like receptor 2DL1 levels,Disease
53502,Killer cell immunoglobulin-like receptor 2DL2 levels,Disease
53504,Integral membrane protein 2B levels,Disease
53505,Inactive tyrosine-protein kinase 7 levels,Disease
53507,"Adenylate kinase 4, mitochondrial levels",Disease
53508,Kallikrein-12 levels,Disease
53509,Frontal QRS-T angle,Disease
53516,Leucine-rich repeat-containing protein 74A levels,Disease
53517,Leucine-rich repeat and fibronectin type III domain-containing protein 1 levels,Disease
53518,Leucine-rich repeat-containing protein 25 levels,Disease
53519,Leucine-rich repeat and transmembrane domain-containing protein 2 levels,Disease
53520,Cadherin-11 levels,Disease
53521,Cadherin-17 levels,Disease
53536,"Cytochrome c oxidase subunit 4 isoform 2, mitochondrial levels",Disease
53537,Collectin-10 levels,Disease
53542,Coagulation factor Xa levels,Disease
53549,Glutathione S-transferase A1 levels,Disease
53550,Glutathione S-transferase A4 levels,Disease
53551,General transcription factor II-I levels,Disease
53553,Glycine N-methyltransferase levels,Disease
53555,GMP reductase 2 levels,Disease
53558,BPI fold-containing family B member 1 levels,Disease
53560,Growth factor receptor-bound protein 7 levels,Disease
53561,Glutamate receptor 4 levels,Disease
53564,Granzyme B levels,Disease
53566,Granzyme K levels,Disease
53567,Scavenger receptor class A member 3 levels,Disease
53568,Small conductance calcium-activated potassium channel protein 1 levels,Disease
53569,Secretogranin-1 levels,Disease
53571,DNA-binding protein SATB2 levels,Disease
53572,Soluble calcium-activated nucleotidase 1 levels,Disease
53573,Sperm acrosome membrane-associated protein 3 levels,Disease
53575,Interleukin-20 receptor subunit alpha levels,Disease
53576,Interleukin-20 receptor subunit beta levels,Disease
53579,Interleukin-23 levels,Disease
53580,Interleukin-36 receptor antagonist protein levels,Disease
53581,Interleukin-37 levels,Disease
53582,Interleukin-5 receptor subunit alpha levels,Disease
53583,Vasomotor rhinitis or allergic rhinitis (MTAG),Disease
53584,Chronic rhinosinusitis (MTAG),Disease
53586,Nasal polyposis (MTAG),Disease
53587,Nasal septal deviation (MTAG),Disease
53588,Chronic inflammatory sinonasal disease,Disease
53590,ICD10 K04: Diseases of pulp and periapical tissues,Disease
53594,SWI/SNF complex subunit SMARCC1 levels,Disease
53603,CD9 antigen levels,Disease
53604,Cadherin-related family member 5 levels,Disease
53605,Leukocyte antigen CD37 levels,Disease
53606,Cyclin-dependent kinase 4 inhibitor C levels,Disease
53611,C-C motif chemokine 28 levels,Disease
53612,C-C motif chemokine 3-like 1 levels,Disease
53613,CD166 antigen levels,Disease
53617,C-C motif chemokine 24 levels,Disease
53618,Cervical dysplasia,Disease
53622,Potassium voltage-gated channel subfamily F member 1 levels,Disease
53623,Potassium voltage-gated channel subfamily G member 4 levels,Disease
53624,Ras-related protein Rab-35 levels,Disease
53625,Rab9 effector protein with kelch motifs levels,Disease
53626,rRNA 2-O-methyltransferase fibrillarin levels,Disease
53627,"Reticulon-4-interacting protein 1, mitochondrial levels",Disease
53629,"Protein PET117 homolog, mitochondrial levels",Disease
53631,Ras-related protein Rab-17 levels,Disease
53632,Ras-related protein Rab-26 levels,Disease
53634,Polycomb protein SCMH1 levels,Disease
53635,Sodium-coupled monocarboxylate transporter 1 levels,Disease
53636,Secreted and transmembrane protein 1 levels,Disease
53638,Stromal cell-derived factor 2 levels,Disease
53639,Protein sel-1 homolog 2 levels,Disease
53640,Advanced metachronous adenoma,Disease
53645,Multiple metachronous adenoma,Disease
53646,Sarcalumenin levels,Disease
53648,ICD10 K05.30-31: Chronic periodontitis,Disease
53650,Spindlin-1 levels,Disease
53651,Serine protease inhibitor Kazal-type 14 levels,Disease
53652,SPARC-like protein 1 levels,Disease
53653,Sodium/potassium-transporting ATPase subunit beta-1 levels,Disease
53661,Spermatogenesis-associated protein 9 levels,Disease
53663,Sorting nexin-7 levels,Disease
53664,SAM pointed domain-containing Ets transcription factor levels,Disease
53666,Serine protease 57 levels,Disease
53670,Low affinity immunoglobulin epsilon Fc receptor levels,Disease
53672,Leukocyte-associated immunoglobulin-like receptor 1 levels,Disease
53676,Layilin levels,Disease
53677,Kv channel-interacting protein 1 levels,Disease
53678,Left-right determination factor 2 levels,Disease
53680,Sulfotransferase 1A3 levels,Disease
53684,Sulfotransferase family cytosolic 2B member 1 levels,Disease
53685,Signal transducer and activator of transcription 5B levels,Disease
53686,Stabilin-2 levels,Disease
53696,Microtubule-associated proteins 1A/1B light chain 3B levels,Disease
53698,O-acetyl-ADP-ribose deacetylase MACROD1 levels,Disease
53699,Macrophage-stimulating protein receptor levels,Disease
53700,Endothelial differentiation-related factor 1 levels,Disease
53701,Lymphokine-activated killer T-cell-originated protein kinase levels,Disease
53702,Isoform L-VEGF165 levels,Disease
53703,Radiation-inducible immediate-early gene IEX-1 levels,Disease
53707,Heparan-sulfate 6-O-sulfotransferase 1 levels,Disease
53708,Regulator of G-protein signaling 19 levels,Disease
53709,Regulator of G-protein signaling 8 levels,Disease
53710,Rhophilin-2 levels,Disease
53711,Hephaestin-like protein 1 levels,Disease
53712,Hexokinase-3 levels,Disease
53714,Sialate O-acetylesterase levels,Disease
53716,SH3 and multiple ankyrin repeat domains protein 3 levels,Disease
53717,Methotrexate-induced liver injury in rheumatoid arthritis,Disease
53719,C-C motif chemokine 1 levels,Disease
53721,Chromobox protein homolog 5 levels,Disease
53722,Cytochrome b-c1 complex subunit 7 levels,Disease
53723,Cerebellin-1 levels,Disease
53728,Carboxypeptidase E levels,Disease
53729,Carboxypeptidase M levels,Disease
53730,17-beta-hydroxysteroid dehydrogenase 14 levels,Disease
53731,ATP-dependent RNA helicase DHX8 levels,Disease
53732,Disks large homolog 3 levels,Disease
53733,Delta-like protein 1 levels,Disease
53735,Desmin levels,Disease
53736,Desmoglein-1 levels,Disease
53737,Desmoglein-2 levels,Disease
53738,Differentially expressed in FDCP 6 homolog levels,Disease
53740,Alzheimer disease (MTAG),Disease
53749,Complement C3d fragment levels,Disease
53752,Complement component C8 levels,Disease
53753,Glutaredoxin-like protein C5orf63 levels,Disease
53754,RBC levels of Sphingosine 1-phosphate,Disease
53757,RBC levels of Threonine,Disease
53759,RBC levels of Urate (uM),Disease
53761,RBC levels of LPS20:4,Disease
53762,RBC levels of S-Adenosyl-L-homocysteine,Disease
53768,Relative index of whole blood hyposectomy,Disease
53776,Whole blood low cut reduction viscosity,Disease
53778,Plasma viscosity,Disease
53780,Pharyngeal disease,Disease
53781,Sinonasal disease,Disease
53783,3-ketodihydrosphingosine reductase levels,Disease
53784,"Keratin, type II cytoskeletal 7 levels",Disease
53790,Calcineurin subunit B type 2 levels,Disease
53791,Calcium/calmodulin-dependent protein kinase type 1D levels,Disease
53792,Caspase-8 levels,Disease
53793,Catenin beta-1 levels,Disease
53798,Cullin-9 levels,Disease
53799,"Cytochrome c oxidase subunit 7A1, mitochondrial levels",Disease
53801,C-X-C motif chemokine 10 levels,Disease
53802,Cysteine and glycine-rich protein 2 levels,Disease
53804,D-dopachrome decarboxylase levels,Disease
53806,ATP-dependent RNA helicase DDX19A levels,Disease
53807,ATP-dependent RNA helicase DDX19B levels,Disease
53808,Probable ATP-dependent RNA helicase DDX46 levels,Disease
53809,C-X-C motif chemokine 17 levels,Disease
53810,C-X-C motif chemokine 5 levels,Disease
53811,Cystatin-8 levels,Disease
53820,Cellular retinoic acid-binding protein 1 levels,Disease
53821,DNA repair protein RAD51 homolog 1 levels,Disease
53823,Ribosome biogenesis protein TSR3 homolog levels,Disease
53824,RAC-beta serine/threonine-protein kinase levels,Disease
53826,2-deoxynucleoside 5-phosphate N-hydrolase 1 levels,Disease
53828,Ribonucleoside-diphosphate reductase subunit M2 levels,Disease
53830,Retinoic acid early transcript 1G protein levels,Disease
53831,Retinoblastoma-associated protein levels,Disease
53832,High affinity immunoglobulin epsilon receptor subunit alpha levels,Disease
53834,Regenerating islet-derived protein 3-alpha levels,Disease
53836,Ras-related protein Rab-27B levels,Disease
53838,RNA-binding protein 24 levels,Disease
53839,Surgical knee osteoarthritis,Disease
53842,Non-surgical knee osteoarthritis,Disease
53843,Serotransferrin levels,Disease
53844,Protein SET levels,Disease
53847,Surgical hip osteoarthritis,Disease
53849,Sperm-associated antigen 11B levels,Disease
53850,SH3 domain-binding glutamic acid-rich-like protein 2 levels,Disease
53851,Secreted frizzled-related protein 3 levels,Disease
53852,Non-surgical hip osteoarthritis,Disease
53853,Liver carboxylesterase 1 levels,Disease
53854,Leukotriene B4 receptor 1 levels,Disease
53862,Leukocyte immunoglobulin-like receptor subfamily B member 2 levels,Disease
53874,Complement receptor type 2 levels,Disease
53879,Cysteine-rich PDZ-binding protein levels,Disease
53884,Age at adiposity rebound x sex interaction,Disease
53886,BMI at adiposity rebound x sex interaction,Disease
53888,BMI at 1.5 -2.5 years old interval,Disease
53892,Apnea hypopnea index,Disease
53894,Apnea hypopnea index during non-REM sleep,Disease
53895,Obstructive sleep apnea trait (percentage of blood oxygen below 90% of total sleep time),Disease
53896,Obstructive sleep apnea trait (oxygen desaturation index),Disease
53897,Obstructive sleep apnea trait (percentage of wake time during sleep period time),Disease
53905,Heterogeneous nuclear ribonucleoprotein Q levels,Disease
53906,Glycoprotein hormone alpha-2 levels,Disease
53908,Heme oxygenase 1 levels,Disease
53909,HEPACAM family member 2 levels,Disease
53911,Hematological and neurological expressed 1 protein levels,Disease
53916,Kin of IRRE-like protein 2 levels,Disease
53918,Insulin receptor levels,Disease
53924,"Cytochrome c oxidase assembly factor 3 homolog, mitochondrial levels",Disease
53925,Coagulation Factor X levels,Disease
53927,C-type lectin domain family 4 member D levels,Disease
53928,Calcium-activated potassium channel subunit beta-3 levels,Disease
53929,C-type lectin domain family 4 member A levels,Disease
53930,Collagen alpha-1(IX) chain levels,Disease
53932,Collagen alpha-1(X) chain levels,Disease
53938,Endothelin-converting enzyme 1 levels,Disease
53940,"Enoyl-CoA delta isomerase 2, mitochondrial levels",Disease
53942,"Histone-lysine N-methyltransferase, H3 lysine-79 specific levels",Disease
53944,Disintegrin and metalloproteinase domain-containing protein 10 levels,Disease
53945,Dipeptidyl peptidase 4 levels,Disease
53946,Diphosphomevalonate decarboxylase levels,Disease
53949,DnaJ homolog subfamily B member 9 levels,Disease
53954,Dipeptidyl peptidase 1 levels,Disease
53959,Non-alcoholic fatty liver disease or type 2 diabetes,Disease
53969,Preeclampsia or other maternal hypertension (maternal genotype effect),Disease
53973,Aortic stenosis,Disease
53975,Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596),Disease
53976,Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598),Disease
53977,Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),Disease
53979,Phospholipids to total lipids in small VLDL percentage (UKB data field 23599),Disease
53980,Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611),Disease
53981,Free cholesterol to total lipids in IDL percentage (UKB data field 23612),Disease
53982,Cholesterol to total lipids in IDL percentage (UKB data field 23610),Disease
53983,Phospholipids to total lipids in IDL percentage (UKB data field 23609),Disease
53988,Cholesterol to total lipids in small LDL percentage (UKB data field 23625),Disease
53989,Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626),Disease
53991,Free cholesterol to total lipids in small LDL percentage (UKB data field 23627),Disease
53992,Triglycerides to total lipids in small LDL percentage (UKB data field 23628),Disease
53993,Margaroylcarnitine (C17) levels,Disease
53995,Phenylacetylcarnitine levels,Disease
53996,Carnitine C18:2 levels,Disease
53997,Carboxyethyl-gaba levels,Disease
53998,Prolylglycine levels,Disease
54000,Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Disease
54001,Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636),Disease
54003,Phospholipids to total lipids in large HDL percentage (UKB data field 23634),Disease
54004,Gamma-glutamylcitrulline levels,Disease
54006,3-amino-2-piperidone levels,Disease
54009,"Cis 3,4-methyleneheptanoate levels",Disease
54010,Vanillic acid glycine levels,Disease
54011,N-succinyl-phenylalanine levels,Disease
54013,"Cis-3,4-methyleneheptanoylcarnitine levels",Disease
54016,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Disease
54017,Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641),Disease
54020,Microscopic colitis,Disease
54021,Creatinine levels (UKB data field 23478),Disease
54024,Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481),Disease
54026,3-hydroxybutyrate levels (UKB data field 23474),Disease
54027,Acetoacetate levels (UKB data field 23476),Disease
54029,Glycoprotein acetyls levels (UKB data field 23480),Disease
54033,Phospholipids in very large VLDL (UKB data field 23490),Disease
54035,Cholesteryl esters in very large VLDL (UKB data field 23492),Disease
54036,Free cholesterol in very large VLDL (UKB data field 23493),Disease
54037,Total lipids in very large VLDL (UKB data field 23489),Disease
54038,Cholesterol in very large VLDL (UKB data field 23491),Disease
54039,Glycine levels (UKB data field 23462),Disease
54041,Tyrosine levels (UKB data field 23469),Disease
54043,Glucose levels (UKB data field 23470),Disease
54045,Lactate levels (UKB data field 23471),Disease
54046,Total concentration of branched-chain amino acids (leucine + isoleucine + valine) (UKB data field 23464),Disease
54047,Isoleucine levels (UKB data field 23465),Disease
54048,Leucine levels (UKB data field 23466),Disease
54049,Valine levels (UKB data field 23467),Disease
54052,Alanine levels (UKB data field 23460),Disease
54053,Pyruvate levels (UKB data field 23472),Disease
54054,Citrate levels (UKB data field 23473),Disease
54057,Glutamine levels (UKB data field 23461),Disease
54058,Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487),Disease
54060,Concentration of very large VLDL particles (UKB data field 23488),Disease
54061,Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486),Disease
54062,Phospholipids in large VLDL (UKB data field 23497),Disease
54063,Cholesteryl esters in large VLDL (UKB data field 23499),Disease
54064,Cholesterol in large VLDL (UKB data field 23498),Disease
54065,Concentration of very small VLDL particles (UKB data field 23516),Disease
54066,Triglycerides in small VLDL (UKB data field 23515),Disease
54067,Total lipids in very small VLDL (UKB data field 23517),Disease
54068,Cholesterol in very small VLDL (UKB data field 23519),Disease
54069,Phospholipids in very small VLDL (UKB data field 23518),Disease
54070,Concentration of large LDL particles (UKB data field 23530),Disease
54071,Cholesterol in large LDL (UKB data field 23533),Disease
54072,Phospholipids in large LDL (UKB data field 23532),Disease
54074,Cholesteryl esters in large LDL (UKB data field 23534),Disease
54075,Total lipids in large LDL (UKB data field 23531),Disease
54076,Triglycerides in IDL (UKB data field 23529),Disease
54078,Concentration of very large HDL particles (UKB data field 23551),Disease
54080,Total lipids in very large HDL (UKB data field 23552),Disease
54081,Phospholipids in very large HDL (UKB data field 23553),Disease
54083,Triglycerides in small LDL (UKB data field 23550),Disease
54087,Cholesterol in large HDL (UKB data field 23561),Disease
54088,Cholesteryl esters in large HDL (UKB data field 23562),Disease
54090,Total lipids in medium HDL (UKB data field 23566),Disease
54091,Cholesterol in medium HDL (UKB data field 23568),Disease
54092,Cholesteryl esters in medium HDL (UKB data field 23569),Disease
54093,Phospholipids in medium HDL (UKB data field 23567),Disease
54094,Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591),Disease
54095,Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588),Disease
54096,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),Disease
54097,Phospholipids to total lipids in large VLDL percentage (UKB data field 23589),Disease
54098,Phospholipids to total lipids in very large VLDL percentage (UKB data field 23584),Disease
54099,Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585),Disease
54100,Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586),Disease
54101,Mitochondrial DNA copy number (raw),Disease
54108,Triglycerides to total lipids in small VLDL percentage (UKB data field 23603),Disease
54109,Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602),Disease
54110,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605),Disease
54111,Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604),Disease
54113,Phospholipids to total lipids in medium LDL percentage (UKB data field 23619),Disease
54114,Cholesteryl esters to total lipids in medium LDL percentage (UKB data field 23621),Disease
54115,Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Disease
54117,X-24241 levels,Disease
54118,Triglycerides to total lipids in large LDL percentage (UKB data field 23618),Disease
54120,X-25109 levels,Disease
54122,X-24947 levels,Disease
54123,X-24949 levels,Disease
54124,X-24518 levels,Disease
54125,X-24531 levels,Disease
54128,Thymol sulfate levels,Disease
54129,Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632),Disease
54130,Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631),Disease
54131,Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),Disease
54135,Free cholesterol to total lipids in large HDL percentage (UKB data field 23637),Disease
54140,3-hydroxyoctanoylcarnitine (1) levels,Disease
54141,3-hydroxyoctanoylcarnitine (2) levels,Disease
54146,Triglycerides to total lipids in medium HDL percentage (UKB data field 23643),Disease
54147,Phospholipids to total lipids in small HDL percentage (UKB data field 23644),Disease
54150,Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),Disease
54151,Cholesteryl esters to total lipids in small VLDL percentage (UKB data field 23601),Disease
54154,Cholesteryl esters to total lipids in large LDL percentage (UKB data field 23616),Disease
54155,Cholesterol to total lipids in large LDL percentage (UKB data field 23615),Disease
54157,Triglycerides to total lipids in IDL percentage (UKB data field 23613),Disease
54158,Phospholipids to total lipids in large LDL percentage (UKB data field 23614),Disease
54159,Free cholesterol to total lipids in large LDL percentage (UKB data field 23617),Disease
54165,X-12839 levels,Disease
54170,X-21829 levels,Disease
54171,Phospholipids to total lipids in very large HDL percentage (UKB data field 23629),Disease
54172,Stearoylcarnitine (C18) levels,Disease
54174,Indolebutyrate levels,Disease
54178,Hydroxy-cmpf levels,Disease
54180,Glycine conjugate of C10H12O2 levels,Disease
54182,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Disease
54183,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at two months after first dose),Disease
54185,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at four months after first dose),Disease
54188,Response to BNT162b2 vaccine (percentage decrease of anti-SARS-CoV-2 Spike antibody levels from two to four months after first dose),Disease
54191,Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592),Disease
54194,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Disease
54195,Triglycerides to total lipids in large VLDL percentage (UKB data field 23593),Disease
54197,Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594),Disease
54198,Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607),Disease
54200,Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606),Disease
54201,Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608),Disease
54202,Phospholipids to total lipids in small LDL percentage (UKB data field 23624),Disease
54203,Triglycerides to total lipids in medium LDL percentage (UKB data field 23623),Disease
54204,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels,Disease
54205,Butyrylcarnitine (C4) levels,Disease
54206,Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622),Disease
54208,Cysteinylglycine disulfide levels,Disease
54209,Succinylcarnitine (C4DC) levels,Disease
54210,"5alpha-androstan-3alpha,17alpha-diol monosulfate levels",Disease
54211,Triglycerides to total lipids in very large HDL percentage (UKB data field 23633),Disease
54214,Methylsuccinoylcarnitine levels,Disease
54215,Furaneol sulfate levels,Disease
54216,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels,Disease
54217,Phospholipids to total lipids in medium HDL percentage (UKB data field 23639),Disease
54218,Triglycerides to total lipids in large HDL percentage (UKB data field 23638),Disease
54221,Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646),Disease
54223,Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),Disease
54224,Triglycerides to total lipids in small HDL percentage (UKB data field 23648),Disease
54225,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Disease
54237,Color vision defects (Deutan-Protan),Disease
54270,Immature platelet fraction,Disease
54272,Immature platelet count,Disease
54280,Hearing difficulty,Disease
54281,Hearing difficulty with background noise,Disease
54282,Hearing difficulty and hearing difficulty with background noise,Disease
54283,Fornix white matter microstructure (isotropic or free water volume fraction),Disease
54311,HDL-cholesterol level in antipsychotic-treated schizophrenia (4-week),Disease
54313,Antipsychotic-induced HDL-cholesterol change in schizophrenia (6-week),Disease
54316,HDL-cholesterol level in antipsychotic-treated schizophrenia (6-week),Disease
54323,Alcohol use frequency,Disease
54379,Platelet side scatter,Disease
54381,Left ventricular end systole anterolateral wall thickness,Disease
54382,Left ventricular end systole inferoseptal wall thickness,Disease
54383,Left ventricular end systole inferolateral wall thickness,Disease
54384,Left ventricular end diastole inferior wall thickness,Disease
54385,Left ventricular end diastole anterolateral wall thickness,Disease
54387,Platelet side fluorescence,Disease
54388,Facial morphology (D497),Disease
54390,Facial morphology (D99),Disease
54392,Gastroparesis,Disease
54394,Plasma oxylipin levels (PC2),Disease
54396,Plasma oxylipin levels (PC1),Disease
54406,Phenotypic age acceleration,Disease
54410,Alcohol use frequency in adulthood,Disease
54417,Alcohol use frequency in early adulthood,Disease
54431,Red blood cell side fluorescence,Disease
54435,Red blood cell side scatter,Disease
54438,Red blood cell forward scatter,Disease
54439,Platelet large cell ratio,Disease
54442,Peptic ulcer disease,Disease
54445,Duodenal ulcer,Disease
54472,Facial morphology (D10),Disease
54474,Facial morphology (D120),Disease
54476,Platelet forward scatter,Disease
54482,Red blood cell forward scatter distribution width,Disease
54484,Hyper-haemoglobinised percentage of red cells,Disease
54486,Macrocytic percentage of red cells,Disease
54490,Microcytic percentage of red cells,Disease
54491,Red blood cell side fluorescence distribution width,Disease
54497,Fornix white matter microstructure (intra-cellular volume fraction),Disease
54498,Fornix white matter microstructure (diffusion tensor mode),Disease
54499,Hearing aid use,Disease
54501,Neonatal circulating Complement Component 3 (C3) protein concentration,Disease
54503,Neonatal circulating Complement Component 4 (C4) protein concentration,Disease
54514,Cranial vault shape (segment 1),Disease
54516,Cranial vault shape (segment 3),Disease
54525,Cranial vault shape (segment 11),Disease
54530,Ulcerative colitis x sex interaction (2df),Disease
54534,Inflammatory bowel disease x sex interaction (2df),Disease
54535,Solar lentigines (non-facial),Disease
54549,Mercury levels in pregnancy,Disease
54563,Lymphatic filariasis,Disease
54566,Lymphatic filariasis with lymphedema,Disease
54568,Delta of the haemoglobin equivalents,Disease
54570,Delta of the red cell haemoglobins,Disease
54589,Chemoradiation-induced hearing loss in nasopharyngeal carcinoma,Disease
54627,Systemic lupus erythematosus (MTAG),Disease
54635,Anxiety x Caesarean-section interaction,Disease
54637,Self-harm x Caesarean-section interaction,Disease
54639,Free androgen index,Disease
54677,Neurocognitive measure (immediate recall) in obsessive-compulsive disorder,Disease
54679,Neurocognitive measure (delayed recall) in obsessive-compulsive disorder,Disease
54681,Neurocognitive measure (copy organization) in obsessive-compulsive disorder,Disease
54706,Interventricular septum cross-sectional area,Disease
54724,Median relapse-independent longitudinal age-related multiple sclerosis severity score in relapse-onset multiple sclerosis,Disease
54726,Median relapse-independent longitudinal Multiple Sclerosis Severity Scale score in relapse-onset multiple sclerosis,Disease
54728,Multiple sclerosis (age of onset),Disease
54746,Alcohol withdrawal factor score,Disease
54782,Hip width to body height ratio,Disease
54784,Shoulder width to body height ratio,Disease
54788,Torso length to body height ratio,Disease
54790,Tibiofemoral angle,Disease
54794,Femur length to body height ratio,Disease
54796,ICD10 127.0 pulmonary arterial hypertension,Disease
54811,Vitamin D levels or COVID-19 (MTAG),Disease
54838,Pelvic organ prolapse x maximum birth weight interaction,Disease
54843,Pelvic organ prolapse x age interaction,Disease
54846,Red meat related metabolomic signature,Disease
54854,Preeclampsia or eclampsia,Disease
54902,Forearm length to body height ratio,Disease
54938,BolA-like protein 2 levels,Disease
54940,Complement C1q tumor necrosis factor-related protein 5 levels,Disease
54941,Complement C1q and tumor necrosis factor-related protein 9A levels,Disease
54943,Butyrophilin subfamily 3 member A3 levels,Disease
54948,Protein BTG2 levels,Disease
54950,Glypican-3 levels,Disease
54955,Insulin growth factor-like family member 3 levels,Disease
54956,Interferon alpha-5 levels,Disease
54958,ICOS ligand levels,Disease
54959,Insulin-like growth factor I levels,Disease
54961,Insulin-like growth factor-binding protein complex acid labile subunit levels,Disease
54963,Insulin-like growth factor-binding protein 3 levels,Disease
54964,Interleukin-10 receptor subunit beta levels,Disease
54965,Immunoglobulin lambda-like polypeptide 1 levels,Disease
54967,Immunoglobulin M levels,Disease
54969,ICD10 J33: nasal polyps,Disease
54970,ICD10 J35: Chronic diseases of tonsils and adenoids,Disease
54971,Somatoliberin levels,Disease
54972,S-methyl-5-thioadenosine phosphorylase levels,Disease
54976,Stromal membrane-associated protein 1 levels,Disease
54983,Casein kinase II subunit alpha levels,Disease
54984,Ceruloplasmin levels,Disease
54985,Chitinase-3-like protein 2 levels,Disease
54986,Chordin levels,Disease
54987,Carcinoembryonic antigen-related cell adhesion molecule 19 levels,Disease
54988,CCAAT/enhancer-binding protein beta levels,Disease
54989,Carbohydrate sulfotransferase 4 levels,Disease
54991,Chymotrypsinogen B levels,Disease
54997,Mitogen-activated protein kinase 13 levels,Disease
55000,Melanoma-associated antigen 5 levels,Disease
55001,Mast/stem cell growth factor receptor Kit levels,Disease
55002,Left ventricular mass indexed by body surface area,Disease
55004,Left ventricular mass,Disease
55024,Triglycerides in large VLDL (UKB data field 23501),Disease
55025,Concentration of medium VLDL particles (UKB data field 23502),Disease
55028,Breast cancer (luminal A),Disease
55031,Total lipids in medium VLDL (UKB data field 23503),Disease
55032,Cholesterol in medium VLDL (UKB data field 23505),Disease
55033,Phospholipids in medium VLDL (UKB data field 23504),Disease
55034,Cholesterol in small VLDL (UKB data field 23512),Disease
55035,Cholesteryl esters in small VLDL (UKB data field 23513),Disease
55036,Free cholesterol in small VLDL (UKB data field 23514),Disease
55037,Total lipids in small VLDL (UKB data field 23510),Disease
55038,Phospholipids in small VLDL (UKB data field 23511),Disease
55039,Cholesteryl esters in IDL (UKB data field 23527),Disease
55040,Cholesterol in IDL (UKB data field 23526),Disease
55041,Free cholesterol in IDL (UKB data field 23528),Disease
55042,Phospholipids in IDL (UKB data field 23525),Disease
55043,Total lipids in IDL (UKB data field 23524),Disease
55044,Total lipids in medium LDL (UKB data field 23538),Disease
55046,Triglycerides in large LDL (UKB data field 23536),Disease
55047,Free cholesterol in large LDL (UKB data field 23535),Disease
55048,Cholesterol in medium LDL (UKB data field 23540),Disease
55049,Phospholipids in medium LDL (UKB data field 23539),Disease
55050,Concentration of medium LDL particles (UKB data field 23537),Disease
55051,Total lipids in small LDL (UKB data field 23545),Disease
55052,Free cholesterol in small LDL (UKB data field 23549),Disease
55053,Cholesterol in small LDL (UKB data field 23547),Disease
55054,Phospholipids in small LDL (UKB data field 23546),Disease
55056,Cholesteryl esters in small LDL (UKB data field 23548),Disease
55057,Concentration of large HDL particles (UKB data field 23558),Disease
55058,Phospholipids in large HDL (UKB data field 23560),Disease
55059,Total lipids in large HDL (UKB data field 23559),Disease
55060,Free cholesterol in large HDL (UKB data field 23563),Disease
55061,Concentration of medium HDL particles (UKB data field 23565),Disease
55062,Movement related adverse drug reaction to aripiprazole in schizophrenia,Disease
55064,Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581),Disease
55065,Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582),Disease
55066,Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579),Disease
55067,Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580),Disease
55068,Cholesterol in small HDL (UKB data field 23575),Disease
55069,Phospholipids in small HDL (UKB data field 23574),Disease
55070,Cholesteryl esters in small HDL (UKB data field 23576),Disease
55071,Free cholesterol in small HDL (UKB data field 23577),Disease
55073,Triglycerides in small HDL (UKB data field 23578),Disease
55074,Descending aorta strain,Disease
55077,Vascular endothelial function,Disease
55099,Phospholipids in LDL (UKB data field 23413),Disease
55101,Phospholipids in VLDL (UKB data field 23412),Disease
55102,Phospholipids in HDL (UKB data field 23414),Disease
55103,Average diameter for HDL particles (UKB data field 23433),Disease
55104,Phosphoglycerides levels (UKB data field 23434),Disease
55105,Triglycerides to phosphoglycerides ratio (UKB data field 23435),Disease
55106,Monounsaturated fatty acids levels (UKB data field 23447),Disease
55107,Saturated fatty acids levels (UKB data field 23448),Disease
55108,Linoleic acid levels (UKB data field 23449),Disease
55109,Docosahexaenoic acid levels (UKB data field 23450),Disease
55123,Descending aorta diameter,Disease
55124,Headache or migraine,Disease
55150,Total lipids in lipoprotein particles (UKB data field 23423),Disease
55151,Free cholesterol in LDL (UKB data field 23421),Disease
55152,Free cholesterol in VLDL (UKB data field 23420),Disease
55153,Free cholesterol in HDL (UKB data field 23422),Disease
55154,Total lipids in VLDL (UKB data field 23424),Disease
55155,Total lipids in LDL (UKB data field 23425),Disease
55156,Total lipids in HDL (UKB data field 23426),Disease
55157,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Disease
55158,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Disease
55159,Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Disease
55160,Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Disease
55161,Linoleic acid to total fatty acids percentage (UKB data field 23456),Disease
55162,Occupational creativity,Disease
55163,Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482),Disease
55164,Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484),Disease
55165,Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485),Disease
55166,Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483),Disease
55171,Concentration of large VLDL particles (UKB data field 23495),Disease
55172,Triglycerides in very large VLDL (UKB data field 23494),Disease
55173,Total lipids in large VLDL (UKB data field 23496),Disease
55174,Free cholesterol in large VLDL (UKB data field 23500),Disease
55175,Free cholesterol in medium VLDL (UKB data field 23507),Disease
55176,Concentration of small VLDL particles (UKB data field 23509),Disease
55177,Triglycerides in medium VLDL (UKB data field 23508),Disease
55178,Cholesteryl esters in medium VLDL (UKB data field 23506),Disease
55179,Free cholesterol in very small VLDL (UKB data field 23521),Disease
55180,Concentration of IDL particles (UKB data field 23523),Disease
55181,Triglycerides in very small VLDL (UKB data field 23522),Disease
55182,Cholesteryl esters in very small VLDL (UKB data field 23520),Disease
55183,Triglycerides in medium LDL (UKB data field 23543),Disease
55184,Cholesteryl esters in medium LDL (UKB data field 23541),Disease
55185,Free cholesterol in medium LDL (UKB data field 23542),Disease
55186,Concentration of small LDL particles (UKB data field 23544),Disease
55190,Systemic sclerosis complicated with interstitial lung disease,Disease
55191,Triglycerides in very large HDL (UKB data field 23557),Disease
55192,Cholesteryl esters in very large HDL (UKB data field 23555),Disease
55193,Cholesterol in very large HDL (UKB data field 23554),Disease
55194,Free cholesterol in very large HDL (UKB data field 23556),Disease
55195,Triglycerides in medium HDL (UKB data field 23571),Disease
55196,Concentration of small HDL particles (UKB data field 23572),Disease
55197,Total lipids in small HDL (UKB data field 23573),Disease
55200,Free cholesterol in medium HDL (UKB data field 23570),Disease
55201,Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583),Disease
55202,Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587),Disease
55204,Gall stone disease or coronary artery disease,Disease
55215,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Stomatitis),Disease
55217,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Neutropenia),Disease
55219,Time to levodopa-induced-dyskinesia onset in Parkinson's disease,Disease
55221,Age at menarche or uterine leiomyomata (pleiotropy),Disease
55222,Age at natural menopause or uterine leiomyomata (pleiotropy),Disease
55223,Age at first birth or uterine leiomyomata (pleiotropy),Disease
55224,Hypothyroidism or rheumatoid arthritis (pleiotropy),Disease
55336,Postmenopausal breast cancer,Disease
55370,Skull bone mineral density,Disease
55389,Mono-(2-ethyl-5-carboxypentyl) phthalate levels (MTAG),Disease
55424,Nonsyndromic biliary atresia,Disease
55429,Hospitalized COVID-19 or BMI (pleiotropy),Disease
55535,Skin luminance,Disease
55539,Skin yellow/blue component,Disease
55541,Femoral neck width,Disease
55542,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60),Disease
55543,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 62),Disease
55544,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 71),Disease
55545,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80),Disease
55547,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 4),Disease
55548,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 42),Disease
55550,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 44),Disease
55551,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 10),Disease
55553,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 22),Disease
55554,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 28),Disease
55556,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 39),Disease
55557,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 7),Disease
55559,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 11),Disease
55561,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16),Disease
55563,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24),Disease
55565,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 117),Disease
55568,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 121),Disease
55569,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 125),Disease
55570,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2),Disease
55571,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 8),Disease
55572,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 114),Disease
55574,PCSK9 levels in statin-naive individuals,Disease
55691,Vegetarianism,Disease
55697,Uterine cancer,Disease
55711,PMA induced IL5 level without BCG vaccination,Disease
55713,PMA induced TNFa level without BCG vaccination,Disease
55715,Preeclampsia in pregnancy,Disease
55745,Facial trait (Forehead height),Disease
55748,Clonal hematopoiesis (overall),Disease
55749,Clonal hematopoiesis (DNMT3A mutation),Disease
55751,Steroid-dependent/frequent relapse nephrotic syndrome,Disease
55758,DTI TBSS MD Fornix,Disease
55762,Body fat percentage (adjusted for testosterone and SHBG),Disease
55768,T1 FreeSurfer DK rh cuneus volume,Disease
55769,T1 FreeSurfer pial lh pericalcarine area,Disease
55771,T1 FreeSurfer pial rh cuneus area,Disease
55772,T1 FIRST volume BrStem,Disease
55773,T1 FreeSurfer DK lh cuneus volume,Disease
55774,T1 FreeSurfer DK rh cuneus area,Disease
55775,T1 FreeSurfer DK rh lateraloccipital area,Disease
55776,T1 FreeSurfer DK rh lingual area,Disease
55777,T1 FreeSurfer DK rh pericalcarine area,Disease
55778,T1 CAT volume R PostcentralGyrus,Disease
55780,T1 CAT volume R SupramarginalGyrusanteriordivision,Disease
55781,T1 CAT volume L X,Disease
55785,Short sleep duration (<5 hours),Disease
55814,Left-hemisphere visual network to left-hemisphere limbic network white-matter structural connectivity,Disease
55919,T1 FreeSurfer DK lh pericalcarine area,Disease
55920,T1 CAT volume L MiddleTemporalGyrusanteriordivision,Disease
55921,T1 FreeSurfer BA rh V1 exvivo area,Disease
55922,T1 FreeSurfer BA rh V2 exvivo area,Disease
55923,T1 FreeSurfer BA lh V1 exvivo area,Disease
55924,DTI autoptx MD ilf l tract,Disease
55926,Long sleep duration (>=10 hours),Disease
55929,T1 FreeSurfer DKT rh rostralanteriorcingulate thickness,Disease
55931,T1 FreeSurfer DKT rh cuneus volume,Disease
55932,REST UKBBICA NET100 0810,Disease
55934,DTI TBSS L2 Fornix,Disease
55935,DTI TBSS L2 Corticospinal tract R,Disease
55937,DTI TBSS FA Posterior thalamic radiation L,Disease
55939,DTI TBSS L1 Fornix,Disease
55940,DTI TBSS L1 Superior corona radiata L,Disease
56024,DTI TBSS L3 Fornix,Disease
56025,DTI TBSS L3 Superior corona radiata R,Disease
56113,Right-hemisphere visual network to right-hemisphere salience/ventral attention network white-matter structural connectivity,Disease
56115,Right-hemisphere visual network to right-hemisphere control network white-matter structural connectivity,Disease
56116,Right-hemisphere visual network to pallidum white-matter structural connectivity,Disease
56118,Left-hemisphere control network to accumbens white-matter structural connectivity,Disease
56120,Left-hemisphere default mode network to right-hemisphere visual network white-matter structural connectivity,Disease
56121,Left-hemisphere control network to right-hemisphere visual network white-matter structural connectivity,Disease
56123,Right-hemisphere visual network to right-hemisphere visual network white-matter structural connectivity,Disease
56124,Left-hemisphere limbic network to thalamus white-matter structural connectivity,Disease
56126,Left-hemisphere limbic network to putamen white-matter structural connectivity,Disease
56127,Left-hemisphere control network to thalamus white-matter structural connectivity,Disease
56128,Left-hemisphere control network to putamen white-matter structural connectivity,Disease
56130,Left-hemisphere visual network to right-hemisphere control network white-matter structural connectivity,Disease
56144,Right-hemisphere somatomotor network to amygdala white-matter structural connectivity,Disease
56146,Right-hemisphere dorsal attention network to hippocampus white-matter structural connectivity,Disease
56148,Right-hemisphere limbic network to thalamus white-matter structural connectivity,Disease
56149,Right-hemisphere limbic network to caudate white-matter structural connectivity,Disease
56150,Right-hemisphere limbic network to putamen white-matter structural connectivity,Disease
56151,Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity,Disease
56153,Right-hemisphere control network to thalamus white-matter structural connectivity,Disease
56154,Right-hemisphere control network to putamen white-matter structural connectivity,Disease
56156,Right-hemisphere control network to hippocampus white-matter structural connectivity,Disease
56157,Right-hemisphere default mode network to hippocampus white-matter structural connectivity,Disease
56229,T1 FreeSurfer a2009s rh S calcarine area,Disease
56230,T1 FreeSurfer a2009s rh S circular insula ant area,Disease
56231,T1 FreeSurfer a2009s rh G cuneus volume,Disease
56232,T1 FreeSurfer a2009s rh G pariet inf-Supramar volume,Disease
56236,T1 FreeSurfer a2009s rh S calcarine volume,Disease
56237,T1 FreeSurfer a2009s lh G cuneus volume,Disease
56238,T1 FreeSurfer a2009s lh G parietal sup volume,Disease
56239,T1 FreeSurfer a2009s rh G cuneus area,Disease
56240,T1 FreeSurfer a2009s lh G cuneus area,Disease
56242,T1 FreeSurfer pial rh pericalcarine area,Disease
56243,T1 FreeSurfer aseg 4th-Ventricle,Disease
56244,T1 FreeSurfer DKT lh pericalcarine area,Disease
56245,T1 FreeSurfer pial rh supramarginal area,Disease
56246,T1 FreeSurfer DKT lh cuneus volume,Disease
56247,T1 FreeSurfer DKT rh cuneus area,Disease
56248,T1 FreeSurfer DKT rh lateraloccipital area,Disease
56249,T1 FreeSurfer DKT rh lingual area,Disease
56250,T1 FreeSurfer DKT rh pericalcarine area,Disease
56301,Drug-induced liver injury (Japanese traditional medicines),Disease
56327,(Z)-4-hydroxytamoxifen to tamoxifen ratio in tamoxifen-treated hormone-receptor-positive breast cancer,Disease
56329,Ascending aorta strain,Disease
56331,Tinnitus-related distress,Disease
56341,Response to metfomin (Fasting glucose levels adjusted for baseline glucose levels),Disease
56343,Total phospholipids in lipoprotein particles (UKB data field 23411),Disease
56344,Triglycerides in HDL (UKB data field 23410),Disease
56345,Triglycerides in VLDL (UKB data field 23408),Disease
56346,Triglycerides in LDL (UKB data field 23409),Disease
56347,Average diameter for LDL particles (UKB data field 23432),Disease
56348,Average diameter for VLDL particles (UKB data field 23431),Disease
56349,Infliximab persistence in Crohn's disease,Disease
56351,Omega-3 fatty acids levels (UKB data field 23444),Disease
56352,Degree of unsaturation (UKB data field 23443),Disease
56354,Polyunsaturated fatty acids levels (UKB data field 23446),Disease
56355,Omega-6 fatty acids levels (UKB data field 23445),Disease
56356,Heart rate variability (corrected root mean square of successive differences),Disease
56357,Heart rate variability (root mean square of successive differences),Disease
56358,Heart rate variability (corrected standard deviation of normal-to-normal intervals),Disease
56359,Heart rate variability (standard deviation of normal-to-normal intervals),Disease
56369,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),Disease
56371,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",Disease
56377,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (adjusted for APOE E4 dosage)",Disease
56386,Insulin resistance,Disease
56388,Clinical LDL cholesterol levels (UKB data field 23404),Disease
56389,LDL cholesterol levels (UKB data field 23405),Disease
56390,HDL cholesterol levels (UKB data field 23406),Disease
56391,Total triglycerides levels (UKB data field 23407),Disease
56392,Total esterified cholesterol levels (UKB data field 23415),Disease
56393,Cholesteryl esters in HDL (UKB data field 23418),Disease
56394,Cholesteryl esters in LDL (UKB data field 23417),Disease
56395,Cholesteryl esters in VLDL (UKB data field 23416),Disease
56396,Total free cholesterol levels (UKB data field 23419),Disease
56397,Apolipoprotein A1 levels (UKB data field 23440),Disease
56398,Apolipoprotein B to apolipoprotein A1 ratio (UKB data field 23441),Disease
56400,Apolipoprotein B levels (UKB data field 23439),Disease
56401,Total fatty acids levels (UKB data field 23442),Disease
56406,Primary sclerosing cholangitis (MTAG),Disease
56423,Concentration of LDL particles (UKB data field 23429),Disease
56424,Concentration of VLDL particles (UKB data field 23428),Disease
56425,Total concentration of lipoprotein particles (UKB data field 23427),Disease
56426,Concentration of HDL particles (UKB data field 23430),Disease
56437,Total cholesterol levels (UKB data field 23400),Disease
56438,VLDL cholesterol levels (UKB data field 23403),Disease
56439,Total cholesterol minus HDL-C levels (UKB data field 23401),Disease
56440,"Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402)",Disease
56448,Phosphatidylcholines levels (UKB data field 23437),Disease
56449,Sphingomyelins levels (UKB data field 23438),Disease
56450,Total cholines levels (UKB data field 23436),Disease
56451,Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Disease
56452,Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Disease
56453,Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Disease
56455,Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Disease
56456,Age at dementia onset in PSEN1 E280A mutation carriers,Disease
56463,Serum levels of protein IGF1,Disease
56464,Serum levels of protein IGFBP3,Disease
56465,IGF-1 and IGFBP-3 levels (bivariate analysis),Disease
56469,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 76),Disease
56470,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79),Disease
56472,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 81),Disease
56473,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82),Disease
56474,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 85),Disease
56475,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 105),Disease
56476,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 108),Disease
56477,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 109),Disease
56479,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 112),Disease
56481,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 52),Disease
56483,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 100),Disease
56484,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101),Disease
56485,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 122),Disease
56489,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels after second dose),Disease
56633,Speech-in-noise perception,Disease
56754,IL6 expression at 6 weeks in PBMC upon Bbmix 10-5 stimulation in Lyme borreliosis,Disease
56756,IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosis,Disease
56781,High-density lipoprotein levels,Disease
56789,Anti-N-methyl-D-aspartate receptor encephalitis,Disease
56792,B-cell lymphoblastic leukemia or hypothyroidism (pleiotropy),Disease
56794,B-cell lymphoblastic leukemia or primary biliary cholangitis (pleiotropy),Disease
56795,B-cell lymphoblastic leukemia or inflammatory bowel disease (pleiotropy),Disease
56797,B-cell lymphoblastic leukemia or Crohn's disease (pleiotropy),Disease
56808,B-cell lymphoblastic leukemia or rheumatoid arthritis (pleiotropy),Disease
56809,B-cell lymphoblastic leukemia or multiple sclerosis (pleiotropy),Disease
56811,Pancreatic cancer x smoking interaction,Disease
56815,Attention deficit hyperactivity disorder or risk-taking behavior (pleiotropy),Disease
56822,Obsessive-compulsive symptoms,Disease
56825,Current medication use (UKB data field 20003),Disease
56829,Age at first sexual intercourse or uterine leiomyoma (pleiotropy),Disease
56830,Lifetime number of sexual partners or uterine leiomyoma (pleiotropy),Disease
56833,Left atrial maximum volume,Disease
56836,Left atrial minimum volume,Disease
56838,Left atrial stroke volume,Disease
56840,Left atrial maximum volume BSA indexed,Disease
56842,Knee extension strength,Disease
56851,Left atrial minimum volume BSA indexed,Disease
56852,Left atrial stroke volume BSA indexed,Disease
56880,Neuroticism general factor,Disease
56892,Neuroticism group factors (worry),Disease
56896,Kidney stone disease,Disease
56908,Pregnancy loss in nulliparas,Disease
56928,Gestational length in nulliparas,Disease
56935,Progression-free survival in glioma,Disease
56937,Apo-CIII0c levels,Disease
56939,Apo-CIII1 levels,Disease
56941,Apo-CIII1/apo-CIII2 ratio,Disease
56943,ECG cardiac MRI latent space,Disease
56949,ECG latent space,Disease
56969,Late-onset Alzheimer's disease (adjusted for APOE),Disease
57007,Oral lichen planus,Disease
57010,Non-oral lichen planus,Disease
57019,T-cell receptor clonality in colorectal cancer,Disease
57021,Preeclampsia in nulliparas,Disease
57024,Gestational diabetes in nulliparas,Disease
57039,Cardiac MRI latent space,Disease
57057,Leukocyte telomere length or COVID-19 infection (MTAG),Disease
57060,Leukocyte telomere length or COVID-19 hospitalization (MTAG),Disease
57063,Leukocyte telomere length or severe COVID-19 infection (MTAG),Disease
57081,ICD10 L43: Lichen planus,Disease
57082,Dry skin (generalised),Disease
57216,Hepatitis B virus antibody levels,Disease
57222,Urine red blood cell levels,Disease
57226,Number of sexual partners in opposite-sex sexual behavior,Disease
57230,IL6 expression at 6 weeks in whole blood upon LPS stimulation in Lyme borreliosis,Disease
57235,Myeloproliferative neoplasms (MTAG),Disease
57567,Total_GRS,PRS
57830,Lipodystrophy1,PRS
57831,ALPNeg,PRS
57832,SHBG_LpA,PRS
57833,Lipodystrophy2,PRS
57834,HyperInsulin,PRS
57835,BetaCell_2,PRS
57836,Liver_Lipid,PRS
57837,Bilirubin,PRS
57838,BetaCell_1,PRS
57839,Proinsulin,PRS
